WO2016107877A1 - Artificial nucleic acid molecules - Google Patents

Artificial nucleic acid molecules Download PDF

Info

Publication number
WO2016107877A1
WO2016107877A1 PCT/EP2015/081366 EP2015081366W WO2016107877A1 WO 2016107877 A1 WO2016107877 A1 WO 2016107877A1 EP 2015081366 W EP2015081366 W EP 2015081366W WO 2016107877 A1 WO2016107877 A1 WO 2016107877A1
Authority
WO
WIPO (PCT)
Prior art keywords
utr
nucleic acid
acid molecule
utr element
protein
Prior art date
Application number
PCT/EP2015/081366
Other languages
French (fr)
Inventor
Stefanie GRUND
Thomas Schlake
Original Assignee
Curevac Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to KR1020177021407A priority Critical patent/KR102580696B1/en
Priority to AU2015373404A priority patent/AU2015373404B2/en
Priority to BR112017009835A priority patent/BR112017009835A2/en
Priority to CA2966092A priority patent/CA2966092A1/en
Priority to EP19152916.3A priority patent/EP3494982A1/en
Priority to MX2017008670A priority patent/MX2017008670A/en
Priority to CN201580070984.3A priority patent/CN107124889A/en
Priority to RU2017127203A priority patent/RU2757675C2/en
Application filed by Curevac Ag filed Critical Curevac Ag
Priority to JP2017534943A priority patent/JP6907116B2/en
Priority to US15/540,610 priority patent/US20180148727A1/en
Priority to EP15820544.3A priority patent/EP3240558A1/en
Priority to SG11201704681QA priority patent/SG11201704681QA/en
Publication of WO2016107877A1 publication Critical patent/WO2016107877A1/en
Priority to US16/523,214 priority patent/US20190345504A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C12N15/68—Stabilisation of the vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/10—Vectors comprising a special translation-regulating system regulates levels of translation
    • C12N2840/105—Vectors comprising a special translation-regulating system regulates levels of translation enhancing translation

Definitions

  • the present invention was made with support from the Government under Agreement No. HR001 1 -1 1 -3-0001 awarded by DARPA. The Government has certain rights in the invention.
  • This application claims the priority of international patent application PCT/EP2014/003479 filed on December 30, 2014, which is incorporated herein by reference.
  • the invention relates to artificial nucleic acid molecules comprising an open reading frame, a 3'-untranslated region element (3'-UTR element) and/or a 5'-untranslated region element (5'-UTR element) and optionally a poly(A) sequence and/or a polyadenylation-signal.
  • the invention relates further to a vector comprising a 3'-UTR element and/or a 5'-UTR element, to a cell comprising the artificial nucleic acid molecule or the vector, to a pharmaceutical composition comprising the artificial nucleic acid molecule or the vector and to a kit comprising the artificial nucleic acid molecule, the vector and/or the pharmaceutical composition, preferably for use in the field of gene therapy and/or genetic vaccination.
  • Gene therapy and genetic vaccination belong to the most promising and quickly developing methods of modern medicine. They may provide highly specific and individual options for therapy of a large variety of diseases. Particularly, inherited genetic diseases but also autoimmune diseases, cancerous or tumour-related diseases as well as inflammatory diseases may be the subject of such treatment approaches. Also, it is envisaged to prevent early onset of such diseases by these approaches.
  • Pathologically altered gene expression may result in lack or overproduction of essential gene products, for example, signalling factors such as hormones, housekeeping factors, metabolic enzymes, structural proteins or the like. Altered gene expression may not only be due to mis-regulation of transcription and/or translation, but also due to mutations within the ORF coding for a particular protein. Pathological mutations may be caused by e.g. chromosomal aberration, or by more specific mutations, such as point or frame-shift-mutations, all of them resulting in l imited functionality and, potentially, total loss of function of the gene product.
  • misregulation of transcription or translation may also occur, if mutations affect genes encoding proteins which are involved in the transcriptional or translational machinery of the cell. Such mutations may lead to pathological up- or down-regulation of genes which are - as such - functional. Genes encoding gene products which exert such regulating functions, may be, e.g., transcription factors, signal receptors, messenger proteins or the like. However, loss of function of such genes encodi ng regulatory proteins may, under certain circumstances, be reversed by artificial introduction of other factors acting further downstream of the impaired gene product. Such gene defects may also be compensated by gene therapy via substitution of the affected gene itself.
  • vaccines may be subdivided into “first”, “second” and “third” generation vaccines.
  • First generation vaccines are, typically, whole-organism vaccines. They are based on either live and attenuated or killed pathogens, e.g. viruses, bacteria or the like.
  • live and attenuated vaccines The major drawback of live and attenuated vaccines is the risk for a reversion to life-threatening variants.
  • pathogens may sti ll intrinsically bear unpredictable risks.
  • Killed pathogens may not be as effective as desired for generating a specific immune response. In order to minimize these risks, "second generation” vaccines were developed.
  • Genetic vaccines i.e. vaccines for genetic vaccination, are usually understood as "third generation” vaccines. They are typically composed of genetically engineered nucleic acid molecules which allow expression of peptide or protein (antigen) fragments characteristic for a pathogen or a tumor antigen in vivo. Genetic vaccines are expressed upon administration to a patient after uptake by target cells. Expression of the administered nucleic acids results in production of the encoded proteins. In the event these proteins are recognized as foreign by the patient's immune system, an immune response is triggered.
  • both methods, gene therapy and genetic vaccination are essentially based on the administration of nucleic acid molecules to a patient and subsequent transcription and/or translation of the encoded genetic information.
  • genetic vaccination or gene therapy may also comprise methods which include isolation of specific body cells from a patient to be treated, subsequent in ex vivo transfection of such cells, and re-administration of the treated cells to the patient.
  • DNA as well as RNA may be used as nucleic acid molecules for administration in the context of gene therapy or genetic vaccination.
  • DNA is known to be relatively stable and easy to handle.
  • the use of DNA bears the risk of undesired insertion of the administered DNA-fragments into the patient's genome potentially resulting mutagenic events such as in loss of function of the impaired genes.
  • the undesired generation of anti-DNA antibodies has emerged.
  • Another drawback is the limited expression level of the encoded peptide or protein that is achievable upon DNA administration because the DNA must enter the nucleus in order to be transcribed before the resulting mRNA can be translated.
  • the expression level of the administered DNA will be dependent on the presence of specific transcription factors which regulate DNA transcription. In the absence of such factors, DNA transcription will not yield satisfying amounts of RNA. As a result, the level of translated peptide or protein obtained is limited.
  • RNA is considered to be a rather unstable molecular species which may readily be degraded by ubiquitous RNAses.
  • RNA degradation contributes to the regulation of the RNA half-life time. That effect was considered and proven to fine tune the regulation of eukaryotic gene expression (Friedel et a/., 2009. conserveed principles of mammalian transcriptional regulation revealed by RNA half-life, Nucleic Acid Research 37(1 7): 1 -12). Accordingly, each naturally occurring mRNA has its individual half-life depending on the gene from which the mRNA is derived and in which cell type it is expressed. It contributes to the regulation of the expression level of this gene. Unstable RNAs are important to realize transient gene expression at distinct points in time. However, long-lived RNAs may be associated with accumulation of distinct proteins or continuous expression of genes.
  • RNAs may also be dependent on environmental factors, such as hormonal treatment, as has been shown, e.g., for insulin-like growth factor I, actin, and albumin mRNA Gohnson et a/., Newly synthesized RNA: Simultaneous measurement in intact cel ls of transcription rates and RNA stability of insulinl ike growth factor I, actin, and albumin in growth hormone-stimulated hepatocytes, Proc. Natl. Acad. Sci., Vol. 88, pp. 5287-5291 , 1 991 ).
  • environmental factors such as hormonal treatment, as has been shown, e.g., for insulin-like growth factor I, actin, and albumin mRNA Gohnson et a/., Newly synthesized RNA: Simultaneous measurement in intact cel ls of transcription rates and RNA stability of insulinl ike growth factor I, actin, and albumin in growth hormone-stimulated hepatocytes, Proc. Natl.
  • RNA For gene therapy and genetic vaccination, usually stable RNA is desired. This is, on the one hand, due to the fact that it is usually desired that the product encoded by the RNA sequence accumulates in vivo. On the other hand, the RNA has to maintain its structural and functional integrity when prepared for a suitable dosage form, in the course of its storage, and when administered. Thus, efforts were made to provide stable RNA molecules for gene therapy or genetic vaccination in order to prevent them from being subject to early degradation or decay.
  • nucleic acids comprising an increased amount of guanine (G) and/or cytosine (C) residues may be functionally more stable than nucleic acids containing a large amount of adenine (A) and thymine (T) or uracil (U) nucleotides.
  • WO02/098443 provides a pharmaceutical composition containing an mRNA that is stabilised by sequence modifications in the coding region. Such a sequence modification takes advantage of the degeneracy of the genetic code.
  • RNA stabi lization is limited by the provisions of the specific nucleotide sequence of each single RNA molecule which is not allowed to leave the space of the desired amino acid sequence. Also, that approach is restricted to coding regions of the RNA.
  • eukaryotic mRNA molecules contain characteristic stabi lising elements.
  • they may comprise so-called untranslated regions (UTR) at their 5'-end (5'-UTR) and/or at their 3'- end (3'-UTR) as well as other structural features, such as a 5'-cap structure or a 3'-poly(A) tai l.
  • UTR untranslated regions
  • 5'-UTR and 3'-UTR are typically transcribed from the genomic DNA and are, thus, an element of the premature mRNA.
  • Characteristic structural features of mature mRNA such as the 5'-cap and the 3'-poly(A) tail (also called poly(A) tail or poly(A) sequence) are usually added to the transcribed (premature) mRNA during mRNA processing.
  • a 3'-poly(A) tail is typically a monotonous sequence stretch of adenosine nucleotides added to the 3 '-end of the transcribed mRNA. It may comprise up to about 400 adenosine nucleotides. It was found that the length of such a 3'-poly(A) tail is a potentially critical element for the stability of the individual mRNA.
  • RNA, 8, pp. 1 526-1537, 2002 may be an important factor for the well-known stability of a-globin mRNA.
  • Rodgers eta/., Regulated a-globin mRNA decay is a cytoplasmic event proceeding through 3'-to-5' exosome-dependent decapping, RNA, 8, pp. 1 526-1537, 2002).
  • the 3'-UTR of ⁇ -globin mRNA is apparently involved in the formation of a specific ribonucleoprotein-complex, the a-complex, whose presence correlates with mRNA stability in vitro (Wang et al., An mRNA stability complex functions with poly(A)-binding protein to stabilize mRNA in vitro, Molecular and Cellular biology, Vol 19, No. 7, July 1999, p. 4552-4560).
  • ribosomal proteins which are typically transcribed in a constant manner so that some ribosomal protein mRNAs such as ribosomal protein S9 or ribosomal protein L32 are referred to as housekeeping genes (Janovick-Guretzky et al., Housekeeping Gene Expression in Bovine Liver is Affected by Physiological State, Feed Intake, and Dietary Treatment, J. Dairy Sci., Vol. 90, 2007, p. 2246-2252).
  • the growth-associated expression pattern of ribosomal proteins is thus mainly due to regulation on the level of translation.
  • nucleic acid molecules which may be suitable for application in gene therapy and/or genetic vaccination.
  • an artificial nucleic acid molecule preferably an mRNA, which is characterized by enhanced expression of the respective protein encoded by said nucleic acid molecule.
  • One particular object of the invention is the provision of an mRNA, wherein the efficiency of translation of the respective encoded protein is enhanced.
  • Another object of the present i nvention is to provide nucleic acid molecules coding for such a superior mRNA species which may be amenable for use in gene therapy and/or genetic vaccination. It is a further object of the present invention to provide a pharmaceutical composition for use in gene therapy and/or genetic vaccination. In summary, it is the object of the present invention to provide improved nucleic acid species which overcome the above discussed disadvantages of the prior art by a cost-effective and straight-forward approach.
  • the adaptive immune response is typically understood to be an antigen-specific response of the immune system. Antigen specificity allows for the generation of responses that are tai lored to specific pathogens or pathogen-infected cells. The ability to mount these tailored responses is usually maintained in the body by "memory cells". Should a pathogen infect the body more than once, these specific memory cel ls are used to quickly eliminate it.
  • the first step of an adaptive immune response is the activation of naive antigen-specific T cel ls or different immune cells able to induce an antigen-specific immune response by antigen-presenting cells. This occurs in the lymphoid tissues and organs through which naive T cel ls are constantly passing.
  • dendritic cells The three cell types that may serve as antigen-presenting cells are dendritic cells, macrophages, and B cells. Each of these cells has a distinct function in eliciting immune responses.
  • Dendritic cells may take up antigens by phagocytosis and macropinocytosis and may become stimulated by contact with e.g. a foreign antigen to migrate to the local lymphoid tissue, where they differentiate into mature dendritic cells.
  • Macrophages ingest particulate antigens such as bacteria and are induced by infectious agents or other appropriate stimuli to express MHC molecules.
  • the unique ability of B cells to bind and internalize soluble protein antigens via their receptors may also be important to induce T cel ls.
  • MHC-molecules are, typically, responsible for presentation of an antigen to T-cells. Therein, presenting the antigen on MHC molecules leads to activation of T cells which induces their proliferation and differentiation into armed effector T cells.
  • effector T cells The most important function of effector T cells is the killing of infected cells by CD8+ cytotoxic T cells and the activation of macrophages by Th1 cells which together make up cell-mediated immunity, and the activation of B cells by both Th2 and Th1 cells to produce different classes of antibody, thus driving the humoral immune response.
  • T cells recognize an antigen by their T cell receptors which do not recognize and bind the antigen directly, but instead recognize short peptide fragments e.g. of pathogen-derived protein antigens, e.g. so-called epitopes, which are bound to MHC molecules on the surfaces of other cells.
  • the adaptive immune system is essentially dedicated to eliminate or prevent pathogenic growth. It typically regulates the adaptive immune response by providing the vertebrate immune system with the abi lity to recognize and remember specific pathogens (to generate immunity), and to mount stronger attacks each time the pathogen is encountered.
  • the system is highly adaptable because of somatic hypermutation (a process of accelerated somatic mutations), and V(D)J recombination (an irreversible genetic recombination of antigen receptor gene segments). This mechanism allows a small number of genes to generate a vast number of different antigen receptors, which are then uniquely expressed on each individual lymphocyte.
  • Adjuvant/adjuvant component in the broadest sense is typically a pharmacological and/or immunological agent that may modify, e.g. enhance, the effect of other agents, such as a drug or vaccine. It is to be interpreted in a broad sense and refers to a broad spectrum of substances. Typical ly, these substances are able to increase the immunogenicity of antigens.
  • adjuvants may be recognized by the innate immune systems and, e.g., may elicit an innate immune response. "Adjuvants" typically do not elicit an adaptive immune response. Insofar, "adjuvants" do not qualify as antigens. Their mode of action is disti nct from the effects triggered by antigens resulting in an adaptive immune response.
  • Antigen refers typically to a substance which may be recognized by the immune system, preferably by the adaptive immune system, and is capable of triggering an antigen-specific immune response, e.g. by formation of antibodies and/or antigen-specific T cells as part of an adaptive immune response.
  • an antigen may be or may comprise a peptide or protein which may be presented by the MHC to T-cells.
  • an antigen may be the product of translation of a provided nucleic acid molecule, preferably an mRNA as defined herein.
  • fragments, variants and derivatives of peptides and proteins comprising at least one epitope are understood as antigens.
  • tumour antigens and pathogenic antigens as defined herein are particularly preferred.
  • An artificial nucleic acid molecule may typically be understood to be a nucleic acid molecule, e.g. a DNA or an RNA, that does not occur naturally.
  • an artificial nucleic acid molecule may be understood as a non- natural nucleic acid molecule.
  • Such nucleic acid molecule may be non-natural due to its individual sequence (which does not occur naturally) and/or due to other modifications, e.g. structural modifications of nucleotides which do not occur natural ly.
  • An artificial nucleic acid molecule may be a DNA molecule, an RNA molecule or a hybrid-molecule comprising DNA and RNA portions.
  • artificial nucleic acid molecules may be designed and/or generated by genetic engineering methods to correspond to a desired artificial sequence of nucleotides (heterologous sequence).
  • an artificial sequence is usually a sequence that may not occur naturally, i.e. it differs from the wild type sequence by at least one nucleotide.
  • wild type may be understood as a sequence occurring in nature.
  • artificial nucleic acid molecule is not restricted to mean “one single molecule” but is, typically, understood to comprise an ensemble of identical molecules. Accordingly, it may relate to a plurality of identical molecules contained in an aliquot.
  • Bicistronic RNA, multicistronic RNA A bicistronic or multicistronic RNA is typically an RNA, preferably an mRNA, that typically may have two (bicistronic) or more (multicistronic) open reading frames (ORF).
  • An open reading frame in this context is a sequence of codons that is translatable into a peptide or protein.
  • Carrier / polymeric carrier A carrier in the context of the invention may typically be a compound that facilitates transport and/or complexation of another compound (cargo).
  • a polymeric carrier is typical ly a carrier that is formed of a polymer.
  • a carrier may be associated to its cargo by covalent or non-covalent interaction.
  • a carrier may transport nucleic acids, e.g. RNA or DNA, to the target cells.
  • the carrier may - for some embodiments - be a cationic component.
  • Cationic component typically refers to a charged molecule, which is positively charged (cation) at a pH value typically from 1 to 9, preferably at a pH value of or below 9 (e.g. from 5 to 9), of or below 8 (e.g. from 5 to 8), of or below 7 (e.g. from 5 to 7), most preferably at a physiological pH, e.g. from 7.3 to 7.4.
  • a cationic component may be any positively charged compound or polymer, preferably a cationic peptide or protein which is positively charged under physiological conditions, particularly under physiological conditions In vivo.
  • a "cationic peptide or protein” may contain at least one positively charged amino acid, or more than one positively charged amino acid, e.g. selected from Arg, His, Lys or Orn. Accordingly, "polycationic" components are also within the scope exhibiting more than one positive charge under the conditions given.
  • a 5'-cap is an entity, typically a modified nucleotide entity, which generally "caps" the 5'-end of a mature mRNA.
  • a 5 '-cap may typically be formed by a modified nucleotide, particularly by a derivative of a guanine nucleotide.
  • the 5'-cap is linked to the 5'- terminus via a 5'-5'-triphosphate linkage.
  • a 5'-cap may be methylated, e.g. m7GpppN, wherein N is the terminal 5' nucleotide of the nucleic acid carrying the 5'-cap, typically the 5'-end of an RNA.
  • 5'cap structures include glyceryl, inverted deoxy abasic residue (moiety), 4', 5' methylene nucleotide, l -(beta-D-erythrofuranosyl) nucleotide, 4'-thio nucleotide, carbocyclic nucleotide, 1 ,5-anhydrohexitol nucleotide, L-nucleotides, alpha-nucleotide, modified base nucleotide, threo-pentofuranosyl nucleotide, acyclic 3',4'- seco nucleotide, acyclic 3,4-dihydroxybutyl nucleotide, acyclic 3,5 dihydroxypentyl nucleotide, 3'-3'-i nverted nucleotide moiety, 3 '-3 '-inverted abasic moiety, 3'-2'-inverted nucleotide moiety, 3
  • Cel lular immunity/cellular immune response relates typical ly to the activation of macrophages, natural killer cells (NK), antigen-specific cytotoxic T-lymphocytes, and the release of various cytokines in response to an antigen.
  • cellular immunity is not based on antibodies, but on the activation of cel ls of the immune system.
  • a cellular immune response may be characterized e.g. by activating antigen- specific cytotoxic T-lymphocytes that are able to induce apoptosis in cells, e.g. specific immune cells like dendritic cel ls or other cells, displaying epitopes of foreign antigens on their surface.
  • Such cells may be virus-infected or infected with intracellular bacteria, or cancer cells displaying tumor antigens. Further characteristics may be activation of macrophages and natural killer cells, enabling them to destroy pathogens and stimulation of cel ls to secrete a variety of cytokines that influence the function of other cells involved in adaptive immune responses and innate immune responses.
  • nucleic acid i.e. for a nucleic acid “derived from” (another) nucleic acid
  • nucleic acid which is derived from (another) nucleic acid, shares at least 50%, preferably at least 60%, preferably at least 70%, more preferably at least 75%, more preferably at least 80%, more preferably at least 85%, even more preferably at least 90%, even more preferably at least 95%, and particularly preferably at least 98% sequence identity with the nucleic acid from which it is derived.
  • sequence identity is typically calculated for the same types of nucleic acids, i.e. for DNA sequences or for RNA sequences.
  • RNA sequence is converted into the corresponding DNA sequence (in particular by replacing the uracils (U) by thymidines (T) throughout the sequence) or, vice versa, the DNA sequence is converted into the corresponding RNA sequence (in particular by replacing the thymidines (T) by uracils (U) throughout the sequence). Thereafter, the sequence identity of the DNA sequences or the sequence identity of the RNA sequences is determined.
  • nucleic acid "derived from” a nucleic acid also refers to nucleic acid, which is modified in comparison to the nucleic acid from which it is derived, e.g. in order to increase RNA stability even further and/or to prolong and/or increase protein production. It goes without saying that such modifications are preferred, which do not impair RNA stability, e.g. in comparison to the nucleic acid from which it is derived.
  • DNA is the usual abbreviation for deoxy-ribonucleic acid. It is a nucleic acid molecule, i.e. a polymer consisting of nucleotides. These nucleotides are usually deoxy- adenosine-monophosphate, deoxy-thymidine-monophosphate, deoxy-guanosine- monophosphate and deoxy-cytidine-monophosphate monomers which are - by themselves - composed of a sugar moiety (deoxyribose), a base moiety and a phosphate moiety, and polymerise by a characteristic backbone structure.
  • the backbone structure is, typically, formed by phosphodiester bonds between the sugar moiety of the nucleotide, i.e. deoxyribose, of a first and a phosphate moiety of a second, adjacent monomer.
  • the specific order of the monomers i.e. the order of the bases linked to the sugar/phosphate-backbone, is called the DNA sequence.
  • DNA may be single stranded or double stranded. In the double stranded form, the nucleotides of the first strand typically hybridize with the nucleotides of the second strand, e.g. by A/T-base-pairing and G/C-base-pairing.
  • Epitope (also called “antigen determinant”) can be distinguished in T cell epitopes and
  • T cell epitopes or parts of the proteins in the context of the present invention may comprise fragments preferably having a length of about 6 to about 20 or even more amino acids, e.g. fragments as processed and presented by MHC class I molecules, preferably having a length of about 8 to about 10 amino acids, e.g. 8, 9, or 10, (or even 1 1 , or 12 amino acids), or fragments as processed and presented by MHC class II molecules, preferably having a length of about 13 or more amino acids, e.g. 13, 14, 15, 16, 1 7, 1 8, 19, 20 or even more amino acids, wherein these fragments may be selected from any part of the amino acid sequence.
  • B cell epitopes are typically fragments located on the outer surface of (native) protein or peptide antigens as defined herein, preferably having 5 to 15 amino acids, more preferably having 5 to 12 amino acids, even more preferably having 6 to 9 amino acids, which may be recognized by antibodies, i.e. in their native form.
  • Such epitopes of proteins or peptides may furthermore be selected from any of the herein mentioned variants of such proteins or peptides.
  • antigenic determinants can be conformationai or discontinuous epitopes which are composed of segments of the proteins or peptides as defined herein that are discontinuous in the amino acid sequence of the proteins or peptides as defined herein but are brought together in the three-dimensional structure or continuous or linear epitopes which are composed of a single polypeptide chain.
  • Fragment of a sequence A fragment of a sequence may typically be a shorter portion of a full-length sequence of e.g. a nucleic acid molecule or an amino acid sequence. Accordingly, a fragment, typically, consists of a sequence that is identical to the corresponding stretch within the full-length sequence.
  • a preferred fragment of a sequence in the context of the present invention consists of a continuous stretch of entities, such as nucleotides or amino acids corresponding to a continuous stretch of entities in the molecule the fragment is derived from, which represents at least 5%, 10%, 20%, preferably at least 30%, more preferably at least 40%, more preferably at least 50%, even more preferably at least 60%, even more preferably at least 70%, and most preferably at least 80% of the total (i.e. full-length) molecule from which the fragment is derived.
  • entities such as nucleotides or amino acids corresponding to a continuous stretch of entities in the molecule the fragment is derived from, which represents at least 5%, 10%, 20%, preferably at least 30%, more preferably at least 40%, more preferably at least 50%, even more preferably at least 60%, even more preferably at least 70%, and most preferably at least 80% of the total (i.e. full-length) molecule from which the fragment is derived.
  • a G/C-modified nucleic acid may typically be a nucleic acid, preferably an artificial nucleic acid molecule as defined herein, based on a modified wild-type sequence comprising a preferably increased number of guanosine and/or cytosine nucleotides as compared to the wild-type sequence. Such an increased number may be generated by substitution of codons containing adenosine or thymidine nucleotides by codons containing guanosine or cytosine nucleotides. If the enriched G/C content occurs in a coding region of DNA or RNA, it makes use of the degeneracy of the genetic code. Accordingly, the codon substitutions preferably do not alterthe encoded amino acid residues, but exclusively increase the G/C content of the nucleic acid molecule.
  • Gene therapy may typically be understood to mean a treatment of a patient's body or isolated elements of a patient's body, for example isolated tissues/cells, by nucleic acids encoding a peptide or protein. It typically may comprise at least one of the steps of a) administration of a nucleic acid, preferably an artificial nucleic acid molecule as defined herein, directly to the patient - by whatever administration route - or in vitro to isolated cells/tissues of the patient, which results in transfection of the patient's cells either in vivo/ex vivo or in vitro; b) transcription and/or translation of the introduced nucleic acid molecule; and optionally c) re-administration of isolated, transfected cells to the patient, if the nucleic acid has not been administered directly to the patient.
  • a nucleic acid preferably an artificial nucleic acid molecule as defined herein
  • Genetic vaccination may typically be understood to be vaccination by administration of a nucleic acid molecule encoding an antigen or an immunogen or fragments thereof.
  • the nucleic acid molecule may be administered to a subject's body or to isolated cells of a subject. Upon transfection of certain cel ls of the body or upon transfection of the isolated cells, the antigen or immunogen may be expressed by those cells and subsequently presented to the immune system, eliciting an adaptive, i.e. antigen-specific immune response.
  • genetic vaccination typically comprises at least one of the steps of a) administration of a nucleic acid, preferably an artificial nucleic acid molecule as defined herein, to a subject, preferably a patient, or to isolated cells of a subject, preferably a patient, which usual ly results in transfection of the subject's cells either in vivo or in vitro; b) transcription and/or translation of the introduced nucleic acid molecule; and optionally c) re- administration of isolated, transfected cells to the subject, preferably the patient, if the nucleic acid has not been administered directly to the patient.
  • a nucleic acid preferably an artificial nucleic acid molecule as defined herein
  • Heterologous sequence Two sequences are typically understood to be 'heterologous' if they are not derivable from the same gene. I.e., although heterologous sequences may be derivable from the same organism, they naturally (in nature) do not occur in the same nucleic acid molecule, such as in the same mRNA.
  • Humoral immunity/humoral immune response Humoral immunity refers typically to antibody production and optionally to accessory processes accompanying antibody production.
  • a humoral immune response may be typically characterized, e.g., by Th2 activation and cytokine production, germinal center formation and isotype switching, affi nity maturation and memory cell generation.
  • Humoral immunity also typically may refer to the effector functions of antibodies, which include pathogen and toxin neutralization, classical complement activation, and opsonin promotion of phagocytosis and pathogen elimination.
  • an immunogen may be typically understood to be a compound that is able to stimulate an immune response.
  • an immunogen is a peptide, polypeptide, or protein.
  • an immunogen in the sense of the present invention is the product of translation of a provided nucleic acid molecule, preferably an artificial nucleic acid molecule as defined herein.
  • an immunogen elicits at least an adaptive immune response.
  • an immunostimulatory composition may be typically understood to be a composition containing at least one component which is able to induce an immune response or from which a component which is able to induce an immune response is derivable. Such immune response may be preferably an innate immune response or a combination of an adaptive and an innate immune response.
  • an immunostimulatory composition in the context of the invention contains at least one artificial nucleic acid molecule, more preferably an RNA, for example an mRNA molecule.
  • the immunostimulatory component, such as the mRNA may be complexed with a suitable carrier.
  • the immunostimulatory composition may comprise an mRN A/carrier- complex.
  • the immunostimulatory composition may comprise an adjuvant and/or a suitable vehicle for the immunostimulatory component, such as the mRNA.
  • Immune response An immune response may typically be a specific reaction of the adaptive immune system to a particular antigen (so called specific or adaptive immune response) or an unspecific reaction of the innate immune system (so called unspecific or innate immune response), or a combination thereof.
  • the immune system may protect organisms from infection. If a pathogen succeeds in passing a physical barrier of an organism and enters this organism, the innate immune system provides an immediate, but non-specific response. If pathogens evade this innate response, vertebrates possess a second layer of protection, the adaptive immune system.
  • the immune system adapts its response during an infection to improve its recognition of the pathogen. This improved response is then retained after the pathogen has been eliminated, in the form of an immunological memory, and allows the adaptive immune system to mount faster and stronger attacks each time this pathogen is encountered.
  • the immune system comprises the innate and the adaptive immune system. Each of these two parts typically contains so called humoral and cellular components.
  • Immunostimulatory RNA in the context of the invention may typically be an RNA that is able to induce an innate immune response. It usually does not have an open reading frame and thus does not provide a peptide-antigen or immunogen but elicits an immune response e.g. by binding to a specific kind of Toll-like- receptor (TLR) or other suitable receptors.
  • TLR Toll-like- receptor
  • mRNAs having an open reading frame and coding for a peptide/protein may induce an innate immune response and, thus, may be immunostimulatory RNAs.
  • the innate immune system also known as non-specific (or unspecific) immune system, typically comprises the cells and mechanisms that defend the host from infection by other organisms in a non-specific manner. This means that the cells of the innate system may recognize and respond to pathogens in a generic way, but unlike the adaptive immune system, it does not confer long-lasting or protective immunity to the host.
  • the innate immune system may be, e.g., activated by ligands of Toll-like receptors (TLRs) or other auxiliary substances such as lipopolysaccharides, TNF-alpha, CD40 ligand, or cytokines, monokines, lymphokines, interleukins or chemokines, IL-1 , IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-1 1 , IL-12, IL-13, IL-14, IL-15, IL-1 6, IL-1 7, IL-18, IL-19, IL-20, IL-21 , IL- 22, IL-23, IL-24, IL-25, IL-26, IL-27, IL-28, IL-29, IL-30, IL-31 , IL-32, IL-33, IFN-alpha, IFN- beta, IFN-gamma, GM-CSF,
  • the pharmaceutical composition according to the present invention may comprise one or more such substances.
  • a response of the innate immune system includes recruiting immune cells to sites of infection, through the production of chemical factors, including specialized chemical mediators, called cytokines; activation of the complement cascade; identification and removal of foreign substances present in organs, tissues, the blood and lymph, by specialized white blood cells; activation of the adaptive immune system; and/or acting as a physical and chemical barrier to infectious agents.
  • a cloning site is typically understood to be a segment of a nucleic acid molecule, which is suitable for insertion of a nucleic acid sequence, e.g., a nucleic acid sequence comprising an open reading frame. Insertion may be performed by any molecular biological method known to the one skilled in the art, e.g. by restriction and ligation.
  • a cloning site typically comprises one or more restriction enzyme recognition sites (restriction sites). These one or more restrictions sites may be recognized by restriction enzymes which cleave the DNA at these sites.
  • a cloning site which comprises more than one restriction site may also be termed a multiple cloning site (MCS) or a polylinker.
  • MCS multiple cloning site
  • Nucleic acid molecule is a molecule comprising, preferably consisting of nucleic acid components.
  • the term nucleic acid molecule preferably refers to DNA or RNA molecules. It is preferably used synonymous with the term "polynucleotide".
  • a nucleic acid molecule is a polymer comprising or consisting of nucleotide monomers which are covalently linked to each other by phosphodiester-bonds of a sugar/phosphate-backbone.
  • the term "nucleic acid molecule” also encompasses modified nucleic acid molecules, such as base-modified, sugar-modified or backbone-modified etc. DNA or RNA molecules.
  • Open reading frame An open reading frame (ORF) in the context of the invention may typically be a sequence of several nucleotide triplets which may be translated into a peptide or protein.
  • An open reading frame preferably contains a start codon, i.e. a combination of three subsequent nucleotides coding usually for the amino acid methionine (ATG), at its 5'- end and a subsequent region which usually exhibits a length which is a multiple of 3 nucleotides.
  • An ORF is preferably terminated by a stop-codon (e.g., TAA, TAG, TGA). Typically, this is the only stop-codon of the open reading frame.
  • an open reading frame in the context of the present invention is preferably a nucleotide sequence, consisting of a number of nucleotides that may be divided by three, which starts with a start codon (e.g. ATG) and which preferably terminates with a stop codon (e.g., TAA, TGA, or TAG).
  • the open reading frame may be isolated or it may be incorporated in a longer nucleic acid sequence, for example in a vector or an mRNA.
  • An open reading frame may also be termed "protein coding region”.
  • a peptide or polypeptide is typically a polymer of amino acid monomers, linked by peptide bonds. It typically contains less than 50 monomer units. Nevertheless, the term peptide is not a disclaimer for molecules having more than 50 monomer units. Long peptides are also called polypeptides, typically having between 50 and 600 monomeric units.
  • a pharmaceutically effective amount in the context of the invention is typically understood to be an amount that is sufficient to induce a pharmaceutical effect, such as an immune response, altering a pathological level of an expressed peptide or protein, or substituting a lacking gene product, e.g., in case of a pathological situation.
  • Protein A protein typically comprises one or more peptides or polypeptides.
  • a protein is typically folded into 3-dimensional form, which may be required for to protein to exert its biological function.
  • a poly(A) sequence also called poly(A) tail or 3'-poly(A) tail, is typically understood to be a sequence of adenosine nucleotides, e.g., of up to about 400 adenosine nucleotides, e.g. from about 20 to about 400, preferably from about 50 to about 400, more preferably from about 50 to about 300, even more preferably from about 50 to about 250, most preferably from about 60 to about 250 adenosine nucleotides.
  • a poly(A) sequence is typically located at the 3'end of an mRNA.
  • a poly(A) sequence may be located within an mRNA or any other nucleic acid molecule, such as, e.g., in a vector, for example, in a vector serving as template for the generation of an RNA, preferably an mRNA, e.g., by transcription of the vector.
  • Polyadenylation is typically understood to be the addition of a poly(A) sequence to a nucleic acid molecule, such as an RNA molecule, e.g. to a premature mRNA. Polyadenylation may be induced by a so called polyadenylation signal. This signal is preferably located within a stretch of nucleotides at the 3'-end of a nucleic acid molecule, such as an RNA molecule, to be polyadenylated.
  • a polyadenylation signal typically comprises a hexamer consisting of adenine and uracil/thymine nucleotides, preferably the hexamer sequence AAUAAA.
  • RNA maturation from pre-mRNA to mature mRNA comprises the step of polyadenylation.
  • restriction site also termed restriction enzyme recognition site, is a nucleotide sequence recognized by a restriction enzyme.
  • a restriction site is typically a short, preferably palindromic nucleotide sequence, e.g. a sequence comprising 4 to 8 nucleotides.
  • a restriction site is preferably specifically recognized by a restriction enzyme.
  • the restriction enzyme typically cleaves a nucleotide sequence comprising a restriction site at this site.
  • the restriction enzyme typically cuts both strands of the nucleotide sequence.
  • RNA, mRNA RNA is the usual abbreviation for ribonucleic-acid.
  • RNA Ribonucleic acid molecule
  • nucleotides usually adenosine- monophosphate, uridine-monophosphate, guanosine-monophosphate and cytidine- monophosphate monomers which are connected to each other along a so-called backbone.
  • the backbone is formed by phosphodiester bonds between the sugar, i.e. ribose, of a first and a phosphate moiety of a second, adjacent monomer.
  • the specific succession of the monomers is called the RNA-sequence.
  • RNA may be obtainable by transcription of a DNA- sequence, e.g., inside a cell.
  • RNA messenger-RNA
  • Processing of the premature RNA comprises a variety of different posttranscriptional-modifications such as splicing, 5'-capping, polyadenylation, export from the nucleus or the mitochondria and the like. The sum of these processes is also called maturation of RNA.
  • the mature messenger RNA usually provides the nucleotide sequence that may be translated into an amino-acid sequence of a particular peptide or protein.
  • a mature mRNA typically comprises a 5'-cap, a 5'-UTR, an open reading frame, a 3'-UTR and a poly(A) sequence.
  • messenger RNA several non-coding types of RNA exist which may be involved in regulation of transcription and/or translation.
  • Sequence of a nucleic acid molecule The sequence of a nucleic acid molecule is typically understood to be the particular and individual order, i.e. the succession of its nucleotides.
  • sequence of a protein or peptide is typically understood to be the order, i.e. the succession of its amino acids.
  • Sequence identity Two or more sequences are identical if they exhibit the same length and order of nucleotides or amino acids.
  • the percentage of identity typically describes the extent to which two sequences are identical, i.e. it typically describes the percentage of nucleotides that correspond in their sequence position with identical nucleotides of a reference-sequence.
  • the sequences to be compared are considered to exhibit the same length, i.e. the length of the longest sequence of the sequences to be compared. This means that a first sequence consisting of 8 nucleotides is 80% identical to a second sequence consisting of 10 nucleotides comprising the first sequence.
  • identity of sequences preferably relates to the percentage of nucleotides of a sequence which have the same position in two or more sequences having the same length. Gaps are usually regarded as non-identical positions, irrespective of their actual position in an alignment.
  • Stabilized nucleic acid molecule is a nucleic acid molecule, preferably a DNA or RNA molecule that is modified such, that it is more stable to disintegration or degradation, e.g., by environmental factors or enzymatic digest, such as by an exo- or endonuclease degradation, than the nucleic acid molecule without the modification.
  • a stabilized nucleic acid molecule in the context of the present invention is stabilized in a cell, such as a prokaryotic or eukaryotic cell, preferably in a mammalian cell, such as a human cell.
  • the stabilization effect may also be exerted outside of cells, e.g. in a buffer solution etc., for example, in a manufacturing process for a pharmaceutical composition comprising the stabilized nucleic acid molecule.
  • Transfection refers to the introduction of nucleic acid molecules, such as DNA or RNA (e.g. mRNA) molecules, into cells, preferably into eukaryotic cells.
  • the term "transfection” encompasses any method known to the skilled person for introducing nucleic acid molecules into cells, preferably into eukaryotic cells, such as into mammalian cells. Such methods encompass, for example, electroporation, lipofection, e.g. based on cationic lipids and/or liposomes, calcium phosphate precipitation, nanoparticle based transfection, virus based transfection, or transfection based on cationic polymers, such as DEAE-dextran or polyethylenimine etc.
  • the introduction is non-viral.
  • a vaccine is typically understood to be a prophylactic or therapeutic material providing at least one antigen, preferably an immunogen.
  • the antigen or immunogen may be derived from any material that is suitable for vaccination.
  • the antigen or immunogen may be derived from a pathogen, such as from bacteria or virus particles etc., or from a tumor or cancerous tissue.
  • the antigen or immunogen stimulates the body's adaptive immune system to provide an adaptive immune response.
  • Vector refers to a nucleic acid molecule, preferably to an artificial nucleic acid molecule.
  • a vector in the context of the present invention is suitable for incorporating or harboring a desired nucleic acid sequence, such as a nucleic acid sequence comprising an open reading frame.
  • Such vectors may be storage vectors, expression vectors, cloning vectors, transfer vectors etc.
  • a storage vector is a vector which allows the convenient storage of a nucleic acid molecule, for example, of an mRNA molecule.
  • the vector may comprise a sequence corresponding, e.g., to a desired mRNA sequence or a part thereof, such as a sequence corresponding to the open reading frame and the 3'-UTR and/or the 5'-UTR of an mRNA.
  • An expression vector may be used for production of expression products such as RNA, e.g. mRNA, or peptides, polypeptides or proteins.
  • an expression vector may comprise sequences needed for transcription of a sequence stretch of the vector, such as a promoter sequence, e.g. an RNA polymerase promoter sequence.
  • a cloning vector is typically a vector that contains a cloning site, which may be used to incorporate nucleic acid sequences into the vector.
  • a cloning vector may be, e.g., a plasmid vector or a bacteriophage vector.
  • a transfer vector may be a vector which is suitable for transferring nucleic acid molecules into cells or organisms, for example, viral vectors.
  • a vector in the context of the present invention may be, e.g., an RNA vector or a DNA vector.
  • a vector is a DNA molecule.
  • a vector in the sense of the present application comprises a cloning site, a selection marker, such as an antibiotic resistance factor, and a sequence suitable for multiplication of the vector, such as an origin of replication.
  • a vector in the context of the present application is a plasmid vector.
  • Vehicle A vehicle is typically understood to be a material that is suitable for storing, transporting, and/or administering a compound, such as a pharmaceutically active compound. For example, it may be a physiologically acceptable liquid which is suitable for storing, transporting, and/or administering a pharmaceutically active compound.
  • 3'-untranslated region 3'-UTR: Generally, the term “3'-UTR” refers to a part of the artificial nucleic acid molecule, which is located 3' (i.e. "downstream") of an open reading frame and which is not translated into protein. Typically, a 3'-UTR is the part of an mRNA which is located between the protein coding region (open reading frame (ORF) or coding sequence (CDS)) and the poly(A) sequence of the mRNA. In the context of the invention, the term 3'- UTR may also comprise elements, which are not encoded in the template, from which an RNA is transcribed, but which are added after transcription during maturation, e.g. a poly(A) sequence.
  • a 3'-UTR of the mRNA is not translated into an amino acid sequence.
  • the 3'-UTR sequence is generally encoded by the gene which is transcribed into the respective mRNA during the gene expression process.
  • the genomic sequence is first transcribed into pre-mature mRNA, which comprises optional introns.
  • the pre-mature mRNA is then further processed into mature mRNA in a maturation process.
  • This maturation process comprises the steps of 5'capping, splicing the pre-mature mRNA to excize optional introns and modifications of the 3'-end, such as polyadenylation of the 3'-end of the pre-mature mRNA and optional endo-/ or exonuclease cleavages etc..
  • a 3'-UTR corresponds to the sequence of a mature mRNA which is located between the the stop codon of the protein coding region, preferably immediately 3' to the stop codon of the protein coding region, and the poly(A) sequence of the mRNA.
  • the term "corresponds to” means that the 3'-UTR sequence may be an RNA sequence, such as in the mRNA sequence used for defining the 3'- UTR sequence, or a DNA sequence which corresponds to such RNA sequence.
  • the term "a 3'-UTR of a gene” is the sequence which corresponds to the 3'-UTR of the mature mRNA derived from this gene, i.e.
  • 3'-UTR of a gene encompasses the DNA sequence and the RNA sequence (both sense and antisense strand and both mature and immature) of the 3'-UTR.
  • the 3'UTRs have a length of more than 20, 30, 40 or 50 nucleotides.
  • 5'-untranslated region 5'-UTR: Generally, the term “5'-UTR” refers to a part of the artificial nucleic acid molecule, which is located 5' (i.e. "upstream") of an open reading frame and which is not translated into protein.
  • a 5'-UTR is typically understood to be a particular section of messenger RNA (mRNA), which is located 5' of the open reading frame of the mRNA.
  • mRNA messenger RNA
  • the 5'-UTR starts with the transcriptional start site and ends one nucleotide before the start codon of the open reading frame.
  • the 5'UTRs have a length of more than 20, 30, 40 or 50 nucleotides.
  • the 5'-UTR may comprise elements for controlling gene expression, also called regulatory elements.
  • the 5'-UTR may be posttranscriptionally modified, for example by addition of a 5'-CAP.
  • a 5'-UTR of the mRNA is not translated into an amino acid sequence.
  • the 5'-UTR sequence is generally encoded by the gene which is transcribed into the respective mRNA during the gene expression process.
  • the genomic sequence is first transcribed into pre-mature mRNA, which comprises optional introns.
  • the pre-mature mRNA is then further processed into mature mRNA in a maturation process.
  • This maturation process comprises the steps of 5'capping, splicing the pre-mature mRNA to excize optional introns and modifications of the 3'-end, such as polyadenylation of the 3'-end of the pre-mature mRNA and optional endo-/ or exonuclease cleavages etc..
  • a 5'-UTR corresponds to the sequence of a mature mRNA which is located between the start codon and, for example, the 5'-CAP.
  • the 5'-UTR corresponds to the sequence which extends from a nucleotide located 3' to the 5 '-CAP, more preferably from the nucleotide located immediately 3' to the 5 '-CAP, to a nucleotide located 5' to the start codon of the protein coding region, preferably to the nucleotide located immediately 5' to the start codon of the protein coding region.
  • the nucleotide located immediately 3' to the 5'- CAP of a mature mRNA typically corresponds to the transcriptional start site.
  • the term “corresponds to” means that the 5'-UTR sequence may be an RNA sequence, such as in the mRNA sequence used for defining the 5'-UTR sequence, or a DNA sequence which corresponds to such RNA sequence.
  • a 5'- UTR of a gene is the sequence which corresponds to the 5'-UTR of the mature mRNA derived from this gene, i.e. the mRNA obtained by transcription of the gene and maturation of the pre-mature mRNA.
  • the term “5'-UTR of a gene” encompasses the DNA sequence and the RNA sequence (both sense and antisense strand and both mature and immature) of the 5'- UTR.
  • the 5'terminal oligopyrimidine tract (TOP) is typically a stretch of pyrimidine nucleotides located in the 5' terminal region of a nucleic acid molecule, such as the 5' terminal region of certain mRNA molecules or the 5' terminal region of a functional entity, e.g. the transcribed region, of certain genes.
  • the sequence starts with a cytidine, which usually corresponds to the transcriptional start site, and is followed by a stretch of usually about 3 to 30 pyrimidine nucleotides.
  • the TOP may comprise 3, 4, 5, 6, 7, 8, 9, 10, 1 1 , 12, 13, 14, 1 5, 1 6, 1 7, 18, 19, 20, 21 , 22, 23, 24, 25, 26, 27, 28, 29, 30 or even more nucleotides.
  • Messenger RNA that contains a 5'terminal oligopyrimidine tract is often referred to as TOP mRNA. Accordingly, genes that provide such messenger RNAs are referred to as TOP genes.
  • TOP sequences have, for example, been found in genes and mRNAs encoding peptide elongation factors and ribosomal proteins.
  • TOP motif In the context of the present invention, a TOP motif is a nucleic acid sequence which corresponds to a 5'TOP as defined above. Thus, a TOP motif in the context of the present invention is preferably a stretch of pyrimidine nucleotides having a length of 3-30 nucleotides.
  • the TOP-motif consists of at least 3 pyrimidine nucleotides, preferably at least 4 pyrimidine nucleotides, preferably at least 5 pyrimidine nucleotides, more preferably at least 6 nucleotides, more preferably at least 7 nucleotides, most preferably at least 8 pyrimidine nucleotides, wherein the stretch of pyrimidine nucleotides preferably starts at its 5'end with a cytosine nucleotide.
  • the TOP-motif preferably starts at its 5'end with the transcriptional start site and ends one nucleotide 5' to the first purin residue in said gene or mRNA.
  • a TOP motif in the sense of the present invention is preferably located at the 5'end of a sequence which represents a 5'-UTR or at the 5'end of a sequence which codes for a 5'-UTR.
  • TOP motif a stretch of 3 or more pyrimidine nucleotides is called "TOP motif" in the sense of the present invention if this stretch is located at the 5'end of a respective sequence, such as the artificial nucleic acid molecule, the 5'-UTR element of the artificial nucleic acid molecule, or the nucleic acid sequence which is derived from the 5'-UTR of a TOP gene as described herein.
  • a stretch of 3 or more pyrimidine nucleotides which is not located at the 5'-end of a 5'-UTR or a 5'-UTR element but anywhere within a 5'-UTR or a 5'-UTR element, is preferably not referred to as "TOP motif".
  • TOP genes are typically characterised by the presence of a 5' terminal oligopyrimidine tract. Furthermore, most TOP genes are characterized by a growth-associated translational regulation. However, also TOP genes with a tissue specific translational regulation are known.
  • the 5'-UTR of a TOP gene corresponds to the sequence of a 5'-UTR of a mature mRNA derived from a TOP gene, which preferably extends from the nucleotide located 3' to the 5'-CAP to the nucleotide located 5' to the start codon.
  • a 5'-UTR of a TOP gene typically does not comprise any start codons, preferably no upstream AUGs (uAUGs) or upstream open reading frames (uORFs).
  • upstream AUGs and upstream open reading frames are typically understood to be AUGs and open reading frames that occur 5' of the start codon (AUG) of the open reading frame that should be translated.
  • the 5'-UTRs of TOP genes are generally rather short.
  • the lengths of 5'-UTRs of TOP genes may vary between 20 nucleotides up to 500 nucleotides, and are typically less than about 200 nucleotides, preferably less than about 150 nucleotides, more preferably less than about 100 nucleotides.
  • Exemplary 5'-UTRs of TOP genes in the sense of the present invention are the nucleic acid sequences extending from the nucleotide at position 5 to the nucleotide located immediately 5' to the start codon (e.g.
  • the present invention relates to an artificial nucleic acid molecule comprising a. at least one open reading frame (ORF); and
  • UTR element and/or the at least one 5'-UTR element prolongs and/or increases protein production from said artificial nucleic acid molecule and wherein the at least one 3'-UTR element and/or the at least one 5'-UTR element is derived from a stable mRNA.
  • the artificial nucleic acid molecule according to the present invention does not comprise a 3'-UTR (element) and/or a 5'-UTR (element) of ribosomal protein S6, of RPL36AL, of rps16 or of ribosomal protein L9. More preferably, the artificial nucleic acid molecule according to the present invention does not comprise a 3'-UTR (element) and/or a 5'-UTR (element) of ribosomal protein S6, of RPL36AL, of rpsl 6 or of ribosomal protein L9 and the open reading frame of the artificial nucleic acid molecule according to the present invention does not code for a GFP protein.
  • the artificial nucleic acid molecule according to the present invention does not comprise a 3'-UTR (element) and/or a 5'-UTR (element) of ribosomal protein S6, of RPL36AL, of rps1 6 or of ribosomal protein L9 and the open reading frame of the artificial nucleic acid molecule according to the present invention does not code for a reporter protein, e.g., selected from the group consisting of globin proteins (particularly beta-globin), luciferase protein, GFP proteins, glucurinodase proteins (particularly beta- glucurinodase) or variants thereof, for example, variants exhibiting at least 70% sequence identity to a globin protein, a luciferase protein, a GFP protein, or a glucurinodase protein.
  • a reporter protein e.g., selected from the group consisting of globin proteins (particularly beta-globin), luciferase protein, GFP proteins, glu
  • 3'-UTR element refers to a nucleic acid sequence which comprises or consists of a nucleic acid sequence that is derived from a 3'-UTR or from a variant or a fragment of a 3'- UTR.
  • a "3'-UTR element” preferably refers to a nucleic acid sequence which is comprised by a 3'-UTR of an artificial nucleic acid sequence, such as an artificial mRNA. Accordingly, in the sense of the present invention, preferably, a 3'-UTR element may be comprised by the 3'-UTR of an mRNA, preferably of an artificial mRNA, or a 3'-UTR element may be comprised by the 3'-UTR of the respective transcription template.
  • a 3'-UTR element is a nucleic acid sequence which corresponds to the 3'-UTR of an mRNA, preferably to the 3'- UTR of an artificial mRNA, such as an mRNA obtained by transcription of a genetically engineered vector construct.
  • a 3'-UTR element in the sense of the present invention functions as a 3'-UTR or codes for a nucleotide sequence that fulfils the function of a 3'-UTR.
  • the term "5'-UTR element” refers to a nucleic acid sequence which comprises or consists of a nucleic acid sequence that is derived from a 5'-UTR or from a variant or a fragment of a 5'-UTR.
  • a "5'-UTR element” preferably refers to a nucleic acid sequence which is comprised by a 5'-UTR of an artificial nucleic acid sequence, such as an artificial mRNA.
  • a 5'-UTR element may be comprised by the 5'-UTR of an mRNA, preferably of an artificial mRNA, or a 5'-UTR element may be comprised by the 5'-UTR of the respective transcription template.
  • a 5'- UTR element is a nucleic acid sequence which corresponds to the 5'-UTR of an mRNA, preferably to the 5'-UTR of an artificial mRNA, such as an mRNA obtained by transcription of a genetical ly engineered vector construct.
  • a 5'-UTR element in the sense of the present invention functions as a 5'-UTR or codes for a nucleotide sequence that fulfils the function of a 5'-UTR.
  • the 3'-UTR element and/or the 5'-UTR element in the artificial nucleic acid molecule according to the present invention prolongs and/or increases protein production from said artificial nucleic acid molecule.
  • the artificial nucleic acid molecule according to the present invention may in particular comprise:
  • a 5'-UTR element which prolongs protein production from said artificial nucleic acid molecule
  • a 5'-UTR element which increases and prolongs protein production from said artificial nucleic acid molecule
  • a 3'-UTR element which increases and prolongs protein production from said artificial nucleic acid molecule and a 5'-UTR element which increases and prolongs protein production from said artificial nucleic acid molecule.
  • the artificial nucleic acid molecule according to the present invention comprises a 3'-UTR element which prolongs protein production from said artificial nucleic acid molecule and/or a 5'-UTR element which increases protein production from said artificial nucleic acid molecule.
  • the artificial nucleic acid molecule according to the present invention comprises at least one 3'-UTR element and at least one 5'-UTR element, i.e. at least one 3'-UTR element which prolongs and/or increases protein production from said artificial nucleic acid molecule and which is derived from a stable mRNA and at least one 5'-UTR element which prolongs and/or increases protein production from said artificial nucleic acid molecule and which is derived from a stable mRNA.
  • “Prolonging and/or increasing protein production from said artificial nucleic acid molecule” in general refers to the amount of protein produced from the artificial nucleic acid molecule according to the present invention with the respective 3'-UTR element and/or the 5'-UTR element in comparison to the amount of protein produced from a respective reference nucleic acid lacking a 3'-UTR and/or a 5'-UTR or comprising a reference 3'-UTR and/or a reference 5'-UTR, such as a 3'-UTR and/or a 5'-UTR naturally occurring in combination with the ORF.
  • the at least one 3'-UTR element and/or the 5'-UTR element of the artificial nucleic acid molecule according to the present invention prolongs protein production from the artificial nucleic acid molecule according to the present invention, e.g. from an mRNA according to the present invention, compared to a respective nucleic acid lacking a 3'-UTR and/or 5'-UTR or comprising a reference 3'-UTR and/or 5'-UTR, such as a 3'- and/or 5'-UTR naturally occurring in combination with the ORF.
  • the at least one 3'-UTR element and/or 5'-UTR element of the artificial nucleic acid molecule according to the present invention increases protein production, in particular the protein expression and/or total protein production, from the artificial nucleic acid molecule according to the present invention, e.g. from an mRNA according to the present invention, compared to a respective nucleic acid lacking a 3'- and/or 5'-UTR or comprising a reference 3'- and/or 5'-UTR, such as a 3'- and/or 5'-UTR naturally occurring in combination with the ORF.
  • the at least one 3'-UTR element and/or the at least one 5'-UTR element of the artificial nucleic acid molecule according to the present invention do not negatively influence translational efficiency of a nucleic acid compared to the translational efficiency of a respective nucleic acid lacking a 3'-UTR and/or a 5'-UTR or comprising a reference 3'-UTR and/or a reference 5'-UTR, such as a 3'-UTR and/or a 5'-UTR naturally occurring in combination with the ORF.
  • the translation efficiency is enhanced by the 3'-UTR and/or a 5'-UTR in comparison to the translation efficiency of the protein encoded by the respective ORF in its natural context.
  • nucleic acid molecule or “reference nucleic acid molecule” as used herein means that - apart from the different 3'-UTRs and/or 5'-UTRs - the reference nucleic acid molecule is comparable, preferably identical, to the inventive artificial nucleic acid molecule comprising the 3'-UTR element and/or the 5'-UTR element.
  • inventive nucleic acid molecule comprising the 3'-UTR element and/or the 5'-UTR element.
  • human cel ls and mouse cells and particularly preferred are the human cell lines HeLa, and U-937 and the mouse cell lines NIH3T3, JAWSIl and L929, furthermore primary cells are particularly preferred, in particular preferred embodiments human dermal fibroblasts (HDF)) by the inventive artificial nucleic acid molecule, the expression of the encoded protein is determined following injection/transfection of the inventive artificial nucleic acid molecule into target cells/tissue and compared to the protein expression induced by the reference nucleic acid. Quantitative methods for determining protein expression are known in the art (e.g. Western-Blot, FACS, ELISA, mass spectrometry).
  • an artificial nucleic acid according to the invention or a reference nucleic acid is introduced into the target tissue or cell, e.g. via transfection or injection, preferably i n a mammalian expression system, such as in mammalian cells, e.g. in HeLa or HDF cells.
  • a target cell sample is collected and measured via FACS and/or lysed. Afterwards the lysates can be used to detect the expressed protein (and thus determine the efficiency of protein expression) using several methods, e.g. Western-Blot, FACS, ELISA, mass spectrometry or by fluorescence or luminescence measurement.
  • the protein expression from an artificial nucleic acid molecule according to the invention is compared to the protein expression from a reference nucleic acid molecule at a specific point in time (e.g. 6, 12, 24, 48 or 72 hours post initiation of expression or post introduction of the nucleic acid molecule), both nucleic acid molecules are introduced separately into target tissue/cells, a sample from the tissue/cells is collected after a specific point in time, protein lysates are prepared according to the particular protocol adjusted to the particular detection method (e.g. Western Blot, ELISA, fluorescence or luminescence measurement, etc. as known in the art) and the protein is detected by the chosen detection method.
  • a specific point in time e.g. 6, 12, 24, 48 or 72 hours post initiation of expression or post introduction of the nucleic acid molecule
  • polystyrene-semiconductor molecule preferably long-chain polystyrene-styrene-styrene-styrene-styrene-styrene-styrene-styrene-styrene-styrene-styrene-styrene-styrene-styrene-styrene-sse.g. comprising a reference 3'- and/or 5'-UTR or lacking a 3'- and/or 5'-UTR, preferably in a mammalian expression system, such as in HeLa or HDF cells.
  • protein produced from the artificial nucleic acid molecule such as the artificial mRNA is observable for a longer period of time than what may be seen for a protein produced from a reference nucleic acid molecule.
  • the amount of protein produced from the artificial nucleic acid molecule such as the artificial mRNA measured at a later point in time is larger than the amount of protein produced from a reference nucleic acid molecule such as a reference mRNA at a corresponding later point in time.
  • a "later point in time” may be, for example, any time beyond 24 hours post initiation of expression, such as post transfection of the nucleic acid molecule, e.g. 36, 48, 60, 72, 96 hours post initiation of expression, i.e. after transfection.
  • the amount of protein produced at a later point in time may be normalized to the amount produced an earlier (reference) point in time, for example the amount of protein at a later point in time may be expressed as percentage of the amount of protein at 24 h after transfection.
  • an encoded reporter protein such as luciferase
  • a mammalian expression system such as in HeLa or HDF cells
  • These relative amounts at a later point in time may then be compared in a step (iv) to relative protein amounts for the corresponding points in time for a nucleic acid molecule lacking a 3'- and/or 5'-UTR, respectively, or comprising a reference 3'- and/or 5'-UTR, respectively.
  • nucleic acid molecule lacking a 3'- and/or 5'-UTR, respectively, or comprising a reference 3'- and/or 5'-UTR, respectively, a factor may be determined by which the protein production from the artificial nucleic acid molecule according to the present invention is prolonged compared to the protein production from the reference nucleic acid molecule.
  • the at least one 3'- and/or 5'-UTR element in the artificial nucleic acid molecule according to the invention prolongs protein production from said artificial nucleic acid molecule at least 1 .2 fold, preferably at least 1 .5 fold, more preferably at least 2 fold, even more preferably at least 2.5 fold, compared to the protein production from a reference nucleic acid molecule lacking 3'- and/or 5'-UTR, respectively, or comprising a reference 3'- and/or 5'-UTR, respectively.
  • the (relative) amount of protein produced from in the artificial nucleic acid molecule according to the invention at a certain later point in time as described above is increased by a factor of at least 1 .2, preferably at least 1 .5, more preferably at least 2, even more preferably at least 2.5, compared to the (relative) amount of protein produced from a reference nucleic acid molecule, which is e.g. lacking a 3'- and/or 5'-UTR, respectively, or comprising a reference 3'- and/or 5'-UTR, respectively, for the same later point in time.
  • the effect of prolonging protein production may also be determined by (i) measuring protein amounts, e.g.
  • an encoded reporter protein such as luciferase
  • a mammalian expression system such as in HeLa or HDF cells
  • the protein production from the artificial nucleic acid molecule such as the artificial mRNA - in an amount which is at least the amount observed in the initial phase of expression, such as 1 , 2, 3, 4, 5, or 6 hours post initiation of expression, such as post transfection of the nucleic acid molecule - is prolonged by at least about 5 hours, preferably by at least about 10 hours, more preferably by at least about 24 hours compared to the protein production from a reference nucleic acid molecule, such as a reference mRNA, in a mammalian expression system, such as in mammalian cells, e.g. in HeLa or HDF cells.
  • the artificial nucleic acid molecule according to the present invention preferably allows for prolonged protein production in an amount which is at least the amount observed in the initial phase of expression, such as 1 , 2, 3, 4, 5, or 6 hours post initiation of expression, such as post transfection, by at least about 5 hours, preferably by at least about 10 hours, more preferably by at least about 24 hours compared to a reference nucleic acid molecule lacking a 3'- and/or 5'-UTR, respectively, or comprising a reference 3'- and/or 5'-UTR, respectively.
  • the period of protein production from the artificial nucleic acid molecule according to the present invention is extended at least 1 .2 fold, preferably at least 1 .5 fold, more preferably at least 2 fold, even more preferably at least 2.5 fold, compared to the protein production from a reference nucleic acid molecule lacking a 3'- and/or 5'-UTR, respectively, or comprising a reference 3'- and/or 5'-UTR, respectively.
  • this prolonging effect on protein production is achieved, while the total amount of protein produced from the artificial nucleic acid molecule according to the present invention, e.g. within a time span of 48 or 72 hours, corresponds at least to the amount of protein produced from a reference nucleic acid molecule lacking a 3'- and/or 5'-UTR, respectively, or comprising a reference 3'- and/or 5'-UTR, respectively, such as a 3'-UTR and/or 5'-UTR naturally occurring with the ORF of the artificial nucleic acid molecule.
  • the present invention provides an artificial nucleic acid molecule which allows for prolonged protein production in a mammalian expression system, such as in mammalian cells, e.g.
  • the total amount of protein produced from said artificial nucleic acid molecule e.g. within a time span of 48 or 72 hours, is at least the total amount of protein produced, e.g. within said time span, from a reference nucleic acid molecule lacking a 3'- and/or 5'-UTR, respectively, or comprising a reference 3'- and/or 5'- UTR, respectively, such as a 3'- and/or 5'-UTR naturally occurring with the ORF of the artificial nucleic acid molecule.
  • the term “prolonged protein expression” also includes “stabilized protein expression”, whereby “stabilized protein expression” preferably means that there is more uniform protein production from the artificial nucleic acid molecule according to the present invention over a predetermined period of time, such as over 24 hours, more preferably over 48 hours, even more preferably over 72 hours, when compared to a reference nucleic acid molecule, for example, an mRNA comprising a reference 3'- and/or 5'-UTR, respectively, or lacking a 3'- and/or 5'-UTR, respectively.
  • the level of protein production e.g. in a mammalian system, from the artificial nucleic acid molecule comprising a 3'- and/or 5'-UTR element according to the present invention, e.g. from an mRNA according to the present invention, preferably does not drop to the extent observed for a reference nucleic acid molecule, such as a reference mRNA as described above.
  • a reference nucleic acid molecule such as a reference mRNA as described above.
  • 24 hours post transfection of the artificial nucleic acid molecule according to the present invention into a cell may be compared to the amount of protein observed 48 hours after initiation of expression, e.g. 48 hours post transfection.
  • the ratio of the amount of protein encoded by the ORF of the artificial nucleic acid molecule according to the present invention such as the amount of a reporter protein, e.g., luciferase, observed at a later point in time, e.g. 48 hours, post initiation of expression, e.g. post transfection, to the amount of protein observed at an earlier point in time, e.g. 24 hours, post initiation of expression, e.g.
  • a reference nucleic acid molecule comprising a reference 3'- and/or 5'-UTR, respectively, or lacking a 3'- and/or 5'-UTR, respectively.
  • the ratio of the amount of protein encoded by the ORF of the artificial nucleic acid molecule according to the present invention is preferably at least 0.2, more preferably at least about 0.3, even more preferably at least about 0.4, even more preferably at least about 0.5, and particularly preferably at least about 0.7.
  • a respective reference nucleic acid molecule e.g. an mRNA comprising a reference 3'- and/or 5'-UTR, respectively, or lacking a 3'- and/or 5'-UTR, respectively, said ratio may be, for example between about 0.05 and about 0.35.
  • the present invention provides an artificial nucleic acid molecule comprising an ORF and a 3'- and/or 5'-UTR element as described above, wherein the ratio of the protein amount, e.g. the amount of luciferase, observed 48 hours after initiation of expression to the protein amount observed 24 hours after initiation of expression, preferably in a mammalian expression system, such as in mammalian cells, e.g. in HDF cells or in HeLa cells, is preferably at least 0.2, more preferably at least about 0.3, more preferably at least about 0.4, even more preferably at least about 0.5, even more preferably at least about 0.6, and particularly preferably at least about 0.7.
  • a mammalian expression system such as in mammalian cells, e.g. in HDF cells or in HeLa cells
  • the total amount of protein produced from said artificial nucleic acid molecule corresponds at least to the total amount of protein produced, e.g. within said time span, from a reference nucleic acid molecule lacking a 3'- and/or 5'-UTR, respectively, or comprising a reference 3'- and/or 5'-UTR, respectively, such as a 3'-UTR and/or 5'-UTR naturally occurring with the ORF of the artificial nucleic acid molecule.
  • the present invention provides an artificial nucleic acid molecule comprising an ORF and a 3'-UTR element and/or a 5'-UTR element as described above, wherein the ratio of the protein amount, e.g. the amount of luciferase, observed 72 hours after initiation of expression to the protein amount observed 24 hours after initiation of expression, preferably in a mammalian expression system, such as in mammalian cells, e.g. in HeLa cells or HDF cells, is preferably above about 0.05, more preferably above about 0.1 , more preferably above about 0.2, even more preferably above about 0.3, wherein preferably the total amount of protein produced from said artificial nucleic acid molecule, e.g.
  • a reference nucleic acid molecule lacking a 3'- and/or 5'-UTR, respectively, or comprising a reference 3'- and/or 5'-UTR, respectively, such as a 3'- and/or 5'-UTR naturally occurring with the ORF of the artificial nucleic acid molecule.
  • “Increased protein expression” or “enhanced protein expression” in the context of the present invention preferably means an increased/enhanced protein expression at one point in time after initiation of expression or an increased/enhanced total amount of expressed protein compared to the expression induced by a reference nucleic acid molecule.
  • the protein level observed at a certain point in time after initiation of expression, e.g. after transfection, of the artificial nucleic acid molecule according to the present invention e.g. after transfection of an mRNA according to the present invention, for example, 6, 12, 24, 48 or 72 hours post transfection, is preferably higher than the protein level observed at the same point in time after initiation of expression, e.g.
  • the maximum amount of protein (as determined e.g. by protein activity or mass) expressed from the artificial nucleic acid molecule is increased with respect to the protein amount expressed from a reference nucleic acid comprising a reference 3'- and/or 5'-UTR, respectively, or lacking a 3'- and/or 5'-UTR, respectively.
  • Peak expression levels are preferably reached within 48 hours, more preferably within 24 hours and even more preferably within 12 hours after, for instance, transfection.
  • the term "increased total protein production” or “enhanced total protein production” from an artificial nucleic acid molecule according to the invention refers to an increased/enhanced protein production over a time span, in which protein is produced from an artificial nucleic acid molecule, e.g. 48 hours or 72 hours, preferably in a mammalian expression system, such as in mammalian cells, e.g. in HeLa or HDF cells in comparison to a reference nucleic acid molecule lacking a 3'- and/or 5'-UTR, respectively, or comprising a reference 3'- and/or 5'-UTR, respectively.
  • the cumulative amount of protein expressed over time is increased when using the artificial nucleic acid molecule according to the invention.
  • the total amount of protein for a specific time period may be determined by (i) collecting tissue or cells at several points in time after introduction of the artificial nucleic acid molecule (e.g. 6, 12, 24, 48 and 72 hours post initiation of expression or post introduction of the nucleic acid molecule), and the protein amount per point in time can be determined as explained above.
  • a mathematical method of determining the total amount of protein can be used, e.g. the area under the curve (AUC) can be determined according to the following formula:
  • total protein production preferably refers to the area under the curve (AUC) representing protein production over time.
  • the at least one 3'- or 5'-UTR element according to the present invention increases protein production from said artificial nucleic acid molecule at least 1 .5 fold, preferably at least 2 fold, more preferably at least 2.5 fold, compared to the protein production from a reference nucleic acid molecule lacking a 3'- and/or 5'-UTR, respectively.
  • post transfection is increased by a factor of at least 1 .5, preferably at least 2, more preferably at least 2.5, compared to the (relative) amount of protein produced from a reference nucleic acid molecule, which is e.g. lacking a 3'- and/or 5'-UTR, respectively, or comprising a reference 3'- and/or 5'-UTR, respectively, for the corresponding later point in time.
  • a reference nucleic acid molecule which is e.g. lacking a 3'- and/or 5'-UTR, respectively, or comprising a reference 3'- and/or 5'-UTR, respectively, for the corresponding later point in time.
  • the mRNA and/or protein production prolonging effect and efficiency and/or the protein production increasing effect and efficiency of the variants, fragments and/or variant fragments of the 3'-UTR and/or the 5'-UTR as well as the mRNA and/or protein production prolonging effect and efficiency and/or the protein production increasing effect and efficiency of the at least one 3'-UTR element and/or the at least one 5'-UTR element of the artificial nucleic acid molecule according to the present invention may be determined by any method suitable for this purpose known to skilled person.
  • artificial mRNA molecules may be generated comprising a coding sequence/open reading frame (ORF) for a reporter protein, such as luciferase, and a 3'-UTR element according to the present invention, i.e. which prolongs and/or increases protein production from said artificial mRNA molecule.
  • a reporter protein such as luciferase
  • a 3'-UTR element according to the present invention, i.e. which prolongs and/or increases protein production from said artificial mRNA molecule.
  • inventive mRNA molecule may further comprise a a 5'-UTR element according to the present invention, i.e. which prolongs and/or increases protein production from said artificial mRNA molecule, no 5'-UTR element or a 5'-UTR element which is not according to the present invention, e.g. a reference 5'-UTR.
  • artificial mRNA molecules may be generated comprising a coding sequence/open reading frame (ORF) for a reporter protein, such as luciferase, and a 5'-UTR element according to the present invention, i.e. which prolongs and/or increases protein production from said artificial mRNA molecule.
  • a reporter protein such as luciferase
  • a 5'-UTR element according to the present invention
  • such an inventive mRNA molecule may further comprise a a 3'-UTR element according to the present invention, i.e. which prolongs and/or increases protein production from said artificial mRNA molecule, no 3'-UTR element or a 3'-UTR element which is not according to the present invention, e.g. a reference 3'-UTR.
  • mRNAs may be generated, for example, by in vitro transcription of respective vectors such as plasmid vectors, e.g. comprising a T7 promoter and a sequence encoding the respective mRNA sequences.
  • the generated mRNA molecules may be transfected into cells by any transfection method suitable for transfecting mRNA, for example they may be lipofected into mammalian cells, such as HeLa cells or HDF cells, and samples may be analyzed certain points in time after transfection, for example, 6 hours, 24 hours, 48 hours, and 72 hours post transfection. Said samples may be analyzed for mRNA quantities and/or protein quantities by methods well known to the skilled person.
  • the quantities of reporter mRNA present in the cells at the sample points in time may be determined by quantitative PCR methods.
  • the quantities of reporter protein encoded by the respective mRNAs may be determined, e.g., by Western Blot, ELISA assays, FACS analysisor reporter assays such as luciferase assays depending on the reporter protein used.
  • the effect of stabilizing protein expression and/or prolonging protein expression may be, for example, analyzed by determining the ratio of the protein level observed 48 hours post transfection and the protein level observed 24 hours post transfection. The closer said value is to 1 , the more stable the protein expression is within this time period.
  • Such measurements may of course also be performed at 72 or more hours and the ratio of the protein level observed 72 hours post transfection and the protein level observed 24 hours post transfection may be determined to determine stability of protein expression.
  • the at least one 3'-UTR element and/or the at least one 5'-UTR element in the artificial nucleic acid molecule according to the present invention is derived from a stable mRNA.
  • "derived" from a stable mRNA means that the at least one 3'-UTR element and/or the at least one 5'-UTR element shares at least 50%, preferably at least 60%, preferably at least 70%, more preferably at least 75%, more preferably at least 80%, more preferably at least 85%, even more preferably at least 90%, even more preferably at least 95%, and particularly preferably at least 98% sequence identity with a 3'-UTR element and/or a 5'-UTR element of a stable mRNA.
  • the stable mRNA is a naturally occurring mRNA and, thus, a 3'-UTR element and/or a 5'-UTR element of a stable mRNA refers to a 3'-UTR and/or a 5'-UTR, or fragments or variants thereof, of naturally occurring mRNA.
  • a 3'-UTR element and/or a 5'-UTR element derived from a stable mRNA preferably also refers to a 3'- UTR element and/or a 5'-UTR element, which is modified in comparison to a naturally occurring 3'-UTR element and/or 5'-UTR element, e.g. in order to increase RNA stability even further and/or to prolong and/or increase protein production.
  • RNA stability e.g. in comparison to a naturally occurring (non-modifed) 3'-UTR element and/or 5'-UTR element.
  • mRNA refers to an mRNA molecule, however, it may also refer to an mRNA species as defined herein.
  • the stability of mRNA i.e. mRNA decay and/or half-life, is assessed under standard conditions, for example standard conditions (standard medium, incubation, etc.) for a certain cell line used.
  • stable mRNA refers in general to an mRNA having a slow mRNA decay.
  • a “stable mRNA” has typically a long half-life.
  • the half-life of an mRNA is the the time required for degrading 50% of the in vivo or in vitro existing mRNA molecules.
  • stability of mRNA is usually assessed in vivo or in vitro.
  • in vitro refers in particular to ("living") cells and/or tissue, including tissue of a living subject.
  • Cells include in particular cell lines, primary cells, cells in tissue or subjects.
  • cell types allowing cell culture may be suitable for the present invention.
  • Particularly preferred are mammalian cells, e.g. human cells and mouse cells.
  • the human cell lines HeLa, and U-937 and the mouse cell lines NIH3T3, JAWSII and L929 are used.
  • primary cells are particularly preferred, in particular preferred embodiments human dermal fibroblasts (HDF) may be used.
  • HDF human dermal fibroblasts
  • the half-life of a "stable mRNA" is at least 5 h, at least 6 h, at least 7 h, at least 8 h, at least 9 h, at least 10 h, at least 1 1 h, at least 12 h, at least 13 h, at least 14 h, and/or at least 15 h.
  • the half-life of an mRNA of interest may be determined by different methods known to the person skilled in the art.
  • the half-life of an mRNA of interest is determined by determining the decay constant, whereby usually an ideal in vivo (or in vitro as defined above) situation is assumed, in which transcription of the mRNA of interest can be "turned off" completely (or at least to an undetectable level). In such an ideal situation it is usually assumed that mRNA decay follows first-order kinetics. Accordingly, the decay of an mRNA may usually be described by the following equation:
  • A(t) Ao * ⁇ - ⁇ with Ao being the amount (or concentration) of the mRNA of interest at time 0, i.e. before the decay starts, A(t) being the amount (or concentration) of the mRNA of interest at a time t during decay and ⁇ being the decay constant.
  • the decay constant ⁇ may be calculated.
  • the amount or concentration of the mRNA is determined during the RNA decay process in vivo (or in vitro as defined above).
  • various methods may be used, which are known to the skilled person. Non-limiting examples of such methods include general inhibition of transcription, e.g. with a transcription inhibitor such as actinomycin D, use of inducible promotors to specifically promote transient transcription, e.g.
  • c-fos serum-inducible promoter system and Tet-off regulatory promotor system and kinetic labelling techniques, e.g. pulse labelling, for example by 4-Thiouridine (4sU), 5-Ethynyluridine (EU) or 5'-Bromo-Uridine (BrU).
  • 4-Thiouridine (4sU) 4-Thiouridine
  • EU 5-Ethynyluridine
  • BrU 5'-Bromo-Uridine
  • a "stable mRNA" in the sense of the present invention has a slower mRNA decay compared to average mRNA, preferably assessed in vivo (or in vitro as defined above).
  • "average mRNA decay” may be assessed by investigating mRNA decay of a plurality of mRNA species, preferably 100, at least 300, at least 500, at least 1000, at least 2000, at least 3000, at least 4000, at least 5000, at least 6000, at least 7000, at least 8000, at least 9000, at least 1 0000, at least 1 1 000, at least 1 2000, at least 1 3000, at least 1 4000, at least 1 5000, at least 1 6000, at least 1 7000, at least 1 8000, at least 1 9000, at least 20000, at least 21 000, at least 22000, at least 23000, at least 24000, at least 25000, at least 26000, at least 27000, at least 28000, at least 29000, at least 30000 mRNA species.
  • mRNA species corresponds to a genomic transcription unit, i.e. usually to a gene.
  • different transcripts may occur, for example, due to mRNA processing.
  • an mRNA species may be represented by a spot on a microarray.
  • a microarray provides an advantageous tool to determine the amount of a plurality of mRNA species, e.g. at a certain point in time during mRNA decay.
  • RNA-seq e.g. RNA-seq, quantitative PCR etc.
  • a stable mRNA is characterized by an mRNA decay wherein the ratio of the amount of said mRNA at a second point in time to the amount of said mRNA at a first point in time is at least 0.5 (50%), at least 0.6 (60%), at least 0.7 (70%), at least 0.75 (75%), at least 0.8 (80%), at least 0.85 (85%), at least 0.9 (90%), or at least 0.95 (95%).
  • the second point in time is later in the decay process than the first point i n time.
  • the first point in time is selected such that only mRNA undergoing a decay process is considered, i.e. emerging mRNA - e.g. in ongoing transcription - is avoided.
  • the first point in time is preferably selected such that the incorporation of the label into mRNA is completed, i.e. no ongoing incorporation of the label into mRNA occurs.
  • the first point in time may be at least 10 min, at least 20 min, at least 30 min, at least 40 min, at least 50 min, at least 60 min, at least 70 min, at least 80 min, or at least 90 min after the end of the experimental labelling procedure, e.g. after the end of the incubation of cells with the label.
  • the first point in time may be preferably from 0 to 6 h after the stop of transcription (e.g. by a transcriptional inhibitor), stop of promotor induction in case of inducible promotors or after stop of pulse or label supply, e.g. after end of labelling.
  • the first point in time may be 30 min to 5 h, even more preferably 1 h to 4 h and particularly preferably about 3 h after the stop of transcription (e.g. by a transcriptional inhibitor), stop of promotor induction in case of inducible promotors or after stop of pulse or label supply, e.g. after end of labelling.
  • stop of transcription e.g. by a transcriptional inhibitor
  • stop of promotor induction in case of inducible promotors or after stop of pulse or label supply, e.g. after end of labelling.
  • the second point in time is selected as late as possible during the mRNA decay process.
  • the second point in time is preferably selected such that still a considerable amount of the plurality of mRNA species, preferably at least 1 0% of the mRNA species, is present in a detectable amount, i.e. in an amount higher than 0.
  • the second point in time is at least 5 h, at least 6 h, at least 7 h, at least 8 h, at least 9 h, at least 1 0 h, at least 1 1 h, at least 12 h, at least 13 h, at least 14 h, or at least 1 5 h after the end of transcription or the end of the experimental label ling procedure.
  • the time span between the first point in time and the second point in time is preferably as large as possible within the above described limits. Therefore, the time span between the first point in time and the second point in time is preferably at least 4 h, at least 5 h, at least 6 h, at least 7 h, at least 8 h, at least 9 h, at least 1 0 h, at least 1 1 h, or at least 12 h.
  • the at least one 3'-UTR element and/or the at least one 5'-UTR element in the artificial nucleic acid molecule according to the present invention is identified by a method for identifying a 3'-UTR element and/or a 5'-UTR element, which is derived from a stable mRNA, according to the present invention as described herein.
  • the at least one 3'-UTR element and/or the at least one 5'-UTR element in the artificial nucleic acid molecule according to the present invention is identified by a method for identifying a 3'-UTR element and/or a 5'-UTR element, which prolongs and/or increases protein production from an artificial nucleic acid molecule and which is derived from a stable mRNA, according to the present invention as described herein.
  • the at least one 3'-UTR element and/or the at least one 5'-UTR element in the artificial nucleic acid molecule according to the present invention comprises or consists of a nucleic acid sequence which is derived from the 3'-UTR and/or the 5'-UTR of a eukaryotic protein coding gene, preferably from the 3'-UTR and/or the 5'-UTR of a vertebrate protein coding gene, more preferably from the 3'-UTR and/or the 5'-UTR of a mammalian protein coding gene, e.g.
  • mouse and human protein coding genes even more preferably from the 3'-UTR and/or the 5'-UTR of a primate or rodent protein coding gene, in particular the 3'- UTR and/or the 5'-UTR of a human or murine protein coding gene.
  • the at least one 3'-UTR element in the artificial nucleic acid molecule according to the present invention comprises or consists of a nucleic acid sequence which is preferably derived from a naturally (in nature) occurring 3'-UTR
  • the at least one 5'-UTR element in the artificial nucleic acid molecule according to the present invention comprises or consists of a nucleic acid sequence which is preferably derived from a naturally (in nature) occurring 5'-UTR.
  • the at least one open reading frame is heterologous to the at least one 3'-UTR element and/or to the at least one 5'-UTR element.
  • heterologous in this context means that two sequence elements comprised by the artificial nucleic acid molecule, such as the open reading frame and the 3'-UTR element and/or the open reading frame and the 5'- UTR element, do not occur naturally (in nature) in this combination. They are typically recombinant.
  • the 3'-UTR element and/or the 5'-UTR element are/is derived from a different gene than the open reading frame.
  • the ORF may be derived from a different gene than the 3'-UTR element and/or to the at least one 5'-UTR element, e.g. encoding a different protein or the same protein but of a different species etc.
  • the open reading frame is derived from a gene which is distinct from the gene from which the 3'-UTR element and/or to the at least one 5'-UTR element is derived.
  • the ORF does not encode a human or plant (e.g., Arabidopsis) ribosomal protein, preferably does not encode human ribosomal protein S6 (RPS6), human ribosomal protein L36a-like (RPL36AL) or Arabidopsis ribosomal protein S1 6 (RPS1 6).
  • the open reading frame does not encode ribosomal protein S6 (RPS6), ribosomal protein L36a-like (RPL36AL) or ribosomal protein S1 6 (RPS1 6).
  • the open reading frame does not code for a reporter protein, e.g., selected from the group consisting of globin proteins (particularly beta- globin), luciferase protein, GFP proteins or variants thereof, for example, variants exhibiting at least 70% sequence identity to a globin protein, a luciferase protein, or a GFP protein.
  • a reporter protein e.g., selected from the group consisting of globin proteins (particularly beta- globin), luciferase protein, GFP proteins or variants thereof, for example, variants exhibiting at least 70% sequence identity to a globin protein, a luciferase protein, or a GFP protein.
  • the open reading frame does not code for a GFP protein.
  • the open reading frame does not encode a reporter gene or is not derived from a reporter gene, wherein the reporter gene is preferably not selected from group consisting of globin proteins (particularly beta-globin), luciferase protein, beta-glucuronidase (GUS) and GFP proteins or variants thereof, preferably not selected from EGFP, or variants of any of the above genes, typically exhibiting at least 70% sequence identity to any of these reporter genes, preferably a globin protein, a luciferase protein, or a GFP protein.
  • the reporter gene is preferably not selected from group consisting of globin proteins (particularly beta-globin), luciferase protein, beta-glucuronidase (GUS) and GFP proteins or variants thereof, preferably not selected from EGFP, or variants of any of the above genes, typically exhibiting at least 70% sequence identity to any of these reporter genes, preferably a globin protein, a luciferase protein, or a GFP protein.
  • the 3'-UTR element and/or the 5'-UTR element is heterologous to any other element comprised in the artificial nucleic acid as defined herein.
  • the artificial nucleic acid according to the invention comprises a 3'-UTR element from a given gene, it does preferably not comprise any other nucleic acid sequence, in particular no functional nucleic acid sequence (e.g. coding or regulatory sequence element) from the same gene, including its regulatory sequences at the 5' and 3' terminus of the gene's ORF.
  • the artificial nucleic acid according to the invention comprises a 5'-UTR element from a given gene, it does preferably not comprise any other nucleic acid sequence, in particular no functional nucleic acid sequence (e.g. coding or regulatory sequence element) from the same gene, including its regulatory sequences at the 5' and 3' terminus of the gene's ORF.
  • no functional nucleic acid sequence e.g. coding or regulatory sequence element
  • the artificial nucleic acid according to the present invention comprises at least one open reading frame, at least one 3'-UTR (element) and at least one 5'- UTR (element), whereby either the at least one 3'-UTR (element) is a 3'-UTR element according to the present invention and/or the at least one 5'-UTR (element) is a 5'-UTR element according to the present invention.
  • each of the at least one open reading frame, the at least one 3'-UTR (element) and the at least one 5'-UTR (element) are heterologous, i.e. neither the at least one 3'-UTR (element) and the at least one 5'-UTR (element) nor the the open reading frame and the 3'-UTR (element) or the 5'-UTR (element), respectively, are occurring naturally (in nature) in this combination.
  • the artificial nucleic acid molecule comprises an ORF, a 3'-UTR (element) and a 5'-UTR (element), all of which are heterologous to each other, e.g. they are recombinant as each of them is derived from different genes (and their 5' and 3' UTR's).
  • the 3'-UTR (element) is not derived from a 3'-UTR (element) of a viral gene or is not of viral origin.
  • the artificial nucleic acid molecule according to the present invention :
  • (i) comprises at least one 3'-UTR element and at least one 5'-UTR element, wherein preferably (each of) the at least one 3'-UTR element and at least one 5'-UTR element comprises or consists of a nucleic acid sequence which is derived from the 3'-UTR, or the 5'-UTR respectively, of a human or murine protein coding gene;
  • the at least one 3'-UTR element, the at least one 5'-UTR element and the at least one open reading frame of the artificial nucleic acid molecule according to the present invention are all heterologous to each other;
  • the at least one 3' UTR element is derived from a gene selected from the group consisting of: housekeeping genes, genes coding for a membrane protein, genes involved in cellular metabolism, genes involved in transcription, translation and replication processes, genes involved in protein modification and genes involved in cell division; and
  • the 3'UTR is not derived from a gene coding for a ribosomal protein or from the Fig4 gene.
  • Housekeeping genes are typically constitutive genes that are required for the maintenance of basic cellular function and that are typically expressed in all cells of an organism under normal and patho-physiological conditions. Although some housekeeping genes are expressed at relatively constant levels in most non-pathological situations, other housekeeping genes may vary depending on experimental conditions. Typically, housekeeping genes are expressed in at least 25 copies per cell and sometimes number in the thousands. Preferred examples of housekeeping genes in the context of the present invention are shown below in Table 10. Acc Definition Symbol 3 Length 1 " Abundance 0
  • NM_001402 Eukaryotic translation elongation factor 1 alpha 1 EEF1A1 387 20011
  • G protein Guanine nucleotide binding protein (G protein), beta polypeptide 2- GNB2L1 45 8910
  • NM_004046 ATP synthase H+ transporting, mitochondrial F1 complex, alpha ATP5A1 64 5434 subunit, isoform 1, cardiac muscle
  • NMJ321019 Myosin, light polypeptide 6, alkali, smooth muscle and non-muscle MYL6 209 3512
  • NM_002635 Solute carrier family 25 mitochondrial carrier; phosphate carrier
  • NM_001658 ADP-ribosylation factor 1 ARF1 1,194 2772
  • NM_000918 Procollagen-proline, 2-oxoglutarate 4-dioxygenase (proline 4- P4HB 868 2659 hydroxylase), beta polypeptide (protein disulfide isomerase; thyroid
  • transcription factor 4 tax-responsive enhancer element ATF4 85 2479
  • NM_001664 Ras homolog gene family member A RHOA 1,045 2426
  • NM_002117 Major histocompatibility complex class I, C HLA-C 434 2278
  • NM_004068 Adaptor-related protein complex 2, mu 1 subunit AP2M1 494 2230
  • NM_005594 Nascent-polypeptide-associated complex alpha polypeptide NACA 133 2075
  • NM_032378 Eukaryotic translation elongation factor 1 delta (guanine nucleotide EEF1D 76 2051 exchange protein)
  • NM_006325 RAN member RAS oncogene family RAN 892 1906
  • NM_003406 Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase YWHAZ 2,013 1892 activation protein, zeta polypeptide
  • NM_006826 Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase YWHAQ 1 ,310 1726 activation protein, Iheta polypeptide
  • NM_ 002140 Heterogeneous nuclear ribonucleoprotein K HNRPK 1 ,227 1725
  • NM_004404 Neural precursor cell expressed, developmenfally down-regulated 5 NEDD5 2,090 1654
  • NM_003753 Eukaryotic translation initiation factor 3, subunit 7 zeta, 66/67kDa EIF3S7 152 1509
  • NM_006908 Ras-related C3 botulinum toxin substrate 1 (rho family, small GTP RAC1 1,536 1437 binding protein Rad)
  • G protein Guanine nucleotide binding protein (G protein), alpha inhibiting GNAI2 512 1435 activity polypeptide 2
  • NM_014390 Staphylococcal nuclease domain containing 1 SND1 556 1422
  • NM_0 4225 Protein phosphatase 2 (formerly 2A), regulatory subunit A (PR 65), PPP2R1A 472 1391 alpha Isoform
  • NM_000454 Superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 SOD1 346 1323
  • NM_014610 Glucosidase, alpha; neutral AB GANAB 1,652 1280
  • NM_021983 Major histocompatibility complex, class II, DR beta 4 HLA- 313 1251
  • NM_013234 Eukaryotic translation initiation factor 3 subunit k elF3k 84 1251
  • NM_003757 Eukaryotic translation initiation factor 3, subunit 2 beta, 36kDa EIF3S2 408 1169
  • NMJ302080 Glutamic-oxaloacetic transaminase 2, mitochondrial (aspartate GOT2 1,039 1114 aminotransferase 2)
  • NM_005731 Actin related protein 23 complex, subunit 2, 34kDa ARPC2 448 1113 N _ 006445 PRP8 pre-mRNA processing factor 8 homo!og (yeast) PRPF8 173 1110
  • NM_003145 Signal sequence receptor, beta (iranslocon-associated protein beta) SSR2 492 1099
  • NM_001788 CDC10 cell division cycle 10 homolog (S. cerevisiae) CDC10 1,015 1094
  • NM_003754 Eukaryotic translation initiation factor 3, subunit 5 epsilon, 47kDa EIF3S5 152 1081
  • NM_004494 Hepatoma-derived growth factor (high-mobility group protein 1-like) HDGF 1,339 1069
  • NM_003752 Eukaryotic translation initiation factor 3, subunit 8, 10kDa EIF3S8 201 1060
  • G protein Guanine nucleotide binding protein (G protein), beta polypeptide 2 GNB2 386 1030
  • NM_007262 Parkinson disease autosomal recessive, early onset 7 PAR 7 253 1002
  • Table 10 List of abundant housekeeping genes (cf. WO 2007/068265 A1 , Table 1 ).
  • the above table was obtained from WO 2007/068265 A1 , Table 1 and is based on the list of the accession numbers as provided by Eisenberg, E. and E. Y. Levanon (2003): Human housekeeping genes are compact; Trends Genet. 1 9(7): 362-365.
  • the accession numbers were used as input for a PERL (Programmed Extraction Report Language) computer program that extracts EST data from the Unigene database.
  • the Unigene database was downloaded as a text file from the NCBI website.
  • the length of the 3'UTR was derived by computationally extracting the 3'UTR (Bakheet, T., Frevel, M., Williams, BR, and K.S. Khabar, 2001 .
  • ⁇ a> is a commonly used abbreviation of the gene product; ⁇ b> is the length of the 3 'UTR; ⁇ c> is the number of ESTs.
  • Preferred housekeeping genes include LDHA, NONO, PGK1 and PPIH.
  • a gene coding for a membrane protein typically refers to such a gene, which codes for a protein that interacts with biological membranes. In most genomes, about 20 - 30% of all genes encode membrane proteins. Common types of proteins include - in addition to membrane proteins - soluble globular proteins, fibrous proteins and disordered proteins. Thus, genes coding for a membrane protein are typically different from genes coding for soluble globular proteins, fibrous proteins or disordered proteins. Membrane proteins include membrane receptors, transport proteins, membrane enzymes and cell adhesion molecules.
  • a gene involved in cellular metabolism typically refers to such a gene, which codes for a protein involved in cellular metabolism, i.e. in the set of life-sustaining chemical transformations within the cells of living organisms.
  • genes involved in cellular metabolism are such genes, which code for enzymes catalyzing a reaction, which allow organisms to grow and reproduce, maintain their structures, and respond to their environments.
  • genes coding for proteins having structural or mechanical function such as those that form the cytoskeleton.
  • proteins involved in cellular metabolism include proteins involved in cell signalling, immune responses, cell adhesion, active transport across membranes and in the cell cycle.
  • Metabolism is usually divided into two categories: catabolism, the breaking down of organic matter by way of cellular respiration, and anabolism, the building up of components of cells such as proteins and nucleic acids.
  • a gene involved in transcription, translation and replication processes typically refers to such a gene, which codes for a protein involved in transcription, translation and replication processes.
  • replication refers preferably to replication of nucleic acids, e.g. DNA replication.
  • Preferred genes involved in transcription, translation and replication processes are genes coding for an enzyme involved in transcription, translation and/or (DNA) replication processes. Other preferred examples include genes coding for a transcription factor or for a translation factor. Ribosomal genes are other preferred examples of genes involved in transcription, translation and replication processes.
  • a gene involved in protein modification typically refers to such a gene, which codes for a protein involved in protein modification.
  • Preferred examples of such genes code for enzymes involved in protein modification, in particular in post-translational modification processes.
  • Preferred examples of enzymes involved in post-translational modification include (i) enzymes involved in the addition of hydrophobic groups, in particular for membrane localization, e.g. enzymes involed in myristoylation, palmitoylation, isoprenylation or prenylation, farnesylation, geranylation or in glypiation; (ii) enzymes involved in the addition of cofactors for enhanced enzymatic activity, e.g.
  • enzymes involved in lipoylation, in the attachment of a flavin moiety, in the attachment of heme C, in phosphopantetheinylation or in retinylidene Schiff base formation enzymes involved in the modification of translation factors, e.g. in diphtamide formation, in ethanolamine phosphoglycerol attachment or in hypusine formation; and (vi) enzymes involved in the addition of smaller chemical groups, e.g. acylation, such as acetylation and formylation, alkylation such as methylation, amide bond formation, such as amidation at C-terminus and amino acid addition (e.g.
  • a gene involved in cell division processes typical ly refers to such a gene, which codes for a protein involved in cell division.
  • Cell division is the process by which a parent cell divides into two or more daughter cells. Cell division usually occurs as part of a larger cell cycle.
  • a vegetative division whereby each daughter cell is genetically identical to the parent cel l (mitosis)
  • a reductive cell division whereby the number of chromosomes in the daughter cells is reduced by half, to produce haploid gametes (meiosis).
  • preferred gene involved in cell division processes code for a protein involved in mitosis and/or meiosis.
  • Fig4 is an abbreviation for Factor-Induced Gene.
  • the Fig4 gene codes for polyphosphoinositide phosphatase also known as phosphatidyl inositol 3,5-bisphosphate 5- phosphatase or SAC domain-containing protein 3 (Sac3).
  • the artificial nucleic acid molecule according to the present invention:
  • (i) comprises at least one 3'-UTR element and at least one 5'-UTR element, wherein preferably (each of) the at least one 3'-UTR element and at least one 5'-UTR element comprises or consists of a nucleic acid sequence which is derived from the 3'-UTR, or the 5'-UTR respectively, of a human or murine protein coding gene; (ii) the at least one 3'-UTR element, the at least one 5'-UTR element and the at least one open reading frame are all heterologous to each other;
  • the at least one 5'-UTR element is derived from a gene selected from the group consisting of: housekeeping genes, genes coding for a membrane protein, genes involved in cellular metabolism, genes involved in transcription, translation and replication processes, genes involved in protein modification and genes involved in cell division;
  • the 5'-UTR is preferably not a 5' TOP UTR
  • the 3'-UTR is preferably not derived from a gene coding for a ribosomal protein or for albumin or from the Fig4 gene.
  • (i) comprises at least one 3'-UTR element and at least one 5'-UTR element, wherein preferably (each of) the at least one 3'-UTR element and at least one 5'-UTR element comprises or consists of a nucleic acid sequence which is derived from the 3'-UTR, or the 5'-UTR respectively, of a human or murine protein coding gene;
  • the at least one 3'-UTR element, the at least one 5'-UTR element and the at least one open reading frame are all heterologous to each other;
  • the at least one 3' UTR element is derived from a human or a murine gene selected from the group consisting of: housekeeping genes, genes coding for a membrane protein, genes involved in cellular metabolism, genes involved in transcription, translation and replication processes, genes involved in protein modification and genes involved in cell division;
  • the 3'UTR is not derived from a gene coding for a ribosomal protein or for albumin or from the Fig4 gene;
  • the at least one 5'-UTR element is derived from a human or a murine gene selected from the group consisting of: housekeeping genes, genes coding for a membrane protein, genes involved in cellular metabolism, genes involved in transcription, translation and replication processes, genes involved in protein modification and genes involved in cell division; and
  • the 5'-UTR is not a 5' TOP UTR.
  • the 3'-UTR and the 5'-UTR are derived from a human or a murine housekeeping gene. It is also preferred that the 3'-UTR and the 5'-UTR are derived from a human or a muri ne gene coding for a membrane protein. It is also preferred that the 3'-UTR and the 5'-UTR are derived from a human or a murine gene involved in cellular metabolism. It is also preferred that the 3'-UTR and the 5'-UTR are derived from a human or a murine gene involved in transcription, translation and replication processes.
  • the 3'-UTR and the 5'-UTR are derived from a human or a murine gene involved in protein modification. It is also preferred that the 3'-UTR and the 5'-UTR are derived from a human or a murine gene involved in cell division.
  • the skilled person is aware that if (i) the 3'-UTR and the 5'-UTR are derived from genes belonging to the same gene class and (ii) the at least one 3'-UTR and the at least one 5'-UTR are heterologous to each other, that the the 3'-UTR and the 5'-UTR are not derived from the same gene, but from distinct genes belonging to the same gene class. Accordingly, it is preferred that the at least one 3'-UTR and the at least one 5'-UTR are derived from distinct genes belonging to the same gene class.
  • gene class refers to the classification of genes.
  • gene classes include (i) housekeeping genes, (ii) genes coding for a membrane protein, (iii) genes involved in cellular metabolism, (iv) genes involved in transcription, translation and replication processes, (v) genes involved in protein modification and (vi) genes involved in cell division.
  • housekeeping genes is one gene class
  • gene classes include (i) housekeeping genes, (ii) genes coding for a membrane protein, (iii) genes involved in cellular metabolism, (iv) genes involved in transcription, translation and replication processes, (v) genes involved in protein modification and (vi) genes involved in cell division.
  • housekeeping genes is one gene class
  • gene class is another gene class
  • gene class is a further gene class, etc.
  • the 3'-UTR and the 5'-UTR are derived from a human or a murine gene selected from the group consisting of: genes coding for a membrane protein, genes involved in cellular metabolism, genes involved in transcription, translation and replication processes, genes involved in protein modification and genes involved in cell division, wherein the 3'-UTR and the 5'-UTR are selected from distinct gene classes.
  • the at least one 3'-UTR element and/or to the at least one 5'-UTR element is functionally linked to the ORF.
  • the 3'-UTR element and/or to the at least one 5'-UTR element is associated with the ORF such that it may exert a function, such as an enhancing or stabilizing function on the expression of the encoded peptide or protein or a stabilizing function on the artificial nucleic acid molecule.
  • the ORF and the 3'-UTR element are associated in 5'- 3' direction and/or the 5'-UTR element and the ORF are associated in 5'->3' direction.
  • the artificial nucleic acid molecule comprises in general the structure 5'-[5'-UTR element]-(optional)-linker-ORF-(optional)- linker-[3'-UTR element]-3', wherein the artificial nucleic acid molecule may comprise only a 5'-UTR element and no 3'-UTR element, only a 3'-UTR element and no 5'-UTR element, or both, a 3'-UTR element and a 5'-UTR element.
  • the linker may be present or absent.
  • the linker may be one or more nucleotides, such as a stretch of 1 -50 or 1 -20 nucleotides, e.g., comprising or consisting of one or more restriction enzyme recognition sites (restriction sites).
  • the at least one 3'-UTR element and/or the at least one 5'-UTR element comprises or consists of a nucleic acid sequence which is derived from the 3'-UTR and/or the 5'-UTR of a transcript of a gene selected from the group consisting of CNAS (guanine nucleotide binding protein, alpha stimulating complex locus), MORN2 (MORN repeat containing 2), GSTM1 (glutathione S-transferase, mu 1 ), NDUFA1 (NADH dehydrogenase (ubiquinone) 1 alpha subcomplex), CBR2 (carbonyl reductase 2), MP68 (RIKEN cDNA 2010107E04 gene), NDUFA4 (NADH dehydrogenase (ubiquinone) 1 alpha subcomplex 4), Ybx1 (Y-Box binding protein 1 ), Ndufb8 (NADH dehydrogenase (ubiquinone) 1 beta subcomplex 8), CNTN1 (contact), CNAS
  • the at least one 3'-UTR element and/or the at least one 5'-UTR element comprises or consists of a nucleic acid sequence which is derived from the 3'-UTR and/or the 5'-UTR of a transcript of a gene selected from the group consisting of GNAS (guanine nucleotide binding protein, alpha stimulating complex locus), MORN2 (MORN repeat containing 2), NDUFA1 (NADH dehydrogenase (ubiquinone) 1 alpha subcomplex), CBR2 (carbonyl reductase 2), MP68 (RIKEN cDNA 2010107E04 gene), NDUFA4 (NADH dehydrogenase (ubiquinone) 1 alpha subcomplex 4), LTA4H, SLC38A6, DECR1, PIGK, FAM175A, PHYH, TBC1D19, PIGB, ALG6, CRYZ, BRP44L, ACADSB, SUPT3H, TMEM14A,
  • the at least one 3'-UTR element and/or the at least one 5'-UTR element comprises or consists of a nucleic acid sequence which is derived from the 3'-UTR and/or the 5'-UTR of a transcript of a gene selected from the group consisting of GNAS (guanine nucleotide binding protein, alpha stimulating complex locus), MORN2 (MORN repeat containing 2), GSTM1 (glutathione S-transferase, mu 1 ), NDUFA1 (NADH dehydrogenase (ubiquinone) 1 alpha subcomplex), CBR2 (carbonyl reductase 2), MP68 (RIKEN cDNA 2010107E04 gene), Ybx1 (Y-Box binding protein 1 ), Ndufb8 (NADH dehydrogenase (ubiquinone) 1 beta subcomplex 8), CNTN1 (contactin 1 ) and NDUFA4 (NADH dehydrogenase (ubiquinone) 1 alpha
  • the at least one 3'-UTR element and/or the at least one 5'-UTR element of the artificial nucleic acid molecule according to the present invention comprises or consists of a "functional fragment", a "functional variant” or a "functional fragment of a variant” of the 3'- UTR and/or the 5'-UTR of a transcript of a gene.
  • the at least one 3'-UTR element and/or the at least one 5'-UTR element comprises a nucleic acid sequence which is derived from the 3'-UTR and/or the 5'-UTR of a transcript of a human gene selected from the group consisting of GNAS (guanine nucleotide binding protein, alpha stimulating complex locus), MORN2 (MORN repeat containing 2), GSTM1 (glutathione S-transferase, mu 1), NDUFA1 (NADH dehydrogenase (ubiquinone) 1 alpha subcomplex), CBR2 (carbonyl reductase 2), MP68 (RIKEN cDNA 2010107E04 gene), NDUFA4 (NADH dehydrogenase (ubiquinone) 1 alpha subcomplex 4), LTA4H, SLC38A6, DECR1, PIGK, FAM175A, PHYH, TBC1D19, PIGB, ALG6, CRYZ, BRP44L, ACA
  • the at least one 3'-UTR element and/or the at least one 5'-UTR element comprises a nucleic acid sequence which is derived from the 3'-UTR and/or the 5'-UTR of a transcript of a murine gene selected from the group consisting of GNAS (guanine nucleotide binding protein, alpha stimulating complex locus), MORN2 (MORN repeat containing 2), GSTM1 (glutathione S-transferase, mu 1), NDUFA1 (NADH dehydrogenase (ubiquinone) 1 alpha subcomplex), CBR2 (carbonyl reductase 2), MP68 (RIKEN cDNA 2010107E04 gene), NDUFA4 (NADH dehydrogenase (ubiquinone) 1 alpha subcomplex 4), Atp5e, Gstm5, Uqcr11, Ifi27l2a, Anapc13, Atp5l, Tmsb10, Nenf, N
  • the at least one 3'-UTR element comprises a nucleic acid sequence which is derived from the 3'-UTR of a transcript of a gene selected from the group consisting of GNAS (guanine nucleotide binding protein, alpha stimulating complex locus), MORN2 (MORN repeat containing 2), GSTM1 (glutathione S-transferase, mu 1), NDUFA1 (NADH dehydrogenase (ubiquinone) 1 alpha subcomplex), CBR2 (carbonyl reductase 2), SLC38A6, DECR1, PIGK, FAM175A, PHYH, TBC1D19, PIGB, ALG6, CRYZ, BRP44L, ACADSB, TMEM14A, GRAMD1C, C11orf80, ANXA4, TBCK, IFI6, C2orf34, ALDH6A1, AGTPBP1, CCDC53, LRRC28, CCDC109B, PUS10, CCDC104, C
  • the at least one 3'-UTR element comprises or consists of a nucleic acid sequence which is derived from the 3'-UTR of a transcript of a gene selected from the group consisting of GNAS (guanine nucleotide binding protein, alpha stimulating complex locus), MORN2 (MORN repeat containing 2), GSTM1 (glutathione S- transferase, mu 1), NDUFA1 (NADH dehydrogenase (ubiquinone) 1 alpha subcomplex), CBR2 (carbonyl reductase 2), Ybx1 (Y-Box binding protein ⁇ ), Ndufb8 (NADH dehydrogenase (ubiquinone) 1 beta subcomplex 8), and CNTN1 (contactin 1).
  • GNAS gallate nucleotide binding protein, alpha stimulating complex locus
  • MORN2 MORN repeat containing 2
  • GSTM1 glutthione S- transferase, mu 1
  • NDUFA1 NADH dehydrogenase (ubi
  • the at least one 3'-UTR element comprises a nucleic acid sequence which is derived from the 3'-UTR of a transcript of a gene selected from the group consisting of GNAS (guanine nucleotide binding protein, alpha stimulating complex locus), MORN2 (MORN repeat containing 2), GSTM1 (glutathione S-transferase, mu 1), NDUFA1 (NADH dehydrogenase (ubiquinone) 1 alpha subcomplex), CBR2 (carbonyl reductase 2), SLC38A6, DECR1, PIGK, FAM175A, PHYH, TBC1D19, PIGB, ALG6, CRYZ, BRP44L, ACADSB, TMEM14A, GRAMD1C, C11orf80, ANXA4, TBCK, IFI6, C2orf34, ALDH6A1, AGTPBP1, CCDC53, LRRC28, CCDC109B, PUS10, CCDC
  • the at least one 3'-UTR element comprises or consists of a nucleic acid sequence which is derived from the 3'-UTR of a transcript of a gene selected from the group consisting of GNAS (guanine nucleotide binding protein, alpha stimulating complex locus), MORN2 (MORN repeat containing 2), GSTM1 (glutathione S- transferase, mu 1), NDUFA1 (NADH dehydrogenase (ubiquinone) 1 alpha subcomplex), CBR2 (carbonyl reductase 2), Ybx1 (Y-Box binding protein 1 ), Ndufb8 (NADH dehydrogenase (ubiquinone) 1 beta subcomplex 8), and CNTN1 (contactin 1).
  • the at least one 3'-UTR element comprises a nucleic acid sequence which is derived from the 3'-UTR of a transcript of a human gene selected from the group consisting of GNAS (guanine nucleotide binding protein, alpha stimulating complex locus), MORN2 (MORN repeat containing 2), GSTM1 (glutathione S-transferase, mu 1), NDUFA1 (NADH dehydrogenase (ubiquinone) 1 alpha subcomplex), CBR2 (carbonyl reductase 2), SLC38A6, DECR1, PIGK, FAM175A, PHYH, TBC1D19, PIGB, ALG6, CRYZ, BRP44L, ACADSB, TMEM14A, GRAMD1C, C11orf80, ANXA4, TBCK, IFI6, C2orf34, ALDH6A1, AGTPBPI, CCDC53, LRRC28, CCDC109B, PUS10, CCDC104
  • the at least one 3'-UTR element comprises a nucleic acid sequence which is derived from the 3'-UTR of a transcript of a murine gene selected from the group consisting of GNAS (guanine nucleotide binding protein, alpha stimulating complex locus), MORN2 (MORN repeat containing 2), GSTM1 (glutathione S- transferase, mu 1 ), NDUFA1 (NADH dehydrogenase (ubiquinone) 1 alpha subcomplex), CBR2 (carbonyl reductase 2), Ybx1 (Y-Box binding protein 1 ), Ndufb8 (NADH dehydrogenase (ubiquinone) 1 beta subcomplex 8), and CNTN1 (contactin 1 ), Ndufal , Atp5e, Gstm5, Uqcr1 1 , Ifi27l2a, Cbr2, Atp5l, Tmsbl O, Nenf, Atp5k,
  • the at least one 5'-UTR element comprises a nucleic acid sequence which is derived from the 5'-UTR of a transcript of a gene selected from the group consisting of MP68 (RIKEN cDNA 2010107E04 gene), NDUFA4 (NADH dehydrogenase (ubiquinone) 1 alpha subcomplex 4), LTA4H, DECR1 , PIGK, TBC1 D1 9, BRP44L, ACADSB, SUPT3H, TMEM14A, C9orf46, ANXA4, IFI6, C2orf34, ALDH6A1 , CCDC53, CCDC104, CASP1 , NDUFB6, BC DHB, BBS2, HERC5, FAM1 75A, NT5DC1 , RAB7A, AGA, TP 1 , MBNL3, MCCC2, CAT, ANAPC4, PHKB, ABCB7, GPD2, TMEM38B, NFU1 , LOC128322/
  • the at least one 5'-UTR element comprises or consists of a nucleic acid sequence which is derived from the 5'-UTR of a transcript of MP68 (RIKEN cDNA 2010107E04 gene) or NDUFA4 (NADH dehydrogenase (ubiquinone) 1 alpha subcomplex 4).
  • the at least one 5'-UTR element comprises a nucleic acid sequence which is derived from the 5'-UTR of a transcript of a gene selected from the group consisting of MP68 (RIKEN cDNA 2010107E04 gene), NDUFA4 (NADH dehydrogenase (ubiquinone) 1 alpha subcomplex 4), LTA4H, DECR1 , PIGK, TBC1 D1 9, BRP44L, ACADSB, SUPT3H, TMEM14A, C9orf46, ANXA4, IFI6, C2orf34, ALDH6A1 , CCDC53, CASP1 , NDUFB6, BCKDHB, BBS2, HERC5, FAM1 75A, NT5DC1 , RAB7A, AGA, TPK1 , MBNL3, MCCC2, CAT, ANAPC4, PHKB, ABCB7, GPD2, TMEM38B, NFU1 , LOC128322/
  • the at least one 5'-UTR element comprises or consists of a nucleic acid sequence which is derived from the 5'-UTR of a transcript of MP68 (RIKEN cDNA 2010107E04 gene) or NDUFA4 (NADH dehydrogenase (ubiquinone) 1 alpha subcomplex 4).
  • the at least one 5'-UTR element comprises a nucleic acid sequence which is derived from the 5'-UTR of a transcript of a human gene selected from the group consisting of MP68 (RIKEN cDNA 2010107E04 gene), NDUFA4 (NADH dehydrogenase (ubiquinone) 1 alpha subcomplex 4), LTA4H, DECR1 , PIGK, TBC1 D19, BRP44L, ACADSB, SUPT3H, TMEM14A, C9orf46, ANXA4, IFI6, C2orf34, ALDH6A1 , CCDC53, CCDC104, CASP1 , NDUFB6, BCKDHB, BBS2, HERC5, FAM1 75A, NT5DC1 , RAB7A, AGA, TPK1 , MBNL3, MCCC2, CAT, ANAPC4, PHKB, ABCB7, GPD2, TMEM38B, NFU1 , LOC1283
  • the at least one 5'-UTR element comprises a nucleic acid sequence which is derived from the 5'-UTR of a transcript of a murine gene selected from the group consisting of MP68 (RIKEN cDNA 2010107E04 gene), NDUFA4 (NADH dehydrogenase (ubiquinone) 1 alpha subcomplex 4), Ndufal , Atp5e, Gstm5, Cbr2, Anapcl 3, Ndufa7, Atp5k, 1 1 10008P14Rik, Cox4i1 , Ndufs6, Sec61 b, Snrpd2, Mgst3, Prdx4; Pgcp; Myeov2; Ndufa4; Ndufs5; Gstml ; Atp5o; Tspo; Taldol ; Blod sl ; and Hexa; preferably, the at least one 5'-UTR element comprises or consists of a nucle
  • nucleic acid sequence which is derived from the 3'-UTR and/or the 5'-UTR of a of a transcript of a gene preferably refers to a nucleic acid sequence which is based on the 3'-UTR sequence and/or on the 5'-UTR sequence of a transcript of a gene or a fragment or part thereof, preferably a naturally occurring gene or a fragment or part thereof.
  • This phrase includes sequences corresponding to the entire 3'-UTR sequence and/or the entire 5'-UTR sequence, i.e.
  • a fragment of a 3'-UTR and/or a 5'-UTR of a transcript of a gene consists of a continuous stretch of nucleotides corresponding to a continuous stretch of nucleotides in the full-length 3'-UTR and/or 5'-UTR of a transcript of a gene, which represents at least 5%, 10%, 20%, preferably at least 30%, more preferably at least 40%, more preferably at least 50%, even more preferably at least 60%, even more preferably at least 70%, even more preferably at least 80%, and most preferably at least 90% of the full- length 3'-UTR and/or 5'-UTR of a transcript of a gene.
  • Such a fragment in the sense of the present invention, is preferably a functional fragment as described herein.
  • the fragment retains a regulatory function for the translation of the ORF linked to the 3'-UTR and/or 5'-UTR or fragment thereof.
  • variant of the 3'-UTR and/or variant of the 5'-UTR of a of a transcript of a gene refers to a variant of the 3'-UTR and/or 5'-UTR of a transcript of a naturally occurring gene, preferably to a variant of the 3'-UTR and/or 5'-UTR of a transcript of a vertebrate gene, more preferably to a variant of the 3'-UTR and/or 5'-UTR of a transcript of a mammalian gene, even more preferably to a variant of the 3'-UTR and/or 5'-UTR of a transcript of a primate gene, in particular a human gene as described above.
  • Such variant may be a modified 3'-UTR and/or 5'-UTR of a transcript of a gene.
  • a variant 3'-UTR and/or a variant of the 5'-UTR may exhibit one or more nucleotide deletions, insertions, additions and/or substitutions compared to the naturally occurring 3'-UTR and/or 5'-UTR from which the variant is derived.
  • a variant of a 3'-UTR and/or variant of the 5'-UTR of a of a transcript of a gene is at least 40%, preferably at least 50%, more preferably at least 60%, more preferably at least 70%, even more preferably at least 80%, even more preferably at least 90%, most preferably at least 95% identical to the naturally occurring 3'-UTR and/or 5'-UTR the variant is derived from.
  • the variant is a functional variant as described herein.
  • a nucleic acid sequence which is derived from a variant of the 3'-UTR and/or from a variant of the 5'-UTR of a of a transcript of a gene preferably refers to a nucleic acid sequence which is based on a variant of the 3'-UTR sequence and/or the 5'-UTR of a transcript of a gene or on a fragment or part thereof as described above.
  • This phrase includes sequences corresponding to the entire sequence of the variant of the 3'-UTR and/or the 5'-UTR of a transcript of a gene, i.e.
  • the full length variant 3'-UTR sequence and/or the full length variant 5'-UTR sequence of a transcript of a gene and sequences corresponding to a fragment of the variant 3'-UTR sequence and/or a fragment of the variant 5'-UTR sequence of a transcript of a gene.
  • a fragment of a variant of the 3'-UTR and/or the 5'-UTR of a transcript of a gene consists of a continuous stretch of nucleotides corresponding to a continuous stretch of nucleotides in the full-length variant of the 3'-UTR and/or the 5'-UTR of a transcript of a gene, which represents at least 20%, preferably at least 30%, more preferably at least 40%, more preferably at least 50%, even more preferably at least 60%, even more preferably at least 70%, even more preferably at least 80%, and most preferably at least 90% of the full- length variant of the 3'-UTR and/or the 5'-UTR of a transcript of a gene.
  • Such a fragment of a variant is preferably a functional fragment of a variant as described herein.
  • the terms "functional variant”, “functional fragment”, and “functional fragment of a variant” in the context of the present invention, mean that the fragment of the 3'-UTR and/or the 5'-UTR, the variant of the 3'-UTR and/or the 5'-UTR, or the fragment of a variant of the 3'-UTR and/or the 5'-UTR of a transcript of a gene fulfils at least one, preferably more than one function of the naturally occurring 3'-UTR and/or 5'-UTR of a transcript of a gene of which the variant, the fragment, or the fragment of a variant is derived.
  • Such function may be, for example, stabilizing mRNA and/or enhancing, stabilizing and/or prolonging protein production from an mRNA and/or increasing protein expression or total protein production from an mRNA, preferably in a mammalian cell, such as in a human cell.
  • the function of the 3'-UTR and/or the 5'-UTR concerns the translation of the protein encoded by the ORF. More preferably, the function comprises enhancing translation efficiency of the ORF linked to the 3'-UTR and/or the 5'-UTR or fragment or variant thereof.
  • the variant, the fragment, and the variant fragment in the context of the present invention fulfil the function of stabilizing an mRNA, preferably in a mammalian cell, such as a human cell, compared to an mRNA comprising a reference 3'- UTR and/or a reference 5'-UTR or lacking a 3'-UTR and/or a 5'-UTR, and/or the function of enhancing, stabilizing and/or prolonging protein production from an mRNA, preferably in a mammalian cell, such as in a human cell, compared to an mRNA comprising a reference 3'- UTR and/or a reference 5'-UTR or lacking a 3'-UTR and/or a 5'-UTR, and/or the function of increasing protein production from an mRNA, preferably in a mammalian cell, such as in a human cell, compared to an mRNA comprising a reference 3'-UTR and/or a reference 5'- UTR or lacking
  • a reference 3'-UTR and/or a reference 5'-UTR may be, for example, a 3'-UTR and/or a 5'-UTR naturally occurring in combination with the ORF.
  • a functional variant, a functional fragment, or a functional variant fragment of a 3'-UTR and/or a 5'-UTR of a transcript of a gene preferably does not have a substantially diminishing effect on the efficiency of translation of the mRNA which comprises such variant, fragment, or variant fragment of a 3'-UTR and/or a 5'-UTR compared to the wild type 3'-UTR and/or the wild-type 5'-UTR from which the variant, the fragment, or the variant fragment is derived.
  • a particularly preferred function of a "functional fragment", a “functional variant” or a “functional fragment of a variant” of the 3'-UTR and/or the 5'-UTR of a transcript of a gene in the context of the present invention is the enhancement, stabilization and/or prolongation of protein production by expression of an mRNA carrying the functional fragment, functional variant or functional fragment of a variant as described above.
  • the efficiency of the one or more functions exerted by the functional variant, the functional fragment, or the functional variant fragment is increased by at least 5%, more preferably by at least 10%, more preferably by at least 20%, more preferably by at least 30%, more preferably by at least 40%, more preferably by at least 50%, more preferably by at least 60%, even more preferably by at least 70%, even more preferably by at least 80%, most preferably by at least 90% with respect to the mRNA and/or protein production stabilizing efficiency and/or the protein production increasing efficiency exhibited by the naturally occurring 3'-UTR and/or 5'-UTR of a transcript of a gene from which the variant, the fragment or the variant fragment is derived.
  • a fragment of the 3'-UTR and/or of the 5'-UTR of a transcript of a gene or of a variant of the 3'-UTR and/or of the 5'-UTR of a transcript of a gene preferably exhibits a length of at least about 3 nucleotides, preferably of at least about 5 nucleotides, more preferably of at least about 10, 15, 20, 25 or 30 nucleotides, even more preferably of at least about 50 nucleotides, most preferably of at least about 70 nucleotides.
  • such fragment of the 3'-UTR and/or of the 5'-UTR of a transcript of a gene or of a variant of the 3'-UTR and/or of the 5'-UTR of a transcript of a gene is a functional fragment as described above.
  • the 3'-UTR and/or the 5'-UTR of a transcript of a gene or a fragment or variant thereof exhibits a length of between 3 and about 500 nucleotides, preferably of between 5 and about 150 nucleotides, more preferably of between 10 and 100 nucleotides, even more preferably of between 15 and 90, most preferably of between 20 and 70.
  • the 5'-UTR element and/or the 3'-UTR element is characterized by less than 500, 400, 300, 200, 1 50 or less than 100 nucleotides.
  • the at least one 3'-UTR element comprises or consists of a nucleic acid sequence which has an identity of at least about 1 , 2, 3, 4, 5, 10, 15, 20, 30 or 40%, preferably of at least about 50%, preferably of at least about 60%, preferably of at least about 70%, more preferably of at least about 80%, more preferably of at least about 90%, even more preferably of at least about 95%, even more preferably of at least about 99% to a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 1 to 24 and SEQ ID NOs: 49 to 31 8 or the corresponding RNA sequence, respectively, or wherein the at least one 3'-UTR element comprises or consists of a fragment of a nucleic acid sequence which has an identity of at least about 40%, preferably of at least about 50%, preferably of at least about 60%, preferably of at least about 70%, more preferably of at least about 80%, more preferably of at least about 90%, even more preferably of at least about 95%, even more preferably of

Abstract

The invention relates to an artificial nucleic acid molecule comprising at least one open reading frame and at least one 3'-untranslated region element (3'-UTR element) and/or at least one 5'-untranslated region element (5'-UTR element), wherein the at least one 3'-UTR element and/or the at least one 5'-UTR element prolongs and/or increases protein production from said artificial nucleic acid molecule and wherein the at least one 3'-UTR element and/or the at least one 5'-UTR element is derived from a stable mRNA. The invention further relates to the use of such an artificial nucleic acid molecule in gene therapy and/or genetic vaccination. Furthermore, methods for identifying a 3'-UTR element and/or a 5'-UTR derived from a stable mRNA element are disclosed.

Description

Applicant:
CureVac AG
ARTIFICIAL NUCLEIC ACID MOLECULES The present invention was made with support from the Government under Agreement No. HR001 1 -1 1 -3-0001 awarded by DARPA. The Government has certain rights in the invention.This application claims the priority of international patent application PCT/EP2014/003479 filed on December 30, 2014, which is incorporated herein by reference. The invention relates to artificial nucleic acid molecules comprising an open reading frame, a 3'-untranslated region element (3'-UTR element) and/or a 5'-untranslated region element (5'-UTR element) and optionally a poly(A) sequence and/or a polyadenylation-signal. The invention relates further to a vector comprising a 3'-UTR element and/or a 5'-UTR element, to a cell comprising the artificial nucleic acid molecule or the vector, to a pharmaceutical composition comprising the artificial nucleic acid molecule or the vector and to a kit comprising the artificial nucleic acid molecule, the vector and/or the pharmaceutical composition, preferably for use in the field of gene therapy and/or genetic vaccination. Gene therapy and genetic vaccination belong to the most promising and quickly developing methods of modern medicine. They may provide highly specific and individual options for therapy of a large variety of diseases. Particularly, inherited genetic diseases but also autoimmune diseases, cancerous or tumour-related diseases as well as inflammatory diseases may be the subject of such treatment approaches. Also, it is envisaged to prevent early onset of such diseases by these approaches.
The main conceptual rational behind gene therapy is appropriate modulation of impaired gene expression associated with pathological conditions of specific diseases. Pathologically altered gene expression may result in lack or overproduction of essential gene products, for example, signalling factors such as hormones, housekeeping factors, metabolic enzymes, structural proteins or the like. Altered gene expression may not only be due to mis-regulation of transcription and/or translation, but also due to mutations within the ORF coding for a particular protein. Pathological mutations may be caused by e.g. chromosomal aberration, or by more specific mutations, such as point or frame-shift-mutations, all of them resulting in l imited functionality and, potentially, total loss of function of the gene product. However, misregulation of transcription or translation may also occur, if mutations affect genes encoding proteins which are involved in the transcriptional or translational machinery of the cell. Such mutations may lead to pathological up- or down-regulation of genes which are - as such - functional. Genes encoding gene products which exert such regulating functions, may be, e.g., transcription factors, signal receptors, messenger proteins or the like. However, loss of function of such genes encodi ng regulatory proteins may, under certain circumstances, be reversed by artificial introduction of other factors acting further downstream of the impaired gene product. Such gene defects may also be compensated by gene therapy via substitution of the affected gene itself.
Genetic vaccination al lows evoking a desired immune response to selected antigens, such as characteristic components of bacterial surfaces, viral particles, tumour antigens or the like. Generally, vaccination is one of the pivotal achievements of modern medicine. However, effective vaccines are currently avai lable only for a limited number of diseases. Accordingly, infections that are not preventable by vaccination still affect mil lions of people every year.
Commonly, vaccines may be subdivided into "first", "second" and "third" generation vaccines. "First generation" vaccines are, typically, whole-organism vaccines. They are based on either live and attenuated or killed pathogens, e.g. viruses, bacteria or the like. The major drawback of live and attenuated vaccines is the risk for a reversion to life-threatening variants. Thus, although attenuated, such pathogens may sti ll intrinsically bear unpredictable risks. Killed pathogens may not be as effective as desired for generating a specific immune response. In order to minimize these risks, "second generation" vaccines were developed. These are, typically, subunit vaccines, consisting of defined antigens or recombinant protein components which are derived from pathogens. Genetic vaccines, i.e. vaccines for genetic vaccination, are usually understood as "third generation" vaccines. They are typically composed of genetically engineered nucleic acid molecules which allow expression of peptide or protein (antigen) fragments characteristic for a pathogen or a tumor antigen in vivo. Genetic vaccines are expressed upon administration to a patient after uptake by target cells. Expression of the administered nucleic acids results in production of the encoded proteins. In the event these proteins are recognized as foreign by the patient's immune system, an immune response is triggered. As can be seen from the above, both methods, gene therapy and genetic vaccination, are essentially based on the administration of nucleic acid molecules to a patient and subsequent transcription and/or translation of the encoded genetic information. Alternatively, genetic vaccination or gene therapy may also comprise methods which include isolation of specific body cells from a patient to be treated, subsequent in ex vivo transfection of such cells, and re-administration of the treated cells to the patient.
DNA as well as RNA may be used as nucleic acid molecules for administration in the context of gene therapy or genetic vaccination. DNA is known to be relatively stable and easy to handle. However, the use of DNA bears the risk of undesired insertion of the administered DNA-fragments into the patient's genome potentially resulting mutagenic events such as in loss of function of the impaired genes. As a further risk, the undesired generation of anti-DNA antibodies has emerged. Another drawback is the limited expression level of the encoded peptide or protein that is achievable upon DNA administration because the DNA must enter the nucleus in order to be transcribed before the resulting mRNA can be translated. Among other reasons, the expression level of the administered DNA will be dependent on the presence of specific transcription factors which regulate DNA transcription. In the absence of such factors, DNA transcription will not yield satisfying amounts of RNA. As a result, the level of translated peptide or protein obtained is limited.
By using RNA instead of DNA for gene therapy or genetic vaccination, the risk of undesired genomic integration and generation of anti-DNA antibodies is minimized or avoided. However, RNA is considered to be a rather unstable molecular species which may readily be degraded by ubiquitous RNAses.
Typically, RNA degradation contributes to the regulation of the RNA half-life time. That effect was considered and proven to fine tune the regulation of eukaryotic gene expression (Friedel et a/., 2009. Conserved principles of mammalian transcriptional regulation revealed by RNA half-life, Nucleic Acid Research 37(1 7): 1 -12). Accordingly, each naturally occurring mRNA has its individual half-life depending on the gene from which the mRNA is derived and in which cell type it is expressed. It contributes to the regulation of the expression level of this gene. Unstable RNAs are important to realize transient gene expression at distinct points in time. However, long-lived RNAs may be associated with accumulation of distinct proteins or continuous expression of genes. In vivo, the half-life of mRNAs may also be dependent on environmental factors, such as hormonal treatment, as has been shown, e.g., for insulin-like growth factor I, actin, and albumin mRNA Gohnson et a/., Newly synthesized RNA: Simultaneous measurement in intact cel ls of transcription rates and RNA stability of insulinl ike growth factor I, actin, and albumin in growth hormone-stimulated hepatocytes, Proc. Natl. Acad. Sci., Vol. 88, pp. 5287-5291 , 1 991 ).
For gene therapy and genetic vaccination, usually stable RNA is desired. This is, on the one hand, due to the fact that it is usually desired that the product encoded by the RNA sequence accumulates in vivo. On the other hand, the RNA has to maintain its structural and functional integrity when prepared for a suitable dosage form, in the course of its storage, and when administered. Thus, efforts were made to provide stable RNA molecules for gene therapy or genetic vaccination in order to prevent them from being subject to early degradation or decay.
It has been reported that the G/C-content of nucleic acid molecules may influence their stabi lity. Thus, nucleic acids comprising an increased amount of guanine (G) and/or cytosine (C) residues may be functionally more stable than nucleic acids containing a large amount of adenine (A) and thymine (T) or uracil (U) nucleotides. In this context, WO02/098443 provides a pharmaceutical composition containing an mRNA that is stabilised by sequence modifications in the coding region. Such a sequence modification takes advantage of the degeneracy of the genetic code. Accordingly, codons which contain a less favourable combination of nucleotides (less favourable in terms of RNA stability) may be substituted by alternative codons without altering the encoded amino acid sequence. This method of RNA stabi lization is limited by the provisions of the specific nucleotide sequence of each single RNA molecule which is not allowed to leave the space of the desired amino acid sequence. Also, that approach is restricted to coding regions of the RNA.
As an alternative option for mRNA stabilisation, it has been found that naturally occurring eukaryotic mRNA molecules contain characteristic stabi lising elements. For example, they may comprise so-called untranslated regions (UTR) at their 5'-end (5'-UTR) and/or at their 3'- end (3'-UTR) as well as other structural features, such as a 5'-cap structure or a 3'-poly(A) tai l. Both, 5'-UTR and 3'-UTR are typically transcribed from the genomic DNA and are, thus, an element of the premature mRNA. Characteristic structural features of mature mRNA, such as the 5'-cap and the 3'-poly(A) tail (also called poly(A) tail or poly(A) sequence) are usually added to the transcribed (premature) mRNA during mRNA processing. A 3'-poly(A) tail is typically a monotonous sequence stretch of adenosine nucleotides added to the 3 '-end of the transcribed mRNA. It may comprise up to about 400 adenosine nucleotides. It was found that the length of such a 3'-poly(A) tail is a potentially critical element for the stability of the individual mRNA. Also, it was shown that the 3'-UTR of a-globin mRNA may be an important factor for the well-known stability of a-globin mRNA (Rodgers eta/., Regulated a-globin mRNA decay is a cytoplasmic event proceeding through 3'-to-5' exosome-dependent decapping, RNA, 8, pp. 1 526-1537, 2002). The 3'-UTR of α-globin mRNA is apparently involved in the formation of a specific ribonucleoprotein-complex, the a-complex, whose presence correlates with mRNA stability in vitro (Wang et al., An mRNA stability complex functions with poly(A)-binding protein to stabilize mRNA in vitro, Molecular and Cellular biology, Vol 19, No. 7, July 1999, p. 4552-4560).
An interesting regulatory function has further been demonstrated for the UTRs in ribosomal protein mRNAs: while the 5'-UTR of ribosomal protein mRNAs controls the growth- associated translation of the mRNA, the stringency of that regulation is conferred by the respective 3'-UTR in ribosomal protein mRNAs (Ledda et al., Effect of the 3'-UTR length on the translational regulation of 5'-terminal oligopyrimidine mRNAs, Gene, Vol. 344, 2005, p. 213-220). This mechanism contributes to the specific expression pattern of ribosomal proteins, which are typically transcribed in a constant manner so that some ribosomal protein mRNAs such as ribosomal protein S9 or ribosomal protein L32 are referred to as housekeeping genes (Janovick-Guretzky et al., Housekeeping Gene Expression in Bovine Liver is Affected by Physiological State, Feed Intake, and Dietary Treatment, J. Dairy Sci., Vol. 90, 2007, p. 2246-2252). The growth-associated expression pattern of ribosomal proteins is thus mainly due to regulation on the level of translation. Irrespective of factors influencing mRNA stability, effective translation of the administered nucleic acid molecules by the target cells or tissue is crucial for any approach using nucleic acid molecules for gene therapy or genetic vaccination. As can be seen from the examples cited above, along with the regulation of stability, also translation of the majority of mRNAs is regulated by structural features like UTRs, 5'-cap and 3'-poly(A) tail. In this context, it has been reported that the length of the poly(A) tail may play an important role for translational efficiency as well. Stabilizing 3'-elements, however, may also have an attenuating effect on translation.
It is the object of the invention to provide nucleic acid molecules which may be suitable for application in gene therapy and/or genetic vaccination. Particularly, it is the object of the invention to provide an mRNA species which is stabi lized against preterm degradation or decay without exhibiting significant functional loss in translational efficiency. It is also an object of the invention to provide an artificial nucleic acid molecule, preferably an mRNA, which is characterized by enhanced expression of the respective protein encoded by said nucleic acid molecule. One particular object of the invention is the provision of an mRNA, wherein the efficiency of translation of the respective encoded protein is enhanced. Another object of the present i nvention is to provide nucleic acid molecules coding for such a superior mRNA species which may be amenable for use in gene therapy and/or genetic vaccination. It is a further object of the present invention to provide a pharmaceutical composition for use in gene therapy and/or genetic vaccination. In summary, it is the object of the present invention to provide improved nucleic acid species which overcome the above discussed disadvantages of the prior art by a cost-effective and straight-forward approach.
The object underlying the present invention is solved by the claimed subject matter.
For the sake of clarity and readability the following definitions are provided. Any technical feature mentioned for these definitions may be read on each and every embodiment of the invention. Additional definitions and explanations may be specifically provided in the context of these embodiments.
Adaptive immune response: The adaptive immune response is typically understood to be an antigen-specific response of the immune system. Antigen specificity allows for the generation of responses that are tai lored to specific pathogens or pathogen-infected cells. The ability to mount these tailored responses is usually maintained in the body by "memory cells". Should a pathogen infect the body more than once, these specific memory cel ls are used to quickly eliminate it. In this context, the first step of an adaptive immune response is the activation of naive antigen-specific T cel ls or different immune cells able to induce an antigen-specific immune response by antigen-presenting cells. This occurs in the lymphoid tissues and organs through which naive T cel ls are constantly passing. The three cell types that may serve as antigen-presenting cells are dendritic cells, macrophages, and B cells. Each of these cells has a distinct function in eliciting immune responses. Dendritic cells may take up antigens by phagocytosis and macropinocytosis and may become stimulated by contact with e.g. a foreign antigen to migrate to the local lymphoid tissue, where they differentiate into mature dendritic cells. Macrophages ingest particulate antigens such as bacteria and are induced by infectious agents or other appropriate stimuli to express MHC molecules. The unique ability of B cells to bind and internalize soluble protein antigens via their receptors may also be important to induce T cel ls. MHC-molecules are, typically, responsible for presentation of an antigen to T-cells. Therein, presenting the antigen on MHC molecules leads to activation of T cells which induces their proliferation and differentiation into armed effector T cells. The most important function of effector T cells is the killing of infected cells by CD8+ cytotoxic T cells and the activation of macrophages by Th1 cells which together make up cell-mediated immunity, and the activation of B cells by both Th2 and Th1 cells to produce different classes of antibody, thus driving the humoral immune response. T cells recognize an antigen by their T cell receptors which do not recognize and bind the antigen directly, but instead recognize short peptide fragments e.g. of pathogen-derived protein antigens, e.g. so-called epitopes, which are bound to MHC molecules on the surfaces of other cells.
Adaptive immune system: The adaptive immune system is essentially dedicated to eliminate or prevent pathogenic growth. It typically regulates the adaptive immune response by providing the vertebrate immune system with the abi lity to recognize and remember specific pathogens (to generate immunity), and to mount stronger attacks each time the pathogen is encountered. The system is highly adaptable because of somatic hypermutation (a process of accelerated somatic mutations), and V(D)J recombination (an irreversible genetic recombination of antigen receptor gene segments). This mechanism allows a small number of genes to generate a vast number of different antigen receptors, which are then uniquely expressed on each individual lymphocyte. Because the gene rearrangement leads to an irreversible change in the DNA of each cel l, all of the progeny (offspring) of such a cell will then inherit genes encoding the same receptor specificity, including the Memory B cells and Memory T cells that are the keys to long-lived specific immunity.
Adjuvant/adjuvant component: An adjuvant or an adjuvant component in the broadest sense is typically a pharmacological and/or immunological agent that may modify, e.g. enhance, the effect of other agents, such as a drug or vaccine. It is to be interpreted in a broad sense and refers to a broad spectrum of substances. Typical ly, these substances are able to increase the immunogenicity of antigens. For example, adjuvants may be recognized by the innate immune systems and, e.g., may elicit an innate immune response. "Adjuvants" typically do not elicit an adaptive immune response. Insofar, "adjuvants" do not qualify as antigens. Their mode of action is disti nct from the effects triggered by antigens resulting in an adaptive immune response.
Antigen: In the context of the present i nvention "antigen" refers typically to a substance which may be recognized by the immune system, preferably by the adaptive immune system, and is capable of triggering an antigen-specific immune response, e.g. by formation of antibodies and/or antigen-specific T cells as part of an adaptive immune response. Typically, an antigen may be or may comprise a peptide or protein which may be presented by the MHC to T-cells. In the sense of the present invention an antigen may be the product of translation of a provided nucleic acid molecule, preferably an mRNA as defined herein. In this context, also fragments, variants and derivatives of peptides and proteins comprising at least one epitope are understood as antigens. In the context of the present invention, tumour antigens and pathogenic antigens as defined herein are particularly preferred.
Artificial nucleic acid molecule: An artificial nucleic acid molecule may typically be understood to be a nucleic acid molecule, e.g. a DNA or an RNA, that does not occur naturally. In other words, an artificial nucleic acid molecule may be understood as a non- natural nucleic acid molecule. Such nucleic acid molecule may be non-natural due to its individual sequence (which does not occur naturally) and/or due to other modifications, e.g. structural modifications of nucleotides which do not occur natural ly. An artificial nucleic acid molecule may be a DNA molecule, an RNA molecule or a hybrid-molecule comprising DNA and RNA portions. Typically, artificial nucleic acid molecules may be designed and/or generated by genetic engineering methods to correspond to a desired artificial sequence of nucleotides (heterologous sequence). In this context an artificial sequence is usually a sequence that may not occur naturally, i.e. it differs from the wild type sequence by at least one nucleotide. The term "wild type" may be understood as a sequence occurring in nature. Further, the term "artificial nucleic acid molecule" is not restricted to mean "one single molecule" but is, typically, understood to comprise an ensemble of identical molecules. Accordingly, it may relate to a plurality of identical molecules contained in an aliquot. Bicistronic RNA, multicistronic RNA: A bicistronic or multicistronic RNA is typically an RNA, preferably an mRNA, that typically may have two (bicistronic) or more (multicistronic) open reading frames (ORF). An open reading frame in this context is a sequence of codons that is translatable into a peptide or protein. Carrier / polymeric carrier: A carrier in the context of the invention may typically be a compound that facilitates transport and/or complexation of another compound (cargo). A polymeric carrier is typical ly a carrier that is formed of a polymer. A carrier may be associated to its cargo by covalent or non-covalent interaction. A carrier may transport nucleic acids, e.g. RNA or DNA, to the target cells. The carrier may - for some embodiments - be a cationic component.
Cationic component: The term "cationic component" typically refers to a charged molecule, which is positively charged (cation) at a pH value typically from 1 to 9, preferably at a pH value of or below 9 (e.g. from 5 to 9), of or below 8 (e.g. from 5 to 8), of or below 7 (e.g. from 5 to 7), most preferably at a physiological pH, e.g. from 7.3 to 7.4. Accordingly, a cationic component may be any positively charged compound or polymer, preferably a cationic peptide or protein which is positively charged under physiological conditions, particularly under physiological conditions In vivo. A "cationic peptide or protein" may contain at least one positively charged amino acid, or more than one positively charged amino acid, e.g. selected from Arg, His, Lys or Orn. Accordingly, "polycationic" components are also within the scope exhibiting more than one positive charge under the conditions given.
5'-cap: A 5'-cap is an entity, typically a modified nucleotide entity, which generally "caps" the 5'-end of a mature mRNA. A 5 '-cap may typically be formed by a modified nucleotide, particularly by a derivative of a guanine nucleotide. Preferably, the 5'-cap is linked to the 5'- terminus via a 5'-5'-triphosphate linkage. A 5'-cap may be methylated, e.g. m7GpppN, wherein N is the terminal 5' nucleotide of the nucleic acid carrying the 5'-cap, typically the 5'-end of an RNA. Further examples of 5'cap structures include glyceryl, inverted deoxy abasic residue (moiety), 4', 5' methylene nucleotide, l -(beta-D-erythrofuranosyl) nucleotide, 4'-thio nucleotide, carbocyclic nucleotide, 1 ,5-anhydrohexitol nucleotide, L-nucleotides, alpha-nucleotide, modified base nucleotide, threo-pentofuranosyl nucleotide, acyclic 3',4'- seco nucleotide, acyclic 3,4-dihydroxybutyl nucleotide, acyclic 3,5 dihydroxypentyl nucleotide, 3'-3'-i nverted nucleotide moiety, 3 '-3 '-inverted abasic moiety, 3'-2'-inverted nucleotide moiety, 3 '-2 '-inverted abasic moiety, 1 ,4-butanediol phosphate, 3'- phosphoramidate, hexylphosphate, aminohexyl phosphate, 3'-phosphate, 3'phosphorothioate, phosphorodithioate, or bridging or non-bridging methylphosphonate moiety. Cel lular immunity/cellular immune response: Cel lular immunity relates typical ly to the activation of macrophages, natural killer cells (NK), antigen-specific cytotoxic T-lymphocytes, and the release of various cytokines in response to an antigen. In more general terms, cellular immunity is not based on antibodies, but on the activation of cel ls of the immune system. Typically, a cellular immune response may be characterized e.g. by activating antigen- specific cytotoxic T-lymphocytes that are able to induce apoptosis in cells, e.g. specific immune cells like dendritic cel ls or other cells, displaying epitopes of foreign antigens on their surface. Such cells may be virus-infected or infected with intracellular bacteria, or cancer cells displaying tumor antigens. Further characteristics may be activation of macrophages and natural killer cells, enabling them to destroy pathogens and stimulation of cel ls to secrete a variety of cytokines that influence the function of other cells involved in adaptive immune responses and innate immune responses.
The term "derived from" as used throughout the present specification in the context of a nucleic acid, i.e. for a nucleic acid "derived from" (another) nucleic acid, means that the nucleic acid, which is derived from (another) nucleic acid, shares at least 50%, preferably at least 60%, preferably at least 70%, more preferably at least 75%, more preferably at least 80%, more preferably at least 85%, even more preferably at least 90%, even more preferably at least 95%, and particularly preferably at least 98% sequence identity with the nucleic acid from which it is derived. The skilled person is aware that sequence identity is typically calculated for the same types of nucleic acids, i.e. for DNA sequences or for RNA sequences. Thus, it is understood, if a DNA is "derived from" an RNA or if an RNA is "derived from" a DNA, in a first step the RNA sequence is converted into the corresponding DNA sequence (in particular by replacing the uracils (U) by thymidines (T) throughout the sequence) or, vice versa, the DNA sequence is converted into the corresponding RNA sequence (in particular by replacing the thymidines (T) by uracils (U) throughout the sequence). Thereafter, the sequence identity of the DNA sequences or the sequence identity of the RNA sequences is determined. Preferably, a nucleic acid "derived from" a nucleic acid also refers to nucleic acid, which is modified in comparison to the nucleic acid from which it is derived, e.g. in order to increase RNA stability even further and/or to prolong and/or increase protein production. It goes without saying that such modifications are preferred, which do not impair RNA stability, e.g. in comparison to the nucleic acid from which it is derived.
DNA: DNA is the usual abbreviation for deoxy-ribonucleic acid. It is a nucleic acid molecule, i.e. a polymer consisting of nucleotides. These nucleotides are usually deoxy- adenosine-monophosphate, deoxy-thymidine-monophosphate, deoxy-guanosine- monophosphate and deoxy-cytidine-monophosphate monomers which are - by themselves - composed of a sugar moiety (deoxyribose), a base moiety and a phosphate moiety, and polymerise by a characteristic backbone structure. The backbone structure is, typically, formed by phosphodiester bonds between the sugar moiety of the nucleotide, i.e. deoxyribose, of a first and a phosphate moiety of a second, adjacent monomer. The specific order of the monomers, i.e. the order of the bases linked to the sugar/phosphate-backbone, is called the DNA sequence. DNA may be single stranded or double stranded. In the double stranded form, the nucleotides of the first strand typically hybridize with the nucleotides of the second strand, e.g. by A/T-base-pairing and G/C-base-pairing.
Epitope: (also called "antigen determinant") can be distinguished in T cell epitopes and
B cell epitopes. T cell epitopes or parts of the proteins in the context of the present invention may comprise fragments preferably having a length of about 6 to about 20 or even more amino acids, e.g. fragments as processed and presented by MHC class I molecules, preferably having a length of about 8 to about 10 amino acids, e.g. 8, 9, or 10, (or even 1 1 , or 12 amino acids), or fragments as processed and presented by MHC class II molecules, preferably having a length of about 13 or more amino acids, e.g. 13, 14, 15, 16, 1 7, 1 8, 19, 20 or even more amino acids, wherein these fragments may be selected from any part of the amino acid sequence. These fragments are typically recognized by T cells in form of a complex consisting of the peptide fragment and an MHC molecule, i.e. the fragments are typically not recognized in their native form. B cell epitopes are typically fragments located on the outer surface of (native) protein or peptide antigens as defined herein, preferably having 5 to 15 amino acids, more preferably having 5 to 12 amino acids, even more preferably having 6 to 9 amino acids, which may be recognized by antibodies, i.e. in their native form. Such epitopes of proteins or peptides may furthermore be selected from any of the herein mentioned variants of such proteins or peptides. In this context antigenic determinants can be conformationai or discontinuous epitopes which are composed of segments of the proteins or peptides as defined herein that are discontinuous in the amino acid sequence of the proteins or peptides as defined herein but are brought together in the three-dimensional structure or continuous or linear epitopes which are composed of a single polypeptide chain. Fragment of a sequence: A fragment of a sequence may typically be a shorter portion of a full-length sequence of e.g. a nucleic acid molecule or an amino acid sequence. Accordingly, a fragment, typically, consists of a sequence that is identical to the corresponding stretch within the full-length sequence. A preferred fragment of a sequence in the context of the present invention, consists of a continuous stretch of entities, such as nucleotides or amino acids corresponding to a continuous stretch of entities in the molecule the fragment is derived from, which represents at least 5%, 10%, 20%, preferably at least 30%, more preferably at least 40%, more preferably at least 50%, even more preferably at least 60%, even more preferably at least 70%, and most preferably at least 80% of the total (i.e. full-length) molecule from which the fragment is derived. G/C modified: A G/C-modified nucleic acid may typically be a nucleic acid, preferably an artificial nucleic acid molecule as defined herein, based on a modified wild-type sequence comprising a preferably increased number of guanosine and/or cytosine nucleotides as compared to the wild-type sequence. Such an increased number may be generated by substitution of codons containing adenosine or thymidine nucleotides by codons containing guanosine or cytosine nucleotides. If the enriched G/C content occurs in a coding region of DNA or RNA, it makes use of the degeneracy of the genetic code. Accordingly, the codon substitutions preferably do not alterthe encoded amino acid residues, but exclusively increase the G/C content of the nucleic acid molecule.
Gene therapy: Gene therapy may typically be understood to mean a treatment of a patient's body or isolated elements of a patient's body, for example isolated tissues/cells, by nucleic acids encoding a peptide or protein. It typically may comprise at least one of the steps of a) administration of a nucleic acid, preferably an artificial nucleic acid molecule as defined herein, directly to the patient - by whatever administration route - or in vitro to isolated cells/tissues of the patient, which results in transfection of the patient's cells either in vivo/ex vivo or in vitro; b) transcription and/or translation of the introduced nucleic acid molecule; and optionally c) re-administration of isolated, transfected cells to the patient, if the nucleic acid has not been administered directly to the patient.
Genetic vaccination: Genetic vaccination may typically be understood to be vaccination by administration of a nucleic acid molecule encoding an antigen or an immunogen or fragments thereof. The nucleic acid molecule may be administered to a subject's body or to isolated cells of a subject. Upon transfection of certain cel ls of the body or upon transfection of the isolated cells, the antigen or immunogen may be expressed by those cells and subsequently presented to the immune system, eliciting an adaptive, i.e. antigen-specific immune response. Accordingly, genetic vaccination typically comprises at least one of the steps of a) administration of a nucleic acid, preferably an artificial nucleic acid molecule as defined herein, to a subject, preferably a patient, or to isolated cells of a subject, preferably a patient, which usual ly results in transfection of the subject's cells either in vivo or in vitro; b) transcription and/or translation of the introduced nucleic acid molecule; and optionally c) re- administration of isolated, transfected cells to the subject, preferably the patient, if the nucleic acid has not been administered directly to the patient.
Heterologous sequence: Two sequences are typically understood to be 'heterologous' if they are not derivable from the same gene. I.e., although heterologous sequences may be derivable from the same organism, they naturally (in nature) do not occur in the same nucleic acid molecule, such as in the same mRNA. Humoral immunity/humoral immune response: Humoral immunity refers typically to antibody production and optionally to accessory processes accompanying antibody production. A humoral immune response may be typically characterized, e.g., by Th2 activation and cytokine production, germinal center formation and isotype switching, affi nity maturation and memory cell generation. Humoral immunity also typically may refer to the effector functions of antibodies, which include pathogen and toxin neutralization, classical complement activation, and opsonin promotion of phagocytosis and pathogen elimination.
Immunogen: In the context of the present invention an immunogen may be typically understood to be a compound that is able to stimulate an immune response. Preferably, an immunogen is a peptide, polypeptide, or protein. In a particularly preferred embodiment, an immunogen in the sense of the present invention is the product of translation of a provided nucleic acid molecule, preferably an artificial nucleic acid molecule as defined herein. Typically, an immunogen elicits at least an adaptive immune response.
Immunostimulatory composition: In the context of the invention, an immunostimulatory composition may be typically understood to be a composition containing at least one component which is able to induce an immune response or from which a component which is able to induce an immune response is derivable. Such immune response may be preferably an innate immune response or a combination of an adaptive and an innate immune response. Preferably, an immunostimulatory composition in the context of the invention contains at least one artificial nucleic acid molecule, more preferably an RNA, for example an mRNA molecule. The immunostimulatory component, such as the mRNA may be complexed with a suitable carrier. Thus, the immunostimulatory composition may comprise an mRN A/carrier- complex. Furthermore, the immunostimulatory composition may comprise an adjuvant and/or a suitable vehicle for the immunostimulatory component, such as the mRNA.
Immune response: An immune response may typically be a specific reaction of the adaptive immune system to a particular antigen (so called specific or adaptive immune response) or an unspecific reaction of the innate immune system (so called unspecific or innate immune response), or a combination thereof.
Immune system: The immune system may protect organisms from infection. If a pathogen succeeds in passing a physical barrier of an organism and enters this organism, the innate immune system provides an immediate, but non-specific response. If pathogens evade this innate response, vertebrates possess a second layer of protection, the adaptive immune system. Here, the immune system adapts its response during an infection to improve its recognition of the pathogen. This improved response is then retained after the pathogen has been eliminated, in the form of an immunological memory, and allows the adaptive immune system to mount faster and stronger attacks each time this pathogen is encountered. According to this, the immune system comprises the innate and the adaptive immune system. Each of these two parts typically contains so called humoral and cellular components.
Immunostimulatory RNA: An immunostimulatory RNA (isRNA) in the context of the invention may typically be an RNA that is able to induce an innate immune response. It usually does not have an open reading frame and thus does not provide a peptide-antigen or immunogen but elicits an immune response e.g. by binding to a specific kind of Toll-like- receptor (TLR) or other suitable receptors. However, of course also mRNAs having an open reading frame and coding for a peptide/protein may induce an innate immune response and, thus, may be immunostimulatory RNAs.
Innate immune system: The innate immune system, also known as non-specific (or unspecific) immune system, typically comprises the cells and mechanisms that defend the host from infection by other organisms in a non-specific manner. This means that the cells of the innate system may recognize and respond to pathogens in a generic way, but unlike the adaptive immune system, it does not confer long-lasting or protective immunity to the host. The innate immune system may be, e.g., activated by ligands of Toll-like receptors (TLRs) or other auxiliary substances such as lipopolysaccharides, TNF-alpha, CD40 ligand, or cytokines, monokines, lymphokines, interleukins or chemokines, IL-1 , IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-1 1 , IL-12, IL-13, IL-14, IL-15, IL-1 6, IL-1 7, IL-18, IL-19, IL-20, IL-21 , IL- 22, IL-23, IL-24, IL-25, IL-26, IL-27, IL-28, IL-29, IL-30, IL-31 , IL-32, IL-33, IFN-alpha, IFN- beta, IFN-gamma, GM-CSF, G-CSF, M-CSF, LT-beta, TNF-alpha, growth factors, and hGH, a ligand of human Toll-like receptor TLR1 , TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9, TLR10, a ligand of murine Toll-like receptor TLR1 , TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9, TLR10, TLR1 1 , TLR12 or TLR13, a ligand of a NOD-like receptor, a ligand of a RIG-I like receptor, an immunostimulatory nucleic acid, an immunostimulatory RNA (isRNA), a CpG-DNA, an antibacterial agent, or an anti-viral agent. The pharmaceutical composition according to the present invention may comprise one or more such substances. Typically, a response of the innate immune system includes recruiting immune cells to sites of infection, through the production of chemical factors, including specialized chemical mediators, called cytokines; activation of the complement cascade; identification and removal of foreign substances present in organs, tissues, the blood and lymph, by specialized white blood cells; activation of the adaptive immune system; and/or acting as a physical and chemical barrier to infectious agents.
Cloning site: A cloning site is typically understood to be a segment of a nucleic acid molecule, which is suitable for insertion of a nucleic acid sequence, e.g., a nucleic acid sequence comprising an open reading frame. Insertion may be performed by any molecular biological method known to the one skilled in the art, e.g. by restriction and ligation. A cloning site typically comprises one or more restriction enzyme recognition sites (restriction sites). These one or more restrictions sites may be recognized by restriction enzymes which cleave the DNA at these sites. A cloning site which comprises more than one restriction site may also be termed a multiple cloning site (MCS) or a polylinker.
Nucleic acid molecule: A nucleic acid molecule is a molecule comprising, preferably consisting of nucleic acid components. The term nucleic acid molecule preferably refers to DNA or RNA molecules. It is preferably used synonymous with the term "polynucleotide". Preferably, a nucleic acid molecule is a polymer comprising or consisting of nucleotide monomers which are covalently linked to each other by phosphodiester-bonds of a sugar/phosphate-backbone. The term "nucleic acid molecule" also encompasses modified nucleic acid molecules, such as base-modified, sugar-modified or backbone-modified etc. DNA or RNA molecules.
Open reading frame: An open reading frame (ORF) in the context of the invention may typically be a sequence of several nucleotide triplets which may be translated into a peptide or protein. An open reading frame preferably contains a start codon, i.e. a combination of three subsequent nucleotides coding usually for the amino acid methionine (ATG), at its 5'- end and a subsequent region which usually exhibits a length which is a multiple of 3 nucleotides. An ORF is preferably terminated by a stop-codon (e.g., TAA, TAG, TGA). Typically, this is the only stop-codon of the open reading frame. Thus, an open reading frame in the context of the present invention is preferably a nucleotide sequence, consisting of a number of nucleotides that may be divided by three, which starts with a start codon (e.g. ATG) and which preferably terminates with a stop codon (e.g., TAA, TGA, or TAG). The open reading frame may be isolated or it may be incorporated in a longer nucleic acid sequence, for example in a vector or an mRNA. An open reading frame may also be termed "protein coding region".
Peptide: A peptide or polypeptide is typically a polymer of amino acid monomers, linked by peptide bonds. It typically contains less than 50 monomer units. Nevertheless, the term peptide is not a disclaimer for molecules having more than 50 monomer units. Long peptides are also called polypeptides, typically having between 50 and 600 monomeric units.
Pharmaceutically effective amount: A pharmaceutically effective amount in the context of the invention is typically understood to be an amount that is sufficient to induce a pharmaceutical effect, such as an immune response, altering a pathological level of an expressed peptide or protein, or substituting a lacking gene product, e.g., in case of a pathological situation. Protein A protein typically comprises one or more peptides or polypeptides. A protein is typically folded into 3-dimensional form, which may be required for to protein to exert its biological function.
Poly(A) sequence: A poly(A) sequence, also called poly(A) tail or 3'-poly(A) tail, is typically understood to be a sequence of adenosine nucleotides, e.g., of up to about 400 adenosine nucleotides, e.g. from about 20 to about 400, preferably from about 50 to about 400, more preferably from about 50 to about 300, even more preferably from about 50 to about 250, most preferably from about 60 to about 250 adenosine nucleotides. A poly(A) sequence is typically located at the 3'end of an mRNA. In the context of the present invention, a poly(A) sequence may be located within an mRNA or any other nucleic acid molecule, such as, e.g., in a vector, for example, in a vector serving as template for the generation of an RNA, preferably an mRNA, e.g., by transcription of the vector.
Polyadenylation: Polyadenylation is typically understood to be the addition of a poly(A) sequence to a nucleic acid molecule, such as an RNA molecule, e.g. to a premature mRNA. Polyadenylation may be induced by a so called polyadenylation signal. This signal is preferably located within a stretch of nucleotides at the 3'-end of a nucleic acid molecule, such as an RNA molecule, to be polyadenylated. A polyadenylation signal typically comprises a hexamer consisting of adenine and uracil/thymine nucleotides, preferably the hexamer sequence AAUAAA. Other sequences, preferably hexamer sequences, are also conceivable. Polyadenylation typically occurs during processing of a pre-mRNA (also called premature- mRNA). Typically, RNA maturation (from pre-mRNA to mature mRNA) comprises the step of polyadenylation.
Restriction site: A restriction site, also termed restriction enzyme recognition site, is a nucleotide sequence recognized by a restriction enzyme. A restriction site is typically a short, preferably palindromic nucleotide sequence, e.g. a sequence comprising 4 to 8 nucleotides. A restriction site is preferably specifically recognized by a restriction enzyme. The restriction enzyme typically cleaves a nucleotide sequence comprising a restriction site at this site. In a double-stranded nucleotide sequence, such as a double-stranded DNA sequence, the restriction enzyme typically cuts both strands of the nucleotide sequence. RNA, mRNA: RNA is the usual abbreviation for ribonucleic-acid. It is a nucleic acid molecule, i.e. a polymer consisting of nucleotides. These nucleotides are usually adenosine- monophosphate, uridine-monophosphate, guanosine-monophosphate and cytidine- monophosphate monomers which are connected to each other along a so-called backbone. The backbone is formed by phosphodiester bonds between the sugar, i.e. ribose, of a first and a phosphate moiety of a second, adjacent monomer. The specific succession of the monomers is called the RNA-sequence. Usually RNA may be obtainable by transcription of a DNA- sequence, e.g., inside a cell. In eukaryotic cells, transcription is typically performed inside the nucleus or the mitochondria. Typically, transcription of DNA usually results in the so- called premature RNA which has to be processed into so-called messenger-RNA, usually abbreviated as mRNA. Processing of the premature RNA, e.g. in eukaryotic organisms, comprises a variety of different posttranscriptional-modifications such as splicing, 5'-capping, polyadenylation, export from the nucleus or the mitochondria and the like. The sum of these processes is also called maturation of RNA. The mature messenger RNA usually provides the nucleotide sequence that may be translated into an amino-acid sequence of a particular peptide or protein. Typically, a mature mRNA comprises a 5'-cap, a 5'-UTR, an open reading frame, a 3'-UTR and a poly(A) sequence. Aside from messenger RNA, several non-coding types of RNA exist which may be involved in regulation of transcription and/or translation.
Sequence of a nucleic acid molecule: The sequence of a nucleic acid molecule is typically understood to be the particular and individual order, i.e. the succession of its nucleotides. The sequence of a protein or peptide is typically understood to be the order, i.e. the succession of its amino acids.
Sequence identity: Two or more sequences are identical if they exhibit the same length and order of nucleotides or amino acids. The percentage of identity typically describes the extent to which two sequences are identical, i.e. it typically describes the percentage of nucleotides that correspond in their sequence position with identical nucleotides of a reference-sequence. For determination of the degree of identity, the sequences to be compared are considered to exhibit the same length, i.e. the length of the longest sequence of the sequences to be compared. This means that a first sequence consisting of 8 nucleotides is 80% identical to a second sequence consisting of 10 nucleotides comprising the first sequence. In other words, in the context of the present invention, identity of sequences preferably relates to the percentage of nucleotides of a sequence which have the same position in two or more sequences having the same length. Gaps are usually regarded as non-identical positions, irrespective of their actual position in an alignment. Stabilized nucleic acid molecule: A stabilized nucleic acid molecule is a nucleic acid molecule, preferably a DNA or RNA molecule that is modified such, that it is more stable to disintegration or degradation, e.g., by environmental factors or enzymatic digest, such as by an exo- or endonuclease degradation, than the nucleic acid molecule without the modification. Preferably, a stabilized nucleic acid molecule in the context of the present invention is stabilized in a cell, such as a prokaryotic or eukaryotic cell, preferably in a mammalian cell, such as a human cell. The stabilization effect may also be exerted outside of cells, e.g. in a buffer solution etc., for example, in a manufacturing process for a pharmaceutical composition comprising the stabilized nucleic acid molecule. Transfection: The term "transfection" refers to the introduction of nucleic acid molecules, such as DNA or RNA (e.g. mRNA) molecules, into cells, preferably into eukaryotic cells. In the context of the present invention, the term "transfection" encompasses any method known to the skilled person for introducing nucleic acid molecules into cells, preferably into eukaryotic cells, such as into mammalian cells. Such methods encompass, for example, electroporation, lipofection, e.g. based on cationic lipids and/or liposomes, calcium phosphate precipitation, nanoparticle based transfection, virus based transfection, or transfection based on cationic polymers, such as DEAE-dextran or polyethylenimine etc. Preferably, the introduction is non-viral.
Vaccine: A vaccine is typically understood to be a prophylactic or therapeutic material providing at least one antigen, preferably an immunogen. The antigen or immunogen may be derived from any material that is suitable for vaccination. For example, the antigen or immunogen may be derived from a pathogen, such as from bacteria or virus particles etc., or from a tumor or cancerous tissue. The antigen or immunogen stimulates the body's adaptive immune system to provide an adaptive immune response. Vector: The term "vector" refers to a nucleic acid molecule, preferably to an artificial nucleic acid molecule. A vector in the context of the present invention is suitable for incorporating or harboring a desired nucleic acid sequence, such as a nucleic acid sequence comprising an open reading frame. Such vectors may be storage vectors, expression vectors, cloning vectors, transfer vectors etc. A storage vector is a vector which allows the convenient storage of a nucleic acid molecule, for example, of an mRNA molecule. Thus, the vector may comprise a sequence corresponding, e.g., to a desired mRNA sequence or a part thereof, such as a sequence corresponding to the open reading frame and the 3'-UTR and/or the 5'-UTR of an mRNA. An expression vector may be used for production of expression products such as RNA, e.g. mRNA, or peptides, polypeptides or proteins. For example, an expression vector may comprise sequences needed for transcription of a sequence stretch of the vector, such as a promoter sequence, e.g. an RNA polymerase promoter sequence. A cloning vector is typically a vector that contains a cloning site, which may be used to incorporate nucleic acid sequences into the vector. A cloning vector may be, e.g., a plasmid vector or a bacteriophage vector. A transfer vector may be a vector which is suitable for transferring nucleic acid molecules into cells or organisms, for example, viral vectors. A vector in the context of the present invention may be, e.g., an RNA vector or a DNA vector. Preferably, a vector is a DNA molecule. Preferably, a vector in the sense of the present application comprises a cloning site, a selection marker, such as an antibiotic resistance factor, and a sequence suitable for multiplication of the vector, such as an origin of replication. Preferably, a vector in the context of the present application is a plasmid vector. Vehicle: A vehicle is typically understood to be a material that is suitable for storing, transporting, and/or administering a compound, such as a pharmaceutically active compound. For example, it may be a physiologically acceptable liquid which is suitable for storing, transporting, and/or administering a pharmaceutically active compound.
3'-untranslated region (3'-UTR): Generally, the term "3'-UTR" refers to a part of the artificial nucleic acid molecule, which is located 3' (i.e. "downstream") of an open reading frame and which is not translated into protein. Typically, a 3'-UTR is the part of an mRNA which is located between the protein coding region (open reading frame (ORF) or coding sequence (CDS)) and the poly(A) sequence of the mRNA. In the context of the invention, the term 3'- UTR may also comprise elements, which are not encoded in the template, from which an RNA is transcribed, but which are added after transcription during maturation, e.g. a poly(A) sequence. A 3'-UTR of the mRNA is not translated into an amino acid sequence. The 3'-UTR sequence is generally encoded by the gene which is transcribed into the respective mRNA during the gene expression process. The genomic sequence is first transcribed into pre-mature mRNA, which comprises optional introns. The pre-mature mRNA is then further processed into mature mRNA in a maturation process. This maturation process comprises the steps of 5'capping, splicing the pre-mature mRNA to excize optional introns and modifications of the 3'-end, such as polyadenylation of the 3'-end of the pre-mature mRNA and optional endo-/ or exonuclease cleavages etc.. In the context of the present invention, a 3'-UTR corresponds to the sequence of a mature mRNA which is located between the the stop codon of the protein coding region, preferably immediately 3' to the stop codon of the protein coding region, and the poly(A) sequence of the mRNA. The term "corresponds to" means that the 3'-UTR sequence may be an RNA sequence, such as in the mRNA sequence used for defining the 3'- UTR sequence, or a DNA sequence which corresponds to such RNA sequence. In the context of the present invention, the term "a 3'-UTR of a gene", is the sequence which corresponds to the 3'-UTR of the mature mRNA derived from this gene, i.e. the mRNA obtained by transcription of the gene and maturation of the pre-mature mRNA. The term "3'-UTR of a gene" encompasses the DNA sequence and the RNA sequence (both sense and antisense strand and both mature and immature) of the 3'-UTR. Preferably, the 3'UTRs have a length of more than 20, 30, 40 or 50 nucleotides.
5 '-untranslated region (5'-UTR): Generally, the term "5'-UTR" refers to a part of the artificial nucleic acid molecule, which is located 5' (i.e. "upstream") of an open reading frame and which is not translated into protein. A 5'-UTR is typically understood to be a particular section of messenger RNA (mRNA), which is located 5' of the open reading frame of the mRNA. Typically, the 5'-UTR starts with the transcriptional start site and ends one nucleotide before the start codon of the open reading frame. Preferably, the 5'UTRs have a length of more than 20, 30, 40 or 50 nucleotides. The 5'-UTR may comprise elements for controlling gene expression, also called regulatory elements. Such regulatory elements may be, for example, ribosomal binding sites. The 5'-UTR may be posttranscriptionally modified, for example by addition of a 5'-CAP. A 5'-UTR of the mRNA is not translated into an amino acid sequence. The 5'-UTR sequence is generally encoded by the gene which is transcribed into the respective mRNA during the gene expression process. The genomic sequence is first transcribed into pre-mature mRNA, which comprises optional introns. The pre-mature mRNA is then further processed into mature mRNA in a maturation process. This maturation process comprises the steps of 5'capping, splicing the pre-mature mRNA to excize optional introns and modifications of the 3'-end, such as polyadenylation of the 3'-end of the pre-mature mRNA and optional endo-/ or exonuclease cleavages etc.. In the context of the present invention, a 5'-UTR corresponds to the sequence of a mature mRNA which is located between the start codon and, for example, the 5'-CAP. Preferably, the 5'-UTR corresponds to the sequence which extends from a nucleotide located 3' to the 5 '-CAP, more preferably from the nucleotide located immediately 3' to the 5 '-CAP, to a nucleotide located 5' to the start codon of the protein coding region, preferably to the nucleotide located immediately 5' to the start codon of the protein coding region. The nucleotide located immediately 3' to the 5'- CAP of a mature mRNA typically corresponds to the transcriptional start site. The term "corresponds to" means that the 5'-UTR sequence may be an RNA sequence, such as in the mRNA sequence used for defining the 5'-UTR sequence, or a DNA sequence which corresponds to such RNA sequence. In the context of the present invention, the term "a 5'- UTR of a gene" is the sequence which corresponds to the 5'-UTR of the mature mRNA derived from this gene, i.e. the mRNA obtained by transcription of the gene and maturation of the pre-mature mRNA. The term "5'-UTR of a gene" encompasses the DNA sequence and the RNA sequence (both sense and antisense strand and both mature and immature) of the 5'- UTR.
5 'Terminal Oligopyrimidine Tract (TOP): The 5'terminal oligopyrimidine tract (TOP) is typically a stretch of pyrimidine nucleotides located in the 5' terminal region of a nucleic acid molecule, such as the 5' terminal region of certain mRNA molecules or the 5' terminal region of a functional entity, e.g. the transcribed region, of certain genes. The sequence starts with a cytidine, which usually corresponds to the transcriptional start site, and is followed by a stretch of usually about 3 to 30 pyrimidine nucleotides. For example, the TOP may comprise 3, 4, 5, 6, 7, 8, 9, 10, 1 1 , 12, 13, 14, 1 5, 1 6, 1 7, 18, 19, 20, 21 , 22, 23, 24, 25, 26, 27, 28, 29, 30 or even more nucleotides. The pyrimidine stretch and thus the 5' TOP ends one nucleotide 5' to the first purine nucleotide located downstream of the TOP. Messenger RNA that contains a 5'terminal oligopyrimidine tract is often referred to as TOP mRNA. Accordingly, genes that provide such messenger RNAs are referred to as TOP genes. TOP sequences have, for example, been found in genes and mRNAs encoding peptide elongation factors and ribosomal proteins.
TOP motif: In the context of the present invention, a TOP motif is a nucleic acid sequence which corresponds to a 5'TOP as defined above. Thus, a TOP motif in the context of the present invention is preferably a stretch of pyrimidine nucleotides having a length of 3-30 nucleotides. Preferably, the TOP-motif consists of at least 3 pyrimidine nucleotides, preferably at least 4 pyrimidine nucleotides, preferably at least 5 pyrimidine nucleotides, more preferably at least 6 nucleotides, more preferably at least 7 nucleotides, most preferably at least 8 pyrimidine nucleotides, wherein the stretch of pyrimidine nucleotides preferably starts at its 5'end with a cytosine nucleotide. In TOP genes and TOP mRNAs, the TOP-motif preferably starts at its 5'end with the transcriptional start site and ends one nucleotide 5' to the first purin residue in said gene or mRNA. A TOP motif in the sense of the present invention is preferably located at the 5'end of a sequence which represents a 5'-UTR or at the 5'end of a sequence which codes for a 5'-UTR. Thus, preferably, a stretch of 3 or more pyrimidine nucleotides is called "TOP motif" in the sense of the present invention if this stretch is located at the 5'end of a respective sequence, such as the artificial nucleic acid molecule, the 5'-UTR element of the artificial nucleic acid molecule, or the nucleic acid sequence which is derived from the 5'-UTR of a TOP gene as described herein. In other words, a stretch of 3 or more pyrimidine nucleotides, which is not located at the 5'-end of a 5'-UTR or a 5'-UTR element but anywhere within a 5'-UTR or a 5'-UTR element, is preferably not referred to as "TOP motif".
TOP gene: TOP genes are typically characterised by the presence of a 5' terminal oligopyrimidine tract. Furthermore, most TOP genes are characterized by a growth-associated translational regulation. However, also TOP genes with a tissue specific translational regulation are known. As defined above, the 5'-UTR of a TOP gene corresponds to the sequence of a 5'-UTR of a mature mRNA derived from a TOP gene, which preferably extends from the nucleotide located 3' to the 5'-CAP to the nucleotide located 5' to the start codon. A 5'-UTR of a TOP gene typically does not comprise any start codons, preferably no upstream AUGs (uAUGs) or upstream open reading frames (uORFs). Therein, upstream AUGs and upstream open reading frames are typically understood to be AUGs and open reading frames that occur 5' of the start codon (AUG) of the open reading frame that should be translated. The 5'-UTRs of TOP genes are generally rather short. The lengths of 5'-UTRs of TOP genes may vary between 20 nucleotides up to 500 nucleotides, and are typically less than about 200 nucleotides, preferably less than about 150 nucleotides, more preferably less than about 100 nucleotides. Exemplary 5'-UTRs of TOP genes in the sense of the present invention are the nucleic acid sequences extending from the nucleotide at position 5 to the nucleotide located immediately 5' to the start codon (e.g. the ATG) in the sequences according to SEQ ID Nos. 1 -1363 of the patent application WO2013/143700, whose disclosure is incorporated herewith by reference. In this context a particularly preferred fragment of a 5'-UTR of a TOP gene is a 5'-UTR of a TOP gene lacking the 5'TOP motif. The terms "5'-UTR of a TOP gene" or "5'-TOP UTR" preferably refer to the 5'-UTR of a naturally occurring TOP gene. In a first aspect, the present invention relates to an artificial nucleic acid molecule comprising a. at least one open reading frame (ORF); and
b. at least one 3'-untranslated region element (3'-UTR element) and/or at least one 5'-untranslated region element (5'-UTR element), wherein the at least one 3'-
UTR element and/or the at least one 5'-UTR element prolongs and/or increases protein production from said artificial nucleic acid molecule and wherein the at least one 3'-UTR element and/or the at least one 5'-UTR element is derived from a stable mRNA.
Preferably, the artificial nucleic acid molecule according to the present invention does not comprise a 3'-UTR (element) and/or a 5'-UTR (element) of ribosomal protein S6, of RPL36AL, of rps16 or of ribosomal protein L9. More preferably, the artificial nucleic acid molecule according to the present invention does not comprise a 3'-UTR (element) and/or a 5'-UTR (element) of ribosomal protein S6, of RPL36AL, of rpsl 6 or of ribosomal protein L9 and the open reading frame of the artificial nucleic acid molecule according to the present invention does not code for a GFP protein. Even more preferably, the artificial nucleic acid molecule according to the present invention does not comprise a 3'-UTR (element) and/or a 5'-UTR (element) of ribosomal protein S6, of RPL36AL, of rps1 6 or of ribosomal protein L9 and the open reading frame of the artificial nucleic acid molecule according to the present invention does not code for a reporter protein, e.g., selected from the group consisting of globin proteins (particularly beta-globin), luciferase protein, GFP proteins, glucurinodase proteins (particularly beta- glucurinodase) or variants thereof, for example, variants exhibiting at least 70% sequence identity to a globin protein, a luciferase protein, a GFP protein, or a glucurinodase protein.
The term "3'-UTR element" refers to a nucleic acid sequence which comprises or consists of a nucleic acid sequence that is derived from a 3'-UTR or from a variant or a fragment of a 3'- UTR. A "3'-UTR element" preferably refers to a nucleic acid sequence which is comprised by a 3'-UTR of an artificial nucleic acid sequence, such as an artificial mRNA. Accordingly, in the sense of the present invention, preferably, a 3'-UTR element may be comprised by the 3'-UTR of an mRNA, preferably of an artificial mRNA, or a 3'-UTR element may be comprised by the 3'-UTR of the respective transcription template. Preferably, a 3'-UTR element is a nucleic acid sequence which corresponds to the 3'-UTR of an mRNA, preferably to the 3'- UTR of an artificial mRNA, such as an mRNA obtained by transcription of a genetically engineered vector construct. Preferably, a 3'-UTR element in the sense of the present invention functions as a 3'-UTR or codes for a nucleotide sequence that fulfils the function of a 3'-UTR.
Accordingly, the term "5'-UTR element" refers to a nucleic acid sequence which comprises or consists of a nucleic acid sequence that is derived from a 5'-UTR or from a variant or a fragment of a 5'-UTR. A "5'-UTR element" preferably refers to a nucleic acid sequence which is comprised by a 5'-UTR of an artificial nucleic acid sequence, such as an artificial mRNA. Accordingly, in the sense of the present invention, preferably, a 5'-UTR element may be comprised by the 5'-UTR of an mRNA, preferably of an artificial mRNA, or a 5'-UTR element may be comprised by the 5'-UTR of the respective transcription template. Preferably, a 5'- UTR element is a nucleic acid sequence which corresponds to the 5'-UTR of an mRNA, preferably to the 5'-UTR of an artificial mRNA, such as an mRNA obtained by transcription of a genetical ly engineered vector construct. Preferably, a 5'-UTR element in the sense of the present invention functions as a 5'-UTR or codes for a nucleotide sequence that fulfils the function of a 5'-UTR. The 3'-UTR element and/or the 5'-UTR element in the artificial nucleic acid molecule according to the present invention prolongs and/or increases protein production from said artificial nucleic acid molecule. Thus, the artificial nucleic acid molecule according to the present invention may in particular comprise:
— a 3'-UTR element which increases protein production from said artificial nucleic acid molecule,
— a 3'-UTR element which prolongs protein production from said artificial nucleic acid molecule,
— a 3'-UTR element which increases and prolongs protein production from said artificial nucleic acid molecule,
— a 5'-UTR element which increases protein production from said artificial nucleic acid molecule,
— a 5'-UTR element which prolongs protein production from said artificial nucleic acid molecule, — a 5'-UTR element which increases and prolongs protein production from said artificial nucleic acid molecule,
— a 3'-UTR element which increases protein production from said artificial nucleic acid molecule and a 5'-UTR element which increases protein production from said artificial nucleic acid molecule,
— a 3'-UTR element which increases protein production from said artificial nucleic acid molecule and a 5'-UTR element which prolongs protein production from said artificial nucleic acid molecule,
— a 3'-UTR element which increases protein production from said artificial nucleic acid molecule and a 5'-UTR element which increases and prolongs protein production from said artificial nucleic acid molecule,
— a 3'-UTR element which prolongs protein production from said artificial nucleic acid molecule and a 5'-UTR element which increases protein production from said artificial nucleic acid molecule,
— a 3'-UTR element which prolongs protein production from said artificial nucleic acid molecule and a 5'-UTR element which prolongs protein production from said artificial nucleic acid molecule,
— a 3'-UTR element which prolongs protein production from said artificial nucleic acid molecule and a 5'-UTR element which increases and prolongs protein production from said artificial nucleic acid molecule,
— a 3'-UTR element which increases and prolongs protein production from said artificial nucleic acid molecule and a 5'-UTR element which increases protein production from said artificial nucleic acid molecule,
— a 3'-UTR element which increases and prolongs protein production from said artificial nucleic acid molecule and a 5'-UTR element which prolongs protein production from said artificial nucleic acid molecule, or
— a 3'-UTR element which increases and prolongs protein production from said artificial nucleic acid molecule and a 5'-UTR element which increases and prolongs protein production from said artificial nucleic acid molecule.
Preferably, the artificial nucleic acid molecule according to the present invention comprises a 3'-UTR element which prolongs protein production from said artificial nucleic acid molecule and/or a 5'-UTR element which increases protein production from said artificial nucleic acid molecule.
Preferably, the artificial nucleic acid molecule according to the present invention comprises at least one 3'-UTR element and at least one 5'-UTR element, i.e. at least one 3'-UTR element which prolongs and/or increases protein production from said artificial nucleic acid molecule and which is derived from a stable mRNA and at least one 5'-UTR element which prolongs and/or increases protein production from said artificial nucleic acid molecule and which is derived from a stable mRNA.
"Prolonging and/or increasing protein production from said artificial nucleic acid molecule" in general refers to the amount of protein produced from the artificial nucleic acid molecule according to the present invention with the respective 3'-UTR element and/or the 5'-UTR element in comparison to the amount of protein produced from a respective reference nucleic acid lacking a 3'-UTR and/or a 5'-UTR or comprising a reference 3'-UTR and/or a reference 5'-UTR, such as a 3'-UTR and/or a 5'-UTR naturally occurring in combination with the ORF.
In particular, the at least one 3'-UTR element and/or the 5'-UTR element of the artificial nucleic acid molecule according to the present invention prolongs protein production from the artificial nucleic acid molecule according to the present invention, e.g. from an mRNA according to the present invention, compared to a respective nucleic acid lacking a 3'-UTR and/or 5'-UTR or comprising a reference 3'-UTR and/or 5'-UTR, such as a 3'- and/or 5'-UTR naturally occurring in combination with the ORF. In particular, the at least one 3'-UTR element and/or 5'-UTR element of the artificial nucleic acid molecule according to the present invention increases protein production, in particular the protein expression and/or total protein production, from the artificial nucleic acid molecule according to the present invention, e.g. from an mRNA according to the present invention, compared to a respective nucleic acid lacking a 3'- and/or 5'-UTR or comprising a reference 3'- and/or 5'-UTR, such as a 3'- and/or 5'-UTR naturally occurring in combination with the ORF. Preferably, the at least one 3'-UTR element and/or the at least one 5'-UTR element of the artificial nucleic acid molecule according to the present invention do not negatively influence translational efficiency of a nucleic acid compared to the translational efficiency of a respective nucleic acid lacking a 3'-UTR and/or a 5'-UTR or comprising a reference 3'-UTR and/or a reference 5'-UTR, such as a 3'-UTR and/or a 5'-UTR naturally occurring in combination with the ORF. Even more preferably, the translation efficiency is enhanced by the 3'-UTR and/or a 5'-UTR in comparison to the translation efficiency of the protein encoded by the respective ORF in its natural context. The term "respective nucleic acid molecule" or "reference nucleic acid molecule" as used herein means that - apart from the different 3'-UTRs and/or 5'-UTRs - the reference nucleic acid molecule is comparable, preferably identical, to the inventive artificial nucleic acid molecule comprising the 3'-UTR element and/or the 5'-UTR element. In order to assess the protein production in vivo or in vitro as defined herein (i.e. in vitro referring to ("living") cells and/or tissue, including tissue of a living subject; cells include in particular cell lines, primary cells, cells in tissue or subjects, preferred are mammalian cells, e.g. human cel ls and mouse cells and particularly preferred are the human cell lines HeLa, and U-937 and the mouse cell lines NIH3T3, JAWSIl and L929, furthermore primary cells are particularly preferred, in particular preferred embodiments human dermal fibroblasts (HDF)) by the inventive artificial nucleic acid molecule, the expression of the encoded protein is determined following injection/transfection of the inventive artificial nucleic acid molecule into target cells/tissue and compared to the protein expression induced by the reference nucleic acid. Quantitative methods for determining protein expression are known in the art (e.g. Western-Blot, FACS, ELISA, mass spectrometry). Particularly useful in this context is the determination of the expression of reporter proteins like luciferase, Green fluorescent protein (GFP), or secreted alkaline phosphatase (SEAP). Thus, an artificial nucleic acid according to the invention or a reference nucleic acid is introduced into the target tissue or cell, e.g. via transfection or injection, preferably i n a mammalian expression system, such as in mammalian cells, e.g. in HeLa or HDF cells. Several hours or several days (e.g. 6, 12, 24, 48 or 72 hours) post initiation of expression or post introduction of the nucleic acid molecule, a target cell sample is collected and measured via FACS and/or lysed. Afterwards the lysates can be used to detect the expressed protein (and thus determine the efficiency of protein expression) using several methods, e.g. Western-Blot, FACS, ELISA, mass spectrometry or by fluorescence or luminescence measurement.
Therefore, if the protein expression from an artificial nucleic acid molecule according to the invention is compared to the protein expression from a reference nucleic acid molecule at a specific point in time (e.g. 6, 12, 24, 48 or 72 hours post initiation of expression or post introduction of the nucleic acid molecule), both nucleic acid molecules are introduced separately into target tissue/cells, a sample from the tissue/cells is collected after a specific point in time, protein lysates are prepared according to the particular protocol adjusted to the particular detection method (e.g. Western Blot, ELISA, fluorescence or luminescence measurement, etc. as known in the art) and the protein is detected by the chosen detection method. As an alternative to the measurement of expressed protein amounts in cell lysates - or, in addition to the measurement of protein amounts in cell lysates prior to lysis of the collected cells or using an aliquot in parallel - protein amounts may also be determined by using FACS analysis.
The term "prolonging protein production" from an artificial nucleic acid molecule such as an artificial mRNA preferably means that the protein production from the artificial nucleic acid molecule such as the artificial mRNA is prolonged compared to the protein production from a reference nucleic acid molecule such as a reference mRNA, e.g. comprising a reference 3'- and/or 5'-UTR or lacking a 3'- and/or 5'-UTR, preferably in a mammalian expression system, such as in HeLa or HDF cells. Thus, protein produced from the artificial nucleic acid molecule such as the artificial mRNA is observable for a longer period of time than what may be seen for a protein produced from a reference nucleic acid molecule. In other words, the amount of protein produced from the artificial nucleic acid molecule such as the artificial mRNA measured at a later point in time, e.g. 48 hours or 72 hours after transfection, is larger than the amount of protein produced from a reference nucleic acid molecule such as a reference mRNA at a corresponding later point in time. Such a "later point in time" may be, for example, any time beyond 24 hours post initiation of expression, such as post transfection of the nucleic acid molecule, e.g. 36, 48, 60, 72, 96 hours post initiation of expression, i.e. after transfection. Moreover, for the same nucleic acid, the amount of protein produced at a later point in time may be normalized to the amount produced an earlier (reference) point in time, for example the amount of protein at a later point in time may be expressed as percentage of the amount of protein at 24 h after transfection.
Preferably, this effect of prolonging protein production is determined by (i) measuring protein amounts, e.g. obtained by expression of an encoded reporter protein such as luciferase, preferably in a mammalian expression system such as in HeLa or HDF cells, over time, (ii) determining the amount of protein observed at a "reference" point in time ti, for example ti = 24h after transfection, and setting this protein amount to 100%, (iii) determining the amount of protein observed at one or more later points in time t2, t3, etc., for example h = 48h and t3 = 72h after transfection, and calculating the relative amount of protein observed at a later point in time as a percentage of the protein amount at a point in time ti. For example, a protein which is expressed at ti in an amount of "80", at t2 in an amount of "20", and at t3 in an amount of "10", the relative amount of protein at t2 would be 25%, and at t3 12,5%. These relative amounts at a later point in time may then be compared in a step (iv) to relative protein amounts for the corresponding points in time for a nucleic acid molecule lacking a 3'- and/or 5'-UTR, respectively, or comprising a reference 3'- and/or 5'-UTR, respectively. By comparing the relative protein amount produced from the artificial nucleic acid molecule according to the present invention to the relative protein amount produced from the reference nucleic acid molecule, i.e. the nucleic acid molecule lacking a 3'- and/or 5'-UTR, respectively, or comprising a reference 3'- and/or 5'-UTR, respectively, a factor may be determined by which the protein production from the artificial nucleic acid molecule according to the present invention is prolonged compared to the protein production from the reference nucleic acid molecule. Preferably, the at least one 3'- and/or 5'-UTR element in the artificial nucleic acid molecule according to the invention prolongs protein production from said artificial nucleic acid molecule at least 1 .2 fold, preferably at least 1 .5 fold, more preferably at least 2 fold, even more preferably at least 2.5 fold, compared to the protein production from a reference nucleic acid molecule lacking 3'- and/or 5'-UTR, respectively, or comprising a reference 3'- and/or 5'-UTR, respectively. In other words, the (relative) amount of protein produced from in the artificial nucleic acid molecule according to the invention at a certain later point in time as described above is increased by a factor of at least 1 .2, preferably at least 1 .5, more preferably at least 2, even more preferably at least 2.5, compared to the (relative) amount of protein produced from a reference nucleic acid molecule, which is e.g. lacking a 3'- and/or 5'-UTR, respectively, or comprising a reference 3'- and/or 5'-UTR, respectively, for the same later point in time. Alternatively, the effect of prolonging protein production may also be determined by (i) measuring protein amounts, e.g. obtained by expression of an encoded reporter protein such as luciferase, preferably in a mammalian expression system such as in HeLa or HDF cells, over time, (ii) determining the point in time at which the protein amount undercuts the amount of protein observed, e.g., at 1 , 2, 3, 4, 5, or 6 hours post initiation of expression, e.g. 1 , 2, 3, 4, 5, or 6 hours post transfection of the artificial nucleic acid molecule, and (iii) comparing the point in time at which the protein amount undercuts the protein amount observed at 1 , 2, 3, 4, 5, or 6 hours post initiation of expression to said point in time determined for a nucleic acid molecule lacking a 3'- and/or 5'-UTR, respectively, or comprising a reference 3'- and/or 5'-UTR, respectively.
For example, the protein production from the artificial nucleic acid molecule such as the artificial mRNA - in an amount which is at least the amount observed in the initial phase of expression, such as 1 , 2, 3, 4, 5, or 6 hours post initiation of expression, such as post transfection of the nucleic acid molecule - is prolonged by at least about 5 hours, preferably by at least about 10 hours, more preferably by at least about 24 hours compared to the protein production from a reference nucleic acid molecule, such as a reference mRNA, in a mammalian expression system, such as in mammalian cells, e.g. in HeLa or HDF cells. Thus, the artificial nucleic acid molecule according to the present invention preferably allows for prolonged protein production in an amount which is at least the amount observed in the initial phase of expression, such as 1 , 2, 3, 4, 5, or 6 hours post initiation of expression, such as post transfection, by at least about 5 hours, preferably by at least about 10 hours, more preferably by at least about 24 hours compared to a reference nucleic acid molecule lacking a 3'- and/or 5'-UTR, respectively, or comprising a reference 3'- and/or 5'-UTR, respectively. In preferred embodiments, the period of protein production from the artificial nucleic acid molecule according to the present invention is extended at least 1 .2 fold, preferably at least 1 .5 fold, more preferably at least 2 fold, even more preferably at least 2.5 fold, compared to the protein production from a reference nucleic acid molecule lacking a 3'- and/or 5'-UTR, respectively, or comprising a reference 3'- and/or 5'-UTR, respectively.
Preferably, this prolonging effect on protein production is achieved, while the total amount of protein produced from the artificial nucleic acid molecule according to the present invention, e.g. within a time span of 48 or 72 hours, corresponds at least to the amount of protein produced from a reference nucleic acid molecule lacking a 3'- and/or 5'-UTR, respectively, or comprising a reference 3'- and/or 5'-UTR, respectively, such as a 3'-UTR and/or 5'-UTR naturally occurring with the ORF of the artificial nucleic acid molecule. Thus, the present invention provides an artificial nucleic acid molecule which allows for prolonged protein production in a mammalian expression system, such as in mammalian cells, e.g. in HeLa or HDF cells, as specified above, wherein the total amount of protein produced from said artificial nucleic acid molecule, e.g. within a time span of 48 or 72 hours, is at least the total amount of protein produced, e.g. within said time span, from a reference nucleic acid molecule lacking a 3'- and/or 5'-UTR, respectively, or comprising a reference 3'- and/or 5'- UTR, respectively, such as a 3'- and/or 5'-UTR naturally occurring with the ORF of the artificial nucleic acid molecule.
Moreover, the term "prolonged protein expression" also includes "stabilized protein expression", whereby "stabilized protein expression" preferably means that there is more uniform protein production from the artificial nucleic acid molecule according to the present invention over a predetermined period of time, such as over 24 hours, more preferably over 48 hours, even more preferably over 72 hours, when compared to a reference nucleic acid molecule, for example, an mRNA comprising a reference 3'- and/or 5'-UTR, respectively, or lacking a 3'- and/or 5'-UTR, respectively.
Accordingly, the level of protein production, e.g. in a mammalian system, from the artificial nucleic acid molecule comprising a 3'- and/or 5'-UTR element according to the present invention, e.g. from an mRNA according to the present invention, preferably does not drop to the extent observed for a reference nucleic acid molecule, such as a reference mRNA as described above. To assess to which extent the protein production from a specific nucleic acid molecule drops, for example, the amount of a protein (encoded by the respective ORF) observed 24 hours after initiation of expression, e.g. 24 hours post transfection of the artificial nucleic acid molecule according to the present invention into a cell, such as a mammalian cell, may be compared to the amount of protein observed 48 hours after initiation of expression, e.g. 48 hours post transfection. Thus, the ratio of the amount of protein encoded by the ORF of the artificial nucleic acid molecule according to the present invention, such as the amount of a reporter protein, e.g., luciferase, observed at a later point in time, e.g. 48 hours, post initiation of expression, e.g. post transfection, to the amount of protein observed at an earlier point in time, e.g. 24 hours, post initiation of expression, e.g. post transfection, is preferably higher than the corresponding ratio (including the same points in time) for a reference nucleic acid molecule comprising a reference 3'- and/or 5'-UTR, respectively, or lacking a 3'- and/or 5'-UTR, respectively.
Preferably, the ratio of the amount of protein encoded by the ORF of the artificial nucleic acid molecule according to the present invention, such as the amount of a reporter protein, e.g., luciferase, observed at a later point in time, e.g. 48 hours, post initiation of expression, e.g. post transfection, to the amount of protein observed at an earlier point in time, e.g. 24 hours, post initiation of expression, e.g. post transfection, is preferably at least 0.2, more preferably at least about 0.3, even more preferably at least about 0.4, even more preferably at least about 0.5, and particularly preferably at least about 0.7. For a respective reference nucleic acid molecule, e.g. an mRNA comprising a reference 3'- and/or 5'-UTR, respectively, or lacking a 3'- and/or 5'-UTR, respectively, said ratio may be, for example between about 0.05 and about 0.35.
Thus, the present invention provides an artificial nucleic acid molecule comprising an ORF and a 3'- and/or 5'-UTR element as described above, wherein the ratio of the protein amount, e.g. the amount of luciferase, observed 48 hours after initiation of expression to the protein amount observed 24 hours after initiation of expression, preferably in a mammalian expression system, such as in mammalian cells, e.g. in HDF cells or in HeLa cells, is preferably at least 0.2, more preferably at least about 0.3, more preferably at least about 0.4, even more preferably at least about 0.5, even more preferably at least about 0.6, and particularly preferably at least about 0.7. Thereby, preferably the total amount of protein produced from said artificial nucleic acid molecule, e.g. within a time span of 48 hours, corresponds at least to the total amount of protein produced, e.g. within said time span, from a reference nucleic acid molecule lacking a 3'- and/or 5'-UTR, respectively, or comprising a reference 3'- and/or 5'-UTR, respectively, such as a 3'-UTR and/or 5'-UTR naturally occurring with the ORF of the artificial nucleic acid molecule.
Preferably, the present invention provides an artificial nucleic acid molecule comprising an ORF and a 3'-UTR element and/or a 5'-UTR element as described above, wherein the ratio of the protein amount, e.g. the amount of luciferase, observed 72 hours after initiation of expression to the protein amount observed 24 hours after initiation of expression, preferably in a mammalian expression system, such as in mammalian cells, e.g. in HeLa cells or HDF cells, is preferably above about 0.05, more preferably above about 0.1 , more preferably above about 0.2, even more preferably above about 0.3, wherein preferably the total amount of protein produced from said artificial nucleic acid molecule, e.g. within a time span of 72 hours, is at least the total amount of protein produced, e.g. within said time span, from a reference nucleic acid molecule lacking a 3'- and/or 5'-UTR, respectively, or comprising a reference 3'- and/or 5'-UTR, respectively, such as a 3'- and/or 5'-UTR naturally occurring with the ORF of the artificial nucleic acid molecule.
"Increased protein expression" or "enhanced protein expression" in the context of the present invention preferably means an increased/enhanced protein expression at one point in time after initiation of expression or an increased/enhanced total amount of expressed protein compared to the expression induced by a reference nucleic acid molecule. Thus, the protein level observed at a certain point in time after initiation of expression, e.g. after transfection, of the artificial nucleic acid molecule according to the present invention, e.g. after transfection of an mRNA according to the present invention, for example, 6, 12, 24, 48 or 72 hours post transfection, is preferably higher than the protein level observed at the same point in time after initiation of expression, e.g. after transfection, of a reference nucleic acid molecule, such as a reference mRNA comprising a reference 3'- and/or 5'-UTR, respectively, or lacking a 3'- and/or 5'-UTR, respectively. In a preferred embodiment, the maximum amount of protein (as determined e.g. by protein activity or mass) expressed from the artificial nucleic acid molecule is increased with respect to the protein amount expressed from a reference nucleic acid comprising a reference 3'- and/or 5'-UTR, respectively, or lacking a 3'- and/or 5'-UTR, respectively. Peak expression levels are preferably reached within 48 hours, more preferably within 24 hours and even more preferably within 12 hours after, for instance, transfection. Preferably, the term "increased total protein production" or "enhanced total protein production" from an artificial nucleic acid molecule according to the invention refers to an increased/enhanced protein production over a time span, in which protein is produced from an artificial nucleic acid molecule, e.g. 48 hours or 72 hours, preferably in a mammalian expression system, such as in mammalian cells, e.g. in HeLa or HDF cells in comparison to a reference nucleic acid molecule lacking a 3'- and/or 5'-UTR, respectively, or comprising a reference 3'- and/or 5'-UTR, respectively. According to a preferred embodiment, the cumulative amount of protein expressed over time is increased when using the artificial nucleic acid molecule according to the invention.
The total amount of protein for a specific time period may be determined by (i) collecting tissue or cells at several points in time after introduction of the artificial nucleic acid molecule (e.g. 6, 12, 24, 48 and 72 hours post initiation of expression or post introduction of the nucleic acid molecule), and the protein amount per point in time can be determined as explained above. In order to calculate the cumulative protein amount, a mathematical method of determining the total amount of protein can be used, e.g. the area under the curve (AUC) can be determined according to the following formula:
Figure imgf000036_0001
a
In order to calculate the area under the curve for total amount of protein, the integral of the equation of the expression curve from each end point (a and b) is calculated.
Thus, "total protein production" preferably refers to the area under the curve (AUC) representing protein production over time.
Preferably, the at least one 3'- or 5'-UTR element according to the present invention increases protein production from said artificial nucleic acid molecule at least 1 .5 fold, preferably at least 2 fold, more preferably at least 2.5 fold, compared to the protein production from a reference nucleic acid molecule lacking a 3'- and/or 5'-UTR, respectively. In other words, the total amount of protein produced from in the artificial nucleic acid molecule according to the invention at a certain point in time, e.g. 48 hours or 72 hours post initiation of expression, e.g. post transfection, is increased by a factor of at least 1 .5, preferably at least 2, more preferably at least 2.5, compared to the (relative) amount of protein produced from a reference nucleic acid molecule, which is e.g. lacking a 3'- and/or 5'-UTR, respectively, or comprising a reference 3'- and/or 5'-UTR, respectively, for the corresponding later point in time.
The mRNA and/or protein production prolonging effect and efficiency and/or the protein production increasing effect and efficiency of the variants, fragments and/or variant fragments of the 3'-UTR and/or the 5'-UTR as well as the mRNA and/or protein production prolonging effect and efficiency and/or the protein production increasing effect and efficiency of the at least one 3'-UTR element and/or the at least one 5'-UTR element of the artificial nucleic acid molecule according to the present invention may be determined by any method suitable for this purpose known to skilled person. For example, artificial mRNA molecules may be generated comprising a coding sequence/open reading frame (ORF) for a reporter protein, such as luciferase, and a 3'-UTR element according to the present invention, i.e. which prolongs and/or increases protein production from said artificial mRNA molecule. In addition such an inventive mRNA molecule may further comprise a a 5'-UTR element according to the present invention, i.e. which prolongs and/or increases protein production from said artificial mRNA molecule, no 5'-UTR element or a 5'-UTR element which is not according to the present invention, e.g. a reference 5'-UTR. Accordingly, artificial mRNA molecules may be generated comprising a coding sequence/open reading frame (ORF) for a reporter protein, such as luciferase, and a 5'-UTR element according to the present invention, i.e. which prolongs and/or increases protein production from said artificial mRNA molecule. In addition such an inventive mRNA molecule may further comprise a a 3'-UTR element according to the present invention, i.e. which prolongs and/or increases protein production from said artificial mRNA molecule, no 3'-UTR element or a 3'-UTR element which is not according to the present invention, e.g. a reference 3'-UTR.
According to the present invention mRNAs may be generated, for example, by in vitro transcription of respective vectors such as plasmid vectors, e.g. comprising a T7 promoter and a sequence encoding the respective mRNA sequences. The generated mRNA molecules may be transfected into cells by any transfection method suitable for transfecting mRNA, for example they may be lipofected into mammalian cells, such as HeLa cells or HDF cells, and samples may be analyzed certain points in time after transfection, for example, 6 hours, 24 hours, 48 hours, and 72 hours post transfection. Said samples may be analyzed for mRNA quantities and/or protein quantities by methods well known to the skilled person. For example, the quantities of reporter mRNA present in the cells at the sample points in time may be determined by quantitative PCR methods. The quantities of reporter protein encoded by the respective mRNAs may be determined, e.g., by Western Blot, ELISA assays, FACS analysisor reporter assays such as luciferase assays depending on the reporter protein used. The effect of stabilizing protein expression and/or prolonging protein expression may be, for example, analyzed by determining the ratio of the protein level observed 48 hours post transfection and the protein level observed 24 hours post transfection. The closer said value is to 1 , the more stable the protein expression is within this time period. Such measurements may of course also be performed at 72 or more hours and the ratio of the protein level observed 72 hours post transfection and the protein level observed 24 hours post transfection may be determined to determine stability of protein expression.
Moreover, the at least one 3'-UTR element and/or the at least one 5'-UTR element in the artificial nucleic acid molecule according to the present invention, is derived from a stable mRNA. Thereby, "derived" from a stable mRNA means that the at least one 3'-UTR element and/or the at least one 5'-UTR element shares at least 50%, preferably at least 60%, preferably at least 70%, more preferably at least 75%, more preferably at least 80%, more preferably at least 85%, even more preferably at least 90%, even more preferably at least 95%, and particularly preferably at least 98% sequence identity with a 3'-UTR element and/or a 5'-UTR element of a stable mRNA. Preferably, the stable mRNA is a naturally occurring mRNA and, thus, a 3'-UTR element and/or a 5'-UTR element of a stable mRNA refers to a 3'-UTR and/or a 5'-UTR, or fragments or variants thereof, of naturally occurring mRNA. Moreover, a 3'-UTR element and/or a 5'-UTR element derived from a stable mRNA preferably also refers to a 3'- UTR element and/or a 5'-UTR element, which is modified in comparison to a naturally occurring 3'-UTR element and/or 5'-UTR element, e.g. in order to increase RNA stability even further and/or to prolong and/or increase protein production. It goes without saying that such modifications are preferred, which do not impair RNA stability, e.g. in comparison to a naturally occurring (non-modifed) 3'-UTR element and/or 5'-UTR element. In particular, the term mRNA as used herein refers to an mRNA molecule, however, it may also refer to an mRNA species as defined herein.
Preferably, the stability of mRNA, i.e. mRNA decay and/or half-life, is assessed under standard conditions, for example standard conditions (standard medium, incubation, etc.) for a certain cell line used.
The term "stable mRNA" as used herein refers in general to an mRNA having a slow mRNA decay. Thus, a "stable mRNA" has typically a long half-life. The half-life of an mRNA is the the time required for degrading 50% of the in vivo or in vitro existing mRNA molecules. Accordingly, stability of mRNA is usually assessed in vivo or in vitro. Thereby, in vitro refers in particular to ("living") cells and/or tissue, including tissue of a living subject. Cells include in particular cell lines, primary cells, cells in tissue or subjects. In specific embodiments cell types allowing cell culture may be suitable for the present invention. Particularly preferred are mammalian cells, e.g. human cells and mouse cells. In particularly preferred embodiments the human cell lines HeLa, and U-937 and the mouse cell lines NIH3T3, JAWSII and L929 are used. Furthermore primary cells are particularly preferred, in particular preferred embodiments human dermal fibroblasts (HDF) may be used. Alternatively also a tissue of a subject may be used.
Preferably, the half-life of a "stable mRNA" is at least 5 h, at least 6 h, at least 7 h, at least 8 h, at least 9 h, at least 10 h, at least 1 1 h, at least 12 h, at least 13 h, at least 14 h, and/or at least 15 h. The half-life of an mRNA of interest may be determined by different methods known to the person skilled in the art. Typically, the half-life of an mRNA of interest is determined by determining the decay constant, whereby usually an ideal in vivo (or in vitro as defined above) situation is assumed, in which transcription of the mRNA of interest can be "turned off" completely (or at least to an undetectable level). In such an ideal situation it is usually assumed that mRNA decay follows first-order kinetics. Accordingly, the decay of an mRNA may usually be described by the following equation:
A(t) = Ao * θ-λι with Ao being the amount (or concentration) of the mRNA of interest at time 0, i.e. before the decay starts, A(t) being the amount (or concentration) of the mRNA of interest at a time t during decay and λ being the decay constant. Thus, if the amount (or concentration) of the mRNA of interest at time 0 (Ao) and the amount (or concentration) of the mRNA of interest at a certain time t during the decay process (A(t) and t) are known, the decay constant λ may be calculated. Based on the decay constant λ, the half-life hn can be calculated by the following equation: ti/2 = In2 / λ. since per definition A(t)/A0 = 1 /2 at h/i. Thus, to assess the half-life of an mRNA of interest, usually the amount or concentration of the mRNA is determined during the RNA decay process in vivo (or in vitro as defined above). To determine the amount or concentration of mRNA during the RNA decay process in vivo (or in vitro as defined above), various methods may be used, which are known to the skilled person. Non-limiting examples of such methods include general inhibition of transcription, e.g. with a transcription inhibitor such as actinomycin D, use of inducible promotors to specifically promote transient transcription, e.g. c-fos serum-inducible promoter system and Tet-off regulatory promotor system, and kinetic labelling techniques, e.g. pulse labelling, for example by 4-Thiouridine (4sU), 5-Ethynyluridine (EU) or 5'-Bromo-Uridine (BrU). Further details and preferred embodiments regarding how to determine the amount or concentration of mRNA during the RNA decay are outlined below, in the context of a method for identifying a 3'-UTR element and/or the at least one 5'-UTR element, which is derived from a stable mRNA, according to the present invention. The respective description and preferred embodiments of how to determine the amount or concentration of mRNA during the RNA decay apply here as well.
Preferably, a "stable mRNA" in the sense of the present invention has a slower mRNA decay compared to average mRNA, preferably assessed in vivo (or in vitro as defined above). For example, "average mRNA decay" may be assessed by investigating mRNA decay of a plurality of mRNA species, preferably 100, at least 300, at least 500, at least 1000, at least 2000, at least 3000, at least 4000, at least 5000, at least 6000, at least 7000, at least 8000, at least 9000, at least 1 0000, at least 1 1 000, at least 1 2000, at least 1 3000, at least 1 4000, at least 1 5000, at least 1 6000, at least 1 7000, at least 1 8000, at least 1 9000, at least 20000, at least 21 000, at least 22000, at least 23000, at least 24000, at least 25000, at least 26000, at least 27000, at least 28000, at least 29000, at least 30000 mRNA species. It is particularly preferred that the whole transcriptome is assessed, or as many mRNA species of the transcriptome as possible. This may be achieved, for example, by using a micro array providing whole transcript coverage.
An "mRNA species", as used herein, corresponds to a genomic transcription unit, i.e. usually to a gene. Thus, within one "mRNA species" different transcripts may occur, for example, due to mRNA processing. For example, an mRNA species may be represented by a spot on a microarray. Accordingly, a microarray provides an advantageous tool to determine the amount of a plurality of mRNA species, e.g. at a certain point in time during mRNA decay. However, also other techniques known to the ski lled person, e.g. RNA-seq, quantitative PCR etc. may be used.
In the present invention it is particularly preferred that a stable mRNA is characterized by an mRNA decay wherein the ratio of the amount of said mRNA at a second point in time to the amount of said mRNA at a first point in time is at least 0.5 (50%), at least 0.6 (60%), at least 0.7 (70%), at least 0.75 (75%), at least 0.8 (80%), at least 0.85 (85%), at least 0.9 (90%), or at least 0.95 (95%). Thereby, the second point in time is later in the decay process than the first point i n time.
Preferably, the first point in time is selected such that only mRNA undergoing a decay process is considered, i.e. emerging mRNA - e.g. in ongoing transcription - is avoided. For example, if kinetic labelling techniques, e.g. pulse labelling, are used, the first point in time is preferably selected such that the incorporation of the label into mRNA is completed, i.e. no ongoing incorporation of the label into mRNA occurs. Thus, if kinetic labelling is used, the first point in time may be at least 10 min, at least 20 min, at least 30 min, at least 40 min, at least 50 min, at least 60 min, at least 70 min, at least 80 min, or at least 90 min after the end of the experimental labelling procedure, e.g. after the end of the incubation of cells with the label. For example, the first point in time may be preferably from 0 to 6 h after the stop of transcription (e.g. by a transcriptional inhibitor), stop of promotor induction in case of inducible promotors or after stop of pulse or label supply, e.g. after end of labelling. More preferably, the first point in time may be 30 min to 5 h, even more preferably 1 h to 4 h and particularly preferably about 3 h after the stop of transcription (e.g. by a transcriptional inhibitor), stop of promotor induction in case of inducible promotors or after stop of pulse or label supply, e.g. after end of labelling.
Preferably, the second point in time is selected as late as possible during the mRNA decay process. However, if a plurality of mRNA species is considered, the second point in time is preferably selected such that still a considerable amount of the plurality of mRNA species, preferably at least 1 0% of the mRNA species, is present in a detectable amount, i.e. in an amount higher than 0. Preferably, the second point in time is at least 5 h, at least 6 h, at least 7 h, at least 8 h, at least 9 h, at least 1 0 h, at least 1 1 h, at least 12 h, at least 13 h, at least 14 h, or at least 1 5 h after the end of transcription or the end of the experimental label ling procedure.
Thus, the time span between the first point in time and the second point in time is preferably as large as possible within the above described limits. Therefore, the time span between the first point in time and the second point in time is preferably at least 4 h, at least 5 h, at least 6 h, at least 7 h, at least 8 h, at least 9 h, at least 1 0 h, at least 1 1 h, or at least 12 h.
Moreover, it is preferred that the at least one 3'-UTR element and/or the at least one 5'-UTR element in the artificial nucleic acid molecule according to the present invention, which is derived from a stable mRNA, is identified by a method for identifying a 3'-UTR element and/or a 5'-UTR element, which is derived from a stable mRNA, according to the present invention as described herein. It is particularly preferred that the at least one 3'-UTR element and/or the at least one 5'-UTR element in the artificial nucleic acid molecule according to the present invention, is identified by a method for identifying a 3'-UTR element and/or a 5'-UTR element, which prolongs and/or increases protein production from an artificial nucleic acid molecule and which is derived from a stable mRNA, according to the present invention as described herein. Preferably, the at least one 3'-UTR element and/or the at least one 5'-UTR element in the artificial nucleic acid molecule according to the present invention comprises or consists of a nucleic acid sequence which is derived from the 3'-UTR and/or the 5'-UTR of a eukaryotic protein coding gene, preferably from the 3'-UTR and/or the 5'-UTR of a vertebrate protein coding gene, more preferably from the 3'-UTR and/or the 5'-UTR of a mammalian protein coding gene, e.g. from mouse and human protein coding genes, even more preferably from the 3'-UTR and/or the 5'-UTR of a primate or rodent protein coding gene, in particular the 3'- UTR and/or the 5'-UTR of a human or murine protein coding gene. In general, it is understood that the at least one 3'-UTR element in the artificial nucleic acid molecule according to the present invention comprises or consists of a nucleic acid sequence which is preferably derived from a naturally (in nature) occurring 3'-UTR, whereas the at least one 5'-UTR element in the artificial nucleic acid molecule according to the present invention comprises or consists of a nucleic acid sequence which is preferably derived from a naturally (in nature) occurring 5'-UTR.
Preferably, the at least one open reading frame is heterologous to the at least one 3'-UTR element and/or to the at least one 5'-UTR element. The term "heterologous" in this context means that two sequence elements comprised by the artificial nucleic acid molecule, such as the open reading frame and the 3'-UTR element and/or the open reading frame and the 5'- UTR element, do not occur naturally (in nature) in this combination. They are typically recombinant. Preferably, the 3'-UTR element and/or the 5'-UTR element are/is derived from a different gene than the open reading frame. For example, the ORF may be derived from a different gene than the 3'-UTR element and/or to the at least one 5'-UTR element, e.g. encoding a different protein or the same protein but of a different species etc. I.e. the open reading frame is derived from a gene which is distinct from the gene from which the 3'-UTR element and/or to the at least one 5'-UTR element is derived. In a preferred embodiment, the ORF does not encode a human or plant (e.g., Arabidopsis) ribosomal protein, preferably does not encode human ribosomal protein S6 (RPS6), human ribosomal protein L36a-like (RPL36AL) or Arabidopsis ribosomal protein S1 6 (RPS1 6). In a further preferred embodiment, the open reading frame (ORF) does not encode ribosomal protein S6 (RPS6), ribosomal protein L36a-like (RPL36AL) or ribosomal protein S1 6 (RPS1 6). In specific embodiments it is preferred that the open reading frame does not code for a reporter protein, e.g., selected from the group consisting of globin proteins (particularly beta- globin), luciferase protein, GFP proteins or variants thereof, for example, variants exhibiting at least 70% sequence identity to a globin protein, a luciferase protein, or a GFP protein. Thereby, it is particularly preferred that the open reading frame does not code for a GFP protein. It is also particularly preferred that the open reading frame (ORF) does not encode a reporter gene or is not derived from a reporter gene, wherein the reporter gene is preferably not selected from group consisting of globin proteins (particularly beta-globin), luciferase protein, beta-glucuronidase (GUS) and GFP proteins or variants thereof, preferably not selected from EGFP, or variants of any of the above genes, typically exhibiting at least 70% sequence identity to any of these reporter genes, preferably a globin protein, a luciferase protein, or a GFP protein.
Even more preferably, the 3'-UTR element and/or the 5'-UTR element is heterologous to any other element comprised in the artificial nucleic acid as defined herein. For example, if the artificial nucleic acid according to the invention comprises a 3'-UTR element from a given gene, it does preferably not comprise any other nucleic acid sequence, in particular no functional nucleic acid sequence (e.g. coding or regulatory sequence element) from the same gene, including its regulatory sequences at the 5' and 3' terminus of the gene's ORF. Accordingly, for example, if the artificial nucleic acid according to the invention comprises a 5'-UTR element from a given gene, it does preferably not comprise any other nucleic acid sequence, in particular no functional nucleic acid sequence (e.g. coding or regulatory sequence element) from the same gene, including its regulatory sequences at the 5' and 3' terminus of the gene's ORF.
Moreover, it is preferred that the artificial nucleic acid according to the present invention comprises at least one open reading frame, at least one 3'-UTR (element) and at least one 5'- UTR (element), whereby either the at least one 3'-UTR (element) is a 3'-UTR element according to the present invention and/or the at least one 5'-UTR (element) is a 5'-UTR element according to the present invention. In such a preferred artificial nucleic acid according to the present invention, which comprises at least one open reading frame, at least one 3'-UTR (element) and at least one 5'-UTR (element), it is particularly preferred that each of the at least one open reading frame, the at least one 3'-UTR (element) and the at least one 5'-UTR (element) are heterologous, i.e. neither the at least one 3'-UTR (element) and the at least one 5'-UTR (element) nor the the open reading frame and the 3'-UTR (element) or the 5'-UTR (element), respectively, are occurring naturally (in nature) in this combination. This means that the artificial nucleic acid molecule comprises an ORF, a 3'-UTR (element) and a 5'-UTR (element), all of which are heterologous to each other, e.g. they are recombinant as each of them is derived from different genes (and their 5' and 3' UTR's). In another preferred embodiment, the 3'-UTR (element) is not derived from a 3'-UTR (element) of a viral gene or is not of viral origin. Preferably, the artificial nucleic acid molecule according to the present invention:
(i) comprises at least one 3'-UTR element and at least one 5'-UTR element, wherein preferably (each of) the at least one 3'-UTR element and at least one 5'-UTR element comprises or consists of a nucleic acid sequence which is derived from the 3'-UTR, or the 5'-UTR respectively, of a human or murine protein coding gene;
(ii) the at least one 3'-UTR element, the at least one 5'-UTR element and the at least one open reading frame of the artificial nucleic acid molecule according to the present invention are all heterologous to each other;
(iii) the at least one 3' UTR element is derived from a gene selected from the group consisting of: housekeeping genes, genes coding for a membrane protein, genes involved in cellular metabolism, genes involved in transcription, translation and replication processes, genes involved in protein modification and genes involved in cell division; and
(iv) the 3'UTR is not derived from a gene coding for a ribosomal protein or from the Fig4 gene.
Housekeeping genes are typically constitutive genes that are required for the maintenance of basic cellular function and that are typically expressed in all cells of an organism under normal and patho-physiological conditions. Although some housekeeping genes are expressed at relatively constant levels in most non-pathological situations, other housekeeping genes may vary depending on experimental conditions. Typically, housekeeping genes are expressed in at least 25 copies per cell and sometimes number in the thousands. Preferred examples of housekeeping genes in the context of the present invention are shown below in Table 10. Acc Definition Symbol3 Length1" Abundance0
NM_001402 Eukaryotic translation elongation factor 1 alpha 1 EEF1A1 387 20011
NMJ301614 Actin, gamma 1 ACTG1 718 16084
NM_002046 Glyceraldehyde-3-phosphate dehydrogenase GAPD 201 15931
N _001 01 Actin, beta ACTB 593 15733
NM_000967 Ribosomal protein L3 RPL3 74 10924
NMJ306082 Tubulin, alpha, ubiquitous K-ALPHA-1 174 10416
N _001428 Eno!ase 1, (alpha) EN01 357 9816
N _006098 Guanine nucleotide binding protein (G protein), beta polypeptide 2- GNB2L1 45 8910
NM_002032 Ferritin, heavy polypeptide 1 FTH1 138 8861
NM_002654 Pyruvate kinase, muscle PKM2 643 7413
NM_004048 Beta-2-microglobuiin B2M 568 7142
NMJ306597 Heat shock 70kDa protein 8 HSPA8 258 6066
N _000034 Aldolase A, fructose-bisphosphate ALDOA 252 5703
NM_0210Q9 Ubiquitin C UBC 67 5579
NM_006013 Ribosomal protein L10 RPL10 1,503 5572
NM_012423 Ribosomal protein L13a RPL13A 509 5552
NM_007355 Heat shock 90kDa protein 1, beta HSPCB 309 5436
NM_004046 ATP synthase, H+ transporting, mitochondrial F1 complex, alpha ATP5A1 64 5434 subunit, isoform 1, cardiac muscle
NM_0005 6 GNAS complex locus GNAS 362 4677
N _001743 Calmodulin 2 (phosphoryiase kinase, delta) CALM2 611 4306
N J305566 Lactate dehydrogenase A LDHA 566 4186
NM_000973 Ribosomal protein L8 RPL8 92 4042
NM_002948 Ribosomal protein L15 RPL15 1,368 3861
NM_000977 Ribosomal protein L13 RPL13 424 3774
NM_002952 Ribosomal protein S2 RPS2 86 3758
NMJ505507 Cofilin 1 (non-musde) CFL1 508 3616
N _O04O39 Annexin A2 ANXA2 294 3560'
NMJ321019 Myosin, light polypeptide 6, alkali, smooth muscle and non-muscle MYL6 209 3512
NM_002300 Lactate dehydrogenase B LDHB 230 3501
N JJ03217 Testis enhanced gene transcript (BAX inhibitor 1) TEGT 1,847 3438
NM_002568 Pofy(A) binding protein, cytoplasmic 1 PABPC1 445 3241
NM_001015 Ribosomal protein S11 RPS11 85 3220
NM_003973 Ribosomal protein L14 RPL14 156 3198
NM_000969 Ribosomal protein L5 RPL5 78 3167
NM_007 04 Ribosomal protein L10a RPL10A 32 3079
N _001642 Amyloid beta (A4) precursor-like protein 2 APLP2 1,364 3002
NM_001418 Eukaryotic translation initiation factor 4 gamma, 2 EIF4G2 791 2913
NM_002635 Solute carrier family 25 (mitochondrial carrier; phosphate carrier), SLC25A3 197 2900 member 3
NM_001009 Ribosomal protein S5 RPS5 58 2897
NM_000291 Phosphoglycerate kinase 1 PGK1 1,016 2858
N _001728 Basigin (OK blood group) BSG 769 2827
NM_001658 ADP-ribosylation factor 1 ARF1 1,194 2772
NM_001003 Ribosomal protein, large, P1 RPLP1 39 2770
NM_0 8955 Ubiquitin B UBB 144 2732
N _005998 Chaperanin containing TCP1 , subunit 3 (gamma) CCT3 255 2709
N _001967 Eukaryotic translation initiation factor 4A, isoform 2 EIF4A2 626 2693
NM_001469 Thyroid autoaniigen 70kDa (Ku antigen) G22P1 259 2682
NM_000918 Procollagen-proline, 2-oxoglutarate 4-dioxygenase (proline 4- P4HB 868 2659 hydroxylase), beta polypeptide (protein disulfide isomerase; thyroid
hormone binding protein p55)
NM_002574 Perox!redoxin 1 PRDX1 323 2604
NM_001020 Ribosomal protein S16 RPS16 78 2573 NM_007363 Non-POU domain containing, octamer-binding NONO 1,119 2557
NM_001022 Ribosomal protein S19 RPS19 63 2533
NMJ301675 Activating transcription factor 4 (tax-responsive enhancer element ATF4 85 2479
B67)
NM_005617 Ribosomal protein S14 RPS14 78 2465
NM_001664 Ras homolog gene family, member A RHOA 1,045 2426
NM_005801 Putative translation Initiation factor SUI1 836 2425
NM_000981 Ribosomal protein L19 RPL19 80 2381
NM_000979 Ribosomal protein L18 RPL18 49 2362
NM_001026 Ribosomal protein S24 RPS24 77 2355
N _000975 Ribosomal protein L11 RPL11 53 2314
NM_002117 Major histocompatibility complex, class I, C HLA-C 434 2278
NM_004068 Adaptor-related protein complex 2, mu 1 subunit AP2M1 494 2230
NM_006429 Chaperonin containing TCP1, subunit 7 (eta) CCT7 164 2216
NM_022551 Ribosomal protein S18 RPS18 5,538 2208
NM_001013 Ribosomal protein S9 RPS9 73 2113
NM_005594 Nascent-polypeptide-associated complex alpha polypeptide NACA 133 2075
NM_001028 Ribosomal protein S25 RPS25 74 2066
NM_032378 Eukaryotic translation elongation factor 1 delta (guanine nucleotide EEF1D 76 2051 exchange protein)
NM_000999 Ribosomal protein L38 RPL38 50 2007
NM_000994 Ribosomal protein L32 RPL32 64 2003
NM_007008 Reticulon 4 RTN4 973 1969
NM_001909 Cathepsin D (lysosomal aspartyl protease) CTSD 834 1940
NM_006325 RAN, member RAS oncogene family RAN 892 1906
NM_003406 Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase YWHAZ 2,013 1892 activation protein, zeta polypeptide
NM_006888 Calmodulin 1 (phosphorylase kinase, delta) CALM1 3,067 1880
NM_004339 Pituitary tumor-transforming 1 interacting protein PTTG1IP 1,985 1837
N _005022 Profilin 1 PFN1 289 1787
NM_001961 Eukaryotic translation elongation factor 2 EEF2 504 1754
NM_003091 Small nuclear ribonucleoprotein polypeptides B and B1 SNRPB 295 1735
NM_006826 Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase YWHAQ 1 ,310 1726 activation protein, Iheta polypeptide
NM_ 002140 Heterogeneous nuclear ribonucleoprotein K HNRPK 1 ,227 1725
NMJJ01064 Transketolase (Wernicke-Korsakoff syndrome) TKT 167 1721
NM_021 03 Thymosin, beta 10 TMSB10 317 1714
NM_004309 Rho GDP dissociation inhibitor (GDI) alpha ARHGDIA 1 ,206 1702
NM_002473 Myosin, heavy polypeptide 9, non-muscle MYH9 1,392 1692
NMJ0OO884 IMP (inosine monophosphate) dehydrogenase 2 IMPDH2 63 1690
N _001004 Ribosomal protein, large P2 RPLP2 59 1688
N _001746 Calnexin CANX 2,302 1677
NM_0028 9 Polypyrimidine tract binding protein 1 PTBP1 1,561 1663
NM_000988 Ribosomal protein L27 RPL27 59 1660
NM_004404 Neural precursor cell expressed, developmenfally down-regulated 5 NEDD5 2,090 1654
NM_005347 Heat shock 70kDa protein 5 (glucose-regulated protein, 78kDa) HSPA5 1,757 1651
NM_000 5 Glucose phosphate isomerase GPI 296 1635
NM_001207 Basic transcription factor 3 BTF3 300 1632
NM_003186 Transgelin TAGLN 405 1612
NM_003334 Ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature UBE1 199 1590 sensitivity complementing)
NM_ 001018 Ribosomal protein S15 RPS15 32 1574
N _003404 Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase YWHAB 2,088 1523 activation protein, beta polypeptide
NM_003753 Eukaryotic translation initiation factor 3, subunit 7 zeta, 66/67kDa EIF3S7 152 1509
NM_005762 Tripartite motif-containing 28 TRIM28 193 1507
N _005381 Nucleolin NCL 284 1501
NM_000995 Ribosomal protein L34 RPL34 450 1495
NM_002823 Prothymosin, alpha (gene sequence 28) PTMA 720 1462
NMJJ02415 Macrophage migration inhibitory factor (glycosylation-inhibiting MIF 117 1459 factor) N _002128 High-mobility group box 1 HMGB1 1,527 1457
NM_006908 Ras-related C3 botulinum toxin substrate 1 (rho family, small GTP RAC1 1,536 1437 binding protein Rad)
NM_002070 Guanine nucleotide binding protein (G protein), alpha inhibiting GNAI2 512 1435 activity polypeptide 2
NM_001997 Finkel-Biskis-Reilly murine sarcoma virus (FBR-MuSV) ubiquitously FAU 68 1428 expressed (fox derived); ribosomal protein S30
NM_014390 Staphylococcal nuclease domain containing 1 SND1 556 1422
N _0 4764 DAZ associated protein 2 DAZAP2 1,322 1419
NM_005917 Malate dehydrogenase 1, NAD (soluble) MDH1 208 1396
NM_001494 GDP dissociation inhibitor 2 GDI2 785 1395
NM_0 4225 Protein phosphatase 2 (formerly 2A), regulatory subunit A (PR 65), PPP2R1A 472 1391 alpha Isoform
N _001660 ADP-ribosy!ation factor 4 ARF4 858 1382
N _001823 Creatine kinase, brain CKB 206 1381
NM_003379 Villin 2 (ezrin) V1L2 1,272 1380
NM_000182 Hydroxyacyl-Coenzyme A dehydrogenase/3-ketoacyl-Coenzyme A HADHA 647 1379 thiolase/enoyl-Coenzyme A hydratase (trifunctionai protein), alpha
subunit
NM_003746 Dynein, cytoplasmic, light polypeptide 1 DNCL1 281 1375
NM_007103 NADH dehydrogenase (ubiquinone) flavoprotein 1, 51kDa NDUFV1 03 1352
NM_000992 Ribosomal protein L29 RPL29 164 1349
N _007209 Ribosomal protein L35 RPL35 35 1345
NM_006623 Phosphoglycerate dehydrogenase PHGDH 231 1340
N _002796 Proteasome (prosome, macropaln) subunit, beta type, 4 PSMB4 108 1340
NM_002808 Proteasome (prosome, macropaln) 26S subunit, non-ATPase, 2 PSMD2 231 1326
NM_000454 Superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 SOD1 346 1323
(adult))
NM_003915 RNA binding motif protein 2 RBM12 216 1323
NM_004924 Actinin, alpha 4 ACTN4 1,099 1316
N _006086 Tubulin, beta 3 TUBB3 296 1314
NM_001016 Ribosomal protein S12 RPS12 56 1304
NM_003365 Ubiquinol-cytochrome c reductase core protein I UQCRC1 126 1303
NM_003016 Splicing factor, arginine/serine-rich 2 SFRS2 1,059 1301
N _007273 Repressor of estrogen receptor activity REA 332 1281
NM_014610 Glucosidase, alpha; neutral AB GANAB 1,652 1280
N _001749 Calpa!n, small subunit 1 CAPNS1 514 1270
NM_005080 X-box binding protein 1 XBP1 1,003 1269
NM_005216 Dolichyl-diphosphooligosaccharide-protein glycosyltransferase DDOST 616 1268
N _004640 HLA-B associated transcript 1 BAT1 237 1262
NM_021983 Major histocompatibility complex, class II, DR beta 4 HLA- 313 1251
DRB1
NM_013234 Eukaryotic translation initiation factor 3 subunit k elF3k 84 1251
NM_004515 Interleukin enhancer binding factor 2, 45kDa ILF2 384 1249
N _000997 Ribosomal protein L37 RPL37 50 1244
NM_000801 FK506 binding protein 1A, 12kDa FKBP1A 1,149 1243
NM_000985 Ribosomal protein L17 RPL17 58 1243
N _001014 Ribosomal protein S10 RPS10 57 1232
NM_001069 Tubulin, beta 2 TUBB2 194 1230
NM_004960 Fusion (involved in t(12;16) in malignant liposarcoma) FUS 166 1197
NM_005165 Aldolase C, fructose-bisphosphafe ALDOC 432 1195
NMJTO4930 Capping protein (actin filament) muscle Z-line, beta CAPZB 259 1193
NMJ 00239 Lysozyme (renal amyloidosis) LYZ 1,016 1190
N _007263 Coatomer protein complex, subunit epsilon COPE 263 1179
NM_001861 Cytochrome c oxidase subunit IV isoform 1 COX4I1 129 1178
NM_003757 Eukaryotic translation initiation factor 3, subunit 2 beta, 36kDa EIF3S2 408 1169
NM_005745 B-cell receptor-associated protein 31 BCAP31 438 1166
NM_002743 Protein kinase C substrate 80K-H PRKCSH 337 1158
N _004161 RAB1A, member RAS oncogene family RAB1A 638 1115
NMJ302080 Glutamic-oxaloacetic transaminase 2, mitochondrial (aspartate GOT2 1,039 1114 aminotransferase 2)
NM_005731 Actin related protein 23 complex, subunit 2, 34kDa ARPC2 448 1113 N _ 006445 PRP8 pre-mRNA processing factor 8 homo!og (yeast) PRPF8 173 1110
NMJ01867 Cytochrome c oxidase subunit Vile COX7C 168 1106
N _002375 Microtubule-associated protein 4 MAP4 1,164 1102
NM_003145 Signal sequence receptor, beta (iranslocon-associated protein beta) SSR2 492 1099
NM_001788 CDC10 cell division cycle 10 homolog (S. cerevisiae) CDC10 1,015 1094
NMJ)06513 Seryl-tRNA synthetase SARS 323 1085
NM_003754 Eukaryotic translation initiation factor 3, subunit 5 epsilon, 47kDa EIF3S5 152 1081
N _005112 WD repeat domain 1 WDR1 845 1080
N _004893 H2A histone family, member Y H2AFY 635 1072
NM_004494 Hepatoma-derived growth factor (high-mobility group protein 1-like) HDGF 1,339 1069
NM_001436 Fibrillarin FBL 111 1069
NM_003752 Eukaryotic translation initiation factor 3, subunit 8, 10kDa EIF3S8 201 1060
NM_003321 Tu translation elongation factor, mitochondrial TUFM 207 1038
N _001119 Adducln 1 (alpha) ADD1 1,569 1037
NM_005273 Guanine nucleotide binding protein (G protein), beta polypeptide 2 GNB2 386 1030
NM_006755 Transaldolase 1 TALD01 256 1026
NM_023009 ARCKS-tike 1 MARCKSL 774 1014
1
NMJD02799 Proteasome (prosome, macropain) subunit, beta type, 7 PS S7 162 1012
NM_002539 Ornithine decarboxylase 1 ODC1 343 1009
NM_006801 KDEL (Lys-Asp-Glu-Leu) endoplasmic reticulum protein retention KDELR1 742 1007 receptor 1
NM_0 4944 Calsyntenin 1 CLSTN1 1,481 1003
NM_007262 Parkinson disease (autosomal recessive, early onset) 7 PAR 7 253 1002
Table 10. List of abundant housekeeping genes (cf. WO 2007/068265 A1 , Table 1 ).
The above table was obtained from WO 2007/068265 A1 , Table 1 and is based on the list of the accession numbers as provided by Eisenberg, E. and E. Y. Levanon (2003): Human housekeeping genes are compact; Trends Genet. 1 9(7): 362-365. The accession numbers were used as input for a PERL (Programmed Extraction Report Language) computer program that extracts EST data from the Unigene database. The Unigene database was downloaded as a text file from the NCBI website. The length of the 3'UTR was derived by computationally extracting the 3'UTR (Bakheet, T., Frevel, M., Williams, BR, and K.S. Khabar, 2001 . ARED: Human AU-rich element-containing mRNA database reveals unexpectedly diverse functional repertoire of encoded proteins. Nucleic Acids Research. 29:246-254). <a> is a commonly used abbreviation of the gene product; <b> is the length of the 3 'UTR; <c> is the number of ESTs. Preferred housekeeping genes include LDHA, NONO, PGK1 and PPIH.
A gene coding for a membrane protein typically refers to such a gene, which codes for a protein that interacts with biological membranes. In most genomes, about 20 - 30% of all genes encode membrane proteins. Common types of proteins include - in addition to membrane proteins - soluble globular proteins, fibrous proteins and disordered proteins. Thus, genes coding for a membrane protein are typically different from genes coding for soluble globular proteins, fibrous proteins or disordered proteins. Membrane proteins include membrane receptors, transport proteins, membrane enzymes and cell adhesion molecules. A gene involved in cellular metabolism typically refers to such a gene, which codes for a protein involved in cellular metabolism, i.e. in the set of life-sustaining chemical transformations within the cells of living organisms. These are typically enzyme-catalyzed reactions, which allow organisms to grow and reproduce, maintain their structures, and respond to their environments. Accordingly, preferred genes involved in cellular metabolism are such genes, which code for enzymes catalyzing a reaction, which allow organisms to grow and reproduce, maintain their structures, and respond to their environments. Other examples for a gene involved in cellular metabolism include genes coding for proteins having structural or mechanical function, such as those that form the cytoskeleton. Other proteins involved in cellular metabolism include proteins involved in cell signalling, immune responses, cell adhesion, active transport across membranes and in the cell cycle. Metabolism is usually divided into two categories: catabolism, the breaking down of organic matter by way of cellular respiration, and anabolism, the building up of components of cells such as proteins and nucleic acids. A gene involved in transcription, translation and replication processes typically refers to such a gene, which codes for a protein involved in transcription, translation and replication processes. In particular, the term "replication", as used in this context, refers preferably to replication of nucleic acids, e.g. DNA replication. Preferred genes involved in transcription, translation and replication processes are genes coding for an enzyme involved in transcription, translation and/or (DNA) replication processes. Other preferred examples include genes coding for a transcription factor or for a translation factor. Ribosomal genes are other preferred examples of genes involved in transcription, translation and replication processes. A gene involved in protein modification typically refers to such a gene, which codes for a protein involved in protein modification. Preferred examples of such genes code for enzymes involved in protein modification, in particular in post-translational modification processes. Preferred examples of enzymes involved in post-translational modification include (i) enzymes involved in the addition of hydrophobic groups, in particular for membrane localization, e.g. enzymes involed in myristoylation, palmitoylation, isoprenylation or prenylation, farnesylation, geranylation or in glypiation; (ii) enzymes involved in the addition of cofactors for enhanced enzymatic activity, e.g. enzymes involved in lipoylation, in the attachment of a flavin moiety, in the attachment of heme C, in phosphopantetheinylation or in retinylidene Schiff base formation; (iii) enzymes involved in the modification of translation factors, e.g. in diphtamide formation, in ethanolamine phosphoglycerol attachment or in hypusine formation; and (vi) enzymes involved in the addition of smaller chemical groups, e.g. acylation, such as acetylation and formylation, alkylation such as methylation, amide bond formation, such as amidation at C-terminus and amino acid addition (e.g. arginylation, polyglutamylation and polyglycylation), butyrylation, gamma-carboxylation, glycosylation, malonylation, hydroxylation, iodination, nucleotide addition, oxidation, phosphate ester or phosphoramidate formation such as phosphorylation and adenylation, propionylation, pyroglutamate formation, S-glutathionylation, S-nitrosylation, succinylation and sulfation.
A gene involved in cell division processes typical ly refers to such a gene, which codes for a protein involved in cell division. Cell division is the process by which a parent cell divides into two or more daughter cells. Cell division usually occurs as part of a larger cell cycle. In eukaryotes, there are two distinct types of cell division: a vegetative division, whereby each daughter cell is genetically identical to the parent cel l (mitosis), and a reductive cell division, whereby the number of chromosomes in the daughter cells is reduced by half, to produce haploid gametes (meiosis). Accordingly, preferred gene involved in cell division processes code for a protein involved in mitosis and/or meiosis. Fig4 is an abbreviation for Factor-Induced Gene. The Fig4 gene codes for polyphosphoinositide phosphatase also known as phosphatidyl inositol 3,5-bisphosphate 5- phosphatase or SAC domain-containing protein 3 (Sac3).
Preferably, the artificial nucleic acid molecule according to the present invention:
(i) comprises at least one 3'-UTR element and at least one 5'-UTR element, wherein preferably (each of) the at least one 3'-UTR element and at least one 5'-UTR element comprises or consists of a nucleic acid sequence which is derived from the 3'-UTR, or the 5'-UTR respectively, of a human or murine protein coding gene; (ii) the at least one 3'-UTR element, the at least one 5'-UTR element and the at least one open reading frame are all heterologous to each other;
(iii) the at least one 5'-UTR element is derived from a gene selected from the group consisting of: housekeeping genes, genes coding for a membrane protein, genes involved in cellular metabolism, genes involved in transcription, translation and replication processes, genes involved in protein modification and genes involved in cell division;
(iv) the 5'-UTR is preferably not a 5' TOP UTR; and
(v) the 3'-UTR is preferably not derived from a gene coding for a ribosomal protein or for albumin or from the Fig4 gene.
More preferably, such an artificial nucleic acid molecule according to the present invention:
(i) comprises at least one 3'-UTR element and at least one 5'-UTR element, wherein preferably (each of) the at least one 3'-UTR element and at least one 5'-UTR element comprises or consists of a nucleic acid sequence which is derived from the 3'-UTR, or the 5'-UTR respectively, of a human or murine protein coding gene;
(ii) the at least one 3'-UTR element, the at least one 5'-UTR element and the at least one open reading frame are all heterologous to each other;
(iii) the at least one 3' UTR element is derived from a human or a murine gene selected from the group consisting of: housekeeping genes, genes coding for a membrane protein, genes involved in cellular metabolism, genes involved in transcription, translation and replication processes, genes involved in protein modification and genes involved in cell division;
(iv) the 3'UTR is not derived from a gene coding for a ribosomal protein or for albumin or from the Fig4 gene;
(v) the at least one 5'-UTR element is derived from a human or a murine gene selected from the group consisting of: housekeeping genes, genes coding for a membrane protein, genes involved in cellular metabolism, genes involved in transcription, translation and replication processes, genes involved in protein modification and genes involved in cell division; and
(vi) the 5'-UTR is not a 5' TOP UTR. Thereby, it is preferred in the artificial nucleic acid molecule according to the present invention that the 3'-UTR and the 5'-UTR are derived from a human or a murine housekeeping gene. It is also preferred that the 3'-UTR and the 5'-UTR are derived from a human or a muri ne gene coding for a membrane protein. It is also preferred that the 3'-UTR and the 5'-UTR are derived from a human or a murine gene involved in cellular metabolism. It is also preferred that the 3'-UTR and the 5'-UTR are derived from a human or a murine gene involved in transcription, translation and replication processes. It is also preferred that the 3'-UTR and the 5'-UTR are derived from a human or a murine gene involved in protein modification. It is also preferred that the 3'-UTR and the 5'-UTR are derived from a human or a murine gene involved in cell division. In this context, the skilled person is aware that if (i) the 3'-UTR and the 5'-UTR are derived from genes belonging to the same gene class and (ii) the at least one 3'-UTR and the at least one 5'-UTR are heterologous to each other, that the the 3'-UTR and the 5'-UTR are not derived from the same gene, but from distinct genes belonging to the same gene class. Accordingly, it is preferred that the at least one 3'-UTR and the at least one 5'-UTR are derived from distinct genes belonging to the same gene class.
As used herein the term "gene class" refers to the classification of genes. Examples of gene classes include (i) housekeeping genes, (ii) genes coding for a membrane protein, (iii) genes involved in cellular metabolism, (iv) genes involved in transcription, translation and replication processes, (v) genes involved in protein modification and (vi) genes involved in cell division. In other words, "housekeeping genes" is one gene class, whereas "genes involved in transcription" is another gene class, "genes involved in cellular metabolism" is a further gene class, etc.. It is also preferred in the artificial nucleic acid molecule according to the present invention as described herein, that the 3'-UTR and the 5'-UTR are derived from a human or a murine gene selected from the group consisting of: genes coding for a membrane protein, genes involved in cellular metabolism, genes involved in transcription, translation and replication processes, genes involved in protein modification and genes involved in cell division, wherein the 3'-UTR and the 5'-UTR are selected from distinct gene classes. Preferably, the at least one 3'-UTR element and/or to the at least one 5'-UTR element is functionally linked to the ORF. This means preferably that the 3'-UTR element and/or to the at least one 5'-UTR element is associated with the ORF such that it may exert a function, such as an enhancing or stabilizing function on the expression of the encoded peptide or protein or a stabilizing function on the artificial nucleic acid molecule. Preferably, the ORF and the 3'-UTR element are associated in 5'- 3' direction and/or the 5'-UTR element and the ORF are associated in 5'->3' direction. Thus, preferably, the artificial nucleic acid molecule comprises in general the structure 5'-[5'-UTR element]-(optional)-linker-ORF-(optional)- linker-[3'-UTR element]-3', wherein the artificial nucleic acid molecule may comprise only a 5'-UTR element and no 3'-UTR element, only a 3'-UTR element and no 5'-UTR element, or both, a 3'-UTR element and a 5'-UTR element. Furthermore, the linker may be present or absent. For example, the linker may be one or more nucleotides, such as a stretch of 1 -50 or 1 -20 nucleotides, e.g., comprising or consisting of one or more restriction enzyme recognition sites (restriction sites).
Preferably, the at least one 3'-UTR element and/or the at least one 5'-UTR element comprises or consists of a nucleic acid sequence which is derived from the 3'-UTR and/or the 5'-UTR of a transcript of a gene selected from the group consisting of CNAS (guanine nucleotide binding protein, alpha stimulating complex locus), MORN2 (MORN repeat containing 2), GSTM1 (glutathione S-transferase, mu 1 ), NDUFA1 (NADH dehydrogenase (ubiquinone) 1 alpha subcomplex), CBR2 (carbonyl reductase 2), MP68 (RIKEN cDNA 2010107E04 gene), NDUFA4 (NADH dehydrogenase (ubiquinone) 1 alpha subcomplex 4), Ybx1 (Y-Box binding protein 1 ), Ndufb8 (NADH dehydrogenase (ubiquinone) 1 beta subcomplex 8), CNTN1 (contactin 1 ), LTA4H, SLC38A6, DECR1 , PIGK, FAM1 75A, PHYH, TBC1 D19, PIGB, ALG6, CRYZ, BRP44L, ACADSB, SUPT3H, TMEM14A, GRAMD1 C, C1 1 orf80, C9orf46, ANXA4, TBCK, IFI6, C2orf34, ALDH6A1 , AGTPBP1 , CCDC53, LRRC28, CCDC109B, PUS10, CCDC104, CASP1 , SNX14, SKAP2, NDUFB6, EFHA1 , BCKDHB, BBS2, LMBRD1 , ITGA6, HERC5, NT5DC1 , RAB7A, AGA, TPK1 , MBNL3, HADHB, MCCC2, CAT, ANAPC4, PCCB, PHKB, ABCB7, PGCP, GPD2, TMEM38B, NFU1 , OMA1 , LOC128322/NUTF2, NUBPL, LANCL1 , HHLA3, PIR, ACAA2, CTBS, GSTM4, ALG8, Atp5e, Gstm5, Uqcrl l , Ifi27l2a, Anapc13, Atp5l, Tmsb10, Nenf, Ndufa7, Atp5k, 1 1 10008P14Rik, Cox4i1 , Cox6a1 , Ndufs6, Sec61 b, Romol , Snrpd2, Mgst3, Aldh2, Ssr4, Myl6, Prdx4, Ubl5, 1 1 10001J03Rik, Ndufa13, Ndufa3, Gstp2, Tmem1 60, Ergic3, Pgcp, Slpi, Myeov2, Ndufs5, 1 81002701 ORik, Atp5o, Shfml, Tspo, S100a6, Taldol, Bloclsl, Hexa, Ndufb11, Map1 Ic3a, Gpx4, Mif, Cox6b1, RI EN CDNA2900010J23 (Swi5), Sec61g, 2900010M23Rik, Anapc5, Mars2, Phptl, Pfdn5, Arpc3, Ndufb7, Atp5h, Mrpl23, Uba52, Tomm6, Mtchi, Pcbd2, Ecm1, Hrsp12, Mecr, Uqcrq, Gstm3, Lsm4, Park7, Usmg5, Cox8a, Ly6c1, Cox7b, Ppib, Bag1, S100a4, Bcap31, Tecr, Rabacl, Robld3, Sod1, Nedd8, Higd2a, Trappc6a, Ldhb, Nme2, Snrpg, Ndufa2, Serfl, Oazl, Rps4x, Rps13, Seppl, Gaa, ACTR10, PIGF, MGST3, SCP2, HPRT1, ACSF2, VPS13A, CTH, NXT2, MGST2, C11orf67, PCCA, GLMN, DHRS1, PON2, NME7, ETFDH, ALG13, DDX60, DYNC2LI1, VPS8, ITFG1, CDK5, C1orf112, IFT52, CLYBL, FAM114A2, NUDT7, A D1, MAGED2, HRSP12, STX8, ACAT1 , IFT74, KIFAP3, CAPN1, COX11, GLT8D4, HACL1, IFT88, NDUFB3, ANO10, ARL6, LPCAT3, ABCD3, COPG2, MIPEP, LEPR, C2orf76, ABCA6, LY96, CROT, ENPP5, SERPINB7, TCP11 L2, IRAKI BP1 , CDKL2, GHR, KIAA1107, RPS6KA6, CLGN, TMEM45A, TBC1D8B, ACP6, RP6-213H19.1 , SNRPN, GLRB, HERC6, CFH, GALC, PDE1A, GSTM5, CADPS2, AASS, TRIM6-TRIM34 (readthrough transcript), SEPP1, PDE5A, SATB1, CCPG1, LMBRD2, TLR3, BCAT1 , TOM1 L1, SLC35A1, GLYATL2, STAT4, GULP1, EHHADH, NBEAL1 , KIAA1598, HFE, KIAA1324L, and MANSC1.
In a particularly preferred embodiment the at least one 3'-UTR element and/or the at least one 5'-UTR element comprises or consists of a nucleic acid sequence which is derived from the 3'-UTR and/or the 5'-UTR of a transcript of a gene selected from the group consisting of GNAS (guanine nucleotide binding protein, alpha stimulating complex locus), MORN2 (MORN repeat containing 2), NDUFA1 (NADH dehydrogenase (ubiquinone) 1 alpha subcomplex), CBR2 (carbonyl reductase 2), MP68 (RIKEN cDNA 2010107E04 gene), NDUFA4 (NADH dehydrogenase (ubiquinone) 1 alpha subcomplex 4), LTA4H, SLC38A6, DECR1, PIGK, FAM175A, PHYH, TBC1D19, PIGB, ALG6, CRYZ, BRP44L, ACADSB, SUPT3H, TMEM14A, GRAMD1C, C11orf80, C9orf46, ANXA4, TBCK, IFI6, C2orf34, ALDH6A1, AGTPBP1, CCDC53, LRRC28, CCDC109B, PUS10, CASP1, SNX14, SKAP2, NDUFB6, EFHA1, BCKDHB, BBS2, ITGA6, HERC5, NT5DC1, RAB7A, AGA, TPK1, MBNL3, HADHB, MCCC2, CAT, ANAPC4, PCCB, PHKB, ABCB7, PGCP, GPD2, TMEM38B, NFU1, OMA1, LOC128322/NUTF2, NUBPL, LANCL1, HHLA3, PIR, ACAA2, CTBS, GSTM4, ALG8, Atp5e, Gstm5, Uqcr11, Ifi27l2a, Anapc13, Atp5l, Nenf, Ndufa7, Atp5k, 1110008P14Rik, Cox4i1, Cox6a1, Ndufs6, Sec61b, Romol, Snrpd2, Mgst3, Aldh2, Ssr4, Myl6, Prdx4, Ubl5, 1110001J03Rik, Ndufa13, Ndufa3, Gstp2, Tmem160, Ergic3, Pgcp, Slpi, Ndufs5, 181002701 ORik, Atp5o, Shfml , Tspo, S100a6, Taldol , Bloc! s1 , Hexa, Ndufbl 1 , Map1 Ic3a, Gpx4, Mif, Cox6b1 , RI EN cDNA2900010J23 (Swi5), Sec61 g, 2900010M23Rik/ Anapc5, Mars2, Phptl , Ndufb8, Pfdn5, Arpc3, Ndufb7, Atp5h, Mrpl23, Tomm6, Mtchl , Pcbd2, Ecm1 , Hrsp12, Mecr, Uqcrq, Gstm3, Lsm4, Park7, Usmg5, Cox8a, Ly6c1 , Cox7b, Ppib, Bag1 , S100a4, Bcap31 , Tecr, Rabad , Robld3, Sod1 , Nedd8, Higd2a, Ldhb, Nme2, Snrpg, Ndufa2, Serfl , Oaz1 , Ybxl , Seppl , Gaa, ACTR10, PIGF, MGST3, SCP2, HPRT1 , ACSF2, VPS 13 A, CTH, NXT2, MGST2, C1 1 orf67, PCCA, GLMN, DHRS1 , PON2, NME7, ETFDH, ALG1 3, DDX60, DYNC2LI1 , VPS8, ITFG1 , CD 5, C1 orf1 12, IFT52, CLYBL, FAM1 14A2, NUDT7, AKD1 , MAGED2, HRSP12, STX8, ACAT1 , IFT74, IFAP3, CAPN1 , COX1 1 , GLT8D4, HACL1 , 1FT88, NDUFB3, ANO10, ARL6, LPCAT3, ABCD3, COPG2, MIPEP, C2orf76, ABCA6, LY96, CROT, ENPP5, SERPINB7, TCP1 1 L2, IRAKI BP1 , CDKL2, GHR, KIAA1 107, RPS6KA6, CLGN, TMEM45A, TBC1 D8B, ACP6, RP6-213H1 9.1 , SNRPN, GLRB, HERC6, CFH, GALC, PDE1 A, GSTM5, CADPS2, AASS, TRIM6-TRIM34 (readthrough transcript), SEPP1 , PDE5A, SATB1 , CCPG1 , CNTN1 , LMBRD2, TLR3, BCAT1 , TOM1 L1 , SLC35A1 , GLYATL2, STAT4, GULP1 , EHHADH, NBEAL1 , KIAA1598, HFE, KIAA1324L, and MANSC1 .
More preferably, the at least one 3'-UTR element and/or the at least one 5'-UTR element comprises or consists of a nucleic acid sequence which is derived from the 3'-UTR and/or the 5'-UTR of a transcript of a gene selected from the group consisting of GNAS (guanine nucleotide binding protein, alpha stimulating complex locus), MORN2 (MORN repeat containing 2), GSTM1 (glutathione S-transferase, mu 1 ), NDUFA1 (NADH dehydrogenase (ubiquinone) 1 alpha subcomplex), CBR2 (carbonyl reductase 2), MP68 (RIKEN cDNA 2010107E04 gene), Ybx1 (Y-Box binding protein 1 ), Ndufb8 (NADH dehydrogenase (ubiquinone) 1 beta subcomplex 8), CNTN1 (contactin 1 ) and NDUFA4 (NADH dehydrogenase (ubiquinone) 1 alpha subcomplex 4).
Preferably, the at least one 3'-UTR element and/or the at least one 5'-UTR element of the artificial nucleic acid molecule according to the present invention comprises or consists of a "functional fragment", a "functional variant" or a "functional fragment of a variant" of the 3'- UTR and/or the 5'-UTR of a transcript of a gene.
Preferably, the at least one 3'-UTR element and/or the at least one 5'-UTR element comprises a nucleic acid sequence which is derived from the 3'-UTR and/or the 5'-UTR of a transcript of a human gene selected from the group consisting of GNAS (guanine nucleotide binding protein, alpha stimulating complex locus), MORN2 (MORN repeat containing 2), GSTM1 (glutathione S-transferase, mu 1), NDUFA1 (NADH dehydrogenase (ubiquinone) 1 alpha subcomplex), CBR2 (carbonyl reductase 2), MP68 (RIKEN cDNA 2010107E04 gene), NDUFA4 (NADH dehydrogenase (ubiquinone) 1 alpha subcomplex 4), LTA4H, SLC38A6, DECR1, PIGK, FAM175A, PHYH, TBC1D19, PIGB, ALG6, CRYZ, BRP44L, ACADSB, SUPT3H, TMEM14A, GRAMD1C, C11orf80, C9orf46, ANXA4, TBCK, IFI6, C2orf34, ALDH6A1, AGTPBP1, CCDC53, LRRC28, CCDC109B, PUS10, CCDC104, CASP1, SNX14, SKAP2, NDUFB6, EFHA1, BCKDHB, BBS2, LMBRD1, ITGA6, HERC5, NT5DC1, RAB7A, AGA, TPK1, MBNL3, HADHB, MCCC2, CAT, ANAPC4, PCCB, PHKB, ABCB7, PGCP, GPD2, TMEM38B, NFU1, OMA1, LOCI 28322/NUTF2, NUBPL, LANCL1, HHLA3, PIR, ACAA2, CTBS, GSTM4, ALG8, ACTR10, PIGF, MGST3, SCP2, HPRT1, ACSF2, VPS 13 A, CTH, NXT2, MGST2, C11orf67, PCCA, GLMN, DHRS1, PON2, NME7, ETFDH, ALG13, DDX60, DYNC2LI1, VPS8, ITFG1, CDK5, C1orf112, IFT52, CLYBL, FAM114A2, NUDT7, AKD1, MAGED2, HRSP12, STX8, ACAT1, IFT74, KIFAP3, CAPN1, COX11, GLT8D4, HACL1, IFT88, NDUFB3, ANO10, ARL6, LPCAT3, ABCD3, COPG2, MIPEP, LEPR, C2orf76, ABCA6, LY96, CROT, ENPP5, SERPINB7, TCP11 L2, IRAKI BP1 , CDKL2, GHR, KIAA1107, RPS6KA6, CLGN, TMEM45A, TBC1D8B, ACP6, RP6-213H19.1, SNRPN, GLRB, HERC6, CFH, GALC, PDE1A, GSTM5, CADPS2, AASS, TR1M6-TRIM34 (readthrough transcript), SEPP1, PDE5A, SATB1, CCPG1, CNTN1, LMBRD2, TLR3, BCAT1, TOM1L1, SLC35A1, GLYATL2, STAT4, GULP1, EHHADH, NBEAL1 , KIAA1598, HFE, KIAA1324L, and MANSC1.
Alternatively or additionally, it is also preferred that the at least one 3'-UTR element and/or the at least one 5'-UTR element comprises a nucleic acid sequence which is derived from the 3'-UTR and/or the 5'-UTR of a transcript of a murine gene selected from the group consisting of GNAS (guanine nucleotide binding protein, alpha stimulating complex locus), MORN2 (MORN repeat containing 2), GSTM1 (glutathione S-transferase, mu 1), NDUFA1 (NADH dehydrogenase (ubiquinone) 1 alpha subcomplex), CBR2 (carbonyl reductase 2), MP68 (RIKEN cDNA 2010107E04 gene), NDUFA4 (NADH dehydrogenase (ubiquinone) 1 alpha subcomplex 4), Atp5e, Gstm5, Uqcr11, Ifi27l2a, Anapc13, Atp5l, Tmsb10, Nenf, Ndufa7, Atp5k, 1110008P14Rik, Cox4i1, Cox6a1, Ndufs6, Sec61b, Romol, Snrpd2, Mgst3, Aldh2, Ssr4, Myl6, Prdx4, Ubl5, 1110001J03Rik, Ndufa13, Ndufa3, Gstp2, Tmem160, Ergic3, Pgcp, Slpi, Myeov2, Ndufs5, 181002701 ORik, Atp5o, Shfml, Tspo, S100a6, Taldol, Blodsl, Hexa, Ndufb11, Map1lc3a, Gpx4, Mif, Cox6b1, RIKEN cDNA2900010J23 (Swi5), Sec61g, 2900010M23 Rik, Anapc5, Mars2, Phpti, Nclufb8, Pfdn5, Arpc3, Ndufb7, Atp5h, Mrpl23, Uba52, Tomm6, Mtchl, Pcbd2, Ecm1, Hrsp12, Mecr, Uqcrq, Gstm3, Lsm4, Park7, Usmg5, Cox8a, Ly6c1, Cox7b, Ppib, Bag1, S100a4, Bcap31, Tecr, Rabad, Robld3, Sodi, Nedd8, Higd2a, Trappc6a, Ldhb, Nme2, Snrpg, Ndufa2, Serfl, Oaz1, Rps4x, Rps13, Ybx1, Seppl, and Gaa.
Preferably, the at least one 3'-UTR element comprises a nucleic acid sequence which is derived from the 3'-UTR of a transcript of a gene selected from the group consisting of GNAS (guanine nucleotide binding protein, alpha stimulating complex locus), MORN2 (MORN repeat containing 2), GSTM1 (glutathione S-transferase, mu 1), NDUFA1 (NADH dehydrogenase (ubiquinone) 1 alpha subcomplex), CBR2 (carbonyl reductase 2), SLC38A6, DECR1, PIGK, FAM175A, PHYH, TBC1D19, PIGB, ALG6, CRYZ, BRP44L, ACADSB, TMEM14A, GRAMD1C, C11orf80, ANXA4, TBCK, IFI6, C2orf34, ALDH6A1, AGTPBP1, CCDC53, LRRC28, CCDC109B, PUS10, CCDC104, CASP1, SNX14, SKAP2, NDUFB6, EFHA1, BCKDHB, BBS2, LMBRD1, ITGA6, HERC5, HADHB, ANAPC4, PCCB, ABCB7, PGCP, NFU1, OMA1, HHLA3, ACAA2, GSTM4, ALG8, Atp5e, Gstm5, Uqcr11, Ifi27l2a, Cbr2, Atp5l, Tmsb10, Nenf, Atp5k, 1110008P14Rik, Cox4i1, Cox6a1, Ndufs6, Sec61b, Romol, Gnas, Snrpd2, Mgst3, Aldh2, Ss4, Myl6, Prdx4, Ubl5, 1110001 J03Rik, Ndufa13, Ndufa3, Gstp2, Tmem160, Ergic3, Pgcp, Slpi, Myeov2, Ndufa4, Ndufs5, Gstml, 181002701 ORik, Atp5o, Shfml, Tspo, S100a6, Taldol, Blodsl, Ndufb11, Map1 Ic3a, Morn2, Gpx4, Mif, Cox6b1, RIKEN cDNA2900010J23 (Swi5), Sec61g, 2900010M23Rik, Anapc5, Mars2, Phpti, Ndufb8, Pfdn5, Arpc3, Ndufb7, Atp5h, Mrpl23, Uba52, Tomm6, Mtchl, Pcbd2, Ecml, Hrsp12, Mecr, Uqcrq, Gstm3, Lsm4, Park7, Usmg5, Cox8a, Ly6c1, Cox7b, Ppib, Bag1, S100a4, Bcap31, Tecr, Rabad, Robld3, Sodi, Nedd8, Higd2a, Trappc6a, Ldhb, Nme2, Snrpg, Ndufa2, Serfl, Oaz1, Rps4x, Rps13, Ybx1, Seppl, Gaa, ACTR10, PIGF, MGST3, SCP2, HPRT1, ACSF2, VPS13A, CTH, NXT2, MGST2, C11orf67, PCCA, GLMN, DHRS1 , PON2, NME7, ETFDH, ALG13, DDX60, DYNC2LI1 , VPS8, ITFG1 , CDK5, C1 orfl 12, IFT52, CLYBL, FAM114A2, NUDT7, AKD1, MAGED2, HRSP12, STX8, ACAT1, IFT74, KIFAP3, CAPN1, COX11, GLT8D4, HACL1, IFT88, NDUFB3, ANO10, ARL6, LPCAT3, ABCD3, COPG2, MIPEP, LEPR, C2orf76, ABCA6, LY96, CROT, ENPP5, SERPINB7, TCP11 L2, IRAKI BP1, CDKL2, GHR, KIAA1107, RPS6KA6, CLGN, TMEM45A, TBC1 D8B, ACP6, RP6- 213H19.1, SNRPN, GLRB, HERC6, CFH, GALC, PDE1A, GSTM5, CADPS2, AASS, TRIM6- TR1M34 (readthrough transcript), SEPP1, PDE5A, SATB1, CCPG1, CNTN1, LMBRD2, TLR3, BCAT1 , TOM1L1, SLC35A1, GLYATL2, STAT4, GULP1, EHHADH, NBEAL1, KIAA1598, HFE, IAA1324L, and MANSC1. More preferably, the at least one 3'-UTR element comprises or consists of a nucleic acid sequence which is derived from the 3'-UTR of a transcript of a gene selected from the group consisting of GNAS (guanine nucleotide binding protein, alpha stimulating complex locus), MORN2 (MORN repeat containing 2), GSTM1 (glutathione S- transferase, mu 1), NDUFA1 (NADH dehydrogenase (ubiquinone) 1 alpha subcomplex), CBR2 (carbonyl reductase 2), Ybx1 (Y-Box binding protein Ί ), Ndufb8 (NADH dehydrogenase (ubiquinone) 1 beta subcomplex 8), and CNTN1 (contactin 1). In a particularly preferred embodiment, the at least one 3'-UTR element comprises a nucleic acid sequence which is derived from the 3'-UTR of a transcript of a gene selected from the group consisting of GNAS (guanine nucleotide binding protein, alpha stimulating complex locus), MORN2 (MORN repeat containing 2), GSTM1 (glutathione S-transferase, mu 1), NDUFA1 (NADH dehydrogenase (ubiquinone) 1 alpha subcomplex), CBR2 (carbonyl reductase 2), SLC38A6, DECR1, PIGK, FAM175A, PHYH, TBC1D19, PIGB, ALG6, CRYZ, BRP44L, ACADSB, TMEM14A, GRAMD1C, C11orf80, ANXA4, TBCK, IFI6, C2orf34, ALDH6A1, AGTPBP1, CCDC53, LRRC28, CCDC109B, PUS10, CCDC104, CASPl, SNX14, SKAP2, NDUFB6, EFHA1, BCKDHB, BBS2, LMBRD1, ITGA6, HERC5, HADHB, ANAPC4, PCCB, ABCB7, PGCP, NFU1, OMA1, HHLA3, ACAA2, GSTM4, ALG8, Atp5e, Gstm5, Uqcrll, Ifi27l2a, Cbr2, Atp5l, TmsblO, Nenf, Atp5k, 1110008P14Rik, Cox4i1, Cox6a1, Ndufs6, Sec61b, Romol, Gnas, Snrpd2, Mgst3, Aldh2, Ss4, Myl6, Prdx4, Ubl5, 1110001J03Rik, Ndufa 3, Ndufa3, Gstp2, Tmem160, Ergic3, Pgcp, Slpi, Myeov2, Ndufa4, Ndufs5, Gstml, 181002701 ORik, Atp5o, Shfml, Tspo, S100a6, Taldol, Bloclsl, Ndufb11, Map1lc3a, Morn2, Gpx4, Mif, Cox6b1, RIKEN cDNA2900010J23 (Swi5), Sec61g, 290001 OM23Rik, Anapc5, Mars2, Phptl , Ndufb8, Pfdn5, Arpc3, Ndufb7, Atp5h, Mrpl23, Tomm6, Mtchl, Pcbd2, Ecml, Hrsp12, Mecr, Uqcrq, Gstm3, Lsm4, Park7, Usmg5, Cox8a, Ly6c1, Cox7b, Ppib, Bag1, S100a4, Bcap31, Tecr, Rabad, Robld3, Sod1, Nedd8, Higd2a, Trappc6a, Ldhb, Nme2, Snrpg, Ndufa2, Serfl, Oaz1, Ybx1, Seppl, Gaa, ACTR10, PIGF, MGST3, SCP2, HPRT1, ACSF2, VPS13A, CTH, NXT2, MGST2, C11orf67, PCCA, GLMN, DHRS1 , PON2, NME7, ETFDH, ALG13, DDX60, DYNC2LI1 , VPS8, ITFG1 , CDK5, C1 orfl 12, IFT52, CLYBL, FAM114A2, NUDT7, AKD1, MAGED2, HRSP12, STX8, ACAT1, IFT74, KIFAP3, CAPN1, COX11, GLT8D4, HACL1, IFT88, NDUFB3, ANO10, ARL6, LPCAT3, ABCD3, COPG2, MIPEP, LEPR, C2orf76, ABCA6, LY96, CROT, ENPP5, SERPINB7, TCP11 L2, IRAKI BP1, CDKL2, GHR, KIAA1107, RPS6KA6, CLGN, TMEM45A, TBC1 D8B, ACP6, RP6- 213H19.1, SNRPN, GLRB, HERC6, CFH, GALC, PDE1 A, GSTM5, CADPS2, AASS, TRIM6- TRIM34 (readthrough transcript), SEPP1, PDE5A, SATB1, CCPG1, CNTN1, LMBRD2, TLR3, BCAT1 , TOM1L1, SLC35A1, GLYATL2, STAT4, GULP1, EHHADH, NBEAL1, KIAA1598, HFE, KlAAl 324L, and MANSC1. More preferably, the at least one 3'-UTR element comprises or consists of a nucleic acid sequence which is derived from the 3'-UTR of a transcript of a gene selected from the group consisting of GNAS (guanine nucleotide binding protein, alpha stimulating complex locus), MORN2 (MORN repeat containing 2), GSTM1 (glutathione S- transferase, mu 1), NDUFA1 (NADH dehydrogenase (ubiquinone) 1 alpha subcomplex), CBR2 (carbonyl reductase 2), Ybx1 (Y-Box binding protein 1 ), Ndufb8 (NADH dehydrogenase (ubiquinone) 1 beta subcomplex 8), and CNTN1 (contactin 1).
More preferably, the at least one 3'-UTR element comprises a nucleic acid sequence which is derived from the 3'-UTR of a transcript of a human gene selected from the group consisting of GNAS (guanine nucleotide binding protein, alpha stimulating complex locus), MORN2 (MORN repeat containing 2), GSTM1 (glutathione S-transferase, mu 1), NDUFA1 (NADH dehydrogenase (ubiquinone) 1 alpha subcomplex), CBR2 (carbonyl reductase 2), SLC38A6, DECR1, PIGK, FAM175A, PHYH, TBC1D19, PIGB, ALG6, CRYZ, BRP44L, ACADSB, TMEM14A, GRAMD1C, C11orf80, ANXA4, TBCK, IFI6, C2orf34, ALDH6A1, AGTPBPI, CCDC53, LRRC28, CCDC109B, PUS10, CCDC104, CASP1 , SNX14, SKAP2, NDUFB6, EFHA1, BCKDHB, BBS2, LMBRD1, ITGA6, HERC5, HADHB, ANAPC4, PCCB, ABCB7, PGCP, NFU1, OMA1, HHLA3, ACAA2, GSTM4, ALG8, ACTR10, PIGF, MGST3, SCP2, HPRT1, ACSF2, VPS13A, CTH, NXT2, MGST2, C11orf67, PCCA, GLMN, DHRS1, PON2, NME7, ETFDH, ALG13, DDX60, DYNC2LI1, VPS8, ITFG1, CDK5, C1orf112, IFT52, CLYBL, FAM114A2, NUDT7, AKD1, MAGED2, HRSP12, STX8, ACAT1, IFT74, KIFAP3, CAPN1, COX11, GLT8D4, HACL1, IFT88, NDUFB3, ANO10, ARL6, LPCAT3, ABCD3, COPG2, MIPEP, LEPR, C2orf76, ABCA6, LY96, CROT, ENPP5, SERPINB7, TCP11 L2, IRAKI BP1, CDKL2, GHR, KIAA1107, RPS6KA6, CLGN, TMEM45A, TBC1D8B, ACP6, RP6-213H19.1, SNRPN, GLRB, HERC6, CFH, GALC, PDE1A, GSTM5, CADPS2, AASS, TRIM6-TRIM34 (readthrough transcript), SEPP1, PDE5A, SATB1, CCPG1, CNTN1, LMBRD2, TLR3, BCAT1, TOM1L1, SLC35A1, GLYATL2, STAT4, GULP1, EHHADH, NBEAL1, KIAA1598, HFE, KIAA1324L, and MANSC1 ; preferably, the at least one 3'-UTR element comprises or consists of a nucleic acid sequence which is derived from the 3'-UTR of a transcript of a human gene selected from the group consisting of GNAS (guanine nucleotide binding protein, alpha stimulating complex locus), MORN2 (MORN repeat containing 2), GSTM1 (glutathione S- transferase, mu 1 ), NDUFA1 (NADH dehydrogenase (ubiquinone) 1 alpha subcomplex), CBR2 (carbonyl reductase 2), Ybx1 (Y-Box binding protein 1 ), Ndufb8 (NADH dehydrogenase (ubiquinone) 1 beta subcomplex 8), and CNTN1 (contactin 1 ).
Accordingly, it is also more preferable that the at least one 3'-UTR element comprises a nucleic acid sequence which is derived from the 3'-UTR of a transcript of a murine gene selected from the group consisting of GNAS (guanine nucleotide binding protein, alpha stimulating complex locus), MORN2 (MORN repeat containing 2), GSTM1 (glutathione S- transferase, mu 1 ), NDUFA1 (NADH dehydrogenase (ubiquinone) 1 alpha subcomplex), CBR2 (carbonyl reductase 2), Ybx1 (Y-Box binding protein 1 ), Ndufb8 (NADH dehydrogenase (ubiquinone) 1 beta subcomplex 8), and CNTN1 (contactin 1 ), Ndufal , Atp5e, Gstm5, Uqcr1 1 , Ifi27l2a, Cbr2, Atp5l, Tmsbl O, Nenf, Atp5k, 1 1 10008P14Rik, Cox4i1 , Cox6a1 , Ndufs6, Sec61 b, Romol , Gnas, Snrpd2, Mgst3, Aldh2, Ssr4, Myl6, Prdx4, Ubl5, 1 1 10001J03Rik, Ndufal 3, Ndufa3, Gstp2, Tmem160, Ergic3, Pgcp, Slpi, Myeov2, Ndufa4, Ndufs5, Gstml , 181002701 ORik, Atp5o, Shfml , Tspo, S100a6, Taldol , Blod sl , Ndufb1 1 , Map1 lc3a, Morn2, Gpx4, Mif, Cox6b1 , RIKEN cDNA2900010J23 (Swi5), Sec61 g, 290001 OM23Rik, Anapc5, Mars2, Phpti , Ndufb8, Pfdn5, Arpc3, Ndufb7, Atp5h, Mrpl23, Uba52, Tomm6, Mtchl , Pcbd2, Ecm1 , Hrsp12, Mecr, Uqcrq, Gstm3, Lsm4, Park7, Usmg5, Cox8a, Ly6c1 , Cox7b, Ppib, Bag1 , S100a4, Bcap31 , Tecr, Rabad , Robld3, Sod1 , Nedd8, Higd2a, Trappc6a, Ldhb, Nme2, Snrpg, Ndufa2, Serfl , Oaz1 , Rps4x, Rps13, Ybx1 , Seppl , and Gaa; preferably, the at least one 3'-UTR element comprises or consists of a nucleic acid sequence which is derived from the 3'-UTR of a transcript of a murine gene selected from the group consisting of GNAS (guanine nucleotide binding protein, alpha stimulating complex locus), MORN2 (MORN repeat containing 2), GSTM1 (glutathione S-transferase, mu 1 ), NDUFA1 (NADH dehydrogenase (ubiquinone) 1 alpha subcomplex), CBR2 (carbonyl reductase 2), Ybx1 (Y-Box binding protein 1 ), Ndufb8 (NADH dehydrogenase (ubiquinone) 1 beta subcomplex 8), and CNTN1 (contactin 1 ).
Preferably, the at least one 5'-UTR element comprises a nucleic acid sequence which is derived from the 5'-UTR of a transcript of a gene selected from the group consisting of MP68 (RIKEN cDNA 2010107E04 gene), NDUFA4 (NADH dehydrogenase (ubiquinone) 1 alpha subcomplex 4), LTA4H, DECR1 , PIGK, TBC1 D1 9, BRP44L, ACADSB, SUPT3H, TMEM14A, C9orf46, ANXA4, IFI6, C2orf34, ALDH6A1 , CCDC53, CCDC104, CASP1 , NDUFB6, BC DHB, BBS2, HERC5, FAM1 75A, NT5DC1 , RAB7A, AGA, TP 1 , MBNL3, MCCC2, CAT, ANAPC4, PHKB, ABCB7, GPD2, TMEM38B, NFU1 , LOC128322/NUTF2, NUBPL, LANCL1 , PIR, CTBS, GSTM4, Ndufal , Atp5e, Gstm5, Cbr2, Anapd 3, Ndufa7, Atp5k, 1 1 10008P14Rik, Cox4i1 , Ndufs6, Sec61 b, Snrpd2, Mgst3, Prdx4; Pgcp; Myeov2; Ndufa4; Ndufs5; Gstml ; Atp5o; Tspo; Taldol ; Blod sl ; and Hexa. More preferably, the at least one 5'-UTR element comprises or consists of a nucleic acid sequence which is derived from the 5'-UTR of a transcript of MP68 (RIKEN cDNA 2010107E04 gene) or NDUFA4 (NADH dehydrogenase (ubiquinone) 1 alpha subcomplex 4).
In a particularly preferred embodiment, the at least one 5'-UTR element comprises a nucleic acid sequence which is derived from the 5'-UTR of a transcript of a gene selected from the group consisting of MP68 (RIKEN cDNA 2010107E04 gene), NDUFA4 (NADH dehydrogenase (ubiquinone) 1 alpha subcomplex 4), LTA4H, DECR1 , PIGK, TBC1 D1 9, BRP44L, ACADSB, SUPT3H, TMEM14A, C9orf46, ANXA4, IFI6, C2orf34, ALDH6A1 , CCDC53, CASP1 , NDUFB6, BCKDHB, BBS2, HERC5, FAM1 75A, NT5DC1 , RAB7A, AGA, TPK1 , MBNL3, MCCC2, CAT, ANAPC4, PHKB, ABCB7, GPD2, TMEM38B, NFU1 , LOC128322/NUTF2, NUBPL, LANCL1 , PIR, CTBS, GSTM4, Ndufal , Atp5e, Gstm5, Cbr2, Anapd 3, Ndufa7, Atp5k, 1 1 10008P14Rik, Cox4i1 , Ndufs6, Sec61 b, Snrpd2, Mgst3, Prdx4; Pgcp; Ndufa4; Ndufs5; Atp5o; Tspo; Taldol ; Blod sl ; and Hexa. More preferably, the at least one 5'-UTR element comprises or consists of a nucleic acid sequence which is derived from the 5'-UTR of a transcript of MP68 (RIKEN cDNA 2010107E04 gene) or NDUFA4 (NADH dehydrogenase (ubiquinone) 1 alpha subcomplex 4).
More preferably, the at least one 5'-UTR element comprises a nucleic acid sequence which is derived from the 5'-UTR of a transcript of a human gene selected from the group consisting of MP68 (RIKEN cDNA 2010107E04 gene), NDUFA4 (NADH dehydrogenase (ubiquinone) 1 alpha subcomplex 4), LTA4H, DECR1 , PIGK, TBC1 D19, BRP44L, ACADSB, SUPT3H, TMEM14A, C9orf46, ANXA4, IFI6, C2orf34, ALDH6A1 , CCDC53, CCDC104, CASP1 , NDUFB6, BCKDHB, BBS2, HERC5, FAM1 75A, NT5DC1 , RAB7A, AGA, TPK1 , MBNL3, MCCC2, CAT, ANAPC4, PHKB, ABCB7, GPD2, TMEM38B, NFU1 , LOC128322/NUTF2, NUBPL, LANCL1 , PIR, CTBS, and GSTM4; preferably, the at least one 5'-UTR element comprises or consists of a nucleic acid sequence which is derived from the 5'-UTR of a human transcript of MP68 (RIKEN cDNA 2010107E04 gene) or NDUFA4 (NADH dehydrogenase (ubiquinone) 1 alpha subcomplex 4). Accordingly, it is also more preferable that the at least one 5'-UTR element comprises a nucleic acid sequence which is derived from the 5'-UTR of a transcript of a murine gene selected from the group consisting of MP68 (RIKEN cDNA 2010107E04 gene), NDUFA4 (NADH dehydrogenase (ubiquinone) 1 alpha subcomplex 4), Ndufal , Atp5e, Gstm5, Cbr2, Anapcl 3, Ndufa7, Atp5k, 1 1 10008P14Rik, Cox4i1 , Ndufs6, Sec61 b, Snrpd2, Mgst3, Prdx4; Pgcp; Myeov2; Ndufa4; Ndufs5; Gstml ; Atp5o; Tspo; Taldol ; Blod sl ; and Hexa; preferably, the at least one 5'-UTR element comprises or consists of a nucleic acid sequence which is derived from the 5'-UTR of a murine transcript of MP68 (RIKEN cDNA 2010107E04 gene) or NDUFA4 (NADH dehydrogenase (ubiquinone) 1 alpha subcomplex 4). The phrase "nucleic acid sequence which is derived from the 3'-UTR and/or the 5'-UTR of a of a transcript of a gene" preferably refers to a nucleic acid sequence which is based on the 3'-UTR sequence and/or on the 5'-UTR sequence of a transcript of a gene or a fragment or part thereof, preferably a naturally occurring gene or a fragment or part thereof. This phrase includes sequences corresponding to the entire 3'-UTR sequence and/or the entire 5'-UTR sequence, i.e. the full length 3'-UTR and/or 5'-UTR sequence of a transcript of a gene, and sequences corresponding to a fragment of the 3'-UTR sequence and/or the 5'-UTR sequence of a transcript of a gene. Preferably, a fragment of a 3'-UTR and/or a 5'-UTR of a transcript of a gene consists of a continuous stretch of nucleotides corresponding to a continuous stretch of nucleotides in the full-length 3'-UTR and/or 5'-UTR of a transcript of a gene, which represents at least 5%, 10%, 20%, preferably at least 30%, more preferably at least 40%, more preferably at least 50%, even more preferably at least 60%, even more preferably at least 70%, even more preferably at least 80%, and most preferably at least 90% of the full- length 3'-UTR and/or 5'-UTR of a transcript of a gene. Such a fragment, in the sense of the present invention, is preferably a functional fragment as described herein. Preferably, the fragment retains a regulatory function for the translation of the ORF linked to the 3'-UTR and/or 5'-UTR or fragment thereof. The terms "variant of the 3'-UTR and/or variant of the 5'-UTR of a of a transcript of a gene" and "variant thereof" in the context of a 3'-UTR and/or a 5'-UTR of a transcript of a gene refers to a variant of the 3'-UTR and/or 5'-UTR of a transcript of a naturally occurring gene, preferably to a variant of the 3'-UTR and/or 5'-UTR of a transcript of a vertebrate gene, more preferably to a variant of the 3'-UTR and/or 5'-UTR of a transcript of a mammalian gene, even more preferably to a variant of the 3'-UTR and/or 5'-UTR of a transcript of a primate gene, in particular a human gene as described above. Such variant may be a modified 3'-UTR and/or 5'-UTR of a transcript of a gene. For example, a variant 3'-UTR and/or a variant of the 5'-UTR may exhibit one or more nucleotide deletions, insertions, additions and/or substitutions compared to the naturally occurring 3'-UTR and/or 5'-UTR from which the variant is derived. Preferably, a variant of a 3'-UTR and/or variant of the 5'-UTR of a of a transcript of a gene is at least 40%, preferably at least 50%, more preferably at least 60%, more preferably at least 70%, even more preferably at least 80%, even more preferably at least 90%, most preferably at least 95% identical to the naturally occurring 3'-UTR and/or 5'-UTR the variant is derived from. Preferably, the variant is a functional variant as described herein.
The phrase "a nucleic acid sequence which is derived from a variant of the 3'-UTR and/or from a variant of the 5'-UTR of a of a transcript of a gene" preferably refers to a nucleic acid sequence which is based on a variant of the 3'-UTR sequence and/or the 5'-UTR of a transcript of a gene or on a fragment or part thereof as described above. This phrase includes sequences corresponding to the entire sequence of the variant of the 3'-UTR and/or the 5'-UTR of a transcript of a gene, i.e. the full length variant 3'-UTR sequence and/or the full length variant 5'-UTR sequence of a transcript of a gene, and sequences corresponding to a fragment of the variant 3'-UTR sequence and/or a fragment of the variant 5'-UTR sequence of a transcript of a gene. Preferably, a fragment of a variant of the 3'-UTR and/or the 5'-UTR of a transcript of a gene consists of a continuous stretch of nucleotides corresponding to a continuous stretch of nucleotides in the full-length variant of the 3'-UTR and/or the 5'-UTR of a transcript of a gene, which represents at least 20%, preferably at least 30%, more preferably at least 40%, more preferably at least 50%, even more preferably at least 60%, even more preferably at least 70%, even more preferably at least 80%, and most preferably at least 90% of the full- length variant of the 3'-UTR and/or the 5'-UTR of a transcript of a gene. Such a fragment of a variant, in the sense of the present invention, is preferably a functional fragment of a variant as described herein. The terms "functional variant", "functional fragment", and "functional fragment of a variant" (also termed "functional variant fragment") in the context of the present invention, mean that the fragment of the 3'-UTR and/or the 5'-UTR, the variant of the 3'-UTR and/or the 5'-UTR, or the fragment of a variant of the 3'-UTR and/or the 5'-UTR of a transcript of a gene fulfils at least one, preferably more than one function of the naturally occurring 3'-UTR and/or 5'-UTR of a transcript of a gene of which the variant, the fragment, or the fragment of a variant is derived. Such function may be, for example, stabilizing mRNA and/or enhancing, stabilizing and/or prolonging protein production from an mRNA and/or increasing protein expression or total protein production from an mRNA, preferably in a mammalian cell, such as in a human cell. Preferably, the function of the 3'-UTR and/or the 5'-UTR concerns the translation of the protein encoded by the ORF. More preferably, the function comprises enhancing translation efficiency of the ORF linked to the 3'-UTR and/or the 5'-UTR or fragment or variant thereof. It is particularly preferred that the variant, the fragment, and the variant fragment in the context of the present invention fulfil the function of stabilizing an mRNA, preferably in a mammalian cell, such as a human cell, compared to an mRNA comprising a reference 3'- UTR and/or a reference 5'-UTR or lacking a 3'-UTR and/or a 5'-UTR, and/or the function of enhancing, stabilizing and/or prolonging protein production from an mRNA, preferably in a mammalian cell, such as in a human cell, compared to an mRNA comprising a reference 3'- UTR and/or a reference 5'-UTR or lacking a 3'-UTR and/or a 5'-UTR, and/or the function of increasing protein production from an mRNA, preferably in a mammalian cell, such as in a human cell, compared to an mRNA comprising a reference 3'-UTR and/or a reference 5'- UTR or lacking a 3'-UTR and/or a 5'-UTR. A reference 3'-UTR and/or a reference 5'-UTR may be, for example, a 3'-UTR and/or a 5'-UTR naturally occurring in combination with the ORF. Furthermore, a functional variant, a functional fragment, or a functional variant fragment of a 3'-UTR and/or a 5'-UTR of a transcript of a gene preferably does not have a substantially diminishing effect on the efficiency of translation of the mRNA which comprises such variant, fragment, or variant fragment of a 3'-UTR and/or a 5'-UTR compared to the wild type 3'-UTR and/or the wild-type 5'-UTR from which the variant, the fragment, or the variant fragment is derived. A particularly preferred function of a "functional fragment", a "functional variant" or a "functional fragment of a variant" of the 3'-UTR and/or the 5'-UTR of a transcript of a gene in the context of the present invention is the enhancement, stabilization and/or prolongation of protein production by expression of an mRNA carrying the functional fragment, functional variant or functional fragment of a variant as described above.
Preferably, the efficiency of the one or more functions exerted by the functional variant, the functional fragment, or the functional variant fragment, such as mRNA and/or protein production stabilizing efficiency and/or the protein production increasing efficiency, is increased by at least 5%, more preferably by at least 10%, more preferably by at least 20%, more preferably by at least 30%, more preferably by at least 40%, more preferably by at least 50%, more preferably by at least 60%, even more preferably by at least 70%, even more preferably by at least 80%, most preferably by at least 90% with respect to the mRNA and/or protein production stabilizing efficiency and/or the protein production increasing efficiency exhibited by the naturally occurring 3'-UTR and/or 5'-UTR of a transcript of a gene from which the variant, the fragment or the variant fragment is derived. In the context of the present invention, a fragment of the 3'-UTR and/or of the 5'-UTR of a transcript of a gene or of a variant of the 3'-UTR and/or of the 5'-UTR of a transcript of a gene preferably exhibits a length of at least about 3 nucleotides, preferably of at least about 5 nucleotides, more preferably of at least about 10, 15, 20, 25 or 30 nucleotides, even more preferably of at least about 50 nucleotides, most preferably of at least about 70 nucleotides. Preferably, such fragment of the 3'-UTR and/or of the 5'-UTR of a transcript of a gene or of a variant of the 3'-UTR and/or of the 5'-UTR of a transcript of a gene is a functional fragment as described above. In a preferred embodiment, the 3'-UTR and/or the 5'-UTR of a transcript of a gene or a fragment or variant thereof exhibits a length of between 3 and about 500 nucleotides, preferably of between 5 and about 150 nucleotides, more preferably of between 10 and 100 nucleotides, even more preferably of between 15 and 90, most preferably of between 20 and 70. Typically, the 5'-UTR element and/or the 3'-UTR element is characterized by less than 500, 400, 300, 200, 1 50 or less than 100 nucleotides.
Preferably, the at least one 3'-UTR element comprises or consists of a nucleic acid sequence which has an identity of at least about 1 , 2, 3, 4, 5, 10, 15, 20, 30 or 40%, preferably of at least about 50%, preferably of at least about 60%, preferably of at least about 70%, more preferably of at least about 80%, more preferably of at least about 90%, even more preferably of at least about 95%, even more preferably of at least about 99% to a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 1 to 24 and SEQ ID NOs: 49 to 31 8 or the corresponding RNA sequence, respectively, or wherein the at least one 3'-UTR element comprises or consists of a fragment of a nucleic acid sequence which has an identity of at least about 40%, preferably of at least about 50%, preferably of at least about 60%, preferably of at least about 70%, more preferably of at least about 80%, more preferably of at least about 90%, even more preferably of at least about 95%, even more preferably of at least about 99% to a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 1 to 24 and SEQ ID NOs: 49 to 318 or the corresponding RNA sequence, respectively: Homo sapiens SLC38A6 3' -UTR
SLC38A6-001 ENST00000267488
AAGAAATATTTTCCTACTTCTTACAAGAATAATATACCCCTAGTTGCAAG ATGAATTATTCCGGA AGACACCCTGGATGAAAAATAACATTT ATAAAAAT ATTAACAGAAAAGCAGAACAAAATGGCA GTGGGTATGGGGAAGTAAGAGTGTGGCAGTTTTAATCAAAAAAAGAAACAAACTCGAAATGCTCTT AAA
(SEQ ID NO: 49)
Homo sapiens DECR1 3' -UTR
NM_001359.1
GACCACTTTGGCCTTCATCTTGGTTACAGAAAAGGGAATAGAAATGAAACAAATTATCTCTCATCT TTTGAC ATTTCAAGTCTAATAAATTCTT ATTAAC
(SEQ ID NO:50)
Homo sapiens PIGK 3' -UTR
ACTTGATGATGAATGAAGAATGCATGGAGGACTGCAAACTTGGATAATAATTTATGTCATTATATA TTTTTAAAAATGTGTTTCTCTTGTATGAATTGGAAATAAGTATAAGGAAACTAAATTTGAATCAAC TATTAATTTTATAACTTAAAGAAAAATAATTGTTAATGCAACTGCTTAATGGCACTAAATATATTC CAGTTTTGTATTTTGTG ATTA AAAAGCGAATGAGACAGAGATCAGAATACATTGACTGTTTTTG AAAATAGTAATTTCCCCTTATCCCCTTTTCATTTGGAAAAGAAACAATTGTGAAGACATTAAATTC TCACTAACAGAAGTAACTTTGGTTAATTATTTTTTGTAT
(SEQ ID NO:51)
Homo sapiens FAM175A 3' -UTR
FAM175A-009 ENST00000506553
TCCTTTTAACCTTACAAGGAGATTTTTTTATTTGGCTGATGGGTAAAGCCAAACATTTCTATTGTT TTTACTATGTTGAGCTACTTGCAGTAAGTTCATTTGTTTTTACTATGTTCACCTGTTTGCAGTAAT ACACAGATAACTCTTAGTGCATTTACTTCACAAAGTAC τTTTTCAAACATCAGATGCTTTTATTTC CAAACCTTTTTTTCACCTTTCACTAAGTTGTTGAGGGGAAGGCTTACACAGACACATTCTTTAGAA TTGGAAAAGTGAGACCAGGCACAGTGGCTCACACCTGTAATCCCAGCACTTAGGGAAGACAAGTCA GGAGGATTGATTGAAGTTAGGAGTTAGAGACCAGCCTGGGCAACGTATTGAGACCATGTCTATTAA AAAATAAAATGGAAAAGCAAGAATAGCCTTATTTTCAAAATATGGAAAGAAATTTATATGAAAA
(SEQ ID NO: 52)
Homo sapiens PHYH 3' -UTR
PHYH-002 ENST00000396913
AATAGCCATCTGCTATAACTCTTTCAACAGAAAACCAAAACCAAACGAAATGTCTAAGGAAAATGT TTTCTTAATGAGATGATGTAACCTTTTCTATCACTTGTTAAAAGCAGAAAACATGTATCAGGTACT TAATTGCATAGAGTTAGTTTTGCAGCACAATGGTGTTGCTTTAATGGAAAAAAAAAACAGTAAAAG TGAAATATTACTGTTTTAAGGAAAACTAATTTAGGGTGGCAGCCAATAAAGGTGGTTGGTGTCTAA TTTAAGTGTTAAATCAATTTCTTTCATTCAGTTAGCTCTTTACCCAAGAAGAAGTGAATGATTTGG AGCTTAGGGTATGTTTTGTATCCCCTTTCTGATAAACCCATTCCCTACCAATTTTATGTCATAAGA GATTTTTTTCCCCCAAATCTAGAACAATGTATAATACATTCACATCTAGTCAAGGGCATAGGAACG GTGTCATGGAGTCCAAATAAAGTGGATATTCCTGCTCGGACAA
(SEQ ID NO: 53)
Homo sapiens TBC1D19 3'-UTR
TBC1D19-001 ENST00000264866
TCTTCTTCACAGTCACTGGCAACACATCTAGTTTTTCATTAGAAACAAATCATGAAC ATGCAAAC TCTGCATAAAACCAAAATGAAACTTTGCATATAAGCCAATAAAGATCATGTTCCCTCTTCAGTTAA ACCTAAGTAGTTTCTCACTTTTTGAAACAATAACTCTGCACCAAATATTGCATCGCATGCTGCTGA TTTTCAAGAGAGAAGCAATAAACACAACTTCTGCTAAATTGAGCATTATATATATAATATTATAAT ATATATATAATCCTGACTTGTCAATGGCATGTAATAATATATGCAATAAGAACTAAAGATACTGTA ATAAACTTCAAGAGGTAATGTAGCTTCTTGGATAATTCTTTTATGTCAGTTTATAAATTTATCTCT AGATAATG
(SEQ ID NO:54)
Homo sapiens TBC1D19 NM_018317.2 3'-UTR
TCTTCTTCACAGTCACTGGCAACACATCTAGTTTTTCATTAGAAACAAATCATGAACTATGCAAAC TCTGCATAAAACCAAAATGAAACTTTGCATATAAGCCAATAAAGATCATGTTCCCTCTTCAGTΤΆΑ ACCTAAGTAGTTTCTCACTTTTTGAAACAATAACTCTGCACCAAATATTGCATCGCATGCTGCTGA TTTTCAAGAGAGAAGCAATAAACACAACTTCTGCTAAATTGAGCATTATATATATAATATTATAAT ATATATATAATCCTGACTTGTCAATGGCATGTAATAATATATGCAATAAGAACTAAAGATACTGTA ATAAACTTCAAGAGGTAAAAAAA
(SEQ ID NO: 55)
Homo sapiens PIGB 3'-UTR
PIGB-201 ENST00000539642
AAATTCAACATGAAGATGAAATTCTGAACTTTCCTAGATAAATTAACATTGCTGGGTGGAAATATT CAGATGCTGCTTAAATACTTCGGTAAACACTGGGTAAGATTCATGGAACTTAGAAAAAAGCTGTAT GAACTGCTTTACCAAATATCACTACTGAGGAAATGTA AAAA ACCACATAGTATAAAATTACATG TTAATACAATGCCAGATTTTAAATAAAGACCTTTAGTTTTCCTC
(SEQ ID NO: 56)
Homo sapiens ALG6 3'-UTR
ALG6-006 ENST00000263440
CTGTATTCCTAAACAAATTGTTTCCTAAACAAATGTGAAAATGTGAACAGTGCTGAAAGGTTTTGT GAACTTTTTGCTATGTATAAATGAAATTACCATTTTGAGAACCATGGAACCACAGGAAAGGAAATG GTGAAAAGTCATTGTTGTCTACACA
(SEQ ID NO:57)
Homo sapiens CRYZ 3'-UTR
CRYZ-005 ENST00000370871
TGATTAATTCTTTCATGGATTTCCTATGTAATTAGAGGTACTGTCTTTCCCCCAGTTGTACTTACC CTATCTTTTCTTTAATTAACATTCGATTCCATGAGCTTCTTATGTGAAAAAATAAGATTTTTCTTT AGAGAGCAGAAGCAGAAGAGTAAAATTTATTGTATAGCTAGCAATATTTTTTTATGCCATCTGTCT CAAATCAAAGAGTCATCATAGTAGGAAATAACATGTTAGTTGTCATTTGGCATGAGTGTGCATTCC AGTAATTCTTAATTGATATTTGATTAATTCCATACCTTTGATTAAAACATGCTAGTTCAA
(SEQ ID NO: 58)
Homo sapiens BRP44L 3'-UTR BRP44L-001 ENST00000360961
CAATGGAAAAGGAAGAACAAGGTCTTGAAGGGACAGCATTGCCAGCTGCTGCTGAGTCACAGATTT CATTATAAATAGCCTCCCTAAGGAAAATACACTGAATGCTATTTTTACTAACCATTCTATTTTTAT AGAAATAGCTGAGAGTTTCTAAACCAACTCTCTGCTGCCTTACAAGTATTAAATATTTTACTTCTT TCCATAAAGAGTAGCTCAAAATATGCAATTAATTTAATAATTTCTGATGATGGTTTTATCTGCAGT AATATG A ATCATCTAT AGAATT ACTTAATGAAAAACTGAAGAGAACAAAATTTGTAACCACT AGCACTTAAGTACTCCTGATTCTTAACATTGTCTTTAATGACCACAAGACAACCAACAGCTGGCCA CGTACTTAAAATTTTGTCCCCACTGTTTAAAAATGTTACCTGTGTATTTCCATGCAGTGTATATAT TGAGATGCTGTAACTTAATGGCAATAAATGATTTAAATATTTGTTAAA
(SEQ ID NO: 59)
Homo sapiens ACADSB 3'-UTR
ACADSB-004
CGTCTATAGGAGTGGGACCCCTCCCTGGTGTCACTGCTGTAAAATTTTAAACGGTTGTGTCTTGTT GGGAGTAAGTGCCTTGCGTGGGAATAAACTTCCACAGCATTCGAATATTTTAATGAAGCCCTTAGT CAGGGTCCTGGTGTTGGCCTTTTTGGTTTTCTCTTTTCAGGCTGTTTAACTTAGGCACAGGAGATC CACTTTTAAACTTGGGAAATAAGCACCTGTATTTTTTTCCAAAACTGTTTTTAAAGCTGTATACGC ATACATATATATATTTTTACTCTGTCTTACTCTGTCACCCAGGCTAGAGTGCAGTGGCGCGATCTC AGCTCACTGCAGCCTTGACCTCCT
(SEQ ID NO: 60)
Homo sapiens TMEM14A 3'-UTR
NM_014051.3
GCATCTGGAGGAACAGAAAACTAAGTTCATGTCATCCTGCTGTAATGGGCAGAGCATATTTTTTTT GTATTTAAAAGATAAACTTCAATATGGAATGCTAGAAACACAAATAGCACTGTCACCTCTAATATG AACATTAGTTTGAGGTAGTTTTTTTCTAAAGCAAAAATTTTAACTGTTTTCTAATTGTCAAGCACT ATTTTCATTAAAAGTGTCTAATGAATCATGATATACTCTTCCATTTGTTGTGTCTATTTTTTATAT ATTTGGTATTTTTTGAAAATTCCAAATACTCATGTCTCAAGTAAGCTTAAACTACAACTTGTCACA TAAAGGAAGTCTTAAGTGGAGTTCACAGAATGATAATGTATCTATTTGTCATTTGTGTTATATTTG AAATTATTAGAAATTATGCTTTTTCCATTTTAATTGTATTGCTGCCAGTGCTATTTTTTTCTTTAA AAAATTTTATTCTTAGCACACTGTTATGTCCTAACTGAATGTATTCAGTATTCAAATAAAAGACAT TTTGGTTCAAA
(SEQ ID NO: 61)
Homo sapiens GRAMD1C 3'-UTR
GRAMDlC-005 ENST00000472026
TGATCTGAAGGACTAAAACCGCAGAGATACTTGGAACTTAAAGAAAATACCTGGAAGAAAACCAGA CGAATGAAGGATTTTGGCATAGAACATTTCTATGTTTTTTCATTATTGAGATTTCTAATATGAACA TTTCTTTCAGTAACATTTATTTGATAATTAGTTTCTGCTGGCCTTAATAATCCATCCTTTCACTTC TTATAGATATTTTTAAGCTGTGAATTTCTTCAGTGAACCATGAAATATATTATAGAACTGAATTTC TCTGATACAAAAAGAAAATGACACACCC
(SEQ ID NO: 62)
Homo sapiens Cllorf80 3'-UTR
Cllorf80-201 ENST00000360962
GCCGGGTCCCCTTCCGCAAGCGCCCACCGATCCGGAGGCTGCGGGCAGCCGTTATCCCGTGGTTTA ATAAAGCTGCCGCGCGCTCACCAAGTCC
(SEQ ID NO: 63)
Homo sapiens ANXA4 3'-UTR ANXA4-002 ENST00000409920
AATAAAAATCCCAGAAGGACAGGAGGATTCTCAACACTTTGAATTTTTTTAACTTCATTTTTCTAC ACTGCTATTATCATTATCTCAGAATGCTTATTTCCAATTAAAACGCCTACAGCTGCCTCCTAGAAT ATAGACTGTCTGTATTATTATTCACCTATAATTAGTCATTATGATGCTTTAAAGCTGTACTTGCAT TTCAAAGCTTATAAGATATAAATGGAGATTTTAAAGTAGAAATAAATATGTATTCCATGTTTTTAA AA
(SEQ ID NO: 64)
Homo sapiens TBCK 3'-UTR
TBCK-002 ENST00000361687
AGAACCAAGAGTGTGACTGCCAAAACTTAGTGTGGCATCAGCACCAACAGCACAGTTCTTCATATC CACGCCACTCTCAGACAAAAC AGATGTCCAGATTGTTGCATTTCCG AAAGTTTGTCACGAGACA TTTTTTAAAATCTCATAACCCACATGTTCAGTTATCCATGCAAGAAACTTGACTCTACATGTATTG CTGAAAGAATTTTCTTAACAGTGAAATCTGATCATATATTTTTACCACACTGCCACATAAAGCCCA AGAAATTCAGCTGACAAGACAGATTTAGCATTATCAAGAAATCCCATTTGCCCTGAAAAAGCTGTC CTCCATTGTACTGAACAGACAGTCCTGTCGATTGTGTTATTTAGAAACATACACTGAATGTGGGCT GAAATCATCATCTTTCCATAATGAAAACTGAGAAACTATTCACAATGCATTCCTTATAAATAAATG C ACATT AGTAACTCATTTCACCCAAA
(SEQ ID NO:65)
Homo sapiens IFI6 3'-UTR
IFI6-001 ENST00000361157
CCAGCAGCTCCCAGAACCTCTTCTTCCTTCTTGGCCTAACTCTTCCAGTTAGGATCTAGAACTTTG CCTTTTTTTTTTTTTTTTTTTTTTTGAGATGGGTTCTCACTATATTGTCCAGGCTAGAGTGCAGTG GCTATTCACAGATGCGAACATAGTACACTGCAGCCTCCAACTCCTAGCCTCAAGTGATCCTCCTGT CTCAACCTCCCAAGTAGGATTACAAGCATGCGCCGACGATGCCCAGAATCCAGAACTTTGTCTATC ACTCTCCCCAACAACCTAGATGTGAAAACAGAATAAACTTCACCCAGAAAACACTT
(SEQ ID NO: 66)
Homo sapiens CAMKMT 3'-UTR
(synonym C2orf34) ENST00000378494
AAGATTAAGCTTCTCAAAGACGAAGAAACGTATCAAGTGCATAGGGAATATTTTTACAAAAACGGA AATCTGTAAGGGGTATAATCGCCTGCCTGCGCCCTTTGCAGCATTTCACGTGTGGGCTATGGACTC CACCTGTCCTCACCCACGTTATTCCCCAGCTGCCCTCTCCAGCTCCCTCCCCGCCTCTTTTTACAC TCTGCTTGTTGCTCGTCCTGCCCTAAACCTTTGTTTGTCTTTAAATGTGTATAAGCTGCCTGTCTG TGACTTGAATTTGACTGGTGAACAAACTAAATATTTTTCCCTGTAATTGAGACAGAATTTCTTTTG ATGATACCCATCCCTCCTTCATTTTTTTTTTTTTTTTGGTCTTTGTTCTGTTTTGGTGGTGGTAGT TTTTAATCAGTAAACCCAGCAAATATCATGATTCTTTCCTGGTTAGAAAAATAAATAAAGTGTATC TTTTTATCTCCCTCCAA
(SEQ ID NO: 67)
Homo sapiens ALDH6A1 3'-UTR
NM_005589.2
AAACAAGTTTGTTTAAGACTGACTCCATCCTGAGTAATCTCCCTTTATTTTTGACCAGCTTCATTT GTCAGCTTTGCTCAGATCAGATCGATGGGATTGGAATACATTGTAACTAAAATCTTCCTCAGGACT ATTAACCCCCGCAAAGTTTCTATAGGGAACTGCCTAGTGTAACAATGAAACCAGATTTCTCACTTG CTCTTCATACTTCTATTTTGAGGTAACTGTTGTAACTATGAAATGCTTATCTGAAAGTAGTGCTTA AACCTGATTTCTAAAAATTATCCCATTTTCTGATGATTTGAAGGGGAGAAAAGCCAGTGTATGTAA AGAAAATGTTCCAGCCAGGCGCGGTGGCTCACGCCTGTAATTCCATCATTTTGGGAGGCCACAGTG GGCAGATTGCTTGAGCCCAGGAGTTGAAGAACGTGGCGAAACCCCGTATCTATTATTTAAAAAAAT TGAAAAAGTAAAAA
(SEQ ID NO: 68) Homo sapiens AGTPBP1 3'-UTR
AGTPBP1-004 ENST00000357081
GCCCGCTGCCATCTCTTGTTAACTGCAAAGAATAAATGAAATATCTTGGTTTTTATTTCCCAGGAA GCTTGAGAGAAATGAGTTTATACAGAGCTGACTCAAAAAGACAAAAAGTAACTTGGGCCAGTTTGG TTTCAAGATAATAAATGTGTTATTAATTAATGATAAAATTGGCGCTTGTTTTATTTTCGATATTCA ATGCACTTTATGTAGCATTGAATGATCAAATATTGGATTTACCTTTAAAAAAAAAACCTGAGTATC ATTGCATGAATTTTTATCTCCCTATGGTTATATCCTGCATCAAGTGGATAATTTTGAAGTGTGTTC AGAATATAAAATTGAAATTTTAGAGTTGTTGAAAATCCTGACTTGTTGAAAACTAATATATATGTA CATGGATTTCTATAGATGTGTTTGTTTAGAAGTGGGTAGATATTGCAGATAAGACTGTTCTTCAGA ATCATGTTAACTATTGGGTTGTGACTGAAGTAGTCCAGGGTTTGCCTTGAAACCATTACATTCTAC ATT ACCAAATTAAACAAATAAAAACTGTATTAAATGTT
(SEQ ID NO: 69)
Homo sapiens CCDC53 3'-UTR
CCDC53-001 ENST00000240079
GCTTAATTTTGATAAGAATTACATATGCATGCATAGGGGTACATTTACATTCTGTAAGAGATTGAG CCTGAACTCTCTTAGTCATAAAAACATCAAATGGCCACATGTCCACTACCAAGCTTCTTCTATGTT AAAAAAATAATAATAAAGCAGTTTTAACCTGCCAGTA
(SEQ ID NO:70)
Homo sapiens LRRC28 3'-UTR
LRRC28-002 ENST00000331450
TAAACACTCAAGAACCTCAGGAGCGCTGCCAGCTTGACACTGGGGAATCCAGCCAGTCCAGCACAC TCTTCCATCCTGTCCTGTCCAATGCGGGGGCACTGCAGAACTCTCTAGAAATGTCATGATTGAGCT TCAGAGCTAAAATGCCTTCACCCTTCCCCCAAGTTGGAATATATCCTCCCCCAAATTAAGGA
(SEQ ID NO:71)
Homo sapiens CCDC109B 3'-UTR
NM__017918.4
TCTTACAGTTTTAAATGTCGTCAGATTTTCCATTATGTATTGATTTTGCAACTTAGGATGTTTTTG AGTCCCATGGTTCATTTTGATTGTTTAATCTTTGTTATTAAATTCTTGTAAAAC
(SEQ ID NO: 72)
Homo sapiens PUS10 3'-UTR
PUSlO-001 ENST00000316752
CTTTCAAATTTGGAGACAAAGAGTATGGTTTTCCTGGCATGATGTGGACATCCATGGAGCACATGC CGTAAAATGGCTGTTTACCCACCATAACGGTGTCTTGAAAACTATTTGGATCATGTTGATCTATAT AATTGTTAATTTGTTGTAACATCTCAGGATCTATATATGTGTATATTTTGTGTTAAATTGTTCCAA GGATGTCTTAGGATTTTTCTCATTCCCTCTTTCACCCCCACAAACCAAACTATGAATAATGAAATA ATTCTCCTTAATTCTTTCATTTAGAGAGGTGCACAAACAGGACACATTCTCTGTTAACCTAAGAAG CTGTAATTTCAGCAAGATTTCCCTCCACAAGAGATATACCACCTTTAAAATCATGTTCTAATTTTT GTAAATTATCTGAATAAAAGTTATATCTAG
(SEQ ID NO:73)
Homo sapiens CCDC104 3'-UTR
CCDC104-002 ENST00000339012
TAATTAAGAACAATTTAACAAAATGGAAGTTCAAATTGTCTTAAAAATAAATTATTTAGTCCTTAC ACTGA
(SEQ ID NO:74)
Homo sapiens CASP1 3'-UTR CASPl-007 ENST00000527979
AATAAGGAAACTGTATGAATGTCTGTGGGCAGGAAGTGAAGAGATCCTTCTGTAAAGGTTTTTGGA ATTATGTCTGCTGAATAATAAACTTTTTTGAAATAATAAATCTGGTAGAAAAATGAAAA
(SEQ ID NO:75)
Homo sapiens SNX14 3'-UTR
SNX14-007 ENST00000513865
ACACTTGGATTTGGTATAGAATAACCCATTGAAATTTCTGCTGTGCGAGGGTGGTAGAAATTTACT TTTTTGGGTATATTCTTATATATATTATGTACATCGCTGTCTGAAATTTTAGTTATTTTTTGTTTT TAATAAAGACTAACACAAACTTAATGATTAAAAGTGATTGAG
(SEQ ID NO: 76)
Homo sapiens SKAP2 3'-UTR
SKAP2-201 (part of SKAP2.001 ENST00000345317 )
GAGTCCTGGAAAAGGAAAATTCTTCTGCTTGTCTGCAAATGCTTTGGATTTAGAAGCGTCATGAAA GCACGAGTGACAGCTCCTAACCTCTCCTTGTTTTATTAAACATTACTTATCTTTGACTGTTATTTT ATGCAGTCGCTCATTAAAATATTCCTCTGATGTGAAATTAAATGAAGGATATTAATGTAAATTAGA TGCAACCAGTTAAGTTATACCTGTTGCTATTTTGCAAAG
(SEQ ID NO:77)
Homo sapiens NDUFB6 3'-UTR
NM_182739.2
AGATTATGTAAAAAGTTAAAAGGCTTATGAGCCTAAGTTTGTTCCTATATTACCATATTTACTGAA TTTTCTGGAAAAGTAACTTTAATAAAGTTTAATCTCAGAAATTGTCATATCTGTTTTCAAGCATTG TACAATTTGAGACTGAG AATTTAACAATAAGTAAAAAGTGGACATGCTAAACAAATATGAGAGAC TACCTACTTTTTCTGGTCATTCTTGACTTGGAAAACGGTATGGAAAAGTATTTAGTTACATGTTTG TTTGTTTTTTTCTTACACAGTACTTACACTAATTTGGTATCAGGGTATGCAACAGTGAAATATCAC AATAAACAAATGTAAGAACAAAAAAAAAAAAA
(SEQ ID NO:78)
Homo sapiens EFHA1 3'-UTR
EFHAl-001 ENST00000382374
TAAAAGATATAATAGTATGGCAATTATATTGTTCCAAATGTCAAAATTTGTGATTTTTTAGAAGTA CTTGCTATTTATCTTCTTAAGTCTTCATTGATATTCTGTGTGAAATAAGCATGTCTTGTACTTGCT TTCTGATTCATAATTTTATTAAAGAACTTAGTAGAAAGAAAAGTAAGTATAAAAATAGATATTGGA TTCTGTCAGAAGGCCTAGATTTGAAATAATGTTTTGTACTTCGGTAAGATGGAAAACTTAGTGATT CACTGATTTCTTAGACACTCTAATATGATATGCTTTCTGGAAGGATAAAACAAATACATATGGGAA AAAGTACTTGAGACCAAGGCCAGCATCAATTCCAGACATCTTCATGTTCCTAATAGGCTAAATGAA GTTAAAAACTTATTTCAGATTTTTCTCATCTGTACCTTATATCTCATAAATTTATTGCATATTTTA TGTCAGTAGCTTAGCTGTTTATTGTCTTTAAAATAACATGTAAACTTCAATGTTCTATCTGGAAGC AGAATAAAATATTTAC TAGA
(SEQ ID NO:79)
Homo sapiens BCKDHB 3'-UTR
BCKDHB-005 ENST00000356489
CCATATAGAAAAGCTGGAAGATTATGACTAGATATGGAAATATTTTTTCTGAATTTTTTTTTATAT TTCCTCCGACTTACCTCTTTTTGAAAAGAGAGTTTTTATTAAGTGAACCATCACGATATTGGCTGA AAAGTTCTACATTCTATTATTGTATTGTAACACACATGTATTGATGATTTTCATTAAGAGTTTCAG ATTAACTTTGAAAAATATTCCACATGGTAATCTTATAAATTCTGTTTAATTACATCTGTAAATATT ATGTGTGTGATAGTATTCAATAAA
(SEQ ID NO:80) Homo sapiens BCKDHB 3'-UTR
NM_001164783.1
GACCTGCTCAGCCCACCCCCACCCATCCTCAGCTACCCCGAGAGGTAGCCCCACTCTAAGGGGAGC AGGGGGACCTGACAGCACACCACTGTCTTCCCCAGTCAGCTCCCTCTAAAATACTCAGCGGCCAGG GCGGCTGCCACTCTTCACCCCTGCTCCTCCCGGCTGTTACATTGTCAGGGGACAGCATCTGCAGCA GTTGCTGAGGCTCCGTCAGCCCCCTCTTCACCTGTTGTTACAGTGCCTTCTCCCAGGGGCTGGGTG AGGGCACATTCAGGACTAGAAGCCCCTCTGGGCATGGGGTGGACATGGCAGGTCAGCCTGTGGAAC TTGCGCAGGTGCGAGTGGCCAGCAGAGGTCACGAATAAACTGCATCTCTGCGCCTGGCTCTCTACC AAAAAAAAAAAAAAAAAA
(SEQ ID NO: 81)
Homo sapiens BBS2 3'-UTR
NMJ331885.3
GTGAGGAAAATACAGGTCATGAAGTTCCTGGCAAAGATTTTCTGTTAAAAACCTATGCTGGTTTGC TTTGGATCACACCCTGGTGAACCCCGGGTGCTAAGAATGAAAATAACCTTGGTGAGTTGTACAAAT TAAAGACAAAGAACTACATGTGAAGATAGACTTGCTTTCTATTTTTAAATCAGTAGTAGTACTGTT GCTGAATAATACTAGGTTTTTATGGAATAGGATGAATGCTTTTGAAGTATTAGGGCTTCAGAGTCC AATTTTGCTTATTTATGGTATATAAATACATATTTTTTTCTTGAAATTGCAATTGAGTTTGTACTT TTCAAATAGATTATCTACTTTTTCATTAAAATGTAAAGATGTTAAACTTTGTGTTGATTGATTATA AAATCACC CCAAATCAG
(SEQ ID NO:82)
Homo sapiens LMBRD1 3'UTR
NM_018368.3
CAGCCTTCTGTCTTAAAGGTTTTATAATGCTGACTGAATATCTGTTATGCATTTTTAAAGTATTAA ACTAACATTAGGATTTGCTAACTAGCTTTCATCAAAAATGGGAGCATGGCTATAAGACAACTATAT TTTATTATATGTTTTCTGAAGTAACATTG ATCATAGATTAACATTTTAAATTACCATAATCATGC TATGTAAATATAAGACTACTGGCTTTGTGAGGGAATGTTTGTGCAAAATTTTTTCCTCTAATGTAT AATAGTGTTAAATTGATTAAAAATCTTCCAGAATTAATATTCCCTTTTGTCACTTTTTGAAAACAT AATAAATCATCTGTATCTGTGCCTTAGGTTCTCCAGAGTGATGTGGAATTTTAAAGTGTCTCTCTC TGATTGCCTCCAA
(SEQ ID NO: 83)
Homo sapiens ITGA6 3'-UTR
ITGA6-003 ENST00000409532
TATTGATCTACTTCTGTAATTGTGTGGATTCTTTAAACGCTCTAGGTACGATGACAGTGTTCCCCG ATACCATGCTGTAAGGATCCGGAAAGAAGAGCGAGAGATCAAAGATGAAAAGTATATTGATAACCT TGAAAAAAAACAGTGGATCACAAAGTGGAACGAAAATGAAAGCTACTCATAGCGGGGGCCTAAAAA AAAAAAGCTTCACAGTACCCAAACTGCTTTTTCCAACTCAGAAATTCAATTTGGATTTAAAAGCCT GCTCAATCCCTGAGGACTGATTTCAGAGTGACTACACACAGTACGAACCTACAGTTTTAACTGTGG ATATTGTTACGTAGCCTAAGGCTCCTGTTTTGCACAGCCAAATTTAAAACTGTTGGAATGGATTTT TCTTTAACTGCCGTAATTTAACTTTCTGGGTTGCCTTTATTTTTGGCGTGGCTGACTTACATCATG TGTT
(SEQ ID NO:84)
Homo sapiens HERC5 3'-UTR
HERC5-001 ENST00000264350
CCAGCTTGCTTGTCCAACAGCCTTATTTTGTTGTTGTTATCGTTGTTGTTGTTGTTGTTGTTGTTG TTTCTCTACTTTGTTTTGTTTTAGGCTTTTAGCAGCCTGAAGCCATGGTTTTTCATTTCTGTCTCT AGTGATAAGCAGGAAAGAGGGATGAAGAAGAGGGTTTACTGGCCGGTTAGAACCCGTGACTGTATT CTCTCCCTTGGATACCCCTATGCCTACATCATATTCCTTACCTCTTTTGGGAAATATTTTTCAAAA ATAAAATAACCGAAAAATTAA
(SEQ ID NO: 85)
Homo sapiens HADHB 3'-UTR
HADHB-001 ENST00000317799
TAGATCCAGAAGAAGTGACCTGAAGTTTCTGTGCAACACTCACACTAGGCAATGCCATTTCAATGC ATTACTAAATGACATTTGTAGTTCCTAGCTCCTCTTAGGAAAACAGTTCTTGTGGCCTTCTATTAA ATAGTTTGCACTTAAGCCTTGCCAGTGTTCTGAGCTTTTCAATAATCAGTTTACTGCTCTTTCAGG GATTTCTAAGCCACCAGAATCTCACATGAGATGTGTGGGTGGTTGTTTTTGGTCTCTGTTGTCACT AAAGACTAAATGAGGGTTTGCAGTTGGGAAAGAGGTCAACTGAGATTTGGAAATCATCTTTGTAAT ATTTGCAAATTATACTTGTTCTTATCTGTGTCCTAAAGATGTGTTCTCTATAAAATACAAACCAAC GTGCCTAATTAAT ATGGAAAAA AATTCAGAATCTAAACACCACTGAAAACT A AAAAAATGTT TAGATACATAAATATGGTGGTCAGCGTTAATAAAGTGGAGAAATATTGGAGAA
(SEQ ID NO: 86)
Homo sapiens ANAPC4 3'-UTR
ANAPC4-001 ENST00000315368
TCTAGCTTGCCATTATTGTGTGTGTAATTATGGCCAAAAGGACATAGGAGATGGACTAAGATGTCT TGGACCACCTTTGTGTAACAAAGAAATAAACAGTAAATTTTAT τTTTTCA
(SEQ ID NO: 87)
Homo sapiens PCCB 3'-UTR
NM_000532.4
ACAAATCAAAGGAAAAGAAACCAAGAACTGAATTACTGTCTGCCCATTCACATCCCATTCCTGCCT TTTGCAATCATGAAACCTGGGAATCCAAATAGTTGGATAACTTAGAATAACTAAGTTTATTAAATT CTAGAAAGATCTCAAAAAAAAA
(SEQ ID NO:88)
Homo sapiens ABCB7 3'-UTR
ABCB7-001 ENST00000253577
GTCACATAAGACATTTTCTTTTTTTGTTGTTTTGGACTACATATTTGCACTGAAGCAGAATTGTTT TATTAAAAAAATCATACATTCCCA
(SEQ ID NO: 89)
Homo sapiens PGCP 3'-UTR
CPQ-001 ENST00000220763
AAACAGTAAGAAAGAAACGTTTTCATGCTTCTGGCCAGGAATCCTGGGTCTGCAACTTTGGAAAAC TCCTCTTCACATAACAATTTCATCCAATTCATCTTCAAAGCACAACTCTATTTCATGCTTTCTGTT ATTATCTTTCTTGATACTTTCCAAATTCTCTGATTCTAGAAAAAGGAATCATTCTCCCCTCCCTCC CACCACATAGAATCAACATATGGTAGGGATTACAGTGGGGGCATTTCTTTATATCACCTCTTAAAA ACATTGTTTCCACTTTAAAAGTAAACACTTAATAAATTTTTGGAAGATCTCTGA
(SEQ ID NO: 90)
Homo sapiens NFU1 3'-UTR
NM_001002755.2
AATAATCTGGATTTTCTTTGGGCATAACAGTCAGACTTGTTGATAATATATATCAAGTTTTTATTA TTAATATGCTGAGGAACTTGAAGATTAATAAAATATGCTCTTCAGAGAATGATATATAAATATTGC
A
(SEQ ID NO: 91)
Homo sapiens OMA1 3'-UTR OMAl-001 ENST00000371226
ATTAAAATTTATGAGACACAAGATATATGAAGAATGTTGCAGTCCTTATCATTTTATGTTACTTTT TAAAAAATGATGTTTGAAGTGAAAAAAAAAAGGATATTCAGGGTCAAATCATGTACATTACAGATA TTATCTAAATTCTTCTAGAATTTATTTTTCATGAAATATTGATGTATTTTAATCTATGTTAAAATA TCTTCAATGAGGAAAATGTCACAGAATAAATTTATATTACACATTTTA
(SEQ ID NO: 92)
Homo sapiens HHLA3 3'-UTR
NM_001036646.1
GGCGAATCCATAGAGTAAGCTTAGTGATGTGTGTCAGACCTCTGAGCCCAAGCAAAGCCATCATAT CCCCTGTGACCTGCATGTATACATCCAGATGGCCTGAAGCAAGTGAAGAATCACAAAAGAAGTGAA AAGGGCCGGTTCCTGCCTTAACTGATGACATTCCACCATTGTGATTTGTTCCTGCCCCACCTTAAC TGAGCGATTAACCTGTGAACTTCCTTCTCCTGGCTCAGAAGCTTCCCCACTGAGCACCTTGTGACC CCCGCCCCTGCCTGCCATAGAACAACCCCCTTTGATTGTAATTTTCCTTTACCTACCCAAATCCTA TAAAACGGCCCCACCCCTATCTCCCTTCGCTGACACTCTCTTTGGACTCAGCCTGCCTGCACCTAG GTGATTAAAAAGCTTTATTGCTCACGC
(SEQ ID NO: 93)
Homo sapiens HHLA3 3'-UTR
NM_001031693.2
AAAGGGCCGGTTCCTGCCTTAACTGATGACATTCCACCATTGTGATTTGTTCCTGCCCCACCTTAA CTGAGCGATTAACCTGTGAACTTCCTTCTCCTGGCTCAGAAGCTTCCCCACTGAGCACCTTGTGAC CCCCGCCCCTGCCTGCCATAGAACAACCCCCTTTGATTGTAATTTTCCTTTACCTACCCAAATCCT ATAAAACGGCCCCACCCCTATCTCCCTTCGCTGACACTCTCTTTGGACTCAGCCTGCCTGCACCTA GGTGATTAAAAAGCTTTATTGCTCACGC
(SEQ ID NO: 94)
Homo sapiens ACAA2 3'-UTR
NM_006111.2
AGAGACCAGTGAGCTCACTGTGACCCATCCTTACTCTACTTGGCCAGGCCACAGTAAAACAAGTGA CCTTCAGAGCAGCTGCCACAACTGGCCATGCCCTGCCATTGAAACAGTGATTAAGTTTGATCAAGC CATGGTGACACAAAAATGCATTGATCATGAATAGGAGCCCATGCTAGAAGTACATTCTCTCAGATT TGAACCAGTGAAATATGATG ATTTCTGAGC AAAACTCAAC A AGAAGACATTAAAAGAAATCG TATTCTTGCCAAGTAACCACCACTTCTGCCTTAGATAATATGATTATAAGGAAATCAAATAAATGT TGCCTTAACTTC
(SEQ ID NO: 95)
Homo sapiens GSTM4 3'-UTR
GSTM4-001 ENST00000369836
TGCCTTGAAGGCCAGGAGGTGGGAGTGAGGAGCCCATACTCAGCCTGCTGCCCAGGCTGTGCAGCG CAGCTGGACTCTGCATCCCAGCACCTGCCTCCTCGTTCCTTTCTCCTGTTTATTCCCATCTTTACC CCCAAGACTTTATTGGGCCTCTTCACTTCCCCTAAACCCCTGTCCCATGCAGGCCCTTTGAAGCCT CAGCTACCCACTTTCCTTCATGAACATCCCCCTCCCAACACTACCCTTCCCTGCACTAAAGCCAGC CTGACCTTCCTTCCTGTTAGTGGTTGTATCTGCTTTGAAGGGCCTACCTGGCCCCTCGCCTGTGGA GCTCAGCCCTGAGCTGTCCCCGTGTTGCATGACAGCATTGACTGGTTTACAGGCCCTGCTCCTGCA GCATGGCCCCTGCCTTAGGCCTACCTGATCAAAATAAAGCCTCAGCCACA
(SEQ ID NO: 96)
Homo sapiens GSTM4 3'-UTR
GSTM4-003 ENST00000326729
TGGTCAATTTTCTGCATCAACTTGACTGGGCTAAGGGATGCTCAGATGGCAGGTAAAATCATTGTG CTTGTGAGGGTGTTTCCAGAAGAGATTTGCCTTTGAATCAGAAGACAGCAAAGATTTCCTTCAGCA ATGAAGGAGGCATCCACCAAACTGTCAGGGCCCAGAGAGAAGAAAAAGACAGGAAGGGTGAATTTG ACCTCTCTGACTGGGACATCCATCTCTGCCTATCCTGGGACCTCCACACTCCTGGTTCTCTGGCCT TCAGACTTGATCAGGGACTAACACCATCGCCTCCCACCCCCACCTTTGTTCTGAGGCCTTTAGCCT CTGAATGATACCACTGGCTTTCCTGCTTCTCTATCCTGCAGTCGGCAGATCATGGGACTTCTTCAC TCCAAAATTGTGTGAGCCAATTCCCATAACAGATAGATAAATTTATAAATAAACACACAAATTTCC TAC
(SEQ ID NO: 97)
Homo sapiens ALG8 3'-UTR
M_001007027 . 2
CTGAAACCTCCGCCTCCCAGAAAAGAAAAACCTCTTTTTAATTGGATGGAAACTTTCTACCTGCTT GGCCTGGGGCCTCTGGAAGTCTGCTGTGAATTTGTATTCCCTTTCACCTCCTGGAAGGTGAAGTAC CCCTTCATCCCTTTGTTACTAACCTCAGTGTATTGTGCAGTAGGCATCACATATGCTTGGTTCAAA CTGTATGTTTCAGTATTGATTGACTCTGCTATTGGCAAGACAAAGAAACAATGAATAAAGGAACTG CTTAGATATG
(SEQ ID NO: 98)
Homo sapiens Cllorf74 3'UTR
TTCACAGAGGCATTTTGTGTGTGTGTGCTTATTTTAATTTTGTTCTTATTCTAGCAACATTAGAAT AAAAGATAAACCTACTATAATTCCCTTTGTGGAAATTTAAAAAAAAAAAAAAAAAA
(SEQ ID NO: 99)
Mus musculus Ndufal 3'-UTR
Ndufal-001 ENSMUST00000016571
GGAAGCATTTTCCTGGCTGATTAAAAGAAATTACTCAGCTATGGTCATCTGTTCCTGTTAGAAGGC TATGCAGCATATTATATACTATGCGCATGTTATGAAATGCATAATAAAAAATTTTAAAAAATCTAA
A
(SEQ ID NO: 100)
Mus musculus Atp5e 3'-UTR
NMJ325983
CTGAATCTGAAGCCTGAAGTGCTGAGTCTTGAAGGTGAAGCATGTGGGCCCCTGTTCTGGCAGATG GAAATCAACCTCACCTCCTGGGGGACAGGCTGCCCATCTCGTTGATAAATTGACTATGCCAATAAA TTAACATGGTTCACTTTCAAAAA
(SEQ ID NO:101)
Mus musculus Gstm5 3'-UTR
NM_010360
GCCAGAGCTCGCTGCTGCTGAGCCATCTTGCCCTGAGGGGCCCACACTCTTAGCTCACTGTCAGTC TTGTTCCATCCTGTCCTGAGGGCCCCCACTCTGTCTCCTCTGCTCTTTCTAATAAACAGCAGTTGC ATTA
(SEQ ID NO: 102)
Mus musculus Uqcrll 3'-UTR
NM_025650
GCAGCCCCTCCCCCACCACAGGCCTCGATGGTACCATGTGCCGAGGCCTCAGACACAGCGTAGTCC TGTGGAAGACACTGAGGAAGCTGGACACTGGAGAGGTCTGCACCGCTCAGGGAGCTTCCATGTTGA CAGACACTAGGGCTGCCTTGATGGGTGCAGCATTAAACCTTATTCTTATGCCTTGGA
(SEQ ID NO: 103)
Mus musculus IFi27I2a 3'-UTR
IFi27l2a-001 ENSMUST00000055071 ; NM 029803 GCTTAGGAGATGACACTTCTATCAGCTCAACTCAAAGCCTGTACAGACTACGCAGGAGATGAAGTT CCAAAAGGCACCTTCAGAACCCTCACTGATGTCAAAGAATGATGAAAACAACAAAGTATATGGGCT GGTGTTCCTAA
(SEQ ID NO: 104)
Mus musculus Cbr2 3'-UTR
NM_007621
TCTGCTCAGTTGCCGCGGACATCTGAGTGGCCTTCTTAGCCCCACCCTCAGCCAAAGCATTTACTG ATCTCGTGACTCCGCCCTCATGCTACAGCCACGCCCACCACGCAGCTCACAGTTCCACCCCCATGT TACTGTCGATCCCACAACCACTCCAGGCGCAGACCTTGTTCTCTTTGTCCACTTTGTTGGGCTCAT TTGCCTAAATAAACGGGCCACCGCGTTACCTTTAACTAT
(SEQ ID NO: 105)
Mus musculus Atp51 3'-UTR
Atp51-201 ENSMUST00000043675
AGACCAATCTTTAACTTCTGATTTGAGTTCTTATTTGAATGTTCTTGGACCATGTGTAACAGGACT GCTATCTGAATAAAATACTAGGTGTTGAAAACACTGCTGTGTTTTCTCTGTC
(SEQ ID NO: 106)
Mus musculus TmsblO 3'-UTR
NM__025284
AAGCCTAGGAAGATTTCCCCACCCCACCCCACCCCGCCCCATCATCTCCAAGACCCCCTCGTGATG TGGAGGAAGAGCCACCTGCAAGATGGACGCGAGCCACAAGCTGCACTGTGAAACCCGGGCACTCCG AGCCGATGCCACCGGCCCGCGGGTCTCTGAAGGGGACCCCTCCACTAATCGGACTGCCAAATTTCA CCGGTTTGCCCTGGGATATTATAGAAAATTATTTGTATGATTGATGAAAATAAAAACACCTCGTGG CATGGTT
(SEQ ID NO: 107)
Mus musculus Nenf 3'-UTR
NM_025424
TGTCTAGCTGAGAAGCAGCCGGTTCTAGGGAGAAGTGAGGGGACAGGAGTTAAGTGTCCCTCGGAA CAAGCGGAGGAAGCCTCCGAGTGCCCTGCAGCTGAATAAAGCGAATGTTT
(SEQ ID NO: 108)
Mus musculus Atp5k 3'-UTR
NM__007507
GGCGTCAGCGAGCTTGCTTTTCTCTAGTCGTTGAGAACGAATAAAGCTTCATTGTGTGAAAAAAAA ΑΑΆΆΆΑΑΑΑΑΑΑΑΑΑΑΑΑΑΑΑΆΑΑΑΑΑΑΑΑΑΑΑΑΑΆΑΑΑΑΑΆΆΆΑΑΆΑΑΑΑΑΑΑΑΑΑ
(SEQ ID NO: 109)
Mus musculus 1110008P14Rik 3'-UTR
1110008 P14Rik-001 ENSMUST00000048792
GTGCCGGGAGCCCCCATCCAGGCCCTACCCTCACCTCTCTAGGCCATGTTCTGGCCTGGGTAGATA CTACTTGGCTTAGACACCATCTCGGGTACTGGCCTCCAGATCCTAGTGGGTCTACCAGCCTGGACC AGTCCCCATTCACTGCCCATCACCCTTCCTGGAGTCAGGTGCAATCCTACAGTTCTCCCACTTGTC TGTCTTCTTTCCCCTCCATCCAGACTGAGAGTCCGAATTAAAGATGTCTCCCACACCACTGC
(SEQ ID NO: 110)
Mus musculus Cox4il 3'-UTR
NM_009941
GAGCCCGCTGCCTGCCGGCTCCCTGCCTCCCTCACTCCCTCGGCATGCTGGAAGCTGCCGTATCCA ATGGTCCATGCTAATAAAAGACCAGTTTACGTGGTG (SEQ ID NO: 111)
Mus musculus Cox6al 3'-UTR
NM_007748
AGAGAACCTGGCCTCCCCCAGGCAACAAAGGGACCACAGCACTGGTTTTGGACCCTTACTCTGTGT GGACCACGAAAACCCTTTGGATGCTAAGCTCGTGTCTCCTTTCCTCAGATGGCGACCATTACTCTG ATCTTCCATCCCTTCTGCTTGTAAGAGGAGATGCCTTAAATAAATAACTTAAACTCA
(SEQ ID NO: 112)
Mus musculus Ndufs6 3'-UTR
NM_010888
TGTGGGCTGTGTCCTGGTCCTCTGACTCCTATGGAACATCTCCACGCTGGGTGTTCTGTGTGAGGC CACTGCTCTGTGAATGGTGTCCCTTGTTTTGAATAAAGGATGCTCCCACCATGAAAAAAAAAAAAA AAAAAAA
(SEQ ID NO: 113)
Mus musculus Sec61b 3'-UTR
NM_024171
ATTGGGCTACATCCATCTGTCATCTGAAGAAGAAGAAGAAGGAAAAAAACCCAACATATCTTGGAC CAAAAGTGTAGTGATTTTCTGTTCACGTGTATTATTTTACAGAGAATAAGAATTGACTTTGAGAAA TCAGTTTTTTCTATGGCTAATAAACTTTGGAATTGCTTT
(SEQ ID NO: 114)
Mus musculus Romol 3'-UTR
NM_025946
TTAGGGCTAGGATGCCCTGCAATACCTAAACTTCCCCATCCATTTCGACCCTTGTACAATAATAAA
GTTGTTTTCTTCTCGTTAAAAAAAAAAAAAAAAAA
(SEQ ID NO: 115)
Mus musculus Gnas 3'-UTR
NM_010309
GAAGGGAACACCCAAATTTAATTCAGCCTTAAGCACAATTAATTAAGAGTGAAACGTAATTGTACA AGCAGTTGGTCACCCACCATAGGGCATGATCAACACCGCAACCTTTCCTTTTTCCCCCAGTGATTC TGAAAAACCCCTCTTCCCTTCAGCTTGCTTAGATGTTCCAAATTTAGTAAGCTTAAGGCGGCCTAC AGAAGAAAAAGAAAAAAAAGGCCACAAAAGTTCCCTCTCACTTTCAGTAAATAAAATAAAAGCAGC AACAGAAATAAAGAAA AAATGAAATTCΑΆΑΑΤGAAATΑΑΑΤΆΤTGTGTTGTGCAGCATTAAAAAA TCAATAAAAATTAAAAATGAGCAAAAAAAAAAAAAAAAAA
(SEQ ID NO: 116)
Mus musculus Snrpd2 3'-UTR
NM_026943
AGCCTGCTCCCTGCCCTGCGAAGGCCTGCAGAACCCTGCCCAGTGGGCGAGAAATAAAACCCTGTG CTTTTTGGTTAAAAAAAAAAAAAAAAAAAA
(SEQ ID NO: 117)
Mus musculus Mgst3 3'-UTR
NMJ325569
GGTGTGGAGGGCCTTCCGACTCTCACTCACCTCCAGCGACTCACCCTGATTTCCAGTTGCACTGGT TTTTTTTTTTTTTTTAA ATAATAAAAACTTATCTGGCATCAGCCTCATACCT
(SEQ ID NO:118)
Mus musculus Aldh2 3'-UTR NM_009656
AGCGGCATGCCTGCTTCCTCAGCCCGCACCCGAAAACCCAACAAGATATACTGAGAAAAACCGCCA CACACACTGCGCCTCCAAAGAGAAACCCCTTCACCAAAGTGTCTTGGGTCAAGAAAGAATTTTATA AACAGGGCGGGGCTGGTGGGGGGGAAAGCTCCTGATAAACTGGGTAGGGGATGAAGCTCAATGCAG ACCGATCACGCGTCCAGATGTGCAGGATGCTGCCTTCAACCTGCAGTCCCTAAGCAGCAAATGAGC AATAAAAATCAGCAGATCAAAGCCACGGGGTCAGTTCTCT
(SEQ ID NO: 119)
Mus musculus Mp68 (2010107E04Rik) 3'-UTR
NM_027360
CTGCTCCGAATCCACAAGATGAAGACGTCGGCTAAACTTGAGCAAGCTTTGTTAGATGGGAACATG GAACATCACTGTACACTTATCTAAGTACCATTTATAATGTGGCATTAATAAATGTATCTGTGAATA CC
(SEQ ID NO: 120)
Mus musculus Ssr4 3'-UTR
NM_001166480
GGGCAGCAACTTCAGCCGTCCATTGCTTCTTTCAATAAACAGTCACTATTTGACATGAGTACATTC AAGAAAAAAAAAAAAAAAAAA
(SEQ ID NO: 121)
Mus musculus Myl6 3'-UTR
NM_010860
GGACATTCTGTATCCCGAGTCTGTTCCTTGCCCAGTGTGATTTCTGTGTGGCTCCAGAGGCTCCCC TGTCACAGCACCTTGCCCATTTGGTTTCTTTTGGATGATGTTTGCCTTCCCCAAATAAAATTTGCT CTCTTTGCCCTCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
(SEQ ID NO: 122)
Mus musculus Prdx4 3'-UTR
Prdx4-001, NM_016764
AAAGTACTTCAGTTATGATGTTTGGACCTTCTCAATAAAGGTCATTGTGTTATTACCA
(SEQ ID NO: 123)
Mus musculus Ubl5 3'-UTR
NM_025401
AGGGGGATTCCTTCTCCTCCTCGCCCTGCTCTGCCCTGCCCTCCTCTCCCATCCTCATCTGACACT GGTGTAGATGGTCATTTTTAACAGTTCACATGAATAAAAACTTGGCTGCTGCTTTGCTGCTGTC
(SEQ ID NO: 124)
Mus musculus 1110001J03Rik 3'-UTR
NM_025363
TGCAGAGAGTCCTCAGATGTTCCTTCATTCAAGAGTTTAACCATTTCTAACAATATGTAGTTATCA TTAAATCTTTTTTAAAGTGTG
(SEQ ID NO: 125)
Mus musculus Ndufal3 3'-UTR
Ndufal3-201 ENSMUST00000110167
GGCCTGAGCCAACGCACATAATAAAGAGTGGTC
(SEQ ID NO: 126)
Mus musculus Ndufa3 3'-UTR
NM 025348 ATGCCTCTGCTGATGGAAGAGGCCCCTTCCCTGTTGCTCTCCAATAAAAATGTGAAAACTAATAAC CCC
(SEQ ID NO: 127)
Mus musculus Gstp2 3'-UTR
NM_181796
TGGACTGAAGAGACAAGAGCTTCTTGTCCCCGTTTTCCCAGCACTAATAAAGTTTGTAAGACAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
(SEQ ID NO: 128)
Mus musculus Tmeml60 3'-UTR
NM__026938
ACAACAGGGCTGTGGGGACTGGCTGGGCCTGACGACTGGGACATTAAAACCTGACCCTTCCGCAAA AAAAAAAAAAAAAAAAAAAAAAA
(SEQ ID NO: 129)
Mus musculus Ergic3 3'-UTR
NM_025516
CTCTCTCCCTTCCCCACAGCTTGTCCTGCCCTCTCTTCCCCTGTGGGTTTACCCTCCAGCCTGTCA ACTACCCATATCCTCTCCTCAGCCAGCCCAGCCCAGGGCAATAAATATGAATTGTGATAGGAA
(SEQ ID NO: 130)
Mus musculus Pgcp 3'-UTR
NM_018755
GGAGAACAAGAAGAGAGGACCTTGTTCTCTGTAGTTGGGAATCCCAACTCTGAATCTTTACAACAT CCATCGTCACAAAAGAGTGTTATACATTTAATCCACAGGGCATAGTTTTCTTTATACCTTCTGTTA ATCATCTTTCCTTAATACTTTCTTATCTGTTTCTAGAATAAATCATGATCCCTACTGCACCACCTT GAAAATGTTGTTTCCAGTTTTAAAATAAGCAATAAATATTTGAAATGCTTCTGATTTTTCATTTTC ATTTAAAAACATTAAATTAAATG AATGAGA
(SEQ ID NO: 131)
Mus musculus Slpi 3'-UTR
NM__01141
GCCTGATCCCTGACATTGGCGCCGGCTCTGGACTCGTGCTCGGTGTGCTCTGGAAACTACTTCCCT GCTCCCAGGCGTCCCTGCTCCGGGTTCCATGGCTCCCGGCTCCCTGTATCCCAGGCTTGGATCCTG TGGACCAGGGTTACTGTTTTACCACTAACATCTCCTTTTGGCTCAGCATTCACCGATCTTTAGGGA AATGCTGTTGGAGAGCAAATAAATAAACGCATTCATTTCTCTATGCAAAAAAAAAAAAAAAAAAA
(SEQ ID NO: 132)
Mus musculus Myeov2 3'-UTR
NM_001163425
GGCCGCCCGGTCCTATGTGCTCCATGTCTGTGATGTGTCTGGAGTCTCTCGGGACACGACCAGCTG ATTGTAGACACCGTGTTGATATC CTAGAAATGAAG CCTTGTC ACCAATAGAGGAACTGTCTGA ACCAACTGGGTACTGATGTCTCTGGGAATGCCAGCCCGTGTCCTTGTTTAAGTTAATAAAGAACAC TGTAACACGCAGGGTGATTTTAAAAAAAAAAAAAAAAAAAAAA
(SEQ ID NO: 133)
Mus musculus Ndufa4 3'-UTR
NM_010886
ACTATGAAGTTCACTGTAAAGCTGCTGATAATGAAGGTCTTTCAGAAGCCATCCGCACAATTTTCC ACTTAAGCAGGAAATATGTCTCTGAATGCATGAAATCATGTTGATTTTTTTTTTTTTTGGAGTTTA TTACACTGATGAATAAATCTCTGAAACTTG (SEQ ID NO: 134)
Mus musculus Ndufs5 3'-UTR
NM_001030274
GCGGGGCAGCTGGAGGCCGCTGTCATGCTCTGTTTTCCCCTGGAGAGAATATTTAAGGAAAGCTCC TTCATTAAGTATTAAGTATGTGGAAATAAAGAATTACTCAGTCTTAAAAAAAAAAAAAAAAAAAAA AAAAAAAAAAA
(SEQ ID NO: 135)
Mus musculus Gstml 3'-UTR
NM_010358
GCCCTTGCTACACGGGCACTCACTAGGAGGACCTGTCCACACTGGGGATCCTGCAGGCCCTGGGTG GGGACAGCACCCTGGCCTTCTGCACTGTGGCTCCTGGTTCTCTCTCCTTCCCGCTCCCTTCTGCAG CTTGGTCAGCCCCATCTCCTCACCCTCTTCCCAGTCAAGTCCACACAGCCTTCATTCTCCCCAGTT TCTTTCACATGGCCCCTTCTTCATTGGCTCCCTGACCCAACCTCACAGCCCGTTTCTGCGAACTGA GGTCTGTCCTGAACTCACGCTTCCTAGAATTACCCCGATGGTCAACACTATCTTAGTGCTAGCCCT CCCTAGAGTTACCCCGAAGGTCAATACTTGAGTGCCAGCCTGTTCCTGGTGGAGTAGCCTCCCCAG GTCTGTCTCGTCTACAATAAAGTCTGAAACACACTTGCCATGAAAAAAAAAAAAAAAAA
(SEQ ID NO: 136)
Mus musculus 1810027O10Rik 3'-UTR
1810027O10Rik-001 ENSMUST00000094065
AGTCTCTTGTTTAAGCGCCCAGTCCTGGCCTTTCTGGGTAATTGGGCGCAGAGGGAAGGAGCCAAT GTTGAAGCAGAAAAGAAATTAAAAGAAAAAGGCATATAAAGAA
(SEQ ID NO:137)
Mus musculus 1810027O10Rik 3'-UTR
BC117077
AGTCTCTTGTTTAAGCGCCCAGTCCTGGCCTTTCTGGGTAATTGGGCGC
(SEQ ID NO: 138)
Mus musculus Atp5o 3'-UTR
NM_138597
GAGACTGTCACCTGTGTGAGCTCTTGTCCTTGGAGCAACAATAAAATGCTTCCTG
(SEQ ID NO: 139)
Mus musculus Shfml 3'-UTR
NM_009169
CATCTGGGAATGTCCCAGGAACCTCAATCATGGACTCTACCACAGTCTAGGACAGAGAAAGCAGGA CGGGATACTTTAAAGAACATGTTTATTTCATTATCTGCTTCAATTTATTTTTGTTTTATAACAAAA AAAATAAGTAAATAAATGTTTTGATTTAATCTTTTTGGTTCA
(SEQ ID NO: 140)
Mus musculus Tspo 3'-UTR
NM_009775
AGGCACCCAGCCATCAGGAATGCAGCCCTGCCAGCCAGGCACCATGGGTGGCAGCCATCATGCTTT TATGACCATTGGGCCTGCTGGTCTACCTGGTCTTAGCCCAGGAAGCCACCAGGTAGGTTAGGGTGG TCAGTGCCGAGTCTCCTGCAGACACAGTTATACCTGCCTTTCTGCACTGCTCCAGGCATGCCCTTA GAGCATGGTGTTTTAAAGCTAAATAAAGTCTCTAACTTCATGTGTAAAAAAAAAAAAAAAAA
(SEQ ID NO: 141)
Mus musculus S100a6 3'-UTR NM_011313
AATGGGACCGTTGAGATGACTTCCGGGGGCCTCTCTCGGTCAAATCCAGTGGTGGGTAGTTATACA ATAAATATTTCGTTTTTGTTATGCCT
(SEQ ID NO: 142)
us musculus Taldol 3'-UTR
NM_011528
TGCAACACCCGAGGCCCCAGTCCTGCACCGAGGCTGACCCCAGACCTGCACTGCCTTTGAGCTGGG TCCTAATTGCACATGGCTTGTGACGAATGAATCTTGCATTTTTTAGTGATCGGAGAAGGGATGGAT CATAGGATTCTGATTTTATGTGAAATTTTGTCTAATTCATTAAAGCAGTTGCTTTTCCTATGCTGT TT
( SEQ ID NO: 143)
Mus musculus Bloclsl 3'-UTR
NM_015740
ACTAAAACCCACCCCTCTTACTTCACCCTCCTGGACAGGAGGGAAACTGGTGAGCCACGAATAAAA ACACAAGCTTCCATTCT
(SEQ ID NO: 144)
Mus musculus Ndufbll 3'-UTR
NM_019435
TGGCTTACCGAGCAGGGCCTAAGAAGCATTACTCATCCGCTGCTTGTTATTTACCTGGTTCCTCAG AACACCTTATTAAAGGAATTGAAAGTA
(SEQ ID NO: 145)
Mus musculus Mapllc3a 3'-UTR
NM_025735
GTCAAGAGGAGGGGAGGGGGGTGGCTGGGAGTTCTGGTCAGGTTCTCCCCAGGGAGGTCCTGGCTC CTAAACTAAGCTATTTCAGTCCCCAGTGGATTAGGCAGAGATGTGACACCCACTCCCCCCCCCAGG TAGGGGCCACCAGCCAGCCTACCACATCCTGGGTAGGTCCTGGGCCAGTCATGTTCGGGTTGCTCT TTTGGGTGCTGGCTGGGTTGGGAGTGGGTGGGGAGCAGCATCCCTGCTCTGTGGGGTTTGTCATTT TGTTAGGCCCTTGCCTGTCTGCCCATCTTGCCCCTCATCCACCTGAGGCTTTGCCTCCTGCCAGGA CCTGCCCCACCCCTGAAAGGCTGGCTCCCCTTGTCCTGACTCGGTGTATGGATCTGTGGTCATTTC CTCTGCAGAAAGAATAAAGACTGCTCAGGCCTGCCTGGCCAAAAAAAAAAAAAAAAAA
(SEQ ID NO: 146)
Mus musculus Morn2 3'-UTR
NM_194269
ACCTGCTGCCTTAACGCTGAGATGTGGCCTCTGCAACCCCCCTTAGGCAAAGCAACTGAACCTTCT GCTAAAGTGACCTGCCCTCTTCCGTAAGTCCAATAAAGTTGTCATGCACCCACAAAAAAAAAAAAA AAA
(SEQ ID NO: 147)
Mus musculus Gpx4 3'-UTR
NM_008162.2
CTAGCCCTACAAGTGTGTGCCCCTACACCGAGCCCCCCTGCCCTGTGACCCCTGGAGCCTTCCACC CCGGCACTCATGAAGGTCTGCCTGAAAACCAGCCTGCTGGTGGGGCAGTCCTGAGGACCTGGCGTG CATCCCTGCCGGAGGAAGGTCCAGAGGCCTGTGGCCCTGGGCTCGAGCTTCACCCTGGCTGCCTTG TGGGAATAAAATGTAGAAATGTGAAAAAAAAAAAAAAAAA
(SEQ ID NO:148)
Mus musculus Mif 3'-UTR NM_010798.2
GTCCTGGCCCCACTTACCTGCACCGCTGTTCTTTGAGCCTCGCTCCACGTAGTGTTCTGTGTTTAT CCACCGGTAGCGATGCCCACCTTCCAGCCGGGAGAAATAAATGGTTTATAAGAGACCA
(SEQ ID NO: 149)
Mus musculus Cox6bl 3'-UTR
NM_025628
CCTGGCTCCGCCCACCTCTCCTCTGTTCTTTGTCTTTCTCCCCGGATAGAAAAGGGGGACCTCAGC ATATGATGGTCCTTACCCTGGGACCCTGAATCATGATGCAACTACTAATAAAAACTCACTGGAAAA GTT
(SEQ ID NO:150)
Mus musculus RIKEN CDNA2900010J23 (Swi5) 3'-UTR
NM_175190
GCAGCTTCTTGGAGATTTTCATCTACAGCCCACAGGGACAGGAGGATGGGGGCATAAAAGGCAGAG TCTAGACAGTATGTTCATATGGTTTTCAGATTTTAAAAGATGCTAGAAGCCCTCCAAAGTTTGGGG TGGGTTCTAGAGAAGAGGAGTATTGGGAGGGGTGGGTATTGTCAATGTTAAGGTTCCTAAACATAC TTGTGAGTAGGTGTGTGTGGTTGTCCCTTTTGTTAATAAACATATGAGCAGTCAAAAAAAAAAAAA AAA
(SEQ ID NO: 151)
Mus musculus Sec61g 3'-UTR
NM_011343.3
GTCCTTCTCATCATGGGACGAGTGAGCCAGAGCGGGGGAAAGGGCATGAAGTAAAGCGTTGCCTGA ATGCTGTGTGGTGTTTTGTTTCTTCCTCCTTCCTATGAGGTTTTCTACTTCTCAATTAAAATAATT TCAAAA AAAC CTTTTTCCATAACAGA
(SEQ ID NO: 152)
Mus musculus 2900010M23Rik 3'-UTR
BC_030629
CCGTGGGGTCTGATACTCATCAATAAAACTGCCTGGTTTCTCCCACAAAAAAAAAAAAAAAA
(SEQ ID NO: 153)
Mus musculus Anapc5 3'-UTR
Anapc5-201 ENSMUST00000086216
CCAGGACTCCCTGCTTGATGGTGTGCATTTAGGGGTGGGTCATTACATGCTATCTTGTCAATAAAC TGTTCTGATCAGTTTGTCTGAAGTGGGTTTTTTTTTATTTTTCTGGGTTGAATTGTCAGTATCTTT GTTAAGAACTGTGTATCTAGGGGCTGGAGAGATGGCTTAGCAGTTAAGAGCACTAACTGTTCTTCT AAAGGACCTGGGTTCAATTCCTAGCACCCTCATGACAGCTCACAGCTGTCTGTAACTCCTGTTCCA GGGACTCTGACACCCTCAGGCAGACATAAAAGCAGTCAAAACACCGATGTACATAAAATTAAAATA AATTATTT
(SEQ ID NO: 154)
Mus musculus Mars2 3'-UTR
BC132343.1
GAACTCAGCTCTTACTGACTGGTAGTAAAAGATCAAATGTATTCTTTTTGCGTTTTTAAGTAAAGT CATGC
(SEQ ID NO: 155)
Mus musculus Phptl 3'-UTR
NM_029293
AGCTCTGCCCCACCCCCCACCCCCCGGACTAAGTCAGGTCTCTGCTCTTGCTGTGTTCTGTTTTGA GGGGCTGGCCCTGTGCTTTCCTTTTGTACCTTAGGCAGCATAGCACCTGCCAGGCCTTAGAGGCCA GACCAATCTGGTCCATAGGAATTAAAAGCATTGATATGCCTACT
(SEQ ID NO: 156)
Mus musculus Ndufb8 3'-UTR
NM_026061
GGAGGCTTGATGGGCTTTTTGCCCTCGTTCCTAGAGGCTTAACCATAATAAAATCCCTAATAAAGC
(SEQ ID NO: 157)
Mus musculus Pfdn5 3' -UTR
NM_027044
GAGTGCACTGCAGAAATGAAGCAGAGTGAGGGACCCTTCTTCAAGGGGCCTGGGACTTTTTCCGGC AATGGCCTCCTGGGAAAGTGGCCTGGGAAGAGAGTGTTTTGTGTTTAATGTTAATAAATGTGACCG CTGCGCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
(SEQ ID NO: 158)
Mus musculus Arpc3 3'-UTR
NM_019824
GAGGAGCCTGGGCAGCACCATCACGTGGAGACACATCATAGGACACACAGGCCAATGTGTCTGTTC ATACCTACCGTATCAAGGAGAGAAGAGAGCCTGTCTTTGCTGGAAAAGCTCTTGGTCAAGAATTGG GAGGGTGGGTGTTGGGCGATTTCGATTTTTGGCAGTTTTAAGCTGGTACTTAATATATAATAAATG TCACTGCTTATGTTAGACATTGAATTAAAACATTTTTGAGAAAAAGCTTTAAAAAAAAAAAAAAAA AAAAAAAAAAAAAA
(SEQ ID NO: 159)
Mus musculus Ndufb7 3'-UTR
NM_025843
GGATTACCCGCCAGCCTGTGGACCTATCAGTGAAATAAAAGCTTTGGGTCACCTGCCT
(SEQ ID NO: 160)
Mus musculus Atp5h 3' -UTR
NM_027862
AGCAGCCTGGGACGGAGCCCCGGCCGACATGAAATAAAACATTTAAATAGT
(SEQ ID NO: 161)
Mus musculus Mrpl23 3' -UTR
NM_011288
CCTATGACAGCAGGATTTGGACCACAGACCCTAGTGAGCACAGTGGTTCTGACAAGCCCAAATAAA AATTCTTTGTGGAG
(SEQ ID NO: 162)
Mus musculus Tomm6 3' -UTR
NMJ325365.3
CCAGAGAATGGAACTCCTGTGTATTCAGACTTTCCAAAGACAGCCTACTGTCTGTGACCACAAGAT CCTACCTGAGTGGCAGCTGAAGTTGACTCCCTCTCCTTGCCTGAACCCCCCCCCACTGCCCCCCCA TCCCCCAGTGTCGGCTGAGATGTTGCCTCTGCACGGTTCTGTGTGCAGTTCCCAACTTTCTGCAGA AGATGGTCCTTGCCCTTGTCCTGAAGAGTAGTAATGGTTCTTGAAAAAGATTTCAAATAAAGCCTG CACATAAAAGACAGGTATTTTATTCTTTTAATAAGAAACTTATTACAAAAACAAGGTGTAAAAAGT CCGCTTACAAAAATCAAATAAACATGACTTGTATTTCAAAAAAAAAAAAAAAAAAAA
(SEQ ID NO: 163)
Mus musculus Tomm6 3' -UTR Tomm6-002 ENSMUST00000113301
CCAGGTGAGAGCAGTTCTCCTGTGTTTCCCCGTTTCTGATGCTGTTATCTGCTTACAGAGAATGGA ACTCCTGTGTATTCAGACTTTCCAAAGACAGCCTACTGTCTGTGACCACAAGATCCTACCTGAGTG GCAGCTGAAGTTGACTCCCTCTCCTTGCCTGAACCCCCCCCCACTGCCCCCCCATCCCCCAGTGTC GGCTGAGATGTTGCCTCTGCACGGTTCTGTGTGCAGTTCCCAACTTTCTGCAGAAGATGGTCCTTG CCCTTGTCCTGAAGAGTAGTAATGGTTCTTGAAAAAGATTTCAAATAAAGCCTGCACATAAAA
(SEQ ID NO: 164)
Mus musculus Tomm6 3'-UTR
CCAGAGAATGGAACTCCTGTGTATTCAGACTTTCCAAAGACAGCCTACTGTCTGTGACCACAAGAT CCTACCTGAGTGGCAGCTGAAGTTGACTCCCTCTCCTTGCCTGAACCCCCCCCCACTGCCCCCCCA TCCCCCAGTGTCGGCTGAGATGTTGCCTCTGCACGGTTCTGTGTGCAGTTCCCAACTTTCTGCAGA AGATGGTCCTTGCCCTTGTCCTGAAGAGTAGTAATGGTTCTTGAAAAAGATTTCAAATAAAGCCTG CACATAAAA
(SEQ ID NO:165)
Mus musculus Mtchl 3'-UTR
NM_019880
CCTAAGCTGCCCGACCAAACATTTATGGGGTCTTAGCCTACCCCTGGTGAGGACCCATCATCTCAG ATGCCCAAGGGTGACTCCAGCCCAGCCTGGCTTCATGTCCATATTTGCCATGTGTCTGTCCAGATG TGGGCTGGTGGAGGTGGGTCACCTGGGACCTGGGGAAGCCTGGGGGAGCAGTGTTGGGGTGGCATC CCCTTCCTGCCTAGAGGTACTGGAGTCCATCTTGTACTCAGGCAGAGGCAGGCTGCAGAGGCAAAC GTCACTCAGTGGCAAGGCTTCCCTGCACCTCTAGCCCAGCTCATCCTGCCAGTCAGCCAGAAGCAC CCCCGCCCCCCACTTCCTGCTTTGTAAATTGGGCGCCATCACACCTGGGCCATGGGAGGCTGGAGC TATGTTCCCAACACTAATTTTCTTATACAAGGGTGGTGCCTTCTCCTGAATAGGAAATCATGTTCT CCTCAGACCATCCCCTCATCTGCTTGTCTGTGCTGGTGACGCCAGGTGTGAGGGTTCAGTCACTGT GCTGGGTGCGAATACGCACAGGTTACATAGGCCGACATCTAGTCCTCCCCTCGTGGTAAGATAGAC CCATCTCCTCGAATAAATGTATTGGTGGTGATTTGGA
(SEQ ID NO: 166)
Mus musculus Pcbd2 3'-UTR
NM_028281
TCTGCGCCTGCCTTGTCTGCAGCGTTGTTTGCAAGCCACTTATGTTAATAAATTGTCATAAAGTAG TTCATAGTTACATGTATACATTGTTGTATQATTGATGCTCAAATACAGAATGATTTGAAGCCAAAA AAAAAAAAAAAAAAAAAAAAAAAAAA
(SEQ ID NO: 167)
Mus musculus Ecml 3'-UTR
NM_007899
GTCACCCTGAGCCTCAGAGGATTAGATGGGGGAACTCCGCCCTACTCCACCCTCCTCGAACACTCA TTACAATAAATGCCTCTTGGATTTGGC
(SEQ ID NO:168)
Mus musculus Hrspl2 3'-UTR
Hrspl2-001 ENSMUST00000022946
CTATAAGTAGCCATGCTGATGTTGACTCCGGAGGTTTTAGAATGTCTTTCACACTTTAATTTTTAC AAATGATGCTGGGAAGTATAAAAATGACCAGAGTGGTTGAAGTTATTGTGGAAGTGATCAAATATG TGGAGATTTGACATTAATTGGAGATTATTCAGTATAGTGACTGATGTTCTAATTTCACTTATGTTG CTGGGTGTGAGAGAAGAGGTGCACAGCTACTGAGATGGGAAGCAGAAGGAAAGATGGGCTGTTGTA CATGAGAAATAGTAAGGAGCACATCTACTTAAATCATATTAATTTGCTCATGTGAAATACTTAGTT CTTATGTTAGATATAAGAAAC AAATTGAAATATTCAAACTTGAA AGTACCAGGAGAACAAGTGG ACCAAAATCTTATACAGATAATATTACTTTAATTGAAATAAAAAATAGATGTGTAACTTTCC (SEQ ID NO: 169)
Mus musculus Mecr 3'-UTR
NM_025297
TTGCTCCAGAGGACCAGGAGGAAAGCAGGAGAGGCAAGACTGGCTGTCTGCTGGCCCCTCCATGAG AACCCCAGCCTTCCCAGACTGCCTCACCCATATTGTCTCTTCCTACCAGGAGGGTGGGGGACCAAC TCTAGGCTCCCTAATAAACCCTTAACTTCCCGAGTGGAGGATGAAGAGTAC
(SEQ ID NO: 170)
Mus musculus Uqcrq 3'-UTR
NM_025352
ACGGCCTGCACCTGGGTGACAGTCCCCTGCCTCTGAAAGACCCTTCTCTGGGAGAGGAATCCACAC TGTAGTCTTGAAGACAATAAACTACTTATGGACTTCCCTTTGAAAAAAAAAAAA
(SEQ ID NO: 171)
Mus musculus Gstm3 3'-UTR
N J10359
GCCCCTGCCATGCTGTCACTCAGAGTGGGGGACCTGTCCATACTGCGGATCCTGCAGGCTCTGGGT GGGGACAGCACCCTGGCCTTCTGCACTGTGGCTCCCGGTTCTCTCTCCTTCCCGCTCCCTTCTGCA GCTTGGTCAGCCCCATCTCCTCATCCTCACCCCAGTCAAGCCCATGCAGCCTTTATTCTCCCCATT TTTTTTTCACATGGCCCCTTCTTCATTGGTGCCCAGACCCAACCTCACAGCCCTTTTCTGCAATCT GAGGTCTGTCCTGAACTCAGGCTCCCTAGAGTTACCCCAATGGTCAACACTATCTTAGTGCCAGCC CTCCCTAGAGATACCCTGATGGTCAATACTATCTTAGTGACGGCCCTCCCTAGAGTTACCCTGAAG GTCAATACTCGAGTGCCAGCCTGTTCCTGTTTAAGGAGCTGCCCCAGGCCTGTCTCATGTACAATA AAGCCTGAAACACACTTGAAACACAATAAACACTGAACACTTGCTGTGA
(SEQ ID NO: 172)
Mus musculus Lsm4 3'-UTR
NM_015816
TCACTCCCTGCCTGAGCCGAGCCCAGAACGGTGGGTGAGGCCTCAGGGCACCTTTGTGTGAAGCCC CACTTGGCGTCTGGTCCAGTGAAGTCCCTCGCTGGCCACTGACTCAGTTTCTGGAAGGTTCCGAGT CTGAGGTGCCTGTGGAGCCTTAGATGCCCTTTGAAGGGCTGACTTCTTCCAGGCATGTTTGAGTTT CAGTTGGAGCTGCAGGCTCAGCCCATGGCGGCTCACCTGTCCTTTACCAGCCATACCCTGTACATC TTCTGTTTGAAAAATAAAAGCAAACACCA GAAAGAAAAAAAAAAAA
(SEQ ID NO:173)
Mus musculus Park7 3'-UTR
NM_020569
AGCCCAAGCCCTGGGCCCCACGCTTGAGCAGGCATTGGAAGCCCACTGGTGTGTCCAGAGCCCAGG GAACCTCAGCAGTAGTATGTGAAGCAGCCGCCACACGGGGCTCTCATCCCGGGTCTGTATGTTTCT GAACCTTGCTAGTAGAATAAACAGTTTACCAAGCTCCTGCCAGCTAAAAAAAAAAAAAAAAAA
(SEQ ID NO: 174)
Mus musculus Usmg5 3'-UTR
NM_023211
ATGGATTTTGAAATGTCTGACCTCACCTGTTAAGTCCCATGCCTGAAGAAGCTGATGTGAACTCAT CATGTAATACTCAATTTGTACAATAAATTATGAACCCAAAAAAAAAAAAAAAAAAAAAAAAAAAA
(SEQ ID NO: 175)
Mus musculus Cox8a 3'-UTR
NM_007750
AGGGAGCAGTCTTCCCTCATCCTTTGACTAGACCACTTTTGCCAGCCCACCTTGATCATGTTGCCT GCATTCCTGGCTGGCCTTCCCCGGGATCATGTTATTCAATTCCAGTCACCTCTTCTGCAATCATGA CCTCTCGATGTCTCCATGGTGACAACTGGGACCACATGTATTGGCTCTGCTTGGTGGGGTCCCCCT TTGTAACAATAAAGTCTATTTAAACCTTGCTCC
(SEQ ID NO: 176)
Mus musculus Ly6cl 3'-UTR
NM_010741
TGGTCCTTCCAATGACCCCCACCCTTTTCCTTTTATCTTCATGTGCAACCACTCTTTCCTGGAGTC CTCTAGTGACAAATTATATGTTATAGAAGGTCCAATGTGGGGATAGTGTGTGGAACACCCTGTTTC ACCTTTATAGCCCCTGCTGGGTAAGTGCCCGACTCCTCTCTAGGGCTTTCAAATCTGTACTTCTTG CAATGCCATTTAGTTGTGGATTTCTATTCTTGGCCCTGGAGGCATGTGGCCAGCACATGCAACAGG CAGTATTCCAAGGTATTATAGTATCACCATCCACACATAAGTATCTGGGGTCCTGCAGGGTTCCCA TGTATGCCTGTCAATGACCCCTGTTGAGTCCAATAAAAGCTTTGTTCTCCCAGCCAAAAAAAAAAA ΑΑΑΑΑΑΆ
(SEQ ID NO:177)
Mus musculus Ly6cl 3 ' -UTR
NM_001252058.1
ACTCATAAAAATGCTCCTGCCTCGGTCTTCCAAGTTCTAGGATTGCAAGTCTGACTTCAACATGCC TTACAGACAACTCTGGGACATCCAGGCCTAGTGGCATGTTGCCCAGATATGGGGATGCTCTGTGGC CCCTGCATAAGAAGTGAGTCACTCCCTGATTTCTTGCAGACTCTCAAAGAAGGAAACTAAAGACCC GTCAGTGCCTTTCTTTCTGCCCTGCTGGTGTGCCAATCAGGGATCCTAACATCAGGGAGAGGACTT CCTGTTGCAGCGAAGACCTCTGCAATGCAGCAGTTCCCACTGCAG
(SEQ ID NO: 178)
Mus musculus Cox7b 3'-UTR
NM_025379
TCGTGCCAGCTGGTACAATAATCAAGGAATTGTTTAAAACCAACTTATAAGTGAATGCCAAGTCAA AGAATCATGTACTCATTATACTATGGCAGATTGAAGAACAAATAAAGAAATAAAGTACCTTAACCT TCATTCTAGGCTTTGTTTTTTTCCTTTGTAAATGAAGCCCAAGCATGGTGACTTCTCATTTATTTA AGCTGTATTGTCTCTTAAAATGGCTTTTTACCCTATGAGGTGGTATGAGGGAAATCTATGATCAGG AGGGCACCTTTATAGTAAGCTGAAATTACAGAGAATGAAGAAATAAGCACAGAGCTGTTTTAGGAG CCCACTGGGTCATTGGCCATATAGGTTATGCTTACTGCCCTCTACCTCGTGGTTATATTTGGAATT GCCATTAGCTCCCTTCTGCTTAGAGACTGGACTGTCACCAAACCCAAGGGGATAGTGATCCTGTAA TGATCCTGTGTGAACTAGGTTTGCTAAAGACTACCACCTCCTTACACTGTATGGCATATTCATCTG AAATAGGTGCTAATTTTTCAGCATAATCCTTAATCTTTAGGATCTGTCATACTTCCTAGTAATTTA ACTGTTGCTGAAGAAATAAAGGCTATCTGTTAAAAAAAAAA7AAAAAAAAAAAAAAAAAAAAAAAAA ΑΑΑΑΑΑΑΑΑΑΑΑΑΑΑΑΑΑΑΑΑΑΑΑΑΑΆΑΑΑΑΑΑΑΑΑΑΑΑΑΑΑΑΑΑΑΑΑΑΑΆΑΑ AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA7AAAAA
AAAAAAAAAA
(SEQ ID NO: 179)
Mus musculus Ppib 3'-UTR
NM_011149
AGAGCCTGGGGGACCTCATCCCTCTAAGCAGCTGTCTGTGTGGGTCCTGTC7AATCCCCACACAGAC
GAAGGTAGCCAGTCACAAGGTTCTGTGCCACCCTGGCCCTAGTGCTTCCATCTGATGGGGTGACCA
CACCCCTCACATTCCACAGGCCTGATTTTTATAAAAAACTACCAATGCTGATCAATAAAGTGGGTT TTTTTTATAGCTTGAAAAAAAAAAAAAAAAAAA
(SEQ ID NO: 180)
Mus musculus Bagl 3'-UTR NM_009736
AGTGCAGTGGAGAGTGGCTGTACTGGCCTGAAGAGCAGCTTTACAGCCCTGCCCTCTCTGGAACAG AAGTCGCCTGTTTCTCCATGGCTGCCAGGGGCAACTAGCCAAATGTCAATTTCCCTGCTCCTCCGT CGGTTCTCAATGAAAAAGTCCTGTCTTTGCAACCTGAATTAGACTTGTGTTTTCTCAAAAAAAAAA AAAAAAA
(SEQ ID NO: 181)
Mus musculus S100a4 3'-UTR
S100a4-201 ENSMUST00000001046
AGACTCCTCAGATGAAGTGTTGGGGTGTAGTTTGCCAGTGGGGGATCTTCCCTGTTGGCTGTGAGC ATAGTGCCTTACTCTGGCTTCTTCGCACATGTGCACAGTGCTGAGCAAATTCAATAAAAGGTTTTG AAACTATT
(SEQ ID NO: 182)
Mus musculus Bcap31 3'-UTR
NM_012060
AGGCTTGGTGTTTCCCTGCCTGCCGCTGGCTTCTACCTGACCCATGCTTACTGCTTCCTTGGAGCC CAGACTATCCCTCTGGTACTTGGGTTTATTCCCTACTTCCCCAATTTTCTTCCATGGCTTATAGAT CATTATTTTGGCACCATTACACATACTGCTCTTATACCAAAAGGGACCTGATTGTTGTTTATTCAG AGTACTTTTGCCACTGTTCTGCCTGGCTAGGGCACTTTCCACTCCTGGAAGTGTAGAAAAGCACTG GTGACCTGGCCTGCAGTTTGAACCCCTTTTTATTTTGCAATGTACCCTAAAGGAGGCTGCTGTGAA GCAGGTCAACTGTTTTATCCTGAGGGGAATAAATGTTGTTATGT
(SEQ ID NO: 183)
Mus musculus Tecr 3'-UTR
NM_134118
GCAGCTCCTCACGGCTCTGCCCAGTAATACTCTCCACCCCTCACTGCCCCTGTCCTGATGTGTGGC TGGCCATGGCTCTCCAGCAGCAACAATAAAACCTGCTTACCCAAAAAAAAAAAAAAAAAA
(SEQ ID NO: 184)
Mus musculus Rabacl 3'-UTR
NM_010261
AGTGTCCTCCAGGACCTGCCGGCCTCTCCTGCCGGCCGGCTGTCCCATCTCTGTCTGTTCTCGTCC TACCTGGCCTTGCTGCTCAGCTCCGAGCCTTCCACCTGAGGCCTCAAACCCAGGGAGGGGCTTTTG TCTTTGGAAATAAAGCTGTTACAATTGCTATTTGGCCAA
(SEQ ID NO:185)
Mus musculus Robld3 3'-UTR
NM_031248 (Lamtor2)
CAGCGTGATGGAGGCTGGAGTAGAAAAGGGATGATGATCTGGAGGGAGGGGCGGGGCCCTAGAAAC GCCATATCGGGCGAGGTACAGGAAGGGGGGGTTGCTTTTTTCTGAATAAATTTTCAACTCTTAAAA AAAAAAAAAAAA
(SEQ ID NO: 186)
Mus musculus Sodl 3'-UTR
NM__011434
ACATTCCCTGTGTGGTCTGAGTCTCAGACTCATCTGCTACCCTCAAACCATTAAACTGTAATCTGA AAAAAAAAAAAAAA
(SEQ ID NO: 187)
Mus musculus Nedd8 3'-UTR
NM 008683 AGAAACTTGGTTCCGTTTACCTCCTTGCCCTGCCAATCATAATGTGGCATCACATATCCTCTCACT CTCTGGGACACCAGAGCCACTGCCCCCTCTCTTGGATGCCCAATCTTGTGTGTCTACTGGTGGGAG AATGTGAGGACCCCAGGGTGCAGTGTTCCTGGCCCAGATGGCCCCTGCTGGCTATTGGGTTTTAGT TTGCAGTCATGTGTGCTTCCCTGTCTTATGGCTGTATCCTTGGTTATCAATAAAATATTTCCTG
(SEQ ID NO: 188)
Mus musculus Higd2a 3'-UTR
NM_025933
GTATAGCCGGGTCTTAAAGCGCCATGGAAACCATTACAAAACCCAGGAACAACAGACATCCCTGTC AGACTTGCTCCCTCCGTTTCAGACCGGACCTTATTGTCATTTGGGTGAGGAAGTGGCCGATTTTGT AACTGATTTGCGCTTCCACCGCTGCCCCCTCCCGCTCCCAAAATCCCAGGTTCATTTCAGTTGGGT TGCATGCTTCTATTTGTGATGCGTCCCCTTAATTACTTAATAAAAGCTTATTACACTTG
(SEQ ID NO: 189)
Mus musculus Trappc6a 3'-UTR
Trappc6a-001 ENSMUST00000002112
GGACCCCAGACCCCAGGCTTGCCCTTCCCTAAGCTTAGCCTCGGAATGTGGCACCTGACCCTGCCT CACTGCTCACCTTTGCAGGTCGCCTTGAAGCTGGAGCTCACAGGCTCTGGGGAGGTCACATGTGCT TCAGACAAGGGAATGAAAGGGCCGGGAGGGTCCCGGGAGGTGGGACCATCCCCTGAGTTCCAAGTC AGCATGGAGGGACATTAGGGCATCACCCAGATGACAGATGTTCAGTAAAGGTTCTTTATGTGCAAA CAGA
(SEQ ID NO: 190)
Mus musculus Ldhb 3' -UTR
Ldhb-001 ENSMUST00000032373
CTGCCAGTCTCTAGGCTGTAGAACACAAACCTCCAATGTGACCATGAACCTTTAGTCTTCAGCCAT GTATGTAGGTCACAGTTTGCTTCTTCCCTGACATGTGATATGAGCTCACAGATCAAAGCCCAGGCT TGTTTGATGTTTGCACTAGGAGCTCCTGATCAAATAAAGTTAGCAATTGCAGCATA
(SEQ ID NO: 191)
Mus musculus Nme2 3' -UTR
Nme2-001 ENSMUST00000021217
ACATGAAGAAACCAGAATCCTTTTCAGCACTACTGATGGGTTTCTGGACAGAGCTCTTCATCCCAC TGACAGGATGGATCATCTTTTCTAAAACAATAAAGACTTTGGAACT
(SEQ ID NO: 192)
Mus musculus Snrpg 3' -UTR
NMJ326506
CCTGTGCTCAGCAAGCAGTGTCCACATCCCTCCCCAAAGGCCTGTTTGATTGTGATGTAGAATTAG GTCATGTACATTTTCATATGGAACTTTTTACTAAATAAACTTTTGTGATACTC
(SEQ ID NO: 193)
Mus musculus Ndufa2 3' -UTR
NM_010885
AGGTCTCCACTGAGGACTGTGAGCGAGAGCAGCTGAACCTGCTGGACTGAAGACAGTGTGGGGAAA TGTGTGCTTTGGGTCCTTATAAAGCTTACGCTGTACAGTGTCCCTTCAGAATGTCCTCTTCATTAC CTTCTCCCTCTTACTGCGCAACACTGAGGCAAAGTAGTTTTATATAAAAATACTCCTTTATTTCTC CTCAAAAAAAAAAAAAAAAAAAACCCACCAGGTGCCA
(SEQ ID NO: 194) Mus musculus Serfl 3'-UTR
Serfl-003 ENSMUST00000142155
TGACTGGCTTTTTGGAAAACCTGGGTGCTATTGCCAGTGGGTGCATCATACGCTCTAAGATTAAAA TTTCACAGTGACTAATCATTATATGTGTTATAACTTGTCCTTATAAAACTATTTTAAACTTTACTC TTCAGCC ATCTTAATGTGATGTTTTAAGACCATCAAAAAATAAAGTACTG CCTTGCATGTΑΆ
(SEQ ID NO: 195)
Mus musculus Oazl 3'-UTR
Oazl-001 ENSMUST00000180036
GTGCCAGCCCTGCCCAGTGTCCCTGTGCCCTCTCCTGGGTTAGTCCACATGTCGTGATTGTGCAGA ATAAACGCTCACTCCATTAGCGGGGTGCTTCTTCGAGCTGAATGCTGTGTTTGTCACACTCAAGTG TTGGCTTTAATTCTAAATAAAGGTTTCTATTTTACTTTTTTATTGCTGTTTAAGATGGTCAGGTGA CCTATGCTATAGCAGTCTCCTTTGAAGTCTGGAAAAATAGTGTCACCTCCCCTGGCTCAAATCCAA TAAAGTGATCTCGTTCATTGGC
(SEQ ID NO:196)
Mus musculus Ybxl 3'-UTR
Ybxl-001 ENSMUST00000079644
ATGCCGGCTTACCATCTCTACCATCATCCGGTTTGGTCATCCAACAAGAAGAAATGAATATGAAAT TCCAGCAATAAGAAATGAACAAAGATTGGAGCTGAAGACCTTAAGTGCTTGCTTTTTGCCCTCTGA CCAGATAACATTAGAACTATCTGCATTATCTATGCAGCATGGGGTTTTTATTATTTTTACCTAAAG ATGTCTCTTTTTGGTAATGACAAACGTGTTTTTTAAGAAAAAAAAAAAAAAGGCCTGGTTTTTCTC AATACACCTTTAACGGTTTTTAAATTGTTTCATATCTGGTCAAGTTGAGATTTTTAAGAACTTCAT TTTTAATTTGTAATAAAGTTTACAACTTGATTTTTTCAAAAAAGTCAACAAACTGCAAGCACCTGT TAATAAAGGTCTTAAATAATAA
(SEQ ID NO: 197)
Mus musculus Ybxl(v2) 3'-UTR
with mutation T128bpG and deletion del236-237bp
ITTTTATGCCGGCTTACCATCTCTACCATCA
TCCGGTTTGGTCATCCAACAAGAAGAAATGAATATGAAATTCCAGCAATAAGAAATGAAC AAAGATTGGAGCTGAAGACCTTAAGTGCTTGCTTTTTGCCCGCTGACCAGATAACATTAG AACTATCTGCATTATCTATGCAGCATGGGGTTTTTATTATTTTTACCTAAAGATGTCTCT TTTTGGTAATGACAAACGTGTTTTTTAAGAAAAAAAAAAAAGGCCTGGTTTTTCTCAATA CACCTTTAACGGTTTTTAAATTGTTTCATATCTGGTCAAGTTGAGATTTTTAAGAACTTC ATTTTTAATTTGTAATAAAGTTTACAACTTGATTTTTTCAAAAAAGTCAACAAACTGCAA GCACCTGTTAATAAAGGTCTTAAATAATAA
(SEQ ID NO:198)
Mus musculus Seppl 3'-UTR
NM_009155
ATTATTTAAAACAAGGCATACCTCTCCCCAACTCAGTCTAAAGACACAATTTCATTTTGAGAATGT TTACAGCCCATTTAATTAATCAGTGAACTAAAAGTCATAGAAATTGGATTTGTGCAAATGTAGAGA AATCTACCATATTGGCTTCCAAAATTTAAAAATTTTATGCCACAGAACATTTCATCCAAATCAGAT TTGTACAATAGGGCACCTGAAAAGTGACTGCAGCCTTTGGTTAATATGTCTTTCTTTTTCCTTTTT CCAGTGTTCTAGTTACATTAATGAGAACAGAAACATAAACTATGACCTAGGGGTTTCTGTTGGATA GCTTGTAATTAAGAACGGAGAAAGAACAACAAAGACATATTTTCCAGTTTTTTTTTTCTTTACTTA AACTCTGAAAACAACAGAAACTTTGTCTTCCTACTCTTACATTCTAAACCGATGAAATCTTTAACA GATTACACTTTAAATATCTACTCATCATTTTCTCTCTCAGAGTCCTAGCTTGAGTTGCACTGCATG TATCTGTGCATCTTGTTCTCTTCATTTAATGCTGTACTGTTCTGCTGAGCTCTGAGGGACTATCTT GAGAGATGTAATGGAAGGAAAGCGTGGTGTTAATCTGCGTACTGCTTAAGACAGTATTTCCATAAT CAATGATGGTTTCATAGAGAAACTAAGTCCTATGAACCTGACCTCTTTTATGGCTAATACGACTAA GCAAGAATGGAGTACAGAATTAAGTGGCTACAGTACACACTTATCAAAATAAATGCAATTTTAAAA CCTTTC
(SEQ ID NO:199)
Mus musculus Gaa 3'-UTR
Gaa-001 ENSMUST00000106259
GAGAGTCCGTCGTTTACAGAGGCCTCCAGGGAGGCAGAGGGAGCTTGAGCTGGCTCTGGCTGGTGG CTCCTGTAAGGACCTGCGTCCTGCTCTCCTGACACATCTTTGAGCTTTTCCCACCGTGTTACTGCA TGCGCCCCTGAAGCTCTGTGTTCTTAGGAGAGTGAGGCTCGCCTCACCTGCCCCACCCCAGCTGTC TGTCCCTCACCTGGCACTAGAGAATGTGGAGCTCGGCGTGGGGACATCGTGTCTGCACCAACATCA GGCTGTGCAGCCACTGCAGCCGCAACCCTGCAGAGACAGAGCTGGTGCCTTCACCAGGTTCCCAAG ACTCGAGAAACTTACTGTGAAGTGTACTTACTTTTAATAAAAAGGATATTGTTTGGAAGC
(SEQ ID NO:200)
Homo sapiens ACTR10 3'-UTR
ACTRlO-002 ENST00000254286
AAGTTTGATTAAAAATCAACCTTGCTTCATATCAAATATTTAACCAATTATAAGCAAATTGTACAA AGTATGTAGGATGTTTTGTTATAGAGGACTATAGTGGAAGTGAAAGCATTCTGTGTTTACTCTTTG CATTAATATATAATTCTTTTGACTTTGTTTCTCTTGTGTAGTGGTAAAATGGTAGCTGGTGCTTAT TGAGATTTGCTGTATTTATATCAATAAAGTATAGTAAAGCAGTTTGATTTTGGAAGTTTGTTATGT GGCTTTTTTTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCACTTAGGCTGGAGTGCAGTGG CACAATCTCTACTCATTGCAAGCTCCGCCTCCCGGGTTTACGCCATTCTGTCTCAGCCTCCTGAGT AGCTGGGACTATAGGCATACGCCACCCCGCCCGGCTAATTTTTTGTATATTTAGTAGAGACGGGGT TTCACCATGTTAGCCAGGA
(SEQ ID NO:201)
Homo sapiens PIGF 3'-UTR
NM_173074
GTAACTTAATCCTGACAACCGTAGTGCAAGGTATGGCCCATCTCCTGTACGCTTGGAGCGACCTTT GGCTACGTGGCTGGCCTTGTTATTTCACCACTCTGGATATACTGGAATAGAAAGCAACTTACATAC AAGAACAATTAACTGGAGCAAAGGGAGATATTTCTTTGTGCAGATTCTGTAAGGGCTGGGCAGAAA TGTGTATGGTCAAAGCCAAGCAGTTCCATTTACAGCTCTGTTTTTTACGTAGTTACAACATGATGT GATTGTAGCTTTTTAAACTATGAAACCCCTGAGAGATTGTACCTTCTAGTTGAAATAAAGTATTTA TAATAGATTGTGGCTTC
(SEQ ID NO:202)
Homo sapiens PIGF 3'-UTR
NM_002643.3
CTGGAGCAAAGGGAGATATTTCTTTGTGCAGATTCTGTAAGGGCTGGGCAGAAATGTGTATGGTCA AAGCCAAGCAGTTCCATTTACAGCTCTGTTTTTTACGTAGTTACAACATGATGTGATTGTAGCTTT TTAAACTATGAAACCCCTGAGAGATTGTACCTTCTAGTTGAAATAAAGTATTTATAATAGATTGTG GCTTCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
(SEQ ID NO:203)
Homo sapiens MGST3 3'-UTR
MGST3-001 ENST00000367889
AGAATTATAGGGGTTTAAAAACTCTCATTCATTTTAAATGACTTACCTTTATTTCCAGTTACATTT
TTTTTCTAAATATAATAAAAACTTACCTGGCATCAGCCTCATACCTAAAA
(SEQ ID NO:204) Homo sapiens SCP2 3'-UTR
NM_001193599
AGAACTCCCTTTGGCTACTTTTGAAAATCAAGATGAGATΑΤΆΤAGATATATATCCA ACATTTTAT TGTCAGAATTTAGACTGAAACTACACATTGGCAAATAGCGTGGGATAGATTTGTTTCTTAATGGGT GTGACCAATCCTGTTTTTCCTATGCTCTGGGTGAATAGAGCCTGATGGTATACTACTGCTTTGCGG AATTGCATACAACTGTGCATTACAAAGTTAATATGGTAATTATGGTCTGGGGTAAAATTGAGTTTC AGAATAAAATTAGGAACAGTAAAATCCAAAGAACTATGTAAACAAAAAAGCTTTTGTTTTGCTTAC AAAGTATATTTAAGGATTATTCTGCTGAAGATTCAGTTTAAGAGTTTTCCTTGGGAGAACTAAGTA AGAAACACAATGCCAACAGCTGGCCAGTAATTAGTGTTGTGCACTTCATGTCATTAATCAATTTCT CAATAGTTCTTAAAATTAGTGAGATTAAAAATCTAAAAATTTTGCATTTCATGCTATCAGAAACAG TATTTTCTTCCCAAATCAAAATAAAAGAAATATGATCAGAGCTTGAACACAGGCTTATTTTTAAAA TAAAAATATTTTTAACATGGGTTTCCTTATTGAAAAATCAGTGTATTAGTCATAAAACACCATCAT TAAGAATAATTGAACAATAAAGTTTGCTTTCAGATGCAGTTTTCAAATTATAATCTCATTTCAATT TATAACGTTCTCAGTCCTTTGTTATAATTTTCCTTTTTCATGTAAGTTTAATTATCTGCATTTATC TTTTTTCCTAGTTTTTCTAATACTAATGTTATTTCTTAAAATTCAGTGAGATATAGGATAAAATAA TGCTTTGAGAAGAATGTTTAATAGAAAATTAAAATAACTTTTTCTGGCCTCTCTT
(SEQ ID NO:205)
Homo sapiens SCP2 3'-UTR
SCP2-015 ENST00000435345
AGAACTCCCTTTGGCTACTTTTGAAAATCAAGATGAGATATATAGATATATATCCATACATTTTAT TGTCAGAATTTAGACTGAAACTACACATTGGCAAATAGCGTGGGATAGATTTGTTTCTTAATGGGT GTGACCAATCCTGTTTTTCCTATGCTCTGGGTGAATAGAGCCTGATGGTATACTACTGCTTTGCGG AATTGCATACAACTGTGCATTACAAAGTTAATATGGTAATTATGGTCTGGGGTAAAATTGAGTTTC AGAATAAAATTAGGAACAGTAAAATCCAAAGAACTATGTAAACAAAAAAGCTTTTGTTTTGCTTAC AAAGTATATTTAAGGATTATTCTGCTGAAGATTCAGTTTAAGAGTTTTCCTTGGGAGAACTAAGTA AGAAACACAATGC
(SEQ ID NO:206)
Homo sapiens HPRT1 3'-UTR
HPRTl-001 ENST00000298556
GATGAGAGTTCAAGTTGAGTTTGGAAACATCTGGAGTCCTATTGACATCGCCAGTAAAATTATCAA TGTTCTAGTTCTGTGGCCATCTGCTTAGTAGAGCTTTTTGCATGTATCTTCTAAGAATTTTATCTG TTTTGTACTTTAGAAATGTCAGTTGCTGCATTCCTAAACTGTTTATTTGCACTATGAGCCTATAGA CTATCAGTTCCCTTTGGGCGGATTGTTGTTTAACTTGTAAATGAAAAAATTCTCTTAAACCACAGC ACTATTGAGTGAAACATTGAACTCATATCTGTAAGAAATAAAGAGAAGATATATTAGTTTTTTAAT TGGTATTTTAATTTTTATATATGCAGGAAAGAATAGAAGTGATTGAATATTGTTAATTATACCACC GTGTGTTAGAAAAGTAAGAAGCAGTCAATTTTCACATCAAAGACAGCATCTAAGAAGTTTTGTTCT GTCCTGGAATTATTTTAGTAGTGTTTCAGTAATGTTGACTGTATTTTCCAACTTGTTCAAATTATT ACCAGTGAATCTTTGTCAGCAGTTCCCTTTTAAATGCAAATCAATAAATTCCCAAAAATTTAA
(SEQ ID NO:207)
ACSF2
Homo sapiens
ATAAAGCAGCAGGCCTGTCCTGGCCGGTTGGCTTGACTCTCTCCTGTCAGAATGCAACCTGGCTTT ATGCACCTAGATGTCCCCAGCACCCAGTTCTGAGCCAGGCACATCAAATGTCAAGGAATTGACTGA ACGAACTAAGAGCTCCTGGATGGGTCCGGGAACTCGCCTGGGCACAAGGTGCCAAAAGGCAGGCAG CCTGCCCAGGCCCTCCCTCCTGTCCATCCCCCACATTCCCCTGTCTGTCCTTGTGATTTGGCATAA AGAGCTTCTGTTTTCTTTG
(SEQ ID NO:208) Homo sapiens VPS13A 3'-UTR
NM_033305
AATTCATATGTTCTTTATTTTACTTGGAATGTTTCATTAACATGTTTTGTATGACTTATACCATAA TGCCCATATGTCCATTTATAGGGAGGTAAAACACATTTTCTTTTAAAATGTTTTCCTACACATTTT CATAAAGCAAAATAATTGTATTATTTAAGCACAGAAAAAAATGTATCTTACATCCAAAGTAGGGAG GGCATCCAACATATTATAGATTTGCTTTTATATATTTTATAGCTTTGTATTGCATAGTTTGTCTTT AAGAGTTCAAGTTAGACTTAAATATAATTTTGATGTTCACTGGTTTTATTTTAAATTGCCTTCTTA TTTGTTAGCAAAATGCCTTTTTTTAATGGTCTCTGTAAATTTTCTGGGCTTTAATGTAATGCCACT GTGTAAAAAAAAAGGAAGAAAATAGTAATAGCCATTTAATGTTTTATATTTATCATTTTAAAGATA TTTTTGTCAAATTTCTTTTAATAATAATAAACATATGTAATCTAAAAAAAAAAAAAAAAAAAAAAA ΑΑΑΑΆΑΑΑΑΑΑΑΑΑΑΑΑΑΑΑΑΑΑΑΑΑΑ
(SEQ ID NO:209)
Homo sapiens CTH 3'-UTR
NM_001190463.1
TATTCCAGAGCTGCTATTAGAAGCTGCTTCCTGTGAAGATCAAATCTTCCTGAGTAATTAAATGGA CCAACAATGAGCCTTTGCAAAATTTTCAAGCGGAAATTTTAAGGCACCTCATTATCTTTCATAACT GTAATTTTCTTAGGGATCATCTCTGTTAAAAAGTTTTCTGTATGTCATGTTATAATTACAGGTCAA TTCTGTTAATATCTTTTTGTTAATTTTGCTCTATGTTTGCCTCTGAAGGAGGTGAGATTTGTGCTA CTTTGGGAGATTATGTTCTTTTTTCATGTCTAAGATTTATTTTGATCATGTTTATAATATAATGGT AATTCATTTTTGATGTTTTGTGAAGAATTTAAATTTAAACGAATGTTCTTAAATCAAGTGTGATTT TTTTGCATATCATTGAAAAGAACATTAAAAGCAATGGTTTACACTTAGTTACCATAAGCCGAAAAT CAAATACTTGAAAAGTTTACTGTGAAATTCTACTGATTTAAGACTATACTTAATATTTTTAAAAAA ATAAATCAGCTGGGCGCGGTGGCTCACGCATGTAATGCCAGCACTTTTGGAGGATAAGGCGGGCGG ATCACGAGGTCAGGAGATTGAGACCATCCTGGCTAGCGCAGTGAAACCCCCATCTCTACTAAAAAT GCAAAAAAAATTAGACGGACGTGGTGGCGGGTGCCTGTAGTCCCAGCTACTTGGGAGGCTGAGG
(SEQ ID NO: 210}
Homo sapiens CTH 3'-UTR
CTH-001 ENST00000370938
TATTCCAGAGCTGCTATTAGAAGCTGCTTCCTGTGAAGATCAAATCTTCCTGAGTAATTAAATGGA CCAACAATGAGCCTTTGCAAAATTTTCAAGCGGAAATTTTAAGGCACCTCATTATCTTTCATAACT GTAATTTTCTTAGGGATCATCTCTGTTAAAAAGTTTTCTGTATGTCATGTTATAATTACAGGTCAA TTCTGTTAATATCTTTTTGTTAATTTTGCTCTATGTTTGCCTCTGAAGGAGGTGAGATTTGTGCTA CTTTGGGAGATTATGTTCTTTTTTCATGTCTAAGATTTATTTTGATCATGTTTATAATATAATGGT AATTCATTTTTGATGTTTTGTGAAGAATTTAAATTTAAACGAATGTTCTTAAATCAAGTGTGATTT TTTTGCATATCATTGAAAAGAACAT AAAAGCAATGGTTTACACTTA
(SEQ ID NO:211)
Homo sapiens CTH 3'-UTR
CTH-002 ENST00000346806
TATTCCAGAGCTGCTATTAGAAGCTGCTTCCTGTGAAGATCAAATCTTCCTGAGTAATTAAATGGA CCAAC ATGAG
(SEQ ID NO:212)
Homo sapiens NXT2 3'-UTR
NXT2-004 ENST00000372107
AGGGGCAAAAGTCCATTCTCATTTGGTCCATTAGTTCCAGCAATTGAAATTTATGTGAATTATTTT GATTGTAGAAGCACTATAATATGTGCTGAAACTAAATTTCTTTAATATTTTCTATTCCTGTCAGCA CCTTTTCTAGCAGCTGCCAGTTTGGAGCATTGCCCTCTAAGAGCTTTAAAACTATTTTTTTACATG CCTTATATACATTCCACTAATGACATTCTTATAATAATATTAAACACATGATCTTGGTACTAACAT ACTCACTGTGAACCCAGCCTAT (SEQ ID NO:213)
Homo sapiens MGST2 3'-UTR
NM___002413
CTTTTTCTCTTCCCTTTAATGCTTGCAGAAGCTGTTCCCACCATGAAGGTAATATGGTATCATTTG TTAAATAAAAATAAAGTCTTTATTCTGTTTTTCTTGAAAAAAAAAAAAAAAAAAA
(SEQ ID NO:214)
Homo sapiens MGST2 3'-UTR
N _001204366.1
CTTTTTCTCTTCCCTTTAATGCTTGCAGAAGCTGTTCCCACCATGAAGGCTTGAAGCCACAGTGCA TGGCCAGAACCAGCCAGACCTTTGGAGTTCAAGAACTCGAGAGGTGGGTGAAAACTGCCATTGCCT CCACAGACTGTCTTCTCCGTGGAAAGAAGACCTGAGTCACCAGGGCTGGGAAACCTGCACCACTGA GACGAGCACAGCCTCTGCCGGCATGCAAGTGGCCGCTGTCAGGACACATGGACTGAAAGTGGTTTG TCAGCTGCTCCATTAGGTTTTTTTTACCCATATGTTTGCTACCTTTCTTTCCTTGATTTAAAAATA GGGAGGGGGAGCAGTCTCAGCTGTCTTCAGCTGCTAGGGAGATTTTTTTCCCCCTCCTGAGCTACT GTTTCCCCCAACCCGAGCCTTTCTCTCTTATTGTACCCACCCTTTCTGATGAAGTCATCAAAGCAA AGATTGCATAACTGATGCATAGGCCTATCTTGTGTTATACTGGGAGACAGGCCAATGTTTCCATTA ATAGACAAGAGCACCACCACGCTGCCAAATGGAGCTCTCTGCTGCAACCACTAC
(SEQ ID NO:215)
Homo sapiens Cllorf67 3'-UTR
AAMDC-005 ENST00000526415
TGGAGCCTTAAGAGGAGAAT AATCACTAAGTGCCTA
(SEQ ID NO:216)
Homo sapiens PCCA 3'-UTR
NMJ300282
AGGATTTATAACCTTTCAGTCATCACCCAATTTAATTAGCCATTTGCATGATGCTTTCACACACAA TTGATTCAAGCATTATACAGGAACACCCCTGTGCAGCTACGTTTACGTCGTCATTTATTCCACAGA GTCAAGACCAATATTCTGCCAAAAAATCACCAATGGAAATTTTCATTGATATAAATACTTGTACAT ATGATTTGTACTTCTGCTGTGAGATTCCCTAGTGTCAAAATTAAATCAATAAAACTGAGCATTTGT CT
(SEQ ID NO:217)
Homo sapiens GL N 3'-UTR
NM__053274
AAGTTCCATTTCCTAAATAAAAACTAATAAAATATAGTACTTTCCATTATGATTCATTTAATACCT TTATAAAAAATTTTTCTGTAAAAATTTACTGCTTGAAAAATAAATGTAGCTTTTCTCATTTATCAA AAAAAAAAAA
(SEQ ID NO:218)
Homo sapiens DHRS1 3'-UTR
NM_001136050
CCCTCCTGGTCTGACACTACGTCTCTGCTTGTCTTCTCATTTGGACTTGGTGGTTCGTCCTGTCTC AGTGAAACAGCAGCCTTTCTTGTTTACCCATACCCTTGATATGAAGAGAAGCCCTCTGCTGTGTGT CCGTGGTGAGTTCTGGGGTGCGCCTAGGTCCCTTCTTTGTGCCTTGGTTTTCCTTGTCCTTCTTTT TACTTTTTGCCTTAGTATTGAAAAATGCTCTTGGAGCTAATAAAAGTCTCATTTCTCTTTCAAAAA AAAAAAAAAAAA
(SEQ ID NO:219) Homo sapiens PON2 3'-UTR
PON2-001 ENST00000433091
ATTGTACTTTTGGCATGAAAGTGCGATAACTTAACAATTAATTTTCTATGAATTGCTAATTCTGAG GGAATTTAACCAGCAACATTGACCCAGAAATGTATGGCATGTGTAGTTAATTTTATTCCAGTAAGG AACGGCCCTTTTAGTTCTTAGAGCACTTTTAACAAAAAAGGAAAATGAACAGGTTCTTTAAAATGC CAAGCAAGGGACAGAAAAGAAAGCTGCTTTCGAATAAAGTGAATACATTTTGCACAAAGTAAGCCT CACCTTTGCCTTCCAACTGCCAGAACATGGATTCCACTGAAATAGAGTGAATTATATTTCCTTAAA ATGTGAGTGACCTCACTTCTGGCACTGTGACTACTATGGCTGTTTAGAACTACTGATAACGTATTT TGATGTTTTGTACTTACATCTTTGTTTACCATTAAAAAGTTGGAGTTATATTAA
(SEQ ID NO:220)
Homo sapiens NME7 3'-UTR
NM_013330
TGGTGTGGAAAGTAAAGAAGTCACAGGTTGGGACATTTAGACAAGAGTGAATCACACACGAGGAAT GTGTTCATTCTTTTATTGTCCGTTGTTTTAACCTGACTGAATACAAGATCAACAAGAGCACTGTAC TCCTGGCAATTATTACATATGTTAGAACATGGATTTTGCACTGTAGACAACATTTAACACCAGTCT ATGGGGTACTGCATTGCTTTTTATAAAGTTCAAAATAAAGATTTATTTTCAAACAAAAAAAAAAAA AAAAAAAAAAAAA
(SEQ ID NO:221)
Homo sapiens ETFDH 3'-UTR
NM_004453
ACTGCAGCTAGCCAGTTTCTTTCAAGTATGGCAAGCTAACGTTAAAATGTTTAGAGATTAACAGAT TTCAGAATGTCTTTCTGCATATTACTGAACAGAAT GTCACAAAATGATTATCAAATAAAAATTTT A AC ATATGTAAGATTGTCCCATAAAGAAA
(SEQ ID NO:222)
Homo sapiens ALG13 3'-UTR
BC117377
GATCCAGCAGTATGAAGTATTCTTGCACTGCCATTTTCTTGCTGTTTTTGTTTTTAAAAAGTATTT TATGTTAGTGGTTAAATGATTTAGGTGATTAGTGTTTACTATTGTATTTGTCTTTAAAATTATTTT ATCTTTTGATTTAAAATAGTACTTTAAAATTAAGGGGTATTATTTTGGGCTGTGACTAAGGAAATT GAGATGGATGTACAACTAGCCCCATATTGAGCATACTTCATTGTATTCAGCTGTTTTCCTGTCAGC CATTTGTCAGC
(SEQ ID NO:223)
Homo sapiens ALG13 3'-UTR
NM_001099922.2
GATCCAGCAGTATGAAGTATTCTTGCACTGCCATTTTCTTGCTGTTTTTGTTTTTAAAAAGTATTT TATGTTAGTGGTTAAATGATTTAGGTGATTAGTGTTTACTATTGTATTTGTCTTTAAAATTATTTT ATCTTTTGATTTAAAATAGTACTTTAAAATTAAGGGGTATTATTTTGGGCTGTGACTAAGGAAATT GAGATGGATGTACAACTAGCCCCATATTGAGCATACTTCATTGTATTCAGCTGTTTTCCTGTCAGC CATTTGTCAGCTTTATATTAGCTGATGGTACCAATTGATAAAATGAATATAAAGTATTTCATTGGT TCAAAAATCACACATCATATTAAACCATGCAGAATTGGAGTAACTTCCACTTTTTTCTAGAAAGTA AAACCAAGAGCCTTTGCTTCTGGATAACTCACTTAATATTAAATTAAAGAGCTCTTCACGTTTCTT GAGAATTATCTGAAGCCAGTTGCATTCTGTGATATCAGTTTTGAAGGCACATGGTTCTCTGCTTTA GATTTATCCCATATGCTATTGTTTAATACTGGATGTATGTAAGTGTTTTACTGCACTGTATTGAAT TGGTGTCTTTTGCACAGTTAGCAGTAAATAAAAATTAGCATTTAAAATTGCCAAAAAAAAAAAAAA AAAA
(SEQ ID NO:224) Homo sapiens DDX60 3'-UTR
DDX60-001 ENST00000393743
AAACAAAGTCTATGCAAACCACTTAAAAATAATTCCATAGTAGTTTTTCAGGTCACGTTTTTGATT CTTATGCTTCTTGCCAGAAATACATTATGATAAAGTGGAAATACATTACGATGAAGTGGAAAGAGC AAACACTTTGGAATCAAACAGAGTTGCAATCAAACCTGCCATGTTCTGTCATGAA ACTCACAAAT TATTTAGTATACCTGAATCTTGGTTTCTTTTTATAACTGAGTAATAATGGTTACATCTCAGGTAGT TTGAGGATTGACTAAAAAAATGCGAGAATGTTGTATGTGACTGAATAACAATTTTTACTCTGCGAA GCCAAAGTAAATATAATATTATCAGTAACTTTATCCCCAGTGTCAGTATTTATAAAATGTTTATTA AGGCTAGAAAAAATGAA ACAA ATCCTGAAGGTGAAATA ATTCTCTTCAATTAGCATAAA ATG ATTTACATAAGTTAGCTATACAGCTATTGAGATAGTACTTTCTAGTAAACTTAAACTACTTTTTAA ACATACATTTTGTGATGATTTAACAAAAATATAGAGAATGATTTGCTTTATTGTAATTGTATATAA GTGACTGGAAAAGCACAAAGAAATAAAGTGGGTTCGATCTGTTTAC
(SEQ ID NO:225)
Homo sapiens DYNC2LI 1 3'-UTR
NM_015522.3
AATTCATTTGATGTAGATGAACCTGTTCACTGGAAAATTACAGCAATTTATTAAAACCTCAGTAAG AGCAAAACAAGGAAGAAGATTCCTTATATCTTCTTGTTAGACATCTTCTGTGATTGTTATGGCATA TTACACCAATCAGAGAAATAGAGTTTTAAAGTAGTGGTTTGATATTGATTTTATAATCTCTGTAAA AATGAAGATAAAAAGCCAGATTGTACAAAAGTCACCTGACAAAGACTAGATGAAGCTACAACTTTA AGCAAGGGGTAGAGTTGTAATAGCCTTCACCATCACTCTGTATTTTACATTCATTTCGTTTCTGTC ACTTATTCAGTATCTTTTTATCATCTGACAGCTAATTAAATTATAAAGTTGCTATGATGGTAACAC AAGTTCTTCAAATACAATAATAAATATCATCATCTGGAAAAAAAAAAAAAAAAAA
(SEQ ID NO:226)
Homo sapiens VPS8 3'-UTR
NM_001009921, NM_015303
TGACTCCATGGAGCCTGGCCCAGGAGAACCAGAGATGATCCCGAGGCAGCTGGGGAGAGGCCCCGC CTCTGGTGGGCTTGGCCTCCACCACCTCCCACGCTTCTGAGAAGAGGTTCCAAATTGGGCTTCTGT GCCCAGAGCGTCCACAGCACCATTCCCAGTGTAGACTCCCAGTCTTCTCCACATTGCTGTCATGGC GTCAGTTCACCAGACTCATTGATTTTGTTTTGCTTGTTAAGCAAAGGAATGTCACATACCTCTGTC CAGCTTTTTAGGAAATACATTTCGCCTATTGCGACTTTTTCCATTTACCCTGAAGCCTAGAAAGTA GGTGGAACTCACACAAATGGCATTCCAGAGTCTGCCATACTCCGTCTCCTCCAGCTGCTGGATAAT ACAGAGGAACTTCAACTTCTACAGGGAACAGTGGTTGGCCAGGCTGCAGTATAACTGAAGCATGCC TTGGAGAGAGCAGACACTGTGGGGGCCAGGGCCATCTCCCTTTAATGTGTTCATGTTAAAACCTAT TTGAGTGTAAGACTTGCCCTTTCTAACAATAAATGCTCCGTGTTTAAGTTCTGCAGGTCTCAAAAA AAAAAAAAAAAA
(SEQ ID NO:227)
Homo sapiens ITFG1 3'-UTR
NM_030790
CTTGCCTTTAATATTACATAATGGAATGGCTGTTCACTTGATTAGTTGAAACACAAATTCTGGCTT GAAAAAATAGGGGAGATTAAATATTATTTATAAATGATGTATCCCATGGTAATTATTGGAAAGTAT TCAAATAAATATGGTTTGAATATGTCACAAGGTCTTTTTTTTTAAAGCACTTTGTATATAAAAATT TGGGTTCTCTATTCTGTAGTGCTGTACATTTTTGTTCCTTTGTGGAATGTGTTGCATGTACTCCAG TGTTTGTGTATTTATAATCTTATTTGCATCATGATGATGGAAAAAGTTGTGTAAATAAAAATAATT AAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
(SEQ ID NO:228)
Homo sapiens CDK5 3'-UTR
NM 004935 GCCCCGGGACCCCCGGCCTCCAGGCTGGGGCCTGGCCTATTTAAGCCCCCTCTTGAGAGGGGTGAG ACAGTGGGGGTGCCTGGTGCGCTGTGCTCCAGCAGTGCTGGGCCCAGCCGGGGTGGGGTGCCTGAG CCCGAATTTCTCACTCCCTTTGTGGACTTTATTTAATTTCATAAATTGGCTCCTTTCCCACAGTCA AAAAAAAAAAAAAAAAA
(SEQ ID NO:229)
Homo sapiens Clorfll2 3'-UTR
BC091516
AACTTATCACTAGGCAGAACTGGGTTTGATGCTTTGTCAACTGAAAATACTTATGTCTGTACATTT TCTAACAGATATAAAACAAATTTTGTAAAGTTGAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA AAAAAAAAAAAAAA
(SEQ ID NO:230)
Homo sapiens IFT52 3'-UTR
NM_016004
AGACCATGCCTCTTGAAGCTTTTTCTGCCTCCTGATTCTCTCTTTGTAAACTATTTTCAAATTGTT TTTCAACTCCTTATCAAAATTGTTTATACACTCTTTCCTCCATGAGCTCTGGAAGGTATATGCATC TTCTGTAATACTCAGATAGGTATAAGATTTTTCACAAAATCCTTATGTAAGATACATTCCATTTTT AAAAATTAAATGTATGGTTGCATCTGTCTTTTTATACCCTA
(SEQ ID NO:231)
Homo sapiens CLYBL 3'-UTR
CLYBL-003 ENST00000339105
TCTGTTAAATGAAGCTGTCATCAGGCTAAAGGGTATTGAAGCTGCAGAGGGATCAACTTGTGCTTG CCAGAGGACGCCAATGAAGTTTGAAACACCAACAATC GAGATTTTGTTTCTGTTCCTCATTAAAT CATGAGCTTTTGTG
(SEQ ID NO:232)
Homo sapiens FAM11 A2 3'-UTR
FAM114A2-006 ENST00000520667
AGAATGGAGACGTTTTGACCTGGGACTTGTGACGGCCAAGGAATGCCACCTTATTCTGGCTACTCC TGCAGAAATGAAGGAGTGGGGTTATTTTAGTATATAAAAATTCAGGCAGGAGAGATGGTTTAAAGA GGAAGATTGTTGCCTTCAGTGTTTGATTGAAGTATTCAGGTTCTCACAGTATTCTTTCCAGTTGTT GTAATTCATAAATTATTTGAAAAGAAACTTTTGTAGAAAGTCCAAGAATAATAACTCTAGATAAAG ATTAGTGGGACACTCAGGCAAAAATGTTGGTCTTTCTTTGACATGTTGCAAAATGTTATCAATTTT GTCATGGATATAATTTGCAGCCCATGGATATAACTGGTTGATAAGCCAGAGAAAAATAATTTAGTG TTCTAAAATTCATGGCATGTGTGGTTTATTAATGCCATGTACTTTCTCCTTTCTGGAATAAAATCT ATGGCTTTAAGAAAA
(SEQ ID NO:233)
Homo sapiens NUDT7 3'-UTR
NM_001243661
TTTACTAGAGCAAGAGACAAAGAACTATTCACGAGGATTCTGTGTGTGCTTATTCGTAGAACAACA ACAATGCCAGCTGTTGGAATTTGACAGGTGTGAATATTTTTTCTGCAGTATGTAGTTAGAATCCTT GCCTCTTTTCCAGTTGCCTTCTATTGTCTGAAAAAGTAAAAGCCATTCAAAAATGAAAACTATGTT CATAGTGTTGCATATTTTCACCCACAATATGTTAATAATATTTTTCTTACACATATAATAAAGAAT ATCTGGCACATACTAGGCCCTTAATAAAGATTTTTTGAATATATAA
(SEQ ID NO:234)
Homo sapiens AKD1 3'-UTR
NM 001145128 TTTACTTAGGTGATAGCAGCCTGAATCTCAAGAGTTATCTGAAAGTGATAGAGGGAAACTGAGAGA AGTAGATTGAAAATCTGGGCCTCTTGGAAGTACTTTTGCCTCCTGAGCAAGGTACCATGGCTGCCA GACTTCAGGTGAACTCAAAGGTCTGCCAGCCAGGAAGGAGCACTCTTATGGAAACAAGTTTTAATA CAATTTTAAAATGTATTGCTCTTTGCCTGAACTTTGATGCTTTAACAAAATAAACATTCTATTTAT AATTCCATATAGAAAAGTTAAGTGACTTATTTAATAAATGTATTATTTTCCTTTTTAACATTTTCA GTAGAAAAGTCAGTCTCTGTTAAAATTACTCATTAAATGTTAGAAAGCTTTAAGACATTTAACATT GTTATAAATGAAACCAAAATATGGGTTATACATTTTACATACAAAACTGTTTGTGAACTTTGTGAA CATAAGATACTATCATTTTCCCAATAAAATAAATGGATTTTGCAACAACTT
(SEQ ID NO:235)
Homo sapiens MAGED2 3' -UTR
NM_014599
GATTTTAGATATTGTTAATCCTGCCAGTCTTTCTCTTCAAGCCAGGGTGCATCCTCAGAAACCTAC TCAACACAGCACTCTAGGCAGCCACTATCAATCAATTGAAGTTGACACTCTGCATTAAATCTATTT GCCATTTCAAAAAAAAAAAAAAAAAAAA
(SEQ ID NO:236)
Homo sapiens HRSP12 3'-UTR
HRSP12-001 ENST00000254878
GTGGGCCCAGTGCTGTGTAGTCTGGAATTGTTAACATTTTAATTTTTACAATTGATGTAACATCTT AATTAACC TTTAATTTTCACAATTGATGACAGTGTGAGTTTGATGAAAATATCTGAAGCTATTAT GGAAATACCATGTAATAGGGAGAGTTGAACATGAATATTAGAGAAGGAATCCAGTTACTTTTTTAA ATTACACCTGTGTGCACCTGTATTACTGAATATAGGAAAGAGATACCCATTACATAGTTACTCAGT AAACAAAAGAGAAATACCAGGTAGGAAAGAAGAGTTACTATTCCTGAGAAATAATCAAGAACATAT TTAATTTAAACTAATGATGTGAACTATTTAGTTTTGATGTCCGTTATGTGATTCTGCTTTTACTTG AGTAAAATTAAAGTGTTTAAATTTGAGATCAAGGAGAAGATAGTGGAACAAAATGTTATATAGATA AT TTTTTCTAATGGAAATAAAATAGGCAGATTTCC
(SEQ ID NO:237)
Homo sapiens STX8 NM_004853 3' -UTR
TGGCAGTAAAGAGACCACCAGCAGTGACACCTGCCAATGACAGATGCAAGCCCAACACCCTTTTGG TACGCAAAACCTGCTCTCAATAAATTCCCCCAAAGCTCTGAAAAAAAAAAAAAAAAAAAAA
(SEQ ID NO:238)
Homo sapiens ACAT1 3' -UTR
ACATl-001 ENST00000265838
ACAACCTCTGCTATTTAAGGAGACAACCCTATGTGACCAGAAGGCCTGCTGTAATCAGTGTGACTA CTGTGGGTCAGCTTATATTCAGATAAGCTGTTTCATTTTTTATTATTTTCTATGTTAACTTTTAAA AATCAAAATGATGAAATCCCAAAACATTTTGAAATTAAAAATAAATTTCTTCTTCTGCTTTTTTCT TGGTAACCTTGAAAAGTTTGATACATTTTTGCATTCTGAGTCTATACTTATCGAAATATGGTAGAA ATACCAATGTGTAATATTAGTGACTTACATAAGTAGCTAGAAGTTTCCATTTGTGAGAACACATTT ATATTTTTGAGGATTGTTAAAGGTCAAGTGAATGCTCTTTATAGGTAATTTACATT
(SEQ ID NO:239)
Homo sapiens IFT74 3' -UTR
IFT74-201 ENST00000433700
GTTTAAGTCCACTGAAAGTCTCTAAGGAAGTATCCTCTTGCTGCTAAACTTGGTACAAGTTGACTA CCAAAAAAAAAAAAAGCTTACTTTTGGAGTTTACCTAAAATTTCTGAATGTTATAATTTTTGTGGC CTCTTTTAAGAATGATATTTTAAAATAGTAAATAGTTCAATAAATGGTTTGCATATT
(SEQ ID NO:240) Homo sapiens KIFAP3 3'-UTR
NM_014970
TAAAGTATCTGTTTCCATGTGTAATCTCAGCTTAGAAGAAATCTGTGTGGGTTGGGTTAATTTTGG ATCTTTGCCTAATAATGCATGTTGATGTTATTGTGGGTCTGTGTTTGTTTTTATTTTTATATGTTG TTAGCTGCAGATTAACCCCAGCCCCTCTGTCTTCTGTTAAGTACAGTTGATACTGACATTGTTCAC TCATCAAACCACATCTTGATGCTAAGTAACATTTCCCATGAGCCACAAAACTGAATGCTGAAAAGC TACTAGACTGGAAAACAAACACTGCATTATGTATGTTAAGTGACTAATTTAATTTCAATTAAAAAG CGTAAAGTGAAAATGAAAAAAAAAAAAAAAA
(SEQ ID NO:241)
Homo sapiens CAPN1 3'-UTR
NM__005186
GGCAGGGACTCGGTCCCCCTTGCCGTGCTCCCCTCCCTCCTCGTCTGCCAAGCCTCGCCTCCTACC ACACCACACCAGGCCACCCCAGCTGCAAGTGCCTTCCTTGGAGCAGAGAGGCAGCCTCGTCCTCCT GTCCCCTCTCCTCCCAGCCACCATCGTTCATCTGCTCCGGGCAGAACTGTGTGGCCCCTGCCTGTG CCAGCCATGGGCTCGGGATGGACTCCCTGGGCCCCACCCATTGCCAAGCCAGGAAGGCAGCTTTCG CTTGTTCCTGCCTCGGGACAGCCCCGGGTTTCCCCAGCATCCTGATGTGTCCCCTCTCCCCACTTC AGAGGCCACCCACTCAGCACCACCGGCCTGGCCTTGCCTGCAGACTATAAACTATAACCACTAGCT CGACACAGTCTGCAGTCCAGGCGTGTGGAGCCGCCTCCCGGCTCGGGGAGGCCCCGGGGCTGGGAA CGCCTGTGCCTTCCTGCGCCGAAGCCAACGCCCCCTCTGTCCTTCCCTGGCCCTGCTGCCGACCAG GAGCTGCCCAGCCTGTGGGCGGTCGGCCTTCCCTCCTTCGCTCCTTTTTTATATTAGTGATTTTAA AGGGGACTCTTCAGGGACTTGTGTACTGGTTATGGGGGTGCCAGAGGCACTAGGCTTGGGGTGGGG AGGTCCCGTGTTCCATATAGAGGAACCCCAAATAATAAAAGGCCCCACATCTGTCTGTGAAAAAAA ΑΑΑΑΑΑΑΆΑΑΑΑΑΑΑΑΑΑΑΑΑΑΑΆΑΑΑΑΑΑΑΑΑΑΑΑΑΑΑΑΑΑΑΑΑΆΑΑΑΑΑΑΑΑΑΑΑ
(SEQ ID NO:242)
Homo sapiens COX11 3'-UTR
NM_001162861
AGAGTTGGCACCTTTGATGTGGTAGTGAGCTGATCATCCACTTTCTTCTAAAATAAAGAGAAGAAA ATGGCCAGTAAAAAAAAAAAAA
(SEQ ID NO:243)
Homo sapiens GLT8D4 3'-UTR
BC127733
ATATTTTGTCTTGTTGCAAGTCAATTAGGTGTCTTGTGAACAAGGAAATACTAATCTCTAAGCTGC CTGGGTCTTTT
(SEQ ID NO:244)
Homo sapiens GLT8D4 3'-UTR
NM_001080393
ATATTTTGTCTTGTTGCAAGTCAATTAGGTGTCTTGTGACCAAGGAAATACTAATCTCTAAGCTGC CTGGGTCTTTTTGTGTGAATATTTAATGGTGCTCCATGACTGTTGAGTTTTAAAAACCTCGTTAAA TTTTGCCAAATCAGTTGCCCCCAAAAGGGAATATGCTTTTCCTTATTTTTTTTTCTAAAATGCTAT TTATCTCTAAGGAAAAA
(SEQ ID NO:245)
Homo sapiens HACL1 3'-UTR
NM_012260
ATAAAGACGCCAGTTGGTGGTCTTGAGTTTTCTCTTTCTTGCAAGATGAAATTTTATTTTCCACAG CAAAATTACTCTACTGTTAAAATTGTGCAAAATAAAATAAACATTTAAAATGACATTTTACAGTAA AAAAAAAA
(SEQ ID NO:246) Homo sapiens IFT88 3'-UTR
N _175605
TATTCACTTTAATATTTATTAAAGGAAAGAAATTGCCTTATGAGATCATCCTCATGTTAAACCTTG GATTAAATATCTAACCTGTAATTATTTTTTTTCACTGTCAAAACTTAAGTAAGTGTATTCTATTCT GTATGTATGCATTTAAGTTGTTTTTTTCTTTTAAGGAATAAAAACAGGTAAAACTAATACTTTAGG CCAGTGACTTCCTTAGCTTTTTGAAAACATTGACACACAGGAAGAAATAAATTTCATAACACAAAA AAAAAAAAA
(SEQ ID NO:247)
Homo sapiens IFT88 3'-UTR
IFT88-001 ENST00000351808
TATTCACTTTAATATTTATTAAAGGAAAGAAATTGCCTTATGAGATCATCCTCATGTTAAACCTTG GATTAAATATCTAACCTGTAATTATTTTTTTTCACTGTCAAAACTTAAGTAAGTGTATTCTATTCT GTATGTATGCATTTAAGTTGTTTTTTTCTTTTAAGGAATAAAAACAGGTAAAACT
(SEQ ID NO:248)
Homo sapiens NDUFB3 3'-UTR
NM_002491
AGATAATACCTGGAAGCATCATAGTGGTTTCTTAACTCTCCAAAATAAGATTTCTTCTCTGTAGCC TACTTGTCTGGTTTATCCCTTACAGAATATTAGTAAGATTTAATCAATTAAAATATATATATATGC CAAAAAAAAAAAAAAAAA
(SEQ ID NO:249)
Homo sapiens ANO10 3'-UTR
NM_018075
GTGCCCAGCGTGCCCAGCTGCCCTGTTGGCAGAGGCCTGTGTCTGTGCCACACCTGCCACGGTGGC AGGGGGGGTACCCGGGGCAGCATCGTGGCTCCTGAACCCAGACCCAATGCTTAGCCAAACGAAGTG GCTCCCATGTGGCAAGCACCCTTCTCAGTTTCGCAGTGGCTTGGCTCGGGATCCTTGGCAGTTCCC CCAGCCCCACCCTGTCTGCTCCTTCCCAGTTCCTTCCCGGGCCCCACACGCTGCTCCAGCTGCCAA CTTTGCTGCAGAGCCACTGCCGCCCTTGAGCCTCTCACCATGAGTGAGCCACCAGCTCTCCACGTT CCCCTCATAGCAGTGTCACTCCCAACCCCACCATGGCCCAGGGACCCGTGGACAGGTTGGGGATGG GGTGTGTGCCCACTGTGCTCATCACAGGAGCCTCAGTTGAGAGTGAGCGGGGTACAGTAAGGCAGT GCTTCCCACACTGGACCTCTTTCCTGGTTCTCTTTTGCAATACATTAACAGACCCTTTATCAACAT AAACAATAGTAACTGAGCTATTAAAGGCAACCTCTCTGACTCCTTCTGCCTAAAAAAAAAA
(SEQ ID NO:250)
Homo sapiens ANO10 3'-UTR
ANO10-005 ENST00000451430
GTGCCCAGCGTGCCCAGCTGCCCTGTTGGCAGAGGCCTGTGTCTGTGCCACACCTGCCACGGTGGC AGGGGGGGTACCCGGGGCAGCATCGTGGCTCCTGAACCCAGACCCAATGCTTAGCCAAACGAAGTG GCTCCCATGTGGCAAGCACCCTTCTCAGTTTCGCAGTGGCTTGGCTCGGGATCCTTGGCAGTTCCC CCAGCCCCACCCTGTCTGCTCCTTCCCAGTTCCTTCCCGGGCCCCACACGCTGCTCCAGCTGCCA
(SEQ ID NO:251)
Homo sapiens ARL6 3'-UTR
NM__032146
AAAGATAATAGTTGGAAACCTCAGCAATTTTCAATTCAAGGAATCTATCTAAGACAAATAGAATAC ATTTTGTAAAAGATGTTTATGCATCAAAAAATATAATTTTCTGCTTGCATTTATGGACTCTGACCT TTTTAAGAACATAGGACTTCAGGTATGCTAATTTGGCCATTAATTATTTAAAAACTAAATATTCCC TCAAAAGGGCTCCCTAGAATTATCAAGTTCTTAGTGAAGGTCTACATTTGATTGTACGTAGAATGT TTAAAAGTCAGTTATAAGCCATCTCATCCCATCATAATTTATGATATGTTTAATATATTTTATTTT TTAATTGTCTTTTTAAAAAATTTAGTTTATGACTTTGCAGTATGAATTGTGCTTGTGAAAAAGAAC TTTAAATATTTATAAGGGACCATGGGTAATTAATATATATTCAATTTTTACTATGTGTCACTGTCA ATAAAATGTAAAATATAATGTGCC
(SEQ ID NO:252)
Homo sapiens LPCAT3 3'-UTR
NM_005768
TCCATTTCCCTGGTGGCCTGTGCGGGACTGGTGCAGAAACTACTCGTCTCCCTTTTCACAGCACTC CTTTGCCCCAGAGCAGAGAATGGAAAAGCCAGGGAGGTGGAAGATCGATGCTTCCAGCTGTGCCTC TGCTGCCAGCCAAGTCTTCATTTGGGGCCAAAGGGGAAACTTTTTTTTGGAGAAGGCGTCTTGCTT TGTCACCCACGCTGGAATGCAGTGGCGGGATCTCAGCTCACCGCAACCTCCACCTCCTGGGTTCAA GTGATTTTCCTGCCTCAGCCTCCCAAGTAGCTGGGAATACAGGCACGCCACCATGCCCAGCTAATT TTTGTATTTTCAGTAGAAACGGGATTTCACCACGTTGGCCAGGCTGGTCTCGAACTCCTGACCGCA AGTGATCCACCCGCCTCCGCCTCCCAAAGTGCTGGGATTACAGGCGTGAGCCACCGTGCCCGGCCC AAAGGGGAAACTCTTGTGGGAGGAGCAGAGGGGCTCACATCTCCCCTCTGATTCCCCCATGCACAT TGCCTTATCTCTCCCCATCTAGCCAGGAATCTATTGTGTTTTTCTTCTGCCAATTTACTATGATTG TGTATGTGCCGCTACCACCACCCCCCCCATGGGGGGGTGGAGAGGGGTGCAAGGCCCTGCCTGCTC CACTTTTTCTACCTTGGAACTGTATTAGATAAAATCACTTCTGTTTGTTCAGTTTTTCA
(SEQ ID NO:253)
Homo sapiens ABCD3 3'-UTR
NM_001122674
AAACCAGACAAATGTATTGGCCAGGCGTGGTGGCTCATGCCTGTAATCCCAGCACTTTGGGAGGCT GAGATGGGAGGATCGCTTGAATCCAGGAGTTCGAGACAAGCCTGGACAAAAAGCGAGACCCGCTTC TTTAAAAAATAATAATAAAACA
(SEQ ID NO:254)
Homo sapiens COPG2 3'-UTR
NM_012133
ATGCTTACTGGACAAGAGGAAACTGATGCACACTACATGGTCAGTGGGCTTTTAGGCTAGTGGCAT CAGTTTCCCAGAATCAGACTTTTGAAGATGAATGACTTTGGAGAAGCAAATTAAACATTTGGCCCT GAGCCAGCAGATCAAGCAAATGTCTATCTTTGCGCATGGGTTGTTTTTTTTTTTTTTCTTTTTATT CTACTTGGTCAGCTTTGGGACGATAGTGCAGCTTTGGGTGATCTTGAAAATCAAATACTATCCTAT ACTCCAGCTGCTTAACTTCATTTTATTCTTTAATGTGTACCTGAAAGCTCCTGGCAATGCTGGAAA ATTTTTATCCCAGAGGGGTGGGGGGGAGGGGGGAGGGGAAGCCAGAGTCCACTTTTGTCACAATTC ATTTT ATTAATAGAAAA AAACACTTATTCCAGTTTCΑΑΑΑΑΑΑΆΑΑΆΑΑΆ
(SEQ ID NO:255)
Homo sapiens MIPEP 3'-UTR
NM_005932
AAGAAACACTCTACACCTCTTAAATCAAGGTCATGTAGATAATGACTTTGTTATAAATGCTACAGC TGTGAGAGCTTGTTTCTGATTTCATTGTTCGCTTCTGTAATTCTGAAAAACTTTAAACTGGTAGAA CTTGGAATAAATAATTTGTTTTAATTAAAAAAAAAAAAAAAAAA
(SEQ ID NO:256)
Homo sapiens LEPR 3'-UTR
NM_002303
TTTCACTGAAGAAACCTTCAGATTTGTGTTATAATGGGTAATATAAAGTGTAATAGATTATAGTTG TGGGTGGGAGAGAGAAAAGAAACCAGAGTCAAATTTGAAAATAATTGTTCCAAATGAATGTTGTCT GTTTGTTCTCTCTTAGTAACATAGACAAAAAATTTGAGAAAGCCTTCATAAGCCTACCAATGTAGA CACGCTCTTCTATTTTATTCCCAAGCTCTAGTGGGAAGGTCCCTTGTTTCCAGCTAGAAATAAGCC CAACAGACACCATCTTTTGTGAGATGTAATTGTTTTTTCAGAGGGCGTGTTGTTTTACCTCAAGTT TTTGTTTTGTACCAACACACACACACACACACATTCTTAACACATGTCCTTGTGTGTTTTGAGAGT ATATTATGTATTTATATTTTGTGCTATCAGACTGTAGGATTTGAAGTAGGACTTTCCTAAATGTTT AAGATAAACAGAATTC
(SEQ ID NO:257)
Homo sapiens LEPR 3'-UTR
NM_001198688
GAAATGCTTGTAGACTACGTCCTACCTCGCTGCCGCACCTGCTCTCCCTGAGGTGTGCACAATG
(SEQ ID NO-.258)
Homo sapiens C2orf76 3'-UTR
NM_001017927
AAACATCTCGAGGGCTTCCTTTTTGCAT
(SEQ ID NO:259)
Homo sapiens C2orf76 3'-UTR
C2orf76-001 ENST00000409466
AAACATCTCGAGGGCTTCCTTTTTGCA ACCTGTATTAAGCTCTTTATTCCACTGCTGAATTTTTG AAATTGACAAACAAATCTTAAAAAATTAATCCCAGGCTATACTCTTTGAGCTAAAATCTGGTTATT TCTTTCTCTTCAGGTCTTTCCTTCTCTCTTTCTTTTTCTTTGTTGTTGTAAAATAATATATTATGA GAAAAACATTTGATCTTTTTAAAGGGAAATAAATTGTTATTAAAAA
(SEQ ID NO:260)
Homo sapiens ABCA6 3 ' -UTR
NM_080284.2
AACCTCAAACCTAGTAATTTTTTGTTGATCTCCTATAAACTCATGTTTTATGTAATAATTAATAGT ATGTTTAATTTTAAAGATCATTTAAAATTAACATCAGGTATATTTTGTAAATTTAGTTAACAAATA CATAAATTTTAAAATTATTCTTCCTCTCAAACATAGGGGTGATAGCAAACCTGTGATAAAGGCAAT ACAAAATATTAGTAAAGTCACCCAAAGAGTCAGGCACTGGGTATTGTGGAAATAAAACTATATAAA CTT
(SEQ ID NO:261)
Homo sapiens LY96 3'-UTR
NMJ315364.4
AATAAATTGAGTATTTAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
(SEQ ID NO:262)
Homo sapiens CROT 3'-UTR
NM_ 001243745.1
TGATGATGTTTAAAGAATGATAAATAAAAAGTGCATAGTTTTTATTTTTAAATTATTGCTGTAAAA ATTTTTACAGTTATTATTGTTATTTTCATAATCCAAAAGAAGGAATGAATCACTTAACTTTGGGAG TTTTCAGTGGGTGGATTCGGGAACTTGTTAAAATGCAGATTTGCTGGGATAAGTGATTCTGATTCA CATGGCTGGAATGAGGCCCAGAGATTCTTATTTTAACAATCACTTCATGTGGTTTGGCTGCAGGTA ATCTGTAGACCATGCTGAAGGAAAACATTTTGTCCAGGTGACTAGCTTGAAAAATCAGAAACACTA AAATAGACATGTCACATAGGTGGCATAGAAATATTTTCGTAGTACAATGGAGAAAGGGAATCATTA AAAATCAGAGTGGAGAATGGTTATGTATATTGTATATTTCAGTTAGATAAATTGAGGAAGCTAGTA TAATAATTATTGAAGGTCTCAATAATTTTCCACAAAATTCTTTAACTTCTTCAGCTCAACCATTTC TGTACTTCTCTACTATGAATCAGAGGATGAGGTTGTATAATTCAAAAGCATTGCCTTAGTCTAGAA ATAATTATTGTACCTATCATTTAGTTTTAGAAATAAAAAGCAAGCTGATTTTTTTTGATGAACCAT TTATATCTGTGATGGAATAATAAAATTTCACACTTCCGGATTCCTTTGTTCTCAATTTTGAGCCTT GAGTTGTTTTAATTAAAGAGGGGTAAAGG
(SEQ ID NO:263) Homo sapiens ENPP5 3'-UTR
ENPP5-002 ENST00000230565
TGTTACTTTGAAGTGGATTTGCATATTGAAGTGGAGATTCCATAATTATGTCAGTGTTTAAAGGTT TCAAATTCTGGGAAACCAGTTCCAAACATTTGCAGAAACCATTAAGCAGTTACATATTTAGGTATA CACACACACACACACACACATACACACACACGGACCAAAATACT ACACCTGCAAAGGAATAAAG TGTGAGAGTATGTCTCCATTGTTCACTGTAGCATAGGGATAGATAAGATCCTGCTTTATTTGGACT TGGCGCAGATAATGTATATATTTAGCAACTTTGCACTATGTAAAGTACCTTATGTATTGCACTTTA AATTTCTCTCCTGATGGGTACTTTAATTTGAAATGCACTTTATGCACAGTTATGTCTTATAACTTG ATTGAAAATGACAACTTTTTGCACCCATGTCACAGAATACTTGTTACGCATTGTTCAAACTGAAGG AAATTTCTAATAATCCCGAATAATGAACGTAGAAATC ATCTCCATAAATTGAGAGAAGAAGAAGG TGATAAGTGTTGAAAATTAAATGTGATAACCTTTGAACCTTGAATTTTGGAGATGTATTCCCAACA GCAGAATGCAACTGTGGGCATTTCTTGTCTTATTTCTTTCCAGAGAACGTGGTTTTCATTTATTTT TCCCTCAAAAGAGAGTCAAATACTGACAGATTCGTTCTAAATATATTGTTTCTGTCATAAAATTAT TGTGATTTCCTGATGAGTCATATTACTGTGATTTTCATAATAATGAAGACACCATGAATATACTTT TTTTCTATATAGTTCAGCAATGGCCTGAATAGAAGCAACCAGGCACCATCTCAGCAATGTTTTCTC TTGTTTGTAATTATTTGCTCCTTTGAAAATTAAATCACTATTAATTACATTAA
(SEQ ID NO:264)
Homo sapiens SERPINB7 3'-UTR
SERPINB7-203 ENST00000546027
AAATCCAATTGGTTTCTGTTATAGCAGTCCCCACAACATCAAAGAACCACCACAAGTCAATAGATT TGAGTTTAATTGGAAAAATGTGGTGTTTCCTTTGAGTTTATTTCTTCCTAACATTGGTCAGCAGAT GACACTGGTGACTTGACCCTTCCTAGACACCTGGTTGATTGTCCTGATCCCTGCTCTTAGCATTCT ACCACCATGTGTCTCACCCATTTCTAATTTCATTGTCTTTCTTCCCACGCTCATTTCTATCATTCT CCCCCATGACCCGTCTGGAAATTATGGAGAGTGCTC
(SEQ ID NO:265)
Homo sapiens TCP11L2 3'-UTR
N _152772
AGAAGAACTGACATTGGACGAGAGATTGGAAATCCAGTACTTTGGTATCCAGTCCACTTCCATTGA TGGCATTAGAGATCCAGCACATTCTCAGTACTGTGGTGCAGTATTAGCCCAAATCTGTGTAATGGG TAATATTAGCATTACAGAAGACACACACATCACATAGACCCTCAGAAGACGTAAACATCACATAGA CCCTATTTGTGCATCATTTTCAAGTTTAAAACAGATATTTGTAATG ACAGAAAACAATTTGTAAT TAATTATATTACCTATATAATACTTGTAAATGTTTTCTTAACCATTTATATTTGGCTTATGACATT TAACCCCTAAGGAGTTGTTTTTCTCACTTGTTATTATCAAACCTAATGGTTTTTAATTTTGGTACA ACTCCTTAAAGGGTTGAAGGTTGTGACAATAACTGAGGGAACTGATGTTCTGAATAAATGATGTGA AGTAAACACAATTGTATTTGAAAAAAAAAAAAAAAAAAAAAAAAAAA
(SEQ ID NO:266)
Homo sapiens IRAKIBPI 3'-UTR
NM_001010844
AATTCCAAACAAATTATATTGTACTTGTATCTTTTTACCTATTTTTATACTTTTTATAATGTTTAC GTTTGTCCTGAATATATA
(SEQ ID NO:267)
Homo sapiens CDKL2 3'-UTR
CDKL2-002 ENST00000307465
GAACCATTTTGGTTCTGAACTGGATGATGCTCTTGCACTTGAGATGACATCTTCTTGCAGCAAGAG TGCTGATATCCCAAGAGGAGAGATTCATGGTTTTGATCATTTCCTTCTGAACTGCCTGCATTTTCT GAGGAAGGCCTTCTAGAAGAAGGAAAGACAAAGACTTCCAAATGTTTCAAAGGAAGATTGAACAAA TGGCCCTCCCCAACTGTTATCCCATTACCTTTCACGTCCACCGATGCTATTTCAAGACATATCCAG TGGAATAACAGTGATATGGTTCTTGTTACATGAATGTGTATTTACTGTTAGGAGATTGTATATTTT AAGTTACC
(SEQ ID NO:268)
Homo sapiens GHR 3'-UTR
GHR-202 ENST00000537449
CCTTTCTTTGGTTTCCCAAGAGCTACGTATTTAATAGCAAAGAATTGACTGGGGCAATAACGTTTA AGCCAAAACAATGTTTAAACCTTTTTTGGGGGAGTGACAGGATGGGGTATGGATTCTAAAATGCCT TTTCCCAAAATGTTGAAATATGATGT AAAAAAA AAGAAGAATGCTTAATCAGATAGATATTCCT ATTGTGCAATGTAAATATTTTAAAGAATTGTGTCAGACTGTTTAGTAGCAGTGATTGTCTTAATAT TGTGGGTGTTAATTTTTGATACTAAGCATTGAATGGCTATGTTTTTAATGTATAGTAAATCACGCT TTTTGAAAAAGCGAAAAAATCAGGTGGCTTTTGCGGT
(SEQ ID NO:269)
Homo sapiens KIAA1107 3'-UTR
NM_015237
GTGTTAACATTTTGGAAAAATTTATGCCACTCCTTTATTTTTTGATGCCTATATTATATCCAAATG ATAATTGCATTAGCCGGATATAAACTTTCTTTAATATTGAGTCTTTCCAATTTAATGAGGTAAACA TAGTTTATTTATTAATATATCACATATAGAAAAATGTTTTTCTAAAGTTTTTGAGCATGTTTTCTC TAATTATTAGAGAAATTAGAAGACTTATAAGGAAACCCTAGCTTCAGTTTTCCTTTCCTAGCTGAT GATTTGTTCACTTAATCATTATTCAAGAATTTAAAATGTGAATGCAGAAGTAGATCAGTCCCTTTA CTTTTTGCTCTGCATAGGGTAACATAGTAATTTAACAATAAAAACTTACCGTGCTTGTGTCCAAAA AAAAAAAAAA
(SEQ ID NO:270)
Homo sapiens RPS6KA6 3'-UTR
RPS6KA6-001 ENST00000262752
GATTTGTGGTGTTCCTAGGCCAAACTGGATGAAGATGAAATTAAATGTGTGGCTTTTTTCCTATTC TTATCAAAGGCATCGTTGTCTGCTAAATTACTTGAATATTAAGTAATATTAAATCCCCATTTTTAG GGGAAGTGAGATTTAAAAAACCATTCACAGGTCCACAATATTCATACTATGTGTTTGCAGTAGTGT TCAAGTGTTTATTTAAGCATATAATTGGTGTCCACCAGGTCCTCACAACTTCTCTGCACACAAGCT TCTAAAATTCCTTTCAAATAAAGTTACTTTAATATTT
(SEQ ID NO:271)
Homo sapiens CLGN 3'-UTR
NMJ304362, NM_001130675
ACTAGATTGAAATATTTTTAATTCCCGAGAGGGATGTTTGGCATTGTAAAAATCAGCATGCCAGAC CTGAACTTTAATCAGTCTGCACATCCTGTTTCTAATATCTAGCAACATTATATTCTTTCAGACATT TATTTTAGTCCTTCATTTCAGAGGAAAAAGAAGCAACTTTGAAGTTACCTCATCTTTGAATTTAGA ATAAAAGTGGCACATTACATATCGGATCTAAGAGATTAATACCATTAGAAGTTACACAGTTTTAGT TGTTTGGAGATAGTTTTGGTTTGTACAGAACAAAATAATATGTAGCAGCTTCATTGCTATTGGAAA AATCAGTTATTGGAATTTCCACTTAAATGGCTATACAACAATATAACTGGTAGTTCTATAATAAAA ATGAGCATATGTTCTGTTGTGAAGAGCTAAATGCAATAAAGTTTCTGTATGGTTGTTTGATTCTAT CAACAATTGAAAGTGTTGTATATGACCCACATTTACCTAGTTTGTGTCAAATTATAGTTACAGTGA GTTGTTTGCTTAAATTATAGATTCCTTTAAGGACATGCCTTGTTCATAAAATCACTGGATTATATT GCAGCATATTTTACATTTGAATACAAGGATAATGGGTTTTATCAAAACAAAATGATGTACAGATTT TTTTTCAAGTTTTTATAGTTGCTTTATGCCAGAGTGGTTTACCCCATTCACAAAATTTCTTATGCA TACATTGCTATTGAAAATAAAATTTAAATATTTTTTCATCCTGAAAAAAAA
(SEQ ID NO:272) Homo sapiens CLGN-202 3'-UTR
NM_004362, NM_001130675
ENST00000325617
ACTAGATTGAAATATTTTTAATTCCCGAGAGGGATGTTTGGCATTGTAAAAATCAGCATGCCAGAC CTGAACTTTAATCAGTCTGCACATCCTGTTTCTAATATCTAGCAACATTATATTCTTTCAGACATT TATTTTAGTCCTTCATTTCAGAGGAAAAAGAAGCAACTTTGAAGTTACCTCATCTTTGAATTTAGA ATAAAAGTGGCACATTACATATCGGATCTAAGAGATTAATACCATTAGAAGTTACACAGTTTTAGT TGTTTGGAGATAGTTTTGGTTTGTACAGAACAAAATAATATGTAGCAGCTTCATTGCTATTGGAAA AATCAGTTATTGGAATTTCCACTTAAATGGCTATACAACAATATAACTGGTAGTTCTATAATAAAA ATGAGCATATGTTCTGTTGTGAAGAGCTAAATGCAATAAAGTTTCTGTATGGTTGTTTGATTCTAT CAAC
(SEQ ID NO:273)
Homo sapiens TMEM45A 3'-UTR
NM_018004
CTTTGATGAGCTTCCAGTTTTTCTAGATAAACCTTTTCTTTTTTACATTGTTCTTGGTTTTGTTTC TCGATCTTTTGTTTGGAGAACAGCTGGCTAAGGATGACTCTAAGTGTACTGTTTGCATTTCCAATT TGGTTAAAGTATTTGAATTTAAATATTTTCTTTTTAGCTTTGAAAATATTTTGGGTGATACTTTCA TTTTGCACATCATGCACATCATGGTATTCAGGGGCTAGAGTGATTTTTTTCCAGATTATCTAAAGT TGGATGCCCACACTATGAAAGAAATATTTGTTTTATTTGCCTTATAGATATGCTCAAGGTTACTGG GCTTGCTACTATTTGTAACTCCTTGACCATGGAATTATACTTGTTTATCTTGTTGCTGCAATGAGA AATAAATGAATGTATGTATTTTGGTGC
(SEQ ID NO:274)
Homo sapiens TBC1D8B 3'-UTR
TBC1D8B-007 ENST00000276175
ATCCCTAGGAATTGCCTATCATAGACAAGTTTACTAACATTCCTGTAGCTGTCAGTTTGATTCCTG TGAGTAGGGCTCAGGGATTTATCTTGTTACCAATGTGTCTGAAGGCCAAAATATATATCCAGAAGC ACAATGCATCATTCCTTTGT
(SEQ ID NO:275)
Homo sapiens ACP6 3'-UTR
NM_016361
CTGATTTATAAAAGCAGGATGTGTTGATTTTAAAATAAAGTGCCTTTATACAATGCCAAAAAAAAA AAAAAAAAAAAAAAA
(SEQ ID NO:276)
Homo sapiens RP6-213H19.1 3' -UTR
MST4-003 (RBM4B-003 ENST00000496850)
GAAACTTATTATTGGCTTCTGTTTCATATGGACCCAGAGAGCCCCACCAAACCTACGTCAAGATTA ACAATGCTTAACCCATGAGCTCCATGTGCCTTTTGGATCTTTGCA
(SEQ ID NO:277)
Homo sapiens SNRPN 3' -UTR
NM_022807
CATACTGTTGATCCATCTCAGTCACTTTTTCCCCTGCAATGCGTCTTGTGAAATTGTGTAGAGTGT TTGTGAGCTTTTTGTTCCCTCATTCTGCATTAATAATAGCTAATAATAAATGCATAGAGCAATTAA ACTGTG
(SEQ ID NO:278) Homo sapiens GLRB 3'-UTR
GLRB-005 ENST00000512619
GATCTAATGACTTCAGCATTGTTGGAAGCTTACCAAGAGATTTTGAACTATCCAATTATGACTGCT ATGGAAAACCCATTGAAGTTAACAACGGACTTGGGAAATCTCAGGCTAAGAACAACAAGAAGCCTC CCCCTGCGAAACCTGTTATTCCAACAGCAGCAAAGCGAATTGATCTTTATGCAAGAGCATTGTTTC CTTTCTGCTTCTTGTTCTTCAATGTTATATATTGGTCTATATATTTATGATAAATCTTTTCCATTT GTACAAAATAAAATTCCATTTCATTGTGACCTACTCCTTTCATAAATGCCAATCTGTGAGAACTTT TGAATTTTCATAGCAACATTGCATTTTGGATGCCATTTGATTGTAATAAAACTGTGGCACCTTAAT TTTGAATGGCAGCATGATCATGTAATATC
(SEQ ID NO:279)
Homo sapiens HERC6 3'-UTR
NM_017912
TCACCTCTGAGAGACTCAGGGTGGGCTTTCTCACACTTGGATCCTTCTGTTCTTCCTTACACCTAA ATAATACAAGAGATTAATGAATAGTGGTTAGAAGTAGTTGAGGGAGAGATTGGGGGAATGGGGAGA TGATGATGATGGTCAAAGGGTGCAAAATCTCACACAAGACTGAGGCAGGAGAATAGGGTACAGAGA TAGGGATCTAAGGATGACTTGGACACACTCCCTGGCACTGAAGAGTCTGAACACTGGCCTGTGATT GGTCCATTCCAGGACCTTCATTTGCATAAGGTATCAAACCACATCAGCCTCTGATTGGCCATGGGC CAGACCTGCACTCTGGCCAATGATTGGTTCATTCCAGGACATTCATTTGCATAAGGAGTCAAACCA CACCAGTCTTGGATTGGCTGTGAGCCAATTCACCTCAGTCTCTAATTGGCTGTGAGTCAGTCTTTC ATTTACATAGGGTGTAACCATCAAGAAACCTCTACAGGGTACTTAAGCCCCAGAAGATTTTGCTAC CAGGGCTCTTGAGCCACTTGCTCTAGCCCACTCCCACCCTGTGGAATGTACTTTCACTTTTGCTGC TTCACTGCCTTGTGCTCCAATAAATCCACTCCTTCACCACCCAAAAAAAAAAAAAAA
(SEQ ID NO:280)
Homo sapiens CFH 3'-UTR
NM_000186
AATCAATCATAAAGTGCACACCTTTATTCAGAACTTTAGTATTAAATCAGTTCTCAATTTCATTTT TTATGTATTGTTTTACTCCTTTTTATTCATACGTAAAATTTTGGATTAATTTGTGAAAATGTAATT ATAAGCTGAGACCGGTGGCTCTCTTCTTAAAAGCACCATATTAAATCCTGGAAAACTAAAAAAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
(SEQ ID NO:281)
Homo sapiens GALC 3'-UTR
GALC-002 ENST00000393569
TACTTAACAGGGCATCATAGAATACTCTGGATTTTCTTCCCTTCTTTTTGGTTTTGGTTCAGAGCC AATTCTTGTTTCATTGGAACAGTATATGAGGCTTTTGAGACTAAAAATAATGAAGAGTAAAAGGGG AGAGAAATTTATTTTTAATTTACCCTGTGGAAGATTTTATTAGAATTAATTCCAAGGGGAAAACTG GTGAATCTTTAACATTACCTGGTGTGTTCCCTAACATTCAAACTGTGCATTGGCCATACCCTTAGG AGTGGTTTGAGTAGTACAGACCTCGAAGCCTTGCTGCTAACACTGAGGTAGCTCTCTTCATCTTAT TTGCAAGCGGTCCTGTAGATGGCAGTAACTTGATCATCACTGAGATGTATTTATGCATGCTGACCG TGTGT
(SEQ ID NO:282)
Homo sapiens GALC 3'-UTR
GALC-005 ENST00000393568
TACTTAACAGGGCATCATAGAATACTCTGGATTTTCTTCCCTTCTTTTTGG
(SEQ ID NO:283)
Homo sapiens PDE1A 3'-UTR
NM 001003683.2 ACACCTTTAAGTAAAACCTCGTGCATGGTGGCAGCTCTAATTTGACCAAAAGACTTGGAGATTTTG ATTATGCTTGCTGGAAATCTACCCTGTCCTGTGTGAGACAGGAAATCTATTTTTGCAGATTGCTCA ATAAGCATCATGAGCCACATAAATAACAGCTGTAAACTCCTTAATTCACCGGGCTCAACTGCTACC GAACAGATTCATCTAGTGGCTACATCAGCACCTTGTGCTTTCAGATATCTGTTTCAATGGCATTTT GTGGCATTTGTCTTTACCGAGTGCCAATAAATTTTCTTTGAGCAGCTAATTGCTAATTTTGTCATT TCTACAATAAAGCTTGGTCCACCTGTTTTC
(SEQ ID NO:284)
Homo sapiens PDE1A 3'-UTR
PDE1A-003 ENST00000410103
ACACCTTTAAGTAAAACCTCGTGCATGGTGGCAGCTCTAATTTGACCAAAAGACTTGGAGATTTTG ATTATGCTTGCTGGAAATCTACCCTGTCCTGTGTGAGACAGGAAATCTATTTTTGCAGATTGCTCA ATAAGCATCATGAGCCACATAAATAACAGCTGTAAACTCCTTAATTCACCGGGCTCAACTGCTACC GAACAGATTCATCTAGTGGCTACATCAGCACCTTGTGCTTTCAGATATCTGTTTCAATGGCATTTT GTGGCATTTGTCTTTACCGAGTGCCAATAAATTTTCTTTGAGCA
(SEQ ID NO:285)
Homo sapiens GSTM5 3'-UTR
NM_000851
GGCCCAGTGATGCCAGAAGATGGGAGGGAGGAGCCAACCTTGCTGCCTGCGACCCTGGAGGACAGC CTGACTCCCTGGACCTGCCTTCTTCCTTTTTCCTTCTTTCTACTCTCTTCTCTTCCCCAAGGCCTC ATTGGCTTCCTTTCTTCTAACATCATCCCTCCCCGCATCGAGGCTCTTTAAAGCTTCAGCTCCCCA CTGTCCTCCATCAAAGTCCCCCTCCTAACGTCTTCCTTTCCCTGCACTAACGCCAACCTGACTGCT TTTCCTGTCAGTGCTTTTCTCTTCTTTGAGAAGCCAGACTGATCTCTGAGCTCCCTAGCACTGTCC TCAAAGACCATCTGTATGCCCTGCTCCCTTTGCTGGGTCCCTACCCCAGCTCCGTGTGATGCCCAG TAAAGCCTGAACCATGCCTGCCATGTCTTGTCTTATTCCCTGAGGCTCCCTTGACTCAGGACTGTG CTCGAATTGTGGGTGGTTTTTTGTCTTCTGTTGTCCACAGCCAGAGCTTAGTGGATGGGTGTGTGT GTGTGTGTGTTGGGGGTGGTGATCAGGCAGGTTCATAAATTTCCTTGGTCATTTCTGCCCTCTAGC CACATCCCTCTGTTCCTCACTGTGGGGATTACTACAGAAAGGTGCTCTGTGCCAAGTTCCTCACTC ATTCGCGCTCCTGTAGGCCGTCTAGAACTGGCATGGTTCAAAGAGGGGCTAGGCTGATGGGGAAGG GGGCTGAGCAGCTCCCAGGCAGACTGCCTTCTTTCACCCTGTCCTGATAGACTTCCCTGATCTAGA TATCCTTCGTCATGACACTTCTCAATAAAACGTATCCCACCGTATTGTAAAAAAAAAAAAAAA
(SEQ ID NO:286)
Homo sapiens CADPS2 3'-UTR
CADPS2-002 ENST00000412584
TATCACACAGCTTTGCAGAAGGAAGGAAGACCTTGATCGACATTGTTTTTTATTTTTTTAACCTTG TCCTTGTAATTACATTCATTGTTTGTTTTGGCCAAATAAAAATGCTTGTATTTCTTTAAAAAGTAA GCCTGAATGTAGAGTAAAAGGGGAAATGCCAAGATTTTGGGGTTTTTTTGTTTCCTTTTTTTGTTT GTTTGTTTGTTTGTTTTTTTGGAGAAGAGCATCCTCTTTTGTGTAGTTTGACCTAAAAATGAACCT TGGCTCTGCTTGTGATCAGAACATGAACTTTTTTTTTTAAAGAAGATTTGAGCATTTTTCTGTAAT CACATCAAAATGATGTTTTCTGTGTAAAGCGAGATACATATTTCTCATAATGCAGCATTGTGAGAA GTCAGTTCGGACCACTGCACCAA
(SEQ ID NO:287)
Homo sapiens CADPS2 3'-UTR
CADPS2-001 ENST00000449022
TATCACACAGCTTTGCAGAAGGAAGGAAGACCTTGATCGACATTGTTTTTTATTTTTTTAACCTTG TCCTTGTAATTACATTCATTGTTTGTTTTGGCCAAATAAAAATGCTTGTATTTCTTTAAAAAGTAA GCCTGAATGTAGAGTAAAAGGGGAAATGCC
(SEQ ID NO:288) Homo sapiens AASS 3'-UTR
AASS-001 ENST00000417368
TTGGGAATTATATTTTGTTTTTTTCTTCCCAGGCAATACACCTCTGAACATGTGTGTGATAAATGG GTTTGCTAATGTGCTGTTTTAAAGTATAAAGCATAATATGTTTTGGTTAACACAATGTACTTTTTG AACTATAAATCTTTATTTTAATATGGAAATGTTTGGAACAGGAGATGCAAGCCACTAACAGAGAAC TTTAATAATTCTACCCTGTATTTTATAAATACGTATGTGAAAGTGATGA
(SEQ ID NO: 289)
Homo sapiens TRIM6-TRIM34 3'-UTR
NM_001003819
ATTTTCTCATTTCTTCACCTACAACCCTTTGTCTTGACTTATCTCCTGCAACTGACTCATCTGCAA CATTCACACCATTGCTTCCTTGTGGTTTCCCTTCTTTAGAACTTTTACTCATCCTTGAGATGTATG GTGTATTTGGCTTGAGTTATGAGAGATGCTTATTTATTCATTTACTCTTTTTCATATTTTCAGAGA AAGTTACCTAATCCCTCCTAAAGACACAGCAGTATGGGTATAACATCCTTGCCTTCCCATTTATCC ATGTTTCACTTTATCACTGATATGAAGAGGCCCAAAGCCTGTTAGCCACCATCCATGCTACCTAGG TAGTCCATAGGAACCACCCCCATGACCACCACCAACATCAACTAAAGGTTCTTGGAGGGTATGTCA GTGTGTTGCTCAGGATACCCCAGGTACATCAAGGAATCAAGGAGAGGAAAATATGAGCAATATGTG TATTCAGAGTGAAGATTTTATGTCCAGAGTATTTGAGCTCAAACCTTGCCTGTTGTTTTCTAATCA TGATGAATACTTTCTCAGTTTCTTTTTCCTGAAATATAAATTGGGATTTAAGACTGTACCTAACTA TTAAGATCACTGTGTAAAACTAAGTGTCTCTAAATGTAATGCATCGATTTAGTGTCTGGAACATAA TAAATATTTGCTCTCATGATTGCTAAAAAAAAAAA
(SEQ ID NO:290)
Homo sapiens SEPP1 3'-UTR
NMJD05410
ATATTTAAAATAGGACATACTCCCCAATTTAGTCTAGACACAATTTCATTTCCAGCATTTTTATAA AC ACCAAATTAGTGAACCAAAAATAGAAATTAGATTTGTGCAAACATGGAGAAATCTACTGAATT GGCTTCCAGATTTTAAATTTTATGTCATAGAAATATTGACTCAAACCATATTTTTTATGATGGAGC AACTGAAAGGTGATTGCAGCTTTTGGTTAATATGTCTTTTTTTTTCTTTTTCCAGTGTTCTATTTG CTTTAATGAGAATAGAAACGTAAACTATGACCTAGGGGTTTCTGTTGGATAATTAGCAGTTTAGAA TGGAGGAAGAACAACAAAGACATGCTTTCCATTTTTTTCTTTACTTATCTCTCAAAACAATATTAC TTTGTCTTTTCAATCTTCTACTTTTAACTAATAAAATAAGTGGATTTTGTATTTTAAGATCCAGAA ATACTTAACACGTGAATATTTTGCTAAAAAAGCATATATAACTATTTTAAATATCCATTTATCTTT TGTATATCTAAGACTCATCCTGATTTTTACTATCACACATGAATAAAGCCTTTGTATCTTTCTTTC TCTAATGTTGTATCATACTCTTCTAAAACTTGAGTGGCTGTCTTAAAAGATATAAGGGGAAAGATA ATATTGTCTGTCTCTATATTGCTTAGTAAGTATTTCCATAGTCAATGATGGTTTAATAGGTAAACC AAACCCTATAAACCTGACCTCCTTTATGGTTAATACTATTAAGCAAGAATGCAGTACAGAATTGGA TACAGTACGGATTTGTCCAAATAAATTCAATAAAAACCTTAAAGCTGAAAAAAAAAAAAAAAAAAA ΑΑΑΑΑΑΑΑΑΑΑΑΑΑΑΑΑΑΑΑΑΑΑΑΑΑΑΑΑΑΑΑΑΆΑΆΑΑΑΑΑΑΑΑΑΑΑΑΑΆΑΑΑΑΑΑΑΑΑΑ
(SEQ ID NO:291)
Homo sapiens SEPP1 3'-UTR
SEPP1-004 ENST00000506577
ATATTTAAAATAGGACATACTCCCCAATTTAGTCTAGACACAATTTCATTTCCAGCATTTTTATAA ACTACCAAATTAGTGAACCAAAAATAGAAATTAGATTTGTGCAAACATGGAGAAATCTACTGAATT GGCTTCCAGATTTTAAATTTTATGTCA AGAAA ATTGACTCAAACCATATTTTTTATGATGGAGC AACTGAAAGGTGATTGCAGCTTTTGGTTAATATGTCTTTTTTTTTCTTTTTCCAGTGTTCTATTTG CTTTAATGAGAATAGAAACGTAAACTATGACCTAGGGGTTTCTGTTGGATAATTAGCAGTTTAGAA TGGAGGAAGAACAACAAAGACATGCTTTCCATTTTTTTCTTTACTTATCTCTCAAAACAATATTAC TTTGTCTTTTCAATCTTCTACTTTTAACTAATAAAATAAGTGGATTTTGTATTTTAAGATCCAGAA ATACTTAACACGTGAATATTTTGCTAAAAAAGCATATATAACTATTTTAAATATCCATTTATCTTT TGTATATCTAAGACTCATCCTGATTTTTACTATCACACATGAATAAAGCCTTTGTATCTTT (SEQ ID NO:292)
Homo sapiens PDE5A 3'-UTR
PDE5A-002 ENST00000264805
GTGGCCTATTTCATGCAGAGTTGAAGTTTACAGAGATGGTGTGTTCTGCAATATGCCTAG
(SEQ ID NO:293)
Homo sapiens SATB1 3'-UTR
SATB1-004 ENST00000417717
GATAAAAGTATTTGTTTCGTTCAACAGTGCCACTGGTATTTACTAACAAAATGAAAAGTCCACCTT GTCTTCTCTCAGAAAACCTTTGTTGTTCATTGTTTGGCCAATGAATCTTCAAAAACTTGCACAAAC AGAAAAGTTGGAAAAGGATAATACAGACTGCACTAAATGTTTTCCTCTGTTTTACAAACTGCTTGG CAGCCCCAGGTGAAGCATCAAGGATTGTTTGGTATTAAAATTTGTGTTCACGGGATGCACCAAAGT GTGTACCCCGTAAGCATGAAACCAGTGTTTTTTGTTTTTTTTTTAGTTCTTATTCCGGAGCCTCAA ACAAGCATTATACCTTCTGTGATTATGATTTCCTCTCCTATAATTATTTCTGTAGCACTCCACACT GATCTTTGGAAACTTGCCCCTTATTT
(SEQ ID NO:294)
Homo sapiens CCPG1 3'-UTR
CCPGl-002 ENST00000442196
TTCACAATTGAGTTAAATTAGACAACTGTAAGAGAAAAATTTATGCTTTGTATAATGTTTGGTATT GAAACTAATGAAATTACCAAGATGACAATGTCTTTTCTTTTGTTTCTAAGTATCAGTTTGATAACT TTATATTATTCCTCAGAAGCATTAGTTAAAAGTCTACTAACCTGCATTTTCCTGTAGTTTAGCTTC GTTGAATTTTTTTTGACACTGGAAATGTTCAACTGTAGTTTTATTAAGGAAGCCAGGCATGCAACA GATTTTGTGCATGAAATGAGACTTCCTTTCAGTGTAAGAGCTTAAAGCAAGCTCAGTCATACATGA CAAAGTGTAATTAACACTGATGTTTGTGTTAAATTTGCAGCAGAGCTTGAGAAAAGTACATTGTTC TGGAATTTCATCATTAACATTTTATAATCTTACACTCACTTCTTGTCTTTTTGTGGGTTCAAGAGC CCTCTGACTTGTGAAGAATTTGCTGCCCTCTTAAGAGCTTGCTGACTTGTTTTCTTGTGAAATTTT TTGCACATCTGAATATCGTGGAAGAAACAATAAAACTACACCATGAGGAAAACTAAAGGTCTTTAT TTAAAATCTGGCATTGTATTAACATGTAATTTTATACTATGTGGTATTTTATACATTTCCTCAGTA GTGATATTTGGTAAAGCAGTTCATACAGCTTTTTTCTAAGTTCCATGAATCTTACCCAGTGTTTAC CGAAGTATTTAAGCAGCATCTGAATATTTCCACCCAGCAATGTTAATTTATCTAGGAAAGTTCAGA ATTTCATCTTCATGTTGAATTTCCCTTTTAACTTCCGTTCATAGACATATATGTGACTTCCAATTC GACCCTCTGGCAAGTGAGTGTGGAAGAAAACAGCAGTTCTTTTATAATTGCTTGAAATTAGGAAAG CGCTTATTTCCTAGAAGCAAATAAATGTTTAAGTAAATAAAGGCTACATTTTGCTGA
(SEQ ID NO:295)
Homo sapiens CCPG1 3'-UTR
CCPGl-004 ENST00000425574
TTCACAATTGAGTTAAATTAGACAACTGTAAGAGAAAAATTTATGCTTTGTATAATGTTTGGTATT GAAACTAATGAAATTACCAAGATGACAATGTCTTTTCTTTTGTTTCTAAGTATCAGTTTGATAACT TTATATTATTCCTCAGAAGCATTAGTTAAAAGTCTACTAACCTGCATTTTCCTGTAGTTTAGCTTC GTTGAATTTTTTTTGACACTGGAAATGTTCAACTGTAGTTTTATTAAGGAAGCCAGGCATGCAACA GATTTTGTGCATGAAATGAGACTTCCTTTCAGTGTAAGAGCTTAAAGCAAGCTCAGTCATACATGA CAAAGTGTAATTAACACTGATGTTTGTGTTAAATTTGCAGCAGAGCTTGAGAAAAGTACATTGTTC TGGAATTTCATCATTAACATTTTATAATCTTACACTCACTTCTTGTCTTTTTGTGGGTTCAAGAGC CCTCTGACTTGTGAAGAATTTGCTGCCCTCTTAAGAGCTTGCTGACTTGTTTTCTTGTGAAATTTT TTGCACATCTGAATATCGTGGAAGAAACAATAAAACTACACCATGAG
(SEQ ID NO:296) Homo sapiens CNTN1 3'-UTR
CNTNl-002 ENST00000348761
ATGTGTTGTGACAGCTGCTGTTCCCATCCCAGCTCAGAAGACACCCTTCAACCCTGGGATGACCAC AATTCCTTCCAATTTCTGCGGCTCCATCCTAAGCCAAATAAATTATACTTTAACAAACTATTCAAC TGATTTACAACACACATGATGACTGAGGCATTCGGGAACCCCTTCATCCAAAAGAATAAACTTTTA AATGGATATAAATGATTTTTAACTCGTTCCAA
(SEQ ID NO:297)
Homo sapiens CNTN1 3'-UTR
CNTNl-004 ENST00000547849
TCGTTGACACTCACCATTTCTGTGAAAGACTTTTTTTTTTTTAACATATTATACTAGATTTGACTA ACTCAATCTTGTAGCTTCTGCAGTTCTCCCCACCCCCAACCTAGTTCTTAGAGTATGTTTCCCCTT TTGAAACATGTAAACATACTTTGGGCATAAATATTTTTTAAAATATAACTATAATGCTTCACTAAT ACCTTAAAAATGCCTAGTGAACTAACTCAGTACATTATATAATGGCCAAGTGAAAGTTTTGTGTTT TCATGTCCTGTTTTTCTTTGAAATTATATAGCCCAGAAATTAGCTCATTATCTGAAAAACGTATGA AGAACTGATGAATTGTATAATACAGGAGTATTGCCATTGAATGTACTGTTTGATTTATTCAAGCAG GTAATGAACAATGTTGTCAAACTCTCTAATGAGACATCATAATTAGGACATAAGCTAAAAGGGGCA TTACTCCGGCAGTCTTTTTTTCTTAATCCTAGTACCATACATATTCTTTGGCATGAAAGAATGAAA AGCATTAGTAAACAACTGAAGTCCTACCATGGCTCTGTAGGGTTTTTGGAACAATTCCTGGAATTG GAAAGTGAAAATGGATAGCATGTGGGGGAAACCCTCATCTGAGTAGCAAGATTTTAGTAAAGATGA CTAAGCCATTAACAGCATGCATTCATATTTAATTTTATTGACTCCTGCCATCAGCTTTTGTAGATC GTTTGGGTGGAAGGTTGTGATTTTTACTGGGAGGACTTGAGTAGAAGTGGATGATTAAAATTGAGG AGTATATAATTCTTTCTGGGACTGCTTAAATGTTATTGTTTGAAAATACCTTCACTTTCCCCCTTT GGTCAAAGAGATGTGCTTAAAATTCTTATTCCTTCACAATAAATAATTTTGATTTTCTTAGACA
(SEQ ID NO:298)
Homo sapiens CNTN1 3'-UTR
CNTNl-004 ENST00000547849
+T at pos. 30bp, mutations G727bpT, A840bpG
rrTTTTCGTTGACACTCACCATTTCTGTGAA
AGACTTTTTTTTTTTTTAACATATTATACTAGATTTGACTAACTCAATCTTGTAGCTTCT GCAGTTCTCCCCACCCCCAACCTAGTTCTTAGAGTATGTTTCCCCTTTTGAAACATGTAA ACATACTTTGGGCATAAATATTTTTTAAAATATAACTATAATGCTTCACTAATACCTTAA AAATGCCTAGTGAACTAACTCAGTACATTATATAATGGCCAAGTGAAAGTTTTGTGTTTT CATGTCCTGTTTTTCTTTGAAATTATATAGCCCAGAAATTAGCTCATTATCTGAAAAACG TATGAAGAACTGATGAATTGTATAATACAGGAGTATTGCCATTGAATGTACTGTTTGATT TATTCAAGCAGGTAATGAACAATGTTGTCAAACTCTCTAATGAGACATCATAATTAGGAC ATAAGCTAAAAGGGGCATTACTCCGGCAGTCTTTTTTTCTTAATCCTAGTACCATACATA TTCTTTGGCATGAAAGAATGAAAAGCATTAGTAAACAACTGAAGTCCTACCATGGCTCTG TAGGGTTTTTGGAACAATTCCTGGAATTGGAAAGTGAAAATGGATAGCATGTGGGGGAAA CCCTCATCTGAGTAGCAAGATTTTAGTAAAGATGACTAAGCCATTAACAGCATGCATTCA TATTTAATTTTATTGACTCCTGCCATCAGCTTTTGTAGATCTTTTGGGTGGAAGGTTGTG ATTTTTACTGGGAGGACTTGAGTAGAAGTGGATGATTAAAATTGAGGAGTATATAATTCT TTCTGGGACTGCTTAAATGTTATTGTTTGAAAATGCCTTCACTTTCCCCCTTTGGTCAAA GAGATGTGCTTAAAATTCTTATTCCTTCACAATAAATAATTTTGATTTTCTTAGACA
(SEQ ID NO:299)
Homo sapiens LMBRD2 3'-UTR
AGTCTGAAAAAGTTTGTGGGACCACTAACCAAGGTCAACACATCAGTTCAGTCTTGATGAACATCT GTGTACCCTAGAATTTCCTCTATACACAGTGAAAAGTGTCAAGATAACAAAAAAGGCACTGAGAAT TAATTATATCTTAGGAATAATAGTTTAATGTGCATTGAATAGAGTATCACCTTTTTCAACAAGATT TATTACATATCATTTCCTAAGCATCTGCCTTAGAAATACAGTTACAGTGGAAGGACTTTAAGAAAG ATCAACATATGTTAAGAACATGCAGTTCAGTTTGTTTCAGATTAATTTTTTTTCAAGAGAGTTATT TTAAAGATTCAAGGAAGCCATAAGTCATACTAAATAATATTATATACAGTTTTGTTATTGTGACTT ACATTTTTGTTACTTCTAAAAAGTATATTCAACCTGTATTTCCCAAAGAAATGTAAGTGAATGGAG ACCTCAAATAATAACTGTATTCATAAAACTCGTGTCTTAAAACAAGGCTTACTTACTAGACATAAC TGAATGTAAAAAGTGCTTTTTCAAATCTGTTTGCAAACTCGTGGGGGATTTTTGCATGTATAAGAT TAAGATTATACTTCAAGTGATGCGTGTCTGTGTATTTAGCATGTGTACTATAATCAGGTGATATAG TATTCCTTCAGTCTTTGTAGTAACTGGATTTTTTTATGCTTCTGGTATTGCTTTATAAAAGATTTT CATTTCAG
(SEQ ID NO:300)
Homo sapiens TLR3 3'-UTR
NM_003265
ATTTATTTAAATATTCAATTAGCAAAGGAGAAACTTTCTCAATTTAAAAAGTTCTATGGCAAATTT AAGTTTTCCATAAAGGTGTTATAATTTGTTTATTCATATTTGTAAATGATTATATTCTATCACAAT TACATCTCTTCTAGGAAAATGTGTCTCCTTATTTCAGGCCTATTTTTGACAATTGACTTAATTTTA CCCAAAATAAAACATATAAGCACGTAAAAAAAAAAAAAAAAAA
(SEQ ID NO:301)
Homo sapiens BCAT1 3'-UTR
BCATl-002 ENST00000342945
ATGGAAAATAGAGGATACAATGGAAAATAGAGGATACCAACTGTATGCTACTGGGACAGACTGTTG CATTTGAATTGTGATAGATTTCTTTGGCTACCTGTGCATAATGTAGTTTGTAGTATCAATGTGTTA CAAGAGTGATTGTTTCTTCATGCCAGAGAAAATGAATTGCAATCATCAAATGGTGTTTCATAACTT GGTAGTAGTAACTTACCTTACCTTACCTAGAAAAACATTAATGTAAGCCATATAACATGGGATTTT CCTCAATGATTTTAGTGCCTCCTTTTGTACTTCACTCAGATACTAAATAGTAGTTTATTCTTTAAT ATAAGTTACATTCTGCTCCTCAAACAAATGCAATTTTTTGTGTGTGTTTGAAAGCTAATTTGAGAA AATTTCATAGGTTACATTTCCTGCAGCCTATCTTTATCCACAGAAAGTGTTTTCTTTTTTTTAAAT CAAGACTTTTAAAACTGGATTTCCTCCCATCACTGTTTTTTGAAGGTCCTCCAAGTCCGTGTTAA
(SEQ ID NO:302)
Homo sapiens BCAT1 3'-UTR
ATGGAAAATAGAGGATACAATGGAAAATAGAGGATACCAACTGTATGCTACTGGGACAGACTGTTG CATTTGAATTGTGATAGATTTCTTTGGCTACCTGTGCATAATGTAGTTTGTAGTATCAATGTGTTA CAAGAGTGATTGTTTCTTCATGCCAGAGAAAATGAATTGCAATCATCAAATGGTGTTTCATAACTT
G
(SEQ ID NO: 303)
Homo sapiens TOM1L1 3'-UTR
TOMlLl-001 ENST00000575882
GAAGAAAGTGGATGATCAGCTCACTACCACATCAAAGGTGCCAACTCTCTAAAACGTAGACTCTGT GCAGCTTTGAAGCCTGGAAGACAATACCTACCAACATGTCAAAGCCATGGTGGCACATTTCTGCTA TAATGAAGATTAAATAGAATAACAGTTCCAGGATAACACTGATTCCTGACAACAGCGTGAGATTTC AACAGAACTTGTTTGGAACAAATACTCACTTAAAACTTCAGCAGAAGAAAAATTACTTAGTCCTTA GGCCAACCAATTTAACTGCAGTGTCATGTTTCACAGGCCTTCCTACATTTAGAAATCGTCACACAG CTGTGAT AGAG AGAT ATTT C ATGAAATAATTCTGAATAG TGAAAGCATAAAATGTGAGA AACTGAATGTATTATTCAGGAAGAATACTGAGTGCCTTCATTTAACTAAAGTTGAATGTAAAAGTC AATTTGCACTTCTTTATAATCCTCTGGTTTAGAATTATAAATTGTTAAAACCTTGATAATTGTCAT TTAATTATATTTCAGGTGTCCTGAACAGGTCACTAGACTCTACATTGGGCAGCCTTTAAATATGAT TCTTTGTAATGCTAAATAGCCTTTTTTTCTCTTTTTACTGCAACTTAATATTTCTATTTAGAACAC AGAAAATGAAAATATTTAGAATAAGTTGTACATTTGATGACAAATAAATCACTATT
(SEQ ID NO: 304) Homo sapiens SLC35A1 3'-UTR
SLC35A1-201 ENST00000369556
TTTTAGCCTCACGTGAGACTCCTTTTAAGACTAAACCATTTGCATTAAACTAGAGCCTTAAGTCAA TCTCAGAAGGTAGCATAAACAAATAAAAATTAACTGTATGGCATGATCAGTGCGGTTATGTGGAAA CAACAACAAACAAACGAAGCTATCTGAGTGAACTGCTAATACAGAAACTTAATGTAGACCTGTTTG GGGTCTACTATTGTTTTAGAATGAAGGAATTGTATTATTGTGTGTATATATAATTTGTAAATAAAA AGTATGGAGATGATACGGTGTTAAAAAAAATCATGGTAAGGCTACAATACTCAAGTAACAAGGTTT GGGACAATGTCTAAGGGTTAAAGTGCCAAAGCCATTTCTGTACTAACTGTTCTCTTGTTCCGGTAC CGGGGAGAAGGATGACCCCTCCTTATTCTCCAATTCATGTACAGTATTTTGTCCTAGCAGCATAAA GACCTAGCTCTTTTCTTACAAGAGGCAGAAACAAGACAGGCTAGTTCATAAACAAACTGTGTAACT TCTCAAAATGAATCTATTTCATAACTCGGACAATTTCTGGGTGGTGACTGAGTACCCCTTTAGTGA GTACCCCTTTAGTGCTATATTTGTGCCATTCATTATCTGGTTCATATTTCTTTTCTGTTAGATGAT ACACATTTCTTCAAAAAAATTTCTAATGTCACTTTTGTACTTTTTTAAATAAAGTATGTTTAACTG TTGGGCTCTCAATAATTTGTGAAATTTCAGTGTTTTCTATAATGTTAATGGGGAAATTCAGCAATA AACTTTATTTGT
(SEQ ID NO:305)
Homo sapiens GLYATL2 3'-UTR
GLYATL2-003 ENST00000532258
TTGATTCCACTGTCCATTTCAAATCTTTCTTATCAGTAAAAAAACATTAATTCAAACACAAGCATT GTGATCTACATTAGCACAAAATGCAACTGATTATCTAGGATCTGTGTATTACTTAAGCTCACCCTT AACAGTTTTACCTTCCTTCTCCTCTGTATTCTTACAGAAAATTAGAAGCTCAATTTTATGGTCTCA TAATTTCCTTTATGACAGACATCTCAGAATTAAAATCACCCAAAGCCAATCATTAGTGCCAAGATA ACCCTTTAACGGCAACACTTTCTTAAATGAAGACTATTTCTTTCATGAAAAAATTCACTTTTATGA CT
(SEQ ID NO:306)
Homo sapiens S AT4 3'-UTR
STAT4-002 ENST00000392320
CAGGATAAACTCTGACGCACCAAGAAAGGAAGCAAATGAAAAAGTTTAAAGACTGTTCTTTGCCCA ATAACCACATTTTATTTCTTCAGCTTTGTAAATACCAGGTTCTAGGAAATGTTTGACATCTGAAGC TCTCTTCACACTCCCGTGGCACTCCTCAATTGGGAGTGTTGTGACTGAAATGCTTGAAACCAAAGC TTCAGATAAACTTGCAAGATAAGACAACTTTAAGAAACCAGTGTTAATAACAATATTAACAG
( SEQ ID NO: 307)
Homo sapiens GULP1 3'-UTR
GULP1-002 ENST00000409609
CATCAAGAACAAGAAATCCTGATTCATGTTAAATGTGTTTGTATACACATGTCATTTATTATTATT ACTTTAAGATAGGTATTATTCATGTGTCAATGTTTTTGAATATTTTAATATTTTGAAAATTTTCTC AGTTAAATTTCCTCACCTTCACTATTGATCTGTAATTTTTATTTTAAAAACAGCTTACTGTAAAGT AGATCATACTTTTATGTTCCTTTCTGTTTCTACTGTAGATGAATTTGTAATTGAAAGACATATTAT ACAAAT
(SEQ ID NO:308)
Homo sapiens GULPl 3'-UTR
GULPl-010 ENST00000409805
CATCAAGAACAAGAAATCCTGATTCATGTTAAATGTGTTTGTATACACATGTCATTTATTATTATT ACTTTAAGATAGG
(SEQ ID NO: 309) Homo sapiens EHHADH 3'-UTR
EHHADH-002 ENST00000456310
TTCAGTCTTCCAGATTATGCCTCACATGCTAGCATCAGGTAATGCTGACTGAATTTCAGTGAAATT AAATCAAAAATCCAAAGTAAGATTGTTCTGAAATACAAAGCAAAATAAATAATCATTAGAATCTTC TGTGTAACGACTCTAATGGTCAAATCTTTAGGAATGTGCTTCCTATGCCTCTGAATCTGTCCTTAT CAGATAAATTCAATGCATGAACTTGTGTGAATATAATACCATAATAGCTAATGAAAGA
(SEQ ID NO:310)
Homo sapiens NBEAL1 3'-UTR
NM_001114132.1
TTGTTATTTCCATTTTCTGTTATGATTACTGAAACCTGATTTATTGCTTTGTCACTTTAACCACAT CTCTCAACTCTCTGCAATGTTGCAAGGCTTTTATCCCTGAAAATCATTTACAGATAACCACAATTT GCTGTGGTATATAAACTAATTCTTGGTCTATACTAAGATGTATTTGAGAAAATACATTTGATTTGA TTTTGTGGCCCATTCCTAAAGGTCATTGTATCCATTTTTAAAACAAACTAAAATGAGAACATTAGG TTCAATTTTCTTATTATTCCAAATGATAAAATTTAAGATTTTTCTAATAAAAGAGTACAGATAATG GGACAGTTGAGAGAGATGGCTTTAAATACATTCTTAAGTAATCATTTTCCTATTTACTGACCACTG TAATGAAAATATATCAATTTATTTATGGAACTCCTGATTGGGGATAATATTTTAAAGGTATCTGTT GCACACTTGGATTTTCAAAACTCGGTGAAAGTTACAAGTTTGCATGGTAAGAATAAAATAAGAATA TTGAAACTGGTACATTAGCTAATTCTATTACTACTTAGCGTGTTTCTAATGAGAAGTTACTGAAAT CTATTACTGTCCTTAATAAAAATTGAGTAGAAAAAAGTGGAACTAG
(SEQ ID NO:311)
Homo sapiens KIAA1598 3'-UTR
NM_001258299.1
TCTGAATCAGAAAATACTGCAACTCCTTCCTCCTTTTGTCTGCCTTTTGTTCTCCAAAAGTAAGTG GAAATTACATTTCCAAGAAAGGAAATGAAATAATTGCAGGCCCAAGGTCTGCAAAATATGTGTTGA ATTGACAGTGAAAAGGATCCATGTGTTGACAGACACAGTTGTTAGATGCCATAAAGGCAGATGTGA AGCTCAATTTATTTCTCATCTTGCTTG
(SEQ ID NO:312)
Homo sapiens HFE 3'-UTR
HFE-006 ENST00000317896
CACGCAGCCTGCAGACTCACTGTGGGAAGGAGACAAAACTAGAGACTCAAAGAGGGAGTGCATTTA TGAGCTCTTCATGTTTCAGGAGAGAGTTGAACCTAAACATAGAAATTGCCTGACGAACTCCTTGAT TTTAGCCTTCTCTGTTCATTTCCTCAAAAAGATTTCCCCATTTAGGTTTCTGAGTTCCTGCATGCC GGTGATCCCTAGCTGTGACCTCTCCCCTGGAACTGTCTCTCATGAACCTCAAGCTGCATCTAGAGG CTTCCTTCATTTCCTCCGTCACCTCAGAGACATACACCTATGTCATTTCATTTCCTATTTTTGGAA GAGGACTCCTTAAATTTGGGGGACTTACATGATTCATTTTAACATCTGAGAAAAGCTTTGAACCCT GGGACGTGGCTAGTCATAACCTTACCAGATTTTTACACATGTATCTATGCATTTTCTGGACCCGTT CAACTTTTCCTTTGAATCCTCTCTCTGTGTTACCCAGTAACTCATCTGTCACCAAGCCTTGGGGAT TCTTCCATCTGATTGTGATGTGAGTTGCACAGCTATGAAGGCTGTACACTGCACGAATGGAAGAGG CACCTGTCCCAGAAAAAGCATCATGGCTATCTGTGGGTAGTATGATGGGTGTTTTTAGCAGGTAGG AGGCAAATATCTTGAAAGGGGTTGTGAAGAGGTGTTTTTTCTAATTGGCATGAAGGTGTCATACAG ATTTGCAAAGTTTAATGGTGCCTTCATTTGGGATGCTACTCTAGTATTCCAGACCTGAAGAATCAC AATAATTTTCTACCTGGTCTCTCCTTGTTCTGATAATGAAAATTATGATAAGGATGATAAAAGCAC TTACTTCGTGTCCGACTCTTCTGAGCACCTACTTACATGCATTACTGCATGCACTTCTTACAATAA TTCTATGAGATAGGTACTATTATCCCCATTTCTTTTTTAAATGAAGAAAGTGAAGTAGGCCGGGCA
C
(SEQ ID NO:313) Homo sapiens HFE 3'-UTR
HFE-004 ENST00000349999
CACGCAGCCTGCAGACTCACTGTGGGAAGGAGACAAAACTAGAGACTCAAAGAGGGAGTGCATTTA TGAGCTCTTCATGTTTCAGGAGAGAGTTGAACCTAAACATAGAAATTGCCTGACGAACTCCTTGAT TTTAGCCTTCTCTGTTCATTTCCTCAAAAAGATTTCCCCATTTAGGTTTCTGAGTTCCTGCATGCC GGTGATCCCTAGCTGTGACCTCTCCCCTGGAACTGTCTCTCATGAACCTCAAGCTGCATCTAGAGG CTTCCTTCATTTCCTCCGTCACCTCAGAGACATACACCTATGTCATTTCATTTCCTATTTTTGGAA GAGGACTCCTTAAATTTGGGGGACTTACATGATTCATTTTAACATCTGAGAAAAGCTTTGAACCCT GGGACGTGGCTAGTCATAACCTTACCAGATTTTTACACATGTATCTATGCATTTTCTGGACCCGTT CAACTTTTCCTTTGAATCCTCTCTCTGTGTTACCCAGTAACTCATCTGTCACCAAGCCTTGGGGAT TCTTCCATCTGATTGTGATGTGAGTTGCACAGCTATGAAGGCTGTACACTGCACGAATGGAAGAGG CACCTGTCCCAGAAAAAGCATCATGGCTATCTGTGGGTAGTATGATGGGTGTTTTTAGCAGGTAGG AGGCAAATATCTTGAAAGGGGTTGTGAAGAGGTGTTTTTTCTAATTGGCATGAAGGTGTCATACAG ATTTGCAAAGTTTAATGGTGCCTTCATTTGGGATG
(SEQ ID NO:314)
Homo sapiens HFE 3'-UTR
HFE-005 ENST00000397022
CACGCAGCCTGCAGACTCACTGTGGGAAGGAGACAAAACTAGAGACTCAAAGAGGGAGTGCATTTA TGAGCTCTTCATGTTTCAGGAGAGAGTTGAACCTAAACATAGAAATTGCCTGACGAACTCCTTGAT TTTAGCCTTC
(SEQ ID NO:315)
Homo sapiens HFE 3'-UTR
HFE-012 ENST00000336625
CACGCAGCCTGCAGACTCACTGTGGGAAGGA
(SEQ ID NO:316)
Homo sapiens KIAA1324L 3'-UTR
KIAA1324L-005 ENST00000416314
AGAGACAGTGCTGTAGCCTTGAGACTAATGAACAAAGAAACCTGCTCTAGTTTTACAGGACCATAT TTTAGGGTCTGTCCTCATACCTGTCACATTGGTGATCTCACAGAGGAGGGCCATGCCGCTGAAAAG GGAAGGAGATTGAAACATTTGATTGCCTTATCACATGGTCAAGTACCTTGCCAAATAAAGGAAAGC AAATGATTTGGGTCTCAACTGAAGATGAAGCTCAACTCAGGAAGAGATTTATCTGTATATACACAT AACTGAAAACCAAGTTTAAGCCCACCAATGCACTGCTGATGCATGCCATATAATTAATGGGTAACT TTTATTCTTTATGATGTCTACATAACAAGTGTGATTTGGAAGGCACATGTGAGCATATGCATTA
(SEQ ID NO:317)
Homo sapiens MANSC1 NM_018050 3'-UTR
GGATGGAACTCGGTGTCTCTTAATTCATTTAGTAACCAGAAGCCCAAATGCAATGAGTTTCTGCTG ACTTGCTAGTCTTAGCAGGAGGTTGTATTTTGAAGACAGGAAAATGCCCCCTTCTGCTTTCCTTTT TTTTTTTTGGAGACAGAGTCTTGCTTTGTTGCCCAGGCTGGAGTGCAGTAGCACGATCTCGGCTCT CACCGCAACCTCCGTCTCCTGGGTTCAAGCGATTCTCCTGCCTCAGCCTCCTAAGTATCTGGGATT ACAGGCATGTGCCACCACACCTGGGTGATTTTTGTATTTTTAGTAGAGACGGGGTTTCACCATGTT GGTCAGGCTGGTCTCAAACTCCTGACCTAGTGATCCACCCTCCTCGGCCTCCCAAAGTGCTGGGAT TACAGGCATGAGCCACCACAGCTGGCCCCCTTCTGTTTTATGTTTGGTTTTTGAGAAGGAATGAAG TGGGAACCAAATTAGGTAATTTTGGGTAATCTGTCTCTAAAATATTAGCTAAAAACAAAGCTCTAT GTAAAGTAATAAAGTATAATTGCCATATAAATTTCAAAATTCAACTGGCTTTTATGCAAAGAAACA GGTTAGGACATCTAGGTTCCAATTCATTCACATTCTTGGTTCCAGATAAAATCAACTGTTTATATC AATTTCTAATGGATTTGCTTTTCTTTTTATATGGATTCCTTTAAAACTTATTCCAGATGTAGTTCC TTCCAATTAAATATTTG
(SEQ ID NO:318) Preferably, the at least one 5'-UTR element comprises or consists of a nucleic acid sequence which has an identity of at least about 1 , 2, 3, 4, 5, 1 0, 1 5, 20, 30 or 40%, preferably of at least about 50%, preferably of at least about 60%, preferably of at least about 70%, more preferably of at least about 80%, more preferably of at least about 90%, even more preferably of at least about 95%, even more preferably of at least about 99% to a nucleic acid sequence selected from the group consisting of SEQ ID NO: 25 or SEQ ID NO: 30 and SEQ ID NOs: 31 9 to 382 or the corresponding DNA or RNA sequence, respectively, or wherein the at least one 5'-UTR element comprises or consists of a fragment of a nucleic acid sequence which has an identity of at least about 40%, preferably of at least about 50%, preferably of at least about 60%, preferably of at least about 70%, more preferably of at least about 80%, more preferably of at least about 90%, even more preferably of at least about 95%, even more preferably of at least about 99% to a nucleic acid sequence selected from the group consisting of SEQ ID NO: 25 or SEQ ID NO: 30 and SEQ ID NOs: 31 9 to 382 or the corresponding DNA or RNA sequence, respectively:
Homo sapiens LTA4H 5'-UTR
LTA4H-001 ENST00000228740
AAGAAACTTCCTTTCCCGGCGTGCACCGCGAATCCCTCCTCCTCTTCTTTACCTCTCTCCCTCCTC CTCAGGTTCTCTATCGACGAGTCTGGTAGCTGAGCGTTGGGCTGTAGGTCGCTGTGCTGTGTGATC CCCCAGAGCC
(SEQ ID NO:319)
Homo sapiens DECR1 5'-UTR
DECRl-001 ENST00000220764
TCCAGCCCCGAGAACTTTGTTCTTTTTGTCCCGCCCCCTGCGCCC7AACCGCCTGCGCCGCCTTCCG GCCCGAGTTCTGGAGACTCAAC
(SEQ ID NO:320)
Homo sapiens PIGK 5'-UTR
ACTGCCTCCGCCCCTTCAGGTGCGGGAAGTCTGAAGCCGGTAAAC
(SEQ ID NO:321)
Homo sapiens BRP44L 5'-UTR
BRP44L-001
GTCGTGAGGCGGGCCTTCGGGCTGGCTCGCCGTCGGCTGCCGGGGGGTTGGCCGGGGTGTCATTGG CTCTGGGAAGCGGCAGCAGAGGCAGGGACCACTCGGGGTCTGGTGTCGGCACAGCC
(SEQ ID NO: 322)
Homo sapiens ACADSB 5'-UTR
ACADSB-004 NM_001609.3 ENST00000368869
AGGGATTAAGGGGGGGTGTGTGCGGGGCGGGTACTGAGTGGGCGGGGCCTTGCTCGGGTAACTCCC AGGGGCTGGCTAGAGACCCAGAGGCGCAGAGCGGAGAGGCCTGCGGCGAGG (SEQ ID NO: 323)
Homo sapiens SUPT3H 5'-UTR
SUPT3H-006 ENST00000371459
CACAGCCGAGTCACCTTTTCCCTTTCTACACTCCACACTCTCAGTCCCCCACCCCGCCCCTTTCCA AGCGTGTCCCGGGCCGCAGCAGCAGAAACCGCACCATCTCCACCCCCACATTCTCCTCGCGGGAAG CGCAGCAGTGCCTCCAAGGGTTCTTAAAGCAGAG
(SEQ ID NO: 324)
Homo sapiens TMEM14A 5'-UTR
N _014051.3
GTTTCCAGGAGGGAGCGGCCTTTGCTCAGCGCGAGACGGCTGGGCGCCGAGTGGGACAGCGCTGGT GCGGAGACTGCTTCCGGACTCCAGGTACCGCGCTTGGCGGCAGCTGGCCCCAGACTTCTGTCTTTT CAGCTGCAGTGAAGGCTCGGGGCTGCAGAATTGCAACCTTGCCA
(SEQ ID NO:325)
Homo sapiens C9orf46 5'-UTR
AF225420.1
GAGCGAGGCCCGGTCCCTGCAGCGGGCGAAAGGAGCCCGGGCCTGGAGGTTTGCGTACCGGTCGCC TGGTCCCGGCACCAGCGCCGCCCAGTGTGGTTTCCCATAAGGAAGCTCTTCTTCCTGCTTGGCTTC CACCTTTAACCCTTCCACCTGGGAGCGTCCTCTAACACATTCAGACTACAAGTCCAGACCCAGGAG AGCAAGGCCCAGAAAGAGGTCAAA
(SEQ ID NO:326)
Homo sapiens ANXA4 5'-UTR
NM_001153.3
GCCCCAGGTGCGCTTCCCCTAGAGAGGGATTTTCCGGTCTCGTGGGCAGAGGAACAACCAGGAACT TGGGCTCAGTCTCCACCCCACAGTGGGGCGGATCCGTCCCGGATAAGACCCGCTGTCTGGCCCTGA GTAGGGTGTGACCTCCGCAGCCGCAGAGGAGGAGCGCAGCCCGGCCTCGAAGAACTTCTGCTTGGG TGGCTGAACTCTGATCTTGACCTAGAGTC
(SEQ ID NO: 327)
Homo sapiens IFI6 5'-UTR
NM_022873.2
CCAGCCTTCAGCCGGAGAACCGTTTACTCGCTGCTGTGCCCATCTATCAGCAGGCTCCGGGCTGAA GATTGCTTCTCTTCTCTCCTCCAAGGTCTAGTGACGGAGCCCGCGCGCGGCGCCACC
(SEQ ID NO:328)
Homo sapiens C2orf34 5'-UTR
CAMKMT -008 ENST00000402247
TCCTGGCAGGGGACGAGCTGCGGCGGTGGCACCTCCGGGTGTGGAAGGCTCCAGTGAG
(SEQ ID NO:329)
Homo sapiens C2orf34 5'-UTR
NM_024766.3
GAGGGTGCCGGGCGTCACAGGTCCTGACAGGGAAGAAGTTGGCAGGTCCTGGCAGGGGACGAGCTG CGGCGGTGGCACCTCCGGGTGTGGAAGGCTCCAGTGAG
(SEQ ID NO:330)
Homo sapiens ALDH6A1 5' -UTR
ALDH6A1-002 ENST00000350259
AGTGCTTCTGGGCAGTAGAGGCGCGGGGTGCGGAGCTAGGGCGGCCGAGAGCC (SEQ ID NO:331)
Homo sapiens CCDC53 5'-UTR
CCDC53-002 ENST00000545679
GGAAGGGCCCCGGAGGCGGGCACTTGGGGGGAAAGTTGAGACGTGATTACCGGGTTGGGCGGGCCC CATCTGGGAGGGGTTTGTGGGTGAACTCGGGGTCCACCGCCCGCTGAGGAG
(SEQ ID NO: 332)
Homo sapiens CASP1 5'-UTR
NM_001257119.1
ATACTTTCAGTTTCAGTCACACAAGAAGGGAGGAGAGAAAAGCC
(SEQ ID NO:333)
Homo sapiens NDUFB6 5'-UTR
NM_182739.2
GTAATAACCGCGCGCGGCGCTCGGCGTTCCCGCAAGGTCGCTTTGCAGAGCGGGAGCGCGCTTAAG TAACTAGTCCGTAGTTCGAGGGTGCGCCGTGTCCTTTTGCGTTGGTACCAGCGGCGAC
(SEQ ID NO:334)
Homo sapiens BCKDHB 5'-UTR
BCKDHB-002 ENST00000369760
AGGCGGCGTGCGGCTGCATAGCCTGAGAATCCCGGTGGTGAGCGGGG
(SEQ ID NO: 335)
Homo sapiens BCKDHB 5'-UTR
NMJ301164783.1
CTACGTGAGTGCCGGACCGCTGAGTGGTTGTTAGCCAAG
(SEQ ID NO:336)
Homo sapiens BBS2 5'-UTR
NM_031885.3
CACAGAAGGCGCCGAGGCTCCACCGCGCAGCCGCAAAAAGAGCGGACGGGTCTGCGCCGCCGCAGG AGGAGCAGGCGGTACCTGGACGGGTTCGTCCCGGGCTGTTTCGCGTCCGGCCTGAGGCGGCTGGGG CCGCGCAGGTAGTGTCCCTGCACTTCTTGCCCGGGCGCGTGAGGCCAGCTCCGCTGCGCTTGTCTC CAGCTTCCAGCCCTCCTCCCCTAAGCCGCCGCCATC
(SEQ ID NO: 337)
Homo sapiens HERC5 5'-UTR
HERC5-001 ENST00000264350
TCAGTAGCTGAGGCTGCGGTTCCCCGACGCCACGCAGCTGCGCGCAGCTGGTTCCCGCTCTGCAGC GCAACGCCTGAGGCAGTGGGCGCGCTCAGTCCCGGGACCAGGCGTTCTCTCCTCTCGCCTCTGGGC CTGGGACCCCGCAAAGCGGCG
(SEQ ID NO:338)
Homo sapiens FAM175A 5'-UTR
NM_139076.2
ACCACAGGGTCTTGCCTCCGCGCGCCCCGCCCTCGTCCTCTTGTGTAGCCTGAGGCGGCGGTAGC
(SEQ ID NO:339)
Homo sapiens NT5DC1 5'-UTR NT5DC1-002 ENST00000319550
CGGTCCTGTCCCGCAGCGTCCCGCCAGCCAGCTCCTTGCACCCTTCGCGGCCGAGGCGCTCCCTGG TGCTCCCCGCGCAGCC
(SEQ ID NO: 340)
Homo sapiens RAB7A 5'-UTR
RAB7A-001 ENST00000265062
GTCTCGTGACAGGTACTTCCGCTCGGGGCGGCGGCGGTGGCGGAAGTGGGAGCGGGCCTGGAGTCT TGGCCATAAAGCCTGAGGCGGCGGCAGCGGCGGAGTTGGCGGCTTGGAGAGCTCGGGAGAGTTCCC TGGAACCAGAACTTGGACCTTCTCGCTTCTGTCCTCCGTTTAGTCTCCTCCTCGGCGGGAGCCCTC GCGACGCGCCCGGCCCGGAGCCCCCAGCGCAGCGGCCGCGTTTGAAGG
(SEQ ID NO: 341)
Homo sapiens AGA 5' -UTR
AGA-001 ENST00000264595
AGGGACGCCTGAGCGAACCCCCGAGAGAGCGGGCGTGGGCGCCAGGCGGGCGGGGCACTGGGGATT AATTGTTCGGCGATCGCTGGCTGCCGGGACTTTTCTCGCGCTGGTCTCTTCGGTGGTCAGGG
(SEQ ID NO: 342)
Homo sapiens TPK1 5' -UTR
TPKl-001 ENST00000360057
AAGGCTCCTCAGCCGAGCGCCGAGCGGTCGATCGCCGTAGCTCCCGCAGCCTGCGATCTCCAGTCT GTGGCTCCTACCAGCCATTGTAGGCCAATAATCCGTT
(SEQ ID NO:343)
Homo sapiens MBNL3 5' -UTR
MBNL3-001 ENST00000370839
AATTCATTTTTAATCCTTTAATAGTCCACAGTAATATTGTCCTAAAGAGGGTACATTGGATTTTAA TTTTGCTTTCAAT
(SEQ ID NO:344)
Homo sapiens MCCC2 5' -UTR
MCCC2-001 ENST00000340941
AGAATCAGAGAAACCTTCTCTGGGGCTGCAAGGACCTGAGCTCAGCTTCCGCCCCAGCCAGGGAAG CGGCAGGGGAAAGCACCGGCTCCAGGCCAGCGTGGGCCGCTCTCTCGCTCGGTGCCCGCCGCC
(SEQ ID NO:345)
Homo sapiens CAT 5' -UTR
CAT-001 ENST00000241052
ACTCGGGGCAACAGGCAGATTTGCCTGCTGAGGGTGGAGACCCACGAGCCGAGGCCTCCTGCAGTG TTCTGCACAGCAAACCGCACGCT
(SEQ ID NO:346)
Homo sapiens ANAPC4 5' -UTR
ANAPC4-001 ENST00000315368
CCCGACGCCGGAAGTGCCTGGAGCGCGCGACAGCGGCGGGGCGGGGCGGCCTGGAGGCTGTGGCGC GCGGCCGGCAGAGGGAGGGGAGAGGCCACTGGGGCCGTGTTAGTCTGCCGGTGGGGACTCTTGCAG GGCCGTCCCC
(SEQ ID NO: 347) Homo sapiens PHKB 5'-UTR
PHKB-002 ENST00000323584
GGCCAAGGCGGCGACCGGAGCGCG
(SEQ ID NO: 348)
Homo sapiens ABCB7 5'-UTR
ABCB7-001 ENST00000253577
CTCGGTTCCTCTTTCCTCGCTCAAG
(SEQ ID NO: 349)
Homo sapiens GPD2 5'-UTR
GPD2-002 ENST00000438166
CCCGCGCGCCTCGCTGGGAGCACCCGGGCCGAGGCTCTGATTCTGGGGGGAGGCCGACTCCACCCT GGCTGGAGGAACTGGGTGCTCCTGCCCGCTGGCCCCTCGCGCGTGAGGATCTATCTCAGGCTAAGA
A
(SEQ ID NO:350)
Homo sapiens TMEM38B 5'-UTR
TMEM38B-001 ENST00000374692
GCTGGAGCCGGCGCGGAGGAGCGGGCGGCCGCGGCTGTGCCCTCTCCTACTCCTCACCGCGCGAGC GCGGGGAACCAGTAGCCGCGGCTGCTTCGGTTGCCGCGGTCGGTGGTCGTT
(SEQ ID NO: 351)
Homo sapiens NFU1 5'-UTR
NM_001002755.2
GGGAAAGGTTCCCCGGCCTCTCTTGGTCAGGGTGACGCAGTAGCCTGCAAACCTCGGCGCGTAGGC CACCGCACTTATCCGCAGCAGGACCGCCCGCAGCCGGTAGGGTGGGCTCTTCCCAGTGCCCGCCCA GCTACCGGCCAGCCTGCGGCTGCGCAGATCTTTCGTGGTTCTGTCAGGGAGACCCTTAGGCACTCC GGACTAAG
(SEQ ID NO: 352)
Homo sapiens LOC128322/NUTF2 5' -UTR
NM_005796.1
GGAAGGGACAGTCGGCCGCAGACCGCGCTGGGTTGCCGCTGCCGCTGCCGCCATCGTGCCAGCCCC TCGGGTCTCCGTGAGGCCGGGTGACGCTCCAGA
(SEQ ID NO:353)
Homo sapiens NUBPL 5' -UTR
NM_025152.2
ACTCCGCGCCACCCGCGACAGTTTCCCAGCAGGGCTCACAGCAGCGTTCCGCGTC
(SEQ ID NO: 354)
Homo sapiens LANCL1 5' -UTR
LANCLl-004 ENST00000233714
GAGAAGGGCTTCAGGACGCGGGAGGCGCACTTGCTTCAAGTCGCGGGCGTGGGAACGGGGCTTGCT TCCGGCGTC
(SEQ ID NO:355)
Homo sapiens PIR 5' -UTR
PIR-002 ENST00000380420
CCTCCCGCCTCCTCTAGGCCGCCGGCCGCGAAGCGCTGAGTCACGGTGAGGCTACTGGACCCACAC TCTCTTAACCTGCCCTCCCTGCACTCGCTCCCGGCGGCTCTTCGCGTCACCCCCGCCGCTAAGGCT CCAGGTGCCGCTACCGCAGCCCCTCCATCCTCTACAGCTCAGCATCAGAACACTCTCTTTTTAGAC TCCGAT
(SEQ ID NO:356)
Homo sapiens CTBS 5 ' -UTR
NM_004388.2
GACGCGCAGCAGGCCCCGCCCACCCAGGCGGTAGGAACCCACTCCGGCCCGCTAGACCTGCTGCT
(SEQ ID NO: 357)
Homo sapiens GSTM4 5' -UTR
NM_000850.4
AAGCTGGCGAGGCCGAGCCCCTCCTAGTGCTTCCGGACCTTGCTCCCTGAACACTCGGAGGTGGCG GTGGATCTTACTCCTTCCAGCCAGTGAGGATCCAGCAACCTGCTCCGTGCCTCCCGCGCCTGTTGG TTGGAAGTGACGACCTTGAAGATCGGCCGGTTGGAAGTGACGACCTTGAAGATCGGCGGGCGCAGC GGGGCCGAGGGGGCGGGTCTGGCGCTAGGTCCAGCCCCTGCGTGCCGGGAACCCCAGAGGAGGTCG CAGTTCAGCCCAGCTGAGGCCTGTCTGCAGAATCGACACCAACCAGCATC
(SEQ ID NO:358)
Mus musculus Ndufal 5' -UTR
Ndufal-001 ENSMUST00000016571
GCCGGAAGAGAGGTAAAGCCGGGTCACCTCTGAGGAGCCGGTGACGGGTTGGCGTGCGAGTAACGG TGCGGAG
(SEQ ID NO:359)
Mus musculus Atp5e 5' -UTR
NM_025983
CCCACCCCTTCCGCTACTCAGGCCTGACCTTCCTGCTGCCGGGCCGGTTTGAGGCTACTCTGAAGC GACCCAGCGGTTCTGCCCGACGCGCCCGCTCGAGACACC
(SEQ ID NO:360)
Mus musculus Gstm5 5' -UTR
NM_010360
GAGACAGTTCGGTCGCGTCAGCCCGGCCCACAGCGTCCAGTATAAAGTTAGCCGCCCACAGTCCAT CGCTGTATCCCCGAAGGGGCTAAGATCGCCCAAA
(SEQ ID NO:361)
Mus musculus Cbr2 5' -UTR
NM_007621
ATAAAAGCTGAGCCCATCTCTTGCTTCGGAAGAAGCTGGTGTCAGCAGC
(SEQ ID NO:362)
Mus musculus Anapcl3 5' -UTR
NM__181394
GTGACCCAGAAGAAGGGCGGGGCCGGGAGGAAGCCGACGCGCGCGCAGTGGGCCTGACAAGATCAA AGCTGCAGGAGG
(SEQ ID NO: 363)
Mus musculus Ndufa7 5' -UTR
NM_023202
TCGGAGCGGAAGGAAT
(SEQ ID NO:364) Mus musculus Atp5k 5' -UTR
NM_007507
CGAAGGTCACGGACAAA
(SEQ ID NO:365)
Mus musculus Cox4il 5' -UTR
NM_009941
CTTCCGGTCGCGAGCACCCCAGGGTGTAGAGGGCGGTCGCGGCGGTCGCCTGGGCAGCGGTGGCAG
A
(SEQ ID NO:366)
Mus musculus Ndufs6 5' -UTR
NM_010888
TTGGTACGACGCGTGGGGTCAAGGGTCACCGGCAAG
(SEQ ID NO: 367)
Mus musculus Sec61b 5' -UTR
NM_024171
AGAGCCTGTATCTACGAGAGTTCTGAGTGCTCGGCAACTTCACGACTTCCCTCTTCCTGCCTCCTG TGCCCACCGTTCTTAGGCATCAGC
(SEQ ID NO:368)
Mus musculus Snrpd2 5' -UTR
NMJ326943
AAGGCTGGAGCAACGCGCTTGGAGGCGGGAGTGATCTGCGAGCGAAACCTACACC
(SEQ ID NO: 369)
Mus musculus Mgst3 5' -UTR
NM_025569
ACTGCTGTGCTTCTCAGGTCTGTACCAGGCGCACGAAGGTGAGCCAGAGCCAAG
(SEQ ID NO:370)
Mus musculus Mp68 (2010107E04Rik) 5' -UTR
NM_027360
CTTTCCCATTCTGTAGCAGAATTTGGTGTTGCCTGTGGTCTTGGTCCCGCGGAG
(SEQ ID NO: 371)
Mus musculus Prdx4-001, 5' -UTR
NM_016764
GCGCGGTCTCCAGCGCGCCGTTTTAGCTGGCTGCCTGGCGGCAGGGGACTCTGTGCTTTAGCAGAG GGACGTGTTTTCGCGCTTGCTTGGTC
(SEQ ID NO: 372)
Mus musculus Pgcp 5' -UTR
NM__176073
GCTGTCCTGGCACACAAAGAAGCCAGGCCTGCAGACTACTGGGGCTCCGGGCTGTTCCTGAGGCCT CTGGAGGCCCGCCCTGTGGCTCCAGTGCGCTCTGAGGACCTTCCTGGTCCCGCCCCCGAACGTGCC TGTGGTCTGCAGGCCTCACCGGGTGTTGTGGCCGCTGCTGCTCCGCAGAGCCTCGTGATCAGGAAG AAAAGCAACTAGGAACA
(SEQ ID NO:373) Mus musculus Myeov2 5'-UTR
NM_001163425
AGAAGGGGCTGGCCGGAAGTGAGCGCAACGCCGCCTTGTCGAG
(SEQ ID NO:374)
Mus musculus Ndufa4 5'-UTR
NM_010886
GTCCGCTCAGCCAGGTTGCAGAAGCGGCTTAGCGTGTGTCCTAATCTTCTCTCTGCGTGTAGGTAG GCCTGTGCCGCAAAC
(SEQ ID NO:375)
Mus musculus Ndufs5 5'-UTR
NM_001030274
ACGGCAGGCGTCTGCGTCCTCCCGCAGCCGGCGGTCGGGAATTGCACCAGGGACCTGACAAGGGCA CTGCAGAGCC
(SEQ ID NO:376)
Mus musculus Gstml 5'-UTR
NM_010358
CTGCCTTCCGCTTTAGGGTCTGCTGCTCTGGTTACAGACCTAGGAAGGGGAGTGCCTAATTGGGAT TGGTGCAGGGTTGGGAGGGACCCGCTGTTTTGTCCTGCCCACGTTTCTCTAGTAGTCTGTATAAAG TCACAACTCCAAACACACAGGTCAGTCCTGCTGAAGCCAGTTTGAGAAGACCACAGCACCAGCACC
(SEQ ID NO:377)
Mus musculus Atp5o 5'-UTR
NM_138597
CTGGCGCGCGCGCGTGCGCTCTGGCGCCAGTAGTCTCTTTTCATTTGGGTTTGACCTACAGCCGCC CGGGAAAAG
(SEQ ID NO:378)
Mus musculus Tspo 5'-UTR
NM_009775
GTCAGCGGCTACCAACCTCTGTGCGCAGTGTCCTTCACGGAACAACCAGCGACTGCGTGAGCGGGG CTGTGGATCTTTCCAGAACATCAGTTGCAATCACC
(SEQ ID NO:379)
Mus musculus Taldol 5' -UTR
NM_011528
GACGCGCGGGGCATTGTGGGTTAGCACGCACCGGCTACCGCCTCAGCTGTTCGCGTTTCGCC
(SEQ ID NO: 380)
Mus musculus Bloclsl 5' -UTR
NMJ315740
GTGACGCCTTCCGGGTGAGCCAAGGCATAGTCCAGTTCCTGCAGCCTTAGGGAGGGGTCCGCCGTG CCCACACCCAGCCAGACTCGACC
(SEQ ID NO:381)
Mus musculus Hexa 5' -UTR
NM_010421
AGCTGACCGGGGCTCACGTGGGCTCAGCCTGCTGGAAGGGGAGCTGGCCGGTGGGCC
(SEQ ID NO: 382) Preferably, the at least one 3'-UTR element of the artificial nucleic acid molecule according to the present invention comprises or consists of a nucleic acid sequence which has an identity of at least about 40%, preferably of at least about 50%, preferably of at least about 60%, preferably of at least about 70%, more preferably of at least about 80%, more preferably of at least about 90%, even more preferably of at least about 95%, even more preferably of at least about 99%, most preferably of 100% to the 3'-UTR sequence of a transcript of a gene selected from the group consisting of GNAS (guanine nucleotide binding protein, alpha stimulating complex locus), MORN2 (MORN repeat containing 2), GSTM1 (glutathione S- transferase, mu 1 ), NDUFA1 (NADH dehydrogenase (ubiquinone) 1 alpha subcomplex), CBR2 (carbonyl reductase 2), Ybx1 (Y-Box binding protein 1 ), Ndufb8 (NADH dehydrogenase (ubiquinone) 1 beta subcomplex 8), and CNTN1 (contactin 1 ; whereby CNTN1 -004 is particularly preferred). Most preferably, the at least one 3'-UTR element of the artificial nucleic acid molecule according to the present invention comprises or consists of a nucleic acid sequence which has an identity of at least about 40%, preferably of at least about 50%, preferably of at least about 60%, preferably of at least about 70%, more preferably of at least about 80%, more preferably of at least about 90%, even more preferably of at least about 95%, even more preferably of at least about 99%, most preferably of 100% to a sequence selected from the group consisting of SEQ ID NO: 1 to SEQ ID NO: 24, or the corresponding RNA sequences, respectively:
SEQ ID NO: 1
GAAGGGAACACCCAAATTTAATTCAGCCTTAAGCACAATTAATTAAGAGTGAAACGTAATGTACAA GCAGTTGGTCACCCACCATAGGGCATGATCAACACCGCAACCTTTCCTTTTTCCCCCAGTGATTCT GAAAAACCCCTCTTCCCTTCAGCTTGCTTAGATGTTCCAAATTTAGTAAGCTTAAGGCGGCCTACA GAAGAAAAAGAAAAAAAAGGCCACAAAAGTTCCCTCTCACTTTCAGTAAATAAAATAAAAGCAGCA ACAGAAA AAAGAAATAAATGAAATTCAAAATGΑΆΑΤAAATATTGTTTGTGCAGCAT AAAAAATC AATAAAAATTAAAAATGAGCA
(Mus musculus GNAS 3'-UTR)
SEQ ID NO: 2
GAAGGGAACACCCAAATTTAATTCAGCCTTAAGCACAATTAATTAAGAGTGAAACGTAATTGTACA AGCAGTTGGTCACCCACCATAGGGCATGATCAACACCGCAACCTTTCCTTTTTCCCCCAGTGATTC TGAAAAACCCCTCTTCCCTTCAGCTTGCTTAGATGTTCCAAATTTAGTAAGCTTAAGGCGGCCTAC AGAAGAAAAAGAAAAAAAAGGCCACAAAAGTTCCCTCTCACTTTCAGTAAATAAAATAAAAGCAGC AACAGAAATAAAGAAATAAATGAAATTCAAAATGAAATAAATATTGTGTTGTGCAGCATTAAAAAA TCAATAAAAATTAAAAATGAGCA
(Mus musculus GNAS 3'-UTR) SEQ ID NO: 3
GAAGGGAACCCCCAAATTTAATTAAAGCCTTAAGCACAATTAATTAAAAGTGAAACGTAATTGTAC AAGCAGTTAATCACCCACCATAGGGCATGATTAACAAAGCAACCTTTCCCTTCCCCCGAGTGATTT TGCGAAACCCCCTTTTCCCTTCAGCTTGCTTAGATGTTCCAAATTTAGAAAGCTTAAGGCGGCCTA CAGAAAAAGGAAAAAAGGCCACAAAAGTTCCCTCTCACTTTCAGTAAAAATAAATAAAACAGCAGC AGCAAACAAATAAAATGAAATAAAAGAAACAAATGAAATAAATATTGTGTTGTGCAGCATTAAAAA ΑΑΆΤCAAAATAAAAATTAAATGTGAGCAAAGAATGAAAAAAAAAAAAAAAAAAAA
(Homo sapiens GNAS 3'-UTR)
SEQ ID NO: 4
TGGAGGACGCCGTCCAGATTCTCCTTGTTTTCATGGATTCAGGTGCTGGAGAATCTGGTAAAAGCA CCATTGTGAAGCAGATGAGGATCCTGCATGTTAATGGGTTTAATGGAGAGGGCGGCGAAGAGGACC CGCAGGCTGCAAGGAGCAACAGCGATGGCAGTGAGAAGGCAACCAAAGTGCAGGACATCAAAAACA ACCTGAAAGAGGCGATTGAAACCATTGTGGCCGCCATGAGCAACCTGGTGCCCCCCGTGGAGCTGG CCAACCCCGAGAACCAGTTCAGAGTGGACTACATCCTGAGTGTGATGAACGTGCCTGACTTTGACT TCCCTCCCGAATTCTATGAGCATGCCAAGGCTCTGTGGGAGGATGAAGGAGTGCGTGCCTGCTACG AACGCTCCAACGAGTACCAGCTGATTGACTGTGCCCAGTACTTCCTGGACAAGATCGACGTGATCA AGCAGGCTGACTATGTGCCGAGCGATCAGGACCTGCTTCGCTGCCGTGTCCTGACTTCTGGAATCT TTGAGACCAAGTTCCAGGTGGACAAAGTCAACTTCCACATGTTTGACGTGGGTGGCCAGCGCGATG AACGCCGCAAGTGGATCCAGTGCTTCAACGATGTGACTGCCATCATCTTCGTGGTGGCCAGCAGCA GCTACAACATGGTCATCCGGGAGGACAACCAGACCAACCGCCTGCAGGAGGCTCTGAACCTCTTCA AGAGCATCTGGAACAACAGATGGCTGCGCACCATCTCTGTGATCCTGTTCCTCAACAAGCAAGATC TGCTCGCTGAGAAAGTCCTTGCTGGGAAATCGAAGATTGAGGACTACTTTCCAGAATTTGCTCGCT ACACTACTCCTGAGGATGCTACTCCCGAGCCCGGAGAGGACCCACGCGTGACCCGGGCCAAGTACT TCATTCGAGATGAGTTTCTGAGGATCAGCACTGCCAGTGGAGATGGGCGTCACTACTGCTACCCTC ATTTCACCTGCGCTGTGGACACTGAGAACATCCGCCGTGTGTTCAACGACTGCCGTGACATCATTC AGCGCATGCACCTTCGTCAGTACGAGCTGCTCTAAGAAGGGAACCCCCAAATTTAATTAAAGCCTT AAGCACAATTAATTAAAAGTGAAACGTAATTGTACAAGCAGTTAATCACCCACCATAGGGCATGAT TAACAAAGCAACCTTTCCCTTCCCCCGAGTGATTTTGCGAAACCCCCTTTTCCCTTCAGCTTGCTT AGATGTTCCAAATTTAGAAAGCTTAAGGCGGCCTACAGAAAAAGGAAAAAAGGCCACAAAAGTTCC CTCTCACTTTCAGTAAAAATAAATAAAACAGCAGCAGCAAACAAATAAAATGAAATAAAAGAAACA AATGAAATAAATATTGTGTTGTGCAGCATTAAAAAAAATCAAAATAAAAATTAAATGTGAGCAAAG AATGAAAAAAAAAAAAAAAAAAAA
(Homo sapiens GNAS 3'-UTR)
SEQ ID NO: 5
ACCTGCTGCCTTAACGCTGAGATGTGGCCTCTGCAACCCCCCTTAGGCAAAGCAACTGAACCTTCT GCTAAAGTGACCTGCCCTCTTCCGTAAGTCCAATAAAGTTGTCATGCACCC
(Mus musculus MORN2 3'-UTR)
SEQ ID NO: 6
ACCTGCTGCCTTAACGCTGAGATGTGGCCTCTGCAACCCCCCTTAGGCAAAGCAACTGAACCTTCT GCTAAAGTGACCTGCCCTCTTCCGTAAGTCCAATAAAGTTGTCATGCACCCACAAAAAAAAAAAAA AAA
(Mus musculus MORN2 3'-UTR) SEQ ID NO: 7
CATGTAGATGTGATGTTAAATTAAAGTTGAAATGTAGTAATTGAAGCTTTTAGTTGTAAGGAAAGC AACTTAATCTGTTATTTGAAATGACTTCATACACTACCCCTATAAGTTTGCCAATAAAACCATCAC CTGCTTACACCTTTTTGAACTTTATATTCATTGTCTTACAATTAGTTTAAAATAAATGACATGATT CAAAAAAAAAAA
(Homo sapiens MORN2 3'-UTR)
SEQ ID NO: 8
GCCCTTGCTACACGGGCACTCACTAGGAGGACCTGTCCACACTGGGGATCCTGCAGGCCCTGGGTG GGGACAGCACCCTGGCCTTCTGCACTGTGGCTCCTGGTTCTCTCTCCTTCCCGCTCCCTTCTGCAG CTTGGTCAGCCCCATCTCCTCACCCTCTTCCCAGTCAAGTCCACACAGCCTTCATTCTCCCCAGTT TCTTTCACATGGCCCCTTCTTCATTGGCTCCCTGACCCAACCTCACAGCCCGTTTCTGCGAACTGA GGTCTGTCCTGAACTCACGCTTCCTAGAATTACCCCGATGGTCAACACTATCTTAGTGCTAGCCCT CCCTAGAGTTACCCCGAAGGTCAATACTTGAGTGCCAGCCTGTTCCTGGTGGAGTAGCCTCCCCAG GTCTGTCTCGTCTACAATAAAGTCTGAAACACACTTGCCATG
(Mus musculus GSTM1 3' -UTR)
SEQ ID NO: 9
GCCCTTGCTACACGGGCACTCACTAGGAGGACCTGTCCACACTGGGGATCCTGCAGGCCCTGGGTG GGGACAGCACCCTGGCCTTCTGCACTGTGGCTCCTGGTTCTCTCTCCTTCCCGCTCCCTTCTGCAG CTTGGTCAGCCCCATCTCCTCACCCTCTTCCCAGTCAAGTCCACACAGCCTTCATTCTCCCCAGTT TCTTTCACATGGCCCCTTCTTCATTGGCTCCCTGACCCAACCTCACAGCCCGTTTCTGCGAACTGA GGTCTGTCCTGAACTCACGCTTCCTAGAATTACCCCGATGGTCAACACTATCTTAGTGCTAGCCCT CCCTAGAGTTACCCCGAAGGTCAATACTTGAGTGCCAGCCTGTTCCTGGTGGAGTAGCCTCCCCAG GTCTGTCTCGTCTACAATAAAGTCTGAAACACACTTGCCATGAAAAAAAAAAAAAAAAA
(Mus musculus GSTM1 3' -UTR)
SEQ ID NO: 10
GGCCTTGAAGGCCAGGAGGTGGGAGTGAGGAGCCCATACTCAGCCTGCTGCCCAGGCTGTGCAGCG CAGCTGGACTCTGCATCCCAGCACCTGCCTCCTCGTTCCTTTCTCCTGTTTATTCCCATCTTTACT CCCAAGACTTCATTGTCCCTCTTCACTCCCCCTAAACCCCTGTCCCATGCAGGCCCTTTGAAGCCT CAGCTACCCACTATCCTTCGTGAACATCCCCTCCCATCATTACCCTTCCCTGCACTAAAGCCAGCC TGACCTTCCTTCCTGTTAGTGGTTGTGTCTGCTTTAAAGGGCCTGCCTGGCCCCTCGCCTGTGGAG CTCAGCCCCGAGCTGTCCCCGTGTTGCATGAAGGAGCAGCATTGACTGGTTTACAGGCCCTGCTCC TGCAGCATGGTCCCTGCCTTAGGCCTACCTGATGGAAGTAAAGCCTCAACCACAAAAAAAAAAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA AAA
(Homo sapiens GSTM1 3' -UTR)
SEQ ID NO: 11
GGAAGCATTTTCCTGGCTGATTAAAAGAAATTACTCAGCTATGGTCATCTGTTCCTGTTAGAAGGC TATGCAGCATATTATATACTATGCGCATGTTATGAAATGCATAATAAAAAATTTTAAAAAATCTAA
A
(Mus musculus NDUFA1 3' -UTR) SEQ ID NO: 12
GGAAGCATTTTCCTGATTGATGAAAAAAATAACTCAGTTATGGCCATCTACCCCTGCTAGAAGGTT ACAGTGTATTATGTAGCATGCAATGTGTTATGTAGTGCTTAATAAAAATAAAATGAAAAAAATGCA AAAAAAAAAAAAAAAA
(Homo sapiens NDUFA1 3'-UTR)
SEQ ID NO: 13
TCTGCTCAGTTGCCGCGGACATCTGAGTGGCCTTCTTAGCCCCACCCTCAGCCAAAGCATTTACTG ATCTCGTGACTCCGCCCTCATGCTACAGCCACGCCCACCACGCAGCTCACAGTTCCACCCCCATGT TACTGTCGATCCCACAACCACTCCAGGCGCAGACCTTGTTCTCTTTGTCCACTTTGTTGGGCTCAT TTGCCTAAATAAACGGGCCACCGCGTTACCTTTAACTAT
(Mus musculus CBR2 3' -UTR)
SEQ ID NO: 14
ATGCCGGCTTACCATCTCTACCATCATCCGGTTTGGTCATCCAACAAGAAGAAATGAATATGAAAT TCCAGCAATAAGAAATGAACAAAGATTGGAGCTGAAGACCTTAAGTGCTTGCTTTTTGCCCGCTGA CCAGATAACATTAGAACTATCTGCATTATCTATGCAGCATGGGGTTTTTATTATTTTTACCTAAAG ATGTCTCTTTTTGGTAATGACAAACGTGTTTTTTAAGAAAAAAAAAAAAGGCCTGGTTTTTCTCAA TACACCTTTAACGGTTTTTAAATTGTTTCATATCTGGTCAAGTTGAGATTTTTAAGAACTTCATTT TTAATTTGTAATAAAGTTTACAACTTGATTTTTTCAAAAAAGTCAACAAACTGCAAGCACCTGTTA ATAAAGGTCTTAAATAATAA
(Mus musculus YBX1 3' -UTR)
SEQ ID NO: 15
ATGCCGGCTTACCATCTCTACCATCATCCGGTTTGGTCATCCAACAAGAAGAAATGAATATGAAAT TCCAGCAATAAGAAATGAACAAAGATTGGAGCTGAAGACCTTAAGTGCTTGCTTTTTGCCCTCTGA CCAGATAACATTAGAACTATCTGCATTATCTATGCAGCATGGGGTTTTTATTATTTTTACCTAAAG ATGTCTCTTTTTGGTAATGACAAACGTGTTTTTTAAGAAAAAAAAAAAAAAGGCCTGGTTTTTCTC AATACACCTTTAACGGTTTTTAAATTGTTTCATATCTGGTCAAGTTGAGATTTTTAAGAACTTCAT TTTTAATTTGTAATAAAGTTTACAACTTGATTTTTTCAAAAAAGTCAACAAACTGCAAGCACCTGT TAATAAAGGTCTTAAATAATAA
(Mus musculus YBX1 3' -UTR)
SEQ ID NO: 16
ATGCCGGCTTACCATCTCTACCATCATCCGGTTTAGTCATCCAACAAGAAGAAATATGAAATTCCA GCAATAAGAAATGAACAAAAGATTGGAGCTGAAGACCTAAAGTGCTTGCTTTTTGCCCGTTGACCA GATAAATAGAACTATCTGCATTATCTATGCAGCATGGGGTTTTTATTATTTTTACCTAAAGACGTC TCTTTTTGGTAATAACAAACGTGTTTTTTAAAAAAGCCTGGTTTTTCTCAATACGCCTTTAAAGGT TTTTAAATTGTTTCATATCTGGTCAAGTTGAGATTTTTAAGAACTTCATTTTTAATTTGTAATAAA AGTTTACAACTTGATTTTTTCAAAAAAGTCAACAAACTGCAAGCACCTGTTAATAAAGGTCTTAAA TAATAAAAAAAAAAAAAAA
(Homo sapiens YBX1 3' -UTR)
SEQ ID NO: 17
GGAGGCTTGATGGGCTTTTTGCCCTCGTTCCTAGAGGCTTAACCATAATAAAATCCCTAATAAAGC (Mus musculus Ndufb8 3'-UTR)
SEQ ID NO: 18
GGAGGCTTCGTGGGCTTTTGGGTCCTCTAACTAGGACTCCCTCATTCCTAGAAATTTAACCTTAAT GAAATCCCTAATAAAACTCAGTGCTGTGTTATTTGTGCCTCAAAAAAAAAAAAAAAAAA
(Homo sapiens Ndufb8 3 ' -UTR)
SEQ ID NO: 19
GTGAGGAAGAGGAGTGCTGTTCCTGCCTTCCTAGCCCAGCTGGGTCTGACCAGAGGCTACTGTGTA CCCATTTACCATGCGTGATTGTTAACTCAGAGTGGGGTGTAGCCAGGTATTGACTGAATGTATGTT CTTGCTGACCTGTGTTTTTTTCTGTAGGGACCAAAGCAGTATCCTTACAATAATCTGTACCTGGAA CGAGGCGGTGATCCCTCCAAAGAACCAGAGCGGGTGGTTCACTATGAGATCTGAGGAGGCTTCGTG GGCTTTTGGGTCCTCTAACTAGGACTCCCTCATTCCTAGAAATTTAACCTTAATGAAATCCCTAAT AAAACTCAGTGCTGTGTTATTTGTGCCTCAAAAAAAAAAAAAAAAAA
(Homo sapiens Ndufb8 3'-UTR)
SEQ ID NO: 20
TCGTTGACACTCACCATTTCTGTGAAAGACTTTTTTTTTTTTTAACATATTATACTAGATTTGACT AACTCAATCTTGTAGCTTCTGCAGTTCTCCCCACCCCCAACCTAGTTCTTAGAGTATGTTTCCCCT TTTGAAACATGTAAACATACTTTGGGCATAAATATTTTTTAAAATATAACTATAATGCTTCACTAA TACCTTAAAAATGCCTAGTGAACTAACTCAGTACATTATATAATGGCCAAGTGAAAGTTTTGTGTT TTCATGTCCTGTTTTTCTTTGAAATTATATAGCCCAGAAATTAGCTCATTATCTGAAAAACGTATA AGAACTGATGAATTGTATAATACAGGAGTATTGCCATTGAATGTACTGTTTGATTTATTCAAGCAG GTAATGAACAATGTTGTCAAACTCTCTAATGAGACATCATAATTAGGACATAAGCTAAAAGGGGCA TTACTCCGGCAGTCTTTTTTTCTTAATCCTAGTACCATACATATTCTTTGGCATGAAAGAATGAAA AGCATTAGTAAACAACTGAAGTCCTACCATGGCTCTGTAGGGTTTTTGGAACAATTCCTGGAATTG GAAAGTGAAAATGGATAGCATGTGGGGGAAACCCTCATCTGAGTAGCAAGATTTTAGTAAAGATGA CTAAGCCATTAACAGCATGCATTCATATTTAATTTTATTGACTCCTGCCATCAGCTTTTGTAGATC TTTTGGGTGGAAGGTTGTGATTTTTACTGGGAGGACTTGAGTAGAAGTGGATGATTAAAATTGAGG AGTATATAATTCTTTCTGGGACTGCTTAAATGTTATTGTTTGAAAATGCCTTCACTTTCCCCCTTT GGTCAAAGAGATGTGCTTAAAATTCTTATTCCTTCACAATAAATAATTTTGATTTTCTTAGACA
(Homo sapiens CNTNl-004 3'-UTR)
SEQ ID NO: 21
TCGTTGACACTCACCATTTCTGTGAAAGACTTTTTTTTTTTTAACATATTATACTAGATTTGACTA ACTCAATCTTGTAGCTTCTGCAGTTCTCCCCACCCCCAACCTAGTTCTTAGAGTATGTTTCCCCTT TTGAAACATGTAAACATACTTTGGGCATAAATATTTTTTAAAATATAACTATAATGCTTCACTAAT ACCTTAAAAATGCCTAGTGAACTAACTCAGTACATTATATAATGGCCAAGTGAAAGTTTTGTGTTT TCATGTCCTGTTTTTCTTTGAAATTATATAGCCCAGAAATTAGCTCATTATCTGAAAAACGTATGA AGAACTGATGAATTGTATAATACAGGAGTATTGCCATTGAATGTACTGTTTGATTTATTCAAGCAG GTAATGAACAATGTTGTCAAACTCTCTAATGAGACATCATAATTAGGACATAAGCTAAAAGGGGCA TTACTCCGGCAGTCTTTTTTTCTTAATCCTAGTACCATACATATTCTTTGGCATGAAAGAATGAAA AGCATTAGTAAACAACTGAAGTCCTACCATGGCTCTGTAGGGTTTTTGGAACAATTCCTGGAATTG GAAAGTGAAAATGGATAGCATGTGGGGGAAACCCTCATCTGAGTAGCAAGATTTTAGTAAAGATGA CTAAGCCATTAACAGCATGCATTCATATTTAATTTTATTGACTCCTGCCATCAGCTTTTGTAGATC GTTTGGGTGGAAGGTTGTGATTTTTACTGGGAGGACTTGAGTAGAAGTGGATGATTAAAATTGAGG AGTATATAATTCTTTCTGGGACTGCTTAAATGTTATTGTTTGAAAATACCTTCACTTTCCCCCTTT GGTCAAAGAGATGTGCTTAAAATTCTTATTCCTTCACAATAAATAATTTTGATTTTCTTAGACA
(Homo sapiens CNTNl-004 3'-UTR)
SEQ ID NO: 22
rrTTTTCGTTGACACTCACCATTTCTGTGAAAGACTTTTTTTTTTTTTAACATATTATACTAGATT TGACTAACTCAATCTTGTAGCTTCTGCAGTTCTCCCCACCCCCAACCTAGTTCTTAGAGTATGTTT CCCCTTTTGAAACATGTAAACATACTTTGGGCATAAATATTTTTTAAAATATAACTATAATGCTTC ACTAATACCTTAAAAATGCCTAGTGAACTAACTCAGTACATTATATAATGGCCAAGTGAAAGTTTT GTGTTTTCATGTCCTGTTTTTCTTTGAAATTATATAGCCCAGAAATTAGCTCATTATCTGAAAAAC GTATGAAGAACTGATGAATTGTATAATACAGGAGTATTGCCATTGAATGTACTGTTTGATTTATTC AAGCAGGTAATGAACAATGTTGTCAAACTCTCTAATGAGACATCATAATTAGGACATAAGCTAAAA GGGGCATTACTCCGGCAGTCTTTTTTTCTTAATCCTAGTACCATACATATTCTTTGGCATGAAAGA ATGAAAAGCATTAGTAAACAACTGAAGTCCTACCATGGCTCTGTAGGGTTTTTGGAACAATTCCTG GAATTGGAAAGTGAAAATGGATAGCATGTGGGGGAAACCCTCATCTGAGTAGCAAGATTTTAGTAA AGATGACTAAGCCATTAACAGCATGCATTCATATTTAATTTTATTGACTCCTGCCATCAGCTTTTG TAGATCTTTTGGGTGGAAGGTTGTGATTTTTACTGGGAGGACTTGAGTAGAAGTGGATGATTAAAA TTGAGGAGTATATAATTCTTTCTGGGACTGCTTAAATGTTATTGTTTGAAAATGCCTTCACTTTCC CCCTTTGGTCAAAGAGATGTGCTTAAAATTCTTATTCCTTCACAATAAATAATTTTGATTTTCTTA GACA
(Homo sapiens CNTNl-004 3'-UTR)
SEQ ID NO: 23
ATGTGTTGTGACAGCTGCTGTTCCCATCCCAGCTCAGAAGACACCCTTCAACCCTGGGATGACCAC AATTCCTTCCAATTTCTGCGGCTCCATCCTAAGCCAAATAAATTATACTTTAACAAACTATTCAAC TGATT ACAACACACATG TGACTGAGGCATTCGGGAACCCCTTCATCCAAAAGAATAAACTTTTA AATGGATATAAATGATTTTTAACTCGTTCCAATATGCCTTATAAACCACTTAACCTGATTCTGTGA CAGTTGCATGATTTAACCCAATGGGACAAGTTACAGTGTTCAATTCAATACTATAGGCTGTAGAGT GAAAGTCAAATCACCATATACAGGTGCTTTAAATTTAATAACAAGTTGTGAAATATAATAGAGATT GAAATGTTGGTTGTATGTGGTAAATGTAAGAGTAATACAGTCTCTTGTACTTTCCTCACTGTTTTG GGTACTGCATATTATTGAATGGCCCCTATCATTCATGACATCTTGAGTTTTCTTGAAAAGACAATA GAGTGTAACAAATATTTTGTCAGAAATCCCATTATCAAATCATGAGTTGAAAGATTTTGACTATTG AAAACCAAATTCTAGAACTTACTATCAGTATTCTTATTTTCAAAGGAAATAATTTTCTAAATATTT GATTTTCAGAATCAGTTTTTTAATAGTAAAGTTAACATACCATATAGATTTTTTTTTACTTTTATA TTCTACTCTGAAGTTATTTTATGCTTTTCTTATCAATTTCAAATCTCAAAAATCACAGCTCTTATC TAGAGTATCATAATATTGCTATATTTGTTCATATGTGGAGTGACAAATTTTGAAAAGTAGAGTGCT TCCTTTTTTATTGAGATGTGACAGTCTTTACATGGTTAGGAATAAGTGACAGTTAAGTGAATATCA CAATTACTAGTATGTTGGTTTTTCTGCTTCATTCCTAAGTATTACGTTTCTTTATTGCAGATGTCA GATCAAAAAGTCACCTGTAGGTTGAAAAAGCTACCGTATTCCATTTTGTAAAAATAACAATAATAA TAATAATAATAATTAGTTTTAAGCTCATTTCCCACTTCAATGCAATACTGAAAACTGGCTAAAAAT ACCAAATCAATATACTGCTAATGGTACTTTGAAGAGTATGCAAAACTGGAAGGCCAGGAGGAGGCA AATAATATGTCTTTCCGATGGTGTCTCCCAAGTGTTGGTGCTTTGGGTTTTTATAAGTTGTGAAAA GGAAGATGCACATTTCTTCATTCTCCATGGTGTGCATGGAAATGTGTTTGAGTGTGGATGTAAAAG AAATCGAGTAATAAAGAATTAGCTGGCTTGTGAAATAGTGCAGTGTTGGATGCTTCAAGAGGTATA ATCCTATTTTATTAGCACAAACTTGCTAGCTAATTAGAGTTTATCTTTTTAGAAAGGACACCGTAT AGGTTCGTAAAAAATATTTACAGGAAGCAAAATAGATCTATTACTACTTTACCGACTTTACCCCCT TTCTTTAATTTGTATAATTTTTGTACTATATATCGATGTGTAAATGTTTAGAGTCTTCATTATGAA AATATCAATAAATATTTCATTAGTTTACATTTAACTCTGGTATAAAATGAAACTTTTAAAAATAAG TGAAATGGATGATTTCCCAGTGGAAGTATGTCAACAGTCTTAAGATCATTGCCAGATTTCATAAAA TATTTAAGTATTTGAAAAAGAAACAAAATGTCTTCATACTTTAGGGAAACGAATACCCTGTATACC TTCTGTACAAATGTTTGTGTTTTCATTGTTACACTTTGGGGTTTTACTTTTGCAATGTGACCCATG TTGGGCATTTTTATATAATCAACAACTAAATCTTTTGCCAAATGCATGCTTGCCTTTTATTTTCTA ATATATGATAATAACGAGCAAAACTGGTTAGATTTTGCATGAAATGGTTCTGAAAGGTAAGAGGAA AACAGACTTTGGAGGTTGTTTAGTTTTGAATTTCTGACAGAGATAAAGTAGTTTAAAATCTCTCGT ACACTGATAACTCAAGCTTTTCATTTTCTCATACAGTTGTACAGATTTAACTGGGACCATCAGTTT TAAACTGTTGTCAAGCTAACTAATAATCATCTGCTTTAAGACGCAAGATTCTGAATTAAACTTTAT ATAGGTATAGATACATCTGTTGTTTCTTTGTATTTCAGGAAAGGTGATAGTAGTTTTATTTGATAC TGATAAATATTGAATTGATTTTTTAGTTATTTTTTATCATTTTTTCAATGGAGTAGTATAGGACTG TGCTTTGTCCTTTTTATGAATGAAAAAATTAGTATAAAGTAATAAATGTCTTATGTTACCCAAGAA AAAA
(Homo sapiens CNTNl-004 3'-UTR)
SEQ ID NO: 24
TCGTTGACACTCACCATTTCTGTGAAAGACTTTTTTTTTTTTAACATATTATACTAGATTTGACTA ACTCAATCTTGTAGCTTCTGCAGTTCTCCCCACCCCCAACCTAGTTCTTAGAGTATGTTTCCCCTT TTGAAACATGTAAACATACTTTGGGCATAAATATTTTTTAAAATATAACTATAATGCTTCACTAAT ACCTTAAAAATGCCTAGTGAACTAACTCAGTACATTATATAATGGCCAAGTGAAAGTTTTGTGTTT TCATGTCCTGTTTTTCTTTGAAATTATATAGCCCAGAAATTAGCTCATTATCTGAAAAACGTATGA AGAACTGATGAATTGTATAATACAGGAGTATTGCCATTGAATGTACTGTTTGATTTATTCAAGCAG GTAATGAACAATGTTGTCAAACTCTCTAATGAGACATCATAATTAGGACATAAGCTAAAAGGGGCA TTACTCCGGCAGTCTTTTTTTCTTAATCCTAGTACCATACATATTCTTTGGCATGAAAGAATGAAA AGCATTAGTAAACAACTGAAGTCCTACCATGGCTCTGTAGGGTTTTTGGAACAATTCCTGGAATTG GAAAGTGAAAATGGATAGCATGTGGGGGAAACCCTCATCTGAGTAGCAAGATTTTAGTAAAGATGA CTAAGCCATTAACAGCATGCATTCATATTTAATTTTATTGACTCCTGCCATCAGCTTTTGTAGATC GTTTGGGTGGAAGGTTGTGATTTTTACTGGGAGGACTTGAGTAGAAGTGGATGATTAAAATTGAGG AGTATATAATTCTTTCTGGGACTGCTTAAATGTTATTGTTTGAAAATACCTTCACTTTCCCCCTTT GGTCAAAGAGATGTGCTTAAAATTCTTATTCCTTCACAATAAATAATTTTGATTTTCTTAGACAGG TTTGTGTTTAGGTATGAGTTTCTCTTTTACTTCATCTAGCAATTCTCTCTGTGGTCAGAAGAACTC TGAAGAAAGCTTTGAGGGAAATGAATATAACTCTTAAATTATTATATGTGTGTGTATATATATAGT TTAACTTTAAAAATAATTTATTAGTCATCATAAAGAAATAAATGTCTCTGGCTCAAGATGTTACTT ATTTCCTTCTTTTATATTTTCTAGTCTCAATTACTGTTCCAAAAGGAGCTATCTTAGAACTTAGAC TAGAGATCCAGATT A
(Homo sapiens CNTNl-004 3'-UTR)
Preferably, the at least one 5'-UTR element of the artificial nucleic acid molecule according to the present invention comprises or consists of a nucleic acid sequence which has an identity of at least about 40%, preferably of at least about 50%, preferably of at least about 60%, preferably of at least about 70%, more preferably of at least about 80%, more preferably of at least about 90%, even more preferably of at least about 95%, even more preferably of at least about 99%, most preferably of 100% to the 5'-UTR sequence of a transcript of MP68 (RIKEN CDNA 2010107E04 gene), or NDUFA4 (NADH dehydrogenase (ubiquinone) 1 alpha subcomplex 4). Most preferably, the at least one 5'-UTR element of the artificial nucleic acid molecule according to the present invention comprises or consists of a nucleic acid sequence which has an identity of at least about 40%, preferably of at least about 50%, preferably of at least about 60%, preferably of at least about 70%, more preferably of at least about 80%, more preferably of at least about 90%, even more preferably of at least about 95%, even more preferably of at least about 99%, most preferably of 100% to a sequence according to SEQ ID NO: 25 or SEQ ID NO: 30, or the corresponding RNA sequence, respectively:
SEQ ID NO: 25
CTTTCCCATTCTGTAGCAGAATTTGGTGTTGCCTGTGGTCTTGGTCCCGCGGAG
(Mus musculus MP68 5' -UTR)
SEQ ID NO: 26
CTTCCCGGCATCCCCTGCGCGCGCCTGCGCGCTCGGTGACCTTTCCGAGTTGGCTGCAGATTTGTG GTGCGTTCTGAGCCGTCTGTCCTGCGCCAAG
(Homo sapiens MP68 5' -UTR)
SEQ ID NO: 27
CTTCCCGGCATCCCCTGCGCGCGCCTGCGCGCTCGGTGACCTTTCCGAGTTGGCTGCAGATTTGTG GTGCGTTCTGAGCCGTCTGTCCTGCGCCAAGGGAGCGTACCTTGGCCTTGAGAGGTTCAGCTGCCT AACCCAGAGGCTACGCAGAGTTAGAGAAGCCAGAGTCCAAGCCAAGAACTCTGACTCCACATCCAG TCCCTTCTCTCCTTTATAACTCAAGTTTCCTTGCGCCACACTGCCCTCCACGTTATGCTGTACATG ACAACTTGGGTGAGGCAACAGGGAAGCTGAAAAGAGATCATACGGTGCTGA
(Homo sapiens MP68 5' -UTR)
SEQ ID NO: 28
GTCCGCTCAGCCAGGTTGCAGAAGCGGCTTAGCGTGTGTCCTAATCTTCTCTCTGCGTGTAGGTA GGCCTGTGCCGCAAAC
(Mus musculus NDUFA4 5' -UTR)
SEQ ID NO: 29
GUCCGCUCAGCCAGGUUGCAGAAGCGGCUUAGCGUGUGUCCUAAUCUUCUCUCUGCGUGUAGGUA GGCCUGUGCCGCAAAC
(Homo sapiens NDUFA4 5' -UTR)
SEQ ID NO: 30
GGGTCCTTCAGGTAGGAGGTCCTGGGTGACTTTGGAAGTCCGTAGTGTCTCATTGCAGATAATTTT TAGCTTAGGGCCTGGTGGCTAGGTCGGTTCTCTCCTTTCCAGTCGGAGACCTCTGCCGCAAAC
(Homo sapiens NDUFA4 5' -UTR)
The at least one 3'-UTR element of the artificial nucleic acid molecule according to the present invention may also comprise or consist of a fragment of a nucleic acid sequence which has an identity of at least about 40%, preferably of at least about 50%, preferably of at least about 60%, preferably of at least about 70%, more preferably of at least about 80%, more preferably of at least about 90%, even more preferably of at least about 95%, even more preferably of at least about 99%, most preferably of 1 00% to the nucleic acid sequence of the 3'-UTR of a transcript of a gene, such as to the 3'-UTR of a sequence according to SEQ ID NOs: 1 to 24 and SEQ ID NOs: 49 to 31 8, wherein the fragment is preferably a functional fragment or a functional variant fragment as described above. Such fragment preferably exhibits a length of at least about 3 nucleotides, preferably of at least about 5 nucleotides, more preferably of at least about 1 0, 1 5, 20, 25 or 30 nucleotides, even more preferably of at least about 50 nucleotides, most preferably of at least about 70 nucleotides. In a preferred embodiment, the fragment or variant thereof exhibits a length of between 3 and about 500 nucleotides, preferably of between 5 and about 1 50 nucleotides, more preferably of between 1 0 and 1 00 nucleotides, even more preferably of between 1 5 and 90, most preferably of between 20 and 70. Preferably, said variants, fragments or variant fragments are functional variants, functional fragments, or functional variant fragments of the 3'-UTR, prolong protein production from the artificial nucleic acid molecule according to the invention with an efficiency of at least 30%, preferably with an efficiency of at least 40%, more preferably of at least 50%, more preferably of at least 60%, even more preferably of at least 70%, even more preferably of at least 80%, most preferably of at least 90% of the protein production prolonging efficiency exhibited by an artificial nucleic acid molecule comprising the nucleic acid sequence selected from the group consisting of SEQ ID NO: 1 to SEQ ID NO: 24.
The at least one 5'-UTR element of the artificial nucleic acid molecule according to the present invention may also comprise or consist of a fragment of a nucleic acid sequence which has an identity of at least about 40%, preferably of at least about 50%, preferably of at least about 60%, preferably of at least about 70%, more preferably of at least about 80%, more preferably of at least about 90%, even more preferably of at least about 95%, even more preferably of at least about 99%, most preferably of 1 00% to the nucleic acid sequence of the 5'-UTR of a transcript of a gene, such as to the 5'-UTR of a sequence according to SEQ ID NO: 25 or SEQ ID NO: 30 and SEQ ID NOs: 31 9 to 382, wherein the fragment is preferably a functional fragment or a functional variant fragment as described above. Such fragment preferably exhibits a length of at least about 3 nucleotides, preferably of at least about 5 nucleotides, more preferably of at least about 1 0, 1 5, 20, 25 or 30 nucleotides, even more preferably of at least about 50 nucleotides, most preferably of at least about 70 nucleotides. In a preferred embodiment, the fragment or variant thereof exhibits a length of between 3 and about 500 nucleotides, preferably of between 5 and about 1 50 nucleotides, more preferably of between 1 0 and 1 00 nucleotides, even more preferably of between 15 and 90, most preferably of between 20 and 70. Preferably, said variants, fragments or variant fragments are functional variants, functional fragments, or functional variant fragments of the 5'-UTR, increase protein production from the artificial nucleic acid molecule according to the invention with an efficiency of at least 30%, preferably with an efficiency of at least 40%, more preferably of at least 50%, more preferably of at least 60%, even more preferably of at least 70%, even more preferably of at least 80%, most preferably of at least 90% of the protein production increasing efficiency exhibited by an artificial nucleic acid molecule comprising the nucleic acid sequence selected from the group consisting of SEQ ID NO: 25 to SEQ ID NO: 30. Preferably, the at least one 3'-UTR element and/or the at least one 5'-UTR element of the artificial nucleic acid molecule according to the present invention exhibits a length of at least about 3 nucleotides, preferably of at least about 5 nucleotides, more preferably of at least about 10, 1 5, 20, 25 or 30 nucleotides, even more preferably of at least about 50 nucleotides, most preferably of at least about 70 nucleotides. The upper limit for the length of the at least one 3'-UTR element and/or the at least one 5'-UTR element may be 500 nucleotides or less, e.g. 400, 300, 200, 1 50 or 1 00 nucleotides. For other embodiments the upper limit may be chosen within the range of 50 to 1 00 nucleotides. For example, the fragment or variant thereof may exhibit a length of between 3 and about 500 nucleotides, preferably of between 5 and about 1 50 nucleotides, more preferably of between 10 and 1 00 nucleotides, even more preferably of between 1 5 and 90, most preferably of between 20 and 70.
Furthermore, the artificial nucleic acid molecule according to the present invention may comprise more than one 3'-UTR elements and/or more than one 5'-UTR elements as described above. For example, the artificial nucleic acid molecule according to the present invention may comprise one, two, three, four or more 3'-UTR elements, and/or one, two, three, four or more 5'-UTR elements, wherein the individual 3'-UTR elements may be the same or they may be different, and similarly, the individual 5'-UTR elements may be the same or they may be different. For example, the artificial nucleic acid molecule according to the present invention may comprise two essentially identical 3'-UTR elements as described above, e.g. two 3'-UTR elements comprising or consisting of a nucleic acid sequence, which is derived from the 3'-UTR of a transcript of a gene, such as from a sequence according to SEQ ID NOs: 1 to 24 and SEQ ID NO: 49 to 31 8, or from a fragment or variant of the 3'-UTR of a transcript of a gene, functional variants thereof, functional fragments thereof, or functional variant fragments thereof as described above. Accordingly, for example, the artificial nucleic acid molecule according to the present invention may comprise two essentially identical 5'- UTR elements as described above, e.g. two 5'-UTR elements comprising or consisting of a nucleic acid sequence, which is derived from the 5'-UTR of a transcript of a gene, such as from a sequence according to SEQ ID NOs: 25 to 30 and SEQ ID NO: 31 9 to 382, or from a fragment or variant of the 5'-UTR of a transcript of a gene, functional variants thereof, functional fragments thereof, or functional variant fragments thereof as described above.
Surprisingly, the inventors found that an artificial nucleic acid molecule comprising a 3'-UTR element as described above and/or a 5'-UTR element as described above may represent or may provide an mRNA molecule, which allows for increased, prolonged and/or stabilized protein production. Thus, a 3'-UTR element as described herein and/or a 5'-UTR element as described herein may improve stability of protein expression from an mRNA molecule and/or improve translational efficiency.
In particular, the artificial nucleic acid molecule according to the invention may comprise (i) at least one 3'-UTR element and at least one 5'-UTR element, which prolongs and/or increases protein production; (ii) at least one 3'-UTR element, which prolongs and/or increases protein production, but no 5'-UTR element, which prolongs and/or increases protein production; or (iii) at least one 5'-UTR element, which prolongs and/or increases protein production, but no 3'-UTR element, which prolongs and/or increases protein production.
However, in particular in case (ii) and (i ii), but possibly also in case (i), the artificial nucleic acid molecule according to the present invention may further comprise one or more "further 3'-UTR elements and/or 5'-UTR elements", i.e. 3'-UTR elements and/or 5'-UTR elements which do not fulfil the requirements as described above. For example, an artificial nucleic acid molecule according to the invention, which comprises a 3'-UTR element according to the present invention, i .e. a 3'-UTR element which prolongs and/or increases protein production from said artificial nucleic acid molecule, may additional ly comprise any further 3'-UTR and/or any further 5'-UTR, in particular a further 5'-UTR, e.g. a 5'-TOP UTR, or any other 5'-UTR or 5'-UTR element. Similarly for example, an artificial nucleic acid molecule according to the invention, which comprises a 5'-UTR element according to the present invention, i.e. a 5'-UTR element which prolongs and/or increases protein production from said artificial nucleic acid molecule, may additionally comprise any further 3'-UTR and/or any further 5'-UTR, in particular a further 3'-UTR, e.g. a 3'-UTR derived from a 3'-UTR of an albumin gene, particularly preferably a 3'-UTR comprising a sequence according to SEQ ID NO. 31 or 32, in particular to SEQ ID NO. 32, or any other 3'-UTR or 3'-UTR element.
If additionally to the inventive at least one 5'-UTR element and/or to the inventive at least one 3'-UTR element, which prolongs and/or increases protein production, a further 3'-UTR (element) and/ or a further 5'-UTR (element) are present in the artificial nucleic acid molecule according to the invention, the further 5'-UTR (element) and/or the further 3'-UTR (element) may interact with the inventive 3'-UTR element and/or inventive 5'-UTR element and, thus, support the increasing and/or prolonging effect of the inventive 3'-UTR element and/or of the inventive 5'-UTR element, respectively. Such further 3'-UTR and/or 5'-UTR (elements) may further support stability and translational efficiency. Moreover, if both, an inventive 3'-UTR element and an inventive 5'-UTR element are present in the artificial nucleic acid molecule according to the invention, the prolonging and/or increasing effect of the inventive 5'-UTR element and the inventive 3'-UTR element result preferably in enhanced and prolonged protein production in a synergistic way. Preferably, the further 3'-UTR comprises or consists of a nucleic acid sequence which is derived from a 3'-UTR of a gene selected from the group consisting of an albumin gene, an a-globin gene, a β-globin gene, a tyrosine hydroxylase gene, a lipoxygenase gene, and a col lagen alpha gene, such as a collagen alpha 1 (1) gene, or from a variant of a 3'-UTR of a gene selected from the group consisting of an albumin gene, an a-globin gene, a β-globin gene, a tyrosine hydroxylase gene, a lipoxygenase gene, and a collagen alpha gene, such as a collagen alpha 1 (1) gene according to SEQ ID No. 1 369-1 390 of the patent application WO201 3/1 43700 whose disclosure is incorporated herein by reference. In a particularly preferred embodiment, the further 3'-UTR comprises or consists of a nucleic acid sequence which is derived from a 3'-UTR of an albumin gene, preferably a vertebrate albumin gene, more preferably a mammalian albumin gene, most preferably a human albumin gene according to SEQ ID NO. 31 : SEQ ID NO. 31:
CATCACATTT AAAAGCATCT CAGCCTACCA TGAGAATAAG AGAAAGAAAA TGAAGATCAA AAGCTTATTC ATCTGTTTTT CTTTTTCGTT GGTGTAAAGC CAACACCCTG TCTAAAAAAC ATAAATTTCT TTAATCATTT TGCCTCTTTT CTCTGTGCTT CAATTAATAA AAAATGGAAA GAATCT
(Human albumin 3'-UTR; corresponding to SEQ ID No: 1369 of the patent application WO2013/143700)
In this context it is particularly preferred that the inventive nucleic acid molecule comprises a further 3'-UTR element derived from the nucleic acids according to SEQ ID No. 1369-1390 of the patent application WO2013/143700 or a fragment, homolog or variant thereof.
Most preferably the further 3'-UTR comprises the nucleic acid sequence derived from a fragment of the human albumin gene according to SEQ ID NO. 32: SEQ ID NO. 32:
CATCACATT AAAAGCATCTCAGCC ACCATGAG ATAAGAGAAAGAAAATGAAGATCAATAGCTT
ATTCATCTCTTTTTCTTTTTCGTTGGTGTAAAGCCAACACCCTGTCTAAAAAACATAAATTTCTTT
AATCATTTTGCCTCTTTTCTCTGTGCTTCAATTAATAAAAAATGGAAAGAACCT
(albumin7 3'-UTR; corresponding to SEQ ID No: 1376 of the patent application WO2013/143700)
In this context it is particularly preferred that the further 3'-UTR of the inventive artificial nucleic acid molecule comprises or consists of the nucleic acid sequence according to SEQ ID NO. 32, or a corresponding RNA sequence.
The further 3'-UTR may also comprise or consist of a nucleic acid sequence derived from a ribosomal protein coding gene, whereby ribosomal protein coding genes from which a further 3'-UTR may be derived include, but are not limited to, ribosomal protein L9 (RPL9), ribosomal protein L3 (RPL3), ribosomal protein L4 (RPL4), ribosomal protein L5 (RPL5), ribosomal protein L6 (RPL6), ribosomal protein L7 (RPL7), ribosomal protein L7a (RPL7A), ribosomal protein L1 1 (RPL1 1 ), ribosomal protein L12 (RPL12), ribosomal protein L13 (RPL13), ribosomal protein L23 (RPL23), ribosomal protein L18 (RPL18), ribosomal protein L18a (RPL18A), ribosomal protein L19 (RPL19), ribosomal protein L21 (RPL21), ribosomal protein L22 (RPL22), ribosomal protein L23 a (RPL23A), ribosomal protein L17 (RPL17), ribosomal protein L24 (RPL24), ribosomal protein L26 (RPL26), ribosomal protein L27 (RPL27), ribosomal protein L30 (RPL30), ribosomal protein L27a (RPL27A), ribosomal protein L28 (RPL28), ribosomal protein L29 (RPL29), ribosomal protein L31 (RPL31), ribosomal protein L32 (RPL32), ribosomal protein L35a (RPL35A), ribosomal protein L37 (RPL37), ribosomal protein L37a (RPL37A), ribosomal protein L38 (RPL38), ribosomal protein L39 (RPL39), ribosomal protein, large, P0 (RPLPO), ribosomal protein, large, P1 (RPLP1), ribosomal protein, large, P2 (RPLP2), ribosomal protein S3 (RPS3), ribosomal protein S3A (RPS3A), ribosomal protein S4, X- linked (RPS4X), ribosomal protein S4, Y-linked 1 (RPS4Y1), ribosomal protein S5 (RPS5), ribosomal protein S6 (RPS6), ribosomal protein S7 (RPS7), ribosomal protein S8 (RPS8), ribosomal protein S9 (RPS9), ribosomal protein S10 (RPS10), ribosomal protein S11 (RPS11), ribosomal protein S12 (RPS12), ribosomal protein S13 (RPS13), ribosomal protein S15 (RPS15), ribosomal protein S15a (RPS15A), ribosomal protein S16 (RPS16), ribosomal protein S19 (RPS19), ribosomal protein S20 (RPS20), ribosomal protein S21 (RPS21), ribosomal protein S23 (RPS23), ribosomal protein S25 (RPS25), ribosomal protein S26 (RPS26), ribosomal protein S27 (RPS27), ribosomal protein S27a (RPS27a), ribosomal protein S28 (RPS28), ribosomal protein S29 (RPS29), ribosomal protein L15 (RPL15), ribosomal protein S2 (RPS2), ribosomal protein L14 (RPL14), ribosomal protein S14 (RPS14), ribosomal protein L10 (RPL10), ribosomal protein LI 0a (RPL10A), ribosomal protein L35 (RPL35), ribosomal protein L13a (RPL13A), ribosomal protein L36 (RPL36), ribosomal protein L36a (RPL36A), ribosomal protein L41 (RPL41), ribosomal protein S18 (RPS18), ribosomal protein S24 (RPS24), ribosomal protein L8 (RPL8), ribosomal protein L34 (RPL34), ribosomal protein S17 (RPS17), ribosomal protein SA (RPSA), ubiquitin A-52 residue ribosomal protein fusion product 1 (UBA52), Finkel-Biskis-Reilly murine sarcoma virus (FBR- MuSV) ubiquitously expressed (FAU), ribosomal protein L22-like 1 (RPL22L1), ribosomal protein S17 (RPS17), ribosomal protein L39-like (RPL39L), ribosomal protein LI 0-1 ike (RPL10L), ribosomal protein L36a-like (RPL36AL), ribosomal protein L3-like (RPL3L), ribosomal protein S27-like (RPS27L), ribosomal protein L26-like 1 (RPL26L1), ribosomal protein L7-like 1 (RPL7L1), ribosomal protein L13a pseudogene (RPL13AP), ribosomal protein L37a pseudogene 8 (RPL37AP8), ribosomal protein S10 pseudogene 5 (RPS10P5), ribosomal protein S26 pseudogene 1 1 (RPS26P1 1 ), ribosomal protein L39 pseudogene 5 (RPL39P5), ribosomal protein, large, P0 pseudogene 6 (RPLP0P6) and ribosomal protein L36 pseudogene 14 (RPL36P14).
Preferably, the further 5'-UTR comprises or consists of a nucleic acid sequence which is derived from the 5'-UTR of a TOP gene or which is derived from a fragment, homolog or variant of the 5'-UTR of a TOP gene. It is particularly preferred that the 5'-UTR element does not comprise a TOP-motif or a 5'TOP, as defined above. In particular, it is preferred that a 5'-UTR of a TOP gene is a 5'-UTR of a TOP gene lacking the TOP motif.
The nucleic acid sequence which is derived from the 5'-UTR of a TOP gene is derived from a eukaryotic TOP gene, preferably a plant or animal TOP gene, more preferably a chordate TOP gene, even more preferably a vertebrate TOP gene, most preferably a mammalian TOP gene, such as a human TOP gene.
For example, the further 5'-UTR is preferably selected from 5'-UTR elements comprising or consisting of a nucleic acid sequence which is derived from a nucleic acid sequence selected from the group consisting of SEQ ID NOs. 1 -1363, SEQ ID NO. 1395, SEQ ID NO. 1421 and SEQ ID NO. 1422 of the patent application WO2013/143700 whose disclosure is incorporated herein by reference, from the homologs of SEQ ID NOs. 1 -1363, SEQ ID NO. 1395, SEQ ID NO. 1421 and SEQ ID NO. 1422 of the patent application WO2013/143700, from a variant thereof, or preferably from a corresponding RNA sequence. The term "homologs of SEQ ID NOs. 1 -1363, SEQ ID NO. 1395, SEQ ID NO. 1421 and SEQ ID NO. 1422 of the patent application WO2013/143700" refers to sequences of other species than homo sapiens, which are homologous to the sequences according to SEQ ID NOs. 1 -1363, SEQ ID NO. 1395, SEQ ID NO. 1421 and SEQ ID NO. 1422 of the patent application WO2013/143700.
In a preferred embodiment, the further 5'-UTR comprises or consists of a nucleic acid sequence which is derived from a nucleic acid sequence extending from nucleotide position 5 (i.e. the nucleotide that is located at position 5 in the sequence) to the nucleotide position immediately 5' to the start codon (located at the 3' end of the sequences), e.g. the nucleotide position immediately 5' to the ATG sequence, of a nucleic acid sequence selected from SEQ ID NOs. 1 -1363, SEQ ID NO. 1395, SEQ ID NO. 1421 and SEQ ID NO. 1422 of the patent application W02013/143700, from the homologs of SEQ ID NOs. 1 -1 363, SEQ ID NO. 1395, SEQ ID NO. 1421 and SEQ ID NO. 1422 of the patent application W02013/143700, from a variant thereof, or a corresponding RNA sequence. It is particularly preferred that the further 5'-UTR is derived from a nucleic acid sequence extending from the nucleotide position immediately 3' to the 5'TOP to the nucleotide position immediately 5' to the start codon (located at the 3' end of the sequences), e.g. the nucleotide position immediately 5' to the ATG sequence, of a nucleic acid sequence selected from SEQ ID NOs. 1 -1363, SEQ ID NO. 1395, SEQ ID NO. 1421 and SEQ ID NO. 1422 of the patent application W02013/143700, from the homologs of SEQ ID NOs. 1 -1363, SEQ ID NO. 1395, SEQ ID NO. 1421 and SEQ ID NO. 1422 of the patent application WO2013/143700, from a variant thereof, or a corresponding RNA sequence.
In a particularly preferred embodiment, the further 5'-UTR comprises or consists of a nucleic acid sequence which is derived from a 5'-UTR of a TOP gene encoding a ribosomal protein or from a variant of a 5'-UTR of a TOP gene encoding a ribosomal protein. For example, the 5'-UTR element comprises or consists of a nucleic acid sequence which is derived from a 5'- UTR of a nucleic acid sequence according to any of SEQ ID NOs: 1 70, 232, 244, 259, 1284, 1285, 1286, 1287, 1288, 1289, 1290, 1291 , 1292, 1293, 1294, 1295, 1296, 1297, 1298, 1299, 1300, 1301 , 1302, 1303, 1304, 1305, 1 306, 1307, 1308, 1309, 1310, 131 1 , 1312, 1 313, 1314, 131 5, 131 6, 131 7, 1318, 1319, 1320, 1321 , 1322, 1 323, 1324, 1325, 1326, 1327, 1328, 1329, 1330, 1331 , 1332, 1333, 1 334, 1335, 1336, 1337, 1338, 1339, 1340, 1341 , 1342, 1 343, 1344, 1346, 1 347, 1348, 1349, 1350, 1351 , 1352, 1353, 1354, 1355, 1356, 1357, 1358, 1359, or 1360 of the patent application W02013/143700, a corresponding RNA sequence, a homolog thereof, or a variant thereof as described herein, preferably lacking the 5'-TOP motif. As described above, the sequence extending from position 5 to the nucleotide immediately 5' to the ATG (which is located at the 3'end of the sequences) corresponds to the 5'-UTR of said sequences. Preferably, the further 5'-UTR comprises or consists of a nucleic acid sequence which is derived from a 5'-UTR of a TOP gene encoding a ribosomal Large protein (RPL) or from a homolog or variant of a 5'-UTR of a TOP gene encoding a ribosomal Large protein (RPL). For example, the 5'-UTR element comprises or consists of a nucleic acid sequence which is derived from a 5'-UTR of a nucleic acid sequence according to any of SEQ ID NOs: SEQ ID NOs: 67, 259, 1284-131 8, 1344, 1346, 1348-1354, 1357, 1358, 1421 and 1422 of the patent application WO201 3/143700, a corresponding RNA sequence, a homolog thereof, or a variant thereof as described herein, preferably lacking the 5'TOP motif. In a particularly preferred embodiment, the 5'-UTR element comprises or consists of a nucleic acid sequence which is derived from the 5'-UTR of a ribosomal protein Large 32 gene, preferably from a vertebrate ribosomal protein Large 32 (L32) gene, more preferably from a mammalian ribosomal protein Large 32 (L32) gene, most preferably from a human ribosomal protein Large 32 (L32) gene, or from a variant of the 5'-UTR of a ribosomal protein Large 32 gene, preferably from a vertebrate ribosomal protein Large 32 (L32) gene, more preferably from a mammalian ribosomal protein Large 32 (L32) gene, most preferably from a human ribosomal protein Large 32 (L32) gene, wherein preferably the further 5'-UTR does not comprise the 5'TOP of said gene. Accordingly, in a particularly preferred embodiment, the further 5'-UTR comprises or consists of a nucleic acid sequence which has an identity of at least about 40%, preferably of at least about 50%, preferably of at least about 60%, preferably of at least about 70%, more preferably of at least about 80%, more preferably of at least about 90%, even more preferably of at least about 95%, even more preferably of at least about 99% to the nucleic acid sequence according to SEQ ID NO. 33 (5'-UTR of human ribosomal protein Large 32 lacking the 5' terminal oligopyrimidine tract:
GGCGCTGCCTACGGAGGTGGCAGCCATCTCCTTCTCGGCATC (SEQ ID NO. 33);
corresponding to SEQ ID NO. 1368 of the patent application WO2013/143700) or preferably to a corresponding RNA sequence, or wherein the further 5'-UTR comprises or consists of a fragment of a nucleic acid sequence which has an identity of at least about 40%, preferably of at least about 50%, preferably of at least about 60%, preferably of at least about 70%, more preferably of at least about 80%, more preferably of at least about 90%, even more preferably of at least about 95%, even more preferably of at least about 99% to the nucleic acid sequence according to SEQ ID NO. 33 or more preferably to a corresponding RNA sequence, wherein, preferably, the fragment is as described above, i.e. being a continuous stretch of nucleotides representing at least 20% etc. of the full-length 5'-UTR. Preferably, the fragment exhibits a length of at least about 20 nucleotides or more, preferably of at least about 30 nucleotides or more, more preferably of at least about 40 nucleotides or more. Preferably, the fragment is a functional fragment as described herein.
In some embodiments, the artificial nucleic acid molecule comprises a further 5'-UTR which comprises or consists of a nucleic acid sequence which is derived from the 5'-UTR of a vertebrate TOP gene, such as a mammalian, e.g. a human TOP gene, selected from RPSA, RPS2, RPS3, RPS3A, RPS4, RPS5, RPS6, RPS7, RPS8, RPS9, RPS10, RPS1 1 , RPS12, RPS13, RPS14, RPS15, RPS1 5A, RPS1 6, RPS1 7, RPS1 8, RPS1 9, RPS20, RPS21 , RPS23, RPS24, RPS25, RPS26, RPS27, RPS27A, RPS28, RPS29, RPS30, RPL3, RPL4, RPL5, RPL6, RPL7, RPL7A, RPL8, RPL9, RPL10, RPL10A, RPL1 1 , RPL12, RPL13, RPL1 3A, RPL14, RPL15, RPL1 7, RPL18, RPL18A, RPL19, RPL21 , RPL22, RPL23, RPL23A, RPL24, RPL26, RPL27, RPL27A, RPL28, RPL29, RPL30, RPL31 , RPL32, RPL34, RPL35, RPL35A, RPL36, RPL36A, RPL37, RPL37A, RPL38, RPL39, RPL40, RPL41 , RPLP0, RPLP1 , RPLP2, RPLP3, RPLP0, RPLP1 , RPLP2, EEF1 A1 , EEF1 B2, EEF1 D, EEF1 G, EEF2, EIF3E, EIF3F, EIF3H, EIF2S3, EIF3C, EIF3K, EIF3EIP, EIF4A2, PABPC1 , HNRNPA1 , TPT1 , TUBB1 , UBA52, NPM1 , ATP5G2, GNB2L1 , NME2, UQCRB or from a homolog or variant thereof, wherein preferably the further 5'-UTR does not comprise a TOP-motif or the 5'TOP of said genes, and wherein optionally the further 5'-UTR starts at its 5'-end with a nucleotide located at position 1 , 2, 3, 4, 5, 6, 7, 8, 9 or 10 downstream of the 5'terminal oligopyrimidine tract (TOP) and wherein further optionally the further 5'-UTR which is derived from a 5'-UTR of a TOP gene terminates at its 3'-end with a nucleotide located at position 1 , 2, 3, 4, 5, 6, 7, 8, 9 or 10 upstream of the start codon (A(U/T)G) of the gene it is derived from.
The artificial nucleic acid molecule according to the present invention may be RNA, such as mRNA or viral RNA or a replicon, DNA, such as a DNA plasmid or viral DNA, or may be a modified RNA or DNA molecule. It may be provided as a double-stranded molecule having a sense strand and an anti-sense strand, for example, as a DNA molecule having a sense strand and an anti-sense strand. The artificial nucleic acid molecule according to the present invention may further comprise optionally a 5'-cap. The optional 5'-cap is preferably located 5' to the ORF, more preferably 5' to the at least one 5'-UTR or to any further 5'-UTR within the artificial nucleic acid molecule according to the present invention.
Preferably, the artificial nucleic acid molecule according to the present invention further comprises a poly(A) sequence and/or a polyadenylation signal. Preferably, the optional poly(A) sequence is located 3' to the at least one 3'-UTR element or to any further 3'-UTR, more preferably the optional poly(A) sequence is connected to the 3'-end of an 3'-UTR element. The connection may be direct or indirect, for example, via a stretch of 2, 4, 6, 8, 1 0, 20 etc. nucleotides, such as via a linker of 1 -50, preferably of 1 -20 nucleotides, e.g. comprising or consisting of one or more restriction sites. However, even if the artificial nucleic acid molecule according to the present invention does not comprise a 3'-UTR, for example if it only comprises at least one 5'-UTR element, it preferably still comprises a poly(A) sequence and/or a polyadenylation signal.
In one embodiment, the optional polyadenylation signal is located downstream of the 3' of the 3'-UTR element. Preferably, the polyadenylation signal comprises the consensus sequence NN(U/T)ANA, with N = A or U, preferably AA(U T)AAA or A(U T)(U T)AAA. Such consensus sequence may be recognised by most animal and bacterial cell-systems, for example by the polyadenylation-factors, such as cleavage/polyadenylation specificity factor (CPSF) cooperating with CstF, PAP, PAB2, CFl and/or CFII. Preferably, the polyadenylation signal, preferably the consensus sequence NNUANA, is located less than about 50 nucleotides, more preferably less than about 30 bases, most preferably less than about 25 bases, for example 21 bases, downstream of the 3'-end of the 3'-UTR element or of the ORF, if no 3'-UTR element is present.
Transcription of an artificial nucleic acid molecule according to the present invention, e.g. of an artificial DNA molecule, comprising a polyadenylation signal downstream of the 3'-UTR element (or of the ORF) wi ll result in a premature-RNA containing the polyadenylation signal downstream of its 3'-UTR element (or of the ORF). Using an appropriate transcription system will then lead to attachment of a poly(A) sequence to the premature-RNA. For example, the inventive artificial nucleic acid molecule may be a DNA molecule comprising a 3'-UTR element as described above and a polyadenylation signal, which may result in polyadenylation of an RNA upon transcription of this DNA molecule. Accordingly, a resulting RNA may comprise a combination of the inventive 3'-UTR element fol lowed by a poly(A) sequence.
Potential transcription systems are in vitro transcription systems or cellular transcription systems etc. Accordingly, transcription of an artificial nucleic acid molecule according to the invention, e.g. transcription of an artificial nucleic acid molecule comprising an open reading frame, a 3'-UTR element and/or a 5'-UTR element and optionally a polyadenylation-signal, may result in an mRNA molecule comprising an open reading frame, a 3'-UTR element and optionally a poly(A) sequence. Accordingly, the invention also provides an artificial nucleic acid molecule, which is an mRNA molecule comprising an open reading frame, a 3'-UTR element as described above and/or a 5'-UTR element as described above and optionally a poly(A) sequence.
In another embodiment, the 3'-UTR of the artificial nucleic acid molecule according to the invention does not comprise a polyadenylation signal or a poly(A) sequence. Further preferably, the artificial nucleic acid molecule according to the invention does not comprise a polyadenylation signal or a poly(A) sequence. More preferably, the 3'-UTR of the artificial nucleic acid molecule, or the inventive artificial nucleic acid molecule as such, does not comprise a polyadenylation signal, in particular it does not comprise the polyadenylation signal AAU/TAAA.
In a preferred embodiment, the invention provides an artificial nucleic acid molecule which is an artificial RNA molecule comprising an open reading frame and an RNA sequence corresponding to a DNA sequence selected from the group consisting of sequences according to SEQ ID NOs: 1 to 30, preferably from the group consisting of sequences according to SEQ ID NO. 1 , SEQ ID NO. 5, SEQ ID NO. 8, SEQ ID NO. 1 1 , SEQ ID NO. 1 3, SEQ ID NO. 14, SEQ ID NO. 1 7, SEQ ID NO. 20, SEQ ID NO. 25 and SEQ ID NO. 28, or sequences having an identity of at least about 40 % or more to SEQ ID NOs: 1 to 30, preferably to SEQ ID NO. 1 , SEQ ID NO. 5, SEQ ID NO. 8, SEQ ID NO. 1 1 , SEQ ID NO. 13, SEQ ID NO. 14, SEQ ID NO. 1 7, SEQ ID NO. 20, SEQ ID NO. 25 and SEQ ID NO. 28 or a fragment thereof as described above. Moreover, a corresponding artificial DNA molecule is also provided.
In another preferred embodiment, the invention provides an artificial nucleic acid molecule which is an artificial DNA molecule comprising an open reading frame and a sequence selected from the group consisting of sequences according to SEQ ID NOs: 1 to 30, preferably from the group consisting of sequences according to SEQ ID NO. 1 , SEQ ID NO. 5, SEQ ID NO. 8, SEQ ID NO. 1 1 , SEQ ID NO. 13, SEQ ID NO. 14, SEQ ID NO. 1 7, SEQ ID NO. 20, SEQ ID NO. 25 and SEQ ID NO. 28, or sequences having an identity of at least about 40 % or more to SEQ ID NOs: 1 to 30, preferably to SEQ ID NO. 1 , SEQ ID NO. 5, SEQ ID NO. 8, SEQ ID NO. 1 1 , SEQ ID NO. 13, SEQ ID NO. 14, SEQ ID NO. 1 7, SEQ ID NO. 20, SEQ ID NO. 25 and SEQ ID NO. 28.
Accordingly, the invention provides an artificial nucleic acid molecule which may serve as a template for an RNA molecule, preferably for an mRNA molecule, which is stabilised and optimized with respect to translation efficiency. In other words, the artificial nucleic acid molecule may be a DNA which may be used as a template for production of an mRNA. The obtainable mRNA, may, in turn, be translated for production of a desired peptide or protein encoded by the open reading frame. If the artificial nucleic acid molecule is a DNA, it may, for example, be used as a double-stranded storage form for continued and repetitive in vitro or in vivo production of mRNA. Thereby, in vitro refers in particular to ("living") cells and/or tissue, including tissue of a living subject. Cells include in particular cell lines, primary cells, cells in tissue or subjects. In specific embodiments cell types allowing cell culture may be suitable for the present invention. Particularly preferred are mammalian cells, e.g. human cells and mouse cells. In particularly preferred embodiments the human cell lines HeLa, and U-937 and the mouse cell lines NIH3T3, JAWSII and L929 are used. Furthermore primary cells are particularly preferred, in particular preferred embodiments human dermal fibroblasts (HDF) may be used. Alternatively also a tissue of a subject may be used.
In one embodiment, the artificial nucleic acid molecule according to the present invention further comprises a poly(A) sequence. For example, a DNA molecule comprising an ORF, optionally followed by a 3' UTR, may contain a stretch of thymidine nucleotides which can be transcribed into a poly(A) sequence in the resulting mRNA. The length of the poly(A) sequence may vary. For example, the poly(A) sequence may have a length of about 20 adenine nucleotides up to about 300 adenine nucleotides, preferably of about 40 to about 200 adenine nucleotides, more preferably from about 50 to about 1 00 adenine nucleotides, such as about 60, 70, 80, 90 or 100 adenine nucleotides. Most preferably, the inventive nucleic acid comprises a poly(A) sequence of about 60 to about 70 nucleotides, most preferably 64 adenine nucleotides.
Artificial RNA-molecules may also be obtainable in vitro by common methods of chemical- synthesis without being necessarily transcribed from a DNA-progenitor.
In a particularly preferred embodiment, the artificial nucleic acid molecule according to the present invention is an RNA molecule, preferably an mRNA molecule comprising in 5'-to-3'- direction an open reading frame, a 3'-UTR element as described above and a poly(A) sequence or comprising in 5'-to-3'-direction a 5'-UTR element as described above, an open reading frame and a poly(A) sequence.
In a preferred embodiment, the open reading frame is derived from a gene, which is distinct from the gene from which the 3'-UTR element and/or the 5'-UTR element of the inventive artificial nucleic acid is derived. In some further preferred embodiments, the open reading frame does not code for a gene selected from the group consisti ng of GNAS (guanine nucleotide binding protein, alpha stimulating complex locus), MORN2 (MORN repeat containing 2), GSTM1 (glutathione S-transferase, mu 1 ), NDUFA1 (NADH dehydrogenase (ubiquinone) 1 alpha subcomplex), CBR2 (carbonyl reductase 2), MP68 (RIKEN cDNA 201 01 07E04 gene), NDUFA4 (NADH dehydrogenase (ubiquinone) 1 alpha subcomplex 4), Ybx1 (Y-Box binding protein 1 ), Ndufb8 (NADH dehydrogenase (ubiquinone) 1 beta subcomplex 8), CNTN1 (contactin 1 ), preferably CNTN1 -004 or variants thereof, provided that the 3'-UTR element and/or the 5'-UTR element is a sequence which is selected from the group consisting of sequences according to SEQ ID NO. 1 to SEQ ID NO. 30.
In a preferred embodiment, the ORF does not encode human or plant, in particular Arabidopsis, ribosomal proteins, in particular does not encode human ribosomal protein S6 (RPS6), human ribosomal protein L36a-like (RPL36AL) or Arabidopsis ribosomal protein S1 6 (RPS1 6). In a further preferred embodiment, the open reading frame (ORF) does not encode ribosomal protein S6 (RPS6), ribosomal protein L36a-like (RPL36AL) or ribosomal protein S16 (RPS1 6) of whatever origin. In one embodiment, the invention provides an artificial DNA molecule comprising an open reading frame, preferably an open reading frame derived from a gene, which is distinct from the gene from which the 3'-UTR element and/or the 5'-UTR element is derived; a 3'-UTR element comprising or consisting of a sequence which has at least about 60%, preferably at least about 70%, more preferably at least about 80%, more preferably at least about 90%, even more preferably at least about 95%; even more preferably at least 99%; even more preferably 100% sequence identity to a DNA sequence selected from the group consisting of sequences according to SEQ ID NO. 1 to 24, and/or a 5'-UTR element comprising or consisting of a sequence which has at least about 60%, preferably at least about 70%, more preferably at least about 80%, more preferably at least about 90%, even more preferably at least about 95%; even more preferably at least 99%; even more preferably 100% sequence identity to a DNA sequence selected from the group consisting of sequences according to SEQ ID NO. 25 to 30; and a polyadenylation signal and/or a poly(A) sequence.
In a further embodiment there is provided a composition comprising a plurality of RNA molecules of the embodiments in pharmaceutically acceptable carrier, wherein at least about 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or greater of the RNA in the composition comprises a poly(A) sequence that differs in length by no nor that 10 nucleotides. In a preferred embodiment at least about 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or greater of the RNA in the composition comprises a poly(A) sequence of identical length. In certain embodiments, the poly(A) sequence is positioned at the 3' end of the RNA, with no other nucleotides positioned 3' relative the poly(A) sequence. In still a further embodiment, there is provided a composition comprising a plurality of RNA molecules of the embodiments in pharmaceutically acceptable carrier, wherein said plurality of RNA molecules comprise both capped and uncapped RNAs. For example, in some aspects, a composition comprises a plurality of RNA molecules wherein no more than 95%, 90%, 80%, 70% or 60% of the RNAs comprise a cap and the remaining RNA molecules are uncapped. Furthermore, the invention provides an artificial RNA molecule, preferably an artificial mRNA molecule or an artificial viral RNA molecule, comprising an open reading frame, preferably an open readi ng frame is derived from a gene, which is distinct from the gene from which the 3'-UTR element and/or the 5'-UTR element is derived; a 3'-UTR element comprising or consisting of a sequence which has at least about 60%, preferably at least about 70%, more preferably at least about 80%, more preferably at least about 90%, even more preferably at least about 95%; even more preferably at least 99%; even more preferably 1 00% sequence identity to an RNA sequence corresponding to a DNA sequence selected from the group consisting of sequences according to SEQ ID NO. 1 to 24, and/or a 5'-UTR element comprising or consisting of a sequence which has at least about 60%, preferably at least about 70%, more preferably at least about 80%, more preferably at least about 90%, even more preferably at least about 95%; even more preferably at least 99%; even more preferably 100% sequence identity to an RNA sequence corresponding to a DNA sequence selected from the group consisting of sequences according to SEQ ID NO. 25 to 30; and a polyadenylation signal and/or a poly(A) sequence.
The invention provides an artificial nucleic acid molecule, preferably an artificial mRNA, which may be characterized by increased and/or prolonged expression of the encoded peptide or protein. Without being bound by any theory, enhanced stability of protein expression and thus prolonged protein expression may result from reduction in degradation of the artificial nucleic acid molecule, such as an artificial mRNA molecule according to the present invention. Accordingly, the inventive 3'-UTR element and/or the inventive 5'-UTR element may prevent the artificial nucleic acid from degradation and decay.
Preferably, the artificial nucleic acid molecule may additionally comprise a histone stem- loop. Thus, an artificial nucleic acid molecule according to the present invention may, for example, comprise in 5 '-to-3 '-direction an ORF, a 3'-UTR element, an optional histone stem- loop sequence, an optional poly(A) sequence or polyadenylation signal and an optional poly(C) sequence or in 5'-to-3'-direction an 5'-UTR element, an ORF, an optional histone stem-loop sequence, an optional poly(A) sequence or polyadenylation signal and an optional poly(C) sequence or in 5'-to-3'-direction an 5'-UTR element, an ORF, a 3'-UTR element, an optional histone stem-loop sequence, an optional poly(A) sequence or polyadenylation signal and an optional poly(C) sequence. It may also comprise in 5'-to-3'-direction an ORF, an 3'- UTR element, an optional poly(A) sequence, an optional poly (C) sequence and an optional histone stem-loop sequence, or in 5'-to-3'-direction an 5'-UTR element, an ORF, an optional poly(A) sequence, an optional poly(C) sequence and an optional histone stem-loop sequence, or in 5'-to-3'-direction an 5'-UTR element, an ORF, a 3'-UTR element, an optional poly(A) sequence, an optional poly(C) sequence and an optional histone stem-loop sequence.
In a preferred embodiment, the artificial nucleic acid molecule according to the invention further comprises at least one histone stem-loop sequence.
Such histone stem-loop sequences are preferably selected from histone stem-loop sequences as disclosed in WO 2012/01 9780, whose disclosure is incorporated herewith by reference.
A histone stem-loop sequence, suitable to be used within the present invention, is preferably selected from at least one of the fol lowing formulae (I) or (II):
formula (I) (stem-loop sequence without stem bordering elements):
[N0-2GN3-5] [No-4(U/T)No-4] [N3-5CN0-2] steml loop stem2 formula (II) (stem-loop sequence with stem bordering elements):
N1-6 [N0-2GN3.5] [No-4(U/T)No-4] [N3-5CN0-2] N1-6
J . . . Λ j ' steml steml loop stem2 stem2 bordering element bordering element wherein: steml or stem2 bordering elements Ni is a consecutive sequence of 1 to 6, preferably of 2 to 6, more preferably of 2 to 5, even more preferably of 3 to 5, most preferably of 4 to 5 or 5 N, wherein each N is independently from another selected from a nucleotide selected from A, U, T, G and C, or a nucleotide analogue thereof;
steml [N0-2GN3.5] is reverse complementary or partially reverse complementary with element stem2, and is a consecutive sequence between of 5 to 7 nucleotides; wherein N0-2 is a consecutive sequence of 0 to 2, preferably of 0 to 1 , more preferably of 1 N, wherein each N is independently from another selected from a nucleotide selected from A, U, T, G and C or a nucleotide analogue thereof; wherein N3-5 is a consecutive sequence of 3 to 5, preferably of 4 to 5, more preferably of 4 N, wherein each N is independently from another selected from a nucleotide selected from A, U, T, G and C or a nucleotide analogue thereof, and wherein G is guanosine or an analogue thereof, and may be optionally replaced by a cytidine or an analogue thereof, provided that its complementary nucleotide cytidine in stem2 is replaced by guanosine; loop sequence
Figure imgf000148_0001
is located between elements steml and stem2, and is a consecutive sequence of 3 to 5 nucleotides, more preferably of 4 nucleotides; wherein each N0-4 is independent from another a consecutive sequence of 0 to 4, preferably of 1 to 3, more preferably of 1 to 2 N, wherein each
N is independently from another selected from a nucleotide selected from A, U, T, G and C or a nucleotide analogue thereof; and
wherein U T represents uridine, or optionally thymidine; stem2 [N3-5CN0-2] is reverse complementary or partially reverse complementary with element stemi , and is a consecutive sequence between of 5 to 7 nucleotides; wherein N3-5 is a consecutive sequence of 3 to 5, preferably of 4 to 5, more preferably of 4 N, wherein each N is independently from another selected from a nucleotide selected from A, U, T, G and C or a nucleotide analogue thereof; wherein N0-2 is a consecutive sequence of 0 to 2, preferably of 0 to 1 , more preferably of 1 N, wherein each N is independently from another selected from a nucleotide selected from A, U, T, G or C or a nucleotide analogue thereof; and wherein C is cytidine or an analogue thereof, and may be optionally replaced by a guanosine or an analogue thereof provided that its complementary nucleoside guanosine in stemi is replaced by cytidine; wherein
stemi and stem2 are capable of base pairing with each other forming a reverse complementary sequence, wherein base pairing may occur between stemi and stem2, e.g. by Watson-Crick base pairing of nucleotides A and U/T or G and C or by non-Watson-Crick base pairing e.g. wobble base pairing, reverse Watson-Crick base pairing, Hoogsteen base pairing, reverse Hoogsteen base pairing or are capable of base pairing with each other forming a partially reverse complementary sequence, wherein an incomplete base pairing may occur between steml and stem2, on the basis that one ore more bases in one stem do not have a complementary base in the reverse complementary sequence of the other stem.
According to a further preferred embodiment the histone stem-loop sequence may be selected according to at least one of the following specific formulae (la) or (Ma): formula (la) (stem-loop sequence without stem bordering elements):
[N0-1 G N3-5] [Ni-3(U/ )No-2] [N3.5CN0-1 ] steml
Figure imgf000150_0001
stem2 formula (I la) (stem-loop sequence with stem bordering elements):
N2-5 [N0-1 G N3-5 [N3_5CNo steml steml
Figure imgf000150_0002
stem2 stem2
bordering element bordering element wherein:
N, C, G, T and U are as defined above.
According to a further more particularly preferred embodiment of the first aspect, the artificial nucleic acid molecule sequence may comprise at least one histone stem-loop sequence according to at least one of the following specific formulae (lb) or (lib): formula (lb) (stem-loop sequence without stem bordering elements):
Figure imgf000151_0001
formula (Mb) (stem-loop sequence with stem bordering elements): N4-5 [N1 GN4] [N2(U/T)Ni] [N4CN1] N4-5
Ύ >T
steml steml loop stem2 stem2
bordering element bordering element
wherein:
N, C, G, T and U are as defined above. A particular preferred histone stem-loop sequence is the sequence according to SEQ ID NO: 34: CAAAGGCTCTTTTCAGAGCCACCA or more preferably the corresponding RNA sequence of the nucleic acid sequence according to SEQ ID NO: 34.
As an example, the single elements may be present in the artificial nucleic acid molecule in the following order:
5'-cap - 5'-UTR (element) - ORF - 3'-UTR (element) - histone stem-loop - poly(A)/(C) sequence;
5'-cap - 5'-UTR (element) - ORF - 3'-UTR (element) - poly(A)/(C) sequence - histone stem- loop;
5'-cap - 5'-UTR (element) - ORF - IRES - ORF - 3'-UTR (element) - histone stem-loop - poly(A)/(C) sequence;
5'-cap - 5'-UTR (element) - ORF - IRES - ORF - 3'-UTR (element) - histone stem-loop - poly(A)/(C) sequence - poly(A)/(C) sequence;
5'-cap - 5'-UTR (element) - ORF - IRES - ORF - 3'-UTR (element) - poly(A)/(C) sequence - histone stem-loop; 5'-cap - 5'-UTR (element) - ORF - IRES - ORF - 3'-UTR (element) - poly(A)/(C) sequence - poly(A)/(C) sequence - histone stem-loop;
5'-cap - 5'-UTR (element) - ORF - 3'-UTR (element) - poly(A)/(Q sequence - poly(A)/(C) sequence;
5'-cap - 5'-UTR (element) - ORF - 3'-UTR (element) - poly(A)/(C) sequence - poly(A)/(C) sequence - histone stem loop; etc.
In some embodiments, the artificial nucleic acid molecule comprises further elements such as a 5'-cap, a poly(C) sequence and/or an IRES-motif. A 5'-cap may be added during transcription or post-transcriptionally to the 5'end of an RNA. Furthermore, the inventive artificial nucleic acid molecule, particularly if the nucleic acid is in the form of an mRNA or codes for an mRNA, may be modified by a sequence of at least 10 cytidines, preferably at least 20 cytidines, more preferably at least 30 cytidines (so-called "poly(C) sequence"). In particular, the inventive artificial nucleic acid molecule may contain, especially if the nucleic acid is in the form of an (m)RNA or codes for an mRNA, a poly(C) sequence of typically about 10 to 200 cytidine nucleotides, preferably about 10 to 100 cytidine nucleotides, more preferably about 10 to 70 cytidine nucleotides or even more preferably about 20 to 50 or even 20 to 30 cytidine nucleotides. Most preferably, the inventive nucleic acid comprises a poly(C) sequence of 30 cytidine residues. Thus, preferably the artificial nucleic acid molecule according to the present invention comprises, preferably in 5'-to-3' direction, at least one 5'- UTR element as described above, an ORF, at least one 3'-UTR element as described above, a poly(A) sequence or a polyadenylation signal, and a poly(C) sequence or, in 5'-to-3' direction, optionally a further 5'-UTR, an ORF, at least one 3'-UTR element as described above, a poly(A) sequence or a polyadenylation signal, and a poly(C) sequence, or, in 5'-to- 3' direction, at least one 5'-UTR element as described above, an ORF, optionally a further 3'- UTR, a poly(A) sequence or a polyadenylation signal, and a poly(C) sequence .
An internal ribosome entry site (IRES) sequence or IRES-motif may separate several open reading frames, for example if the artificial nucleic acid molecule encodes for two or more peptides or proteins. An IRES-sequence may be particularly helpful if the artificial nucleic acid molecule is a bi- or multicistronic nucleic acid molecule. Furthermore, the artificial nucleic acid molecule may comprise additional 5'-elements, preferably a promoter or a promoter containing-sequence. The promoter may drive and or regulate transcription of the artificial nucleic acid molecule according to the present invention, for example of an artificial DNA-molecule according to the present invention.
Preferably, the artificial nucleic acid molecule according to the present invention, preferably the open reading frame, is at least partially G/C modified. Thus, the inventive artificial nucleic acid molecule may be thermodynamically stabilized by modifying the G (guanosine)/C (cytidine) content of the molecule. The G/C content of the open reading frame of an artificial nucleic acid molecule according to the present invention may be increased compared to the G/C content of the open reading frame of a corresponding wild type sequence, preferably by using the degeneration of the genetic code. Thus, the encoded amino acid sequence of the artificial nucleic acid molecule is preferably not modified by the G/C modification compared to the coded amino acid sequence of the particular wild type sequence. The codons of the coding sequence or the whole artificial nucleic acid molecule, e.g. an mRNA, may therefore be varied compared to the wild type coding sequence, such that they include an increased amount of G/C nucleotides whi le the translated amino acid sequence is maintained. Due to the fact that several codons code for one and the same amino acid (so-called degeneration of the genetic code), it is feasible to alter codons while not altering the encoded peptide/protein sequence (so-called alternative codon usage). Hence, it is possible to specifically introduce certain codons (in exchange for the respective wild-type codons encoding the same amino acid), which are more favourable with respect to stabi lity of RNA and/or with respect to codon usage in a subject (so-cal led codon optimization). Depending on the amino acid to be encoded by the coding region of the inventive artificial nucleic acid molecule as defined herein, there are various possibilities for modification of the nucleic acid sequence, e.g. the open reading frame, compared to its wild type coding region. In the case of amino acids, which are encoded by codons which contain exclusively G or C nucleotides, no modification of the codon is necessary. Thus, the codons for Pro (CCC or CCG), Arg (CGC or CGG), Ala (GCC or GCG) and Gly (GGC or GGG) require no modification, since no A or U/T is present.
In contrast, codons which contain A and/or U F nucleotides may be modified by substitution of other codons which code for the same ami no acids but contai n no A and/or U/T. For example the codons for Pro can be modified from CC(U/T) or CCA to CCC or CCG;
the codons for Arg can be modified from CG(U/T) or CGA or AGA or AGG to CGC or CGG; the codons for Ala can be modified from GC(U/T) or GCA to GCC or GCG;
the codons for Gly can be modified from GG(U/T) or GGA to GGC or GGG.
In other cases, although A or (U/T) nucleotides cannot be el imi nated from the codons, it is however possible to decrease the A and (U/T) content by using codons which contain a lower content of A and/or (U/T) nucleotides. Examples of these are:
The codons for Phe can be modified from (U/T)(U T)(U/T) to (U/T) (U/T)C;
the codons for Leu can be modified from (U/T) (U/T)A, (U/T) (U/T)G, C(U/T) (U/T) or C(U/T)A to C(U/T)C or C(U/T)G;
the codons for Ser can be modified from (U/T)C(U/T) or (U/T)CA or AG(U/T) to (U/T)CC, (UZT)CG or AGC;
the codon for Tyr can be modified from (U T)A(U/T) to (UAT)AC;
the codon for Cys can be modified from (U T)G(U/T) to (U/T)GC;
the codon for His can be modified from CA(U/T) to CAC;
the codon for Gin can be modified from CAA to CAG;
the codons for l ie can be modified from A(U/T)(U/T) or A(U/T)A to A(U/T)C;
the codons for Thr can be modified from AC(U/T) or ACA to ACC or ACG;
the codon for Asn can be modified from AA(U/T) to AAC;
the codon for Lys can be modified from AAA to AAG;
the codons for Val can be modified from G(U/T)(U/T) or G(U/T)A to G(UAT)C or G(U T)G; the codon for Asp can be modified from GA(U T) to GAC;
the codon for Glu can be modified from GAA to GAG;
the stop codon (U/T)AA can be modified to (U/T) AG or (U/T)GA.
I n the case of the codons for Met (A(U/T)G) and Trp ((U/T)GG), on the other hand, there is no possibi lity of sequence modification without alteri ng the encoded ami no acid sequence. The substitutions listed above can be used either individually or in all possible combinations to increase the G/C content of the open reading frame of the inventive artificial nucleic acid molecule as defined herein, compared to its particular wild type open reading frame (i.e. the original sequence). Thus, for example, all codons for Thr occurring in the wild type sequence can be modified to ACC (or ACG).
Preferably, the G/C content of the open reading frame of the inventive artificial nucleic acid molecule as defined herein is increased by at least 7%, more preferably by at least 15%, particularly preferably by at least 20%, compared to the G/C content of the wild type coding region without altering the encoded amino acid sequence, i.e. using the degeneracy of the genetic code. According to a specific embodiment at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, more preferably at least 70 %, even more preferably at least 80% and most preferably at least 90%, 95% or even 100% of the substitutable codons in the open reading frame of the inventive artificial nucleic acid molecule or a fragment, variant or derivative thereof are substituted, thereby increasing the G/C content of said open reading frame.
In this context, it is particularly preferable to increase the G/C content of the open reading frame of the inventive artificial nucleic acid molecule as defined herein, to the maximum (i.e. 100% of the substitutable codons), compared to the wild type open reading frame, without altering the encoded amino acid sequence. Furthermore, the open reading frame is preferably at least partially codon-optimized. Codon- optimization is based on the finding that the translation efficiency may be determined by a different frequency in the occurrence of transfer RNAs (tRNAs) in cells. Thus, if so-called "rare codons" are present in the coding region of the inventive artificial nucleic acid molecule as defined herein, to an increased extent, the translation of the corresponding modified nucleic acid sequence is less efficient than in the case where codons coding for relatively "frequent" tRNAs are present.
Thus, the open reading frame of the inventive artificial nucleic acid molecule is preferably modified compared to the corresponding wild type coding region such that at least one codon of the wild type sequence which codes for a tRNA which is relatively rare in the cell is exchanged for a codon which codes for a tRNA which is comparably frequent in the cell and carries the same amino acid as the relatively rare tRNA. By this modification, the open reading frame of the inventive artificial nucleic acid molecule as defined herein, is modified such that codons for which frequently occurring tRNAs are available may replace codons which correspond to rare tRNAs. In other words, according to the invention, by such a modification all codons of the wi ld type open reading frame which code for a rare tRNA may be exchanged for a codon which codes for a tRNA which is more frequent in the cell and which carries the same amino acid as the rare tRNA. Which tRNAs occur relatively frequently in the cell and which, in contrast, occur relatively rarely is known to a person skil led in the art; cf. e.g. Akashi, Curr. Opin. Genet. Dev. 2001 , 1 1 (6): 660-666. Accordingly, preferably, the open reading frame is codon-optimized, preferably with respect to the system in which the artificial nucleic acid molecule according to the present invention is to be expressed, preferably with respect to the system in which the artificial nucleic acid molecule according to the present invention is to be translated. Preferably, the codon usage of the open reading frame is codon- optimized according to mammalian codon usage, more preferably according to human codon usage. Preferably, the open reading frame is codon-optimized and G/C-content modified.
For further improving degradation resistance, e.g. resistance to in vivo (or in vitro as defi ned above) degradation by an exo- or endonuclease, and/or for further improving stability of protein expression from the artificial nucleic acid molecule according to the present invention, the artificial nucleic acid molecule may further comprise modifications, such as backbone modifications, sugar modifications and/or base modifications, e.g., lipid- modifications or the like. Preferably, the transcription and/or the translation of the artificial nucleic acid molecule according to the present invention is not significantly impaired by said modifications. Generally, the artificial nucleic acid molecule of the present invention may comprise any native (= naturally occurring) nucleotide, e.g. guanosine, uracil, adenosine, and/or cytosine or an analogue thereof. In this respect, nucleotide analogues are defined as natively and non- natively occurring variants of the naturally occurring nucleotides adenosine, cytosine, thymidine, guanosine and uridine. Accordingly, analogues are e.g. chemically derivatized nucleotides with non-natively occurring functional groups, which are preferably added to or deleted from the naturally occurring nucleotide or which substitute the naturally occurring functional groups of a nucleotide. Accordingly, each component of the naturally occurring nucleotide may be modified, namely the base component, the sugar (ribose) component and/or the phosphate component forming the backbone (see above) of the RNA sequence. Analogues of guanosine, uridine, adenosine, thymidine and cytosine include, without implying any limitation, any natively occurring or non-natively occurring guanosine, uridine, adenosine, thymidine or cytosine that has been altered e.g. chemically, for example by acetylation, methylation, hydroxylation, etc., including 1 -methyl-adenosine, 1 -methyl- guanosine, 1 -methyl-inosine, 2,2-dimethyl-guanosine, 2,6-diaminopurine, 2 '-Amino-2'- deoxyadenosine, 2 '-Amino-2 '-deoxycytidine, 2 '-Amino-2 '-deoxyguanosine, 2 '-Amino-2 '- deoxyuridine, 2-Amino-6-chloropurineriboside, 2-Aminopurine-riboside, 2 '-Araadenosine, 2 '-Aracytidine, 2 '-Arauridine, 2 '-Azido-2 '-deoxyadenosine, 2 '-Azido-2 '-deoxycytidine, 2 '- Azido-2'-deoxyguanosine, 2 '-Azido-2 '-deoxyuridine, 2-Chloroadenosine, 2 '-Fluoro-2 '- deoxyadenosine, 2 '-Fluoro-2'-deoxycytidine, 2 '-Fluoro-2 '-deoxyguanosine, 2 '-Fluoro-2 '- deoxyuridine, 2'-Fluorothymidine, 2-methyl-adenosine, 2-methyl-guanosine, 2-methyl-thio- N6-isopenenyl-adenosine, 2 '-0-Methyl-2-aminoadenosine, 2 '-0-Methyl-2 '- deoxyadenosine, 2 '-0-Methyl-2 '-deoxycytidine, 2 '-0-Methyl-2 '-deoxyguanosine, 2 '-0- Methyl-2'-deoxyuridine, 2 '-0-Methyl-5-methyluridine, 2 '-0-Methylinosine, 2'-0- Methylpseudouridine, 2-Thiocytidine, 2-thio-cytosine, 3-methyl-cytosine, 4-acetyl-cytosine,
4- Thiouridine, 5-(carboxyhydroxymethyl)-uracil, 5,6-Dihydrouridine, 5-Aminoal lylcytidine,
5- Aminoallyl-deoxy-uridine, 5-Bromouridine, 5-carboxymehtylaminomethyl-2-thio-uracil,
5- carboxymethylamonomethyl-uracil, 5-Chloro-Ara-cytosine, 5-Fluoro-uridine, 5- lodouridine, 5-methoxycarbonylmethyl-uridine, 5-methoxy-uridine, 5-methyl-2-thio-uridine,
6- Azacytidine, 6-Azauridine, 6-Chloro-7-deaza-guanosine, 6-Chloropurineriboside, 6- Mercapto-guanosine, 6-Methyl-mercaptopurine-riboside, 7-Deaza-2'-deoxy-guanosine, 7- Deazaadenosine, 7-methyl-guanosine, 8-Azaadenosine, 8-Bromo-adenosine, 8-Bromo- guanosine, 8-Mercapto-guanosine, 8-Oxoguanosine, Benzimidazole-riboside, Beta-D- mannosyl-queosine, Dihydro-uraci l, Inosine, N1 -Methyladenosine, N6-([6- Aminohexyl]carbamoylmethyl)-adenosine, N6-isopentenyl-adenosine, N6-methyl- adenosine, N7-Methyl-xanthosine, N-uracil-5-oxyacetic acid methyl ester, Puromycin, Queosine, Uraci l-5-oxyacetic acid, Uracil-5-oxyacetic acid methyl ester, Wybutoxosine, Xanthosine, and Xylo-adenosine. The preparation of such analogues is known to a person skilled in the art, for example from US Patents 4,373,071 , US 4,401 ,796, US 4,41 5,732, US 4,458,066, US 4,500,707, US 4,668,777, US 4,973,679, US 5,047,524, US 5,1 32,41 8, US 5, 1 53,31 9, US 5,262,530 and 5,700,642. In the case of an analogue as described above, particular preference may be given according to certain embodiments of the invention to those analogues that increase the protein expression of the encoded peptide or protein or that increase the immunogenicity of the artificial nucleic acid molecule of the invention and/or do not interfere with a further modification of the artificial nucleic acid molecule that has been introduced.
According to a particular embodiment, the artificial nucleic acid molecule of the present invention can contain a lipid modification.
In a preferred embodiment, the artificial nucleic acid molecule comprises, preferably from 5' to 3' direction, the following elements:
a 5'-UTR element which prolongs and/or increases protein production from said artificial nucleic acid molecule, preferably from a nucleic acid sequence according to any of SEQ ID NO: 25 to 30 and SEQ ID NOs: 31 9 to 382, more preferably of the 5'-UTR of MP68 or NDUFA4; or a further 5'-UTR, preferably a 5'-TOP UTR;
at least one open reading frame (ORF), wherein the ORF preferably comprises at least one modification with respect to the wild type sequence;
a 3'-UTR element which prolongs and/or increases protein production from said artificial nucleic acid molecule, preferably from a nucleic acid sequence according to any of SEQ ID NO: 1 to 24 and SEQ ID NOs: 49 to 318, more preferably of the 3'-UTR of GNAS, MORN2, GSTM1 , NDUFA1 , CBR2, YBX1 , NDUFB8, or CNTN1 ; or a further 3'-UTR, preferably an albumin7 3'-UTR;
a poly(A) sequence, preferably comprising 64 adenylates;
a poly(C) sequence, preferably comprising 30 cytidylates;
a histone stem-loop sequence.
In another preferred embodiment, the artificial nucleic acid molecule comprises or consists of a nucleotide sequence selected from the group consisting of nucleic acid sequences according to SEQ ID NOs: 36 to 40, SEQ ID NOs: 42 and 43, SEQ ID NOs: 45 to 48, and SEQ ID NOs: 384 to 388 (see Fig. 2 to 6, Fig. 8, 9, 1 1 , Fig. 1 9 to 21 and Fig. 26 to 30) or the complementary DNA sequence.
In a particularly preferred embodiment, the artificial nucleic acid molecule according to the invention may further comprise one or more of the modifications described in the following: Chemical modifications:
The term "modification" as used herein with regard to the artificial nucleic acid molecule may refer to chemical modifications comprising backbone modifications as wel l as sugar modifications or base modifications.
In this context, the artificial nucleic acid molecule, preferably an RNA molecule, as defi ned herein may contain nucleotide analogues/modifications, e.g. backbone modifications, sugar modifications or base modifications. A backbone modification in connection with the present invention is a modification, in which phosphates of the backbone of the nucleotides contained in a nucleic acid molecule as defined herein are chemically modified. A sugar modification in connection with the present invention is a chemical modification of the sugar of the nucleotides of the nucleic acid molecule as defined herein. Furthermore, a base modification in connection with the present invention is a chemical modification of the base moiety of the nucleotides of the nucleic acid molecule of the nucleic acid molecule. In this context, nucleotide analogues or modifications are preferably selected from nucleotide analogues which are applicable for transcription and/or translation.
Sugar Modifications:
The modified nucleosides and nucleotides, which may be incorporated into the artificial nucleic acid molecule, preferably an RNA, as described herein, can be modified in the sugar moiety. For example, the 2' hydroxyl group (OH) of an RNA molecule can be modified or replaced with a number of different "oxy" or "deoxy" substituents. Examples of "oxy" -2' hydroxyl group modifications include, but are not limited to, alkoxy or aryloxy (- OR, e.g., R = H, alkyl, cycloalkyl, aryl, aralkyl, heteroaryl or sugar); polyethyleneglycols
(PEG), -0(CH2CH2o)nCH2CH2OR; "locked" nucleic acids (LNA) in which the 2 ' hydroxyl is connected, e.g., by a methylene bridge, to the 4' carbon of the same ribose sugar; and amino groups (-O-amino, wherein the amino group, e.g., NRR, can be alkylamino, dialkylamino, heterocyclyl, arylamino, diarylamino, heteroarylamino, or diheteroaryl amino, ethylene diamine, polyamino) or aminoalkoxy.
"Deoxy" modifications include hydrogen, amino (e.g. NH2; alkylamino, dialkylamino, heterocyclyl, arylamino, diaryl amino, heteroaryl amino, diheteroaryl amino, or amino acid); or the amino group can be attached to the sugar through a linker, wherein the linker comprises one or more of the atoms C, N, and O.
The sugar group can also contain one or more carbons that possess the opposite stereochemical configuration than that of the corresponding carbon in ribose. Thus, a modified nucleic acid molecule can include nucleotides containing, for instance, arabinose as the sugar.
Backbone Modifications:
The phosphate backbone may further be modified in the modified nucleosides and nucleotides, which may be incorporated into the artificial nucleic acid molecule, preferably an RNA, as described herein. The phosphate groups of the backbone can be modified by replacing one or more of the oxygen atoms with a different substituent. Further, the modified nucleosides and nucleotides can include the ful l replacement of an unmodified phosphate moiety with a modified phosphate as described herein. Examples of modified phosphate groups include, but are not limited to, phosphorothioate, phosphoroselenates, borano phosphates, borano phosphate esters, hydrogen phosphonates, phosphoroamidates, alkyl or aryl phosphonates and phosphotriesters. Phosphorodithioates have both non-linking oxygens replaced by sulfur. The phosphate linker can also be modified by the replacement of a linking oxygen with nitrogen (bridged phosphoroamidates), sulfur (bridged phosphorothioates) and carbon (bridged methylene-phosphonates).
Base Modifications:
The modified nucleosides and nucleotides, which may be incorporated into the artificial nucleic acid molecule, preferably an RNA molecule, as described herein, can further be modified in the nucleobase moiety. Examples of nucleobases found in RNA include, but are not limited to, adenine, guanine, cytosine and uracil. For example, the nucleosides and nucleotides described herein can be chemically modified on the major groove face. In some embodiments, the major groove chemical modifications can include an amino group, a thiol group, an alkyl group, or a halo group.
In particularly preferred embodiments of the present invention, the nucleotide analogues/modifications are selected from base modifications, which are preferably selected from 2-amino-6-chloropurineriboside-5 '-triphosphate, 2-Aminopurine-riboside-5'- triphosphate; 2-aminoadenosine-5 '-triphosphate, 2 '-Amino-2 '-deoxycytidine-triphosphate, 2-thiocytidine-5 '-triphosphate, 2-thiouridine-5 '-triphosphate, 2 '-Fluorothymidine-5'- triphosphate, 2 '-0-Methyl inosine-5 '-triphosphate 4-thiouridine-5'-triphosphate, 5- aminoallylcytidine-5 '-triphosphate, 5-aminoally!uridme-5'-triphosphate, 5-bromocytidine- 5 '-triphosphate, 5-bromouridine-5 '-triphosphate, 5-Bromo-2'-deoxycytidine-5 '-triphosphate, 5-Bromo-2'-deoxyuridine-5 '-triphosphate, 5-iodocytidine-5 '-triphosphate, 5-lodo-2 '- deoxycytidine-5 '-triphosphate, 5-iodouridine-5 '-triphosphate, 5-!odo-2 '-deoxyuridine-5'- triphosphate, 5-methyIcytidine-5 '-triphosphate, 5-methyluridine-5 '-triphosphate, 5- Propynyl-2 '-deoxycytidine-5 '-triphosphate, 5-Propynyi-2'-deoxyuridine-5'-triphosphate, 6- azacytidine-5 '-triphosphate, 6-azauridine-5 '-triphosphate, 6-chloropurineriboside-5'- triphosphate, 7-deazaadenosine-5 '-triphosphate, 7-deazaguanosine-5'-triphosphate, 8- azaaderiosine-5 '-triphosphate, 8-azidoadenosine-5 '-triphosphate, benzimidazole-riboside- 5 '-triphosphate, N 1 -methyladenosine-5 '-triphosphate, N1 -methylguanosine-5 '-triphosphate, N6-methyladenosine-5 '-triphosphate, 06-methyiguanosine-5 '-triphosphate, pseudouridine- 5 '-triphosphate, or puromycin-5 '-triphosphate, xanthosine-5'-triphosphate. Particular preference is given to nucleotides for base modifications selected from the group of base- modified nucleotides consisting of 5-methylcytidine-5 '-triphosphate, 7-deazaguanosine-5'- triphosphate, 5-bromocytidine-5 '-triphosphate, and pseudouridine-5'-triphosphate.
In some embodiments, modified nucleosides include pyridin-4-one ribonucleoside, 5-aza- uridine, 2-thio-5-aza-uridine, 2-thiouridine, 4-thio-pseudouridine, 2-thio-pseudouridine, 5- hydroxyuridine, 3-methyluridine, 5-carboxymethyI-uridine, 1 -carboxymethyl-pseudouridine, 5-propynyl-uridine, 1 -propynyl-pseudouridine, 5-taurinomethyluridine, 1 -taurinomethyl- pseudouridine, 5-taurinomethyl-2-thio-uridine, l-taurinomethyl-4-thio-uridine, 5-methyI- uridine, 1 -methyl-pseudouridine, 4-thio- 1 -methyl-pseudouridine, 2-thio-l-methyl- pseudouridine, 1 -methyl- 1 -deaza-pseuclouridine, 2-thio- 1 -methyl- 1 -deaza- pseudouridine, dihydrouridine, dihydropseudouridine, 2-thio-dihydrouridine, 2-thio- dihydropseudouridine, 2-methoxyuridine, 2-methoxy-4-thio-uridine, 4-methoxy- pseudouridine, and 4-methoxy-2-thio-pseudouridine.
In some embodiments, modified nucleosides include 5-aza-cytidine, pseudoisocytidine, 3- methyl-cytidine, N4-acetylcytidine, 5-formylcytidine, N4-methylcytidine, 5- hydroxymethylcytidine, 1 -methyl-pseudoisocytidine, pyrrolo-cytidine, pyrrolo- pseudoisocytidine, 2-thio-cytidine, 2-thio-5-methyl-cytidine, 4-thio-pseudoisocytidine, 4- thio- 1 -methyl-pseudoisocytidine, 4-thio- 1 -methyl- 1 -deaza-pseudoisocytidine, 1 -methyl- 1 -deaza-pseudoisocytidine, zebularine, 5-aza-zebularine, 5-methyl-zebularine, 5-aza-2- thio-zebularine, 2-thio-zebularine, 2-methoxy-cytidine, 2-methoxy-5-methyl-cytidine, 4- methoxy-pseudoisocytidine, and 4-methoxy-l-methyl-pseudoisocytidine .
In other embodiments, modified nucleosides include 2-aminopurine, 2, 6-diaminopurine, 7- deaza-adenine, 7-deaza-8-aza-adenine, 7-deaza-2-aminopurine, 7-deaza-8-aza-2- aminopurine, 7-deaza-2, 6-diaminopurine, 7-deaza-8-aza-2, 6-diaminopurine, 1 - methyladenosine, N6-methyladenosine, N6-isopentenyladenosine, N6-(cis- hydroxyisopentenyl)adenosine, 2-methylthio-N6-(cis-hydroxyisopentenyl) adenosine, N6- glycinylcarbamoyladenosine, N6-threonylcarbamoyladenosine, 2-methylthio-N6-threonyl carbamoyladenosine, N6,N6-dimethyladenosine, 7-methyladenine, 2-methylthio-adenine, and 2-methoxy-adenine.
In other embodiments, modified nucleosides include inosine, 1 -methyl-inosine, wyosine, wybutosine, 7-deaza-guanosine, 7-deaza-8-aza-guanosine, 6-thio-guanosine, 6-thio-7- deaza-guanosine, 6-thio-7-deaza-8-aza-guanosine, 7-methyI-guanosine, 6-thio-7-methyl- guanosine, 7-methylinosine, 6-methoxy-guanosine, 1 -methylguanosine, N2- methylguanosine, N2,N2-dimethylguanosine, 8-oxo-guanosine, 7-methyl-8-oxo-guanosine, l-methyl-6-thio-guanosine, N2-methyl-6-thio-guanosine, and N2,N2-dimethyl-6-thio- guanosine. In some embodiments, the nucleotide can be modified on the major groove face and can include replacing hydrogen on C-5 of uracil with a methyl group or a halo group.
In specific embodiments, a modified nucleoside is 5'-0-(l-Thiophosphate)-Adenosine, 5 ( 1 -Thiophosphate)-Cytidine, 5 ' -0-( 1 -Thiophosphate)-Guanosine, 5 ' -0-( Thiophosphate)-Uridine or 5 '-0-(l-Thiophosphate)-Pseudouridine.
In further specific embodiments the artificial nucleic acid molecule, preferably an RNA molecule, may comprise nucleoside modifications selected from 6-aza-cytidine, 2-thio- cytidine, alpha-thio-cytidine, Pseudo-iso-cytidine, 5-aminoallyl-uridine, 5-iodo-uridine, N1 - methyl-pseudouridine, 5,6-dihydrouridine, alpha-thio-uridine, 4-thio-uridine, 6-aza-uridine, 5-hydroxy-uridine, deoxy-thymidine, 5-methyl-uridine, Pyrrolo-cytidine, inosine, alpha-thio- guanosine, 6-methyl-guanosine, 5-methyl-cytdine, 8-oxo-guanosine, 7-deaza-guanosine, N1 -methyl-adenosine, 2-amino-6-Chloro-purine, N6-methyl-2 -amino-purine, Pseudo-iso- cytidine, 6-Chloro-purine, N6-methyl-adenosine, alpha-thio-adenosine, 8-azido-adenosine, 7-deaza-adenosine.
Lipid modification:
According to a further embodiment, the artificial nucleic acid molecule, preferably an RNA, as defined herein can contain a lipid modification. Such a lipid-modified RNA typically comprises an RNA as defined herein. Such a lipid-modified RNA molecule as defined herein typically further comprises at least one linker covalently linked with that RNA molecule, and at least one lipid covalently linked with the respective linker. Alternatively, the lipid-modified RNA molecule comprises at least one RNAmolecule as defined herein and at least one (bifunctional) lipid covalently linked (without a linker) with that RNA molecule. According to a third alternative, the lipid-modified RNA molecule comprises an artificial nucleic acid molecule, preferably an RNA molecule, as defined herein, at least one linker covalently linked with that RNA molecule, and at least one lipid covalently linked with the respective linker, and also at least one (bifunctional) lipid covalently linked (without a linker) with that RNA molecule. In this context, it is particularly preferred that the lipid modification is present at the terminal ends of a linear RNA sequence.
Modification of the 5'-end of the modified RNA:
According to another preferred embodiment of the invention, the artificial nucleic acid molecule, preferably an RNA molecule, as defined herein, can be modified by the addition of a so-called "5 ' CAP" structure.
A 5 '-cap is an entity, typically a modified nucleotide entity, which general ly "caps" the 5'- end of a mature mRNA. A 5'-cap may typically be formed by a modified nucleotide, particularly by a derivative of a guanine nucleotide. Preferably, the 5'-cap is linked to the 5'- terminus via a 5 '-5 '-triphosphate linkage. A 5'-cap may be methylated, e.g. m7GpppN, wherein N is the terminal 5' nucleotide of the nucleic acid carrying the 5'-cap, typically the 5'-end of an RNA. m7GpppN is the 5'-CAP structure which naturally occurs in mRNA transcribed by polymerase II and is therefore not considered as modification comprised in the modified RNA according to the invention. This means the artificial nucleic acid molecule, preferably an RNA molecule, according to the present invention may comprise a m7GpppN as 5'-CAP, but additionally the artificial nucleic acid molecule, preferably an RNA molecule, comprises at least one further modification as defined herein.
Further examples of 5'cap structures include glyceryl, inverted deoxy abasic residue (moiety), 4', 5' methylene nucleotide, 1 -(beta-D-erythrofuranosyl) nucleotide, 4'-thio nucleotide, carbocyclic nucleotide, 1 ,5-anhydrohexitol nucleotide, L-nucleotides, alpha-nucleotide, modified base nucleotide, threo-pentofuranosyl nucleotide, acyclic 3',4'-seco nucleotide, acyclic 3,4-dihydroxybutyl nucleotide, acyclic 3,5 dihydroxypentyl nucleotide, 3'-3'- inverted nucleotide moiety, 3'-3'-inverted abasic moiety, 3 '-2 '-inverted nucleotide moiety, 3'-2'-inverted abasic moiety, 1 ,4-butanediol phosphate, 3'-phosphoramidate, hexylphosphate, aminohexyl phosphate, 3'-phosphate, 3'phosphorothioate, phosphorodithioate, or bridging or non-bridging methylphosphonate moiety. These modified 5'-CAP structures are regarded as at least one modification comprised in the artificial nucleic acid molecule, preferably in an RNA molecule, according to the present invention.
Particularly preferred modified 5'-CAP structures are CAP1 (methylation of the ribose of the adjacent nucleotide of m7G), CAP2 (methylation of the ribose of the 2nd nucleotide downstream of the m7G), CAP3 (methylation of the ribose of the 3rd nucleotide downstream of the m7G), CAP4 (methylation of the ribose of the 4th nucleotide downstream of the m7G), ARCA (anti-reverse CAP analogue, modified ARCA (e.g. phosphothioate modified ARCA), inosine, N1 -methyl-guanosine, 2'-fluoro-guanosine, 7-deaza-guanosine, 8-oxo-guanosine, 2- amino-guanosine, LNA-guanosine, and 2-azido-guanosine.
In a preferred embodiment, the at least one open reading frame encodes a therapeutic protein or peptide. In another embodiment, an antigen is encoded by the at least one open reading frame, such as a pathogenic antigen, a tumour antigen, an allergenic antigen or an autoimmune antigen. Therein, the administration of the artificial nucleic acid molecule encoding the antigen is used in a genetic vaccination approach against a disease involving said antigen. In an alternative embodiment, an antibody or an antigen-specific T cell receptor or a fragment thereof is encoded by the at least one open reading frame of the artificial nucleic acid molecule according to the invention. Antigens:
Pathogenic antigens:
The artificial nucleic acid molecule according to the present invention may encode a protein or a peptide, which comprises a pathogenic antigen or a fragment, variant or derivative thereof. Such pathogenic antigens are derived from pathogenic organisms, in particular bacterial, viral or protozoo logical (multicellular) pathogenic organisms, which evoke an immunological reaction in a subject, in particular a mammalian subject, more particularly a human. More specifically, pathogenic antigens are preferably surface antigens, e.g. proteins (or fragments of proteins, e.g. the exterior portion of a surface antigen) located at the surface of the virus or the bacterial or protozoological organism.
Pathogenic antigens are peptide or protein antigens preferably derived from a pathogen associated with infectious disease which are preferably selected from antigens derived from the pathogens Acinetobacter baumannii, Anaplasma genus, Anaplasma phagocytophilum, Ancylostoma braziliense, Ancylostoma duodenale, Arcanobacterium haemolyticum, Ascaris lumbricoides, Aspergillus genus, Astroviridae, Babesia genus, Bacillus anthracis, Baci llus cereus, Bartonella henselae, BK virus, Blastocystis hominis, Blastomyces dermatitidis, Bordetella pertussis, Borrelia burgdorferi, Borrelia genus, Borrelia spp, Brucella genus, Brugia malayi, Bunyaviridae family, Burkholderia cepacia and other Burkholderia species, Burkholderia mallei, Burkholderia pseudomallei, Caliciviridae fami ly, Campylobacter genus, Candida albicans, Candida spp, Chlamydia trachomatis, Chlamydophila pneumoniae, Chlamydophila psittaci, CJD prion, Clonorchis sinensis, Clostridium botulinum, Clostridium difficile, Clostridium perfringens, Clostridium perfringens, Clostridium spp, Clostridium tetani, Coccidioides spp, coronaviruses, Corynebacterium diphtheriae, Coxiella burnetii, Crimean-Congo hemorrhagic fever virus, Cryptococcus neoformans, Cryptosporidium genus, Cytomegalovirus (CMV), Dengue viruses (DEN-1 , DEN-2, DEN-3 and DEN-4), Dientamoeba fragi lis, Ebolavirus (EBOV), Echinococcus genus, Ehrlichia chaffeensis, Ehrlichia ewingii, Ehrlichia genus, Entamoeba histolytica, Enterococcus genus, Enterovirus genus, Enteroviruses, mainly Coxsackie A virus and Enterovirus 71 (EV71 ), Epidermophyton spp, Epstein-Barr Virus (EBV), Escherichia coli 01 57:H7, 01 1 1 and O1 04:H4, Fasciola hepatica and Fasciola gigantica, FFI prion, Fi larioidea superfamily, Flaviviruses, Francisella tularensis, Fusobacterium genus, Geotrichum candidum, Giardia intestinalis, Gnathostoma spp, GSS prion, Guanarito virus, Haemophilus ducreyi, Haemophilus influenzae, Helicobacter pylori, Henipavirus (Hendra virus Nipah virus), Hepatitis A Virus, Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Hepatitis D Virus, Hepatitis E Virus, Herpes simplex virus 1 and 2 (HSV-1 and HSV-2), Histoplasma capsulatum, HIV (Human immunodeficiency virus), Hortaea werneckii, Human bocavirus (HBoV), Human herpesvirus 6 (HHV-6) and Human herpesvirus 7 (HHV- 7), Human metapneumovirus (hMPV), Human papil lomavirus (HPV), Human parainfluenza viruses (HPIV), Japanese encephalitis virus, JC virus, Junin virus, Kingella kingae, Klebsiella granulomatis, Kuru prion, Lassa virus, Legionella pneumophila, Leishmania genus, Leptospira genus, Listeria monocytogenes, Lymphocytic choriomeningitis virus (LCMV), Machupo virus, Malassezia spp, Marburg virus, Measles virus, Metagonimus yokagawai, Microsporidia phylum, Molluscum contagiosum virus (MCV), Mumps virus, Mycobacterium leprae and Mycobacterium lepromatosis, Mycobacterium tuberculosis, Mycobacterium ulcerans, Mycoplasma pneumoniae, Naegleria fowleri, Necator americanus, Neisseria gonorrhoeae, Neisseria meningitidis, Nocardia asteroides, Nocardia spp, Onchocerca volvulus, Orientia tsutsugamushi, Orthomyxoviridae family (Influenza), Paracoccidioides brasiliensis, Paragonimus spp, Paragonimus westermani, Parvovirus B1 9, Pasteurella genus, Plasmodium genus, Pneumocystis j irovecii, Pol iovirus, Rabies virus, Respiratory syncytial virus (RSV), Rhinovirus, rhinoviruses, Rickettsia akari, Rickettsia genus, Rickettsia prowazekii, Rickettsia rickettsii, Rickettsia typhi, Rift Valley fever virus, Rotavirus, Rubella virus, Sabia virus, Salmonella genus, Sarcoptes scabiei, SARS coronavirus, Schistosoma genus, Shigel la genus, Sin Nombre virus, Hantavirus, Sporothrix schenckii, Staphylococcus genus, Staphylococcus genus, Streptococcus agalactiae, Streptococcus pneumoniae, Streptococcus pyogenes, Strongyloides stercoralis, Taenia genus, Taenia solium, Tick-borne encephalitis virus (TBEV), Toxocara canis or Toxocara cati, Toxoplasma gondii, Treponema pallidum, Trichinella spiralis, Trichomonas vaginalis, Trichophyton spp, Trichuris trichiura, Trypanosoma brucei, Trypanosoma cruzi, Ureaplasma urealyticum, Varicella zoster virus (VZV), Varicella zoster virus (VZV), Variola major or Variola minor, vCJD prion, Venezuelan equine encephalitis virus, Vibrio cholerae, West Nile virus, Western equine encephalitis virus, Wuchereria bancrofti, Yellow fever virus, Yersinia enterocolitica, Yersinia pestis, and Yersinia pseudotuberculosis. In this context particularly preferred are antigens from the pathogens selected from Influenza virus, respiratory syncytial virus (RSV), Herpes simplex virus (HSV), human Papilloma virus (HPV), Human immunodeficiency virus (HIV), Plasmodium, Staphylococcus aureus, Dengue virus, Chlamydia trachomatis, Cytomegalovirus (CMV), Hepatitis B virus (HBV), Mycobacterium tuberculosis, Rabies virus, and Yellow Fever Virus.
Tumour antigens:
In a further embodiment the artificial nucleic acid molecule according to the present invention may encode a protein or a peptide, which comprises a peptide or protein comprising a tumour antigen, a fragment, variant or derivative of said tumour antigen, preferably, wherein the tumour antigen is a melanocyte-specific antigen, a cancer-testis antigen or a tumour-specific antigen, preferably a CT-X antigen, a non-X CT-antigen, a binding partner for a CT-X antigen or a binding partner for a non-X CT-antigen or a tumour- specific antigen, more preferably a CT-X antigen, a binding partner for a non-X CT-antigen or a tumour-specific antigen or a fragment, variant or derivative of said tumour antigen; and wherein each of the nucleic acid sequences encodes a different peptide or protein; and wherein at least one of the nucleic acid sequences encodes for 5T4, 707-AP, 9D7, AFP, AlbZIP HPG1 , alpha-5-beta-1 -integrin, alpha-5-beta-6-integrin, alpha-actinin-4/m, alpha- methylacyl-coenzyme A racemase, ART-4, ARTC1/m, B7H4, BAGE-1 , BCL-2, bcr/abl, beta- catenin/m, BING-4, BRCA1/m, BRCA2/m, CA 15-3/CA 27-29, CA 1 9-9, CA72-4, CA125, calreticulin, CAMEL, CASP-8/m, cathepsin B, cathepsin L, CD1 9, CD20, CD22, CD25, CDE30, CD33, CD4, CD52, CD55, CD56, CD80, CDC27/m, CDK4/m, CDKN2A/m, CEA, CLCA2, CML28, CML66, COA-1/m, coactosin-like protein, collage XXIII, COX-2, CT- 9/BRD6, Cten, cyclin B1 , cyclin D1 , cyp-B, CYPB1 , DAM-10, DAM-6, DEK-CAN, EFTUD2/m, EGFR, ELF2/m, EMMPRIN, EpCam, EphA2, EphA3, ErbB3, ETV6-AML1 , EZH2, FGF-5, FN, Frau-1 , G250, GAGE-1 , GAGE-2, GAGE-3, GAGE-4, GAGE-5, GAGE-6, GAGE7b, GAGE-8, GDEP, GnT-V, gp100, GPC3, GPNMB/m, HAGE, HAST-2, hepsin, Her2/neu, HERV-K-MEL, HLA-A*0201 -R1 7I, HLA-A1 1/m, HLA-A2/m, HNE, homeobox NKX3.1 , HOM-TES-14/SCP-1 , HOM-TES-85, HPV-E6, HPV-E7, HSP70-2M, HST-2, hTERT, iCE, IGF-1 R, IL-13Ra2, IL-2R, IL-5, immature laminin receptor, kallikrein-2, kallikrein-4, Ki67, KIAA0205, KIAA0205/m, KK-LC-1 , K-Ras/m, LAGE-A1 , LDLR-FUT, MAGE-A1 , MAGE-A2, MAGE- A3, MAGE-A4, MAGE-A6, MAGE-A9, MAGE-A10, MAGE-A12, MAGE-B1 , MAGE- B2, MAGE-B3, MAGE-B4, MAGE-B5, MAGE-B6, MAGE-B10, MAGE-B16, MAGE-B1 7, MAGE-C1 , MAGE-C2, MAGE-C3, MAGE-D1 , MAGE-D2, MAGE-D4, MAGE-E1 , MAGE-E2, MAGE-F1 , MAGE-H1 , MAGEL2, mammaglobin A, MART-1/melan-A, MART-2, MART-2/m, matrix protein 22, MC1 R, M-CSF, ME1/m, mesothelin, MG50/PXDN, MMP1 1 , MN/CA IX- antigen, MRP-3, MUC-1 , MUC-2, MUM-1/m, MUM-2/m, MUM-3/m, myosin class l/m, NA88-A, N-acetylglucosaminyltransferase-V, Neo-PAP, Neo-PAP/m, NFYC/m, NGEP, NMP22, NPM/ALK, N-Ras/m, NSE, NY-ESO-1 , NY-ESO-B, OA1 , OFA-iLRP, OGT, OGT/m, OS-9, OS-9/m, osteocalcin, osteopontin, pi 5, p190 minor bcr-abl, p53, p53/m, PAGE-4, PAI- 1 , PAI-2, PAP, PART-1 , PATE, PDEF, Pim-1 -Kinase, Pin-1 , Pml/PARalpha, POTE, PRAME, PRDX5/m, prostein, proteinase-3, PSA, PSCA, PSGR, PSM, PSMA, PTPRK/m, RAGE-1 , RBAF600/m, RHAMM/CD1 68, RU1 , RU2, S-100, SAGE, SART-1 , SART-2, SART-3, SCC, SIRT2/m, Sp1 7, SSX-1 , SSX-2/HOM-MEL-40, SSX-4, STAMP-1 , STEAP-1 , survivin, survivin- 2B, SYT-SSX-1 , SYT-SSX-2, TA-90, TAG-72, TARP, TEL-AML1 , TGFbeta, TGFbetaRII, TGM- 4, TPI/m, TRAG-3, TRG, TRP-1 , TRP-2/6b, TRP/INT2, TRP-p8, tyrosinase, UPA, VEGFR1 , VEGFR-2/FLK-1 , WT1 and a immunoglobulin idiotype of a lymphoid blood cell or a T cell receptor idiotype of a lymphoid blood cell, or a fragment, variant or derivative of said tumour antigen; preferably survivin or a homologue thereof, an antigen from the MAGE-family or a binding partner thereof or a fragment, variant or derivative of said tumour antigen. Particularly preferred in this context are the tumour antigens NY-ESO-1 , 5T4, MAGE-C1 , MAGE-C2, Survivin, Muc-1 , PSA, PSMA, PSCA, STEAP and PAP.
In a preferred embodiment, the artificial nucleic acid molecule encodes a protein or a peptide, which comprises a therapeutic protein or a fragment, variant or derivative thereof.
Therapeutic proteins as defined herein are peptides or proteins, which are beneficial for the treatment of any inherited or acquired disease or which improves the condition of an individual. Particularly, therapeutic proteins play an important role in the creation of therapeutic agents that could modify and repair genetic errors, destroy cancer cells or pathogen infected cells, treat immune system disorders, treat metabolic or endocrine disorders, among other functions. For instance, Erythropoietin (EPO), a protein hormone can be utilized in treating patients with erythrocyte deficiency, which is a common cause of kidney complications. Furthermore adjuvant proteins, therapeutic antibodies are encompassed by therapeutic proteins and also hormone replacement therapy which is e.g. used in the therapy of women in menopause. In more recent approaches, somatic cells of a patient are used to reprogram them into pluripotent stem cells, which replace the disputed stem cell therapy. Also these proteins used for reprogramming of somatic cells or used for differentiating of stem cel ls are defined herein as therapeutic proteins. Furthermore, therapeutic proteins may be used for other purposes, e.g. wound healing, tissue regeneration, angiogenesis, etc. Furthermore, antigen-specific B cell receptors and fragments and variants thereof are defined herein as therapeutic proteins.
Therefore therapeutic proteins can be used for various purposes including treatment of various diseases like e.g. infectious diseases, neoplasms (e.g. cancer or tumour diseases), diseases of the blood and blood-forming organs, endocrine, nutritional and metabolic diseases, diseases of the nervous system, diseases of the circulatory system, diseases of the respiratory system, diseases of the digestive system, diseases of the skin and subcutaneous tissue, diseases of the musculoskeletal system and connective tissue, and diseases of the genitourinary system, independently if they are inherited or acquired.
In this context, particularly preferred therapeutic proteins which can be used inter alia in the treatment of metabol ic or endocrine disorders are selected from (in brackets the particular disease for which the therapeutic protein is used in the treatment): Acid sphingomyelinase (Niemann-Pick disease), Adipotide (obesity), Agalsidase-beta (human galactosidase A) (Fabry disease; prevents accumulation of lipids that could lead to renal and cardiovascular complications), Alglucosidase (Pompe disease (glycogen storage disease type II)), alpha- galactosidase A (alpha-GAL A, Agalsidase alpha) (Fabry disease), alpha-glucosidase (Glycogen storage disease (GSD), Morbus Pompe), alpha-L-iduronidase (mucopolysaccharidoses (MPS), Hurler syndrome, Scheie syndrome), alpha-N- acetylglucosaminidase (Sanfil ippo syndrome), Amphiregulin (cancer, metabolic disorder), Angiopoietin ((Ang1 , Ang2, Ang3, Ang4, ANGPTL2, ANGPTL3, ANGPTL4, ANGPTL5, ANGPTL6, ANGPTL7) (angiogenesis, stabilize vessels), Betacellulin (metabolic disorder), Beta-glucuronidase (Sly syndrome), Bone morphogenetic protein BMPs (BMP1 , BMP2, BMP3, BMP4, BMP5, BMP6, BMP7, BMP8a, BMP8b, BMP1 0, BMP1 5) (regenerative effect, bone- related conditions, chronic kidney disease (CKD)), CLN6 protein (CLN6 disease - Atypical Late Infantile, Late Onset variant, Early Juvenile, Neuronal Ceroid Lipofuscinoses (NCL)), Epidermal growth factor (EGF) (wound healing, regulation of cell growth, proliferation, and differentiation), Epigen (metabolic disorder), Epiregulin (metabolic disorder), Fibroblast Growth Factor (FGF, FGF-1 , FGF-2, FGF-3, FGF-4, FGF-5, FGF-6, FGF-7, FGF-8, FGF-9, FGF- 1 0, FGF-1 1 , FGF-12, FGF-1 3, FGF-1 4, FGF-1 6, FGF-1 7, FGF-1 7, FGF-1 8, FGF-1 9, FGF-20, FGF-21 , FGF-22, FGF-23) (wound healing, angiogenesis, endocrine disorders, tissue regeneration), Galsulphase (Mucopolysaccharidosis VI), Ghrelin (irritable bowel syndrome (IBS), obesity, Prader-Willi syndrome, type II diabetes mellitus), Glucocerebrosidase (Gaucher's disease), GM-CSF (regenerative effect, production of white blood cells, cancer), Heparin-binding EGF-like growth factor (HB-EGF) (wound healing, cardiac hypertrophy and heart development and function), Hepatocyte growth factor HGF (regenerative effect, wound healing), Hepcidin (iron metabolism disorders, Beta-thalassemia), Human albumin (Decreased production of albumin (hypoproteinaemia), increased loss of albumin (nephrotic syndrome), hypovolemia, hyperbilirubinaemia), Idursulphase (lduronate-2 -sulphatase) (Mucopolysaccharidosis II (Hunter syndrome)), Integrins α.νβ3, aVp5 and α5β1 (Bind matrix macromolecules and proteinases, angiogenesis), luduronate sulfatase (Hunter syndrome), Laronidase (Hurler and Hurler-Scheie forms of mucopolysaccharidosis I), N- acetylgalactosamine-4-sulfatase (rhASB; galsulfase, Arylsulfatase A (ARSA), Arylsulfatase B (ARSB)) (arylsulfatase B deficiency, Maroteaux-Lamy syndrome, mucopolysaccharidosis VI), N-acetylglucosamine-6-sulfatase (Sanfilippo syndrome), Nerve growth factor (NGF, Brain- Derived Neurotrophic Factor (BDNF), Neurotrophin-3 (NT-3), and Neurotrophin 4/5 (NT-4/5) (regenerative effect, cardiovascular diseases, coronary atherosclerosis, obesity, type 2 diabetes, metabolic syndrome, acute coronary syndromes, dementia, depression, schizophrenia, autism, Rett syndrome, anorexia nervosa, bulimia nervosa, wound healing, skin ulcers, corneal ulcers, Alzheimer's disease), Neuregulin (NRG1 , NRG2, NRG3, NRG4) (metabolic disorder, schizophrenia), Neuropilin (NRP-1 , NRP-2) (angiogenesis, axon guidance, cel l survival, migration), Obestatin (irritable bowel syndrome (IBS), obesity, Prader- Willi syndrome, type II diabetes mellitus), Platelet Derived Growth factor (PDGF (PDFF-A, PDGF-B, PDGF-C, PDGF-D) (regenerative effect, wound healing, disorder in angiogenesis, Arteriosclerosis, Fibrosis, cancer), TGF beta receptors (endoglin, TGF-beta 1 receptor, TGF- beta 2 receptor, TGF-beta 3 receptor) (renal fibrosis, kidney disease, diabetes, ultimately end- stage renal disease (ESRD), angiogenesis), Thrombopoietin (THPO) (Megakaryocyte growth and development factor (MGDF)) (platelets disorders, platelets for donation, recovery of platelet counts after myelosuppressive chemotherapy), Transforming Growth factor (TGF (TGF-alpha, TGF-beta (TGFbetal , TGFbeta2, and TGFbeta3))) (regenerative effect, wound healing, immunity, cancer, heart disease, diabetes, Marfan syndrome, Loeys-Dietz syndrome), VEGF (VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGF-E, VEGF-F und PIGF) (regenerative effect, angiogenesis, wound healing, cancer, permeability), Nesiritide (Acute decompensated congestive heart failure), Trypsin (Decubitus ulcer, varicose ulcer, debridement of eschar, dehiscent wound, sunburn, meconium ileus), adrenocorticotrophic hormone (ACTH) ("Addison's disease, Small cell carcinoma, Adrenoleukodystrophy, Congenital adrenal hyperplasia, Cushing's syndrome, Nelson's syndrome, Infantile spasms), Atrial-natriuretic peptide (ANP) (endocrine disorders), Cholecystokinin (diverse), Gastrin (hypogastrinemia), Leptin (Diabetes, hypertriglyceridemia, obesity), Oxytocin (stimulate breastfeeding, non-progression of parturition), Somatostatin (symptomatic treatment of carcinoid syndrome, acute variceal bleeding, and acromegaly, polycystic diseases of the liver and kidney, acromegaly and symptoms caused by neuroendocrine tumors), Vasopressin (antidiuretic hormone) (diabetes insipidus), Calcitonin (Postmenopausal osteoporosis, Hypercalcaemia, Paget's disease, Bone metastases, Phantom limb pain, Spinal Stenosis), Exenatide (Type 2 diabetes resistant to treatment with metformin and a sulphonylurea), Growth hormone (GH), somatotropin (Growth failure due to GH deficiency or chronic renal insufficiency, Prader-Willi syndrome, Turner syndrome, AIDS wasting or cachexia with antiviral therapy), Insulin (Diabetes mellitus, diabetic ketoacidosis, hyperkalemia), Insulinlike growth factor 1 IGF-1 (Growth failure in children with GH gene deletion or severe primary IGF1 deficiency, neurodegenerative disease, cardiovascular diseases, heart failure), Mecasermin rinfabate, IGF-1 analog (Growth failure in children with GH gene deletion or severe primary IGF1 deficiency, neurodegenerative disease, cardiovascular diseases, heart failure), Mecasermin, IGF-1 analog (Growth failure in children with GH gene deletion or severe primary IGF1 deficiency, neurodegenerative disease, cardiovascular diseases, heart failure), Pegvisomant (Acromegaly), Pramlintide (Diabetes mellitus, in combination with insulin), Teriparatide (human parathyroid hormone residues 1 -34) (Severe osteoporosis), Becaplermin (Debridement adjunct for diabetic ulcers), Dibotermin-alpha (Bone morphogenetic protein 2) (Spinal fusion surgery, bone injury repair), Histrelin acetate (gonadotropin releasing hormone; GnRH) (Precocious puberty), Octreotide (Acromegaly, symptomatic relief of VIP-secreting adenoma and metastatic carcinoid tumours), and Palifermin (keratinocyte growth factor; KGF) (Severe oral mucositis in patients undergoing chemotherapy, wound healing). These and other proteins are understood to be therapeutic, as they are meant to treat the subject by replacing its defective endogenous production of a functional protein in sufficient amounts. Accordingly, such therapeutic proteins are typically mammalian, in particular human proteins.
For the treatment of blood disorders, diseases of the circulatory system, diseases of the respiratory system, cancer or tumour diseases, infectious diseases or immunedeficiencies following therapeutic proteins may be used: Alteplase (tissue plasminogen activator; tPA) (Pulmonary embolism, myocardial infarction, acute ischaemic stroke, occlusion of central venous access devices), Anistreplase (Thrombolysis), Antithrombin III (AT-lll) (Hereditary AT- III deficiency, Thromboembolism), Bivalirudin (Reduce blood-clotting risk in coronary angioplasty and heparin-induced thrombocytopaenia), Darbepoetin-alpha (Treatment of anaemia in patients with chronic renal insufficiency and chronic renal failure (+/- dialysis)), Drotrecogin-alpha (activated protein C) (Severe sepsis with a high risk of death), Erythropoietin, Epoetin-alpha, erythropoetin, erthropoyetin (Anaemia of chronic disease, myleodysplasia, anaemia due to renal failure or chemotherapy, preoperative preparation), Factor IX (Haemophilia B), Factor Vila (Haemorrhage in patients with haemophilia A or B and inhibitors to factor VIII or factor IX), Factor VIII (Haemophilia A), Lepirudin (Heparin-induced thrombocytopaenia), Protein C concentrate (Venous thrombosis, Purpura fulminans), Reteplase (deletion mutein of tPA) (Management of acute myocardial infarction, improvement of ventricular function), Streptokinase (Acute evolving transmural myocardial infarction, pulmonary embolism, deep vein thrombosis, arterial thrombosis or embolism, occlusion of arteriovenous cannula), Tenecteplase (Acute myocardial infarction), Urokinase (Pulmonary embolism), Angiostatin (Cancer), Anti-CD22 immunotoxin (Relapsed CD33+ acute myeloid leukaemia), Denileukin diftitox (Cutaneous T-cell lymphoma (CTCL)), Immunocyanin (bladder and prostate cancer), MPS (Metallopanstimulin) (Cancer), Aflibercept (Non-small cell lung cancer (NSCLC), metastatic colorectal cancer (mCRC), hormone-refractory metastatic prostate cancer, wet macular degeneration), Endostatin (Cancer, inflammatory diseases like rheumatoid arthritis as well as Crohn's disease, diabetic retinopathy, psoriasis, and endometriosis), Collagenase (Debridement of chronic dermal ulcers and severely burned areas, Dupuytren's contracture, Peyronie's disease), Human deoxy-ribonuclease I, dornase (Cystic fibrosis; decreases respiratory tract infections in selected patients with FVC greater than 40% of predicted), Hyaluronidase (Used as an adjuvant to increase the absorption and dispersion of injected drugs, particularly anaesthetics in ophthalmic surgery and certain imaging agents), Papain (Debridement of necrotic tissue or liquefication of slough in acute and chronic lesions, such as pressure ulcers, varicose and diabetic ulcers, burns, postoperative wounds, pi lonidal cyst wounds, carbuncles, and other wounds), L- Asparaginase (Acute lymphocytic leukaemia, which requires exogenous asparagine for proliferation), Peg-asparaginase (Acute lymphocytic leukaemia, which requires exogenous asparagine for proliferation), Rasburicase (Paediatric patients with leukaemia, lymphoma, and solid tumours who are undergoing anticancer therapy that may cause tumour lysis syndrome), Human chorionic gonadotropin (HCG) (Assisted reproduction), Human follicle-stimulating hormone (FSH) (Assisted reproduction), Lutropin-alpha (Infertility with luteinizing hormone deficiency), Prolactin (Hypoprolactinemia, serum prolactin deficiency, ovarian dysfunction in women, anxiety, arteriogenic erecti le dysfunction, premature ejaculation, oligozoospermia, asthenospermia, hypofunction of seminal vesicles, hypoandrogenism in men), alpha-1 -Proteinase inhibitor (Congenital antitrypsin deficiency), Lactase (Gas, bloating, cramps and diarrhoea due to inabi lity to digest lactose), Pancreatic enzymes (lipase, amylase, protease) (Cystic fibrosis, chronic pancreatitis, pancreatic insufficiency, post-Billroth II gastric bypass surgery, pancreatic duct obstruction, steatorrhoea, poor digestion, gas, bloating), Adenosine deaminase (pegademase bovine, PEG-ADA) (Severe combined immunodeficiency disease due to adenosine deaminase deficiency), Abatacept (Rheumatoid arthritis (especially when refractory to TNFalpha inhibition)), Alefacept (Plaque Psoriasis ), Anakinra (Rheumatoid arthritis), Etanercept (Rheumatoid arthritis, polyarticular-course juvenile rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, plaque psoriasis, ankylosing spondylitis), lnterleukin-1 (IL-1 ) receptor antagonist, Anakinra (inflammation and cartilage degradation associated with rheumatoid arthritis), Thymulin (neurodegenerative diseases, rheumatism, anorexia nervosa), TNF-alpha antagonist (autoimmune disorders such as rheumatoid arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, hidradenitis suppurativa, refractory asthma), Enfuvirtide (HIV-1 infection), and Thymosin <x1 (Hepatitis B and C).
(in brackets is the particular disease for which the therapeutic protein is used in the treatment)
In a further aspect, the present invention provides a vector comprising
a. an open reading frame (ORF) and/or a cloning site, e.g. for insertion of an open reading frame or a sequence comprising an open reading frame; and b. at least one 3'-untranslated region element (3'-UTR element) and/or at least one 5'- untranslated region element (5'-UTR element), wherein the at least one 3'-UTR element and/or the at least one 5'-UTR element prolongs and/or increases protein production from said artificial nucleic acid molecule and wherein the at least one 3'-UTR element and/or the at least one 5'-UTR element is derived from a stable rriRNA.
In general, the vector according to the present invention may comprise an artificial nucleic acid molecule according to the present invention as described above. In particular, the preferred embodiments described above for an artificial nucleic acid molecule according to the present invention also apply for an artificial nucleic acid molecule according to the present invention, which is comprised by a vector according to the present invention. For example, in the inventive vector the at least one 3'-UTR element and/or the at least one 5'- UTR element and the ORF are as described above for the artificial nucleic acid molecule according to the present invention, including the preferred embodiments. For example, in the vector according to the present invention, the stable mRNA from which the at least one 3'- UTR element and/or the at least one 5'-UTR element is derived may be preferably characterized by an mRNA decay wherein the ratio of the amount of said mRNA at a second point in time to the amount of said mRNA at a first point in time is at least 0.5 (50%), at least 0.6 (60%), at least 0.7 (70%), at least 0.75 (75%), at least 0.8 (80%), at least 0.85 (85%), at least 0.9 (90%), or at least 0.95 (95%).
The cloning site may be any sequence that is suitable for introducing an open reading frame or a sequence comprising an open reading frame, such as one or more restriction sites. Thus, the vector comprising a cloning site is preferably suitable for inserting an open reading frame into the vector, preferably for inserting an open reading frame 3' to the 5'-UTR element and/or 5' to the 3'-UTR element. Preferably the cloning site or the ORF is located 3' to the 5'-UTR element and/or 5' to the 3'-UTR element, preferably in close proximity to the 3'-end of the 5'-UTR element and/or to the 5'-end of the 3'-UTR element. For example, the cloning site or the ORF may be directly connected to the 3'-end of the 5'-UTR element and/or to the 5'-end of the 3'-UTR element or they may be connected via a stretch of nucleotides, such as by a stretch of 2, 4, 6, 8, 10, 20 etc. nucleotides as described above for the artificial nucleic acid molecule according to the present invention. Preferably, the vector according to the present invention is suitable for producing the artificial nucleic acid molecule according to the present invention, preferably for producing an artificial mRNA according to the present invention, for example, by optionally inserting an open reading frame or a sequence comprising an open reading frame into the vector and transcribing the vector. Thus, preferably, the vector comprises elements needed for transcription, such as a promoter, e.g. an RNA polymerase promoter. Preferably, the vector is suitable for transcription using eukaryotic, prokaryotic, viral or phage transcription systems, such as eukaryotic cells, prokaryotic cells, or eukaryotic, prokaryotic, viral or phage in vitro transcription systems. Thus, for example, the vector may comprise a promoter sequence, which is recognized by a polymerase, such as by an RNA polymerase, e.g. by a eukaryotic, prokaryotic, viral, or phage RNA polymerase. In a preferred embodiment, the vector comprises a phage RNA polymerase promoter such as an SP6, T3 or T7, preferably a T7 promoter. Preferably, the vector is suitable for in vitro transcription using a phage based in vitro transcription system, such as a T7 RNA polymerase based in vitro transcription system. In another preferred embodiment, the vector may be used directly for expression of the encoded peptide or protein in cells or tissue. For this purpose, the vector comprises particular elements, which are necessary for expression in those cells/tissue e.g. particular promoter sequences, such as a CMV promoter. The vector may further comprise a poly(A) sequence and/or a polyadenylation signal as described above for the artificial nucleic acid molecule according to the present invention.
The vector may be an RNA vector or a DNA vector. Preferably, the vector is a DNA vector. The vector may be any vector known to the skilled person, such as a viral vector or a plasmid vector. Preferably, the vector is a plasmid vector, preferably a DNA plasmid vector.
In a preferred embodiment, the vector according to the present invention comprises the artificial nucleic acid molecule according to the present invention. Preferably, a DNA vector according to the invention comprises a nucleic acid sequence which has an identity of at least about 1 , 2, 3, 4, 5, 10, 1 5, 20, 30 or 40%, preferably of at least about 50%, preferably of at least about 60%, preferably of at least about 70%, more preferably of at least about 80%, more preferably of at least about 90%, even more preferably of at least about 95%, even more preferably of at least about 99%, most preferably of 100% to the nucleic acid sequence of a 3'-UTR of a transcript of a gene, such as to the nucleic acid sequences according to SEQ ID NOs: 1 to 24 and SEQ ID NOs: 49 to 318. Preferably, a DNA vector according to the invention comprises a nucleic acid sequence which has an identity of at least about 1 , 2, 3, 4, 5, 10, 15, 20, 30 or 40%, preferably of at least about 50%, preferably of at least about 60%, preferably of at least about 70%, more preferably of at least about 80%, more preferably of at least about 90%, even more preferably of at least about 95%, even more preferably of at least about 99%, most preferably of 100% to the nucleic acid sequence of a 5'-UTR of a transcript of a gene, such as to the nucleic acid sequences according to SEQ ID NOs: 25 to 30 and SEQ ID NOs: 31 9 to 382.
Preferably, a DNA vector according to the present invention comprises a sequence selected from the group consisting of DNA sequences according to SEQ ID NOs. 1 to 30 or a sequence having an identity of at least about 40%, preferably of at least about 50%, preferably of at least about 60%, preferably of at least about 70%, more preferably of at least about 80%, more preferably of at least about 90%, even more preferably of at least about 95%; even more preferably of at least about 99% sequence identity to the DNA sequences according to SEQ ID NOs. 1 to 30 or a fragment thereof as described above, preferably a functional fragment thereof.
Preferably, an RNA vector according to the present invention comprises a sequence selected from the group consisting of the sequences according to RNA sequences corresponding to DNA sequences according to SEQ ID NOs: 1 to 30 or a sequence having an identity of at least about 40%, preferably of at least about 50%, preferably of at least about 60%, preferably of at least about 70%, more preferably of at least about 80%, more preferably of at least about 90%, even more preferably of at least about 95%; even more preferably of at least about 99% sequence identity to the RNA sequences corresponding to the DNA sequences according to SEQ ID NOs: 1 to 30 or to a fragment thereof, preferably a functional fragment thereof.
Preferably, the vector is a circular molecule. Preferably, the vector is a double-stranded molecule, such as a double-stranded DNA molecule. Such circular, preferably double stranded DNA molecule may be used conveniently as a storage form for the inventive artificial nucleic acid molecule. Furthermore, it may be used for transfection of cells, for example, cultured cells. Also it may be used for in vitro transcription for obtaining an artificial RNA molecule according to the invention. Preferably, the vector, preferably the circular vector, is linearizable, for example, by restriction enzyme digestion. In a preferred embodiment, the vector comprises a cleavage site, such as a restriction site, preferably a unique cleavage site, located immediately 3' to the ORF, or - if present - located immediately 3' to the 3'-UTR element, or - if present - located 3' to the poly(A) sequence or polyadenylation signal, or - if present - located 3' to the poly(C) sequence, or - if present - located 3' to the histone stem-loop. Thus, preferably, the product obtained by linearizing the vector terminates at the 3'end with the 3'-end of the ORF, or - if present - with the 3'-end of the 3'-UTR element, or - if present - with the 3'-end of the poly(A) sequence or polyadenylation signal, or - if present - with the 3'-end of the poly(C) sequence. In the embodiment, wherein the vector according to the present invention comprises the artificial nucleic acid molecule according to the present invention, a restriction site, preferably a unique restriction site, is preferably located immediately 3' to the 3'-end of the artificial nucleic acid molecule.
In a further aspect, the present invention relates to a cell comprising the artificial nucleic acid molecule according to the present invention or the vector according to present invention. The cell may be any cell, such as a bacterial cell, insect cell, plant cell, vertebrate cell, e.g. a mammalian cell. Such cell may be, e.g., used for replication of the vector of the present invention, for example, in a bacterial cell. Furthermore, the cell may be used for transcribing the artificial nucleic acid molecule or the vector according to the present invention and/or translating the open reading frame of the artificial nucleic acid molecule or the vector according to the present invention. For example, the cell may be used for recombinant protein production.
The cells according to the present invention are, for example, obtainable by standard nucleic acid transfer methods, such as standard transfection, transduction or transformation methods. For example, the artificial nucleic acid molecule or the vector according to the present invention may be transferred into the cell by electroporation, lipofection, e.g. based on cationic lipids and/or liposomes, calcium phosphate precipitation, nanoparticle based transfection, virus based transfection, or based on cationic polymers, such as DEAE-dextran or polyethylenimine etc.
Preferably, the cell is a mammalian cell, such as a cell of human subject, a domestic animal, a laboratory animal, such as a mouse or rat cell. Preferably the cell is a human cell. The cell may be a cell of an established cell line, such as a CHO, BHK, 293T, COS-7, HELA, HEK, etc. or the cell may be a primary cell, such as a human dermal fibroblast (HDF) cell etc., preferably a cell isolated from an organism. In a preferred embodiment, the cell is an isolated cell of a mammalian subject, preferably of a human subject. For example, the cell may be an immune cell, such as a dendritic cell, a cancer or tumor cell, or any somatic cell etc., preferably of a mammalian subject, preferably of a human subject.
In a further aspect, the present invention provides a pharmaceutical composition comprising the artificial nucleic acid molecule according to the present invention, the vector according the present invention, or the cell according to the present invention. The pharmaceutical composition according to the invention may be used, e.g., as a vaccine, for example, for genetic vaccination. Thus, the ORF may, e.g., encode an antigen to be administered to a patient for vaccination. Thus, in a preferred embodiment, the pharmaceutical composition according to the present invention is a vaccine. Furthermore, the pharmaceutical composition according to the present invention may be used, e.g., for gene therapy.
Preferably, the pharmaceutical composition further comprises one or more pharmaceutically acceptable vehicles, diluents and/or excipients and/or one or more adjuvants. In the context of the present invention, a pharmaceutically acceptable vehicle typically includes a liquid or non-liquid basis for the inventive pharmaceutical composition. In one embodiment, the pharmaceutical composition is provided in liquid form. In this context, preferably, the vehicle is based on water, such as pyrogen-free water, isotonic saline or buffered (aqueous) solutions, e.g phosphate, citrate etc. buffered solutions. The buffer may be hypertonic, isotonic or hypotonic with reference to the specific reference medium, i.e. the buffer may have a higher, identical or lower salt content with reference to the specific reference medium, wherein preferably such concentrations of the afore mentioned salts may be used, which do not lead to damage of mammalian cells due to osmosis or other concentration effects. Reference media are e.g. liquids occurring in "in vivo" methods, such as blood, lymph, cytosolic liquids, or other body liquids, or e.g. liquids, which may be used as reference media in "in vitro" methods, such as common buffers or liquids. Such common buffers or liquids are known to a skilled person. Ringer-Lactate solution is particularly preferred as a liquid basis. One or more compatible solid or liquid fillers or diluents or encapsulating compounds suitable for administration to a patient may be used as well for the inventive pharmaceutical composition. The term "compatible" as used herein preferably means that these components of the inventive pharmaceutical composition are capable of being mixed with the inventive artificial nucleic acid, vector or cells as defined herein in such a manner that no interaction occurs which would substantially reduce the pharmaceutical effectiveness of the inventive pharmaceutical composition under typical use conditions.
The pharmaceutical composition according to the present invention may optionally further comprise one or more additional pharmaceutically active components. A pharmaceutically active component in this context is a compound that exhibits a therapeutic effect to heal, ameliorate or prevent a particular indication or disease. Such compounds include, without implying any limitation, peptides or proteins, nucleic acids, (therapeutically active) low molecular weight organic or inorganic compounds (molecular weight less than 5000, preferably less than 1000), sugars, antigens or antibodies, therapeutic agents already known in the prior art, antigenic cells, antigenic cellular fragments, cellular fractions, cell wall components (e.g. polysaccharides), modified, attenuated or de-activated (e.g. chemically or by irradiation) pathogens (virus, bacteria etc.).
Furthermore, the inventive pharmaceutical composition may comprise a carrier for the artificial nucleic acid molecule or the vector. Such a carrier may be suitable for mediating dissolution in physiological acceptable liquids, transport and cellular uptake of the pharmaceutical active artificial nucleic acid molecule or the vector. Accordingly, such a carrier may be a component which may be suitable for depot and delivery of an artificial nucleic acid molecule or vector according to the invention. Such components may be, for example, cationic or polycationic carriers or compounds which may serve as transfection or complexation agent.
Particularly preferred transfection or complexation agents in this context are cationic or polycationic compounds, including protamine, nucleoline, spermine or spermidine, or other cationic peptides or proteins, such as poly-L-lysine (PLL), poly-arginine, basic polypeptides, cell penetrating peptides (CPPs), including HIV-binding peptides, HIV-1 Tat (HIV), Tat- derived peptides, Penetratin, VP22 derived or analog peptides, HSV VP22 (Herpes simplex), MAP, KALA or protein transduction domains (PTDs), PpT620, proline-rich peptides, arginine- rich peptides, lysine-rich peptides, MPG-peptide(s), Pep-1 , L-oligomers, Calcitonin peptide(s), Antennapedia-derived peptides (particularly from Drosophila antennapedia), pAntp, plsl, FGF, Lactoferrin, Transportan, Buforin-2, Bac715-24, SynB, SynB(1 ), pVEC, hCT-derived peptides, SAP, or histones. Furthermore, such cationic or polycationic compounds or carriers may be cationic or polycationic peptides or proteins, which preferably comprise or are additionally modified to comprise at least one -SH moiety. Preferably, a cationic or polycationic carrier is selected from cationic peptides having the following sum formula (I): {(Arg)i;(Lys)m;(His)„;(Orn)0;(Xaa)x}; formula (I) wherein I + m + n + o + x = 3-100, and I, m, n or o independently of each other is any number selected from 0, 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 1 1 , 12, 13, 14, 1 5, 1 6, 1 7, 1 8, 19, 20, 21 -30, 31 - 40, 41 -50, 51 -60, 61 -70, 71 -80, 81 -90 and 91 -100 provided that the overall content of Arg (Arginine), Lys (Lysine), His (Histidine) and Orn (Ornithine) represents at least 10% of all amino acids of the oligopeptide; and Xaa is any amino acid selected from native (= naturally occurring) or non-native amino acids except of Arg, Lys, His or Orn; and x is any number selected from 0, 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 1 1 , 12, 13, 14, 15, 1 6, 1 7, 18, 1 9, 20, 21 -30, 31 - 40, 41 -50, 51 -60, 61 -70, 71 -80, 81 -90, provided, that the overall content of Xaa does not exceed 90 % of all amino acids of the oligopeptide. Any of amino acids Arg, Lys, His, Orn and Xaa may be positioned at any place of the peptide. In this context cationic peptides or proteins in the range of 7-30 amino acids are particular preferred.
Further, the cationic or polycationic peptide or protein, when defined according to formula {(Arg)i;(Lys)m;(His)n;(Orn)o;(Xaa)x} (formula (I)) as shown above and which comprise or are additionally modified to comprise at least one -SH moeity, may be, without being restricted thereto, selected from subformula (la): {(Arg),;(Lys)m;(His)„;(Orn)0;(Xaa')x (Cys)y} subformula (la) wherein (Arg)i;(Lys)m;(H is)n;(Orn)0; and x are as defined herein, Xaa' is any amino acid selected from native (= naturally occurring) or non-native amino acids except of Arg, Lys, His, Orn or Cys and y is any number selected from 0, 1 , 2, 3, 4, 5, 6, 7, 8, 9, 1 0, 1 1 , 12, 1 3, 14, 1 5, 1 6, 1 7, 1 8, 1 9, 20, 21 -30, 31 -40, 41 -50, 51 -60, 61 -70, 71 -80 and 81 -90, provided that the overall content of Arg (Arginine), Lys (Lysine), His (Histidine) and Orn (Ornithine) represents at least 1 0% of all amino acids of the oligopeptide. Further, the cationic or polycationic peptide may be selected from subformula (lb):
{(Arg)i;(Lys)m;(His)n;(Om)0;(Xaa)x} Cys2 subformula (lb) wherein empirical formula {(Arg)i;(Lys)m;(His)n;(Orn)0;(Xaa)x} (formula (III)) is as defined herein and forms a core of an amino acid sequence according to (semiempirical) formula (III) and wherein Cysi and Cys2 are Cysteines proximal to, or terminal to (Arg)i;(Lys)m;(His)n;(Orn)0;(Xaa)x.
Further preferred cationic or polycationic compounds, which can be used as transfection or complexation agent may include cationic polysaccharides, for example chitosan, polybrene, cationic polymers, e.g. polyethyleneimine (PEI), cationic lipids, e.g. DOTMA: [1 -(2,3- sioleyIoxy)propyl)]-N,N,N-trimethylammonium chloride, DMRIE, di-CI 4-amidine, DOTIM, SAINT, DC-Choi, BGTC, CTAP, DOPC, DODAP, DOPE: Dioleyl phosphatidylethanol-amine, DOSPA, DODAB, DOIC, DMEPC, DOGS: Dioctadecylamidoglicylspermin, DIMRI: Dimyristo-oxypropyl dimethyl hydroxyethyl ammonium bromide, DOTAP: dioleoyloxy-3- (trimethylammonio)propane, DC-6-14: 0,0-ditetradecanoyl-N-(a- trimethylammonioacetyl)diethanolamine chloride, CLIP1 : rac-[(2,3-dioctadecyloxypropyl)(2- hydroxyethyl)]-dimethylammonium chloride, CLIP6: rac-[2(2,3-dihexadecyloxypropyl- oxymethyloxy)ethyl]-trimethylammonium, CLIP9: rac-[2(2,3-dihexadecyloxypropyl- oxysuccinyloxy)ethyl]-trimethylammonium, oligofectamine, or cationic or polycationic polymers, e.g. modified polyaminoacids, such as β-aminoacid-polymers or reversed polyamides, etc., modified polyethylenes, such as PVP (poly(N-ethyl-4-vinylpyridinium bromide)), etc., modified acrylates, such as pDMAEMA (poly(dimethylaminoethyl methylacrylate)), etc., modified Amidoamines such as pAMAM (poly(amidoamine)), etc., modified polybetaaminoester (PBAE), such as diamine end modified 1 ,4 butanediol diacrylate-co-5-amino-1 -pentanol polymers, etc., dendrimers, such as polypropylamine dendrimers or pAMAM based dendrimers, etc., polyimine(s), such as PEI: poly(ethyleneimine), poly(propyleneimine), etc., polyallylamine, sugar backbone based polymers, such as cyclodextrin based polymers, dextran based polymers, chitosan, etc., si lan backbone based polymers, such as PMOXA-PDMS copolymers, etc., blockpolymers consisting of a combination of one or more cationic blocks (e.g. selected from a cationic polymer as mentioned above) and of one or more hydrophi lic or hydrophobic blocks (e.g polyethyleneglycole); etc.
According to another embodiment, the pharmaceutical composition according to the invention may comprise an adjuvant in order to enhance the immunostimulatory properties of the pharmaceutical composition. In this context, an adjuvant may be understood as any compound, which is suitable to support administration and delivery of the components such as the artificial nucleic acid molecule or vector comprised in the pharmaceutical composition according to the invention. Furthermore, such an adjuvant may, without being bound thereto, initiate or increase an immune response of the innate immune system, i.e. a non-specific immune response. With other words, when administered, the pharmaceutical composition according to the invention typically initiates an adaptive immune response directed to the antigen encoded by the artificial nucleic acid molecule. Additionally, the pharmaceutical composition according to the invention may generate an (supportive) innate immune response due to addition of an adjuvant as defined herein to the pharmaceutical composition according to the invention. Such an adjuvant may be selected from any adjuvant known to a skilled person and suitable for the present case, i.e. supporting the induction of an immune response in a mammal. Preferably, the adjuvant may be selected from the group consisting of, without being limited thereto, TDM, MDP, muramyl clipeptide, pluronics, alum solution, aluminium hydroxide, ADJUMERTM (polyphosphazene); aluminium phosphate gel; glucans from algae; algammulin; aluminium hydroxide gel (alum); highly protein-adsorbing aluminium hydroxide gel; low viscosity aluminium hydroxide gel; AF or SPT (emulsion of squalane (5%), Tween 80 (0.2%), Pluronic L121 (1 .25%), phosphate-buffered saline, pH 7.4); AVRIDINETM (propanediamine); BAY R1 005TM ((N-(2-deoxy-2-L-leucylamino-b-D-glucopyranosyl)-N- octadecyl-dodecanoyl-amide hydroacetate); CALCITRIOLTM (1 -alpha,25-dihydroxy-vitamin D3); calcium phosphate gel; CAPTM (calcium phosphate nanoparticles); cholera holotoxin, cholera-toxin-A1 -protein-A-D-fragment fusion protein, sub-unit B of the cholera toxin; CRL 1005 (block copolymer P1205); cytokine-containing liposomes; DDA (dimethyldioctadecylammonium bromide); DHEA (dehydroepiandrosterone); DMPC (dimyristoylphosphatidylcholine); DMPG (dimyristoylphosphatidylglycerol); DOC/alum complex (deoxycholic acid sodium salt); Freund's complete adjuvant; Freund's incomplete adjuvant; gamma inulin; Gerbu adjuvant (mixture of: i) N-acetylglucosaminyl-(P1 -4)-N- acetylmuramyl-L-alanyl-D-glutamine (GMDP), ii) dimethyldioctadecylammonium chloride (DDA), iii) zinc-L-proline salt complex (ZnPro-8); GM-CSF); GMDP (N-acetylglucosaminyl- (b1 -4)-N-acetylmuramyl-L-alanyl-D-isoglutamine); imiquimod (1 -(2-methypropyl)-1 H- imidazo[4,5-c]quinoline-4-amine); ImmTherTM (N-acetylglucosaminyl-N-acetylmuramyl-L- Ala-D-isoGlu-L-Ala-glycerol dipalmitate); DRVs (immunoliposomes prepared from dehydration-rehydration vesicles); interferon-gamma; interleukin-1 beta; interleukin-2; interleukin-7; interleukin-12; ISCOMSTM; ISCOPREP 7.0.3. TM; liposomes; LOXORIBINETM (7-allyl-8-oxoguanosine); LT oral adjuvant (E.coli labile enterotoxin-protoxin); microspheres and microparticles of any composition; MF59TM; (squalene-water emulsion); MONTANIDE ISA 51 TM (purified incomplete Freund's adjuvant); MONTANIDE ISA 720TM (metabolisable oil adjuvant); MPLTM (3-Q-desacyl-4'-monophosphoryl lipid A); MTP-PE and MTP-PE liposomes ((N-acetyl-L-alanyl-D-isoglutaminyl-L-alanine-2-(1 ,2-dipalmitoyl-sn-glycero-3- (hydroxyphosphoryloxy))-ethylamide, monosodium salt); MURAMETIDETM (Nac-Mur-L-Ala- D-Gln-OCH3); MURAPALMITINETM and D-MURAPALMITINETM (Nac-Mur-L-Thr-D- isoGln-sn-glyceroldipalmitoyl); NAGO (neuraminidase-galactose oxidase); nanospheres or nanoparticles of any composition; NISVs (non-ionic surfactant vesicles); PLEURANTM ( - glucan); PLGA, PGA and PLA (homo- and co-polymers of lactic acid and glycolic acid; microspheres/nanospheres); PLURONIC L121 TM; PMMA (polymethyl methacrylate); PODDSTM (proteinoid microspheres); polyethylene carbamate derivatives; poly-rA: poly-rU (polyadenylic acid-polyuridylic acid complex); polysorbate 80 (Tween 80); protein cochleates (Avanti Polar Lipids, Inc., Alabaster, AL); STIMULONTM (QS-21 ); Quil-A (Quil-A saponin); S-28463 (4-amino-otec-dimethyl-2-ethoxymethyl-1 H-imidazo[4,5 c]quinoline-1 - ethanol); SAF-1 TM ("Syntex adjuvant formulation"); Sendai proteoliposomes and Sendai- containing lipid matrices; Span-85 (sorbitan trioleate); Specol (emulsion of Marcol 52, Span 85 and Tween 85); squalene or Robane® (2,6,10,1 5, 1 9,23-hexamethyltetracosan and 2,6, 1 0, 1 5, 1 9,23-hexamethyl-2, 6, 1 0,1 4, 1 8,22-tetracosahexane); stearyltyrosine (octadecyltyrosine hydrochloride); Theramid® (N-acetylglucosaminyl-N-acetylmuramyl-L- Ala-D-isoGlu-L-Ala-dipalmitoxypropylamide); Theronyl-MDP (TermurtideTM or [thr 1 ]- MDP; N-acetylmuramyl-L-threonyl-D-isoglutamine); Ty particles (Ty-VLPs or virus-like particles); Walter-Reed liposomes (liposomes containing lipid A adsorbed on aluminium hydroxide), and lipopeptides, including Pam3Cys, in particular aluminium salts, such as Adju-phos, Alhydrogel, Rehydragel; emulsions, including CFA, SAF, IFA, MF59, Provax, TiterMax, Montanide, Vaxfectin; copolymers, including Optivax (CRL1 005), L121 , Poloaxmer401 0), etc.; liposomes, including Stealth, cochleates, including BIORAL; plant derived adjuvants, including QS21 , Quil A, Iscomatrix, ISCOM; adjuvants suitable for costimulation including Tomatine, biopolymers, including PLG, PMM, Inulin,; microbe derived adjuvants, including Romurtide, DETOX, MPL, CWS, Mannose, CpG nucleic acid sequences, CpG7909, ligands of human TLR 1 -10, ligands of murine TLR 1 -1 3, ISS-1 01 8, IC31 , Imidazoquinolines, Ampligen, Ribi529, IMOxine, IRIVs, VLPs, cholera toxin, heat- labi le toxin, Pam3Cys, Flagellin, GPI anchor, LNFPIII/Lewis X, antimicrobial peptides, UC- 1 V1 50, RSV fusion protein, cdiGMP; and adjuvants suitable as antagonists including CGRP neuropeptide.
Suitable adjuvants may also be selected from cationic or polycationic compounds wherein the adjuvant is preferably prepared upon complexing the artificial nucleic acid molecule or the vector of the pharmaceutical composition with the cationic or polycationic compound. Association or complexing the artificial nucleic acid molecule or the vector of the pharmaceutical composition with cationic or polycationic compounds as defined herein preferably provides adjuvant properties and confers a stabilizing effect to the artificial nucleic acid molecule or the vector of the pharmaceutical composition. Particularly such preferred, such cationic or polycationic compounds are selected from cationic or polycationic peptides or proteins, including protamine, nucleoline, spermin or spermidine, or other cationic peptides or proteins, such as poly-L-lysine (PLL), poly-arginine, basic polypeptides, cell penetrating peptides (CPPs), including HIV-binding peptides, Tat, HIV-1 Tat (HIV), Tat- derived peptides, Penetratin, VP22 derived or analog peptides, HSV VP22 (Herpes simplex), MAP, KALA or protein transduction domains (PTDs, PpT620, prolin-rich peptides, arginine- rich peptides, lysine-rich peptides, MPG-peptide(s), Pep-1 , L-oligomers, Calcitonin peptide(s), Antennapedia-derived peptides (particularly from Drosophila antennapedia), pAntp, plsl, FGF, Lactoferrin, Transportan, Buforin-2, Bac71 5-24, SynB, SynB(1 ), pVEC, hCT-derived peptides, SAP, protamine, spermine, spermidine, or histones. Further preferred cationic or polycationic compounds may include cationic polysaccharides, for example chitosan, polybrene, cationic polymers, e.g. polyethyleneimine (PEI), cationic lipids, e.g. DOTMA: 1 - (2,3-sioleyloxy)propyl) -Ν,Ν,Ν-trimethylammonium chloride, DMRIE, di-C14-amidi ne, DOTIM, SAINT, DC-Choi, BGTC, CTAP, DOPC, DODAP, DOPE: Dioleyl phosphatidylethanol-amine, DOSPA, DODAB, DOIC, DMEPC, DOGS: Dioctadecylamidoglicylspermin, DIMRI: Dimyristo-oxypropyl dimethyl hydroxyethyl ammonium bromide, DOTAP: dioleoyloxy-3-(trimethylammonio)propane, DC-6-14: Ο,Ο- ditetradecanoyl-N-( -trimethylammonioacetyl)diethanolamine chloride, CLIP1 : rac-[(2,3- dioctadecyloxypropyl)(2-hydroxyethyl)]-dimethylammonium chloride, CLIP6: rac-[2(2,3- dihexadecyloxypropyl-oxymethyloxy)ethyl]-trimethylammonium, CLIP9: rac-[2(2,3- dihexadecyloxypropyl-oxysuccinyloxy)ethyl]-trimethylammonium, oligofectamine, or cationic or polycationic polymers, e.g. modified polyaminoacids, such as -aminoacid- polymers or reversed polyamides, etc., modified polyethylenes, such as PVP (poly(N-ethyl-4- vinylpyridinium bromide)), etc., modified acrylates, such as pDMAEMA (poly(dimethylaminoethyl methylacrylate)), etc., modified Amidoamines such as pAMAM (poly(amidoamine)), etc., modified polybetaaminoester (PBAE), such as diamine end modified 1 ,4 butanediol diacrylate-co-5-amino-1 -pentanol polymers, etc., dendrimers, such as polypropylamine dendrimers or pAMAM based dendrimers, etc., polyimine(s), such as PEI: poly(ethyleneimine), poly(propyleneimine), etc., polyallylamine, sugar backbone based polymers, such as cyclodextrin based polymers, dextran based polymers, Chitosan, etc., si lan backbone based polymers , such as PMOXA-PDMS copolymers, etc., Blockpolymers consisting of a combination of one or more cationic blocks (e.g. selected of a cationic polymer as mentioned above) and of one or more hydrophilic- or hydrophobic blocks (e.g polyethyleneglycole); etc.
Additionally, preferred cationic or polycationic proteins or peptides, which can be used as an adjuvant by complexing the artificial nucleic acid molecule or the vector, preferably an RNA, of the composition, may be selected from following proteins or peptides having the following total formula (I): (Arg)l;(Lys)m;(His)n;(Orn)o;(Xaa)x, wherein l + m + n +o + x = 8- 1 5, and I, m, n or o independently of each other may be any number selected from 0, 1 , 2, 3, 4, 5, 6, 7, 8, 9, 1 0, 1 1 , 1 2, 1 3, 14 or 1 5, provided that the overal l content of Arg, Lys, His and Orn represents at least 50% of all amino acids of the oligopeptide; and Xaa may be any amino acid selected from native (= naturally occurring) or non-native amino acids except of Arg, Lys, His or Orn; and x may be any number selected from 0, 1 , 2, 3 or 4, provided, that the overall content of Xaa does not exceed 50 % of all amino acids of the oligopeptide. Particularly preferred oligoargi nines in this context are e.g. Arg7, Arg8, Arg9, Arg7, H3R9, R9H3, H3R9H3, YSSR9SSY, (RKH)4, Y(RKH)2R, etc.
The ratio of the artificial nucleic acid or the vector to the cationic or polycationic compound may be calculated on the basis of the nitrogen/phosphate ratio (N/P-ratio) of the entire nucleic acid complex. For example, 1 pg RNA typically contains about 3 nmol phosphate residues, provided the RNA exhibits a statistical distribution of bases. Additionally, 1 pg peptide typically contains about x nmol nitrogen residues, dependent on the molecular weight and the number of basic amino acids. When exemplarily calculated for (Arg)9 (molecular weight 1424 g/mol, 9 nitrogen atoms), 1 pg (Arg)9 contains about 700 pmol (Arg)9 and thus 700 x 9=6300 pmol basic amino acids = 6.3 nmol nitrogen atoms. For a mass ratio of about 1 :1 RNA/(Arg)9 an N/P ratio of about 2 can be calculated. When exemplarily calculated for protamine (molecular weight about 4250 g/mol, 21 nitrogen atoms, when protamine from salmon is used) with a mass ratio of about 2:1 with 2 pg RNA, 6 nmol phosphate are to be calulated for the RNA; 1 pg protamine contains about 235 pmol protamine molecues and thus 235 x 21 = 4935 pmol basic nitrogen atoms = 4.9 nmol nitrogen atoms. For a mass ratio of about 2:1 RNA/protamine an N/P ratio of about 0.81 can be calculated. For a mass ratio of about 8:1 RNA/protamine an N/P ratio of about 0.2 can be calculated. In the context of the present invention, an N/P-ratio is preferably in the range of about 0.1 -10, preferably in a range of about 0.3-4 and most preferably in a range of about 0.5-2 or 0.7-2 regarding the ratio of nucleic acid:peptide in the complex, and most preferably in the range of about 0.7- 1 .5.
Patent application WO2010/037539, the disclosure of which is incorporated herein by reference, describes an immunostimulatory composition and methods for the preparation of an immunostimulatory composition. Accordingly, in a preferred embodiment of the invention, the composition is obtained in two separate steps in order to obtain both, an efficient immunostimulatory effect and efficient translation of the artificial nucleic acid molecule according to the invention. Therein, a so called "adjuvant component" is prepared by complexing - in a first step - the artificial nucleic acid molecule or vector, preferably an RNA, of the adjuvant component with a cationic or polycationic compound in a specific ratio to form a stable complex. In this context, it is important, that no free cationic or polycationic compound or only a neglibly small amount remains in the adjuvant component after complexing the nucleic acid. Accordingly, the ratio of the nucleic acid and the cationic or polycationic compound in the adjuvant component is typically selected in a range that the nucleic acid is entirely complexed and no free cationic or polycationic compound or only a neclectably small amount remains in the composition. Preferably the ratio of the adjuvant component, i.e. the ratio of the nucleic acid to the cationic or polycationic compound is selected from a range of about 6:1 (w/w) to about 0,25:1 (w/w), more preferably from about 5:1 (w/w) to about 0,5:1 (w/w), even more preferably of about 4:1 (w/w) to about 1 :1 (w/w) or of about 3:1 (w/w) to about 1 :1 (w/w), and most preferably a ratio of about 3 :1 (w/w) to about 2:1 (w/w). According to a preferred embodiment, the artificial nucleic acid molecule or vector, preferably an RNA molecule, according to the invention is added in a second step to the complexed nucleic acid molecule, preferably an RNA, of the adjuvant component in order to form the (immunostimulatory) composition of the invention. Therein, the artificial acid molecule or vector, preferably an RNA, of the invention is added as free nucleic acid, i.e. nucleic acid, which is not complexed by other compounds. Prior to addition, the free artificial nucleic acid molecule or vector is not complexed and will preferably not undergo any detectable or significant complexation reaction upon the addition of the adjuvant component.
Suitable adjuvants may furthermore be selected from nucleic acids having the formula (II): GlXmGn, wherein: G is guanosine, uraci l or an analogue of guanosine or uracil; X is guanosine, uracil, adenosine, thymidine, cytosine or an analogue of the above-mentioned nucleotides; I is an integer from 1 to 40, wherein when I = 1 G is guanosine or an analogue thereof, when I > 1 at least 50% of the nucleotides are guanosine or an analogue thereof; m is an integer and is at least 3; wherein when m = 3 X is uraci l or an analogue thereof, when m > 3 at least 3 successive uraci ls or analogues of uraci l occur; n is an integer from 1 to 40, wherei n when n = 1 G is guanosine or an analogue thereof, when n > 1 at least 50% of the nucleotides are guanosine or an analogue thereof. Other suitable adjuvants may furthermore be selected from nucleic acids having the formula (III): ClXmCn, wherein: C is cytosine, uracil or an analogue of cytosine or uracil; X is guanosine, uracil, adenosine, thymidine, cytosine or an analogue of the above-mentioned nucleotides; I is an integer from 1 to 40, wherein when 1 = 1 C is cytosine or an analogue thereof, when I > 1 at least 50% of the nucleotides are cytosine or an analogue thereof; m is an integer and is at least 3; wherein when m = 3 X is uracil or an analogue thereof, when m > 3 at least 3 successive uracils or analogues of uracil occur; n is an integer from 1 to 40, wherein when n = 1 C is cytosine or an analogue thereof, when n > 1 at least 50% of the nucleotides are cytosine or an analogue thereof.
The pharmaceutical composition according to the present invention preferably comprises a "safe and effective amount" of the components of the pharmaceutical composition, particularly of the inventive artificial nucleic acid molecule, the vector and/or the cells as defined herein. As used herein, a "safe and effective amount" means an amount sufficient to significantly induce a positive modification of a disease or disorder as defined herein. At the same time, however, a "safe and effective amount" preferably avoids serious side-effects and permits a sensible relationship between advantage and risk. The determination of these limits typically lies within the scope of sensible medical judgment. In a further aspect, the present invention provides the artificial nucleic acid molecule according to the present invention, the vector according to the present invention, the cell according to the present invention, or the pharmaceutical composition according to the present invention for use as a medicament, for example, as vaccine (in genetic vaccination) or in gene therapy.
The artificial nucleic acid molecule according to the present invention, the vector according to the present invention, the cell according to the present invention, or the pharmaceutical composition according to the present invention are particularly suitable for any medical application which makes use of the therapeutic action or effect of peptides, polypeptides or proteins, or where supplementation of a particular peptide or protein is needed. Thus, the present invention provides the artificial nucleic acid molecule according to the present invention, the vector according to the present invention, the cell according to the present invention, or the pharmaceutical composition according to the present invention for use in the treatment or prevention of diseases or disorders amenable to treatment by the therapeutic action or effect of peptides, polypeptides or proteins or amenable to treatment by supplementation of a particular peptide, polypeptide or protein. For example, the artificial nucleic acid molecule according to the present invention, the vector according to the present invention, the cell according to the present invention, or the pharmaceutical composition according to the present invention may be used for the treatment or prevention of genetic diseases, autoimmune diseases, cancerous or tumour- related diseases, infectious diseases, chronic diseases or the like, e.g., by genetic vaccination or gene therapy. In particular, such therapeutic treatments which benefit from an increased and prolonged presence of therapeutic peptides, polypeptides or proteins in a subject to be treated are especially suitable as medical application in the context of the present invention, since the inventive 3'-UTR element provides for a stable and prolonged expression of the encoded peptide or protein of the inventive artificial nucleic acid molecule or vector and/or the inventive 5'-UTR element provides for an increased expression of the encoded peptide or protein of the inventive artificial nucleic acid molecule or vector. Thus, a particularly suitable medical application for the artificial nucleic acid molecule according to the present invention, the vector according to the present invention, the cell according to the present invention, or the pharmaceutical composition according to the present invention is vaccination. Thus, the present invention provides the artificial nucleic acid molecule according to the present invention, the vector according to the present invention, the cell according to the present invention, or the pharmaceutical composition according to the present invention for vaccination of a subject, preferably a mammalian subject, more preferably a human subject. Preferred vaccination treatments are vaccination against infectious diseases, such as bacterial, protozoal or viral infections, and anti-tumour-vaccination. Such vaccination treatments may be prophylactic or therapeutic.
Depending on the disease to be treated or prevented, the ORF may be selected. For example, the open reading frame may code for a protein that has to be supplied to a patient suffering from total lack or at least partial loss of function of a protein, such as a patient suffering from a genetic disease. Additionally the open reading frame may be chosen from an ORF coding for a peptide or protein which beneficially influences a disease or the condition of a subject. Furthermore, the open reading frame may code for a peptide or protein which effects down- regulation of a pathological overproduction of a natural peptide or protein or elimination of cel ls expressing pathological ly a protein or peptide. Such lack, loss of function or overproduction may, e.g., occur in the context of tumour and neoplasia, autoimmune diseases, allergies, infections, chronic diseases or the like. Furthermore, the open reading frame may code for an antigen or immunogen, e.g. for an epitope of a pathogen or for a tumour antigen. Thus, in preferred embodiments, the artificial nucleic acid molecule or the vector according to the present invention comprises an ORF encoding an amino acid sequence comprising or consisting of an antigen or immunogen, e.g. an epitope of a pathogen or a tumour-associated antigen, a 3'-UTR element as described above and/or a 5'-UTR element as described above, and optional further components, such as a poly(A) sequence etc.
In the context of medical application, in particular, in the context of vaccination, it is preferred that the artificial nucleic acid molecule according to the present invention is RNA, preferably mRNA, since DNA harbours the risk of eliciting an anti-DNA immune response and tends to insert into genomic DNA. However, in some embodiments, for example, if a viral delivery vehicle, such as an adenoviral delivery vehicle is used for delivery of the artificial nucleic acid molecule or the vector according to the present invention, e.g., in the context of gene therapeutic treatments, it may be desirable that the artificial nucleic acid molecule or the vector is a DNA molecule.
The artificial nucleic acid molecule according to the present invention, the vector according to the present invention, the cell according to the present invention, or the pharmaceutical composition according to the present invention may be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally, via an implanted reservoir or via jet injection. The term parenteral as used herein includes subcutaneous, intravenous, intramuscular, intra-articular, intra-synovial, intrasternal, intrathecal, intrahepatic, intralesional, intracranial, transdermal, intradermal, intrapulmonal, intraperitoneal, intracardial, intraarterial, and sublingual injection or infusion techniques. In a preferred embodiment, the artificial nucleic acid molecule according to the present invention, the vector according to the present invention, the cell according to the present invention, or the pharmaceutical composition according to the present invention is administered via needle- free injection (e.g. jet injection). Preferably, the artificial nucleic acid molecule according to the present invention, the vector according to the present invention, the cell according to the present invention, or the pharmaceutical composition according to the present invention is administered parenterally, e.g. by parenteral injection, more preferably by subcutaneous, intravenous, intramuscular, intra-articular, intra-synovial, intrasternal, intrathecal, intrahepatic, intralesional, intracranial, transdermal, intradermal, intrapulmonal, intraperitoneal, intracardial, intraarterial, sublingual injection or via infusion techniques. Particularly preferred is intradermal and intramuscular injection. Sterile injectable forms of the inventive pharmaceutical composition may be aqueous or oleaginous suspension. These suspensions may be formulated according to techniques known in the art using suitable dispersing or wetting agents and suspending agents. Preferably, the solutions or suspensions are administered via needle-free injection (e.g. jet injection). The artificial nucleic acid molecule according to the present invention, the vector according to the present invention, the cell according to the present invention, or the pharmaceutical composition according to the present invention may also be administered orally in any orally acceptable dosage form including, but not limited to, capsules, tablets, aqueous suspensions or solutions.
The artificial nucleic acid molecule according to the present invention, the vector according to the present invention, the cell according to the present invention, or the pharmaceutical composition according to the present invention may also be administered topically, especially when the target of treatment includes areas or organs readily accessible by topical application, e.g. including diseases of the skin or of any other accessible epithelial tissue. Suitable topical formulations are readily prepared for each of these areas or organs. For topical applications, the artificial nucleic acid molecule according to the present invention, the vector according to the present invention, the cell according to the present invention, or the pharmaceutical composition according to the present invention may be formulated in a suitable ointment suspended or dissolved in one or more carriers.
In one embodiment, the use as a medicament comprises the step of transfection of mammalian cells, preferably in vitro or ex vivo transfection of mammalian cells, more preferably in w'iro transfection of isolated cells of a subject to be treated by the medicament. If the use comprises the in vitro transfection of isolated cells, the use as a medicament may further comprise the readministration of the transfected cells to the patient. The use of the inventive artificial nucleic acid molecules or the vector as a medicament may further comprise the step of selection of successfully transfected isolated cells. Thus, it may be beneficial if the vector further comprises a selection marker. Also, the use as a medicament may comprise in vitro transfection of isolated cells and purification of an expression-product, i.e. the encoded peptide or protein from these cells. This purified peptide or protein may subsequently be administered to a subject in need thereof.
The present invention also provides a method for treating or preventing a disease or disorder as described above comprising administering the artificial nucleic acid molecule according to the present invention, the vector according to the present invention, the cell according to the present invention, or the pharmaceutical composition according to the present invention to a subject in need thereof.
Furthermore, the present invention provides a method for treating or preventing a disease or disorder comprising transfection of a cell with an artificial nucleic acid molecule according to the present invention or with the vector according to the present invention. Said transfection may be performed in vitro, ex vivo or in vivo. In a preferred embodiment, transfection of a cell is performed in vitro and the transfected cell is administered to a subject in need thereof, preferably to a human patient. Preferably, the cell which is to be transfected in vitro is an isolated cell of the subject, preferably of the human patient. Thus, the present invention provides a method of treatment comprising the steps of isolating a cell from a subject, preferably from a human patient, transfecting the isolated cell with the artificial nucleic acid according to the present invention or the vector according to the present invention, and administering the transfected cell to the subject, preferably the human patient.
The method of treating or preventing a disorder according to the present invention is preferably a vaccination method or a gene therapy method as described above.
As described above, the inventive 3'-UTR element and/or the inventive 5'-UTR element are capable of prolonging and/or increasing the protein production from an mRNA. Thus, in a further aspect, the present invention relates to a method for increasing and/or prolonging protein production from an artificial nucleic acid molecule, preferably from an mRNA molecule or a vector, the method comprising the step of associating an open reading frame with a 3'-UTR element and/or a 5'-UTR element, wherein the 3'-UTR element and/or the 5'- UTR element prolongs and/or increases protein production from a resulting artificial nucleic acid molecule and wherein the at least one 3'-UTR element and/or the at least one 5'-UTR element is derived from a stable mRNA, to obtain an artificial nucleic acid molecule, preferably an mRNA molecule, according to the present invention as described above or a vector according to the present invention as described above.
Preferably, in the method for increasing and/or prolonging protein production from an artificial nucleic acid molecule, preferably from an mRNA molecule or a vector, according to the present invention the 3'-UTR element and/or the 5'-UTR element comprises or consists of a nucleic acid sequence which is derived from the 3'-UTR and/or the 5'-UTR of a transcript of a gene selected from the group consisting of GNAS (guanine nucleotide binding protein, alpha stimulating complex locus), MORN2 (MORN repeat containing 2), GSTM1 (glutathione S-transferase, mu 1 ), NDUFA1 (NADH dehydrogenase (ubiquinone) 1 alpha subcomplex), CBR2 (carbonyl reductase 2), MP68 (RIKEN cDNA 2010107E04 gene), NDUFA4 (NADH dehydrogenase (ubiquinone) 1 alpha subcomplex 4), LTA4H, SLC38A6, DECR1 , PIGK, FAM1 75A, PHYH, TBC1 D19, PIGB, ALG6, CRYZ, BRP44L, ACADSB, SUPT3H, TMEM14A, GRAMD1 C, C1 1 orf80, C9orf46, ANXA4, TBCK, IFI6, C2orf34, ALDH6A1 , AGTPBP1 , CCDC53, LRRC28, CCDC109B, PUS10, CCDC104, CASP1 , SNX14, SKAP2, NDUFB6, EFHA1 , BCKDHB, BBS2, LMBRD1 , ITGA6, HERC5,NT5DC1 , RAB7A, AGA, TPK1 , MBNL3, HADHB, MCCC2, CAT, ANAPC4, PCCB, PHKB, ABCB7, PGCP, GPD2, TMEM38B, NFU1 , OMA1 , LOC128322/NUTF2, NUBPL, LANCL1 , HHLA3, PIR, ACAA2, CTBS, GSTM4, ALG8, Atp5e, Gstm5, Uqcr1 1 , Ifi27l2a, Anapc13, Atp5l, Tmsbl O, Nenf, Ndufa7, Atp5k, 1 1 10008P14Rik, Cox4i1 , Cox6a1 , Ndufs6, Sec61 b, Romol , Snrpd2, Mgst3, Aldh2, Ssr4, Myl6, Prdx4, Ubl5, 1 1 10001 J03Rik, Ndufa13, Ndufa3, Gstp2, Tmem1 60, Ergic3, Pgcp, Slpi, Myeov2, Ndufs5, 181002701 ORik, Atp5o, Shfml , Tspo, S100a6, Taldol , Blod sl , Hexa, Ndufb1 1 , Map1 lc3a, Gpx4, Mif, Cox6b1 , RIKEN cDNA2900010J23 (Swi5), Sec61 g, 290001 0M23Rik, Anapc5, Mars2, Phptl , Ndufb8, Pfdn5, Arpc3, Ndufb7, Atp5h, Mrpl23, Uba52, Tomm6, Mtchl , Pcbd2, Ecm1 , Hrsp12, Mecr, Uqcrq, Gstm3, Lsm4, Parl<7, Usmg5, Cox8a, Ly6c1 , Cox7b, Ppib, Bag1 , S100a4, Bcap31 , Tecr, Rabad , Robld3, Sodl , Nedd8, Higd2a, Trappc6a, Ldhb, Nme2, Snrpg, Nclufa2, Serfl , Oaz1 , Rps4x, Rps13, Ybx1 , Seppl , Gaa, ACTR1 0, PIGF, MGST3, SCP2, HPRT1 , ACSF2, VPS13A, CTH, NXT2, MGST2, C1 1 orf67, PCCA, GLMN, DHRS1 , PON2, NME7, ETFDH, ALG1 3, DDX60, DYNC2LI1 , VPS8, 1TFG1 , CD 5, C1 orf1 12, 1FT52, CLYBL, FAM1 14A2, NUDT7, AKD1 , MAGED2, HRSP12, STX8, ACAT1 , IFT74, KIFAP3, CAPN1 , COX1 1 , GLT8D4, HACL1 , IFT88, NDUFB3, ANO10, ARL6, LPCAT3, ABCD3, COPG2, MIPEP, LEPR, C2orf76, ABCA6, LY96, CROT, ENPP5, SERPINB7, TCP1 1 L2, IRAKI BP1 , CDKL2, GHR, KIAA1 107, RPS6KA6, CLGN, TMEM45A, TBC1 D8B, ACP6, RP6-213H1 9.1 , SNRPN, GLRB, HERC6, CFH, GALC, PDE1 A, GSTM5, CADPS2, AASS, TRIM6-TRIM34 (readthrough transcript), SEPP1 , PDE5A, SATB1 , CCPG1 , CNTN1 , LMBRD2, TLR3, BCAT1 , TOM1 L1 , SLC35A1 , GLYATL2, STAT4, GULP1 , EHHADH, NBEAL1 , KIAA1 598, HFE, KIAA1324L, and MANSC1 ; preferably from the group consisting of GNAS (guanine nucleotide binding protein, alpha stimulating complex locus), MORN2 (MORN repeat containing 2), GSTMl (glutathione S-transferase, mu 1 ), NDUFA1 (NADH dehydrogenase (ubiquinone) 1 alpha subcomplex), CBR2 (carbonyl reductase 2), MP68 (RIKEN cDNA 2010107E04 gene), NDUFA4 (NADH dehydrogenase (ubiquinone) 1 alpha subcomplex 4), Ybx1 (Y-Box binding protein 1 ), Ndufb8 (NADH dehydrogenase (ubiquinone) 1 beta subcomplex 8), and CNTN1 (contactin 1 ).
The term "associating the artificial nucleic acid molecule or the vector with a 3'-UTR element and/or a 5'-UTR element" in the context of the present invention preferably means functionally associating or functionally combining the artificial nucleic acid molecule or the vector with the 3'-UTR element and/or with the 5'-UTR element. This means that the artificial nucleic acid molecule or the vector and the 3'-UTR element and/or the 5'-UTR element, preferably the 3'-UTR element and/or the 5'-UTR element as described above, are associated or coupled such that the function of the 3'-UTR element and/or of the 5'-UTR element, e.g., the RNA and/or protein production prolonging and/or increasing function, is exerted. Typically, this means that the 3'-UTR element and/or the 5'-UTR element is integrated into the artificial nucleic acid molecule or the vector, preferably the mRNA molecule, 3' and/or 5', respectively, to an open reading frame, preferably immediately 3' to an open reading frame and/or immediately 5' to an open reading frame, the 3'-UTR element preferably between the open reading frame and a poly(A) sequence or a polyadenylation signal. Preferably, the 3'- UTR element and/or the 5'-UTR element is integrated into the artificial nucleic acid molecule or the vector, preferably the mRNA, as 3'-UTR and/or as 5'-UTR respectively, i.e. such that the 3'-UTR element and/or the 5'-UTR element is the 3'-UTR and/or the 5'-UTR, respectively, of the artificial nucleic acid molecule or the vector, preferably the mRNA, i.e., such that the 5'-UTR ends immediately before the 5'-end of the ORF and the 3'-UTR extends from the 3'- side of the open reading frame to the 5'-side of a poly(A) sequence or a polyadenylation signal, optionally connected via a short linker, such as a sequence comprising or consisting of one or more restriction sites. Thus, preferably, the term "associating the artificial nucleic acid molecule or the vector with a 3'-UTR element and/or a 5'-UTR element" means functionally associating the 3'-UTR element and/or the 5'-UTR element with an open reading frame located within the artificial nucleic acid molecule or the vector, preferably within the mRNA molecule. The 3'-UTR and/or the 5'-UTR and the ORF are as described above for the artificial nucleic acid molecule according to the present invention, for example, preferably the ORF and the 3'-UTR are heterologous and/or the ORF and the 5'-UTR are heterologous,respectively, e.g. derived from different genes, as described above. In a further aspect, the present invention provides the use of a 3'-UTR element and/or of a 5'- UTR element, preferably the 3'-UTR element as described above and/or the 5'-UTR element as described above, for increasing and/or prolonging protein production from an artificial nucleic acid molecule, preferably from an mRNA molecule or a vector, wherein the 3'-UTR element and/or the 5'-UTR element comprises or consists of a nucleic acid sequence which is derived from the 3'-UTR and/or the 5'-UTR of a transcript of a gene selected from the group consisting of GNAS (guanine nucleotide binding protein, alpha stimulating complex locus), MORN2 (MORN repeat containing 2), GSTM1 (glutathione S-transferase, mu 1 ), NDUFA1 (NADH dehydrogenase (ubiquinone) 1 alpha subcomplex), CBR2 (carbonyl reductase 2), MP68 (RIKEN cDNA 2010107E04 gene), NDUFA4 (NADH dehydrogenase (ubiquinone) 1 alpha subcomplex 4), LTA4H, SLC38A6, DECR1 , PIGK, FAM1 75A, PHYH, TBC1 D19, PIGB, ALG6, CRYZ, BRP44L, ACADSB, SUPT3H, TMEM14A, GRAMD1 C, C1 1 orf80, C9orf46, ANXA4, TBCK, IF16, C2orf34, ALDH6A1 , AGTPBP1 , CCDC53, LRRC28, CCDC109B, PUS10, CCDC104, CASP1 , SNX14, SKAP2, NDUFB6, EFHA1 , BCKDHB, BBS2, LMBRD1 , ITGA6, HERC5, NT5DC1 , RAB7A, AGA, TPK1 , MBNL3, HADHB, MCCC2, CAT, ANAPC4, PCCB, PHKB, ABCB7, PGCP, GPD2, TMEM38B, NFU1 , OMA1 , LOC128322/NUTF2, NUBPL, LANCL1 , HHLA3, PIR, ACAA2, CTBS, GSTM4, ALG8, Atp5e, Gstm5, Uqcrl l , Ifi27l2a, Anapc13, Atp5l, Tmsb10, Nenf, Ndufa7, Atp5k, 1 1 10008P14Rik, Cox4i1 , Cox6a1 , Ndufs6, Sec61 b, Romol , Snrpd2, Mgst3, Aldh2, Ssr4, Myl6, Prdx4, Ubl5, 1 1 10001J03Rik, Ndufa13, Ndufa3, Gstp2, Tmem1 60, Ergic3, Pgcp, Slpi, Myeov2, Ndufs5, 181002701 ORik, Atp5o, Shfml , Tspo, S100a6, Taldol , Blod sl , Hexa, Ndufbl l , Map1 Ic3a, Gpx4, Mif, Cox6b1 , RIKEN CDNA2900010J23 (Swi5), Sec61 g, 2900010M23Rik, Anapc5, Mars2, Phptl , Ndufb8, Pfdn5, Arpc3, Ndufb7, Atp5h, Mrpl23, Uba52, Tomm6, Mtchl , Pcbd2, Ecm1 , Hrsp12, Mecr, Uqcrq, Gstm3, Lsm4, Park7, Usmg5, Cox8a, Ly6c1 , Cox7b, Ppib, Bag1 , S100a4, Bcap31 , Tecr, Rabad , Robld3, Sod1 , Nedd8, Higd2a, Trappc6a, Ldhb, Nme2, Snrpg, Ndufa2, Serfl , Oaz1 , Rps4x, Rps13, Ybx1 , Seppl , Gaa, ACTR10, PIGF, MGST3, SCP2, HPRT1 , ACSF2, VPS13A, CTH, NXT2, MGST2, C1 1 orf67, PCCA, GLMN, DHRS1 , PON2, NME7, ETFDH, ALG13, DDX60, DYNC2LI1 , VPS8, ITFG1 , CDK5, C1 orf1 12, IFT52, CLYBL, FAM1 14A2, NUDT7, AKD1 , MAGED2, HRSP12, STX8, ACAT1 , IFT74, KIFAP3, CAPN1 , COX1 1 , GLT8D4, HACL1 , IFT88, NDUFB3, ANO10, ARL6, LPCAT3, ABCD3, COPG2, MIPEP, LEPR, C2orf76, ABCA6, LY96, CROT, ENPP5, SERPINB7, TCP1 1 L2, IRAKI BP1 , CDKL2, GHR, KIAA1 107, RPS6KA6, CLGN, TMEM45A, TBC1 D8B, ACP6, RP6-213H19.1 , SNRPN, GLRB, HERC6, CFH, GALC, PDE1 A, GSTM5, CADPS2, AASS, TRIM6-TRIM34 (readthrough transcript), SEPP1 , PDE5A, SATB1 , CCPG1 , CNTN1 , LMBRD2, TLR3, BCAT1 , TOM1 L1 , SLC35A1 , GLYATL2, STAT4, GULP1 , EHHADH, NBEAL1 , KIAA1 598, HFE, KIAA1324L, and MANSC1 ; preferably from the group consisting of GNAS (guanine nucleotide binding protein, alpha stimulating complex locus), MORN2 (MORN repeat containing 2), GSTM1 (glutathione S-transferase, mu 1 ), NDUFA1 (NADH dehydrogenase (ubiquinone) 1 alpha subcomplex), CBR2 (carbonyl reductase 2), MP68 (RIKEN cDNA 2010107E04 gene), NDUFA4 (NADH dehydrogenase (ubiquinone) 1 alpha subcomplex 4), Ybx1 (Y-Box binding protein 1 ), Ndufb8 (NADH dehydrogenase (ubiquinone) 1 beta subcomplex 8), and CNTN1 (contactin 1 ).
The uses according to the present invention preferably comprise associating the artificial nucleic acid molecule, the vector, or the RNA with the 3'-UTR element as described above and/or with the 5'-UTR element as described above.
The compounds and ingredients of the inventive pharmaceutical composition may also be manufactured and traded separately of each other. Thus, the invention relates further to a kit or kit of parts comprising an artificial nucleic acid molecule according to the invention, a vector according to the invention, a cell according to the invention, and/or a pharmaceutical composition according to the invention. Preferably, such kit or kits of parts may, additionally, comprise instructions for use, cells for transfection, an adjuvant, a means for administration of the pharmaceutical composition, a pharmaceutically acceptable carrier and/or a pharmaceutically acceptable solution for dissolution or dilution of the artificial nucleic acid molecule, the vector, the cells or the pharmaceutical composition. In a further aspect the present invention provides a method for identifying a 3'-untranslated region element (3'-UTR element) and/or a 5'-untranslated region element (5'-UTR element), which is derived from a stable mRNA, comprising the following steps:
a) Analyzing the stability of an mRNA comprising the following sub-steps: i. Determining the amount of said mRNA at a first point in time during a decay process of said mRNA,
ii. Determining the amount of said mRNA at a second point in time during a decay process of said mRNA, and
iii. Calculating the ratio of the amount of said mRNA determined in step (i) to the the amount of said mRNA determined in step (ii);
b) Selecting a stable mRNA having a ratio calculated in sub-step (iii) of at least
0.5 (50%), at least 0.6 (60%), at least 0.7 (70%), at least 0.75 (75%), at least 0.8 (80%), at least 0.85 (85%), at least 0.9 (90%), or at least 0.95 (95%); and c) Determining the nucleotide sequence of a 3'- and/or 5'-UTR element of said stable mRNA.
Thereby, the stability of the mRNA is preferably assessed under standard conditions, for example standard conditions (standard medium, incubation, etc.) for a certain cell line or cell type used. In order to analyze the stability of an mRNA, the decay process of this mRNA is assessed by determining the amount or concentration of said mRNA at a first and at a second point in time during the decay process of said mRNA (cf. steps a) i. and a) ii.).
To determine the amount or concentration of mRNA during the RNA decay process in vivo or in vitro as defined above (i.e. in vitro referring in particular to ("living") cells and/or tissue, including tissue of a living subject; cells include in particular cell lines, primary cells, cells in tissue or subjects, preferred are mammalian cells, e.g. human cells and mouse cells and particularly preferred are the human cell lines HeLa, and U-937 and the mouse cell lines NIH3T3, JAWSII and L929 are used; furthermore primary cells are particularly preferred, in particular preferred embodiments human dermal fibroblasts (HDF)), various methods may be used, which are known to the skilled person. Non-limiting examples of such methods include general inhibition of transcription, e.g. with a transcription inhibitor such as Actinomycin D, use of inducible promotors to specifically promote transient transcription, e.g. c-fos serum- inducible promotor system and Tet-off regulatory promoter system, and kinetic labelling techniques, e.g. pulse labelling.
For example, if transcriptional inhibitor-mediated transcriptional arrest is used in step a) to determine the amount or concentration of mRNA during the RNA decay process in vivo or in vitro as defined above, transcriptional inhibitors such as Actinomycin D (ActD), 5,6-dichloro- 1 -D-ribofuranosyl-benzimidazole (DRB) or -amanitin (a-Am) may be used. Hereby, to assess mRNA decay, the transcriptional inhibitors are usually added to the cells and, thereby the transcription is generally inhibited and RNA decay can be observed without interferences of ongoing transcription.
Alternatively, inducible promotors to specifically promote transient transcription may be used in step a), whereby the rationale is to provide a stimulus that activates transcription and leads to a burst of mRNA synthesis, then remove the stimulus to shut off transcription and monitor the decay of mRNA. Thereby, the inducible promoter enables a stringent control, so that induction and silencing of transcription is accomplished within a narrow window of time. In mammalian cells, the cfos promoter is known to be valuable for this purpose, because it can be induced in response to serum addition quickly and transiently, thereby providing a reliable and simple way of achieving a transient burst in transcription. The Tet-off promotor system offers another option that further broadens the application of a transcriptional pulsing approach to study mRNA turnover in mammalian cells.
However, in the present invention kinetic labelling techniques are preferred in step a) for determining the amount of mRNA during the RNA decay process in vivoox in vitro as defined above. In kinetic labelling RNA is usually labelled, whereby labels include in particular labelled nucleotides and labelled nucleosides and labelled uridine and labelled uracil are particularly preferred. Examples of preferred labels include 4-thiouridine (4sU), 2-thiouridine, 6-thioguanosine, 5-ethynyluridine (EU), 5-bromo-uridine (BrU), Biotin-16-Aminoallyluridine, 5-Aminoallyluridine, 5-Aminoal lylcytidine, etc., whereby 4-Thiouridine (4sU), 5- Ethynyluridine (EU) or 5'-Bromo-Uridine (BrU) are more preferred. Particularly preferred is 4- thiouridine (4sU). 4-Thiouridine (4sU) is preferably used in a concentration of 1 00-500 μΜ. Moreover, also radioactively labelled nucleotides may be used, e.g. with Uridine-3H. Also combinations of the above mentioned labelled nucleotides may be used, whereby a combination of 4-thiouridine and 6-thioguanosine is particularly preferred.
In kinetic labelling, usually the emerging RNA is labelled, e.g. by incorporation of labelled uridine or uracil during transcription. After a while, the provision of label is stopped and RNA decay may then be observed by assessing specifically labelled RNA without generally inhibiting transcription.
For determining the amount of mRNA during the RNA decay process in step a), pulse labelling is preferred, and a pulse-chase methodology is particularly preferred. As used herein, the term "pulse labelling refers to a technique in which a label, e.g. the labels described above, is used for the measurement of the rates of synthesis and/or decay of compounds within living cel ls. Typically, cells are exposed to a small quantity of a label for a brief period, hence the term 'pulse'. In the pulse-chase methodology, after pulse-labell ing usually a much larger quantity of an unlabeled compound corresponding to the "pulse" (e.g. unlabelled uridine, if label led uridine is used as pulse) is added following the required period of exposure to the label. The effect of competition between the labelled and the unlabeled compound is to reduce to a negligible level the further uptake of the labelled compound, hence the term "chase".
To determine the amount or concentration of mRNA usually the mRNA has to be isolated. Different techniques for RNA isolation are known to the skilled person, e.g. by Guanidinium thiocyanate-phenol-chloroform extraction or by silica-column based extraction. Also commercially available kits may be used, e.g. RNeasy Kit from Qiagen.
Furthermore, an extraction step may be required, in particular if kinetic labelling is used (in contrast to a transcription inhibitor, wherein the total RNA represents "decaying" RNA since transcription is generally inhibited). In the extraction step, labelled RNA (i.e. representing "decaying" RNA) is extracted from total isolated RNA. Thus, the means of extraction may be selected depending on the label used. For example, immunopurification with antibodies to the label may be used.
Furthermore, for example, for extraction of thio-labelled, e.g. 4-thiouridine (4sU)-labelled, RNA, HPDP-Biotin (pyridyldithiol-activated, sulfhydryl-reactive biotinylation reagent that conjugates via a cleavable (reversible) disulfide bond) may be incubated with the isolated "total RNA". This reagent specifically reacts with the reduced thiols (-SH) in the 4-thiouridine (4sU)-labelled RNA to form reversible disulfide bonds. The biotinylation allows for binding of the thio-labelled e.g. 4-thiouridine (4sU)-labelled RNA to streptavidin and therefore can be extracted from the total RNA by reduction of the disulfide bond with clithioth reitol or beta- mercaptoethanol (or any other reduction agent).
In case biotin-labelled nucleotides, e.g. Biotin-1 6-Aminoallyluridine, streptavidin can directly be used to extract the labelled RNA from total RNA.
For example, for extraction of newly transcribed 5-ethynyluridine (EU)-labelled cellular RNAs from total RNA, biotinylation of EU in a copper-catalyzed cycloaddition reaction (often referred to as click chemistry) may be used, which is followed by purification by streptavidin affinity. This method is commercially available as the Click-iT Nascent RNA Capture Kit (Catalog no. C10365, Invitrogen). The manufacturer's instruction of this kit recommends that the pulse labeling time is 30 to 60 min for a 0.5 mM EU dose, or 1 to 24 h for a 0.1 or 0.2 mM EU dose.
For example, BrU-labeled RNA molecules may be extracted by immunopurification with an anti-Bromodeoxyuridine antibody (e.g. Clone. 2B1 , Catalog no. MI-1 1 -3, MBL), and Protein G Sepharose.
The amount or concentration of mRNA, i.e. the transcript level, may then be measured by various methods known to the person skilled in the art. Non-limiting examples for such methods include micro array analysis, Northern Blot analysis, quantitative PCR or by next generation sequencing (high throughput sequencing). Particularly preferred are micro array analysis and next generation sequencing. Moreover, whole-genome approaches/whole transcriptome approaches are particularly preferred, e.g. in micro array analysis whole genome micro array analysis, e.g. Affymetrix Human Gene 1 .0 ST or 2.0 ST or Affymetrix Mouse Gene 1 .0 ST or 2.0 ST or whole transcriptome analysis by next generation sequencing.
In substeps i. and ii. of step a), the amount of mRNA is determined at a first and at a second point in time during a decay process of the mRNA. Typically, this means that mRNA is in particular isolated at a first and at a second point in time during a decay process of the mRNA to determine the respective amounts. Therefore, "the first point in time" and "the second point in time" are in particular points in time during the RNA decay process, at which RNA is isolated to determine the RNA amount. In general, "the second point in time" is later in the RNA decay process than the "the first point in time".
Preferably, the first point in time is selected such, that only mRNA undergoing a decay process is considered, i.e. emerging mRNA - e.g. in ongoing transcription - is avoided. For example, if kinetic labelling techniques, e.g. pulse labelling, are used, the first point in time is preferably selected such that the incorporation of the label into mRNA is completed, i.e. no ongoing incorporation of the label into mRNA occurs. Thus, if kinetic labelling is used, the first point in time may be at least 10 min, at least 20 min, at least 30 min, at least 40 min, at least 50 min, at least 60 min, at least 70 min, at least 80 min, or at least 90 min after the end of the experimental labelling procedure, e.g. after the end of the incubation of cells with the label.
For example, the first point in time may be preferably from 0 to 6 h after the stop of transcription (e.g. by a transcriptional inhibitor), stop of promotor induction in case of inducible promotors or after stop of pulse or label supply, e.g. after end of labelling. More preferably, the first point in time may be from 30 min to 5 h, even more preferably from 1 h to 4 h and particularly preferably about 3 h after the stop of transcription (e.g. by a transcriptional inhibitor), stop of promotor induction in case of inducible promotors or after stop of pulse or label supply, e.g. after end of labelling.
Preferably, the second point in time is selected as late as possible during the mRNA decay process. However, if a plurality of mRNA species is considered, the second point in time is preferably selected such that still a considerable amount of the plurality of mRNA species, preferably at least 10% of the mRNA species, is present in a detectable amount, i.e. in an amount higher than 0. Preferably, the second point in time is at least 5 h, at least 6 h, at least 7 h, at least 8 h, at least 9 h, at least 10 h, at least 1 1 h, at least 12 h, at least 13 h, at least 14 h, or at least 15 h after the stop of transcription (e.g. by a transcriptional inhibitor), stop of promoter induction in case of inducible promotors or after stop of pulse or label supply, e.g. after end of labelling.
For example, the second point in time may be preferably from 3 to 48 h after the stop of transcription (e.g. by a transcriptional inhibitor), stop of promoter induction in case of inducible promotors or after stop of pulse or label supply, e.g. after end of labelling. More preferably, the second point in time may be from 6 min to 36 h, even more preferably from 10 h to 24 h and particularly preferably about 15 h after the stop of transcription (e.g. by a transcriptional inhibitor), stop of promoter induction in case of inducible promotors or after stop of pulse or label supply, e.g. after end of labelling.
Thus, the time span between the first point in time and the second point in time is preferably as large as possible within the above described limits. Therefore, the time span between the first point in time and the second point in time is preferably at least 4 h, at least 5 h, at least 6 h, at least 7 h, at least 8 h, at least 9 h, at least 10 h, at least 1 1 h, or at least 12 h, whereby a time span of about 12 h is particularly preferred. In general, the second later point in time is at least 10 minutes later than the first point in time.
In sub-step iii. of step a) the ratio of the amount of the mRNA determined in step (i) to the the amount of the mRNA determined in step (ii) is calculated. To this end, the amount of the mRNA (transcript level) determined as described above at the second point in time is divided by the amount of the mRNA (transcript level) determined as described above at the first point in time. This ratio prevents that stable mRNAs, which are already at the first point in time present only in very low amounts, are disregarded in respect to mRNAs, which are present in high amounts.
In step b), such an mRNA is selected, which has a ratio calculated in sub-step (iii) of step a) of at least 0.5 (50%), at least 0.6 (60%), at least 0.7 (70%), at least 0.75 (75%), at least 0.8 (80%), at least 0.85 (85%), at least 0.9 (90%), or at least 0.95 (95%). Such mRNA is in the present invention considered as a particular stable mRNA. In step c), the nucleotide sequence of a 3'- and/or 5'-UTR element of said mRNA, i.e. the mRNA selected in step b), is determined. To this end, different methods known to the skilled person may be applied, e.g. sequencing or selection from a publicly available database, such as e.g. NCBI (National Center for Biotechnology Information). For example, the mRNA sequence of the mRNA selected in step b) may be searched in a database and the 3'- and/or 5'-UTR may then be extracted from the mRNA sequence present in the database.
In particular, in the above described method for identifying a 3'-untranslated region element (3'-UTR element) and/or a 5'-untranslated region element (5'-UTR element), which is derived from a stable mRNA, the term "mRNA" and/or "stable mRNA", respectively, may also refer to an mRNA species as defined herein and/or to a stable mRNA species, respectively.
Furthermore, it is preferred in the present invention that a "stable mRNA" may have a slower mRNA decay compared to average mRNA decay, preferably assessed in vivo or in vitro as defined above. Thereby, "average mRNA decay" may be assessed by investigating mRNA decay of a plurality of mRNA species.
Accordingly, the present invention provides in a further aspect a method for identifying a 3'- untranslated region element (3'-UTR element) and/or a 5 '-untranslated region element (5'- UTR element), which is derived from a stable mRNA, comprising the following steps:
a) Analyzing the stability of a plurality of mRNA species comprising the following sub-steps:
i . Determining the amount of each mRNA species of said plurality of mRNA species at a first point in time during a decay process of said mRNA species,
ii. Determining the amount of each mRNA species of said plurality of mRNA species at a second point in time during a decay process of said mRNA species, and
iii . Calculating for each mRNA species of said plurality of mRNA species the ratio of the amount of said mRNA species determined in step (i) to the the amount of said mRNA species determined in step (i i);
b) Ranking of the mRNA species of the plurality of mRNA species according to the ratio calculated in sub-step (ii i) for each mRNA species; c) Selecting one or more mRNA species having the highest ratio or the highest ratios calculated in sub-step (iii); and
d) Determining the nucleotide sequence of a 3'- and/or 5'-UTR element of said mRNA.
An "mRNA species", as used herein, corresponds to a genomic transcription unit, i.e. usually to a gene. Thus, within one "mRNA species" different transcripts may occur, for example, due to mRNA processing. For example, an mRNA species may be represented by a spot on a microarray. Accordingly, a microarray provides an advantageous tool to determine the amount of a plurality of mRNA species, e.g. at a certain point in time during mRNA decay. However, also other techniques known to the skilled person, e.g. RNA-seq (also called Whole Transcriptome Shotgun Sequencing which is a technology that uses the capabilities of next- generation sequencing to reveal a snapshot of RNA presence and quantity from a genome at a given moment in time), quantitative PCR etc. may be used.
Preferably, "a plurality of mRNA species", refers to at least 100, at least 300, at least 500, at least 1000, at least 2000, at least 3000, at least 4000, at least 5000, at least 6000, at least 7000, at least 8000, at least 9000, at least 10000, at least 1 1000, at least 12000, at least 13000, at least 14000, at least 15000, at least 1 6000, at least 1 7000, at least 18000, at least 19000, at least 20000, at least 21000, at least 22000, at least 23000, at least 24000, at least 25000, at least 26000, at least 27000, at least 28000, at least 29000, or at least 30000 mRNA species. It is particularly preferred that the whole transcriptome is assessed, or as many mRNA species of the transcriptome as possible. This may be achieved, for example, by using a micro array providing whole transcript coverage.
Step a) of this method with its sub-steps i. to iii. corresponds essentially to step a) with its sub- steps i. to iii. of the previously described inventive method, but differs only in that the amount of each mRNA species of a plurality of mRNA species is determined at a first and at a second point in time and in that the ratio is calculated for each mRNA species. Accordingly, the detailed methods and preferred embodiments outlined above apply here as well and the ratio for a single mRNA species (and each single mRNA species, respectively) may be determined as outlined above for "an mRNA". However, in contrast to the above method, the stabi lity of the mRNA is not assessed by the absolute value of the ratio, but by a ranking of the mRNA species of the plurality of mRNA species according to the ratio calculated in sub-step (iii) of step a) for each mRNA species. In sub-step c) one or more mRNA species having the highest ratio or the highest ratios calculated in sub-step (iii) of step a) are then selected.
In this context it is particularly preferred to select the 0.1 %, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1 %, 2%, 3%, 4%, 5%, 1 0%, 1 5%, 20% most stable mRNA species in step c). Alternatively or additionally, in step c) such mRNA species may be selected which show a ratio calculated in sub-step iii. of step a) corresponding to a least 1 00% of the average ratio calculated from al l mRNA species analyzed. More preferably such mRNA species are selected showing a ratio of at least 1 50%, even more preferably of at least 200% and most preferably of at least 300% of the average ratio calculated from all mRNA species analyzed. In step d) the nucleotide sequence of a 3'- and/or 5'-UTR element of the mRNA selected in step c) is determined as described above, for step c) of the previously described inventive method.
Preferably, in both of the above described methods for identifying a 3'-UTR element and/or a 5'-UTR element according to the present invention, the time period between the first point in time and the second point in time is at least 5h, preferably at least 6h, preferably at least 7h, more preferably at least 8h, more preferably at least 9h, even more preferably at least 10h, even more preferably at least 1 1 h, and particularly preferably at least 12h. Preferably, in both of the above described methods for identifying a 3'-UTR element and/or a 5'-UTR element according to the present invention, the stability of an mRNA is analysed by pulse labelling, preferably using a pulse-chase methodology.
In a further aspect, the present invention also provides a method for identifying a 3'- untranslated region element (3'-UTR element) and/or a 5'-untranslated region element (5'- UTR element), which prolongs and/or increases protein production from an artificial nucleic acid molecule and which is derived from a stable mRNA comprising the following steps: a) identifying a 3'-UTR element and/or a 5'-UTR element which is derived from a stable mRNA by a method for identifying a 3'-UTR element and/or a 5'-UTR element according to any of the methods described above;
b) synthesizing an artificial nucleic acid molecule comprising at least one open reading frame and at least one 3'-UTR element and/or at least one 5'-UTR element which corresponds to or is comprised by the 3'-UTR element and/or the 5'-UTR element identified in step a);
c) analyzing the expression of the protein encoded by the at least one open reading frame (ORF) of the artificial nucleic acid molecule synthesized in step b);
d) analyzing the expression of a protein encoded by at least one open reading frame of a reference artificial nucleic acid molecule lacking a 3'-UTR element and/or a 5'-UTR element;
e) comparing the protein expression from the artificial nucleic acid molecule analysed in step c) to the protein expression from the reference artificial nucleic acid molecule analysed in step d); and
f) selecting the 3'-UTR element and/or the 5'-UTR element if the protein expression from the artificial nucleic acid molecule analysed in step c) is prolonged and/or increased in comparison to the protein expression from the reference artificial nucleic acid molecule analysed in step d).
In this method, at first a 3'-UTR element and/or a 5'-UTR element are identified by a method according to the present invention as described above. This enables synthesis of the 3'- and/or the 5'-UTR element by methods known to the skilled person, e.g. by PCR amplification. The primers used for such a PCR may preferably comprise restriction sites for cloning. Alternatively, the 3'- and/or 5'-UTR element may be synthesized e.g. by chemical synthesis or oligo annealing. Accordingly, in step b), an artificial nucleic acid molecule is synthesized comprising at least one open reading frame and at least one 3'-UTR element and/or at least one 5'-UTR element which corresponds to or is comprised by the 3'-UTR element and/or the 5'-UTR element identified in step a). In particular, the at least one 3'-UTR element and/or at least one 5'-UTR element is usually combined with an open reading frame, which results in an artificial nucleic acid comprising a 3'- and/or 5'-UTR element according to the present invention, if the 3'- and/or 5'-UTR element fulfil the respective requirements, i.e. if they prolong and/or increase protein expression. To test this, the 3'- and/or the 5'-UTR element identified in step a), or a PCR fragment or synthesized sequence thereof respectively, may be cloned into a particular vector, preferably in an expression vector, in order to assess protein expression from the respective ORF.
The protein expression from the artificial nucleic acid molecule comprising the at least one 3'-UTR element and/or the at least one 5'-UTR element is then assessed in step c) as described herein and compared to the protein expression assessed in step d) from a respective reference artificial nucleic acid molecule lacking a 3'-UTR element and/or a 5'-UTR element as described herein in step e).
Thereafter, in step f), such a 3'-UTR element and/or 5'-UTR element is selected, which prolongs and/or increases the protein expression from the artificial nucleic acid molecule analysed in step c) in comparison to the protein expression from the reference artificial nucleic acid molecule analysed in step d). The comparison of the protein expression of the inventive nucleic acid molecule to the reference nucleic acid molecule is carried out as described herein, in particular in the context of the inventive artificial nucleic acid molecule.
Furthermore, the present invention provides a particularly preferred method for identifying a 3'-untranslated region element (3'-UTR element) and/or a 5'-untranslated region element (5'- UTR element), which prolongs and/or increases protein production from an artificial nucleic acid molecule and which is derived from a stable mRNA comprising the following steps: a) feeding/incubating cells with a labelled nucleotide for incorporation in newly transcribed RNA molecules (pulse-chase labelling);
b) isolating total RNA of the cel ls at a first point in time and at at least one second later point in time;
c) extracting of the labelled RNA molecules from the total RNA isolated in step b); d) measuring of the amount/transcript level of the different mRNA species comprised in the labelled RNA;
e) calculating the ratio of the amount/transcript level of an mRNA species present at the at least one second later point in time to the amount/transcript level of the mRNA species present at the first point in time;
f) ranking of the mRNA species according to the ratio determined in step e); g) selecting the most stable mRNA species;
h) determinating the nucleotide sequence of the 3'- and/or 5'-UTR of the most stable mRNA species selected in step g);
i) synthesizing a 3'- and/or a 5'-UTR element comprised in the 3'- and/or 5'-UTR determined in step h);
j) combination of the 3'- and/or 5'-UTR element synthesized in step i) with an open reading frame to get a nucleic acid according to the invention as described herein; and
k) optionally comparing the expression of the open reading frame present in the inventive nucleic acid compared to the expression of the open reading frame present in a reference nucleic acid without a 3'- and/or 5'-UTR element as described herein.
Thereby, the details and preferred embodiments described for the inventive methods above also apply herein, within the respective limitation outlined in steps a) to k).
In particular, the following labelled nucleotides are preferred for feeding the cells in step a) of the inventive method: 4-thiouridine (4sU), 2-thiouridine, 6-thioguanosine, 5- ethynyluridine (EU), 5-bromo-uridine (BrU), Biotin-1 6-Aminoallyluridine, 5- Aminoallyluridine, 5-Aminoallylcytidine, etc. Particularly preferred is 4-thiouridine (4sU). 4- thiouridine is preferably used in a concentration of 1 00-500 μΜ. Alternatively radioactively labelled nucleotides may be used, e.g. Uridine-3H. Combinations of the above mentioned labelled nucleotides may be used. Particularly preferred is the combination of 4-thiouridine and 6-thioguanosine
The incubation of the cells with the labelled nucleotide in step a) can be varied. Particularly preferred is an incubation (feeding time) from 1 0 minutes to 24 hours. Particularly preferred are 2 to 6 hours, more preferably 2 to 3 hours.
Cells, which can be used for the inventive method, include in particular cell lines, primary cells, cells in tissue or subjects. In specific embodiments cell types allowing cell culture may be suitable for the inventive method. Particularly preferred are mammalian cells, e.g. human cells and mouse cel ls. In particularly preferred embodiments the human cell lines HeLa, and U-937 and the mouse cel l lines NIH3T3, JAWSII and L929 are used. Furthermore primary cells are particularly preferred; in particular preferred embodiments particularly human dermal fibroblasts (HDF) can be used. Alternatively the labelled nucleotide may also be applied to a tissue of a subject and after the incubation time the RNA of the tissue is isolated according to step c).
For determination of the most stable mRNAs of a cell (type), total RNA is extracted at a first point in time as described above, e.g. 0 to 6 h after labelling, preferably 3 h after labelling and at a second later point in time as described above, e.g. 3 to 48 h after labelling, preferably 1 0 to 24 h, most preferably 1 5 h after labelling. The second later point in timeis at least 1 0 mi nutes later than the first time.
In step f) the mRNA species are ranked according to the ratio calculated in step e). In this context it is particularly preferred to select the 0.1 %, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1 %, 2%, 3%, 4%, 5%, 1 0%, 1 5%, 20% most stable mRNA species.
In this context it is further preferred to select these mRNA species showing at least 50% (0,5 fold), at least 60% (0,6 fold), at least 70% (0,7 fold), at least 90% (0,9 fold) or at least 95% (0,95 fold) transcript level/amount of the mRNA species at the second later time compared to the first time. This embodiment is particularly preferred if the RNA is isolated at 3 hours (first point in time) and at 1 5 hours (second point in time) after labelling.
Alternatively or additionally, these mRNA species are selected showing a ratio calculated in step e) corresponding to a least 100% of the average ratio calculated from all mRNA species analyzed. More preferably these mRNA species are selected showing a ratio of at least 1 50% and more preferably of at least 200% and most preferably of at least 300% of the average ratio calculated from all mRNA species analyzed.
In a further step of the inventive method the nucleotide sequence of the 3'- and/or 5'-UTR of the most stable mRNA species selected in step g) is determined and in step i) the 3'- and/or 5'-UTR element is synthesized e.g. by PCR amplification. The primers used for the PCR may preferably comprise restriction sites for cloning.Alternatively the 3'- and/or 5'-UTR element may be synthesized (e.g. by chemical synthesis or oligo annealing). In step j) of the inventive method the resulting PCR fragment or synthesized sequence is combined with an open reading frame resulting in an artificial nucleic acid comprising a 3'- and/or 5'-UTR element according to the invention. Preferably, the PCR fragment or sequence may be cloned into a vector.
In a particularly preferred embodiment the invention provides a method comprising the steps a) to k) for identifying 3'-untranslated region elements (3'-UTR elements) and/or 5'- untranslated region elements (5'-UTR elements), wherein the 3'-UTR elements and/or the 5'- UTR elements prolong protein production from an artificial nucleic acid molecule comprising at least one of the 3'-UTR elements and/or at least one of the 5'-UTR elements.
In a further aspect, the present invention also provides a method for generating an artificial nucleic acid molecule, wherein an artificial nucleic acid molecule comprising at least one open reading frame and at least one 3'-UTR element and/or at least one 5'-UTR element identified by a method for identifying a 3'-UTR element and/or a 5'-UTR element according to the present invention as described above is synthesized. Synthesizing of such an artificial nucleic acid molecule is typically carried out by methods known to the skilled person, e.g. cloning methods for example as generally known or described herein. Preferably, a vector according to the present invention as described herein is used in such an inventive method for generating an artificial nucleic acid molecule.
Preferably, the artificial nucleic acid molecule generated by such a method for generating an artificial nucleic acid molecule is a nucleic acid molecule according to the present invention as described herein.
In addition, the present invention also provides an artificial nucleic acid molecule obtainable by a method for generating an artificial nucleic acid molecule according to the present invention as described herein.
The following Figures, Sequences and Examples are intended to illustrate the invention further. They are not intended to limit the subject matter of the invention thereto. Figures 1 to 1 1 , 1 9 to 21 and 25 to 30 show sequences encoding mRNAs that can be obtained by in vitro transcription. The following abbreviations are used:
PpLuc (GC): GC-enriched mRNA sequence coding for Photinus pyralis luciferase A64: poly(A)-sequence with 64 adenylates
C30: poly(C)-sequence with 30 cytidylates
hSL: a histone stem-loop sequence taken from (Cakmakci, Lerner, Wagner, Zheng, & Wi lliam F Marzluff, 2008. Mol. Cell. Biol. 28(3):1 182-94)
32L4: 5'-UTR of human ribosomal protein Large 32 lacking the 5' terminal oligopyrimidine tract
albumin7: 3'-UTR of human albumin with three single point mutations introduced to remove a 17 termination signal as well as a Hindlll and Xbal restriction site gnas: 3'-UTR element derived from the 3'-UTR of murine gnas; Mus musculus GNAS (guanine nucleotide binding protein, alpha stimulating ) complex locus (Gnas), mRNA morn2: 3'-UTR element derived from the 3'-UTR of murine morn2; Mus musculus MORN repeat containing 2 (Morn2), mRNA
gstml : 3'-UTR element derived from the 3'-UTR of murine gstml ; Mus musculus glutathione S-transferase, mu 1 (Gstml ), mRNA
ndufal : 3'-UTR element derived from the 3'-UTR of murine ndufal ; Mus musculus NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, (Ndufal ), mRNA cbr2: 3'-UTR element derived from the 3'-UTR of murine cbr2; Mus musculus carbonyl reductase 2 (Cbr2), mRNA
mp68: 5'-UTR element derived from the 5'-UTR of murine mp68; Mus musculus RIKEN cDNA 201 01 07E04 gene (201 01 07E04Rik), mRNA
ndufa4: 5'-UTR element derived from the 5'-UTR of murine nudfa4; Mus musculus NADH dehydrogenase (ubiquinone) 1 alpha subcomplex,4, (Ndufa4), mRNA Ybx1 : 3'-UTR element derived from the 3'-UTR of murine Ybx1 (Y-Box binding protein 1 )
Ndufb8: 3'-UTR element derived from the 3'-UTR of murine Ndufb8 (NADH dehydrogenase (ubiquinone) 1 beta subcomplex 8)
CNTN1 : 3'-UTR element derived from the 3'-UTR of human CNTN1 (contactin 1 ) shows SEQ ID NO. 35, i.e. the mRNA sequence of 32L4 - PpLuc(GC) - A64 - C30 - hSL. (R2464). The 5'-UTR is derived of human ribosomal protein Large 32 mRNA lacking the 5' terminal oligopyrimidine tract. The PpLuc(GC) ORF is highlighted in italics. shows SEQ ID NO. 36, i.e. the mRNA sequence of 32L4 - PpLuc(GC) - gnas-A64- C30-hSL. (R3089). The PpLuc(GC) ORF is highlighted in italics. The 3'-UTR element, which is derived from mouse Gnas transcript, is underlined. shows SEQ ID NO. 37, i.e. the mRNA sequence of 32L4 - PpLuc(GC) - morn2- A64 - C30 - hSL. (R3106). The PpLuc(GC) ORF is highlighted in italics. The 3'- UTR element, which is derived from mouse morn2, is underlined. shows SEQ ID NO. 38, i.e. the mRNA sequence of 32L4 - PpLuc(GC) - gstml - A64 - C30 - hSL. (R3107). The PpLuc(GC) ORF is highlighted in italics. The 3'- UTR element, which is derived from mouse gstml , is underlined. shows SEQ ID NO. 39, i.e. the mRNA sequence of 32L4 - PpLuc(GC) - ndufal - A64 - C30 - hSL. (R3108). The PpLuc(GC) ORF is highlighted in italics. The 3'- UTR element, which is derived from mouse ndufal , is underlined. shows SEQ ID NO. 40, i.e. the mRNA sequence of 32L4 - PpLuc(GC) - cbr2 - A64 - C30 - hSL. (R3109). The PpLuc(GC) ORF is highlighted in italics. The 3'- UTR element, which is derived from mouse cbr2, is underlined. shows SEQ ID NO. 41 , i.e. the mRNA sequence of PpLuc(GC) - albumin7- A64 - C30 - hSL. (R2463). The 3'-UTR is derived from human albumin with three single point mutations introduced to remove a T7 termination signal as well as a Hindlll and Xbal restriction site (albumin7). The PpLuc(GC) ORF is highlighted in italics. shows SEQ ID NO. 42, i.e. the mRNA sequence of Mp68 - PpLuc(GC) - albumin7- A64 - C30 - hSL. (R31 1 1 ). The PpLuc(GC) ORF is highlighted in italics. The 5'- UTR element, which is derived from mouse mp68, is underlined. Fig. 9: shows SEQ ID NO. 43, i .e. the mRNA sequence of Ndufa4 - PpLuc(GC) - albumin7- A64 - C30 - hSL. (R31 1 2). The PpLuc(GC) ORF is highlighted in italics. The 5'-UTR element, which is derived from mouse Ndufa4, is underlined.
Fig. 1 0: shows SEQ ID NO. 44, i.e. the mRNA sequence of PpLuc(GC) - A64 - C30 - hSL
(R2462) The PpLuc(GC) ORF is highlighted in italics.
Fig. 1 1 : shows SEQ ID NO. 45, i.e. the mRNA sequence of PpLuc(GC) - gnas- A64 - C30
- hSL (R31 1 6). The PpLuc(GC) ORF is highlighted in italics. The 3'-UTR element, which is derived from mouse Gnas, is underlined.
Fig. 1 2 : shows that different 3'-UTR elements, namely 3'-UTR elements derived from gnas, morn2, gstml , ndufal and cbr2 markedly prolong protein expression from mRNA. The effect of the inventive 3'-UTR elements derived from gnas, morn2, gstml , ndufal and cbr2 3'-UTRs on Iuciferase expression from mRNA was exami ned, compared to Iuciferase expression from mRNA lacking a 3'-UTR. To this end, human HeLa were transfected with different mRNAs by lipofection. Luciferase levels were measured at different times after transfection. The PpLuc signal was corrected for transfection efficiency by the signal of cotransfected RrLuc.
Normalized PpLuc levels at 24h were set to 1 00% and relative expression to 24h was calculated. The 3'-UTRs prolong luciferase expression. Mean values from three independent experiments are shown. Values are summarized in Example 7.a.
Fig. 1 3 : shows that different 3'-UTR elements, namely 3'-UTR elements derived from gnas, morn2, gstml , ndufal and cbr2 markedly prolong protein expression from mRNA. The effect of the inventive 3'-UTR elements derived from gnas, morn2, gstml , ndufal and cbr2 3'-UTRs on luciferase expression from mRNA was examined, compared to luciferase expression from mRNA lacking a 3'-UTR. To this end,
HDF (human dermal fibroblasts) cells were transfected with different mRNAs by lipofection. Luciferase levels were measured at different times after transfection. The PpLuc signal was corrected for transfection efficiency by the signal of cotransfected RrLuc. Normalized PpLuc levels at 24h were set to 100% and relative expression to 24h was calculated. The 3'-UTRs prolong luciferase expression. Mean values from three independent experiments are shown. Values are summarized in Example 7. a.
Fig. 14: shows that different 5'-UTR elements, namely 5'-UTR elements derived from
Mp68 and ndufa4 markedly increase total protein expression from mRNA.
The effect of the inventive 5'-UTR elements derived from Mp68 and ndufa4 on luciferase expression from mRNA was examined. To this end, human HeLa cells were transfected with different mRNAs by lipofection. Luciferase levels were measured 6, 24, 48, and 72 hours after transfection. The PpLuc signal was corrected for transfection efficiency by the signal of cotransfected RrLuc. Total protein expression (area under the curve) was calculated. To compare the expression levels of the mRNAs containing the inventive 5'-UTR elements to an mRNA lacking a 5'-UTR, expression levels of the control construct without 5' UTR was set to 1 . Mean values from three independent experiments are shown. Values are summarized in Example 7.b.
Fig. 15: shows that different 5'-UTR elements, namely 5'-UTR elements derived from
Mp68 and ndufa4 markedly increase total protein expression from mRNA.
The effect of the inventive 5'-UTR elements derived from Mp68 and ndufa4 on luciferase expression from mRNA was examined. To this end, HDF cells were transfected with different mRNAs by lipofection. Luciferase levels were measured 6, 24, 48, and 72 hours after transfection. The PpLuc signal was corrected for transfection efficiency by the signal of cotransfected RrLuc. Total protein expression (area under the curve) was calculated. To compare the expression levels of the mRNAs containing the inventive 5'-UTR elements to an mRNA lacking a 5'-UTR, expression levels of the control construct without 5' UTR was set to 1 . Mean values from three independent experiments are shown. Values are summarized in Example 7.b.
Fig. 1 6: shows that the 3'-UTR element derived from gnas markedly prolongs protein expression from mRNA. The effect of the inventive 3'-UTR element derived from gnas 3'-UTR on luciferase expression from mRNA was examined, compared to luciferase expression from mRNA lacking a 3'-UTR. To this end, HDF cel ls were transfected with respective mRNAs by lipofection. Luciferase levels were measured at 24, 48, and 72 hours after transfection. The PpLuc signal was corrected for transfection efficiency by the signal of cotransfected RrLuc. Normalized PpLuc levels at 24h were set to 1 00% and relative expression to 24h was calculated. The gnas 3'-UTR prolongs luciferase expression. Values are summarized in Example 7.c.
Fig. 1 7: shows that the 3'-UTR element derived from gnas markedly prolongs protein expression from mRNA.
The effect of the inventive 3'-UTR element derived from gnas 3'-UTR on luciferase expression from mRNA was examined, compared to luciferase expression from mRNA lacking a 3'-UTR. To this end, HeLa cells were transfected with respective mRNAs by lipofection. Luciferase levels were measured at d2 and d3 after transfection. The PpLuc signal was corrected for transfection efficiency by the signal of cotransfected RrLuc. Normalized PpLuc levels at 24h were set to 100% and relative expression to 24h was calculated. The gnas 3'-UTR prolongs luciferase expression. Values are summarized in Example 7.c.
Fig. 1 8: shows that different 3'-UTR elements, namely 3'-UTR elements derived from ybx1 (V2), ndufb8, and cntnl -004(V2) markedly prolong protein expression from mRNA.
The effect of the inventive 3'-UTR elements derived from ybx1 (V2), ndufb8, and cntnl -004(V2) 3'-UTRs on luciferase expression from mRNA was exami ned, compared to luciferase expression from mRNA lacking a 3'-UTR. To this end, HDF cells were transfected with the different mRNAs by lipofection. Luciferase levels were measured at different times after transfection. The PpLuc signal was corrected for transfection efficiency by the signal of cotransfected RrLuc. Normalized PpLuc levels at 24h were set to 1 00% and relative expression to 24h was calculated. The 3'-UTRs prolong luciferase expression. Values are summarized in Example 7.d. Fig. 1 9: shows SEQ ID NO. 46 , i.e. the mRNA sequence of 32L4 - PpLuc(GC) - Ybx1 - 001 (V2)-A64-C30-hSL (R3623) mus musculus 3'UTR with mutation T128bpG and deletion del236-237bp. The PpLuc(GC) ORF is highlighted in italics. The 3'-UTR element, which is derived from mouse Ybxl transcript, is underlined.
Fig. 20: shows SEQ ID NO. 47, i.e. the mRNA sequence of 32L4 - PpLuc(GC) - Ndufb8- A64-C30-hSL (R3624) The PpLuc(GC) ORF is highlighted in italics. The 3'-UTR element, which is derived from mouse Ndufb8 transcript, is underlined. Fig. 21 : shows SEQ ID NO. 48, i.e. the mRNA sequence of 32L4 - PpLuc(GC) - Cntnl - 004(V2)-A64-C30-hSL (R3625) +T at pos. 30bp, mutations G727bpT, A840bpG. The PpLuc(GC) ORF is highlighted in italics. The 3'-UTR element, which is derived from human Cntnl transcript, is underlined. Fig. 22: shows that different 3'-UTR elements, namely 3'-UTR elements derived from gnas, morn2, ndufal (Mm; mus musculus), and NDUFA1 (Hs; homo sapiens) markedly prolong protein expression from mRNA. The effect of the inventive 3'-UTR elements derived from gnas, morn2, ndufal (Mm; mus musculus), and NDUFA1 (Hs; homo sapiens) on luciferase expression from mRNA was examined, compared to luciferase expression from mRNA lacking a 3'-UTR. To this end, human Hela cells were transfected with respective mRNAs by lipofection. Luciferase levels were measured at different times after transfection. The PpLuc signal was corrected for transfection efficiency by the signal of cotransfected RrLuc. Normalized PpLuc levels at 24h were set to 100% and relative expression to 24h is calculated. The 3'UTRs prolong luciferase expression. Mean values from
3 independent experiments are shown. Values are summarized in Table 8.
Fig. 23: shows that different 5'-UTR elements, namely 5'-UTR elements derived from
Mp68 and ndufa4, markedly increase total protein expression from mRNA. The effect of the inventive 5'-UTR elements derived from Mp68 and ndufa4 on luciferase expression from mRNA was examined. To this end, human HeLa cells were transfected with different mRNAs by lipofection. Luciferase levels were measured 6, 24, 48, and 72 hours after transfection. The PpLuc signal was corrected for transfection efficiency by the signal of cotransfected RrLuc. Total protein expression (area under the curve) was calculated. To compare the expression levels of the mRNAs containing the inventive 5'-UTR elements to an mRNA lacking a 5'-UTR, expression levels of the control construct without 5' UTR was set to 1 . Mean values are shown. Values are summarized in Table 9.
Fig. 24: shows that different 5'-UTR elements, namely 5'-UTR elements derived from
Mp68 and ndufa4, markedly increase total protein expression from mRNA. The effect of the inventive 5'-UTR elements derived from Mp68 and ndufa4 on luciferase expression from mRNA was examined. To this end, human Hela cells were transfected with different mRNAs by lipofection. Luciferase levels were measured 24, 48, and 72 hours after transfection. The PpLuc signal was corrected for transfection efficiency by the signal of cotransfected RrLuc. Total protein expression (area under the curve) was calculated. To compare the expression levels of the mRNAs containing the inventive 5'-UTR elements to an mRNA lacking a 5'-UTR, expression levels of the control construct without 5' UTR was set to 1 . Mean values are shown. Values are summarized in Table 9.
Fig. 25 : shows SEQ ID NO. 383, i.e. the mRNA sequence of 32 L4 - PpLuc(GC) - A64- C30-hSL (R2462). The PpLuc(GC) ORF is highlighted in italics.
Fig. 26: shows SEQ ID NO. 384, i.e. the mRNA sequence of PpLuc(GC) - morn2- A64 - C30 - hSL. (R3948). The PpLuc(GC) ORF is highlighted in italics. The 3'-UTR element, which is derived from murine morn2 is underlined.
Fig. 27: shows SEQ ID NO. 385, i.e. the mRNA sequence of PpLuc(GC) - ndufal - A64 - C30 - hSL. (R4043). The PpLuc(GC) ORF is highlighted in italics. The 3'-UTR element, which is derived from murine ndufal is underlined. Fig. 28: shows SEQ ID NO. 386, i.e. the mRNA sequence of PpLuc(GC) - NDFUA1 - A64
- C30 - hSL. (R3948). The PpLuc(GC) ORF is highlighted in italics. The 3'-UTR element, which is derived from human NDUFA1 is underlined. Fig. 29: shows SEQ ID NO. 387, i.e. the mRNA sequence of Mp68 - PpLuc(GC) - A64 - C30 - hSL. (R3954). The PpLuc(GC) ORF is highlighted in italics. The 5'-UTR element, which is derived from murine mp68 is underlined. Fig. 30: shows SEQ ID NO. 388, i.e. the mRNA sequence of Ndufa4 - PpLuc(GC) - A64 - C30 - hSL. (R3951 ). The PpLuc(GC) ORF is highlighted in italics. The 5'-UTR element, which is derived from murine ndufa4 is underlined.
Examples
1 . Identification of 3'-untranslated region elements (3'-UTR elements) and/or 5'- untranslated region elements (5'-UTR elements) prolonging and/or increasing protein production: mRNA decay in different human and murine cell types was assessed by pulse-chase methodology. To this end, three different human cell types (HeLa, HDF and U-937) and three different mouse cell types (NIH3T3, JAWSIl and L929) were plated over night in their respective medium: HeLa, U-937, L929 in RPMI medium, JAWSIl und NIH3T3 in DMEM and HDF in Fibroblast Growth Medium 2. The cells were incubated for 3 h with the respective medium containing 200 μΜ 4-thiouridine (4sU) for labelling of newly synthesized RNA ("pulse"). After incubation (labelling), cells are washed once and the medium was replaced by fresh medium supplemented with 2mM Uridine ("chase"). Cells were incubated further for 3 h (1 st point in time) or 1 5 h (2nd point in time) before harvesting.
Accordingly, cel ls were harvested 3 h (1 st point in time) and 1 5 h (2nd point in time) after end of labelling. The total RNA was isolated from these cells using RNeasy Mini Kit (Qiagen).
HPDP-Biotin (EZ-Link Biotin-HPDP, Thermo Scientific; pyridyldithiol-activated, sulfhydryl- reactive biotinylation reagent that conjugates via a cleavable (reversible) disulfide bond) was then incubated with the total RNA in order to extract the 4-thiouridine (4sU)-labelled RNA. HPDP-Biotin specifically reacts with the reduced thiols (-SH) in the 4-thiouridine (4sU)- labelled RNA to form reversible disulfide bonds. The biotinylated RNA was ultrafiltrated using an Amicon-30 device, incubated with streptavidin-coupled dynabeads (Life Technologies) and recovered from streptavidin by DTT. Subsequently, the RNA was purified using RNeasy Mini Kit. For each cell line 3 independent experiments were performed. The extracted 4sU-labelled RNA was used in a micro array analysis in order to determine the transcript levels of a large variety of mRNA species (i.e. the amounts of the mRNA species) present at a first point in time (3 h after labelling) and the transcript levels of a large variety of mRNA species (i.e. the amounts of the mRNA species) present at a second point in time (1 5 h after labelling). Affymetrix Human Gene 1 .0 ST and Affymetrix Mouse Gene 1 .0 ST micro arrays were used. Affymetrix Human Gene 1 .0 ST comprises 36079 mRNA species. Affymetrix Mouse Gene 1 .0 ST comprises 261 66 mRNA species.
Since these micro arrays provide a whole transcript coverage, i.e. they provide a complete expression profile of mRNA, the ratio of the transcript level of a certain mRNA species at the second point in time to the transcript level of the same mRNA species at the first point in time was accordingly determined for a large number of mRNA species. The ratios thus reflect the x-fold transcript level of the mRNA species (shown as Gene Symbol) at the second point in time as compared to the first point in time. The results from these experiments are shown in Tables 1 - 3 below. Each of the Tables 1 - 3 shows a ranking of the most stable mRNA species, i.e. according to the ratio of the transcript level of this mRNA species at the second point in time to the transcript level of this mRNA species at the first point in time (Table 1 : combined analysis of human cell types (HeLa, HDF and U-937); Table 2: combined analysis of mouse cell lines (NIH3T3, JAWSII and L929); Table 3: human cell line HDF (human dermal fibroblasts)). Such mRNA species were considered as "most stable mRNA species", which show a value for the ratio of the transcript level at the first point in time/ the transcript level at the second point in time of at least 0,5499431 38 (approximately 55%; Table 1 ), 0,676314425 (approximately 68%, Table 2) or 0,8033973 (approximately 80%, Table 3).
Furthermore, the relationship of the ratio of a certain mRNA species to the average ratio (i.e. the average of the ratios of all mRNA species determined, which is shown in the Tables as "Average of the ratio") was calculated and given as % of average. Table 1 : stable mRNAs resulting from the combined analysis of human cell types (HeLa, HDF and U-937) with the Affymetrix Human Gene 1.0 ST micro array.113 mRNA species of the 36079 mRNA species on the micro array were selected as "most stable" mRNA species. This corresponds to 0,31 % of the mRNA species present on the micro array.
Ratio of the
transcript level at
the 2nd time to the
transcript level at Average of
Gene symbol the 1st time the ratio % of average
LTA4H 0,982490359 0,258826017 379,5948991
SLC38A6 0,953694877 368,4694789
DECR1 0,927429689 358,3216631
PIGK 0,875178367 338,1338462
FAM175A 0,849392515 328,1712266
PHYH 0,827905031 319,8693239
NT5DC1 0,815986179 315,2643572
TBC1D19 0,805960687 311,3909086
PIGB 0,805108608 311,0616997
ALG6 0,804875859 310,9717748
CRYZ 0,797694475 308,1971756
BRP44L 0,796150905 307,6008021
ACADSB 0,792385554 306,1460216
SUPT3H 0,792305264 306,1150005
TMEM14A 0,792128439 306,0466827
GRAMD1C 0,78766459 304,3220303
C11orf80 0,778391775 300,739386
C9orf46 0,776061355 299,8390053
ANXA4 0,765663559 295,8217134
RAB7A 0,757621668 292,7146492
TBCK 0,753324047 291,0542204
AGA 0,751782245 290,4585303
IFI6 0,742389518 286,829557
C2orf34 0,737633511 284,9920263
TPK1 0,731359535 282,5680135
ALDH6A1 0,731062569 282,4532776
AGTPBP1 0,725606511 280,3452757
CCDC53 0,725535697 280,3179158
LRRC28 0,722761729 279,2461657
MBNL3 0,716905277 276,9834674
CCDC109B 0,713320794 275,5985668 Ratio of the
transcript level at
the 2nd time to the
transcript level at Average of
Gene symbol the 1 st time the ratio % of average
PUS10 0,70905743 273,9513739
CCDC104 0,706185858 272,8419137
CASP1 0,699081435 270,0970494
SNX14 0,689529842 266,4066965
SKAP2 0,68641 7578 265,2042424
NDUFB6 0,683568924 264,1036366
EFHA1 0,680321463 262,8489478
BCKDHB 0,679714289 262,6143601
BBS2 0,677825758 261 ,8847077
LMBRD1 0,676629332 261 ,4224565
ITGA6 0,660264393 255,0996998
HERC5 0,654495807 252,8709496
HADHB 0,651220796 251 ,6056164
MCCC2 0,650460461 251 ,31 18537
CAT 0,64721 81 83 250,0591 672
ANAPC4 0,646761056 249,882551 7
PCCB 0,641 145931 247,7130926
PHKB 0,639806797 247,1 957046
ABCB7 0,639415266 247,0444329
PGCP 0,636830107 246,0456309
GPD2 0,63484437 245,278421 7
TMEM38B 0,634688463 245,21 81856
NFU1 0,63202654 244,1 897253
OMA1 0,631 592924 244,0221 934
LOC128322 0,63091 5328 243,7603974
NUBPL 0,627949735 242,61461 13
LANCL1 0,627743069 242,5347636
HHLA3 0,627231 1 9 242,3369941
PIR 0,625871255 241 ,81 1 5696
ACAA2 0,624054189 241 ,1095284
CTBS 0,621 758355 240,22251
GSTM4 0,618559637 238,9866536
ALG8 0,61 7468882 238,5652294
ACTR10 0,614629804 237,4683237
PIGF 0,612863425 236,7858655
MGST3 0,607459796 234,6981 198
SCP2 0,604745109 233,6492735
HPRT1 0,604586436 233,5879689 Ratio of the
transcript level at
the 2nd time to the
transcript level at Average of
Gene symbol the 1st time the ratio % of average
ACSF2 0,603568827 233,1948052
VPS13A 0,60079506 232,1231332
CTH 0,598492068 231,2333494
NXT2 0,597938464 231,0194589
MGST2 0,596121512 230,3174615
C11orf67 0,59596274 230,2561181
PCCA 0,595915054 230,2376943
GLMN 0,594596168 229,7281295
DHRS1 0,594391166 229,6489249
PON2 0,594025719 229,5077308
NME7 0,593140523 229,1657265
ETFDH 0,59290737 229,0756456
ALG13 0,591519568 228,5394547
DDX60 0,590567649 228,1716714
DYNC2L11 0,590400874 228,1072359
VPS8 0,586233686 226,4972016
ITFG1 0,585791975 226,3265424
CDK5 0,584517109 225,8339853
C1orf112 0,58415003 225,6921603
1FT52 0,579757269 223,9949738
CLYBL 0,577777391 223,230028
FAM114A2 0,575975081 222,533688
NUDT7 0,575398988 222,3111085
AKD1 0,57519887 222,233791
MAGED2 0,575157132 222,217665
HRSP12 0,574805797 222,0819235
STX8 0,573508131 221,5805571
ACAT1 0,569067306 219,8648003
IFT74 0,568627867 219,695019
KIFAP3 0,567709483 219,3401921
CAPN1 0,567537877 219,2738902
COX11 0,566354405 218,8166442
GLT8D4 0,566035014 218,6932442
HACL1 0,56371793 217,7980159
IFT88 0,562663344 217,3905661
NDUFB3 0,561240987 216,8410243
ANO10 0,561096127 216,7850564
ARL6 0,560155258 216,4215424 Ratio of the
transcript level at
the 2nd time to the
transcript level at Average of
Gene symbol the 1 st time the ratio % of average
LPCAT3 0,559730076 21 6,2572689
ABCD3 0,55747212 21 5,3848853
COPG2 0,5571 80095 21 5,2720583
MIPEP 0,554396343 214, 1 965281
LEPR 0,551 799358 213, 1 931 572
C2orf76 0,5499431 38 212,4759882
Table 2: stable mRNAs resulting from the combined analysis of mouse cell lines (NIH3T3, JAWSII and L929) with the Affymetrix Mouse Gene 1 .0 ST micro array: 99 mRNA species of the 261 66 mRNA species on the micro array were selected as the "most stable" mRNA species. This corresponds to 0,38% of the mRNA species present on the micro array.
Ratio of the
transcript level at
the 2nd time to the
transcript level at Average of ene symbol the 1st time the ratio % of average
Ndufal 1,571557917 0,209425963 750,4121719
Atp5e 1,444730129 689,8524465
Gstm5 1,436992822 686,1579154
Uqcrl 1 1,221605816 583,3115431
Ifi27l2a 1,203811772 574,8149632
Cbr2 1,162403907 555,0428852
Anapd 3 1,153679871 550,8771953
Atp5l 1,126858713 538,0702074
TmsblO 1,048459674 500,6350022
Nenf 1,045891853 499,4088786
Ndufa7 1,03898238 496,1096349
Atp5k 1,03623698 494,7987179
1110008P14Rik 1,029513775 491,5884162
Cox4i1 0,991815573 473,5876865
Cox6a1 0,991620272 473,4944312
Ndufs6 0,989419978 472,4438002
Sec61 b 0,984420709 470,0566705
Romol 0,981642576 468,7301241
Gnas 0,969128675 462,7547898
Snrpd2 0,962862199 459,7625743
Mgst3 0,96060161 458,6831531
Aldh2 0,949761281 453,5069425
2010107E04Rik 0,933570825 445,776069
Ssr4 0,930263069 444,1966294
Myl6 0,920572238 439,5692993
Prdx4 0,914830854 436,8278128
Ubl5 0,902505176 430,9423544
1110001J03Rik 0,888041155 424,0358468
Ndufal 3 0,881735594 421,0249684
Ndufa3 0,880861551 420,6076163
Gstp2 0,87970004 420,0529997
Tmeml 60 0,878001416 419,2419142
Ergic3 0,87481135 417,7186716
Pgcp 0,870441149 415,6319192
Slpi 0,868909664 414,9006418
Myeov2 0,868175997 414,5503186
Ndufa4 0,862009116 411,6056594
Ndufs5 0,857586364 409,4938143 Gstml 0,856672742 409,0575637
1810027O10Rik 0,855929863 408,7028424
Atp5o 0,848957424 405,3735324
Shfml 0,841 951399 402,0281 856
Tspo 0,840567742 401 ,3674952
S100a6 0,8401 63495 401 ,1 744691
Taldol 0,8400757 401 ,1325475
Blod sl 0,838838894 400,541 978
Hexa 0,826597959 394,6969835
Ndufbl 1 0,821 601 877 392,31 1376
Mapl Ic3a 0,81 6696063 389,968871
Morn2 0,810862522 387,18338
Gpx4 0,808459051 386,0357329
Mif 0,804105552 383,9569558
Cox6b1 0,803409855 383,6247633
2900010J23Rik 0,802900813 383,3816981
Sec61 g 0,797138268 380,6301077
2900010M23Rik 0,793618387 378,9493795
Anapc5 0,793224505 378,7613023
Mars2 0,787395376 375,9779182
Phptl 0,785668786 375,153479
Ndufb8 0,784300334 374,5000492
Pfdn5 0,779021 933 371 ,9796349
Arpc3 0,77876305 371 ,85601 97
Ndufb7 0,774103875 369,6312833
Atp5h 0,772255845 368,7488573
Mrpl23 0,77034041 367,834245
Tomm6 0,7548181 8 360,4224467
Mtchl 0,752594518 359,3606576
Pcbd2 0,752256847 359,1 99421
Ecm1 0,752254099 359,1981094
Hrsp12 0,749135357 357,708923
Mecr 0,746269148 356,3403207
Uqcrq 0,7344621 77 350,7025426
Gstm3 0,733839044 350,4049993
Lsm4 0,732100345 349,5747779
Park7 0,7307842 348,9463242
Usmg5 0,724562823 345,9756436
Cox8a 0,720194618 343,8898445
Ly6c1 0,71 6087602 341 ,9287619
Cox7b 0,71351 901 7 340,7022736
Ppib 0,70610671 1 337,1 629288 Bag1 0,70488561 336,5798584
S100a4 0,701675201 335,046902
Bcap31 0,700846929 334,6514056
Tecr 0,699592215 334,0522852
Rabad 0,699161282 333,8465165
Robld3 0,694068018 331,4145049
Sodl 0,691852987 330,356837
Nedd8 0,691415017 330,1477083
Higd2a 0,689498548 329,2326025
Trappc6a 0,688046277 328,5391491
Ldhb 0,686084572 327,6024437
Nme2 0,685974394 327,5498339
Snrpg 0,684247073 326,7250454
Ndufa2 0,683350661 326,2970129
Serf1 0,681148053 325,2452768
Oaz1 0,681139695 325,2412861
Ybx1 0,678927132 324,1847964
Seppl 0,677551422 323,5279009
Gaa 0,676314425 322,9372402
Table 3: stable mRNAs resulting from the analysis of the human cell line HDF (human dermal fibroblasts) with the Affymetrix Human Gene 1.0 ST micro array: 46 mRNA species of the 36079 mRNA species on the micro array were selected as the "most stable" mRNA species. This corresponds to 0,13% of the mRNA species present on the micro array.
Ratio of the
transcript level at
the 2nd time to
thetranscript level at Average of
Gene symbol the 1st time the ratio % of average
ABCA6 2,062835692 0,278262352 741,3276273
LY96 1,719983635 618,1158256
CROT 1,422424006 511,1809038
ENPP5 1,315849211 472,880791
SERPINB7 1,12288882 403,5360196
TCP11 L2 1,103519648 396,5752607
IRAKI BP1 1,05490107 379,1030521
CDKL2 1,042002646 374,4677057
GHR 1,039327135 373,5061992
KIAA1107 1,020519239 366,7471477
RPS6KA6 1,017695602 365,7324085
CLGN 1,007943464 362,2277524
TMEM45A 1,006063873 361,5522781
TBC1D8B 0,979626826 352,0515148
ACP6 0,964241225 346,5223439
RP6-213H19.1 0,960702414 345,2505905
C11orf74 0,960086216 345,0291458
SNRPN 0,939315038 337,5645433
GLRB 0,923441342 331,8599644
HERC6 0,919865006 330,5747254
CFH 0,908835974 326,6111879
GALC 0,90862766 326,5363257
PDE1A 0,908445187 326,4707497
GSTM5 0,902862912 324,4646303
CADPS2 0,89753131 322,5485959
AASS 0,894768872 321,5558503
TRIM6-TRIM34 0,892150571 320,6149031
SEPP1 0,891344657 320,3252795
PDE5A 0,890221551 319,9216656
SATB1 0,885139895 318,0954552
CCPG1 0,88148167 316,7807873
CNTN1 0,87246423 313,5401621
LMBRD2 0,871500964 313,1939903
TLR3 0,86777981 311,8567077
BCAT1 0,864255836 310,5902863
TOM1 L1 0,86240499 309,925142
SLC35A1 0,857201353 308,055095
GLYATL2 0,85132258 305,9424223 STAT4 0,840572034 302,0789653
GULP1 0,83951 8351 301 ,7003001
EHHADH 0,82971807 298,1 783427
NBEAL1 0,82554089 296,6771 768
IAA1 598 0,820341324 294,8085928
HFE 0,81 5037603 292,9025779
KIAA1 324L 0,808279102 290,4737547
MANSC1 0,8033973 288,7193664
2. Cloning of 5'- and 3'-UTR elements of stably expressed mRNAs: The nucleotide sequence of the 5'- and/or 3'-UTRs of the mRNA species shown in Table 1 - 3 were determined by data base search and amplified by PCR or synthesized by oligo annealing. The resulting PCR fragments were cloned into a vector as described in detail in Example 3 below. 5'-UTR elements were cloned into the vector PpLuc(GC) - albumin7 - A64
- C30 - hSL (SEQ ID NO. 41 , Fig. 7); and 3'-UTR elements were cloned into the vector 32L4 - PpLuc(GC) - A64 - C30 - hSL (SEQ ID NO. 35, Fig. 1 ) or into the vector PpLuc(GC) - A64
- C30 - hSL (SEQ ID NO. 44, Fig. 10).
3. Preparation of DNA-templates
A vector for in vitro transcription was constructed containing a T7 promoter and a GC- enriched sequence coding for Photinus pyralis luciferase (PpLuc(GQ). An A64 poly(A) sequence, followed by C30 and a histone stem-loop sequence, was inserted 3' of PpLuc(GC). The histone stem-loop sequence was followed by a restriction site used for linearization of the vector before in vitro transcription.
To investigate the effect of different 3'-UTR elements on protein expression, a vector as described above was used (control) and this vector was modified to include a 3'-UTR element of interest. Alternatively, a vector was constructed as described above, whereby the 5' untranslated region (5'-UTR) of 32L4 (ribosomal protein Large 32) was inserted 5' of PpLuc(GC). This vector was then modified to include either different 3'-UTR elements or no 3'-UTR (control). Particularly, the following mRNAs were obtained from these vectors accordingly by in vitro transcription (the mRNA sequences are depicted in Figures 1 to 6, Figures 10, 1 1 and Figures 19 to 21 ):
32L4 - PpLuc(GC) - A64 - C30 - hSL (SEQ ID NO. 35, Fig. 1 );
32L4 - PpLuc(GC) - gnas - A64 - C30 - hSL (SEQ ID NO. 36, Fig. 2);
32L4 - PpLuc(GC) - morn2 - A64 - C30 - hSL (SEQ ID NO. 37, Fig. 3);
32L4 - PpLuc(GC) - gstml - A64 - C30 - hSL (SEQ ID NO. 38, Fig. 4);
32L4 - PpLuc(GC) - ndufal - A64 - C30 - hSL (SEQ ID NO. 39, Fig. 5);
32 L4 - PpLuc(GC) - cbr2 - A64 - C30 - hSL (SEQ ID NO. 40, Fig. 6);
PpLuc(GC) - A64 - C30 - hSL (SEQ ID NO. 44, Fig. 10);
PpLuc(GC) - gnas - A64 - C30 - hSL (SEQ ID NO. 45, Fig. 1 1 );
32L4 - PpLuc(GC) - Ybx1 (V2)-A64-C30-hSL (SEQ ID NO. 46, Fig. 1 9);
32L4 - PpLuc(GC) - Ndufb8-A64-C30-hSL (SEQ ID NO. 47, Fig. 20); and
32L4 - PpLuc(GC) - Cntnl -004(V2)-A64-C30-hSL (SEQ ID NO. 48, Fig. 21 ).
An alternative sequence for the construct 32 L4 - PpLuc(GC) - A64 - C30 - hSL is shown in
Fig. 25 (SEQ ID NO. 383). However, SEQ ID NO. 35, Fig. 1 was used in the Examples as described herein and is, thus, preferred for the construct 32L4 - PpLuc(GC) - A64 - C30 - hSL.
To investigate the effect of different 5'-UTR elements on protein expression, a vector was constructed as described above, whereby the 3' untranslated region (3'-UTR) of albumin7 (3'- UTR of human albumin with three single point mutations introduced to remove a T7 termination signal as well as a Hindlll and Xbal restriction site) was inserted 3' of PpLuc(GC). This vector was modified to include either different 5'-UTR elements or no 5'-UTR (control).
Particularly, the following mRNAs were obtained from these vectors accordingly by in vitro transcription (the mRNA sequences are depicted in Figures 7 to 9):
PpLuc(GC) - albumin7 - A64 - C30 - hSL (SEQ ID NO. 41 , Fig. 7);
Mp68 - PpLuc(GC) - albumin7 - A64 - C30 - hSL (SEQ ID NO. 42, Fig. 8); and
Ndufa4 - PpLuc(GC) - albumin7 - A64 - C30 - hSL (SEQ ID NO. 43, Fig. 9); 4. In vitro transcription The DNA templates according to Example 2 and 3 were linearized and transcribed in vitro using T7-RNA polymerase. The DNA templates were then digested by DNase-treatment. mRNA transcripts contained a 5'-CAP structure obtained by adding an excess of N7-Methyl- Guanosine-5'-Triphosphate-5'-Guanosine to the transcription reaction. mRNA thus obtained was purified and resuspended in water.
5. Luciferase expression by mRNA lipofection
Human dermal fibroblasts (HDF) and HeLa cells were seeded in 96 well plates at a density of 1 x10" cells per well. The following day, cells were washed in Opti-MEM and then transfected with 12.5 ng per well of Lipofectamine2000-complexed PpLuc-encoding mRNA in Opti- MEM. Untransfected cells served as control. mRNA coding for Renilla reniformis luciferase (RrLuc) was transfected together with PpLuc mRNA to control for transfection efficiency (1 ng of RrLuc mRNA per well). 90 minutes after start of transfection, Opti-MEM was exchanged for medium. 6, 24, 48, 72 hours after transfection, medium was aspirated and cells were lysed in 100 μΙ of Passive Lysis buffer (Promega). Lysates were stored at -80°C until luciferase activity was measured.
6. Luciferase measurement
Luciferase activity was measured as relative light units (RLU) in a Hidex Chameleon plate reader. The activities of Ppluc and Rrluc are measured sequentially from a single sample in a dual luciferase assay. The PpLuc activity was measured first at 2 seconds measuring time using 20 μΙ of lysate and 50 μΙ of Beetle juice (pjk GmbH). After 1500ms delay RrLuc activity is measured with 50 μΙ Renilla juice (pjk GmbH). 7. Results
a. Protein expression from mRNA containing 3'-UTR elements according to the invention is increased and/or prolonged.
To investigate the effect of various 3'-UTR elements on protein expression from mRNA, mRNAs containing different 3'-UTR elements were compared to an mRNA lacking a 3'-UTR. Human HeLa and HDF cells were transfected with Luciferase encoding mRNAs and Luciferase levels (in RLU) were measured 6, 24, 48, and 72 hours after transfecti on. The PpLuc signal was corrected for transfection efficiency by the signal of cotransfected RrLuc. Normalized PpLuc levels at 24h were set to 100% and relative expression to 24h is calculated (see following Table 4 and Figures 12 (HeLa cells) and 13 (HDF cells)).
Table 4:
Figure imgf000231_0001
Table 4 shows relative PpLuc expression normalized to RrLuc (mean values of three independent experiments are given).
Luciferase was expressed from mRNA lacking a 3'-UTR. However, the inventive 3'-UTR elements gnas, morn2, gstml , ndufa and cbr2 significantly prolonged luciferase expression.
b. Protein expression from mRNA containing 5'-UTR elements according to the invention is increased and/or prolonged. To investigate the effect of various 5'-UTR elements on protein expression from mRNA, mRNAs containing different 5'-UTRs were compared to an mRNA lacking a 5'-UTR.
Human HeLa and HDF cells were transfected with Luciferase encoding mRNAs and Luciferase levels were measured 6, 24, 48, and 72 hours after transfection. The PpLuc signal was corrected for transfection efficiency by the signal of cotransfected RrLuc. Total protein expression from 0 to 72 hours was calculated as the area under the curve (AUC). The levels of the control construct without 5' UTR was set to 1 (see following Table 5 and Figure 14 (HeLa cells) and 1 5 (HDF cells)).
Table 5:
Figure imgf000232_0001
Table 5 shows the total PpLuc expression normalized to Rr! uc (mean va ues of three independent experiments are given). Luciferase was expressed from mRNA lacking a 5'-UTR. However, the inventive 5'-UTR elements mp68 and ndufa4 significantly increased luciferase expression.
c. Protein expression from mRNA containing 3'-UTR elements according to the invention is prolonged.
To investigate the effect of various 3'UTRs on protein expression from mRNA, mRNAs containing different 3'UTRs were compared to an mRNA lacking a 3'UTR. Human HeLa and HDF cells were transfected with Luciferase encoding mRNAs and Luciferase levels (in RLU) were measured 24, 48, and 72 hours after transfection. The PpLuc signal was corrected for transfection efficiency by the signal of cotransfected RrLuc. Normalized PpLuc levels at 24h were set to 1 00% and relative expression to 24h is calculated (see fol lowing Table 6 and Figures 1 6 (HeLa cel ls) and 1 7 (HDF cells)). Table 6:
Figure imgf000233_0001
Table 6 shows relative PpLuc expression normalized to RrLuc (mean values of three independent experiments are given).
d. Protein expression from mRNA containing 3'-UTR elements according to the invention is prolonged.
To investigate the effect of various 3'UTRs on protein expression from mRNA, mRNAs containing different 3'UTRs were compared to an mRNA lacking a 3'UTR.
Human HeLa and HDF cells were transfected with Luciferase encoding mRNAs and Luciferase levels were measured 6, 24, 48, and 72 hours after transfection. The PpLuc signal was corrected for transfection efficiency by the signal of cotransfected RrLuc. Total protein expression from 0 to 72 hours was calculated as the area under the curve (AUC). The levels of the control construct without 5' UTR was set to 1 (see following Table 7 and Figure 18 (HDF cells) and 1 7 (HeLa cells)).
Human HeLa and HDF cells were transfected with Luciferase encoding mRNAs and Luciferase levels (in RLU) were measured 24, 48, and 72 hours after transfection. The PpLuc signal was corrected for transfection efficiency by the signal of cotransfected RrLuc. Normalized PpLuc levels at 24h were set to 100% and relative expression to 24h is calculated (see following Table 7 and Figure 1 8 (HDF cells)). Table 7:
HDF
mRNA
24h 48h 72 h
32L4-PpLuc(GC)-Ybx1 -001 (V2)-A64-C30-
100 57,0 28,5
hSL
32L4-PpLuc(GC)-Ndufb8-A64-C30-hSL 100 65,4 37,6 32 L4-PpLuc(GC)-Cntn 1004(V2)-A64-C30-
100 71 ,0 47,7
hSL
32L4-PpLuc(GC)-A64-C30-hSL 100 45,2 21 ,87
Table 7 shows relative PpLuc expression normalized to RrLuc (mean values of three independent experiments are given). 8. Effect of further 3'UTRs on protein expression
To further investigate the effect of various 3'UTRs on protein expression from mRNA, new mRNA constructs were prepared and those mRNAs containing different 3'UTRs were compared to an mRNA lacking a 3'UTR.
To this end, selected 3'-UTR elements (gnas, morn2, ndufal and NDUFA1 ) were cloned into the vector PpLuc(GC) - A64 - C30 - hSL (SEQ ID NO. 44, Fig. 10), which was constructed containing a T7 promoter and a GC-enriched sequence coding for Photinus pyralis luciferase (PpLuc(GC)). An A64 poly(A) sequence, followed by C30 and a histone stem-loop sequence, was inserted 3' of PpLuc(GC). The histone stem-loop sequence was followed by a restriction site used for linearization of the vector before in vitro transcription.
In particular, the following mRNAs were obtained from such vectors by in vitro transcription (the mRNA sequences are depicted in Figures 1 1 and 26 to 28:
PpLuc(GC) - gnas - A64 - C30 - hSL (SEQ ID NO. 45, Fig. 1 1 );
PpLuc(GC) - morn2 - A64 - C30 - hSL (SEQ ID NO. 384, Fig. 26);
PpLuc(GC) - ndufal - A64 - C30 - hSL (SEQ ID NO. 385, Fig. 27); and
PpLuc(GC) - NDUFA1 - A64 - C30 - hSL (SEQ ID NO. 386, Fig. 28). Human HeLa cells were transfected with Luciferase encoding mRNAs and Luciferase levels were measured 24, 48, and 72 hours after transfection. The PpLuc signal was corrected for transfection efficiency by the signal of cotransfected RrLuc (see following Table 8 and Fig. 22). HeLa (expression in %)
mRNA
24h 48h 72 h
PpLuc(GC)-gnas-A64-C30-hSL 100 77,9 36,7
PpLuc(GC)-morn2-A64-C30-hSL 100 53,8 1 7,2
PpLuc(GC)-ndufa1 -A64-C30-hSL 100 55,2 1 7,9
PpLuc(GC)-NDUFA1 -A64-C30-hSL 100 66,9 29,4
PpLuc(GC)-A64-C30-hSL 100 41 ,5 9,6
Table 8: relative PpLuc expression normalized to RrLuc (mean values of 3 independent experiments are given). These data and the data shown in Fig. 22 show that protein expression from mRNA containing 3'-UTR elements according to the invention is prolonged.
9. Effect of further 5'UTRs on protein expression
To further investigate the effect of various 5'UTRs on protein expression from mRNA, new mRNA constructs were prepared and those mRNAs containing different 5'UTRs were compared to an mRNA lacking a 5'UTR. To this end, selected 5'-UTR elements (mp68 and ndufa4) were cloned into the vector PpLuc(GC) - A64 - C30 - hSL (SEQ ID NO. 44, Fig. 10), which was constructed containing a T7 promoter and a GC-enriched sequence coding for Photinus pyralis luciferase (PpLuc(GQ). An A64 poly(A) sequence, followed by C30 and a histone stem-loop sequence, was inserted 3' of PpLuc(GC). The histone stem-loop sequence was followed by a restriction site used for linearization of the vector before in vitro transcription.
In particular, the following mRNAs were obtained from such vectors by in vitro transcription (the mRNA sequences are depicted in Figures 29 and 30:
Mp68 - PpLuc(GC) - A64 - C30 - hSL (SEQ ID NO. 387, Fig. 29); and
Ndufa4 - PpLuc(GC) -A64 - C30 - hSL (SEQ ID NO. 388, Fig. 30). Human HDF and HeLa cells were transfected with Luciferase encoding mRNAs and Luciferase levels were measured 24, 48, and 72 hours after transfection. The PpLuc signal was corrected for transfection efficiency by the signal of cotransfected RrLuc. Total protein expression (area under the curve) was calculated. The levels of the control construct without 5' UTR was set to 1 (see following Table 9 and Figures 23 and 24).
Figure imgf000236_0001
Table 9: total PpLuc expression normalized to RrLuc (mean RLU values are given).
These data and the data shown in Figures 23 and 24 show that protein expression from mRNA containing 5'-UTR elements according to the invention is increased.

Claims

Claims
1 . An artificial nucleic acid molecule comprising a. at least one open reading frame (ORF); and b. at least one 3'-untranslated region element (3'-UTR element) and/or at least one 5'-untranslated region element (5'-UTR element), wherein the at least one 3'-UTR element and/or the at least one 5'-UTR element prolongs and/or increases protein production from said artificial nucleic acid molecule and wherein the at least one 3'-UTR element and/or the at least one 5'-UTR element is derived from a stable mRNA.
2. The artificial nucleic acid molecule according to claim 1 , wherein the open reading frame is derived from a gene, which is distinct from a gene from which the at least one 3'-UTR element and/or the at least one 5'-UTR element is derived.
3. The artificial nucleic acid molecule according to claim 1 or 2 comprising at least one 3'-UTR element and at least one 5'-UTR element.
4. The artificial nucleic acid molecule according to claim 3, wherein each of the at least one open reading frame, the at least one 3'-UTR element and the at least one 5'-UTR element are heterologous to each other.
5. The artificial nucleic acid molecule according to any of claims 1 to 4, wherein the stable mRNA from which the at least one 3'-UTR element and/or the at least one 5'-UTR element is derived is characterized by an mRNA decay wherein the ratio of the amount of said mRNA at a second point in time to the amount of said mRNA at a first point in time is at least 0.5 (50%), at least 0.6 (60%), at least 0.7 (70%), at least 0.75 (75%), at least 0.8 (80%), at least 0.85 (85%), at least 0.9 (90%), or at least 0.95 (95%).
6. The artificial nucleic acid molecule according to any of claims 1 to 5, wherein the artificial nucleic acid molecule does not comprise a 3'-UTR and/or a 5'-UTR of ribosomal protein S6, of RPL36AL, of rps16 or of ribosomal protein L9 and wherein the open reading frame of the artificial nucleic acid molecule does not code for a GFP protein.
7. The artificial nucleic acid molecule according to claim 6, wherein the open reading frame of the artificial nucleic acid molecule does not code for a reporter protein.
8. The artificial nucleic acid molecule according to any one of claims 1 to 7, wherein the at least one 3'-UTR element and/or the at least one 5'-UTR element comprises or consists of a nucleic acid sequence which is derived from the 3'-UTR and/or the 5'-UTR of a eukaryotic protein coding gene, preferably from the 3'-UTR and/or the 5'-UTR of a vertebrate protein coding gene, more preferably from the 3'-UTR and/or the 5'-UTR of a mammalian protein coding gene, even more preferably from the 3'-UTR and/or the 5'-UTR of a primate protein coding gene.
9. The artificial nucleic acid molecule according to claim 8, wherein the at least one 3'-UTR element and/or the at least one 5'-UTR element comprises or consists of a nucleic acid sequence which is derived from the 3'-UTR and/or the 5'-UTR of a human or murine protein coding gene.
10. The artificial nucleic acid molecule according to claim 8 or 9, wherein:
(i) the nucleic acid molecule comprises at least one 3'-UTR element and at least one 5'-UTR element;
(ii) the at least one 3'-UTR element, the at least one 5'-UTR element and the at least one open reading frame are all heterologous to each other;
(iii) the at least one 3' UTR element is derived from a gene selected from the group consisting of: housekeeping genes, genes coding for a membrane protein, genes involved in cellular metabolism, genes involved in transcription, translation and replication processes, genes involved in protein modification and genes involved in cell division; and
(iv) the 3'UTR is not derived from a gene coding for a ribosomal protein or from the Fig4 gene.
1 1 . The artificial nucleic acid molecule according to any of claims 8 to 10, wherein: (i) the nucleic acid molecule comprises at least one 3'-UTR element and at least one 5'-UTR element;
(ii) the at least one 3'-UTR element, the at least one 5'-UTR element and the at least one open reading frame are all heterologous to each other;
(iii) the at least one 5'-UTR element is derived from a gene selected from the group consisting of: housekeeping genes, genes coding for a membrane protein, genes involved in cellular metabolism, genes involved in transcription, translation and replication processes, genes involved in protein modification and genes involved in cel l division;
(iv) the 5'-UTR is preferably not a 5' TOP UTR; and
(v) the 3'-UTR is preferably not derived from a gene coding for a ribosomal protein or for albumin or from the Fig4 gene.
The artificial nucleic acid molecule according to claim 1 0 or 1 1 , wherein:
(i) the nucleic acid molecule comprises at least one 3'-UTR element and at least one 5'-UTR element;
(ii) the at least one 3'-UTR element, the at least one 5'-UTR element and the at least one open reading frame are all heterologous to each other;
(iii) the at least one 3' UTR element is derived from a human or a murine gene selected from the group consisting of: housekeeping genes, genes coding for a membrane protein, genes involved in cellular metabolism, genes involved in transcription, translation and replication processes, genes involved in protein modification and genes involved in cell division;
(iv) the 3'UTR is not derived from a gene coding for a ribosomal protein or for albumin or from the Fig4 gene;
(v) the at least one 5'-UTR element is derived from a human or a murine gene selected from the group consisting of: housekeeping genes, genes coding for a membrane protein, genes involved in cel lular metabolism, genes involved in transcription, translation and replication processes, genes i nvolved in protein modification and genes involved in cell division; and
(vi) the 5'-UTR is not a 5' TOP UTR. The artificial nucleic acid molecule according to any of claims 10 to 12, wherein the 3'-UTR and the 5'-UTR are derived from a human or a murine housekeeping gene.
The artificial nucleic acid molecule according to claim 12, wherein the 3'-UTR and the 5'-UTR are derived from a human or a murine gene selected from the group consisting of: genes coding for a membrane protein, genes involved in cellular metabolism, genes involved in transcription, translation and replication processes, genes involved in protein modification and genes involved in cell division and wherein the 3'-UTR and the 5'-UTR are selected from distinct gene classes.
The artificial nucleic acid molecule according to any of claims 1 to 14, wherein the at least one 3'-UTR element and/or the at least one 5'-UTR element prolongs protein production from said artificial nucleic acid molecule at least 1 .2 fold, preferably at least 1 .5 fold, more preferably at least 2 fold, even more preferably at least 2.5 fold, compared to the protein production from a reference nucleic acid molecule lacking a 3'-UTR and/or the at least one 5'-UTR, respectively, and/or wherein the at least one 3'-UTR element and/or the at least one 5'-UTR element increases protein production from said artificial nucleic acid molecule at least 1 .5 fold, preferably at least 2 fold, more preferably at least 2.5 fold, compared to the protein production from a reference nucleic acid molecule lacking a 3'-UTR and/or the at least one 5'-UTR, respectively.
The artificial nucleic acid molecule according to any one of claims 1 to 1 5, wherein the at least one 3'-UTR element and/or the at least one 5'-UTR element comprises or consists of a nucleic acid sequence which is derived from the 3'- UTR and/or the 5'-UTR of a transcript of a gene selected from the group consisting of NDUFA1 (NADH dehydrogenase (ubiquinone) 1 alpha subcomplex), GNAS (guanine nucleotide binding protein, alpha stimulating complex locus), MORN2 (MORN repeat containing 2), GSTM1 (glutathione S-transferase, mu 1 ), CBR2 (carbonyl reductase 2), MP68 (RIKEN cDNA 20101 07E04 gene), NDUFA4 (NADH dehydrogenase (ubiquinone) 1 alpha subcomplex 4), LTA4H, SLC38A6, DECR1 , PIGK, FAM1 75A, PHYH, TBC1 D19, PIGB, ALG6, CRYZ, BRP44L, ACADSB, SUPT3H, TMEM14A, GRAMD1C, CI 1orf80, C9orf46, ANXA4, TBCK, IFI6, C2orf34, ALDH6A1, ACTPBP1, CCDC53, LRRC28, CCDC109B, PUS10, CCDC104, CASP1, SNX14, SKAP2, NDUFB6, EFHA1, BCKDHB, BBS2, LMBRD1, ITGA6, HERC5, NT5DC1, RAB7A, AGA, TPK1, MBNL3, HADHB, MCCC2, CAT, ANAPC4, PCCB, PHKB, ABCB7, PGCP, GPD2, TMEM38B, NFU1, OMA1, LOC128322/NUTF2, NUBPL, LANCL1, HHLA3, PIR, ACAA2, CTBS, GSTM4, ALG8, Ndufal, Atp5e, Gstm5, Uqcr11, Ifi27l2a, Cbr2, Anapc13, Atp5l, TmsblO, Nenf, Ndufa7, Atp5k, 1110008P14Rik, Cox4i1, Cox6a1, Ndufs6, Sec61b, Romol, Gnas, Snrpd2, Mgst3, Aldh2, Ssr4, Myl6, Prdx4, Ubl5, 1110001J03Rik, Ndufal 3, Ndufa3, Gstp2, Tmem160, Ergic3, Pgcp, Slpi, Myeov2, Ndufa4, Ndufs5, Gstml, 181002701 ORik, Atp5o, Shfml, Tspo, S100a6, Taldol, Bloc1s1, Hexa, Ndufb11, Map1lc3a, Morn2, Gpx4, Mif, Cox6b1, RIKEN CDNA2900010J23 (Swi5), Sec61g, 2900010M23Rik, Anapc5, Mars2, Phptl, Ndufb8, Pfdn5, Arpc3, Ndufb7, Atp5h, Mrpl23, Uba52, Tomm6, Mtchl, Pcbd2, Ecm1, Hrsp12, Mecr, Uqcrq, Gstm3, Lsm4, Park7, Usmg5, Cox8a, Ly6c1, Cox7b, Ppib, Bag1, S100a4, Bcap31, Tecr, Rabad, Robld3, Sod1, Nedd8, Higd2a, Trappc6a, Ldhb, Nme2, Snrpg, Ndufa2, Serfl, Oaz1, Rps4x, Rps13, Ybx1, Seppi, Gaa, ACTR10, PIGF, MGST3, SCP2, HPRT1, ACSF2, VPS13A, CTH, NXT2, MGST2, C11orf67, PCCA, GLMN, DHRS1, PON2, NME7, ETFDH, ALG13, DDX60, DYNC2LI1, VPS8, ITFG1, CDK5, C1orf112, IFT52, CLYBL, FAM114A2, NUDT7, AKD1, MAGED2, HRSP12, STX8, ACAT1, IFT74, KIFAP3, CAPN1, COX11, GLT8D4, HACL1, IFT88, NDUFB3, ANO10, ARL6, LPCAT3, ABCD3, COPG2, MIPEP, LEPR, C2orf76, ABCA6, LY96, CROT, ENPP5, SERPINB7, TCP11L2, IRAKI BP1, CDKL2, GHR, KIAA1107, RPS6KA6, CLGN, TMEM45A, TBC1D8B, ACP6, RP6-213H19.1, SNRPN, GLRB, HERC6, CFH, GALC, PDE1A, GSTM5, CADPS2, AASS, TRIM6-TRIM34 (readthrough transcript), SEPP1, PDE5A, SATB1, CCPG1, CNTN1, LMBRD2, TLR3, BCAT1, TOM1L1, SLC35A1, GLYATL2, STAT4, GULP1, EHHADH, NBEAL1, KIAA1598, HFE, KIAA1324L, and MANSC1; preferably from the group consisting of NDUFA1 (NADH dehydrogenase (ubiquinone) 1 alpha subcomplex), GNAS (guanine nucleotide binding protein, alpha stimulating complex locus), MORN2 (MORN repeat containing 2), GSTM1 (glutathione S-transferase, mu 1), CBR2 (carbonyl reductase 2), MP68 (RIKEN cDNA 2010107E04 gene), NDUFA4 (NADH dehydrogenase (ubiquinone) 1 alpha subcomplex 4), Ybx1 (Y-Box binding protein 1), Ndufb8 (NADH dehydrogenase (ubiquinone) 1 beta subcomplex 8), and CNTN1 (contact! n 1).
17. The artificial nucleic acid molecule according to claim 16, wherein the at least one 3'-UTR element and/or the at least one 5'-UTR element comprises a nucleic acid sequence which is derived from the 3'-UTR and/or the 5'-UTR of a transcript of a human gene selected from the group consisting of NDUFA1 (NADH dehydrogenase (ubiquinone) 1 alpha subcomplex), GNAS (guanine nucleotide binding protein, alpha stimulating complex locus), MORN2 (MORN repeat containing 2), GSTM1 (glutathione S-transferase, mu 1), CBR2 (carbonyl reductase 2), MP68 (RIKEN cDNA 2010107E04 gene), NDUFA4 (NADH dehydrogenase (ubiquinone) 1 alpha subcomplex 4), Ybx1 (Y-Box binding protein 1), Ndufb8 (NADH dehydrogenase (ubiquinone) 1 beta subcomplex 8), CNTN1 (contactin 1), LTA4H, SLC38A6, DECR1, PIGK, FAM175A, PHYH, TBC1D19, PIGB, ALG6, CRYZ, BRP44L, ACADSB, SUPT3H, TMEM14A, GRAMD1C, C11orf80, C9orf46, ANXA4, TBCK, IFI6, C2orf34, ALDH6A1, AGTPBP1, CCDC53, LRRC28, CCDC109B, PUS10, CCDC104, CASP1, SNX14, SKAP2, NDUFB6, EFHA1, BCKDHB, BBS2, LMBRD1, ITGA6, HERC5, NT5DC1, RAB7A, AGA, TPK1, MBNL3, HADHB, MCCC2, CAT, ANAPC4, PCCB, PHKB, ABCB7, PGCP, GPD2, TMEM38B, NFU1,OMA1, LOC128322/NUTF2, NUBPL, LANCL1, HHLA3, , PIR, ACAA2, CTBS, GSTM4, ALG8, ACTR10, PIGF, MGST3, SCP2, HPRT1, ACSF2, VPS13A, CTH, NXT2, MGST2, C11orf67, PCCA, GLMN, DHRS1, PON2, NME7, ETFDH, ALG13, DDX60, DYNC2LI1, VPS8, ITFG1, CDK5, C1orf112, IFT52, CLYBL, FAM114A2, NUDT7, AKD1, MAGED2, HRSP12, STX8, ACAT1, IFT74, KIFAP3, CAPN1, COX11, GLT8D4, HACL1, IFT88, NDUFB3, ANO10, ARL6, LPCAT3, ABCD3, COPG2, MIPEP, LEPR, C2orf76, ABCA6, LY96, CROT, ENPP5, SERPINB7, TCP11L2, IRAKI BP1, CDKL2, GHR, KIAA1107, RPS6KA6, CLGN, TMEM45A, TBC1D8B, ACP6, RP6-213H19.1 , SNRPN, GLRB, HERC6, CFH, GALC, PDE1 A, GSTM5, CADPS2, AASS, TRIM6-TRIM34 (readthrough transcript), SEPP1, PDE5A, SATB1, CCPG1 , LMBRD2, TLR3, BCAT1, TOM1L1, SLC35A1, GLYATL2, STAT4, GULP1 , EHHADH, NBEAL1 , KIAA1598, HFE, KIAA1324L, and MANSC1. The artificial nucleic acid molecule according to claim 1 6, wherein the at least one 3'-UTR element and/or the at least one 5'-UTR element comprises a nucleic acid sequence which is derived from the 3'-UTR and/or the 5'-UTR of a transcript of a murine gene selected from the group consisting of NDUFA1 (NADH dehydrogenase (ubiquinone) Ί alpha subcomplex), GNAS (guanine nucleotide binding protein, alpha stimulating complex locus), MORN2 (MORN repeat containing 2), GSTM1 (glutathione S-transf erase, mu 1 ), CBR2 (carbonyl reductase 2), MP68 (RIKEN cDNA 2010107E04 gene), NDUFA4 (NADH dehydrogenase (ubiquinone) 1 alpha subcomplex 4), Ybx1 (Y-Box binding protein 1 ), Ndufb8 (NADH dehydrogenase (ubiquinone) 1 beta subcomplex 8), CNTN1 (contactin 1 ), Atp5e, Gstm5, Uqcrl 1 , Ifi27l2a, Anapc13, Atp5l, Tmsbl O, Nenf, Ndufa7, Atp5k, 1 1 10008P14Rik, Cox4i1 , Cox6a1 , Ndufs6, Sec61 b, Romol , Snrpd2, Mgst3, Aldh2, Ssr4, Myl6, Prdx4, Ubl5, 1 1 10001J03Rik, Ndufa13, Ndufa3, Gstp2, Tmem1 60, Ergic3, Pgcp, Slpi, Myeov2, Ndufs5, 181002701 ORik, Atp5o, Shfml , Tspo, S100a6, Taldol , Blod sl , Hexa, Ndufb1 1 , Map1 Ic3a, Gpx4, Mif, Cox6b1 , RIKEN CDNA2900010J23 (Swi5), Sec61 g, 2900010M23Rik, Anapc5, Mars2, Phptl , Pfdn5, Arpc3, Ndufb7, Atp5h, Mrpl23, Uba52, Tomm6, Mtchl , Pcbd2, Ecm1 , Hrsp12, Mecr, Uqcrq, Gstm3, Lsm4, Park7, Usmg5, Cox8a, Ly6c1 , Cox7b, Ppib, Bag1 , S1 00a4, Bcap31 , Tecr, Rabad , Robld3, Sod1 , Nedd8, Higd2a, TrappcGa, Ldhb, Nme2, Snrpg, Ndufa2, Serfl , Oaz1 , Rps4x, Rps13, Seppl , and Gaa.
The artificial nucleic acid molecule according to any one of claims 1 6 to 18, wherein the at least one 3'-UTR element comprises a nucleic acid sequence which is derived from the 3'-UTR of a transcript of a gene selected from the group consisting of NDUFA1 (NADH dehydrogenase (ubiquinone) 1 alpha subcomplex), GNAS (guanine nucleotide binding protein, alpha stimulating complex locus), MORN2 (MORN repeat containing 2), GSTM1 (glutathione S- transferase, mu 1 ), CBR2 (carbonyl reductase 2), SLC38A6, DECR1 , PIGK, FAM1 75A, PHYH, TBC1 D1 9, PIGB, ALG6, CRYZ, BRP44L, ACADSB, TMEM14A, GRAMD1 C, C1 1 orf80, ANXA4, TBCK, IFI6, C2orf34, ALDH6A1 , AGTPBP1 , CCDC53, LRRC28, CCDC109B, PUS10, CCDC104, CASP1 , SNX14, SKAP2, NDUFB6, EFHA1 , BCKDHB, BBS2, LMBRD1 , ITGA6, HERC5, HADHB, ANAPC4, PCCB, ABCB7, PGCP, NFU1 , OMA1 , HHLA3, ACAA2, GSTM4, ALG8, Ndufal, Atp5e, Gstm5, Uqcr11, Ifi27l2a, Cbr2, Atp5l, TmsblO, Nenf, Atp5k, m0008P14Rik, Cox4i1, Cox6a1, Ndufs6, Sec61b, Romol, Gnas, Snrpd2, Mgst3, Aldh2, Ssr4, Myl6, Prdx4, Ubl5, 1110001J03Rik, Ndufa13, Ndufa3, Gstp2, Tmem160, Ergic3, Pgcp, Slpi, Myeov2, Ndufa4, Ndufs5, Gstml, 181002701 ORik, Atp5o, Shfml, Tspo, S100a6, Taldol, Bioc1s1, Ndufb11, Map1 Ic3a, Morn2, Gpx4, Mif, Cox6b1, RIKEN cDNA2900010J23 (Swi5), Sec61g, 2900010M23Rik, Anapc5, Mars2, Phpti, Ndufb8, Pfdn5, Arpc3, Ndufb7, Atp5h, Mrpl23, Uba52, Tomm6, Mtchl, Pcbd2, Ecm1, Hrsp12, Mecr, Uqcrq, Gstm3, Lsm4, Park7, Usmg5, Cox8a, Ly6c1, Cox7b, Ppib, Bag1, S100a4, Bcap31, Tecr, Rabad, Robld3, Sod1, Nedd8, Higd2a, Trappc6a, Ldhb, Nme2, Snrpg, Ndufa2, Serfl, Oaz1, Rps4x, Rps13, Ybx1, Seppl, Gaa, ACTR10, PIGF, MGST3, SCP2, HPRT1, ACSF2, VPS13A, CTH, NXT2, MGST2, C11orf67, PCCA, GLMN, DHRS1, PON2, NME7, ETFDH, ALG13, DDX60, DYNC2LI1, VPS8, 1TFG1, CDK5, C1 orfl 12, IFT52, CLYBL, FAM114A2, NUDT7, AKD1 , MAGED2, HRSP12, STX8, ACAT1, IFT74, KIFAP3, CAPN1, COX11, GLT8D4, HACL1, IFT88, NDUFB3, ANO10, ARL6, LPCAT3, ABCD3, COPG2, MIPEP, LEPR, C2orf76, ABCA6, LY96, CROT, ENPP5, SERPINB7, TCP11 L2, IRAKI BP1, CDKL2, GHR, KIAA1107, RPS6KA6, CLGN, TMEM45A, TBC1 D8B, ACP6, RP6-213H19.1, SNRPN, GLRB, HERC6, CFH, GALC, PDE1A, GSTM5, CADPS2, AASS, TRIM6-TRIM34 (readthrough transcript), SEPP1, PDE5A, SATB1, CCPG1, CNTN1, LMBRD2, TLR3, BCAT1, TOM1L1, SLC35A1, GLYATL2, STAT4, GULP1, EHHADH, NBEAL1, KIAA1598, HFE, KIAA1324L, and MANSC1; preferably, the at least one 3'-UTR element comprises or consists of a nucleic acid sequence which is derived from the 3'-UTR of a transcript of a gene selected from the group consisting of NDUFA1 (NADH dehydrogenase (ubiquinone) 1 alpha subcomplex), GNAS (guanine nucleotide binding protein, alpha stimulating complex locus), MORN2 (MORN repeat containing 2), GSTM1 (glutathione S-transferase, mu 1), CBR2 (carbonyl reductase 2), Ybx1 (Y-Box binding protein 1), Ndufb8 (NADH dehydrogenase (ubiquinone) 1 beta subcomplex 8), and CNTN1 (contactin 1).
The artificial nucleic acid molecule according to claim 19, wherein the at least one 3'-UTR element comprises a nucleic acid sequence which is derived from the 3'-UTR of a transcript of a human gene selected from the group consisting of NDUFA1 (NADH dehydrogenase (ubiquinone) 1 alpha subcomplex), GNAS (guanine nucleotide binding protein, alpha stimulating complex locus), MORN2 (MORN repeat containing 2), GSTM1 (glutathione S-transf erase, mu 1), CBR2 (carbonyl reductase 2), SLC38A6, DECR1, PIGK, FAM175A, PHYH, TBC1D19, PIGB, ALG6, CRYZ, BRP44L, ACADSB, TMEM14A, GRAMD1C, C11orf80, ANXA4, TBCK, IFI6, C2orf34, ALDH6A1, AGTPBP1, CCDC53, LRRC28, CCDC109B, PUS10, CCDC104, CASPl, SNX14, SKAP2, NDUFB6, EFHA1, BCKDHB, BBS2, LMBRD1, ITGA6, HERC5, HADHB, ANAPC4, PCCB, ABCB7, PGCP, NFU1, OMA1, HHLA3, ACAA2, GSTM4, ALG8, ACTR10, PIGF, MGST3, SCP2, HPRT1, ACSF2, VPS13A, CTH, NXT2, MGST2, C1lorf67, PCCA, GLMN, DHRS1, PON2, NME7, ETFDH, ALG13, DDX60, DYNC2LI1, VPS8, ITFG1, CDK5, Clorf112, IFT52, CLYBL, FAM114A2, NUDT7, AKD1, MAGED2, HRSP12, STX8, ACAT1, IFT74, KIFAP3, CAPN1, COX11, GLT8D4, HACL1, IFT88, NDUFB3, ANO10, ARL6, LPCAT3, ABCD3, COPG2, MIPEP, LEPR, C2orf76, ABCA6, LY96, CROT, ENPP5, SERPINB7, TCP11 L2, IRAKI BP1, CDKL2, GHR, KIAA1107, RPS6KA6, CLGN, TMEM45A, TBC1 D8B, ACP6, RP6- 213H19.1, SNRPN, GLRB, HERC6, CFH, GALC, PDE1A, GSTM5, CADPS2, AASS, TRIM6-TRIM34 (readthrough transcript), SEPP1, PDE5A, SATB1, CCPG1, CNTNl, LMBRD2, TLR3, BCAT1, TOM1L1, SLC35A1, GLYATL2, STAT4, GULP1, EHHADH, NBEAL1, KIAA1598, HFE, KIAA1324L, and MANSC1; preferably, the at least one 3'-UTR element comprises or consists of a nucleic acid sequence which is derived from the 3'-UTR of a transcript of a human gene selected from the group consisting of NDUFA1 (NADH dehydrogenase (ubiquinone) 1 alpha subcomplex), GNAS (guanine nucleotide binding protein, alpha stimulating complex locus), MORN2 (MORN repeat containing 2), GSTM1 (glutathione S-transferase, mu 1), CBR2 (carbonyl reductase 2), Ybx1 (Y-Box binding protein 1), Ndufb8 (NADH dehydrogenase (ubiquinone) 1 beta subcomplex 8), and CNTN1 (contactin 1).
The artificial nucleic acid molecule according to claim 19, wherein the at least one 3'-UTR element comprises a nucleic acid sequence which is derived from the 3'-UTR of a transcript of a murine gene selected from the group consisting of NDUFA1 (NADH dehydrogenase (ubiquinone) 1 alpha subcomplex), GNAS (guanine nucleotide binding protein, alpha stimulating complex locus), MORN2 (MORN repeat containing 2), GSTM1 (glutathione S-transferase, mu 1), CBR2 (carbonyl reductase 2), Ybxl (Y-Box binding protein 1), Ndufb8 (NADH dehydrogenase (ubiquinone) 1 beta subcomplex 8), and CNTN1 (contactin 1), Ndufal, Atp5e, Gstm5, Uqcrll, ifi27l2a, Cbr2, Atp51, TmsblO, Nenf, Atp5k, ll10008P14Rik, Cox4i1, Cox6a1, Ndufs6, Sec61b, Romol, Gnas, Snrpd2, Mgst3, Aldh2, Ssr4, Myl6, Prdx4, Ubl5, 1110001 J03 Rik, Ndufa13, Ndufa3, Gstp2, Tmem160, Ergic3, Pgcp, Slpi, Myeov2, Ndufa4, Ndufs5, Gstml, 181002701 ORik, Atp5o, Shfml, Tspo, S100a6, Taldol, Bloclsl, Ndufb11, Map1 Ic3a, Morn2, Gpx4, Mif, Cox6b1, RI EN cDNA2900010J23 (Swi5), Sec61g, 2900010M23Rik, Anapc5, Mars2, Phpti, Ndufb8, Pfdn5, Arpc3, Ndufb7, Atp5h, Mrpl23, Uba52, Tomm6, Mtchl, Pcbd2, Ecm1, Hrsp12, Mecr, Uqcrq, Gstm3, Lsm4, Park7, Usmg5, Cox8a, Ly6c1, Cox7b, Ppib, Bag1, S100a4, Bcap31, Tecr, Rabacl, Robld3, Sod1, Nedd8, Higd2a, Trappc6a, Ldhb, Nme2, Snrpg, Ndufa2, Serfl , Oaz1 , Rps4x, Rps13, Ybx1 , Seppl , and Gaa; preferably, the at least one 3'- UTR element comprises or consists of a nucleic acid sequence which is derived from the 3'-UTR of a transcript of a murine gene selected from the group consisting of NDUFA1 (NADH dehydrogenase (ubiquinone) 1 alpha subcomplex), GNAS (guanine nucleotide binding protein, alpha stimulating complex locus), MORN2 (MORN repeat containing 2), GSTM1 (glutathione S-transferase, mu 1), CBR2 (carbonyl reductase 2), Ybx1 (Y-Box binding protein 1), Ndufb8 (NADH dehydrogenase (ubiquinone) 1 beta subcomplex 8), and CNTN1 (contactin 1).
The artificial nucleic acid molecule according to any one of claims 16 to 18, wherein the at least one 5'-UTR element comprises a nucleic acid sequence which is derived from the 5'-UTR of a transcript of a gene selected from the group consisting of MP68 (RIKEN cDNA 2010107E04 gene), NDUFA4 (NADH dehydrogenase (ubiquinone) 1 alpha subcomplex 4), LTA4H, DECR1, PIGK, TBC1D19, BRP44L, ACADSB, SUPT3H, TMEM14A, C9orf46, ANXA4, IFI6, C2orf34, ALDH6A1, CCDC53, CCDC104, CASP1, NDUFB6, BCKDHB, BBS2, HERC5, FAM175A, NT5DC1, RAB7A, AGA, TPK1, MBNL3, MCCC2, CAT, ANAPC4, PHKB, ABCB7, GPD2, TMEM38B, NFU1, LOC128322/NUTF2, NUBPL, LANCL1, PIR, CTBS, GSTM4, Ndufal, Atp5e, Gstm5, Cbr2, Anapc13, Ndufa7, Atp5k, 1110008P14Rik, Cox4i1, Ndufs6, Sec61b, Snrpd2, Mgst3, Prdx4; Pgcp; Myeov2; Ndufa4; Ndufs5; Gstml; Atp5o; Tspo; Taldol; Blodsl; and Hexa; preferably, the at least one 5'-UTR element comprises or consists of a nucleic acid sequence which is derived from the 5'-UTR of a transcript of MP68 (RIKEN cDNA 2010107E04 gene) or NDUFA4 (NADH dehydrogenase (ubiquinone) 1 alpha subcomplex 4).
The artificial nucleic acid molecule according to claim 22, wherein the at least one 5'-UTR element comprises a nucleic acid sequence which is derived from the 5'-UTR of a transcript of a human gene selected from the group consisting of MP68 (RIKEN cDNA 201 0107E04 gene), NDUFA4 (NADH dehydrogenase (ubiquinone) 1 alpha subcomplex 4), LTA4H, DECR1 , P1GK, TBC1 D1 9, BRP44L, ACADSB, SUPT3H, TMEM14A, C9orf46, ANXA4, IFI6, C2orf34, ALDH6A1 , CCDC53, CCDC104, CASP1 , NDUFB6, BCKDHB, BBS2, HERC5, FAM1 75A, NT5DC1 , RAB7A, AGA, TPK1 , MBNL3, MCCC2, CAT, ANAPC4, PHKB, ABCB7, GPD2, TMEM38B, NFU1 , LOC128322/NUTF2, NUBPL, LANCL1 , PIR, CTBS, and GSTM4; preferably, the at least one 5'-UTR element comprises or consists of a nucleic acid sequence which is derived from the 5'-UTR of a human transcript of MP68 (RIKEN cDNA 2010107E04 gene) or NDUFA4 (NADH dehydrogenase (ubiquinone) 1 alpha subcomplex 4).
The artificial nucleic acid molecule according to claim 22, wherein the at least one 5'-UTR element comprises a nucleic acid sequence which is derived from the 5'-UTR of a transcript of a murine gene selected from the group consisting of MP68 (RIKEN cDNA 2010107E04 gene), NDUFA4 (NADH dehydrogenase (ubiquinone) 1 alpha subcomplex 4), Ndufal , Atp5e, Gstm5, Cbr2, Anapc13, Ndufa7, Atp5k, 1 1 10008P14Rik, Cox4i1 , Ndufs6, Sec61 b, Snrpd2, Mgst3, Prdx4; Pgcp; Myeov2; Ndufa4; Ndufs5; Gstml ; Atp5o; Tspo; Taldol ; Blod sl ; and Hexa; preferably, the at least one 5'-UTR element comprises or consists of a nucleic acid sequence which is derived from the 5'-UTR of a murine transcript of MP68 (RIKEN cDNA 2010107E04 gene) or NDUFA4 (NADH dehydrogenase (ubiquinone) 1 alpha subcomplex 4).
The artificial nucleic acid molecule according to any one of claims 1 - 21 , wherein the at least one 3'-UTR element comprises or consists of a nucleic acid sequence which has an identity of at least about 50%, preferably of at least about 60%, preferably of at least about 70%, more preferably of at least about 80%, more preferably of at least about 90%, even more preferably of at least about 95%, even more preferably of at least about 99% to a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 1 to 24 and SEQ ID NOs: 49 to 318 or wherein the at least one 3'-UTR element comprises or consists of a fragment of a nucleic acid sequence which has an identity of at least about 40%, preferably of at least about 50%, preferably of at least about 60%, preferably of at least about 70%, more preferably of at least about 80%, more preferably of at least about 90%, even more preferably of at least about 95%, even more preferably of at least about 99% to fragment of a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 1 to 24 and SEQ ID NOs: 49 to 31 8.
26. The artificial nucleic acid molecule according to any one of claims 1 - 18 and 22 to 24, wherein the at least one 5'-UTR element comprises or consists of a nucleic acid sequence which has an identity of at least about 50%, preferably of at least about 60%, preferably of at least about 70%, more preferably of at least about 80%, more preferably of at least about 90%, even more preferably of at least about 95%, even more preferably of at least about 99% to a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 25 to 30 and SEQ ID NOs: 319 to 382 or wherein the at least one 5'-UTR element comprises or consists of a fragment of a nucleic acid sequence which has an identity of at least about 40%, preferably of at least about 50%, preferably of at least about 60%, preferably of at least about 70%, more preferably of at least about 80%, more preferably of at least about 90%, even more preferably of at least about 95%, even more preferably of at least about 99% to a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 25 to 30 and SEQ ID NOs: 319 to 382.
27. The artificial nucleic acid molecule according to claim 25 or 26, wherein the fragment exhibits a length of between 3 and about 500 nucleotides, preferably of between 5 and about 1 50 nucleotides, more preferably of between 10 and 1 00 nucleotides, even more preferably of between 15 and 90, most preferably of between 20 and 70.
28. The artificial nucleic acid molecule according to any one of claims 1 - 27, wherein the at least one 3'-UTR element and/or the at least one 5'-UTR element exhibits a length of between 3 and about 500 nucleotides, preferably of between 5 and about 1 50 nucleotides, more preferably of between 1 0 and 1 00 nucleotides, even more preferably of between 1 5 and 90, most preferably of between 20 and 70.
29. The artificial nucleic acid molecule according to any one of claims 1 - 28 further comprising c. a poly(A) sequence and/or a polyadenylation signal.
30. The artificial nucleic acid molecule according to claim 29, wherein the poly(A) sequence or the polyadenylation signal is located 3' of the 3'-UTR element.
31 . The artificial nucleic acid molecule according to claim 29 or 30, wherein the polyadenylation signal comprises the consensus sequence NN(U/T)ANA, with N = A or U, preferably AA(U/T)AAA or A(U T)(U/T)AAA.
32. The artificial nucleic acid molecule according to any one of claims 29 - 31 , wherein the polyadenylation signal, preferably the consensus sequence NNUANA, is located less than about 50 nucleotides downstream of the 3'-end of the 3'-UTR element.
33. The artificial nucleic acid molecule according to any one of claims 29 - 32, wherein the poly(A) sequence has a length of about 20 to about 300 adenine nucleotides, preferably of about 40 to about 200 adenine nucleotides, more preferably of about 50 to about 1 00 adenine nucleotides, even more preferably of about 60 to about 70 adenine nucleotides.
34. The artificial nucleic acid molecule according to any one of claims Ί - 33, further comprising a 5'-cap structure, a poly(C) sequence, a histone stem-loop, and/or an IRES-motif.
35. The artificial nucleic acid molecule accordi ng to any one of claims 1 - 34, wherein the histone stem-loop comprises a sequence according to SEQ ID NO: 34. The artificial nucleic acid molecule according to any one of claims 1 - 35, wherein the nucleic acid comprises a promoter.
The artificial nucleic acid molecule according to any one of claims 1 - 36, wherein the nucleic acid comprises a 5'-TOP UTR.
The artificial nucleic acid molecule according to any one of claims 1 - 37, wherein the nucleic acid comprises a 3'-UTR, which comprises or consists of a nucleic acid sequence which is derived from a 3'-UTR of an albumin gene.
The artificial nucleic acid molecule according to any one of claims 1 - 38, wherein the artificial nucleic acid molecule, preferably the open reading frame, is at least partially G/C modified, preferably wherein the G/C content of the open reading frame is increased compared to the wild type open reading frame.
The artificial nucleic acid molecule according to any one of claims 1 - 39, wherein the open reading frame comprises a codon-optimized region, preferably, wherein the open reading frame is codon-optimized.
The artificial nucleic acid molecule according to any one of claims 1 - 40, which is an RNA, preferably an mRNA molecule.
A vector comprising an artificial nucleic acid molecule according to any one of claims 1 - 41 .
The vector according to claim 42, which is a DNA vector.
The vector according to claim 42 or 43, which is a plasmid vector or a viral vector, preferably a plasmid vector.
The vector according to any one of claims 42 - 44, which is a circular molecule.
The vector according to claim 42, wherein the poly(A) sequence, the poly(C) sequence, the histone stem loop or the 3'-UTR element of the coding strand is followed in 5'->3' direction by a restriction site for linearization of the circular vector molecule.
47. A cell comprising the artificial nucleic acid molecule according to any one of claims 1 - 39 or the vector according to any one of claims 42 - 46.
48. The cell according to claim 47, which is a mammalian cell.
49. The cel l according to claim 47 or 48, which is a cel l of a mammalian subject, preferably an isolated cell of a mammal ian subject, preferably of a human subject.
50. A pharmaceutical composition comprising the artificial nucleic acid molecule according to any one of claims 1 - 41 , the vector according to any one of claims 42 - 46, or the cell according to any one of claims 47 - 49.
51 . The pharmaceutical composition according to claim 50, further comprising one or more pharmaceutically acceptable vehicles, diluents and/or excipients and/or one or more adjuvants.
52. The artificial nucleic acid molecule according to any one of claims 1 - 41 , the vector according to any one of claims 42 - 46, the cell according to any one of claims 47 - 49, or the pharmaceutical composition according to claim 50 or 51 for use as a medicament.
53. The artificial nucleic acid molecule according to any one of claims 1 - 41 , the vector according to any one of claims 42 - 46, the cell according to any one of claims 47 - 49, or the pharmaceutical composition according to claim 50 or 51 for use as a vaccine or for use in gene therapy.
54. A method for treating or preventing a disorder comprising administering the artificial nucleic acid molecule according to any one of claims 1 - 41 , the vector according to any one of claims 42 - 46, the cell according to any one of claims 47 - 49, or the pharmaceutical composition according to claim 50 or 51 to a subject in need thereof.
55. A method of treating or preventing a disorder comprising transfection of a cell with an artificial nucleic acid molecule according to any one of claims 1 - 41 or the vector accordi ng to any one of claims 42 - 46. The method according to claim 55, wherein transfection of a cell is performed in vitro/ex vivo and the transfected cell is administered to a subject in need thereof, preferably to a human patient.
The method according to claim 56, wherein the cell which is to be transfected in vitro is an isolated cell of the subject, preferably of the human patient.
The method according to any one of claims 54 - 57, which is a vaccination method or a gene therapy method.
A method for increasing and/or prolonging protein production from an artificial nucleic acid molecule, preferably from an mRNA molecule or a vector, the method comprising the step of associating an open reading frame with a 3'-UTR element and/or a 5'-UTR element, wherein the 3'-UTR element and/or the 5'-UTR element prolongs and/or increases protein production from a resulting artificial nucleic acid molecule and wherein the at least one 3'-UTR element and/or the at least one 5'-UTR element is derived from a stable mRNA, to obtain an artificial nucleic acid molecule, preferably an mRNA molecule, according to any of claims 1 - 41 or a vector according to any of claims 42 - 46.
A method for increasing and/or prolonging protein production from an artificial nucleic acid molecule, preferably from an mRNA molecule or a vector, according to claim 59, wherein the 3'-UTR element and/or the 5'-UTR element comprises or consists of a nucleic acid sequence which is derived from the 3'-UTR and/or the 5'-UTR of a transcript of a gene selected from the group consisting of NDUFA1 (NADH dehydrogenase (ubiquinone) 1 alpha subcomplex), GNAS (guanine nucleotide binding protein, alpha stimulating complex locus), MORN2 (MORN repeat containing 2), GSTM1 (glutathione S-transferase, mu 1 ), CBR2 (carbonyl reductase 2), MP68 (RIKEN cDNA 201 01 07E04 gene), NDUFA4 (NADH dehydrogenase (ubiquinone) 1 alpha subcomplex 4), LTA4H, SLC38A6, DECR1 , PIGK, FAM1 75A, PHYH, TBC1 D1 9, PIGB, ALG6, CRYZ, BRP44L, ACADSB, SUPT3 H, TMEM14A, GRAMD1 C, C1 1 orf80, C9orf46, ANXA4, TBCK, IFI6, C2orf34, ALDH6A1 , AGTPBP1 , CCDC53, LRRC28, CCDC1 09B, PUS1 0, CCDC1 04, CASP1 , SNX14, SKAP2, NDUFB6, EFHA1 , BCKDHB, BBS2, LMBRD1 , ITGA6, HERC5, NT5DC1 , RAB7A, AGA, TPK1 , MBNL3, HADHB, MCCC2, CAT, ANAPC4, PCCB, PHKB, ABCB7, PGCP, GPD2, TMEM38B, NFU1, OMA1, LOC128322/NUTF2, NUBPL, LANCL1, HHLA3, PIR, ACAA2, CTBS, GSTM4, ALG8, Atp5e, Gstm5, Uqcr11, Ifi27l2a, Anapc13, Atp5l, TmsblO, Nenf, Ndufa7, Atp5k, l110008P14Rik, Cox4i1, Cox6al, Ndufs6, Sec61b, Romol, Snrpd2, Mgst3, Aldh2, , Ssr4, Myl6, Prdx4, Ubl5, 1110001J03Rik, Ndufal3, Ndufa3, Gstp2, Tmem160, Ergic3, Pgcp, Slpi, Myeov2, Ndufs5, 181002701 ORik, Atp5o, Shfml, Tspo, S100a6, Taldol, Blodsl, Hexa, Ndufb11, Map1 lc3a, Gpx4, Mif, Cox6b1, RIKEN cDNA2900010J23 (Swi5), Sec61g, 2900010M23Rik, Anapc5, Mars2, Phpti, Ndufb8, Pfdn5, Arpc3, Ndufb7, Atp5h, Mrpl23, Uba52, Tomm6, Mtchl, Pcbd2, Ecm1, Hrsp12, Mecr, Uqcrq, Gstm3, Lsm4, Park7, Usmg5, Cox8a, Ly6c1, Cox7b, Ppib, Bag1, S100a4, Bcap31, Tecr, Rabacl, Robld3, Sod1, Nedd8, Higd2a, Trappc6a, Ldhb, Nme2, Snrpg, Ndufa2, Serfl, Oaz1, Rps4x, Rps13, Ybx1, Seppi, Gaa, ACT R 10, P!GF, MGST3, SCP2, HPRT1, ACSF2, VPS 13 A, CTH, NXT2, MGST2, C11orf67, PCCA, GLMN, DHRS1, PON2, NME7, ETFDH, ALG13, DDX60, DYNC2LI1, VPS8, ITFG1, CDK5, C1orf112, IFT52, CLYBL, FAM114A2, NUDT7, AKD1, MAGED2, HRSP12, STX8, ACAT1, IFT74, KIFAP3, CAPN1, COX11, GLT8D4, HACL1, IFT88, NDUFB3, ANO10, ARL6, LPCAT3, ABCD3, COPG2, MIPEP, LEPR, C2orf76, ABCA6, LY96, CROT, ENPP5, SERPINB7, TCP11L2, IRAKI BP1, CDKL2, GHR, KIAA1107, RPS6KA6, CLGN, TMEM45A, TBC1D8B, ACP6, RP6-213H19.1, SNRPN, GLRB, HERC6, CFH, GALC, PDE1 A, GSTM5, CADPS2, AASS, TRIM6-TRIM34 (readthrough transcript), SEPP1, PDE5A, SATB1, CCPG1, CNTN1, LMBRD2, TLR3, BCAT1, TOM1L1, SLC35A1, GLYATL2, STAT4, GULP1, EHHADH, NBEAL1, KIAA1598, HFE, KIAA1324L, and MANSC1; preferably from the group consisting of NDUFA1 (NADH dehydrogenase (ubiquinone) 1 alpha subcomplex), GNAS (guanine nucleotide binding protein, alpha stimulating complex locus), MORN2 (MORN repeat containing 2), GSTM1 (glutathione S-transferase, mu 1), CBR2 (carbonyl reductase 2), MP68 (RIKEN cDNA 2010107E04 gene), NDUFA4 (NADH dehydrogenase (ubiquinone) 1 alpha subcomplex 4), Ybx1 (Y-Box binding protein 1), Ndufb8 (NADH dehydrogenase (ubiquinone) 1 beta subcomplex 8), and CNTN1 (contact! n 1).
Use of a 3'-UTR element and/or a 5'-UTR element for increasing and/or prolonging protein production from an artificial nucleic acid molecule, preferably from an mRNA molecule or a vector, wherein the 3'-UTR element and/or the 5'- UTR element comprises or consists of a nucleic acid sequence which is derived from the 3'-UTR and/or the 5'-UTR of a transcript of a gene selected from the group consisting of NDUFA1 (NADH dehydrogenase (ubiquinone) 1 alpha subcomplex), GNAS (guanine nucleotide binding protein, alpha stimulating complex locus), MORN2 (MORN repeat containing 2), GSTM1 (glutathione S- transferase, mu 1), CBR2 (carbonyl reductase 2), MP68 (RIKEN cDNA 2010107E04 gene), NDUFA4 (NADH dehydrogenase (ubiquinone) 1 alpha subcomplex 4), LTA4H, SLC38A6, DECR1, PIGK, FAM175A, PHYH, TBC1D19, PIGB, ALG6, CRYZ, BRP44L, ACADSB, SUPT3H, TMEM14A, GRAMD1C,
C11orf80, C9orf46, ANXA4, TBCK, IFI6, C2orf34, ALDH6A1, AGTPBP1, CCDC53, LRRC28, CCDC109B, PUS10, CCDC104, CASP1, SNX14, SKAP2, NDUFB6, EFHA1, BCKDHB, BBS2, LMBRD1, ITGA6, HERC5, NT5DC1, RAB7A, AGA, TPK1, MBNL3, HADHB, MCCC2, CAT, ANAPC4, PCCB, PHKB, ABCB7, PGCP, GPD2, TMEM38B, NFU1 , OMA1 , LOC128322/NUTF2, NUBPL, LANCL1 ,
HHLA3, PIR, ACAA2, CTBS, GSTM4, ALG8, Atp5e, Gstm5, Uqcrll, Ifi27l2a, Anapcl3, Atp5l, TmsblO, Nenf, Ndufa7, Atp5k, 1110008P14Rik, Cox4i1, Cox6a1, Ndufs6, Sec61b, Romol, Snrpd2, Mgst3, Aldh2, Ssr4, Myl6, Prdx4, Ubl5, 1110001J03Rik, Ndufa13, Ndufa3, Gstp2, Tmeml60, Ergic3, Pgcp, Slpi, Myeov2, Ndufs5, 181002701 ORik, Atp5o, Shfml, Tspo, S100a6, Taidol,
Bloc1s1, Hexa, Ndufb11, Map1lc3a, Gpx4, Mif, Cox6b1, RIKEN CDNA2900010J23 (Swi5), Sec61g, 2900010M23Rik, Anapc5, Mars2, Phptl, Ndufb8, Pfdn5, Arpc3, Ndufb7, Atp5h, Mrpl23, Uba52, Tomm6, Mtchl, Pcbd2, Ecm1, Hrsp12, Mecr, Uqcrq, Gstm3, Lsm4, Park7, Usmg5, Cox8a, Ly6c1, Cox7b, Ppib, Bag1, S100a4, Bcap31, Tecr, Rabad, Robld3, Sod1, Nedd8, Higd2a,
Trappc6a, Ldhb, Nme2, Snrpg, Ndufa2, Serfl, Oaz1, Rps4x, Rps13, Ybx1, Seppl, Gaa, ACTR10, PIGF, MGST3, SCP2, HPRT1, ACSF2, VPS 13 A, CTH, NXT2, MGST2, C11orf67, PCCA, GLMN, DHRS1, PON2, NME7, ETFDH, ALG13, DDX60, DYNC2LI1, VPS8, ITFG1, CDK5, C1orf112, IFT52, CLYBL, FAM114A2, NUDT7, AKD1, MAGED2, HRSP12, STX8, ACAT1 , IFT74, KIFAP3, CAPN1,
COX11, GLT8D4, HACL1, IFT88, NDUFB3, ANO10, ARL6, LPCAT3, ABCD3, COPG2, MIPEP, LEPR, C2orf76, ABCA6, LY96, CROT, ENPP5, SERPINB7, TCP11L2, IRAKI BP1, CDKL2, GHR, KIAA1107, RPS6KA6, CLGN, TMEM45A, TBC1 D8B, ACP6, RP6-213H1 9.1 , SNRPN, GLRB, HERC6, CFH, GALC, PDE1 A, GSTM5, CADPS2, AASS, TRIM6-TRIM34 (readthrough transcript), SEPP1 , PDE5A, SATB1 , CCPG1 , CNTN1 , LMBRD2, TLR3, BCAT1 , TOM1 L1 , SLC35A1 , GLYATL2, STAT4, GULP1 , EHHADH, NBEAL1 , KIAA1598, HFE, KIAA1324L, and MANSC1 ; preferably from the group consisting of NDUFA1 (NADH dehydrogenase (ubiquinone) 1 alpha subcomplex), GNAS (guanine nucleotide binding protein, alpha stimulating complex locus), MORN2 (MORN repeat containing 2), GSTM1 (glutathione S-transferase, mu 1 ), CBR2 (carbonyl reductase 2), MP68 (RIKEN cDNA 2010107E04 gene), NDUFA4 (NADH dehydrogenase (ubiquinone) 1 alpha subcomplex 4), Ybx1 (Y-Box binding protein 1 ), Ndufb8 (NADH dehydrogenase (ubiquinone) 1 beta subcomplex 8), and CNTN1 (contactin 1 ).
The method according to claim 60 or the use according to claim 61 , wherein the at least one 3'-UTR element and/or the at least one 5'-UTR element comprises a nucleic acid sequence which is derived from the 3'-UTR and/or the 5'-UTR of a transcript of a human gene selected from the group consisting of NDUFA1 (NADH dehydrogenase (ubiquinone) 1 alpha subcomplex), GNAS (guanine nucleotide binding protein, alpha stimulating complex locus), MORN2 (MORN repeat containing 2), GSTM1 (glutathione S-transferase, mu 1 ), CBR2 (carbonyl reductase 2), MP68 (RIKEN cDNA 2010107E04 gene), NDUFA4 (NADH dehydrogenase (ubiquinone) 1 alpha subcomplex 4), Ybx1 (Y-Box binding protein 1 ), Ndufb8 (NADH dehydrogenase (ubiquinone) 1 beta subcomplex 8), CNTN1 (contactin 1 ), LTA4H, SLC38A6, DECR1 , PIGK, FAM1 75A, PHYH, TBC1 D1 9, PIGB, ALG6, CRYZ, BRP44L, ACADSB, SUPT3H, TMEM14A, GRAMD1 C, C1 1 orf80, C9orf46, ANXA4, TBCK, IFI6, C2orf34, ALDH6A1 , AGTPBP1 , CCDC53, LRRC28, CCDC109B, PUS10, CCDC104, CASP1 , SNX14, SKAP2, NDUFB6, EFHA1 , BCKDHB, BBS2, LMBRD1 , 1TGA6, HERC5, NT5DC1 , RAB7A, AGA, TPK1 , MBNL3, HADHB, MCCC2, CAT, ANAPC4, PCCB, PHKB, ABCB7, PGCP, GPD2, TMEM38B, NFU1 , OMA1 , LOC128322/NUTF2, NUBPL, LANCL1 , HHLA3, PIR, ACAA2, CTBS, GSTM4, ALG8, ACTR1 0, PIGF, MGST3, SCP2, HPRT1 , ACSF2, VPS13A, CTH, NXT2, MGST2, C1 1 orf67, PCCA, GLMN, DHRS1 , PON2, NME7, ETFDH, ALG13, DDX60, DYNC2LI1 , VPS8, ITFG1 , CDK5, C1 orf1 12, IFT52, CLYBL, FAM1 14A2, NUDT7, AKD1 , MAGED2, HRSP12, STX8, ACAT1 , IFT74, KIFAP3, CAPN1, COX11, GLT8D4, HACL1, IFT88, NDUFB3, ANO10, ARL6, LPCAT3, ABCD3, COPG2, MIPEP, LEPR, C2orf76, ABCA6, LY96, CROT, ENPP5, SERPINB7, TCP11L2, IRAKI BP1, CDKL2, GHR, KIAA1107, RPS6KA6, CLGN, TMEM45A, TBC1D8B, ACP6, RP6-213H19.1 , SNRPN, GLRB, HERC6, CFH, GALC, PDE1 A, GSTM5, CADPS2, AASS, TRIM6-TRIM34 (readthrough transcript), SEPP1, PDE5A, SATB1, CCPG1, LMBRD2, TLR3, BCAT1, TOM1L1, SLC35A1, GLYATL2, STAT4, GULP1 , EHHADH, NBEAL1 , KIAA1598, HFE, KIAA1324L, and MANSC1.
The method according to claim 60 or the use according to claim 61 , wherein the at least one 3'-UTR element and/or the at least one 5'-UTR element comprises a nucleic acid sequence which is derived from the 3'-UTR and/or the 5'-UTR of a transcript of a murine gene selected from the group consisting of NDUFA1 (NADH dehydrogenase (ubiquinone) 1 alpha subcomplex), GNAS (guanine nucleotide binding protein, alpha stimulating complex locus), MORN2 (MORN repeat containing 2), GSTM1 (glutathione S-transferase, mu 1), CBR2 (carbonyl reductase 2), MP68 (RIKEN cDNA 2010107E04 gene), NDUFA4 (NADH dehydrogenase (ubiquinone) 1 alpha subcomplex 4), Ybx1 (Y-Box binding protein 1), Ndufb8 (NADH dehydrogenase (ubiquinone) 1 beta subcomplex 8), CNTN1 (contactin 1), Atp5e, Gstm5, Uqcrl 1, Ifi27l2a, Anapc13, Atp5l, TmsblO, Nenf, Ndufa7, Atp5k, 1110008P14Rik, Cox4i1, Cox6a1, Ndufs6, Sec61b, Romol, Snrpd2, Mgst3, Aldh2, Ssr4, Myl6, Prdx4, Ubl5, 1110001J03Rik, Ndufa13, Ndufa3, Gstp2, Tmem160, Ergic3, Pgcp, Slpi, Myeov2, Ndufs5, 181002701 ORik, Atp5o, Shfml, Tspo, S100a6, Taldol, Bloclsl, Hexa, Ndufb11, Map1 Ic3a, Gpx4, Mif, Cox6b1, RIKEN CDNA2900010J23 (Swi5), Sec61g, 2900010M23Rik, Anapc5, Mars2, Phptl, Pfdn5, Arpc3, Ndufb7, Atp5h, Mrpl23, Uba52, Tomm6, Mtchl, Pcbd2, Ecml, Hrsp12, Mecr, Uqcrq, Gstm3, Lsm4, Park7, Usmg5, Cox8a, Ly6c1, Cox7b, Ppib, Bag1, S100a4, Bcap31, Tecr, Rabad, Robld3, Sod1, Nedd8, Higd2a, Trappc6a, Ldhb, Nme2, Snrpg, Ndufa2, Serfl, Oaz1, Rps4x, Rps13, Seppl, and Gaa.
The method or the use according to any one of the claims 60 - 63, wherein the at least one 3'-UTR element comprises a nucleic acid sequence which is derived from the 3'-UTR of a transcript of a gene selected from the group consisting of NDUFA1 (NADH dehydrogenase (ubiquinone) 1 alpha subcomplex), GNAS (guanine nucleotide binding protein, alpha stimulating complex locus), MORN2 (MORN repeat containing 2), GSTM1 (glutathione S-transferase, mu 1), CBR2 (carbonyl reductase 2), SLC38A6, DECR1, PIGK, FAM175A, PHYH, TBC1D19, PIGB, ALG6, CRYZ, BRP44L, ACADSB, TMEM14A, GRAMD1C, C11orf80,
ANXA4, TBCK, IFI6, C2orf34, ALDH6A1, AGTPBP1, CCDC53, LRRC28, CCDC109B, PUS10, CCDC104, CASP1, SNX14, SKAP2, NDUFB6, EFHA1, BCKDHB, BBS2, LMBRD1, ITGA6, HERC5, HADHB, ANAPC4, PCCB, ABCB7, PGCP, NFU1, OMA1, HHLA3, ACAA2, GSTM4, ALG8, Ndufal, Atp5e, Gstm5, Uqcr11, Ifi27l2a, Cbr2, Atp5i, TmsblO, Nenf, Atp5k, 1110008P14Rik, Cox4i1,
Cox6a1, Ndufs6, Sec61b, Romol, Gnas, Snrpd2, Mgst3, Aldh2, Ssr4, Myl6, Prdx4, Ubl5, 1110001J03Rik, Ndufal 3, Ndufa3, Gstp2, Tmem160, Ergic3, Pgcp, Slpi, Myeov2, Ndufa4, Ndufs5, Gstml, 181002701 ORik, Atp5o, Shfml, Tspo, S100a6, Taldol, Bloclsl, NdufbH, Map1lc3a, Morn2, Gpx4, Mif, Cox6b1, RIKEN CDNA2900010J23 (Swi5), Sec61g, 2900010M23Rik, Anapc5, Mars2,
Phptl, Ndufb8, Pfdn5, Arpc3, Ndufb7, Atp5h, Mrpl23, Uba52, Tomm6, Mtchl, Pcbd2, Ecm1, Hrsp12, Mecr, Uqcrq, Gstm3, Lsm4, Park7, Usmg5, Cox8a, Ly6c1, Cox7b, Ppib, Bag1, S100a4, Bcap31, Tecr, Rabad, Robld3, Sod1, Nedd8, Higd2a, Trappc6a, Ldhb, Nme2, Snrpg, Ndufa2, Serfl, Oaz1, Rps4x, Rps13, Ybx1 , Seppl , Gaa, ACTR10, PIGF, MGST3, SCP2, HPRT1 , ACSF2, VPS13A, CTH,
NXT2, MGST2, C11orf67, PCCA, GLMN, DHRS1, PON2, NME7, ETFDH, ALG13, DDX60, DYNC2LI1, VPS8, ITFG1, CDK5, C1orf112, IFT52, CLYBL, FAM114A2, NUDT7, AKD1, MAGED2, HRSP12, STX8, ACAT1, IFT74, KIFAP3, CAPN1, COX11, GLT8D4, HACL1, IFT88, NDUFB3, ANO10, ARL6, LPCAT3, ABCD3, COPG2, MIPEP, LEPR, C2orf76, ABCA6, LY96, CROT, ENPP5,
SERPINB7, TCP11L2, IRAKI BP1, CDKL2, GHR, KIAA1107, RPS6KA6, CLGN, TMEM45A, TBC1D8B, ACP6, RP6-213H19.1, SNRPN, GLRB, HERC6, CFH, GALC, PDE1 A, GSTM5, CADPS2, AASS, TRIM6-TRIM34 (readthrough transcript), SEPP1, PDE5A, SATB1, CCPG1, CNTN1, LMBRD2, TLR3, BCAT1, TOM1L1, SLC35A1, GLYATL2, STAT4, GULP1, EHHADH, NBEAL1, KIAA1598, HFE,
KIAA1324L, and MANSC1 ; preferably, the at least one 3'-UTR element comprises or consists of a nucleic acid sequence which is derived from the 3'-UTR of a transcript of a gene selected from the group consisting of NDUFA1 (NADH dehydrogenase (ubiquinone) 1 alpha subcomplex), GNAS (guanine nucleotide binding protein, alpha stimulating complex locus), MORN2 (MORN repeat containing 2), GSTM1 (glutathione S-transferase, mu 1 ), CBR2 (carbonyl reductase 2), Ybx1 (Y-Box binding protein 1 ), Ndufb8 (NADH dehydrogenase (ubiquinone) 1 beta subcomplex 8), and CNTN 1 (contactin 1 ).
The method or the use according to any one of the claims 60 - 63, wherein the at least one 5'-UTR element comprises a nucleic acid sequence which is derived from the 5'-UTR of a transcript of a gene selected from the group consisting of MP68 (RIKEN cDNA 201 01 07E04 gene), NDUFA4 (NADH dehydrogenase (ubiquinone) 1 alpha subcomplex 4), LTA4H, DECR1 , PIGK, TBC1 D1 9, BRP44L, ACADSB, SUPT3H, TMEM14A, C9orf46, ANXA4, IFI6, C2orf34, ALDH6A1 , CCDC53, CCDC1 04, CASP1 , NDUFB6, BCKDHB, BBS2, HERC5, FAM1 75A, NT5DC1 , RAB7A, AGA, TPK1 , MBNL3, MCCC2, CAT, ANAPC4, PHKB, ABCB7, GPD2, TMEM38B, NFU1 , LOC1 28322/NUTF2, NUBPL, LANCL1 , PIR, CTBS, GSTM4, Ndufal , Atp5e, Gstm5, Cbr2, Anapc13, Ndufa7, Atp5k, 1 1 1 0008P14Rik, Cox4i1 , Ndufs6, Sec61 b, Snrpd2, Mgst3, , Prdx4; Pgcp; Myeov2; Ndufa4; Ndufs5; Gstml ; Atp5o; Tspo; Taldol ; Blocl sl ; and Hexa; preferably, the at least one 5'-UTR element comprises or consists of a nucleic acid sequence which is derived from the 5'-UTR of a transcript of MP68 (RIKEN cDNA 20Ί 0Ί 07Ε04 gene) or NDUFA4 (NADH dehydrogenase (ubiquinone) 1 alpha subcomplex 4).
The method or the use according to any one of the claims 60 - 64, wherein the 3'-UTR element comprises or consists of a nucleic acid sequence which has an identity of at least about 40%, preferably of at least about 50%, preferably of at least about 60%, preferably of at least about 70%, more preferably of at least about 80%, more preferably of at least about 90%, even more preferably of at least about 95%, even more preferably of at least about 99% to a sequence selected from the group consisting of SEQ ID NOs: 1 to 24 and SEQ ID NOs: 49 to 31 8 or wherein the 3'-UTR element comprises or consists of a fragment of a nucleic acid sequence that has an identity of at least about 40%, preferably of at least about 50%, preferably of at least about 60%, preferably of at least about 70%, more preferably of at least about 80%, more preferably of at least about 90%, even more preferably of at least about 95%, even more preferably of at least about 99% to a sequence selected from the group consisting of SEQ ID NOs: 1 to 24 and SEQ ID NOs: 49 to 31 8.
The method or the use according to any one of the claims 60 - 63 and 65, wherein the 5'-UTR element comprises or consists of a nucleic acid sequence which has an identity of at least about 40%, preferably of at least about 50%, preferably of at least about 60%, preferably of at least about 70%, more preferably of at least about 80%, more preferably of at least about 90%, even more preferably of at least about 95%, even more preferably of at least about 99% to a sequence selected from the group consisting of SEQ ID NOs: 25 to 30 and SEQ ID NOs: 31 9 to 382 or wherein the 5'-UTR element comprises or consists of a fragment of a nucleic acid sequence that has an identity of at least about 40%, preferably of at least about 50%, preferably of at least about 60%, preferably of at least about 70%, more preferably of at least about 80%, more preferably of at least about 90%, even more preferably of at least about 95%, even more preferably of at least about 99% to a sequence selected from the group consisting of SEQ ID NOs: 25 to 30 and SEQ ID NOs: 31 9 to 382.
The method or the use according to claim 66 or 67, wherein the fragment exhibits a length of between 3 and about 500 nucleotides, preferably of between 5 and about 1 50 nucleotides, more preferably of between 1 0 and 1 00 nucleotides, even more preferably of between 1 5 and 90, most preferably of between 20 and 70.
The method or the use according to any one of claims 60 - 68, wherein the 3'- UTR element and/or the 5'-UTR element exhibits a length of between 3 and about 500 nucleotides, preferably of between 5 and about 1 50 nucleotides, more preferably of between 1 0 and 1 00 nucleotides, even more preferably of between 1 5 and 90, most preferably of between 20 and 70.
A kit or kit of parts comprising an artificial nucleic acid molecule according to any one of claims 1 - 41 , a vector according to any one of claims 42 - 46, a cell according to any one of claims 47 - 49, and/or a pharmaceutical composition according to claim 50 or 51 . The kit according to claim 70 further comprising instructions for use, cells for transfection, an adjuvant, a means for administration of the pharmaceutical composition, a pharmaceutically acceptable carrier and/or a pharmaceutically acceptable solution for dissolution or di lution of the artificial nucleic acid molecule, the vector, the cells or the pharmaceutical composition.
A method for identifying a 3'-untranslated region element (3'-UTR element) and/or a 5'-untranslated region element (5'-UTR element), which is derived from a stable mRNA comprising the following steps:
a) Analyzing the stabi lity of an mRNA comprising the following sub-steps: i. Determining the amount of said mRNA at a first point in time during a decay process of said mRNA,
i i. Determining the amount of said mRNA at a second point in time during a decay process of said mRNA, and
iii . Calculating the ratio of the amount of said mRNA determined in step (i) to the the amount of said mRNA determined in step (ii); b) Selecting a stable mRNA having a ratio calculated in sub-step (iii) of at least 0.5 (50%), at least 0.6 (60%), at least 0.7 (70%), at least 0.75 (75%), at least 0.8 (80%), at least 0.85 (85%), at least 0.9 (90%), or at least 0.95 (95%); and c) Determining the nucleotide sequence of a 3'- and/or 5'-UTR element of said stable mRNA.
A method for identifying a 3'-untranslated region element (3'-UTR element) and/or a 5'-untranslated region element (5'-UTR element), which is derived from a stable mRNA comprising the following steps:
a) Analyzing the stability of a plurality of mRNA species comprising the following sub-steps:
i. Determining the amount of each mRNA species of said plurality of mRNA species at a first point in time during a decay process of said mRNA species,
ii. Determining the amount of each mRNA species of said plurality of mRNA species at a second point in time during a decay process of said mRNA species, and iii . Calculating for each mRNA species of said plurality of mRNA species the ratio of the amount of said mRNA species determined in step (i) to the the amount of said mRNA species determined in step (ii);
b) Ranking of the mRNA species of the plurality of mRNA species according to the ratio calculated in sub-step (ii i) for each mRNA species;
c) Selecting one or more mRNA species having the highest ratio or the highest ratios calculated in sub-step (iii); and
d) Determining the nucleotide sequence of a 3'- and/or 5'-UTR element of said mRNA.
74. The method for identifying a 3'-UTR element and/or a 5'-UTR element according to claim 72 or 73, wherein the time period between the first point in time and the second point in time is at least 5h, preferably at least 6h, preferably at least 7h, more preferably at least 8h, more preferably at least 9h, even more preferably at least 1 0h, even more preferably at least 1 1 h, and particularly preferably at least 12h.
75. The method for identifying a 3'-UTR element and/or a 5'-UTR element according to any of claims 72 - 74, wherein the stability of an mRNA is analysed by pulse labelling, preferably using a pulse-chase methodology.
76. A method for identifying a 3 '-untranslated region element (3'-UTR element) and/or a 5'-untranslated region element (5'-UTR element), which prolongs and/or increases protein production from an artificial nucleic acid molecule and which is derived from a stable mRNA comprising the following steps:
a) identifying a 3'-UTR element and/or a 5'-UTR element which is derived from a stable mRNA by a method for identifying a 3'-UTR element and/or a 5'-UTR element according to any of claims 72 - 75;
b) synthesizing an artificial nucleic acid molecule comprising at least one open reading frame and at least one 3'-UTR element and/or at least one 5'-UTR element which corresponds to or is comprised by the 3'-UTR element and/or the 5'-UTR element identified in step a);
c) analyzing the expression of the protein encoded by the at least one open reading frame of the artificial nucleic acid molecule synthesized in step b); d) analyzing the expression of a protein encoded by at least one open reading frame (ORF) of a reference artificial nucleic acid molecule lacking a 3'-UTR element and/or a 5'-UTR element;
e) comparing the protein expression from the artificial nucleic acid molecule analysed in step c) to the protein expression from the reference artificial nucleic acid molecule analysed in step d); and
f) selecting the 3'-UTR element and/or the 5'-UTR element if the protein expression from the artificial nucleic acid molecule analysed in step c) is prolonged and/or increased in comparison to the protein expression from the reference artificial nucleic acid molecule analysed in step d).
A method for generating an artificial nucleic acid molecule, wherein an artificial nucleic acid molecule comprising at least one open reading frame and at least one 3'-UTR element and/or at least one 5'-UTR element identified by a method for identifying a 3'-UTR element and/or a 5'-UTR element according to any of claims 72 - 76 is synthesized.
The method for generating an artificial nucleic acid molecule according to claim 77, wherein a vector according to any of claims 42 - 46 is used for synthesizing the artificial nucleic acid molecule.
The method for generating an artificial nucleic acid molecule according to claim 77 or 78, wherein the artificial nucleic acid molecule is an artificial nucleic acid molecule according to any of claims 1 to 41 .
An artificial nucleic acid molecule obtainable by a method for generating an artificial nucleic acid molecule according to any of claims 77 - 79.
PCT/EP2015/081366 2014-12-30 2015-12-29 Artificial nucleic acid molecules WO2016107877A1 (en)

Priority Applications (13)

Application Number Priority Date Filing Date Title
CN201580070984.3A CN107124889A (en) 2014-12-30 2015-12-29 Artificial nucleic acid molecule
BR112017009835A BR112017009835A2 (en) 2014-12-30 2015-12-29 artificial nucleic acid molecules
CA2966092A CA2966092A1 (en) 2014-12-30 2015-12-29 Artificial nucleic acid molecules
EP19152916.3A EP3494982A1 (en) 2014-12-30 2015-12-29 Artificial nucleic acid molecules
MX2017008670A MX2017008670A (en) 2014-12-30 2015-12-29 Artificial nucleic acid molecules.
KR1020177021407A KR102580696B1 (en) 2014-12-30 2015-12-29 Novel artificial nucleic acid molecules
RU2017127203A RU2757675C2 (en) 2014-12-30 2015-12-29 Molecules of new artificial nucleic acids
AU2015373404A AU2015373404B2 (en) 2014-12-30 2015-12-29 Artificial nucleic acid molecules
JP2017534943A JP6907116B2 (en) 2014-12-30 2015-12-29 Artificial nucleic acid molecule
US15/540,610 US20180148727A1 (en) 2014-12-30 2015-12-29 Artificial nucleic acid molecules
EP15820544.3A EP3240558A1 (en) 2014-12-30 2015-12-29 Artificial nucleic acid molecules
SG11201704681QA SG11201704681QA (en) 2014-12-30 2015-12-29 Artificial nucleic acid molecules
US16/523,214 US20190345504A1 (en) 2014-12-30 2019-07-26 Artificial nucleic acid molecules

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EPPCT/EP2014/003479 2014-12-30
EP2014003479 2014-12-30

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US15/540,610 A-371-Of-International US20180148727A1 (en) 2014-12-30 2015-12-29 Artificial nucleic acid molecules
US16/523,214 Division US20190345504A1 (en) 2014-12-30 2019-07-26 Artificial nucleic acid molecules

Publications (1)

Publication Number Publication Date
WO2016107877A1 true WO2016107877A1 (en) 2016-07-07

Family

ID=52814040

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2015/081366 WO2016107877A1 (en) 2014-12-30 2015-12-29 Artificial nucleic acid molecules

Country Status (12)

Country Link
US (2) US20180148727A1 (en)
EP (2) EP3240558A1 (en)
JP (2) JP6907116B2 (en)
KR (1) KR102580696B1 (en)
CN (1) CN107124889A (en)
AU (1) AU2015373404B2 (en)
BR (1) BR112017009835A2 (en)
CA (1) CA2966092A1 (en)
MX (1) MX2017008670A (en)
RU (1) RU2757675C2 (en)
SG (2) SG11201704681QA (en)
WO (1) WO2016107877A1 (en)

Cited By (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105112552A (en) * 2015-09-28 2015-12-02 北京泱深生物信息技术有限公司 Application of IFT52 genes on diagnosis of osteoporosis
WO2018033254A2 (en) 2016-08-19 2018-02-22 Curevac Ag Rna for cancer therapy
WO2018115507A2 (en) 2016-12-23 2018-06-28 Curevac Ag Henipavirus vaccine
WO2018167320A1 (en) 2017-03-17 2018-09-20 Curevac Ag Rna vaccine and immune checkpoint inhibitors for combined anticancer therapy
WO2018172556A1 (en) * 2017-03-24 2018-09-27 Curevac Ag Nucleic acids encoding crispr-associated proteins and uses thereof
US10106800B2 (en) 2005-09-28 2018-10-23 Biontech Ag Modification of RNA, producing an increased transcript stability and translation efficiency
US10155031B2 (en) 2012-11-28 2018-12-18 Biontech Rna Pharmaceuticals Gmbh Individualized vaccines for cancer
WO2019038332A1 (en) 2017-08-22 2019-02-28 Curevac Ag Bunyavirales vaccine
WO2019077001A1 (en) * 2017-10-19 2019-04-25 Curevac Ag Novel artificial nucleic acid molecules
WO2019092153A1 (en) 2017-11-08 2019-05-16 Curevac Ag Rna sequence adaptation
WO2019115635A1 (en) 2017-12-13 2019-06-20 Curevac Ag Flavivirus vaccine
WO2019122371A1 (en) 2017-12-21 2019-06-27 Curevac Ag Linear double stranded dna coupled to a single support or a tag and methods for producing said linear double stranded dna
WO2019121803A1 (en) * 2017-12-21 2019-06-27 Baseclick Gmbh Click-modified mrna
US10369216B2 (en) 2014-04-01 2019-08-06 Curevac Ag Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant
WO2019193183A2 (en) 2018-04-05 2019-10-10 Curevac Ag Novel yellow fever nucleic acid molecules for vaccination
US10485884B2 (en) 2012-03-26 2019-11-26 Biontech Rna Pharmaceuticals Gmbh RNA formulation for immunotherapy
US10501768B2 (en) 2015-07-13 2019-12-10 Curevac Ag Method of producing RNA from circular DNA and corresponding template DNA
WO2020002525A1 (en) 2018-06-27 2020-01-02 Curevac Ag Novel lassa virus rna molecules and compositions for vaccination
US10610605B2 (en) 2012-02-15 2020-04-07 Curevac Ag Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein
US10648017B2 (en) 2013-12-30 2020-05-12 Curevac Real Estate Gmbh Methods for RNA analysis
US10653768B2 (en) 2015-04-13 2020-05-19 Curevac Real Estate Gmbh Method for producing RNA compositions
WO2020128031A2 (en) 2018-12-21 2020-06-25 Curevac Ag Rna for malaria vaccines
US10738355B2 (en) 2011-05-24 2020-08-11 Tron-Translationale Onkologie An Der Universitätsmedizin Der Johannes Gutenberg-Universität Mainz Ggmbh Individualized vaccines for cancer
WO2020161342A1 (en) 2019-02-08 2020-08-13 Curevac Ag Coding rna administered into the suprachoroidal space in the treatment of ophtalmic diseases
US10760070B2 (en) 2015-05-29 2020-09-01 Curevac Real Estate Gmbh Method for producing and purifying RNA, comprising at least one step of tangential flow filtration
US10780054B2 (en) 2015-04-17 2020-09-22 Curevac Real Estate Gmbh Lyophilization of RNA
US10837039B2 (en) 2014-06-10 2020-11-17 Curevac Real Estate Gmbh Methods and means for enhancing RNA production
WO2020254535A1 (en) 2019-06-18 2020-12-24 Curevac Ag Rotavirus mrna vaccine
US10898584B2 (en) 2013-11-01 2021-01-26 Curevac Ag Modified RNA with decreased immunostimulatory properties
WO2021028439A1 (en) 2019-08-14 2021-02-18 Curevac Ag Rna combinations and compositions with decreased immunostimulatory properties
WO2021038089A1 (en) * 2019-08-29 2021-03-04 Universität Zürich Minimal messenger rnas and uses thereof
EP3808380A1 (en) * 2016-12-08 2021-04-21 CureVac AG Rna for treatment or prophylaxis of a liver disease
WO2021156267A1 (en) 2020-02-04 2021-08-12 Curevac Ag Coronavirus vaccine
US11103596B2 (en) 2015-05-11 2021-08-31 Ucl Business Plc Fabry disease gene therapy
US11149278B2 (en) 2014-12-12 2021-10-19 Curevac Ag Artificial nucleic acid molecules for improved protein expression
US11156617B2 (en) 2015-02-12 2021-10-26 BioNTech RNA Pharmaceuticals GbmH Predicting T cell epitopes useful for vaccination
US11173120B2 (en) 2014-09-25 2021-11-16 Biontech Rna Pharmaceuticals Gmbh Stable formulations of lipids and liposomes
WO2021239880A1 (en) 2020-05-29 2021-12-02 Curevac Ag Nucleic acid based combination vaccines
US11222711B2 (en) 2013-05-10 2022-01-11 BioNTech SE Predicting immunogenicity of T cell epitopes
WO2022023559A1 (en) 2020-07-31 2022-02-03 Curevac Ag Nucleic acid encoded antibody mixtures
US11253601B2 (en) 2016-07-11 2022-02-22 Translate Bio Ma, Inc. Nucleic acid conjugates and uses thereof
WO2022043551A2 (en) 2020-08-31 2022-03-03 Curevac Ag Multivalent nucleic acid based coronavirus vaccines
US11298426B2 (en) 2003-10-14 2022-04-12 BioNTech SE Recombinant vaccines and use thereof
RU2775176C2 (en) * 2017-03-24 2022-06-28 Куревак Аг Nucleic acids encoding crispr-associated proteins, and their use
WO2022135993A2 (en) 2020-12-22 2022-06-30 Curevac Ag Pharmaceutical composition comprising lipid-based carriers encapsulating rna for multidose administration
WO2022137133A1 (en) 2020-12-22 2022-06-30 Curevac Ag Rna vaccine against sars-cov-2 variants
US11384375B2 (en) 2015-04-30 2022-07-12 Curevac Ag Immobilized poly(n)polymerase
EP4035659A1 (en) 2016-11-29 2022-08-03 PureTech LYT, Inc. Exosomes for delivery of therapeutic agents
WO2022162027A2 (en) 2021-01-27 2022-08-04 Curevac Ag Method of reducing the immunostimulatory properties of in vitro transcribed rna
US11433027B2 (en) 2015-05-20 2022-09-06 Curevac Ag Dry powder composition comprising long-chain RNA
WO2022200575A1 (en) 2021-03-26 2022-09-29 Glaxosmithkline Biologicals Sa Immunogenic compositions
WO2022207862A2 (en) 2021-03-31 2022-10-06 Curevac Ag Syringes containing pharmaceutical compositions comprising rna
US11492628B2 (en) 2015-10-07 2022-11-08 BioNTech SE 3′-UTR sequences for stabilization of RNA
WO2022233880A1 (en) 2021-05-03 2022-11-10 Curevac Ag Improved nucleic acid sequence for cell type specific expression
WO2022256597A1 (en) 2021-06-04 2022-12-08 Translate Bio, Inc. Assay for quantitative assessment of mrna capping efficiency
US11534405B2 (en) 2015-05-20 2022-12-27 Curevac Ag Dry powder composition comprising long-chain RNA
EP4108774A1 (en) 2015-08-28 2022-12-28 CureVac AG Artificial nucleic acid molecules
US11559570B2 (en) 2015-05-15 2023-01-24 CureVac SE Prime-boost regimens involving administration of at least one mRNA construct
WO2023025404A1 (en) 2021-08-24 2023-03-02 BioNTech SE In vitro transcription technologies
US11649459B2 (en) 2021-02-12 2023-05-16 Alnylam Pharmaceuticals, Inc. Superoxide dismutase 1 (SOD1) iRNA compositions and methods of use thereof for treating or preventing superoxide dismutase 1-(SOD1-) associated neurodegenerative diseases
US11661634B2 (en) 2015-05-08 2023-05-30 CureVac Manufacturing GmbH Method for producing RNA
WO2023101508A1 (en) * 2021-12-03 2023-06-08 Mogam Institute For Biomedical Research 5'-utr with improved translation efficiency, a synthetic nucleic acid molecule including the same, and a vaccine or therapeutic composition including the same
US11697816B2 (en) 2013-12-30 2023-07-11 CureVac SE Artificial nucleic acid molecules
WO2023144330A1 (en) 2022-01-28 2023-08-03 CureVac SE Nucleic acid encoded transcription factor inhibitors
EP4227319A1 (en) 2018-04-17 2023-08-16 CureVac SE Novel rsv rna molecules and compositions for vaccination
US11739125B2 (en) 2013-08-21 2023-08-29 Cure Vac SE Respiratory syncytial virus (RSV) vaccine
US11786590B2 (en) 2015-11-09 2023-10-17 CureVac SE Rotavirus vaccines
WO2023227608A1 (en) 2022-05-25 2023-11-30 Glaxosmithkline Biologicals Sa Nucleic acid based vaccine encoding an escherichia coli fimh antigenic polypeptide
US11865084B2 (en) 2016-12-23 2024-01-09 CureVac SE MERS coronavirus vaccine
US11872280B2 (en) 2020-12-22 2024-01-16 CureVac SE RNA vaccine against SARS-CoV-2 variants
WO2024068545A1 (en) 2022-09-26 2024-04-04 Glaxosmithkline Biologicals Sa Influenza virus vaccines

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014127917A1 (en) 2013-02-22 2014-08-28 Curevac Gmbh Combination of vaccination and inhibition of the pd-1 pathway
PT3766916T (en) 2014-06-25 2022-11-28 Acuitas Therapeutics Inc Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids
EP4098743A1 (en) 2015-05-29 2022-12-07 CureVac AG Method for adding cap structures to rna using immobilized enzymes
US10221127B2 (en) 2015-06-29 2019-03-05 Acuitas Therapeutics, Inc. Lipids and lipid nanoparticle formulations for delivery of nucleic acids
US11225682B2 (en) 2015-10-12 2022-01-18 Curevac Ag Automated method for isolation, selection and/or detection of microorganisms or cells comprised in a solution
IL286515B2 (en) 2015-10-28 2024-02-01 Acuitas Therapeutics Inc Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids
CN108778308A (en) 2015-12-22 2018-11-09 库瑞瓦格股份公司 The method for producing RNA molecule composition
EP3394280A1 (en) 2015-12-23 2018-10-31 CureVac AG Method of rna in vitro transcription using a buffer containing a dicarboxylic acid or tricarboxylic acid or a salt thereof
SG10201913630YA (en) 2016-02-17 2020-03-30 Curevac Ag Zika virus vaccine
US11920174B2 (en) 2016-03-03 2024-03-05 CureVac SE RNA analysis by total hydrolysis and quantification of released nucleosides
WO2017186928A1 (en) 2016-04-29 2017-11-02 Curevac Ag Rna encoding an antibody
WO2017191264A1 (en) 2016-05-04 2017-11-09 Curevac Ag Nucleic acid molecules and uses thereof
US11078247B2 (en) 2016-05-04 2021-08-03 Curevac Ag RNA encoding a therapeutic protein
KR20190029576A (en) 2016-06-09 2019-03-20 큐어백 아게 Nucleic acid carboxy hybrid carrier
WO2018096179A1 (en) 2016-11-28 2018-05-31 Curevac Ag Method for purifying rna
WO2018104540A1 (en) 2016-12-08 2018-06-14 Curevac Ag Rnas for wound healing
WO2018115525A1 (en) 2016-12-23 2018-06-28 Curevac Ag Lassa virus vaccine
WO2018191657A1 (en) 2017-04-13 2018-10-18 Acuitas Therapeutics, Inc. Lipids for delivery of active agents
WO2018200975A1 (en) 2017-04-27 2018-11-01 Vanderbilt University Hepatitis c virus gene sequences and methods of use therefor
WO2018200943A1 (en) 2017-04-28 2018-11-01 Acuitas Therapeutics, Inc. Novel carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids
CN111328287A (en) 2017-07-04 2020-06-23 库瑞瓦格股份公司 Novel nucleic acid molecules
WO2019036008A1 (en) 2017-08-16 2019-02-21 Acuitas Therapeutics, Inc. Lipids for use in lipid nanoparticle formulations
US11542225B2 (en) 2017-08-17 2023-01-03 Acuitas Therapeutics, Inc. Lipids for use in lipid nanoparticle formulations
WO2019036030A1 (en) 2017-08-17 2019-02-21 Acuitas Therapeutics, Inc. Lipids for use in lipid nanoparticle formulations
CN109985230B (en) * 2018-01-02 2023-10-17 上海普佑生物医药有限公司 Application of protein in preparation of medicine for preventing and treating kidney diseases
CA3101320A1 (en) * 2018-05-25 2019-11-28 Bioneer Corporation Amphiregulin gene-specific double-stranded oligonucleotide and composition for preventing and treating fibrosis-related diseases and respiratory diseases, comprising same
CN110699367B (en) * 2018-07-09 2021-06-11 武汉纽福斯生物科技有限公司 Nucleic acid for coding human NADH dehydrogenase subunit 4 protein and application thereof
US11576966B2 (en) 2020-02-04 2023-02-14 CureVac SE Coronavirus vaccine
US11241493B2 (en) 2020-02-04 2022-02-08 Curevac Ag Coronavirus vaccine
CN114717230A (en) * 2021-01-05 2022-07-08 麦塞拿治疗(香港)有限公司 Methods and nucleic acid molecules for cell-free and vector-free in vitro RNA transcription of fibroblast growth factor mRNA
WO2023225360A2 (en) * 2022-05-20 2023-11-23 The University Of South Alabama Capless and tailless therapeutic exogenous mrna and method to produce the same

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013120629A1 (en) * 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein
WO2013143700A2 (en) * 2012-03-27 2013-10-03 Curevac Gmbh Artificial nucleic acid molecules comprising a 5'top utr
WO2013143698A1 (en) * 2012-03-27 2013-10-03 Curevac Gmbh Artificial nucleic acid molecules
WO2015101415A1 (en) * 2013-12-30 2015-07-09 Curevac Gmbh Artificial nucleic acid molecules
WO2015101414A2 (en) * 2013-12-30 2015-07-09 Curevac Gmbh Artificial nucleic acid molecules

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5132418A (en) 1980-02-29 1992-07-21 University Patents, Inc. Process for preparing polynucleotides
US4500707A (en) 1980-02-29 1985-02-19 University Patents, Inc. Nucleosides useful in the preparation of polynucleotides
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4668777A (en) 1981-03-27 1987-05-26 University Patents, Inc. Phosphoramidite nucleoside compounds
US4973679A (en) 1981-03-27 1990-11-27 University Patents, Inc. Process for oligonucleo tide synthesis using phosphormidite intermediates
US4415732A (en) 1981-03-27 1983-11-15 University Patents, Inc. Phosphoramidite compounds and processes
US4401796A (en) 1981-04-30 1983-08-30 City Of Hope Research Institute Solid-phase synthesis of polynucleotides
US4373071A (en) 1981-04-30 1983-02-08 City Of Hope Research Institute Solid-phase synthesis of polynucleotides
US5153319A (en) 1986-03-31 1992-10-06 University Patents, Inc. Process for preparing polynucleotides
US5047524A (en) 1988-12-21 1991-09-10 Applied Biosystems, Inc. Automated system for polynucleotide synthesis and purification
US5262530A (en) 1988-12-21 1993-11-16 Applied Biosystems, Inc. Automated system for polynucleotide synthesis and purification
US5700642A (en) 1995-05-22 1997-12-23 Sri International Oligonucleotide sizing using immobilized cleavable primers
EP2842964A1 (en) 2001-06-05 2015-03-04 Curevac GmbH Virtual method of determining a modified mRNA sequence
CA2632900A1 (en) * 2005-12-12 2007-06-21 Research Corporation Technologies, Inc. Hybrid 3' untranslated regions suitable for efficient protein expression in mammalian cells
JP2009181427A (en) * 2008-01-31 2009-08-13 Toshiba Corp Access management system and access management method
WO2010037408A1 (en) 2008-09-30 2010-04-08 Curevac Gmbh Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
WO2012019630A1 (en) 2010-08-13 2012-02-16 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein
ES2742473T3 (en) * 2012-03-27 2020-02-14 Curevac Ag Artificial nucleic acid molecules for enhanced protein or peptide expression

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013120629A1 (en) * 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein
WO2013143700A2 (en) * 2012-03-27 2013-10-03 Curevac Gmbh Artificial nucleic acid molecules comprising a 5'top utr
WO2013143698A1 (en) * 2012-03-27 2013-10-03 Curevac Gmbh Artificial nucleic acid molecules
WO2015101415A1 (en) * 2013-12-30 2015-07-09 Curevac Gmbh Artificial nucleic acid molecules
WO2015101414A2 (en) * 2013-12-30 2015-07-09 Curevac Gmbh Artificial nucleic acid molecules

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHOI Y J ET AL: "Identification and characterization of a novel mouse and human MOPT gene containing MORN-motif protein in testis", THERIOGENOLOGY, LOS ALTOS, CA, US, vol. 73, no. 3, 1 February 2010 (2010-02-01), pages 273 - 281, XP026817959, ISSN: 0093-691X, [retrieved on 20091113] *
J. DRUMMELSMITH ET AL: "Differential Protein Expression Analysis of Leishmania major Reveals Novel Roles for Methionine Adenosyltransferase and S-Adenosylmethionine in Methotrexate Resistance", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 279, no. 32, 9 June 2004 (2004-06-09), US, pages 33273 - 33280, XP055268706, ISSN: 0021-9258, DOI: 10.1074/jbc.M405183200 *
YOSHIHISA MATSUSHITA ET AL: "Mutation of junctophilin type 2 associated with hypertrophic cardiomyopathy", JOURNAL OF HUMAN GENETICS, SPRINGER-VERLAG, TO, vol. 52, no. 6, 3 May 2007 (2007-05-03), pages 543 - 548, XP019493744, ISSN: 1435-232X *

Cited By (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11298426B2 (en) 2003-10-14 2022-04-12 BioNTech SE Recombinant vaccines and use thereof
US10106800B2 (en) 2005-09-28 2018-10-23 Biontech Ag Modification of RNA, producing an increased transcript stability and translation efficiency
US10738355B2 (en) 2011-05-24 2020-08-11 Tron-Translationale Onkologie An Der Universitätsmedizin Der Johannes Gutenberg-Universität Mainz Ggmbh Individualized vaccines for cancer
US11248264B2 (en) 2011-05-24 2022-02-15 Tron-Translationale Onkologie An Der Universitätsmedizin Der Johannes Gutenberg-Universität Mainz Ggmbh Individualized vaccines for cancer
US10898589B2 (en) 2012-02-15 2021-01-26 Cure Vac AG Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein
US10610605B2 (en) 2012-02-15 2020-04-07 Curevac Ag Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein
US10485884B2 (en) 2012-03-26 2019-11-26 Biontech Rna Pharmaceuticals Gmbh RNA formulation for immunotherapy
US11559587B2 (en) 2012-03-26 2023-01-24 Tron-Translationale Onkologie An Der Universitätsmedizin Der Johannes Gutenberg-Universität Mainz Ggmbh RNA formulation for immunotherapy
US10155031B2 (en) 2012-11-28 2018-12-18 Biontech Rna Pharmaceuticals Gmbh Individualized vaccines for cancer
US11504419B2 (en) 2012-11-28 2022-11-22 BioNTech SE Individualized vaccines for cancer
US11222711B2 (en) 2013-05-10 2022-01-11 BioNTech SE Predicting immunogenicity of T cell epitopes
US11739125B2 (en) 2013-08-21 2023-08-29 Cure Vac SE Respiratory syncytial virus (RSV) vaccine
US10898584B2 (en) 2013-11-01 2021-01-26 Curevac Ag Modified RNA with decreased immunostimulatory properties
US11697816B2 (en) 2013-12-30 2023-07-11 CureVac SE Artificial nucleic acid molecules
US10648017B2 (en) 2013-12-30 2020-05-12 Curevac Real Estate Gmbh Methods for RNA analysis
US10369216B2 (en) 2014-04-01 2019-08-06 Curevac Ag Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant
US11110166B2 (en) 2014-04-01 2021-09-07 Curevac Ag Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant
US10837039B2 (en) 2014-06-10 2020-11-17 Curevac Real Estate Gmbh Methods and means for enhancing RNA production
US11173120B2 (en) 2014-09-25 2021-11-16 Biontech Rna Pharmaceuticals Gmbh Stable formulations of lipids and liposomes
US11761009B2 (en) 2014-12-12 2023-09-19 CureVac SE Artificial nucleic acid molecules for improved protein expression
US11345920B2 (en) 2014-12-12 2022-05-31 Curevac Ag Artificial nucleic acid molecules for improved protein expression
US11286492B2 (en) 2014-12-12 2022-03-29 Curevac Ag Artificial nucleic acid molecules for improved protein expression
US11149278B2 (en) 2014-12-12 2021-10-19 Curevac Ag Artificial nucleic acid molecules for improved protein expression
US11156617B2 (en) 2015-02-12 2021-10-26 BioNTech RNA Pharmaceuticals GbmH Predicting T cell epitopes useful for vaccination
US10653768B2 (en) 2015-04-13 2020-05-19 Curevac Real Estate Gmbh Method for producing RNA compositions
US11744886B2 (en) 2015-04-13 2023-09-05 CureVac Manufacturing GmbH Method for producing RNA compositions
US10780054B2 (en) 2015-04-17 2020-09-22 Curevac Real Estate Gmbh Lyophilization of RNA
US11491112B2 (en) 2015-04-17 2022-11-08 CureVac Manufacturing GmbH Lyophilization of RNA
US11446250B2 (en) 2015-04-17 2022-09-20 Curevac Real Estate Gmbh Lyophilization of RNA
US11384375B2 (en) 2015-04-30 2022-07-12 Curevac Ag Immobilized poly(n)polymerase
US11661634B2 (en) 2015-05-08 2023-05-30 CureVac Manufacturing GmbH Method for producing RNA
US11103596B2 (en) 2015-05-11 2021-08-31 Ucl Business Plc Fabry disease gene therapy
US11559570B2 (en) 2015-05-15 2023-01-24 CureVac SE Prime-boost regimens involving administration of at least one mRNA construct
US11433027B2 (en) 2015-05-20 2022-09-06 Curevac Ag Dry powder composition comprising long-chain RNA
US11534405B2 (en) 2015-05-20 2022-12-27 Curevac Ag Dry powder composition comprising long-chain RNA
US10760070B2 (en) 2015-05-29 2020-09-01 Curevac Real Estate Gmbh Method for producing and purifying RNA, comprising at least one step of tangential flow filtration
US11667910B2 (en) 2015-05-29 2023-06-06 CureVac Manufacturing GmbH Method for producing and purifying RNA, comprising at least one step of tangential flow filtration
US11760992B2 (en) 2015-05-29 2023-09-19 CureVac Manufacturing GmbH Method for producing and purifying RNA, comprising at least one step of tangential flow filtration
US11274293B2 (en) 2015-05-29 2022-03-15 Curevac Real Estate Gmbh Method for producing and purifying RNA, comprising at least one step of tangential flow filtration
US11834651B2 (en) 2015-05-29 2023-12-05 CureVac Manufacturing GmbH Method for producing and purifying RNA, comprising at least one step of tangential flow filtration
US10501768B2 (en) 2015-07-13 2019-12-10 Curevac Ag Method of producing RNA from circular DNA and corresponding template DNA
EP4108774A1 (en) 2015-08-28 2022-12-28 CureVac AG Artificial nucleic acid molecules
CN105112552B (en) * 2015-09-28 2018-02-27 北京泱深生物信息技术有限公司 Application of the IFT52 genes in diagnosis of osteoporosis
CN105112552A (en) * 2015-09-28 2015-12-02 北京泱深生物信息技术有限公司 Application of IFT52 genes on diagnosis of osteoporosis
US11492628B2 (en) 2015-10-07 2022-11-08 BioNTech SE 3′-UTR sequences for stabilization of RNA
US11786590B2 (en) 2015-11-09 2023-10-17 CureVac SE Rotavirus vaccines
US11253601B2 (en) 2016-07-11 2022-02-22 Translate Bio Ma, Inc. Nucleic acid conjugates and uses thereof
WO2018033254A2 (en) 2016-08-19 2018-02-22 Curevac Ag Rna for cancer therapy
EP4035659A1 (en) 2016-11-29 2022-08-03 PureTech LYT, Inc. Exosomes for delivery of therapeutic agents
US11464836B2 (en) 2016-12-08 2022-10-11 Curevac Ag RNA for treatment or prophylaxis of a liver disease
EP3808380A1 (en) * 2016-12-08 2021-04-21 CureVac AG Rna for treatment or prophylaxis of a liver disease
US11865084B2 (en) 2016-12-23 2024-01-09 CureVac SE MERS coronavirus vaccine
WO2018115507A2 (en) 2016-12-23 2018-06-28 Curevac Ag Henipavirus vaccine
WO2018167320A1 (en) 2017-03-17 2018-09-20 Curevac Ag Rna vaccine and immune checkpoint inhibitors for combined anticancer therapy
US11739335B2 (en) 2017-03-24 2023-08-29 CureVac SE Nucleic acids encoding CRISPR-associated proteins and uses thereof
WO2018172556A1 (en) * 2017-03-24 2018-09-27 Curevac Ag Nucleic acids encoding crispr-associated proteins and uses thereof
RU2775176C2 (en) * 2017-03-24 2022-06-28 Куревак Аг Nucleic acids encoding crispr-associated proteins, and their use
JP2020513824A (en) * 2017-03-24 2020-05-21 キュアバック アーゲー NUCLEIC ACID ENCODING CRISPR-RELATED PROTEIN AND USE THEREOF
WO2019038332A1 (en) 2017-08-22 2019-02-28 Curevac Ag Bunyavirales vaccine
WO2019077001A1 (en) * 2017-10-19 2019-04-25 Curevac Ag Novel artificial nucleic acid molecules
JP2021501572A (en) * 2017-10-19 2021-01-21 キュアバック アーゲー New artificial nucleic acid molecule
WO2019092153A1 (en) 2017-11-08 2019-05-16 Curevac Ag Rna sequence adaptation
WO2019115635A1 (en) 2017-12-13 2019-06-20 Curevac Ag Flavivirus vaccine
WO2019122371A1 (en) 2017-12-21 2019-06-27 Curevac Ag Linear double stranded dna coupled to a single support or a tag and methods for producing said linear double stranded dna
WO2019121803A1 (en) * 2017-12-21 2019-06-27 Baseclick Gmbh Click-modified mrna
WO2019193183A2 (en) 2018-04-05 2019-10-10 Curevac Ag Novel yellow fever nucleic acid molecules for vaccination
EP4227319A1 (en) 2018-04-17 2023-08-16 CureVac SE Novel rsv rna molecules and compositions for vaccination
WO2020002525A1 (en) 2018-06-27 2020-01-02 Curevac Ag Novel lassa virus rna molecules and compositions for vaccination
WO2020128031A2 (en) 2018-12-21 2020-06-25 Curevac Ag Rna for malaria vaccines
WO2020161342A1 (en) 2019-02-08 2020-08-13 Curevac Ag Coding rna administered into the suprachoroidal space in the treatment of ophtalmic diseases
WO2020254535A1 (en) 2019-06-18 2020-12-24 Curevac Ag Rotavirus mrna vaccine
WO2021028439A1 (en) 2019-08-14 2021-02-18 Curevac Ag Rna combinations and compositions with decreased immunostimulatory properties
WO2021038089A1 (en) * 2019-08-29 2021-03-04 Universität Zürich Minimal messenger rnas and uses thereof
EP4147717A1 (en) 2020-02-04 2023-03-15 CureVac SE Coronavirus vaccine
DE202021004123U1 (en) 2020-02-04 2022-10-26 Curevac Ag Coronavirus Vaccine
DE202021004130U1 (en) 2020-02-04 2022-10-26 Curevac Ag Coronavirus Vaccine
DE112021000012T5 (en) 2020-02-04 2021-11-18 Curevac Ag Coronavirus vaccine
WO2021156267A1 (en) 2020-02-04 2021-08-12 Curevac Ag Coronavirus vaccine
DE202021003575U1 (en) 2020-02-04 2022-01-17 Curevac Ag Coronavirus Vaccine
WO2021239880A1 (en) 2020-05-29 2021-12-02 Curevac Ag Nucleic acid based combination vaccines
WO2022023559A1 (en) 2020-07-31 2022-02-03 Curevac Ag Nucleic acid encoded antibody mixtures
WO2022043551A2 (en) 2020-08-31 2022-03-03 Curevac Ag Multivalent nucleic acid based coronavirus vaccines
WO2022137133A1 (en) 2020-12-22 2022-06-30 Curevac Ag Rna vaccine against sars-cov-2 variants
WO2022135993A2 (en) 2020-12-22 2022-06-30 Curevac Ag Pharmaceutical composition comprising lipid-based carriers encapsulating rna for multidose administration
US11918643B2 (en) 2020-12-22 2024-03-05 CureVac SE RNA vaccine against SARS-CoV-2 variants
US11872280B2 (en) 2020-12-22 2024-01-16 CureVac SE RNA vaccine against SARS-CoV-2 variants
WO2022162027A2 (en) 2021-01-27 2022-08-04 Curevac Ag Method of reducing the immunostimulatory properties of in vitro transcribed rna
US11649459B2 (en) 2021-02-12 2023-05-16 Alnylam Pharmaceuticals, Inc. Superoxide dismutase 1 (SOD1) iRNA compositions and methods of use thereof for treating or preventing superoxide dismutase 1-(SOD1-) associated neurodegenerative diseases
WO2022200575A1 (en) 2021-03-26 2022-09-29 Glaxosmithkline Biologicals Sa Immunogenic compositions
WO2022207862A2 (en) 2021-03-31 2022-10-06 Curevac Ag Syringes containing pharmaceutical compositions comprising rna
WO2022233880A1 (en) 2021-05-03 2022-11-10 Curevac Ag Improved nucleic acid sequence for cell type specific expression
WO2022256597A1 (en) 2021-06-04 2022-12-08 Translate Bio, Inc. Assay for quantitative assessment of mrna capping efficiency
WO2023025404A1 (en) 2021-08-24 2023-03-02 BioNTech SE In vitro transcription technologies
WO2023101508A1 (en) * 2021-12-03 2023-06-08 Mogam Institute For Biomedical Research 5'-utr with improved translation efficiency, a synthetic nucleic acid molecule including the same, and a vaccine or therapeutic composition including the same
WO2023144330A1 (en) 2022-01-28 2023-08-03 CureVac SE Nucleic acid encoded transcription factor inhibitors
WO2023227608A1 (en) 2022-05-25 2023-11-30 Glaxosmithkline Biologicals Sa Nucleic acid based vaccine encoding an escherichia coli fimh antigenic polypeptide
WO2024068545A1 (en) 2022-09-26 2024-04-04 Glaxosmithkline Biologicals Sa Influenza virus vaccines
US11965000B2 (en) 2023-09-07 2024-04-23 CureVac SE Respiratory syncytial virus (RSV) vaccine

Also Published As

Publication number Publication date
AU2015373404A1 (en) 2017-05-25
KR20170100660A (en) 2017-09-04
EP3240558A1 (en) 2017-11-08
RU2017127203A3 (en) 2020-01-10
MX2017008670A (en) 2017-10-11
EP3494982A1 (en) 2019-06-12
US20180148727A1 (en) 2018-05-31
KR102580696B1 (en) 2023-09-19
RU2757675C2 (en) 2021-10-20
SG10201906673WA (en) 2019-09-27
CA2966092A1 (en) 2016-07-07
AU2015373404B2 (en) 2021-09-09
RU2017127203A (en) 2019-02-01
SG11201704681QA (en) 2017-07-28
JP2021168664A (en) 2021-10-28
US20190345504A1 (en) 2019-11-14
BR112017009835A2 (en) 2017-12-26
CN107124889A (en) 2017-09-01
JP6907116B2 (en) 2021-07-21
JP2018501802A (en) 2018-01-25

Similar Documents

Publication Publication Date Title
AU2015373404B2 (en) Artificial nucleic acid molecules
JP7245878B2 (en) Artificial nucleic acid molecule
US20230399649A1 (en) Artificial nucleic acid molecules
AU2014375402B2 (en) Artificial nucleic acid molecules
EP3230458B1 (en) Artificial nucleic acid molecules for improved protein expression
AU2014375402A1 (en) Artificial nucleic acid molecules
US11254951B2 (en) Artificial nucleic acid molecules
EP3495486B1 (en) Artificial nucleic acid molecules
RU2772349C2 (en) Artificial nucleic acid molecules
EP3090052B1 (en) Artificial nucleic acid molecules

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15820544

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2966092

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2015373404

Country of ref document: AU

Date of ref document: 20151229

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112017009835

Country of ref document: BR

REEP Request for entry into the european phase

Ref document number: 2015820544

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 11201704681Q

Country of ref document: SG

WWE Wipo information: entry into national phase

Ref document number: MX/A/2017/008670

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2017534943

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 15540610

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 20177021407

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2017127203

Country of ref document: RU

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 112017009835

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20170510